DDI-DrugBank.d485.s0|0-6|Ethinyl|O
DDI-DrugBank.d485.s0|8-16|estradiol|O
DDI-DrugBank.d485.s0|19-27|Substrate|O
DDI-DrugBank.d485.s0|32-37|CYP3A4|O
DDI-DrugBank.d485.s0|40-44|major|O
DDI-DrugBank.d485.s0|48-52|3A5-7|O
DDI-DrugBank.d485.s0|55-59|minor|O
DDI-DrugBank.d485.s1|0-7|Inhibits|O
DDI-DrugBank.d485.s1|9-14|CYP1A2|O
DDI-DrugBank.d485.s1|17-20|weak|O
DDI-DrugBank.d485.s1|24-26|2B6|O
DDI-DrugBank.d485.s1|17-20|weak|O
DDI-DrugBank.d485.s1|36-39|2C19|O
DDI-DrugBank.d485.s1|17-20|weak|O
DDI-DrugBank.d485.s1|49-51|3A4|O
DDI-DrugBank.d485.s1|17-20|weak|O
DDI-DrugBank.d485.s1|59-59|.|O
DDI-DrugBank.d485.s2|0-12|Acetaminophen|O
DDI-DrugBank.d485.s2|15-17|May|O
DDI-DrugBank.d485.s2|19-26|increase|O
DDI-DrugBank.d485.s2|28-33|plasma|O
DDI-DrugBank.d485.s2|35-47|concentration|O
DDI-DrugBank.d485.s2|52-60|synthetic|O
DDI-DrugBank.d485.s2|62-70|estrogens|O
DDI-DrugBank.d485.s2|73-80|possibly|O
DDI-DrugBank.d485.s2|85-94|inhibiting|O
DDI-DrugBank.d485.s2|96-106|conjugation|O
DDI-DrugBank.d485.s2|107-107|.|O
DDI-DrugBank.d485.s3|0-10|Combination|O
DDI-DrugBank.d485.s3|12-19|hormonal|O
DDI-DrugBank.d485.s3|21-34|contraceptives|O
DDI-DrugBank.d485.s3|36-38|may|O
DDI-DrugBank.d485.s3|40-43|also|O
DDI-DrugBank.d485.s3|45-52|decrease|O
DDI-DrugBank.d485.s3|58-63|plasma|O
DDI-DrugBank.d485.s3|65-77|concentration|O
DDI-DrugBank.d485.s3|82-94|acetaminophen|O
DDI-DrugBank.d485.s3|95-95|.|O
DDI-DrugBank.d485.s4|0-8|Acitretin|O
DDI-DrugBank.d485.s4|11-20|Interferes|O
DDI-DrugBank.d485.s4|31-43|contraceptive|O
DDI-DrugBank.d485.s4|45-50|effect|O
DDI-DrugBank.d485.s4|55-64|microdosed|O
DDI-DrugBank.d485.s4|66-85|progestin-containing|O
DDI-DrugBank.d485.s4|87-94|minipill|O
DDI-DrugBank.d485.s4|96-107|preparations|O
DDI-DrugBank.d485.s4|108-108|.|O
DDI-DrugBank.d485.s5|0-2|The|O
DDI-DrugBank.d485.s5|4-9|effect|O
DDI-DrugBank.d485.s5|20-33|progestational|O
DDI-DrugBank.d485.s5|35-48|contraceptives|O
DDI-DrugBank.d485.s5|51-52|eg|O
DDI-DrugBank.d485.s5|55-62|implants|O
DDI-DrugBank.d485.s5|65-75|injectables|O
DDI-DrugBank.d485.s5|81-87|unknown|O
DDI-DrugBank.d485.s5|88-88|.|O
DDI-DrugBank.d485.s6|0-16|Aminoglutethimide|O
DDI-DrugBank.d485.s6|19-21|May|O
DDI-DrugBank.d485.s6|23-30|increase|O
DDI-DrugBank.d485.s6|32-34|CYP|O
DDI-DrugBank.d485.s6|36-45|metabolism|O
DDI-DrugBank.d485.s6|50-59|progestins|O
DDI-DrugBank.d485.s6|61-67|leading|O
DDI-DrugBank.d485.s6|72-79|possible|O
DDI-DrugBank.d485.s6|81-88|decrease|O
DDI-DrugBank.d485.s6|93-105|contraceptive|O
DDI-DrugBank.d485.s6|107-119|effectiveness|O
DDI-DrugBank.d485.s6|120-120|.|O
DDI-DrugBank.d485.s7|0-2|Use|O
DDI-DrugBank.d485.s7|9-19|nonhormonal|O
DDI-DrugBank.d485.s7|21-33|contraceptive|O
DDI-DrugBank.d485.s7|35-41|product|O
DDI-DrugBank.d485.s7|46-56|recommended|O
DDI-DrugBank.d485.s7|57-57|.|O
DDI-DrugBank.d485.s8|0-10|Antibiotics|O
DDI-DrugBank.d485.s8|13-22|ampicillin|O
DDI-DrugBank.d485.s8|25-36|tetracycline|O
DDI-DrugBank.d485.s8|40-48|Pregnancy|O
DDI-DrugBank.d485.s8|59-66|reported|O
DDI-DrugBank.d485.s8|68-76|following|O
DDI-DrugBank.d485.s8|78-88|concomitant|O
DDI-DrugBank.d485.s8|90-92|use|O
DDI-DrugBank.d485.s8|95-101|however|O
DDI-DrugBank.d485.s8|104-118|pharmacokinetic|O
DDI-DrugBank.d485.s8|120-126|studies|O
DDI-DrugBank.d485.s8|137-141|shown|O
DDI-DrugBank.d485.s8|143-152|consistent|O
DDI-DrugBank.d485.s8|154-160|effects|O
DDI-DrugBank.d485.s8|173-183|antibiotics|O
DDI-DrugBank.d485.s8|188-193|plasma|O
DDI-DrugBank.d485.s8|195-208|concentrations|O
DDI-DrugBank.d485.s8|213-221|synthetic|O
DDI-DrugBank.d485.s8|223-230|steroids|O
DDI-DrugBank.d485.s8|231-231|.|O
DDI-DrugBank.d485.s9|0-2|Use|O
DDI-DrugBank.d485.s9|9-19|nonhormonal|O
DDI-DrugBank.d485.s9|21-33|contraceptive|O
DDI-DrugBank.d485.s9|35-41|product|O
DDI-DrugBank.d485.s9|46-56|recommended|O
DDI-DrugBank.d485.s9|57-57|.|O
DDI-DrugBank.d485.s10|0-13|Anticoagulants|O
DDI-DrugBank.d485.s10|16-26|Combination|O
DDI-DrugBank.d485.s10|28-35|hormonal|O
DDI-DrugBank.d485.s10|37-50|contraceptives|O
DDI-DrugBank.d485.s10|52-54|may|O
DDI-DrugBank.d485.s10|56-63|increase|O
DDI-DrugBank.d485.s10|68-75|decrease|O
DDI-DrugBank.d485.s10|81-87|effects|O
DDI-DrugBank.d485.s10|92-99|coumarin|O
DDI-DrugBank.d485.s10|101-111|derivatives|O
DDI-DrugBank.d485.s10|112-112|.|O
DDI-DrugBank.d485.s11|0-10|Combination|O
DDI-DrugBank.d485.s11|12-19|hormonal|O
DDI-DrugBank.d485.s11|21-34|contraceptives|O
DDI-DrugBank.d485.s11|36-38|may|O
DDI-DrugBank.d485.s11|40-43|also|O
DDI-DrugBank.d485.s11|45-52|increase|O
DDI-DrugBank.d485.s11|54-57|risk|O
DDI-DrugBank.d485.s11|62-75|thromboembolic|O
DDI-DrugBank.d485.s11|77-85|disorders|O
DDI-DrugBank.d485.s11|86-86|.|O
DDI-DrugBank.d485.s12|0-14|Anticonvulsants|O
DDI-DrugBank.d485.s12|17-29|carbamazepine|O
DDI-DrugBank.d485.s12|32-40|felbamate|O
DDI-DrugBank.d485.s12|43-55|phenobarbital|O
DDI-DrugBank.d485.s12|58-66|phenytoin|O
DDI-DrugBank.d485.s12|69-78|topiramate|O
DDI-DrugBank.d485.s12|82-89|Increase|O
DDI-DrugBank.d485.s12|95-104|metabolism|O
DDI-DrugBank.d485.s12|109-115|ethinyl|O
DDI-DrugBank.d485.s12|117-125|estradiol|O
DDI-DrugBank.d485.s12|127-132|and/or|O
DDI-DrugBank.d485.s12|139-148|progestins|O
DDI-DrugBank.d485.s12|151-157|leading|O
DDI-DrugBank.d485.s12|162-169|possible|O
DDI-DrugBank.d485.s12|171-178|decrease|O
DDI-DrugBank.d485.s12|183-195|contraceptive|O
DDI-DrugBank.d485.s12|197-209|effectiveness|O
DDI-DrugBank.d485.s12|210-210|.|O
DDI-DrugBank.d485.s13|0-2|Use|O
DDI-DrugBank.d485.s13|9-19|nonhormonal|O
DDI-DrugBank.d485.s13|21-33|contraceptive|O
DDI-DrugBank.d485.s13|35-41|product|O
DDI-DrugBank.d485.s13|46-56|recommended|O
DDI-DrugBank.d485.s13|57-57|.|O
DDI-DrugBank.d485.s14|0-7|Ascorbic|O
DDI-DrugBank.d485.s14|9-12|acid|O
DDI-DrugBank.d485.s14|15-19|Doses|O
DDI-DrugBank.d485.s14|24-31|ascorbic|O
DDI-DrugBank.d485.s14|9-12|acid|O
DDI-DrugBank.d485.s14|39-45|vitamin|O
DDI-DrugBank.d485.s14|47-47|C|O
DDI-DrugBank.d485.s14|50-50|1|O
DDI-DrugBank.d485.s14|52-56|g/day|O
DDI-DrugBank.d485.s14|68-75|reported|O
DDI-DrugBank.d485.s14|80-87|increase|O
DDI-DrugBank.d485.s14|89-94|plasma|O
DDI-DrugBank.d485.s14|96-108|concentration|O
DDI-DrugBank.d485.s14|113-121|synthetic|O
DDI-DrugBank.d485.s14|123-131|estrogens|O
DDI-DrugBank.d485.s14|136-138|~47|O
DDI-DrugBank.d485.s14|139-139|%|O
DDI-DrugBank.d485.s14|142-149|possibly|O
DDI-DrugBank.d485.s14|154-163|inhibiting|O
DDI-DrugBank.d485.s14|165-175|conjugation|O
DDI-DrugBank.d485.s15|0-7|clinical|O
DDI-DrugBank.d485.s15|9-20|implications|O
DDI-DrugBank.d485.s15|26-32|unclear|O
DDI-DrugBank.d485.s15|33-33|.|O
DDI-DrugBank.d485.s16|0-11|Atorvastatin|O
DDI-DrugBank.d485.s16|0-11|Atorvastatin|O
DDI-DrugBank.d485.s16|27-35|increases|O
DDI-DrugBank.d485.s16|41-43|AUC|O
DDI-DrugBank.d485.s16|49-61|norethindrone|O
DDI-DrugBank.d485.s16|67-73|ethinyl|O
DDI-DrugBank.d485.s16|75-83|estradiol|O
DDI-DrugBank.d485.s16|84-84|.|O
DDI-DrugBank.d485.s17|0-14|Benzodiazepines|O
DDI-DrugBank.d485.s17|17-27|Combination|O
DDI-DrugBank.d485.s17|29-36|hormonal|O
DDI-DrugBank.d485.s17|38-51|contraceptives|O
DDI-DrugBank.d485.s17|53-55|may|O
DDI-DrugBank.d485.s17|57-64|decrease|O
DDI-DrugBank.d485.s17|70-78|clearance|O
DDI-DrugBank.d485.s17|88-102|benzodiazepines|O
DDI-DrugBank.d485.s17|105-114|alprazolam|O
DDI-DrugBank.d485.s17|117-132|chlordiazepoxide|O
DDI-DrugBank.d485.s17|135-142|diazepam|O
DDI-DrugBank.d485.s17|149-156|increase|O
DDI-DrugBank.d485.s17|70-78|clearance|O
DDI-DrugBank.d485.s17|175-180|others|O
DDI-DrugBank.d485.s17|183-191|lorazepam|O
DDI-DrugBank.d485.s17|194-201|oxazepam|O
DDI-DrugBank.d485.s17|204-212|temazepam|O
DDI-DrugBank.d485.s18|0-8|Clofibric|O
DDI-DrugBank.d485.s18|10-13|acid|O
DDI-DrugBank.d485.s18|16-26|Combination|O
DDI-DrugBank.d485.s18|28-35|hormonal|O
DDI-DrugBank.d485.s18|37-50|contraceptives|O
DDI-DrugBank.d485.s18|52-54|may|O
DDI-DrugBank.d485.s18|56-63|increase|O
DDI-DrugBank.d485.s18|69-77|clearance|O
DDI-DrugBank.d485.s18|82-90|clofibric|O
DDI-DrugBank.d485.s18|10-13|acid|O
DDI-DrugBank.d485.s18|96-96|.|O
DDI-DrugBank.d485.s19|0-11|Cyclosporine|O
DDI-DrugBank.d485.s19|14-24|Combination|O
DDI-DrugBank.d485.s19|26-33|hormonal|O
DDI-DrugBank.d485.s19|35-48|contraceptives|O
DDI-DrugBank.d485.s19|50-52|may|O
DDI-DrugBank.d485.s19|54-60|inhibit|O
DDI-DrugBank.d485.s19|66-75|metabolism|O
DDI-DrugBank.d485.s19|80-91|cyclosporine|O
DDI-DrugBank.d485.s19|94-100|leading|O
DDI-DrugBank.d485.s19|105-113|increased|O
DDI-DrugBank.d485.s19|115-120|plasma|O
DDI-DrugBank.d485.s19|122-135|concentrations|O
DDI-DrugBank.d485.s20|0-6|monitor|O
DDI-DrugBank.d485.s20|8-19|cyclosporine|O
DDI-DrugBank.d485.s20|21-26|levels|O
DDI-DrugBank.d485.s20|27-27|.|O
DDI-DrugBank.d485.s21|0-5|CYP3A4|O
DDI-DrugBank.d485.s21|7-14|inducers|O
DDI-DrugBank.d485.s21|0-5|CYP3A4|O
DDI-DrugBank.d485.s21|7-14|inducers|O
DDI-DrugBank.d485.s21|33-35|may|O
DDI-DrugBank.d485.s21|37-44|decrease|O
DDI-DrugBank.d485.s21|50-63|levels/effects|O
DDI-DrugBank.d485.s21|68-74|ethinyl|O
DDI-DrugBank.d485.s21|76-84|estradiol|O
DDI-DrugBank.d485.s21|85-85|.|O
DDI-DrugBank.d485.s22|0-6|Example|O
DDI-DrugBank.d485.s22|8-15|inducers|O
DDI-DrugBank.d485.s22|17-23|include|O
DDI-DrugBank.d485.s22|25-41|aminoglutethimide|O
DDI-DrugBank.d485.s22|44-56|carbamazepine|O
DDI-DrugBank.d485.s22|59-67|nafcillin|O
DDI-DrugBank.d485.s22|70-79|nevirapine|O
DDI-DrugBank.d485.s22|82-94|phenobarbital|O
DDI-DrugBank.d485.s22|97-105|phenytoin|O
DDI-DrugBank.d485.s22|112-121|rifamycins|O
DDI-DrugBank.d485.s23|0-11|Griseofulvin|O
DDI-DrugBank.d485.s23|0-11|Griseofulvin|O
DDI-DrugBank.d485.s23|27-29|may|O
DDI-DrugBank.d485.s23|31-36|induce|O
DDI-DrugBank.d485.s23|42-51|metabolism|O
DDI-DrugBank.d485.s23|56-66|combination|O
DDI-DrugBank.d485.s23|68-75|hormonal|O
DDI-DrugBank.d485.s23|77-90|contraceptives|O
DDI-DrugBank.d485.s23|92-98|causing|O
DDI-DrugBank.d485.s23|100-108|menstrual|O
DDI-DrugBank.d485.s23|110-116|changes|O
DDI-DrugBank.d485.s24|0-10|pregnancies|O
DDI-DrugBank.d485.s24|22-29|reported|O
DDI-DrugBank.d485.s24|30-30|.|O
DDI-DrugBank.d485.s25|0-2|Use|O
DDI-DrugBank.d485.s25|7-13|barrier|O
DDI-DrugBank.d485.s25|15-18|form|O
DDI-DrugBank.d485.s25|23-35|contraception|O
DDI-DrugBank.d485.s25|40-48|suggested|O
DDI-DrugBank.d485.s25|59-70|griseofulvin|O
DDI-DrugBank.d485.s25|72-78|therapy|O
DDI-DrugBank.d485.s25|79-79|.|O
DDI-DrugBank.d485.s26|0-7|Morphine|O
DDI-DrugBank.d485.s26|10-20|Combination|O
DDI-DrugBank.d485.s26|22-29|hormonal|O
DDI-DrugBank.d485.s26|31-44|contraceptives|O
DDI-DrugBank.d485.s26|46-48|may|O
DDI-DrugBank.d485.s26|50-57|increase|O
DDI-DrugBank.d485.s26|63-71|clearance|O
DDI-DrugBank.d485.s26|76-83|morphine|O
DDI-DrugBank.d485.s26|84-84|.|O
DDI-DrugBank.d485.s27|0-13|Non-nucleoside|O
DDI-DrugBank.d485.s27|15-21|reverse|O
DDI-DrugBank.d485.s27|23-35|transcriptase|O
DDI-DrugBank.d485.s27|37-46|inhibitors|O
DDI-DrugBank.d485.s27|49-54|NNRTIs|O
DDI-DrugBank.d485.s27|58-67|Nevirapine|O
DDI-DrugBank.d485.s27|69-71|may|O
DDI-DrugBank.d485.s27|73-80|decrease|O
DDI-DrugBank.d485.s27|82-87|plasma|O
DDI-DrugBank.d485.s27|89-94|levels|O
DDI-DrugBank.d485.s27|99-109|combination|O
DDI-DrugBank.d485.s27|111-118|hormonal|O
DDI-DrugBank.d485.s27|120-133|contraceptives|O
DDI-DrugBank.d485.s28|0-2|use|O
DDI-DrugBank.d485.s28|9-19|nonhormonal|O
DDI-DrugBank.d485.s28|21-33|contraceptive|O
DDI-DrugBank.d485.s28|35-41|product|O
DDI-DrugBank.d485.s28|46-56|recommended|O
DDI-DrugBank.d485.s28|57-57|.|O
DDI-DrugBank.d485.s29|0-1|No|O
DDI-DrugBank.d485.s29|3-6|data|O
DDI-DrugBank.d485.s29|12-22|delavirdine|O
DDI-DrugBank.d485.s30|0-9|incomplete|O
DDI-DrugBank.d485.s30|11-14|data|O
DDI-DrugBank.d485.s30|20-28|efavirenz|O
DDI-DrugBank.d485.s30|29-29|.|O
DDI-DrugBank.d485.s31|0-11|Prednisolone|O
DDI-DrugBank.d485.s31|14-20|Ethinyl|O
DDI-DrugBank.d485.s31|22-30|estradiol|O
DDI-DrugBank.d485.s31|32-34|may|O
DDI-DrugBank.d485.s31|36-42|inhibit|O
DDI-DrugBank.d485.s31|48-57|metabolism|O
DDI-DrugBank.d485.s31|62-73|prednisolone|O
DDI-DrugBank.d485.s31|76-82|leading|O
DDI-DrugBank.d485.s31|87-95|increased|O
DDI-DrugBank.d485.s31|97-102|plasma|O
DDI-DrugBank.d485.s31|104-117|concentrations|O
DDI-DrugBank.d485.s31|118-118|.|O
DDI-DrugBank.d485.s32|0-7|Protease|O
DDI-DrugBank.d485.s32|9-18|inhibitors|O
DDI-DrugBank.d485.s32|21-30|Amprenavir|O
DDI-DrugBank.d485.s32|33-41|lopinavir|O
DDI-DrugBank.d485.s32|44-53|nelfinavir|O
DDI-DrugBank.d485.s32|60-68|ritonavir|O
DDI-DrugBank.d485.s32|80-84|shown|O
DDI-DrugBank.d485.s32|89-96|decrease|O
DDI-DrugBank.d485.s32|98-103|plasma|O
DDI-DrugBank.d485.s32|105-110|levels|O
DDI-DrugBank.d485.s32|115-125|combination|O
DDI-DrugBank.d485.s32|127-134|hormonal|O
DDI-DrugBank.d485.s32|136-149|contraceptives|O
DDI-DrugBank.d485.s33|0-2|use|O
DDI-DrugBank.d485.s33|9-19|nonhormonal|O
DDI-DrugBank.d485.s33|21-33|contraceptive|O
DDI-DrugBank.d485.s33|35-41|product|O
DDI-DrugBank.d485.s33|46-56|recommended|O
DDI-DrugBank.d485.s33|57-57|.|O
DDI-DrugBank.d485.s34|0-8|Indinavir|O
DDI-DrugBank.d485.s34|19-23|shown|O
DDI-DrugBank.d485.s34|28-35|increase|O
DDI-DrugBank.d485.s34|37-42|plasma|O
DDI-DrugBank.d485.s34|44-49|levels|O
DDI-DrugBank.d485.s34|54-64|combination|O
DDI-DrugBank.d485.s34|66-73|hormonal|O
DDI-DrugBank.d485.s34|75-88|contraceptives|O
DDI-DrugBank.d485.s34|89-89|.|O
DDI-DrugBank.d485.s35|0-1|No|O
DDI-DrugBank.d485.s35|3-6|data|O
DDI-DrugBank.d485.s35|12-21|saquinavir|O
DDI-DrugBank.d485.s35|22-22|.|O
DDI-DrugBank.d485.s36|0-7|Rifampin|O
DDI-DrugBank.d485.s36|0-7|Rifampin|O
DDI-DrugBank.d485.s36|19-27|increases|O
DDI-DrugBank.d485.s36|33-42|metabolism|O
DDI-DrugBank.d485.s36|47-53|ethinyl|O
DDI-DrugBank.d485.s36|55-63|estradiol|O
DDI-DrugBank.d485.s36|74-83|progestins|O
DDI-DrugBank.d485.s36|86-98|norethindrone|O
DDI-DrugBank.d485.s36|101-109|resulting|O
DDI-DrugBank.d485.s36|114-122|decreased|O
DDI-DrugBank.d485.s36|124-136|contraceptive|O
DDI-DrugBank.d485.s36|138-150|effectiveness|O
DDI-DrugBank.d485.s36|156-164|increased|O
DDI-DrugBank.d485.s36|166-174|menstrual|O
DDI-DrugBank.d485.s36|176-189|irregularities|O
DDI-DrugBank.d485.s36|190-190|.|O
DDI-DrugBank.d485.s37|0-2|Use|O
DDI-DrugBank.d485.s37|9-19|nonhormonal|O
DDI-DrugBank.d485.s37|21-33|contraceptive|O
DDI-DrugBank.d485.s37|35-41|product|O
DDI-DrugBank.d485.s37|46-56|recommended|O
DDI-DrugBank.d485.s37|57-57|.|O
DDI-DrugBank.d485.s38|0-8|Salicylic|O
DDI-DrugBank.d485.s38|10-13|acid|O
DDI-DrugBank.d485.s38|16-26|Combination|O
DDI-DrugBank.d485.s38|28-35|hormonal|O
DDI-DrugBank.d485.s38|37-50|contraceptives|O
DDI-DrugBank.d485.s38|52-54|may|O
DDI-DrugBank.d485.s38|56-63|increase|O
DDI-DrugBank.d485.s38|69-77|clearance|O
DDI-DrugBank.d485.s38|82-90|salicylic|O
DDI-DrugBank.d485.s38|10-13|acid|O
DDI-DrugBank.d485.s38|96-96|.|O
DDI-DrugBank.d485.s39|0-9|Selegiline|O
DDI-DrugBank.d485.s39|12-22|Combination|O
DDI-DrugBank.d485.s39|24-31|hormonal|O
DDI-DrugBank.d485.s39|33-46|contraceptives|O
DDI-DrugBank.d485.s39|48-50|may|O
DDI-DrugBank.d485.s39|52-59|increase|O
DDI-DrugBank.d485.s39|65-69|serum|O
DDI-DrugBank.d485.s39|71-83|concentration|O
DDI-DrugBank.d485.s39|88-97|selegiline|O
DDI-DrugBank.d485.s39|98-98|.|O
DDI-DrugBank.d485.s40|0-11|Theophylline|O
DDI-DrugBank.d485.s40|14-20|Ethinyl|O
DDI-DrugBank.d485.s40|22-30|estradiol|O
DDI-DrugBank.d485.s40|32-34|may|O
DDI-DrugBank.d485.s40|36-42|inhibit|O
DDI-DrugBank.d485.s40|48-57|metabolism|O
DDI-DrugBank.d485.s40|62-73|theophylline|O
DDI-DrugBank.d485.s40|76-82|leading|O
DDI-DrugBank.d485.s40|87-95|increased|O
DDI-DrugBank.d485.s40|97-102|plasma|O
DDI-DrugBank.d485.s40|104-117|concentrations|O
DDI-DrugBank.d485.s40|118-118|.|O
DDI-DrugBank.d485.s41|0-8|Tricyclic|O
DDI-DrugBank.d485.s41|10-24|antidepressants|O
DDI-DrugBank.d485.s41|27-39|amitriptyline|O
DDI-DrugBank.d485.s41|42-51|imipramine|O
DDI-DrugBank.d485.s41|54-66|nortriptyline|O
DDI-DrugBank.d485.s41|70-79|Metabolism|O
DDI-DrugBank.d485.s41|81-83|may|O
DDI-DrugBank.d485.s41|88-96|inhibited|O
DDI-DrugBank.d485.s41|101-111|combination|O
DDI-DrugBank.d485.s41|113-120|hormonal|O
DDI-DrugBank.d485.s41|122-135|contraceptives|O
DDI-DrugBank.d485.s41|138-147|increasing|O
DDI-DrugBank.d485.s41|149-154|plasma|O
DDI-DrugBank.d485.s41|156-161|levels|O
DDI-DrugBank.d485.s41|10-23|antidepressant|O
DDI-DrugBank.d485.s42|0-2|use|O
DDI-DrugBank.d485.s42|4-10|caution|O
DDI-DrugBank.d485.s42|11-11|.|O
DDI-DrugBank.d485.s43|0-6|ETHANOL|O
DDI-DrugBank.d485.s43|8-8|/|O
DDI-DrugBank.d485.s43|10-18|NUTRITION|O
DDI-DrugBank.d485.s43|8-8|/|O
DDI-DrugBank.d485.s43|22-25|HERB|O
DDI-DrugBank.d485.s43|27-38|INTERACTIONS|O
DDI-DrugBank.d485.s43|41-44|Food|O
DDI-DrugBank.d485.s43|47-49|CNS|O
DDI-DrugBank.d485.s43|51-57|effects|O
DDI-DrugBank.d485.s43|62-69|caffeine|O
DDI-DrugBank.d485.s43|71-73|may|O
DDI-DrugBank.d485.s43|78-85|enhanced|O
DDI-DrugBank.d485.s43|90-100|combination|O
DDI-DrugBank.d485.s43|102-109|hormonal|O
DDI-DrugBank.d485.s43|111-124|contraceptives|O
DDI-DrugBank.d485.s43|130-133|used|O
DDI-DrugBank.d485.s43|135-146|concurrently|O
DDI-DrugBank.d485.s43|62-69|caffeine|O
DDI-DrugBank.d485.s43|161-161|.|O
DDI-DrugBank.d485.s44|0-9|Grapefruit|O
DDI-DrugBank.d485.s44|11-15|juice|O
DDI-DrugBank.d485.s44|17-25|increases|O
DDI-DrugBank.d485.s44|27-33|ethinyl|O
DDI-DrugBank.d485.s44|35-43|estradiol|O
DDI-DrugBank.d485.s44|45-58|concentrations|O
DDI-DrugBank.d485.s44|64-68|would|O
DDI-DrugBank.d485.s44|73-80|expected|O
DDI-DrugBank.d485.s44|17-24|increase|O
DDI-DrugBank.d485.s44|94-105|progesterone|O
DDI-DrugBank.d485.s44|107-111|serum|O
DDI-DrugBank.d485.s44|113-118|levels|O
DDI-DrugBank.d485.s44|123-126|well|O
DDI-DrugBank.d485.s45|0-7|clinical|O
DDI-DrugBank.d485.s45|9-20|implications|O
DDI-DrugBank.d485.s45|26-32|unclear|O
DDI-DrugBank.d485.s45|33-33|.|O
DDI-DrugBank.d485.s46|0-17|Herb/Nutraceutical|O
DDI-DrugBank.d485.s46|20-21|St|O
DDI-DrugBank.d485.s46|23-27|Johns|O
DDI-DrugBank.d485.s46|29-32|wort|O
DDI-DrugBank.d485.s46|34-36|may|O
DDI-DrugBank.d485.s46|38-45|decrease|O
DDI-DrugBank.d485.s46|51-63|effectiveness|O
DDI-DrugBank.d485.s46|68-78|combination|O
DDI-DrugBank.d485.s46|80-87|hormonal|O
DDI-DrugBank.d485.s46|89-102|contraceptives|O
DDI-DrugBank.d485.s46|107-114|inducing|O
DDI-DrugBank.d485.s46|116-122|hepatic|O
DDI-DrugBank.d485.s46|124-130|enzymes|O
DDI-DrugBank.d485.s46|131-131|.|O
DDI-DrugBank.d485.s47|0-4|Avoid|O
DDI-DrugBank.d485.s47|6-9|dong|O
DDI-DrugBank.d485.s47|11-14|quai|O
DDI-DrugBank.d485.s47|20-24|black|O
DDI-DrugBank.d485.s47|26-31|cohosh|O
DDI-DrugBank.d485.s47|39-46|estrogen|O
DDI-DrugBank.d485.s47|48-55|activity|O
DDI-DrugBank.d485.s48|0-4|Avoid|O
DDI-DrugBank.d485.s48|6-8|saw|O
DDI-DrugBank.d485.s48|10-17|palmetto|O
DDI-DrugBank.d485.s48|20-22|red|O
DDI-DrugBank.d485.s48|24-29|clover|O
DDI-DrugBank.d485.s48|32-38|ginseng|O
DDI-MedLine.d49.s0|0-10|Interaction|O
DDI-MedLine.d49.s0|15-25|clindamycin|O
DDI-MedLine.d49.s0|31-40|gentamicin|O
DDI-MedLine.d49.s0|45-49|vitro|O
DDI-MedLine.d49.s0|50-50|.|O
DDI-MedLine.d49.s1|0-2|The|O
DDI-MedLine.d49.s1|4-10|minimal|O
DDI-MedLine.d49.s1|12-21|inhibitory|O
DDI-MedLine.d49.s1|23-36|concentrations|O
DDI-MedLine.d49.s1|41-51|clindamycin|O
DDI-MedLine.d49.s1|57-66|gentamicin|O
DDI-MedLine.d49.s1|68-72|alone|O
DDI-MedLine.d49.s1|81-92|combinations|O
DDI-MedLine.d49.s1|99-108|determined|O
DDI-MedLine.d49.s1|115-127|microdilution|O
DDI-MedLine.d49.s1|129-134|method|O
DDI-MedLine.d49.s1|140-142|163|O
DDI-MedLine.d49.s1|144-150|aerobic|O
DDI-MedLine.d49.s1|153-163|facultative|O
DDI-MedLine.d49.s1|170-178|anaerobic|O
DDI-MedLine.d49.s1|180-187|clinical|O
DDI-MedLine.d49.s1|189-196|isolates|O
DDI-MedLine.d49.s1|197-197|.|O
DDI-MedLine.d49.s2|0-2|All|O
DDI-MedLine.d49.s2|4-5|77|O
DDI-MedLine.d49.s2|7-13|strains|O
DDI-MedLine.d49.s2|18-31|Staphylococcus|O
DDI-MedLine.d49.s2|33-38|aureus|O
DDI-MedLine.d49.s2|41-51|Diplococcus|O
DDI-MedLine.d49.s2|53-62|pneumoniae|O
DDI-MedLine.d49.s2|65-77|Streptococcus|O
DDI-MedLine.d49.s2|79-86|pyogenes|O
DDI-MedLine.d49.s2|93-101|anaerobic|O
DDI-MedLine.d49.s2|103-110|bacteria|O
DDI-MedLine.d49.s2|113-118|except|O
DDI-MedLine.d49.s2|124-128|three|O
DDI-MedLine.d49.s2|7-13|strains|O
DDI-MedLine.d49.s2|141-151|Clostridium|O
DDI-MedLine.d49.s2|159-167|inhibited|O
DDI-MedLine.d49.s2|172-174|1.6|O
DDI-MedLine.d49.s2|176-178|mug|O
DDI-MedLine.d49.s2|183-186|less|O
DDI-MedLine.d49.s2|191-201|clindamycin|O
DDI-MedLine.d49.s2|203-205|per|O
DDI-MedLine.d49.s2|207-208|ml|O
DDI-MedLine.d49.s2|173-173|.|O
DDI-MedLine.d49.s3|0-9|Gentamicin|O
DDI-MedLine.d49.s3|19-27|interfere|O
DDI-MedLine.d49.s3|38-45|activity|O
DDI-MedLine.d49.s3|50-60|clindamycin|O
DDI-MedLine.d49.s3|62-67|within|O
DDI-MedLine.d49.s3|73-77|range|O
DDI-MedLine.d49.s3|82-95|concentrations|O
DDI-MedLine.d49.s3|97-102|tested|O
DDI-MedLine.d49.s3|105-107|0.1|O
DDI-MedLine.d49.s3|112-114|100|O
DDI-MedLine.d49.s3|116-121|mug/ml|O
DDI-MedLine.d49.s4|9-15|strains|O
DDI-MedLine.d49.s4|17-28|combinations|O
DDI-MedLine.d49.s4|35-45|synergistic|O
DDI-MedLine.d49.s4|46-46|.|O
DDI-MedLine.d49.s5|0-8|Sixty-two|O
DDI-MedLine.d49.s5|11-12|94|O
DDI-MedLine.d49.s5|13-13|%|O
DDI-MedLine.d49.s5|19-20|66|O
DDI-MedLine.d49.s5|22-28|strains|O
DDI-MedLine.d49.s5|33-50|Enterobacteriaceae|O
DDI-MedLine.d49.s5|56-66|Pseudomonas|O
DDI-MedLine.d49.s5|68-77|aeruginosa|O
DDI-MedLine.d49.s5|84-92|inhibited|O
DDI-MedLine.d49.s5|97-99|6.2|O
DDI-MedLine.d49.s5|101-103|mug|O
DDI-MedLine.d49.s5|108-111|less|O
DDI-MedLine.d49.s5|116-125|gentamicin|O
DDI-MedLine.d49.s5|127-129|per|O
DDI-MedLine.d49.s5|131-132|ml|O
DDI-MedLine.d49.s5|98-98|.|O
DDI-MedLine.d49.s6|0-11|Combinations|O
DDI-MedLine.d49.s6|16-26|clindamycin|O
DDI-MedLine.d49.s6|32-41|gentamicin|O
DDI-MedLine.d49.s6|48-58|indifferent|O
DDI-MedLine.d49.s6|64-65|29|O
DDI-MedLine.d49.s6|67-73|strains|O
DDI-MedLine.d49.s6|79-89|synergistic|O
DDI-MedLine.d49.s6|95-96|33|O
DDI-MedLine.d49.s6|67-73|strains|O
DDI-MedLine.d49.s6|105-105|.|O
DDI-MedLine.d49.s7|0-2|All|O
DDI-MedLine.d49.s7|4-5|20|O
DDI-MedLine.d49.s7|7-13|strains|O
DDI-MedLine.d49.s7|18-29|enterococcus|O
DDI-MedLine.d49.s7|32-36|three|O
DDI-MedLine.d49.s7|7-13|strains|O
DDI-MedLine.d49.s7|49-59|Clostridium|O
DDI-MedLine.d49.s7|32-36|three|O
DDI-MedLine.d49.s7|7-13|strains|O
DDI-MedLine.d49.s7|79-89|Escherichia|O
DDI-MedLine.d49.s7|91-94|coli|O
DDI-MedLine.d49.s7|101-103|one|O
DDI-MedLine.d49.s7|7-12|strain|O
DDI-MedLine.d49.s7|115-121|Proteus|O
DDI-MedLine.d49.s7|123-130|rettgeri|O
DDI-MedLine.d49.s7|137-145|resistant|O
DDI-MedLine.d49.s7|155-165|clindamycin|O
DDI-MedLine.d49.s7|168-174|minimal|O
DDI-MedLine.d49.s7|176-185|inhibitory|O
DDI-MedLine.d49.s7|187-199|concentration|O
DDI-MedLine.d49.s7|201-207|greater|O
DDI-MedLine.d49.s7|214-216|3.1|O
DDI-MedLine.d49.s7|218-223|mug/ml|O
DDI-MedLine.d49.s7|230-239|gentamicin|O
DDI-MedLine.d49.s7|168-174|minimal|O
DDI-MedLine.d49.s7|176-185|inhibitory|O
DDI-MedLine.d49.s7|187-199|concentration|O
DDI-MedLine.d49.s7|201-207|greater|O
DDI-MedLine.d49.s7|288-290|6.2|O
DDI-MedLine.d49.s7|218-223|mug/ml|O
DDI-MedLine.d49.s7|215-215|.|O
DDI-MedLine.d49.s8|0-11|Combinations|O
DDI-MedLine.d49.s8|16-26|clindamycin|O
DDI-MedLine.d49.s8|32-41|gentamicin|O
DDI-MedLine.d49.s8|48-58|indifferent|O
DDI-MedLine.d49.s8|64-65|16|O
DDI-MedLine.d49.s8|71-81|synergistic|O
DDI-MedLine.d49.s8|87-88|11|O
DDI-MedLine.d49.s8|97-105|resistant|O
DDI-MedLine.d49.s8|107-113|strains|O
DDI-MedLine.d49.s8|114-114|.|O
DDI-MedLine.d49.s9|0-5|Except|O
DDI-MedLine.d49.s9|11-31|clindamycin-sensitive|O
DDI-MedLine.d49.s9|33-40|isolates|O
DDI-MedLine.d49.s9|43-49|synergy|O
DDI-MedLine.d49.s9|55-61|usually|O
DDI-MedLine.d49.s9|63-70|observed|O
DDI-MedLine.d49.s9|80-93|concentrations|O
DDI-MedLine.d49.s9|98-100|one|O
DDI-MedLine.d49.s9|110-114|drugs|O
DDI-MedLine.d49.s9|130-136|readily|O
DDI-MedLine.d49.s9|138-147|obtainable|O
DDI-MedLine.d49.s9|152-155|vivo|O
DDI-MedLine.d49.s9|156-156|.|O
DDI-MedLine.d49.s10|0-9|Antagonism|O
DDI-MedLine.d49.s10|15-19|never|O
DDI-MedLine.d49.s10|21-28|observed|O
DDI-MedLine.d49.s10|29-29|.|O
DDI-DrugBank.d602.s0|0-6|Caution|O
DDI-DrugBank.d602.s0|11-21|recommended|O
DDI-DrugBank.d602.s0|28-40|administering|O
DDI-DrugBank.d602.s0|42-48|NEXAVAR|O
DDI-DrugBank.d602.s0|55-63|compounds|O
DDI-DrugBank.d602.s0|74-95|metabolized/eliminated|O
DDI-DrugBank.d602.s0|97-109|predominantly|O
DDI-DrugBank.d602.s0|118-123|UGT1A1|O
DDI-DrugBank.d602.s0|125-131|pathway|O
DDI-DrugBank.d602.s0|134-136|e.g|O
DDI-DrugBank.d602.s0|135-135|.|O
DDI-DrugBank.d602.s0|139-148|irinotecan|O
DDI-DrugBank.d602.s1|0-10|Concomitant|O
DDI-DrugBank.d602.s1|12-20|treatment|O
DDI-DrugBank.d602.s1|27-33|NEXAVAR|O
DDI-DrugBank.d602.s1|35-42|resulted|O
DDI-DrugBank.d602.s1|49-50|21|O
DDI-DrugBank.d602.s1|51-51|%|O
DDI-DrugBank.d602.s1|53-60|increase|O
DDI-DrugBank.d602.s1|69-71|AUC|O
DDI-DrugBank.d602.s1|76-86|doxorubicin|O
DDI-DrugBank.d602.s1|87-87|.|O
DDI-DrugBank.d602.s2|0-6|Caution|O
DDI-DrugBank.d602.s2|11-21|recommended|O
DDI-DrugBank.d602.s2|28-40|administering|O
DDI-DrugBank.d602.s2|42-52|doxorubicin|O
DDI-DrugBank.d602.s2|59-65|NEXAVAR|O
DDI-DrugBank.d602.s2|66-66|.|O
DDI-DrugBank.d602.s3|0-8|Sorafenib|O
DDI-DrugBank.d602.s3|10-17|inhibits|O
DDI-DrugBank.d602.s3|19-24|CYP2B6|O
DDI-DrugBank.d602.s3|30-35|CYP2C8|O
DDI-DrugBank.d602.s3|40-44|vitro|O
DDI-DrugBank.d602.s3|51-52|Ki|O
DDI-DrugBank.d602.s3|54-59|values|O
DDI-DrugBank.d602.s3|24-24|6|O
DDI-DrugBank.d602.s3|70-72|1-2|O
DDI-DrugBank.d602.s3|75-75|M|O
DDI-DrugBank.d602.s3|78-89|respectively|O
DDI-DrugBank.d602.s3|90-90|.|O
DDI-DrugBank.d602.s4|0-7|Systemic|O
DDI-DrugBank.d602.s4|9-16|exposure|O
DDI-DrugBank.d602.s4|21-30|substrates|O
DDI-DrugBank.d602.s4|35-40|CYP2B6|O
DDI-DrugBank.d602.s4|46-51|CYP2C8|O
DDI-DrugBank.d602.s4|56-63|expected|O
DDI-DrugBank.d602.s4|68-75|increase|O
DDI-DrugBank.d602.s4|82-96|co-administered|O
DDI-DrugBank.d602.s4|103-109|NEXAVAR|O
DDI-DrugBank.d602.s4|110-110|.|O
DDI-DrugBank.d602.s5|0-6|Caution|O
DDI-DrugBank.d602.s5|11-21|recommended|O
DDI-DrugBank.d602.s5|28-40|administering|O
DDI-DrugBank.d602.s5|42-51|substrates|O
DDI-DrugBank.d602.s5|56-61|CYP2B6|O
DDI-DrugBank.d602.s5|67-72|CYP2C8|O
DDI-DrugBank.d602.s5|79-85|NEXAVAR|O
DDI-DrugBank.d602.s5|86-86|.|O
DDI-DrugBank.d293.s0|0-2|May|O
DDI-DrugBank.d293.s0|4-11|interact|O
DDI-DrugBank.d293.s0|18-24|thyroid|O
DDI-DrugBank.d293.s0|26-35|medication|O
DDI-DrugBank.d293.s0|38-41|e.g.|O
DDI-DrugBank.d293.s0|44-56|levothyroxine|O
DDI-DrugBank.d293.s0|60-76|iodine-containing|O
DDI-DrugBank.d293.s0|78-85|products|O
DDI-DrugBank.d293.s0|88-95|antacids|O
DDI-DrugBank.d293.s0|98-111|H2-antagonists|O
DDI-DrugBank.d293.s0|38-41|e.g.|O
DDI-DrugBank.d293.s0|120-129|famotidine|O
DDI-DrugBank.d293.s0|132-141|ranitidine|O
DDI-DrugBank.d293.s0|149-154|proton|O
DDI-DrugBank.d293.s0|156-159|pump|O
DDI-DrugBank.d293.s0|161-170|inhibitors|O
DDI-DrugBank.d293.s0|38-41|e.g.|O
DDI-DrugBank.d293.s0|179-190|lansoprazole|O
DDI-DrugBank.d293.s0|193-202|omeprazole|O
DDI-DrugBank.d293.s0|39-39|.|O
DDI-DrugBank.d293.s1|0-3|This|O
DDI-DrugBank.d293.s1|5-11|product|O
DDI-DrugBank.d293.s1|17-22|affect|O
DDI-DrugBank.d293.s1|28-34|results|O
DDI-DrugBank.d293.s1|39-45|certain|O
DDI-DrugBank.d293.s1|47-49|lab|O
DDI-DrugBank.d293.s1|51-55|tests|O
DDI-DrugBank.d293.s1|56-56|.|O
DDI-DrugBank.d527.s0|0-0|A|O
DDI-DrugBank.d527.s0|2-7|number|O
DDI-DrugBank.d527.s0|12-21|substances|O
DDI-DrugBank.d527.s0|23-28|affect|O
DDI-DrugBank.d527.s0|30-36|glucose|O
DDI-DrugBank.d527.s0|38-47|metabolism|O
DDI-DrugBank.d527.s0|53-55|may|O
DDI-DrugBank.d527.s0|57-63|require|O
DDI-DrugBank.d527.s0|65-71|insulin|O
DDI-DrugBank.d527.s0|73-76|dose|O
DDI-DrugBank.d527.s0|78-87|adjustment|O
DDI-DrugBank.d527.s0|93-104|particularly|O
DDI-DrugBank.d527.s0|106-110|close|O
DDI-DrugBank.d527.s0|112-121|monitoring|O
DDI-DrugBank.d527.s0|122-122|.|O
DDI-DrugBank.d527.s1|0-2|The|O
DDI-DrugBank.d527.s1|4-12|following|O
DDI-DrugBank.d527.s1|18-25|examples|O
DDI-DrugBank.d527.s1|30-39|substances|O
DDI-DrugBank.d527.s1|46-48|may|O
DDI-DrugBank.d527.s1|50-57|increase|O
DDI-DrugBank.d527.s1|63-84|blood-glucose-lowering|O
DDI-DrugBank.d527.s1|86-91|effect|O
DDI-DrugBank.d527.s1|97-110|susceptibility|O
DDI-DrugBank.d527.s1|115-126|hypoglycemia|O
DDI-DrugBank.d527.s1|129-132|oral|O
DDI-DrugBank.d527.s1|134-145|antidiabetes|O
DDI-DrugBank.d527.s1|147-154|products|O
DDI-DrugBank.d527.s1|157-159|ACE|O
DDI-DrugBank.d527.s1|161-170|inhibitors|O
DDI-DrugBank.d527.s1|173-184|disopyramide|O
DDI-DrugBank.d527.s1|187-194|fibrates|O
DDI-DrugBank.d527.s1|197-206|fluoxetine|O
DDI-DrugBank.d527.s1|209-211|MAO|O
DDI-DrugBank.d527.s1|161-170|inhibitors|O
DDI-DrugBank.d527.s1|225-236|propoxyphene|O
DDI-DrugBank.d527.s1|239-249|salicylates|O
DDI-DrugBank.d527.s1|252-263|somatostatin|O
DDI-DrugBank.d527.s1|265-270|analog|O
DDI-DrugBank.d527.s1|273-276|e.g.|O
DDI-DrugBank.d527.s1|279-288|octreotide|O
DDI-DrugBank.d527.s1|292-302|sulfonamide|O
DDI-DrugBank.d527.s1|304-314|antibiotics|O
DDI-DrugBank.d527.s1|274-274|.|O
DDI-DrugBank.d527.s2|0-2|The|O
DDI-DrugBank.d527.s2|4-12|following|O
DDI-DrugBank.d527.s2|18-25|examples|O
DDI-DrugBank.d527.s2|30-39|substances|O
DDI-DrugBank.d527.s2|46-48|may|O
DDI-DrugBank.d527.s2|50-55|reduce|O
DDI-DrugBank.d527.s2|61-82|blood-glucose-lowering|O
DDI-DrugBank.d527.s2|84-89|effect|O
DDI-DrugBank.d527.s2|94-100|insulin|O
DDI-DrugBank.d527.s2|103-117|corticosteroids|O
DDI-DrugBank.d527.s2|120-126|danazol|O
DDI-DrugBank.d527.s2|129-137|diuretics|O
DDI-DrugBank.d527.s2|140-154|sympathomimetic|O
DDI-DrugBank.d527.s2|156-161|agents|O
DDI-DrugBank.d527.s2|164-167|e.g.|O
DDI-DrugBank.d527.s2|170-180|epinephrine|O
DDI-DrugBank.d527.s2|183-191|albuterol|O
DDI-DrugBank.d527.s2|194-204|terbutaline|O
DDI-DrugBank.d527.s2|208-216|isoniazid|O
DDI-DrugBank.d527.s2|219-231|phenothiazine|O
DDI-DrugBank.d527.s2|233-243|derivatives|O
DDI-DrugBank.d527.s2|246-255|somatropin|O
DDI-DrugBank.d527.s2|258-264|thyroid|O
DDI-DrugBank.d527.s2|266-273|hormones|O
DDI-DrugBank.d527.s2|276-284|estrogens|O
DDI-DrugBank.d527.s2|287-298|progestogens|O
DDI-DrugBank.d527.s2|164-167|e.g.|O
DDI-DrugBank.d527.s2|310-313|oral|O
DDI-DrugBank.d527.s2|315-328|contraceptives|O
DDI-DrugBank.d527.s2|165-165|.|O
DDI-DrugBank.d527.s3|0-12|Beta-blockers|O
DDI-DrugBank.d527.s3|15-23|clonidine|O
DDI-DrugBank.d527.s3|26-32|lithium|O
DDI-DrugBank.d527.s3|34-38|salts|O
DDI-DrugBank.d527.s3|45-51|alcohol|O
DDI-DrugBank.d527.s3|53-55|may|O
DDI-DrugBank.d527.s3|57-62|either|O
DDI-DrugBank.d527.s3|64-73|potentiate|O
DDI-DrugBank.d527.s3|78-83|weaken|O
DDI-DrugBank.d527.s3|89-110|blood-glucose-lowering|O
DDI-DrugBank.d527.s3|112-117|effect|O
DDI-DrugBank.d527.s3|122-128|insulin|O
DDI-DrugBank.d527.s3|129-129|.|O
DDI-DrugBank.d527.s4|0-10|Pentamidine|O
DDI-DrugBank.d527.s4|12-14|may|O
DDI-DrugBank.d527.s4|16-20|cause|O
DDI-DrugBank.d527.s4|22-33|hypoglycemia|O
DDI-DrugBank.d527.s4|12-14|may|O
DDI-DrugBank.d527.s4|46-54|sometimes|O
DDI-DrugBank.d527.s4|59-66|followed|O
DDI-DrugBank.d527.s4|71-83|hyperglycemia|O
DDI-DrugBank.d527.s4|84-84|.|O
DDI-DrugBank.d527.s5|0-1|In|O
DDI-DrugBank.d527.s5|3-10|addition|O
DDI-DrugBank.d527.s5|23-31|influence|O
DDI-DrugBank.d527.s5|36-48|sympatholytic|O
DDI-DrugBank.d527.s5|50-58|medicinal|O
DDI-DrugBank.d527.s5|60-67|products|O
DDI-DrugBank.d527.s5|77-89|beta-blockers|O
DDI-DrugBank.d527.s5|92-100|clonidine|O
DDI-DrugBank.d527.s5|103-114|guanethidine|O
DDI-DrugBank.d527.s5|121-129|reserpine|O
DDI-DrugBank.d527.s5|136-140|signs|O
DDI-DrugBank.d527.s5|145-156|hypoglycemia|O
DDI-DrugBank.d527.s5|158-160|may|O
DDI-DrugBank.d527.s5|165-171|reduced|O
DDI-DrugBank.d527.s5|176-181|absent|O
DDI-DrugBank.d527.s5|182-182|.|O
DDI-DrugBank.d138.s0|0-7|Although|O
DDI-DrugBank.d138.s0|9-16|specific|O
DDI-DrugBank.d138.s0|18-21|drug|O
DDI-DrugBank.d138.s0|23-33|interaction|O
DDI-DrugBank.d138.s0|35-41|studies|O
DDI-DrugBank.d138.s0|57-65|conducted|O
DDI-DrugBank.d138.s0|72-79|ALPHAGAN|O
DDI-DrugBank.d138.s0|74-74|P|O
DDI-DrugBank.d138.s0|88-98|possibility|O
DDI-DrugBank.d138.s0|106-113|additive|O
DDI-DrugBank.d138.s0|118-129|potentiating|O
DDI-DrugBank.d138.s0|131-136|effect|O
DDI-DrugBank.d138.s0|143-145|CNS|O
DDI-DrugBank.d138.s0|147-157|depressants|O
DDI-DrugBank.d138.s0|160-166|alcohol|O
DDI-DrugBank.d138.s0|169-180|barbiturates|O
DDI-DrugBank.d138.s0|183-189|opiates|O
DDI-DrugBank.d138.s0|192-200|sedatives|O
DDI-DrugBank.d138.s0|206-216|anesthetics|O
DDI-DrugBank.d138.s0|229-238|considered|O
DDI-DrugBank.d138.s0|239-239|.|O
DDI-DrugBank.d138.s1|0-13|Alpha-agonists|O
DDI-DrugBank.d138.s1|21-25|class|O
DDI-DrugBank.d138.s1|28-30|may|O
DDI-DrugBank.d138.s1|32-37|reduce|O
DDI-DrugBank.d138.s1|39-43|pulse|O
DDI-DrugBank.d138.s1|49-53|blood|O
DDI-DrugBank.d138.s1|55-62|pressure|O
DDI-DrugBank.d138.s1|63-63|.|O
DDI-DrugBank.d138.s2|0-6|Caution|O
DDI-DrugBank.d138.s2|11-15|using|O
DDI-DrugBank.d138.s2|17-27|concomitant|O
DDI-DrugBank.d138.s2|29-33|drugs|O
DDI-DrugBank.d138.s2|43-55|beta-blockers|O
DDI-DrugBank.d138.s2|58-67|ophthalmic|O
DDI-DrugBank.d138.s2|73-80|systemic|O
DDI-DrugBank.d138.s2|84-101|anti-hypertensives|O
DDI-DrugBank.d138.s2|103-108|and/or|O
DDI-DrugBank.d138.s2|110-116|cardiac|O
DDI-DrugBank.d138.s2|118-127|glycosides|O
DDI-DrugBank.d138.s2|132-138|advised|O
DDI-DrugBank.d138.s2|139-139|.|O
DDI-DrugBank.d138.s3|0-8|Tricyclic|O
DDI-DrugBank.d138.s3|10-24|antidepressants|O
DDI-DrugBank.d138.s3|36-43|reported|O
DDI-DrugBank.d138.s3|48-52|blunt|O
DDI-DrugBank.d138.s3|58-68|hypotensive|O
DDI-DrugBank.d138.s3|70-75|effect|O
DDI-DrugBank.d138.s3|80-87|systemic|O
DDI-DrugBank.d138.s3|89-100|clonidine.It|O
DDI-DrugBank.d138.s3|109-113|known|O
DDI-DrugBank.d138.s3|115-121|whether|O
DDI-DrugBank.d138.s3|127-136|concurrent|O
DDI-DrugBank.d138.s3|138-140|use|O
DDI-DrugBank.d138.s3|151-156|agents|O
DDI-DrugBank.d138.s3|163-170|ALPHAGAN|O
DDI-DrugBank.d138.s3|165-165|P|O
DDI-DrugBank.d138.s3|177-182|humans|O
DDI-DrugBank.d138.s3|188-191|lead|O
DDI-DrugBank.d138.s3|196-204|resulting|O
DDI-DrugBank.d138.s3|206-217|interference|O
DDI-DrugBank.d138.s3|228-230|IOP|O
DDI-DrugBank.d138.s3|232-239|lowering|O
DDI-DrugBank.d138.s3|70-75|effect|O
DDI-DrugBank.d138.s3|98-98|.|O
DDI-DrugBank.d138.s4|0-1|No|O
DDI-DrugBank.d138.s4|3-6|data|O
DDI-DrugBank.d138.s4|15-19|level|O
DDI-DrugBank.d138.s4|24-34|circulating|O
DDI-DrugBank.d138.s4|36-49|catecholamines|O
DDI-DrugBank.d138.s4|57-64|ALPHAGAN|O
DDI-DrugBank.d138.s4|59-59|P|O
DDI-DrugBank.d138.s4|68-81|administration|O
DDI-DrugBank.d138.s4|87-95|available|O
DDI-DrugBank.d138.s4|96-96|.|O
DDI-DrugBank.d138.s5|0-6|Caution|O
DDI-DrugBank.d138.s5|9-15|however|O
DDI-DrugBank.d138.s5|21-27|advised|O
DDI-DrugBank.d138.s5|32-39|patients|O
DDI-DrugBank.d138.s5|41-46|taking|O
DDI-DrugBank.d138.s5|48-56|tricyclic|O
DDI-DrugBank.d138.s5|58-72|antidepressants|O
DDI-DrugBank.d138.s5|84-89|affect|O
DDI-DrugBank.d138.s5|95-104|metabolism|O
DDI-DrugBank.d138.s5|110-115|uptake|O
DDI-DrugBank.d138.s5|120-130|circulating|O
DDI-DrugBank.d138.s5|132-137|amines|O
DDI-DrugBank.d138.s5|138-138|.|O
DDI-DrugBank.d167.s0|0-10|Potentially|O
DDI-DrugBank.d167.s0|12-16|fatal|O
DDI-DrugBank.d167.s0|18-21|drug|O
DDI-DrugBank.d167.s0|23-34|interactions|O
DDI-DrugBank.d167.s0|36-38|may|O
DDI-DrugBank.d167.s0|40-44|occur|O
DDI-DrugBank.d167.s0|51-64|coadministered|O
DDI-DrugBank.d167.s0|71-77|digoxin|O
DDI-DrugBank.d167.s0|36-38|may|O
DDI-DrugBank.d167.s0|92-98|enhance|O
DDI-DrugBank.d167.s0|100-113|cardiovascular|O
DDI-DrugBank.d167.s0|115-124|depression|O
DDI-DrugBank.d167.s0|130-145|bradyarrhythmias|O
DDI-DrugBank.d167.s0|36-38|may|O
DDI-DrugBank.d167.s0|40-44|occur|O
DDI-DrugBank.d167.s0|156-156|.|O
DDI-DrugBank.d167.s1|0-18|Anticholinesterases|O
DDI-DrugBank.d167.s1|21-30|neostgmine|O
DDI-DrugBank.d167.s1|33-45|physostigmine|O
DDI-DrugBank.d167.s1|49-58|lignocaine|O
DDI-DrugBank.d167.s1|61-67|quinine|O
DDI-DrugBank.d167.s1|70-81|procainamide|O
DDI-DrugBank.d167.s1|87-93|enhance|O
DDI-DrugBank.d167.s1|95-102|toxicity|O
DDI-DrugBank.d167.s1|108-112|cause|O
DDI-DrugBank.d167.s1|114-119|cardio|O
DDI-DrugBank.d167.s1|121-131|respiratory|O
DDI-DrugBank.d167.s1|133-142|depression|O
DDI-DrugBank.d167.s1|143-143|.|O
DDI-DrugBank.d167.s2|0-1|In|O
DDI-DrugBank.d167.s2|3-10|addition|O
DDI-DrugBank.d167.s2|13-25|neuromuscular|O
DDI-DrugBank.d167.s2|27-34|blocking|O
DDI-DrugBank.d167.s2|36-41|action|O
DDI-DrugBank.d167.s2|46-53|enhanced|O
DDI-DrugBank.d167.s2|58-64|general|O
DDI-DrugBank.d167.s2|66-76|anesthetics|O
DDI-DrugBank.d167.s2|79-83|local|O
DDI-DrugBank.d167.s2|66-76|anesthetics|O
DDI-DrugBank.d167.s2|97-100|like|O
DDI-DrugBank.d167.s2|102-110|lidocaine|O
DDI-DrugBank.d167.s2|113-120|procaine|O
DDI-DrugBank.d167.s2|123-135|beta-blockers|O
DDI-DrugBank.d167.s2|138-151|metaclopramide|O
DDI-DrugBank.d167.s2|154-160|lithium|O
DDI-DrugBank.d167.s2|162-170|carbonate|O
DDI-DrugBank.d167.s2|177-187|terbutaline|O
DDI-DrugBank.d167.s2|188-188|.|O
DDI-DrugBank.d84.s0|0-2|The|O
DDI-DrugBank.d84.s0|4-14|concomitant|O
DDI-DrugBank.d84.s0|16-29|administration|O
DDI-DrugBank.d84.s0|34-39|Exjade|O
DDI-DrugBank.d84.s0|45-63|aluminum-containing|O
DDI-DrugBank.d84.s0|65-71|antacid|O
DDI-DrugBank.d84.s0|73-84|preparations|O
DDI-DrugBank.d84.s0|99-106|formally|O
DDI-DrugBank.d84.s0|108-114|studied|O
DDI-DrugBank.d84.s0|115-115|.|O
DDI-DrugBank.d84.s1|0-7|Although|O
DDI-DrugBank.d84.s1|9-19|deferasirox|O
DDI-DrugBank.d84.s1|27-31|lower|O
DDI-DrugBank.d84.s1|33-40|affinity|O
DDI-DrugBank.d84.s1|46-53|aluminum|O
DDI-DrugBank.d84.s1|64-67|iron|O
DDI-DrugBank.d84.s1|70-75|Exjade|O
DDI-DrugBank.d84.s1|91-95|taken|O
DDI-DrugBank.d84.s1|102-120|aluminum-containing|O
DDI-DrugBank.d84.s1|122-128|antacid|O
DDI-DrugBank.d84.s1|130-141|preparations|O
DDI-DrugBank.d84.s2|0-1|In|O
DDI-DrugBank.d84.s2|3-9|healthy|O
DDI-DrugBank.d84.s2|11-20|volunteers|O
DDI-DrugBank.d84.s2|23-28|Exjade|O
DDI-DrugBank.d84.s2|37-42|effect|O
DDI-DrugBank.d84.s2|51-66|pharmacokinetics|O
DDI-DrugBank.d84.s2|71-77|digoxin|O
DDI-DrugBank.d84.s2|78-78|.|O
DDI-DrugBank.d84.s3|0-2|The|O
DDI-DrugBank.d84.s3|4-9|effect|O
DDI-DrugBank.d84.s3|14-20|digoxin|O
DDI-DrugBank.d84.s3|25-30|Exjade|O
DDI-DrugBank.d84.s3|32-47|pharmacokinetics|O
DDI-DrugBank.d84.s3|62-68|studied|O
DDI-DrugBank.d84.s3|69-69|.|O
DDI-DrugBank.d84.s4|0-2|The|O
DDI-DrugBank.d84.s4|4-14|concomitant|O
DDI-DrugBank.d84.s4|16-29|administration|O
DDI-DrugBank.d84.s4|34-39|Exjade|O
DDI-DrugBank.d84.s4|45-51|vitamin|O
DDI-DrugBank.d84.s4|53-53|C|O
DDI-DrugBank.d84.s4|68-75|formally|O
DDI-DrugBank.d84.s4|77-83|studied|O
DDI-DrugBank.d84.s4|84-84|.|O
DDI-DrugBank.d84.s5|0-4|Doses|O
DDI-DrugBank.d84.s5|9-15|vitamin|O
DDI-DrugBank.d84.s5|17-17|C|O
DDI-DrugBank.d84.s5|25-27|200|O
DDI-DrugBank.d84.s5|29-30|mg|O
DDI-DrugBank.d84.s5|37-43|allowed|O
DDI-DrugBank.d84.s5|48-55|clinical|O
DDI-DrugBank.d84.s5|57-63|studies|O
DDI-DrugBank.d84.s5|65-71|without|O
DDI-DrugBank.d84.s5|73-80|negative|O
DDI-DrugBank.d84.s5|82-93|consequences|O
DDI-DrugBank.d84.s5|94-94|.|O
DDI-DrugBank.d84.s6|0-2|The|O
DDI-DrugBank.d84.s6|4-14|interaction|O
DDI-DrugBank.d84.s6|19-24|Exjade|O
DDI-DrugBank.d84.s6|31-41|hydroxyurea|O
DDI-DrugBank.d84.s6|56-63|formally|O
DDI-DrugBank.d84.s6|65-71|studied|O
DDI-DrugBank.d84.s6|72-72|.|O
DDI-DrugBank.d84.s7|0-1|No|O
DDI-DrugBank.d84.s7|3-12|inhibition|O
DDI-DrugBank.d84.s7|17-27|deferasirox|O
DDI-DrugBank.d84.s7|29-38|metabolism|O
DDI-DrugBank.d84.s7|43-53|hydroxyurea|O
DDI-DrugBank.d84.s7|58-65|expected|O
DDI-DrugBank.d84.s7|67-71|based|O
DDI-DrugBank.d84.s7|80-86|results|O
DDI-DrugBank.d84.s7|97-101|vitro|O
DDI-DrugBank.d84.s7|103-107|study|O
DDI-DrugBank.d84.s7|108-108|.|O
DDI-DrugBank.d84.s8|0-5|Exjade|O
DDI-DrugBank.d84.s8|21-28|combined|O
DDI-DrugBank.d84.s8|41-44|iron|O
DDI-DrugBank.d84.s8|46-53|chelator|O
DDI-DrugBank.d84.s8|55-63|therapies|O
DDI-DrugBank.d84.s8|69-74|safety|O
DDI-DrugBank.d84.s8|84-95|combinations|O
DDI-DrugBank.d84.s8|110-120|established|O
DDI-DrugBank.d84.s8|121-121|.|O
DDI-DrugBank.d84.s9|0-8|Drug/Food|O
DDI-DrugBank.d84.s9|10-21|Interactions|O
DDI-DrugBank.d84.s9|23-25|The|O
DDI-DrugBank.d84.s9|27-41|bioavailability|O
DDI-DrugBank.d84.s9|44-46|AUC|O
DDI-DrugBank.d84.s9|52-62|deferasirox|O
DDI-DrugBank.d84.s9|68-75|variably|O
DDI-DrugBank.d84.s9|77-85|increased|O
DDI-DrugBank.d84.s9|92-96|taken|O
DDI-DrugBank.d84.s9|105-108|meal|O
DDI-DrugBank.d84.s9|109-109|.|O
DDI-DrugBank.d84.s10|0-10|Deferasirox|O
DDI-DrugBank.d84.s10|22-26|taken|O
DDI-DrugBank.d84.s10|34-38|empty|O
DDI-DrugBank.d84.s10|40-46|stomach|O
DDI-DrugBank.d84.s10|48-49|30|O
DDI-DrugBank.d84.s10|51-57|minutes|O
DDI-DrugBank.d84.s10|66-71|eating|O
DDI-DrugBank.d84.s10|72-72|.|O
DDI-DrugBank.d84.s11|0-5|Exjade|O
DDI-DrugBank.d84.s11|7-13|tablets|O
DDI-DrugBank.d84.s11|19-22|oral|O
DDI-DrugBank.d84.s11|24-33|suspension|O
DDI-DrugBank.d84.s11|42-50|dispersed|O
DDI-DrugBank.d84.s11|55-59|water|O
DDI-DrugBank.d84.s11|62-67|orange|O
DDI-DrugBank.d84.s11|69-73|juice|O
DDI-DrugBank.d84.s11|79-83|apple|O
DDI-DrugBank.d84.s11|69-73|juice|O
DDI-DrugBank.d480.s0|0-2|The|O
DDI-DrugBank.d480.s0|4-8|risks|O
DDI-DrugBank.d480.s0|13-17|using|O
DDI-DrugBank.d480.s0|19-27|Clozapine|O
DDI-DrugBank.d480.s0|32-42|combination|O
DDI-DrugBank.d480.s0|55-59|drugs|O
DDI-DrugBank.d480.s0|75-88|systematically|O
DDI-DrugBank.d480.s0|90-98|evaluated|O
DDI-DrugBank.d480.s0|99-99|.|O
DDI-DrugBank.d480.s1|0-22|Pharmacodynamic-related|O
DDI-DrugBank.d480.s1|24-35|Interactions|O
DDI-DrugBank.d480.s1|38-40|The|O
DDI-DrugBank.d480.s1|42-50|mechanism|O
DDI-DrugBank.d480.s1|55-63|Clozapine|O
DDI-DrugBank.d480.s1|65-71|induced|O
DDI-DrugBank.d480.s1|73-87|agranulocytosis|O
DDI-DrugBank.d480.s1|92-98|unknown|O
DDI-DrugBank.d480.s2|0-10|nonetheless|O
DDI-DrugBank.d480.s2|17-27|possibility|O
DDI-DrugBank.d480.s2|34-42|causative|O
DDI-DrugBank.d480.s2|44-50|factors|O
DDI-DrugBank.d480.s2|52-54|may|O
DDI-DrugBank.d480.s2|56-63|interact|O
DDI-DrugBank.d480.s2|65-79|synergistically|O
DDI-DrugBank.d480.s2|84-91|increase|O
DDI-DrugBank.d480.s2|97-100|risk|O
DDI-DrugBank.d480.s2|102-107|and/or|O
DDI-DrugBank.d480.s2|109-116|severity|O
DDI-DrugBank.d480.s2|121-124|bone|O
DDI-DrugBank.d480.s2|126-131|marrow|O
DDI-DrugBank.d480.s2|133-143|suppression|O
DDI-DrugBank.d480.s2|145-152|warrants|O
DDI-DrugBank.d480.s2|154-166|consideration|O
DDI-DrugBank.d480.s2|167-167|.|O
DDI-DrugBank.d480.s3|0-8|Therefore|O
DDI-DrugBank.d480.s3|11-19|Clozapine|O
DDI-DrugBank.d480.s3|35-38|used|O
DDI-DrugBank.d480.s3|51-56|agents|O
DDI-DrugBank.d480.s3|67-76|well-known|O
DDI-DrugBank.d480.s3|78-86|potential|O
DDI-DrugBank.d480.s3|91-98|suppress|O
DDI-DrugBank.d480.s3|100-103|bone|O
DDI-DrugBank.d480.s3|105-110|marrow|O
DDI-DrugBank.d480.s3|112-119|function|O
DDI-DrugBank.d480.s3|120-120|.|O
DDI-DrugBank.d480.s4|0-4|Given|O
DDI-DrugBank.d480.s4|10-16|primary|O
DDI-DrugBank.d480.s4|18-20|CNS|O
DDI-DrugBank.d480.s4|22-28|effects|O
DDI-DrugBank.d480.s4|33-41|Clozapine|O
DDI-DrugBank.d480.s4|44-50|caution|O
DDI-DrugBank.d480.s4|55-61|advised|O
DDI-DrugBank.d480.s4|66-70|using|O
DDI-DrugBank.d480.s4|75-87|concomitantly|O
DDI-DrugBank.d480.s4|100-109|CNS-active|O
DDI-DrugBank.d480.s4|111-115|drugs|O
DDI-DrugBank.d480.s4|120-126|alcohol|O
DDI-DrugBank.d480.s4|127-127|.|O
DDI-DrugBank.d480.s5|0-10|Orthostatic|O
DDI-DrugBank.d480.s5|12-22|hypotension|O
DDI-DrugBank.d480.s5|27-34|patients|O
DDI-DrugBank.d480.s5|36-41|taking|O
DDI-DrugBank.d480.s5|43-51|clozapine|O
DDI-DrugBank.d480.s5|61-64|rare|O
DDI-DrugBank.d480.s5|66-70|cases|O
DDI-DrugBank.d480.s5|73-85|approximately|O
DDI-DrugBank.d480.s5|87-87|1|O
DDI-DrugBank.d480.s5|66-69|case|O
DDI-DrugBank.d480.s5|94-96|per|O
DDI-DrugBank.d480.s5|98-102|3,000|O
DDI-DrugBank.d480.s5|27-34|patients|O
DDI-DrugBank.d480.s5|118-128|accompanied|O
DDI-DrugBank.d480.s5|133-140|profound|O
DDI-DrugBank.d480.s5|142-149|collapse|O
DDI-DrugBank.d480.s5|155-165|respiratory|O
DDI-DrugBank.d480.s5|167-172|and/or|O
DDI-DrugBank.d480.s5|174-180|cardiac|O
DDI-DrugBank.d480.s5|182-187|arrest|O
DDI-DrugBank.d480.s5|188-188|.|O
DDI-DrugBank.d480.s6|0-3|Some|O
DDI-DrugBank.d480.s6|12-16|cases|O
DDI-DrugBank.d480.s6|21-40|collapse/respiratory|O
DDI-DrugBank.d480.s6|42-55|arrest/cardiac|O
DDI-DrugBank.d480.s6|42-47|arrest|O
DDI-DrugBank.d480.s6|71-77|initial|O
DDI-DrugBank.d480.s6|79-87|treatment|O
DDI-DrugBank.d480.s6|89-96|occurred|O
DDI-DrugBank.d480.s6|101-108|patients|O
DDI-DrugBank.d480.s6|125-136|administered|O
DDI-DrugBank.d480.s6|138-152|benzodiazepines|O
DDI-DrugBank.d480.s7|0-6|similar|O
DDI-DrugBank.d480.s7|8-13|events|O
DDI-DrugBank.d480.s7|25-32|reported|O
DDI-DrugBank.d480.s7|37-44|patients|O
DDI-DrugBank.d480.s7|46-51|taking|O
DDI-DrugBank.d480.s7|59-70|psychotropic|O
DDI-DrugBank.d480.s7|72-76|drugs|O
DDI-DrugBank.d480.s7|8-11|even|O
DDI-DrugBank.d480.s7|86-94|Clozapine|O
DDI-DrugBank.d480.s7|105-105|.|O
DDI-DrugBank.d480.s8|0-7|Although|O
DDI-DrugBank.d480.s8|25-35|established|O
DDI-DrugBank.d480.s8|54-64|interaction|O
DDI-DrugBank.d480.s8|74-82|Clozapine|O
DDI-DrugBank.d480.s8|88-102|benzodiazepines|O
DDI-DrugBank.d480.s8|113-125|psychotropics|O
DDI-DrugBank.d480.s8|128-134|caution|O
DDI-DrugBank.d480.s8|139-145|advised|O
DDI-DrugBank.d480.s8|152-160|clozapine|O
DDI-DrugBank.d480.s8|165-173|initiated|O
DDI-DrugBank.d480.s8|178-185|patients|O
DDI-DrugBank.d480.s8|187-192|taking|O
DDI-DrugBank.d480.s8|88-101|benzodiazepine|O
DDI-DrugBank.d480.s8|113-124|psychotropic|O
DDI-DrugBank.d480.s8|237-240|drug|O
DDI-DrugBank.d480.s8|241-241|.|O
DDI-DrugBank.d480.s9|0-8|Clozapine|O
DDI-DrugBank.d480.s9|10-12|may|O
DDI-DrugBank.d480.s9|14-23|potentiate|O
DDI-DrugBank.d480.s9|29-39|hypotensive|O
DDI-DrugBank.d480.s9|41-47|effects|O
DDI-DrugBank.d480.s9|52-67|antihypertensive|O
DDI-DrugBank.d480.s9|69-73|drugs|O
DDI-DrugBank.d480.s9|83-97|anticholinergic|O
DDI-DrugBank.d480.s9|41-47|effects|O
DDI-DrugBank.d480.s9|110-122|atropine-type|O
DDI-DrugBank.d480.s9|69-73|drugs|O
DDI-DrugBank.d480.s9|129-129|.|O
DDI-DrugBank.d480.s10|0-2|The|O
DDI-DrugBank.d480.s10|4-17|administration|O
DDI-DrugBank.d480.s10|22-32|epinephrine|O
DDI-DrugBank.d480.s10|44-50|avoided|O
DDI-DrugBank.d480.s10|59-67|treatment|O
DDI-DrugBank.d480.s10|72-75|drug|O
DDI-DrugBank.d480.s10|77-83|induced|O
DDI-DrugBank.d480.s10|85-95|hypotension|O
DDI-DrugBank.d480.s10|110-117|possible|O
DDI-DrugBank.d480.s10|119-125|reverse|O
DDI-DrugBank.d480.s10|22-32|epinephrine|O
DDI-DrugBank.d480.s10|139-144|effect|O
DDI-DrugBank.d480.s10|145-145|.|O
DDI-DrugBank.d480.s11|0-22|Pharmacokinetic-related|O
DDI-DrugBank.d480.s11|24-35|Interactions|O
DDI-DrugBank.d480.s11|38-46|Clozapine|O
DDI-DrugBank.d480.s11|53-61|substrate|O
DDI-DrugBank.d480.s11|67-70|many|O
DDI-DrugBank.d480.s11|72-74|CYP|O
DDI-DrugBank.d480.s11|76-78|450|O
DDI-DrugBank.d480.s11|80-87|isozymes|O
DDI-DrugBank.d480.s11|93-102|particular|O
DDI-DrugBank.d480.s11|104-106|1A2|O
DDI-DrugBank.d480.s11|109-111|2D6|O
DDI-DrugBank.d480.s11|118-120|3A4|O
DDI-DrugBank.d480.s11|121-121|.|O
DDI-DrugBank.d480.s12|0-2|The|O
DDI-DrugBank.d480.s12|4-7|risk|O
DDI-DrugBank.d480.s12|12-20|metabolic|O
DDI-DrugBank.d480.s12|22-33|interactions|O
DDI-DrugBank.d480.s12|35-40|caused|O
DDI-DrugBank.d480.s12|48-53|effect|O
DDI-DrugBank.d480.s12|61-70|individual|O
DDI-DrugBank.d480.s12|72-78|isoform|O
DDI-DrugBank.d480.s12|83-91|therefore|O
DDI-DrugBank.d480.s12|93-101|minimized|O
DDI-DrugBank.d480.s12|102-102|.|O
DDI-DrugBank.d480.s13|0-11|Nevertheless|O
DDI-DrugBank.d480.s13|14-20|caution|O
DDI-DrugBank.d480.s13|32-35|used|O
DDI-DrugBank.d480.s13|40-47|patients|O
DDI-DrugBank.d480.s13|49-57|receiving|O
DDI-DrugBank.d480.s13|59-69|concomitant|O
DDI-DrugBank.d480.s13|71-79|treatment|O
DDI-DrugBank.d480.s13|92-96|drugs|O
DDI-DrugBank.d480.s13|107-112|either|O
DDI-DrugBank.d480.s13|114-123|inhibitors|O
DDI-DrugBank.d480.s13|128-135|inducers|O
DDI-DrugBank.d480.s13|146-152|enzymes|O
DDI-DrugBank.d480.s13|153-153|.|O
DDI-DrugBank.d480.s14|0-10|Concomitant|O
DDI-DrugBank.d480.s14|12-25|administration|O
DDI-DrugBank.d480.s14|30-34|drugs|O
DDI-DrugBank.d480.s14|36-40|known|O
DDI-DrugBank.d480.s14|45-50|induce|O
DDI-DrugBank.d480.s14|52-61|cytochrome|O
DDI-DrugBank.d480.s14|63-66|P450|O
DDI-DrugBank.d480.s14|68-74|enzymes|O
DDI-DrugBank.d480.s14|76-78|may|O
DDI-DrugBank.d480.s14|80-87|decrease|O
DDI-DrugBank.d480.s14|93-98|plasma|O
DDI-DrugBank.d480.s14|100-105|levels|O
DDI-DrugBank.d480.s14|110-118|clozapine|O
DDI-DrugBank.d480.s14|119-119|.|O
DDI-DrugBank.d480.s15|0-8|Phenytoin|O
DDI-DrugBank.d480.s15|11-18|nicotine|O
DDI-DrugBank.d480.s15|25-32|rifampin|O
DDI-DrugBank.d480.s15|34-36|may|O
DDI-DrugBank.d480.s15|38-45|decrease|O
DDI-DrugBank.d480.s15|47-55|Clozapine|O
DDI-DrugBank.d480.s15|57-62|plasma|O
DDI-DrugBank.d480.s15|64-69|levels|O
DDI-DrugBank.d480.s15|72-80|resulting|O
DDI-DrugBank.d480.s15|38-45|decrease|O
DDI-DrugBank.d480.s15|99-111|effectiveness|O
DDI-DrugBank.d480.s15|118-127|previously|O
DDI-DrugBank.d480.s15|99-107|effective|O
DDI-DrugBank.d480.s15|47-55|Clozapine|O
DDI-DrugBank.d480.s15|149-152|dose|O
DDI-DrugBank.d480.s15|153-153|.|O
DDI-DrugBank.d480.s16|0-10|Concomitant|O
DDI-DrugBank.d480.s16|12-25|administration|O
DDI-DrugBank.d480.s16|30-34|drugs|O
DDI-DrugBank.d480.s16|36-40|known|O
DDI-DrugBank.d480.s16|45-51|inhibit|O
DDI-DrugBank.d480.s16|57-64|activity|O
DDI-DrugBank.d480.s16|69-78|cytochrome|O
DDI-DrugBank.d480.s16|80-83|P450|O
DDI-DrugBank.d480.s16|85-92|isozymes|O
DDI-DrugBank.d480.s16|94-96|may|O
DDI-DrugBank.d480.s16|98-105|increase|O
DDI-DrugBank.d480.s16|111-116|plasma|O
DDI-DrugBank.d480.s16|118-123|levels|O
DDI-DrugBank.d480.s16|128-136|clozapine|O
DDI-DrugBank.d480.s16|137-137|.|O
DDI-DrugBank.d480.s17|0-9|Cimetidine|O
DDI-DrugBank.d480.s17|12-19|caffeine|O
DDI-DrugBank.d480.s17|26-37|erythromycin|O
DDI-DrugBank.d480.s17|39-41|may|O
DDI-DrugBank.d480.s17|43-50|increase|O
DDI-DrugBank.d480.s17|52-57|plasma|O
DDI-DrugBank.d480.s17|59-64|levels|O
DDI-DrugBank.d480.s17|69-77|Clozapine|O
DDI-DrugBank.d480.s17|80-90|potentially|O
DDI-DrugBank.d480.s17|92-100|resulting|O
DDI-DrugBank.d480.s17|105-111|adverse|O
DDI-DrugBank.d480.s17|113-119|effects|O
DDI-DrugBank.d480.s17|120-120|.|O
DDI-DrugBank.d480.s18|0-7|Although|O
DDI-DrugBank.d480.s18|9-19|concomitant|O
DDI-DrugBank.d480.s18|21-23|use|O
DDI-DrugBank.d480.s18|28-36|Clozapine|O
DDI-DrugBank.d480.s18|42-54|carbamazepine|O
DDI-DrugBank.d480.s18|63-73|recommended|O
DDI-DrugBank.d480.s18|89-93|noted|O
DDI-DrugBank.d480.s18|100-114|discontinuation|O
DDI-DrugBank.d480.s18|9-19|concomitant|O
DDI-DrugBank.d480.s18|42-54|carbamazepine|O
DDI-DrugBank.d480.s18|145-158|administration|O
DDI-DrugBank.d480.s18|160-162|may|O
DDI-DrugBank.d480.s18|164-169|result|O
DDI-DrugBank.d480.s18|177-184|increase|O
DDI-DrugBank.d480.s18|28-36|Clozapine|O
DDI-DrugBank.d480.s18|199-204|plasma|O
DDI-DrugBank.d480.s18|206-211|levels|O
DDI-DrugBank.d480.s18|212-212|.|O
DDI-DrugBank.d480.s19|0-1|In|O
DDI-DrugBank.d480.s19|5-9|study|O
DDI-DrugBank.d480.s19|14-26|schizophrenic|O
DDI-DrugBank.d480.s19|28-35|patients|O
DDI-DrugBank.d480.s19|41-48|received|O
DDI-DrugBank.d480.s19|50-58|clozapine|O
DDI-DrugBank.d480.s19|66-71|steady|O
DDI-DrugBank.d480.s19|73-77|state|O
DDI-DrugBank.d480.s19|79-88|conditions|O
DDI-DrugBank.d480.s19|91-101|fluvoxamine|O
DDI-DrugBank.d480.s19|106-115|paroxetine|O
DDI-DrugBank.d480.s19|121-125|added|O
DDI-DrugBank.d480.s19|130-131|16|O
DDI-DrugBank.d480.s19|137-138|14|O
DDI-DrugBank.d480.s19|28-35|patients|O
DDI-DrugBank.d480.s19|150-161|respectively|O
DDI-DrugBank.d480.s19|162-162|.|O
DDI-DrugBank.d480.s20|0-4|After|O
DDI-DrugBank.d480.s20|6-7|14|O
DDI-DrugBank.d480.s20|9-12|days|O
DDI-DrugBank.d480.s20|17-33|co-administration|O
DDI-DrugBank.d480.s20|36-39|mean|O
DDI-DrugBank.d480.s20|41-46|trough|O
DDI-DrugBank.d480.s20|48-61|concentrations|O
DDI-DrugBank.d480.s20|66-74|clozapine|O
DDI-DrugBank.d480.s20|84-94|metabolites|O
DDI-DrugBank.d480.s20|97-116|N-desmethylclozapine|O
DDI-DrugBank.d480.s20|66-74|clozapine|O
DDI-DrugBank.d480.s20|132-138|N-oxide|O
DDI-DrugBank.d480.s20|146-153|elevated|O
DDI-DrugBank.d480.s20|160-170|fluvoxamine|O
DDI-DrugBank.d480.s20|181-190|three-fold|O
DDI-DrugBank.d480.s20|192-199|compared|O
DDI-DrugBank.d480.s20|204-211|baseline|O
DDI-DrugBank.d480.s20|48-61|concentrations|O
DDI-DrugBank.d480.s20|227-227|.|O
DDI-DrugBank.d480.s21|0-9|Paroxetine|O
DDI-DrugBank.d480.s21|11-18|produced|O
DDI-DrugBank.d480.s21|25-29|minor|O
DDI-DrugBank.d480.s21|31-37|changes|O
DDI-DrugBank.d480.s21|46-51|levels|O
DDI-DrugBank.d480.s21|56-64|clozapine|O
DDI-DrugBank.d480.s21|74-84|metabolites|O
DDI-DrugBank.d480.s21|85-85|.|O
DDI-DrugBank.d480.s22|0-6|However|O
DDI-DrugBank.d480.s22|15-23|published|O
DDI-DrugBank.d480.s22|25-31|reports|O
DDI-DrugBank.d480.s22|33-40|describe|O
DDI-DrugBank.d480.s22|42-47|modest|O
DDI-DrugBank.d480.s22|49-58|elevations|O
DDI-DrugBank.d480.s22|61-64|less|O
DDI-DrugBank.d480.s22|71-78|two-fold|O
DDI-DrugBank.d480.s22|84-92|clozapine|O
DDI-DrugBank.d480.s22|98-107|metabolite|O
DDI-DrugBank.d480.s22|109-122|concentrations|O
DDI-DrugBank.d480.s22|84-92|clozapine|O
DDI-DrugBank.d480.s22|143-147|taken|O
DDI-DrugBank.d480.s22|154-163|paroxetine|O
DDI-DrugBank.d480.s22|166-175|fluoxetine|O
DDI-DrugBank.d480.s22|182-191|sertraline|O
DDI-DrugBank.d480.s23|0-8|Therefore|O
DDI-DrugBank.d480.s23|16-23|combined|O
DDI-DrugBank.d480.s23|25-33|treatment|O
DDI-DrugBank.d480.s23|45-54|approached|O
DDI-DrugBank.d480.s23|61-67|caution|O
DDI-DrugBank.d480.s23|73-80|patients|O
DDI-DrugBank.d480.s23|92-100|monitored|O
DDI-DrugBank.d480.s23|102-108|closely|O
DDI-DrugBank.d480.s23|115-123|Clozapine|O
DDI-DrugBank.d480.s23|16-23|combined|O
DDI-DrugBank.d480.s23|148-152|drugs|O
DDI-DrugBank.d480.s23|155-166|particularly|O
DDI-DrugBank.d480.s23|173-183|fluvoxamine|O
DDI-DrugBank.d480.s23|184-184|.|O
DDI-DrugBank.d480.s24|0-0|A|O
DDI-DrugBank.d480.s24|2-8|reduced|O
DDI-DrugBank.d480.s24|10-18|Clozapine|O
DDI-DrugBank.d480.s24|20-23|dose|O
DDI-DrugBank.d480.s24|35-44|considered|O
DDI-DrugBank.d480.s24|45-45|.|O
DDI-DrugBank.d480.s25|0-0|A|O
DDI-DrugBank.d480.s25|2-7|subset|O
DDI-DrugBank.d480.s25|10-10|3|O
DDI-DrugBank.d480.s25|11-11|%|O
DDI-DrugBank.d480.s25|12-14|-10|O
DDI-DrugBank.d480.s25|11-11|%|O
DDI-DrugBank.d480.s25|25-34|population|O
DDI-DrugBank.d480.s25|40-46|reduced|O
DDI-DrugBank.d480.s25|48-55|activity|O
DDI-DrugBank.d480.s25|60-66|certain|O
DDI-DrugBank.d480.s25|68-71|drug|O
DDI-DrugBank.d480.s25|73-84|metabolizing|O
DDI-DrugBank.d480.s25|86-92|enzymes|O
DDI-DrugBank.d480.s25|106-115|cytochrome|O
DDI-DrugBank.d480.s25|117-120|P450|O
DDI-DrugBank.d480.s25|122-128|isozyme|O
DDI-DrugBank.d480.s25|117-120|P450|O
DDI-DrugBank.d480.s25|135-137|2D6|O
DDI-DrugBank.d480.s25|138-138|.|O
DDI-DrugBank.d480.s26|0-3|Such|O
DDI-DrugBank.d480.s26|5-15|individuals|O
DDI-DrugBank.d480.s26|21-28|referred|O
DDI-DrugBank.d480.s26|36-39|poor|O
DDI-DrugBank.d480.s26|41-52|metabolizers|O
DDI-DrugBank.d480.s26|57-61|drugs|O
DDI-DrugBank.d480.s26|71-81|debrisoquin|O
DDI-DrugBank.d480.s26|84-99|dextromethorphan|O
DDI-DrugBank.d480.s26|106-114|tricyclic|O
DDI-DrugBank.d480.s26|116-130|antidepressants|O
DDI-DrugBank.d480.s26|137-145|clozapine|O
DDI-DrugBank.d480.s26|146-146|.|O
DDI-DrugBank.d480.s27|0-4|These|O
DDI-DrugBank.d480.s27|6-16|individuals|O
DDI-DrugBank.d480.s27|18-20|may|O
DDI-DrugBank.d480.s27|22-28|develop|O
DDI-DrugBank.d480.s27|30-35|higher|O
DDI-DrugBank.d480.s27|42-49|expected|O
DDI-DrugBank.d480.s27|51-56|plasma|O
DDI-DrugBank.d480.s27|58-71|concentrations|O
DDI-DrugBank.d480.s27|76-84|clozapine|O
DDI-DrugBank.d480.s27|91-95|given|O
DDI-DrugBank.d480.s27|97-101|usual|O
DDI-DrugBank.d480.s27|103-107|doses|O
DDI-DrugBank.d480.s27|108-108|.|O
DDI-DrugBank.d480.s28|0-1|In|O
DDI-DrugBank.d480.s28|3-10|addition|O
DDI-DrugBank.d480.s28|13-19|certain|O
DDI-DrugBank.d480.s28|21-25|drugs|O
DDI-DrugBank.d480.s28|36-46|metabolized|O
DDI-DrugBank.d480.s28|56-62|isozyme|O
DDI-DrugBank.d480.s28|65-73|including|O
DDI-DrugBank.d480.s28|75-78|many|O
DDI-DrugBank.d480.s28|80-94|antidepressants|O
DDI-DrugBank.d480.s28|97-105|clozapine|O
DDI-DrugBank.d480.s28|108-116|selective|O
DDI-DrugBank.d480.s28|118-126|serotonin|O
DDI-DrugBank.d480.s28|128-135|reuptake|O
DDI-DrugBank.d480.s28|137-146|inhibitors|O
DDI-DrugBank.d480.s28|153-158|others|O
DDI-DrugBank.d480.s28|162-164|may|O
DDI-DrugBank.d480.s28|137-143|inhibit|O
DDI-DrugBank.d480.s28|178-185|activity|O
DDI-DrugBank.d480.s28|56-62|isozyme|O
DDI-DrugBank.d480.s28|208-211|thus|O
DDI-DrugBank.d480.s28|162-164|may|O
DDI-DrugBank.d480.s28|217-220|make|O
DDI-DrugBank.d480.s28|222-227|normal|O
DDI-DrugBank.d480.s28|229-240|metabolizers|O
DDI-DrugBank.d480.s28|242-249|resemble|O
DDI-DrugBank.d480.s28|251-254|poor|O
DDI-DrugBank.d480.s28|229-240|metabolizers|O
DDI-DrugBank.d480.s28|274-279|regard|O
DDI-DrugBank.d480.s28|284-294|concomitant|O
DDI-DrugBank.d480.s28|296-302|therapy|O
DDI-DrugBank.d480.s28|21-25|drugs|O
DDI-DrugBank.d480.s28|36-46|metabolized|O
DDI-DrugBank.d480.s28|341-346|enzyme|O
DDI-DrugBank.d480.s28|348-353|system|O
DDI-DrugBank.d480.s28|356-362|leading|O
DDI-DrugBank.d480.s28|21-24|drug|O
DDI-DrugBank.d480.s28|372-382|interaction|O
DDI-DrugBank.d480.s28|383-383|.|O
DDI-DrugBank.d480.s29|0-10|Concomitant|O
DDI-DrugBank.d480.s29|12-14|use|O
DDI-DrugBank.d480.s29|19-27|clozapine|O
DDI-DrugBank.d480.s29|40-44|drugs|O
DDI-DrugBank.d480.s29|46-56|metabolized|O
DDI-DrugBank.d480.s29|61-70|cytochrome|O
DDI-DrugBank.d480.s29|72-75|P450|O
DDI-DrugBank.d480.s29|77-79|2D6|O
DDI-DrugBank.d480.s29|81-83|may|O
DDI-DrugBank.d480.s29|85-91|require|O
DDI-DrugBank.d480.s29|93-97|lower|O
DDI-DrugBank.d480.s29|99-103|doses|O
DDI-DrugBank.d480.s29|110-116|usually|O
DDI-DrugBank.d480.s29|118-127|prescribed|O
DDI-DrugBank.d480.s29|133-138|either|O
DDI-DrugBank.d480.s29|19-27|clozapine|O
DDI-DrugBank.d480.s29|40-43|drug|O
DDI-DrugBank.d480.s29|167-167|.|O
DDI-DrugBank.d480.s30|0-8|Therefore|O
DDI-DrugBank.d480.s30|11-27|co-administration|O
DDI-DrugBank.d480.s30|32-40|clozapine|O
DDI-DrugBank.d480.s30|53-57|drugs|O
DDI-DrugBank.d480.s30|68-78|metabolized|O
DDI-DrugBank.d480.s30|88-94|isozyme|O
DDI-DrugBank.d480.s30|97-105|including|O
DDI-DrugBank.d480.s30|107-121|antidepressants|O
DDI-DrugBank.d480.s30|124-137|phenothiazines|O
DDI-DrugBank.d480.s30|140-152|carbamazepine|O
DDI-DrugBank.d480.s30|159-162|Type|O
DDI-DrugBank.d480.s30|164-165|1C|O
DDI-DrugBank.d480.s30|167-181|antiarrhythmics|O
DDI-DrugBank.d480.s30|184-187|e.g.|O
DDI-DrugBank.d480.s30|190-200|propafenone|O
DDI-DrugBank.d480.s30|203-212|flecainide|O
DDI-DrugBank.d480.s30|218-226|encainide|O
DDI-DrugBank.d480.s30|238-244|inhibit|O
DDI-DrugBank.d480.s30|251-256|enzyme|O
DDI-DrugBank.d480.s30|184-187|e.g.|O
DDI-DrugBank.d480.s30|265-273|quinidine|O
DDI-DrugBank.d480.s30|287-296|approached|O
DDI-DrugBank.d480.s30|303-309|caution|O
DDI-DrugBank.d480.s30|185-185|.|O
DDI-DrugBank.d337.s0|0-7|Warfarin|O
DDI-DrugBank.d337.s0|10-20|Concomitant|O
DDI-DrugBank.d337.s0|22-35|administration|O
DDI-DrugBank.d337.s0|40-49|daptomycin|O
DDI-DrugBank.d337.s0|52-52|6|O
DDI-DrugBank.d337.s0|54-58|mg/kg|O
DDI-DrugBank.d337.s0|65-69|every|O
DDI-DrugBank.d337.s0|71-72|24|O
DDI-DrugBank.d337.s0|74-78|hours|O
DDI-DrugBank.d337.s0|84-84|5|O
DDI-DrugBank.d337.s0|86-89|days|O
DDI-DrugBank.d337.s0|96-103|warfarin|O
DDI-DrugBank.d337.s0|106-107|25|O
DDI-DrugBank.d337.s0|54-55|mg|O
DDI-DrugBank.d337.s0|112-117|single|O
DDI-DrugBank.d337.s0|119-122|oral|O
DDI-DrugBank.d337.s0|124-127|dose|O
DDI-DrugBank.d337.s0|137-147|significant|O
DDI-DrugBank.d337.s0|149-154|effect|O
DDI-DrugBank.d337.s0|163-178|pharmacokinetics|O
DDI-DrugBank.d337.s0|183-188|either|O
DDI-DrugBank.d337.s0|190-193|drug|O
DDI-DrugBank.d337.s0|204-206|INR|O
DDI-DrugBank.d337.s0|216-228|significantly|O
DDI-DrugBank.d337.s0|230-236|altered|O
DDI-DrugBank.d337.s0|237-237|.|O
DDI-DrugBank.d337.s1|0-6|HMG-CoA|O
DDI-DrugBank.d337.s1|8-16|Reductase|O
DDI-DrugBank.d337.s1|18-27|Inhibitors|O
DDI-DrugBank.d337.s1|18-27|Inhibitors|O
DDI-DrugBank.d337.s1|0-6|HMG-CoA|O
DDI-DrugBank.d337.s1|52-60|reductase|O
DDI-DrugBank.d337.s1|62-64|may|O
DDI-DrugBank.d337.s1|66-70|cause|O
DDI-DrugBank.d337.s1|72-79|myopathy|O
DDI-DrugBank.d337.s1|91-100|manifested|O
DDI-DrugBank.d337.s1|105-110|muscle|O
DDI-DrugBank.d337.s1|112-115|pain|O
DDI-DrugBank.d337.s1|120-127|weakness|O
DDI-DrugBank.d337.s1|129-138|associated|O
DDI-DrugBank.d337.s1|145-152|elevated|O
DDI-DrugBank.d337.s1|154-159|levels|O
DDI-DrugBank.d337.s1|164-166|CPK|O
DDI-DrugBank.d337.s1|167-167|.|O
DDI-DrugBank.d337.s2|0-4|There|O
DDI-DrugBank.d337.s2|14-20|reports|O
DDI-DrugBank.d337.s2|25-32|skeletal|O
DDI-DrugBank.d337.s2|34-41|myopathy|O
DDI-DrugBank.d337.s2|48-65|placebo-controlled|O
DDI-DrugBank.d337.s2|67-71|Phase|O
DDI-DrugBank.d337.s2|73-73|I|O
DDI-DrugBank.d337.s2|75-79|trial|O
DDI-DrugBank.d337.s2|90-91|10|O
DDI-DrugBank.d337.s2|93-99|healthy|O
DDI-DrugBank.d337.s2|101-108|subjects|O
DDI-DrugBank.d337.s2|113-118|stable|O
DDI-DrugBank.d337.s2|120-130|simvastatin|O
DDI-DrugBank.d337.s2|132-138|therapy|O
DDI-DrugBank.d337.s2|145-151|treated|O
DDI-DrugBank.d337.s2|153-164|concurrently|O
DDI-DrugBank.d337.s2|171-180|daptomycin|O
DDI-DrugBank.d337.s2|183-183|4|O
DDI-DrugBank.d337.s2|185-189|mg/kg|O
DDI-DrugBank.d337.s2|196-200|every|O
DDI-DrugBank.d337.s2|202-203|24|O
DDI-DrugBank.d337.s2|205-209|hours|O
DDI-DrugBank.d337.s2|216-217|14|O
DDI-DrugBank.d337.s2|219-222|days|O
DDI-DrugBank.d337.s2|223-223|.|O
DDI-DrugBank.d337.s3|0-9|Experience|O
DDI-DrugBank.d337.s3|16-32|co-administration|O
DDI-DrugBank.d337.s3|37-43|HMG-CoA|O
DDI-DrugBank.d337.s3|45-53|reductase|O
DDI-DrugBank.d337.s3|55-64|inhibitors|O
DDI-DrugBank.d337.s3|70-77|Fentanyl|O
DDI-DrugBank.d337.s3|82-89|patients|O
DDI-DrugBank.d337.s3|94-100|limited|O
DDI-DrugBank.d337.s3|102-110|therefore|O
DDI-DrugBank.d337.s3|112-124|consideration|O
DDI-DrugBank.d337.s3|136-140|given|O
DDI-DrugBank.d337.s3|145-155|temporarily|O
DDI-DrugBank.d337.s3|157-166|suspending|O
DDI-DrugBank.d337.s3|168-170|use|O
DDI-DrugBank.d337.s3|37-43|HMG-CoA|O
DDI-DrugBank.d337.s3|45-53|reductase|O
DDI-DrugBank.d337.s3|55-64|inhibitors|O
DDI-DrugBank.d337.s3|82-89|patients|O
DDI-DrugBank.d337.s3|216-224|receiving|O
DDI-DrugBank.d337.s3|70-77|Fentanyl|O
DDI-DrugBank.d337.s3|234-234|.|O
DDI-DrugBank.d337.s4|0-14|Drug-Laboratory|O
DDI-DrugBank.d337.s4|16-19|Test|O
DDI-DrugBank.d337.s4|21-32|Interactions|O
DDI-DrugBank.d337.s4|35-39|There|O
DDI-DrugBank.d337.s4|48-55|reported|O
DDI-DrugBank.d337.s4|57-71|drug-laboratory|O
DDI-DrugBank.d337.s4|73-76|test|O
DDI-DrugBank.d337.s4|78-89|interactions|O
DDI-DrugBank.d337.s4|90-90|.|O
DDI-DrugBank.d356.s0|0-3|When|O
DDI-DrugBank.d356.s0|5-13|amiloride|O
DDI-DrugBank.d356.s0|15-17|HCl|O
DDI-DrugBank.d356.s0|22-33|administered|O
DDI-DrugBank.d356.s0|35-47|concomitantly|O
DDI-DrugBank.d356.s0|57-78|angiotensin-converting|O
DDI-DrugBank.d356.s0|80-85|enzyme|O
DDI-DrugBank.d356.s0|87-95|inhibitor|O
DDI-DrugBank.d356.s0|102-105|risk|O
DDI-DrugBank.d356.s0|110-121|hyperkalemia|O
DDI-DrugBank.d356.s0|123-125|may|O
DDI-DrugBank.d356.s0|130-138|increased|O
DDI-DrugBank.d356.s0|139-139|.|O
DDI-DrugBank.d356.s1|0-8|Therefore|O
DDI-DrugBank.d356.s1|14-24|concomitant|O
DDI-DrugBank.d356.s1|26-28|use|O
DDI-DrugBank.d356.s1|39-44|agents|O
DDI-DrugBank.d356.s1|49-57|indicated|O
DDI-DrugBank.d356.s1|70-81|demonstrated|O
DDI-DrugBank.d356.s1|83-93|hypokalemia|O
DDI-DrugBank.d356.s1|111-114|used|O
DDI-DrugBank.d356.s1|121-127|caution|O
DDI-DrugBank.d356.s1|138-145|frequent|O
DDI-DrugBank.d356.s1|147-156|monitoring|O
DDI-DrugBank.d356.s1|161-165|serum|O
DDI-DrugBank.d356.s1|167-175|potassium|O
DDI-DrugBank.d356.s1|176-176|.|O
DDI-DrugBank.d356.s2|0-6|Lithium|O
DDI-DrugBank.d356.s2|8-16|generally|O
DDI-DrugBank.d356.s2|32-36|given|O
DDI-DrugBank.d356.s2|43-51|diuretics|O
DDI-DrugBank.d356.s2|66-71|reduce|O
DDI-DrugBank.d356.s2|77-81|renal|O
DDI-DrugBank.d356.s2|83-91|clearance|O
DDI-DrugBank.d356.s2|97-99|add|O
DDI-DrugBank.d356.s2|103-106|high|O
DDI-DrugBank.d356.s2|108-111|risk|O
DDI-DrugBank.d356.s2|116-122|lithium|O
DDI-DrugBank.d356.s2|124-131|toxicity|O
DDI-DrugBank.d356.s2|132-132|.|O
DDI-DrugBank.d356.s3|0-3|Read|O
DDI-DrugBank.d356.s3|5-13|circulars|O
DDI-DrugBank.d356.s3|19-25|lithium|O
DDI-DrugBank.d356.s3|27-38|preparations|O
DDI-DrugBank.d356.s3|47-49|use|O
DDI-DrugBank.d356.s3|59-69|concomitant|O
DDI-DrugBank.d356.s3|71-77|therapy|O
DDI-DrugBank.d356.s3|78-78|.|O
DDI-DrugBank.d356.s4|0-1|In|O
DDI-DrugBank.d356.s4|8-15|patients|O
DDI-DrugBank.d356.s4|22-35|administration|O
DDI-DrugBank.d356.s4|42-54|non-steroidal|O
DDI-DrugBank.d356.s4|56-72|anti-inflammatory|O
DDI-DrugBank.d356.s4|74-78|agent|O
DDI-DrugBank.d356.s4|84-89|reduce|O
DDI-DrugBank.d356.s4|95-102|diuretic|O
DDI-DrugBank.d356.s4|105-115|natriuretic|O
DDI-DrugBank.d356.s4|122-137|antihypertensive|O
DDI-DrugBank.d356.s4|139-145|effects|O
DDI-DrugBank.d356.s4|150-153|loop|O
DDI-DrugBank.d356.s4|156-172|potassium-sparing|O
DDI-DrugBank.d356.s4|178-185|thiazide|O
DDI-DrugBank.d356.s4|187-195|diuretics|O
DDI-DrugBank.d356.s4|196-196|.|O
DDI-DrugBank.d356.s5|0-8|Therefore|O
DDI-DrugBank.d356.s5|16-22|MIDAMOR|O
DDI-DrugBank.d356.s5|28-40|non-steroidal|O
DDI-DrugBank.d356.s5|42-58|anti-inflammatory|O
DDI-DrugBank.d356.s5|60-65|agents|O
DDI-DrugBank.d356.s5|71-74|used|O
DDI-DrugBank.d356.s5|76-88|concomitantly|O
DDI-DrugBank.d356.s5|95-101|patient|O
DDI-DrugBank.d356.s5|113-120|observed|O
DDI-DrugBank.d356.s5|122-128|closely|O
DDI-DrugBank.d356.s5|133-141|determine|O
DDI-DrugBank.d356.s5|150-156|desired|O
DDI-DrugBank.d356.s5|158-163|effect|O
DDI-DrugBank.d356.s5|172-179|diuretic|O
DDI-DrugBank.d356.s5|184-191|obtained|O
DDI-DrugBank.d356.s5|192-192|.|O
DDI-DrugBank.d356.s6|0-4|Since|O
DDI-DrugBank.d356.s6|6-17|indomethacin|O
DDI-DrugBank.d356.s6|23-39|potassium-sparing|O
DDI-DrugBank.d356.s6|41-49|diuretics|O
DDI-DrugBank.d356.s6|52-60|including|O
DDI-DrugBank.d356.s6|62-68|MIDAMOR|O
DDI-DrugBank.d356.s6|71-73|may|O
DDI-DrugBank.d356.s6|83-92|associated|O
DDI-DrugBank.d356.s6|99-107|increased|O
DDI-DrugBank.d356.s6|109-113|serum|O
DDI-DrugBank.d356.s6|23-31|potassium|O
DDI-DrugBank.d356.s6|125-130|levels|O
DDI-DrugBank.d356.s6|137-145|potential|O
DDI-DrugBank.d356.s6|147-153|effects|O
DDI-DrugBank.d356.s6|23-31|potassium|O
DDI-DrugBank.d356.s6|168-175|kinetics|O
DDI-DrugBank.d356.s6|181-185|renal|O
DDI-DrugBank.d356.s6|187-194|function|O
DDI-DrugBank.d356.s6|206-215|considered|O
DDI-DrugBank.d356.s6|228-233|agents|O
DDI-DrugBank.d356.s6|239-250|administered|O
DDI-DrugBank.d356.s6|252-263|concurrently|O
DDI-DrugBank.d356.s6|264-264|.|O
DDI-DrugBank.d434.s0|0-2|The|O
DDI-DrugBank.d434.s0|4-7|drug|O
DDI-DrugBank.d434.s0|9-19|interaction|O
DDI-DrugBank.d434.s0|21-24|data|O
DDI-DrugBank.d434.s0|26-34|described|O
DDI-DrugBank.d434.s0|44-50|section|O
DDI-DrugBank.d434.s0|57-64|obtained|O
DDI-DrugBank.d434.s0|71-80|controlled|O
DDI-DrugBank.d434.s0|82-89|clinical|O
DDI-DrugBank.d434.s0|91-96|trials|O
DDI-DrugBank.d434.s0|102-108|studies|O
DDI-DrugBank.d434.s0|110-118|involving|O
DDI-DrugBank.d434.s0|120-128|otherwise|O
DDI-DrugBank.d434.s0|130-136|healthy|O
DDI-DrugBank.d434.s0|138-143|adults|O
DDI-DrugBank.d434.s0|150-157|epilepsy|O
DDI-DrugBank.d434.s0|158-158|.|O
DDI-DrugBank.d434.s1|0-2|Use|O
DDI-DrugBank.d434.s1|7-17|Conjunction|O
DDI-DrugBank.d434.s1|24-28|Other|O
DDI-DrugBank.d434.s1|30-42|Antiepileptic|O
DDI-DrugBank.d434.s1|44-48|Drugs|O
DDI-DrugBank.d434.s1|51-53|The|O
DDI-DrugBank.d434.s1|55-62|addition|O
DDI-DrugBank.d434.s1|67-74|Felbatol|O
DDI-DrugBank.d434.s1|80-92|antiepileptic|O
DDI-DrugBank.d434.s1|94-98|drugs|O
DDI-DrugBank.d434.s1|101-104|AEDs|O
DDI-DrugBank.d434.s1|107-113|affects|O
DDI-DrugBank.d434.s1|119-130|steady-state|O
DDI-DrugBank.d434.s1|132-137|plasma|O
DDI-DrugBank.d434.s1|139-152|concentrations|O
DDI-DrugBank.d434.s1|101-104|AEDs|O
DDI-DrugBank.d434.s1|161-161|.|O
DDI-DrugBank.d434.s2|0-2|The|O
DDI-DrugBank.d434.s2|4-6|net|O
DDI-DrugBank.d434.s2|8-13|effect|O
DDI-DrugBank.d434.s2|24-35|interactions|O
DDI-DrugBank.d434.s2|40-49|summarized|O
DDI-DrugBank.d434.s2|58-66|following|O
DDI-DrugBank.d434.s2|68-72|table|O
DDI-DrugBank.d434.s2|75-77|AED|O
DDI-DrugBank.d434.s2|75-77|AED|O
DDI-DrugBank.d434.s2|83-90|Felbatol|O
DDI-DrugBank.d434.s3|0-13|Coadministered|O
DDI-DrugBank.d434.s3|15-27|Concentration|O
DDI-DrugBank.d434.s3|15-27|Concentration|O
DDI-DrugBank.d434.s4|0-8|Phenytoin|O
DDI-DrugBank.d434.s5|0-8|Valproate|O
DDI-DrugBank.d434.s5|13-13|*|O
DDI-DrugBank.d434.s5|13-13|*|O
DDI-DrugBank.d434.s6|0-12|Carbamazepine|O
DDI-DrugBank.d434.s6|15-17|CBZ|O
DDI-DrugBank.d434.s7|0-0|*|O
DDI-DrugBank.d434.s7|1-3|CBZ|O
DDI-DrugBank.d434.s7|5-11|epoxide|O
DDI-DrugBank.d434.s8|0-12|Phenobarbital|O
DDI-DrugBank.d434.s9|0-0|*|O
DDI-DrugBank.d434.s9|1-3|Not|O
DDI-DrugBank.d434.s9|5-16|administered|O
DDI-DrugBank.d434.s9|26-31|active|O
DDI-DrugBank.d434.s9|33-42|metabolite|O
DDI-DrugBank.d434.s9|47-59|carbamazepine|O
DDI-DrugBank.d434.s9|60-60|.|O
DDI-DrugBank.d434.s10|0-0|*|O
DDI-DrugBank.d434.s10|0-0|*|O
DDI-DrugBank.d434.s10|2-3|No|O
DDI-DrugBank.d434.s10|5-15|significant|O
DDI-DrugBank.d434.s10|17-22|effect|O
DDI-DrugBank.d434.s10|23-23|.|O
DDI-DrugBank.d434.s11|0-7|Specific|O
DDI-DrugBank.d434.s11|9-15|Effects|O
DDI-DrugBank.d434.s11|20-27|Felbatol|O
DDI-DrugBank.d434.s11|33-37|Other|O
DDI-DrugBank.d434.s11|39-51|Antiepileptic|O
DDI-DrugBank.d434.s11|53-57|Drugs|O
DDI-DrugBank.d434.s11|59-67|Phenytoin|O
DDI-DrugBank.d434.s11|20-27|Felbatol|O
DDI-DrugBank.d434.s11|80-85|causes|O
DDI-DrugBank.d434.s11|90-97|increase|O
DDI-DrugBank.d434.s11|102-113|steady-state|O
DDI-DrugBank.d434.s11|115-123|phenytoin|O
DDI-DrugBank.d434.s11|125-130|plasma|O
DDI-DrugBank.d434.s11|132-145|concentrations|O
DDI-DrugBank.d434.s11|146-146|.|O
DDI-DrugBank.d434.s12|0-1|In|O
DDI-DrugBank.d434.s12|3-4|10|O
DDI-DrugBank.d434.s12|6-14|otherwise|O
DDI-DrugBank.d434.s12|16-22|healthy|O
DDI-DrugBank.d434.s12|24-31|subjects|O
DDI-DrugBank.d434.s12|38-45|epilepsy|O
DDI-DrugBank.d434.s12|47-55|ingesting|O
DDI-DrugBank.d434.s12|57-65|phenytoin|O
DDI-DrugBank.d434.s12|72-82|steadystate|O
DDI-DrugBank.d434.s12|84-89|trough|O
DDI-DrugBank.d434.s12|92-95|Cmin|O
DDI-DrugBank.d434.s12|57-65|phenytoin|O
DDI-DrugBank.d434.s12|108-113|plasma|O
DDI-DrugBank.d434.s12|115-127|concentration|O
DDI-DrugBank.d434.s12|133-134|17|O
DDI-DrugBank.d434.s12|136-136|5|O
DDI-DrugBank.d434.s12|138-150|micrograms/mL|O
DDI-DrugBank.d434.s12|151-151|.|O
DDI-DrugBank.d434.s13|0-2|The|O
DDI-DrugBank.d434.s13|4-15|steady-state|O
DDI-DrugBank.d434.s13|17-20|Cmin|O
DDI-DrugBank.d434.s13|22-30|increased|O
DDI-DrugBank.d434.s13|35-36|21|O
DDI-DrugBank.d434.s13|38-38|5|O
DDI-DrugBank.d434.s13|40-52|micrograms/mL|O
DDI-DrugBank.d434.s13|59-62|1200|O
DDI-DrugBank.d434.s13|64-69|mg/day|O
DDI-DrugBank.d434.s13|74-82|felbamate|O
DDI-DrugBank.d434.s13|88-101|coadministered|O
DDI-DrugBank.d434.s13|102-102|.|O
DDI-DrugBank.d434.s14|0-9|Increasing|O
DDI-DrugBank.d434.s14|15-23|felbamate|O
DDI-DrugBank.d434.s14|25-28|dose|O
DDI-DrugBank.d434.s14|33-36|1800|O
DDI-DrugBank.d434.s14|38-43|mg/day|O
DDI-DrugBank.d434.s14|48-50|six|O
DDI-DrugBank.d434.s14|61-68|subjects|O
DDI-DrugBank.d434.s14|70-78|increased|O
DDI-DrugBank.d434.s14|84-95|steady-state|O
DDI-DrugBank.d434.s14|97-105|phenytoin|O
DDI-DrugBank.d434.s14|107-110|Cmin|O
DDI-DrugBank.d434.s14|115-116|25|O
DDI-DrugBank.d434.s14|118-118|7|O
DDI-DrugBank.d434.s14|120-132|micrograms/mL|O
DDI-DrugBank.d434.s14|133-133|.|O
DDI-DrugBank.d434.s15|0-1|In|O
DDI-DrugBank.d434.s15|3-7|order|O
DDI-DrugBank.d434.s15|12-19|maintain|O
DDI-DrugBank.d434.s15|21-29|phenytoin|O
DDI-DrugBank.d434.s15|31-36|levels|O
DDI-DrugBank.d434.s15|39-43|limit|O
DDI-DrugBank.d434.s15|45-51|adverse|O
DDI-DrugBank.d434.s15|53-63|experiences|O
DDI-DrugBank.d434.s15|70-76|achieve|O
DDI-DrugBank.d434.s15|82-90|felbamate|O
DDI-DrugBank.d434.s15|92-95|dose|O
DDI-DrugBank.d434.s15|100-103|3600|O
DDI-DrugBank.d434.s15|105-110|mg/day|O
DDI-DrugBank.d434.s15|21-29|phenytoin|O
DDI-DrugBank.d434.s15|92-95|dose|O
DDI-DrugBank.d434.s15|130-138|reduction|O
DDI-DrugBank.d434.s15|143-155|approximately|O
DDI-DrugBank.d434.s15|157-158|40|O
DDI-DrugBank.d434.s15|159-159|%|O
DDI-DrugBank.d434.s15|165-173|necessary|O
DDI-DrugBank.d434.s15|179-183|eight|O
DDI-DrugBank.d434.s15|194-195|10|O
DDI-DrugBank.d434.s15|197-204|subjects|O
DDI-DrugBank.d434.s15|205-205|.|O
DDI-DrugBank.d434.s16|0-1|In|O
DDI-DrugBank.d434.s16|5-14|controlled|O
DDI-DrugBank.d434.s16|16-23|clinical|O
DDI-DrugBank.d434.s16|25-29|trial|O
DDI-DrugBank.d434.s16|34-35|20|O
DDI-DrugBank.d434.s16|36-36|%|O
DDI-DrugBank.d434.s16|38-46|reduction|O
DDI-DrugBank.d434.s16|55-63|phenytoin|O
DDI-DrugBank.d434.s16|65-68|dose|O
DDI-DrugBank.d434.s16|77-86|initiation|O
DDI-DrugBank.d434.s16|91-98|Felbatol|O
DDI-DrugBank.d434.s16|101-107|therapy|O
DDI-DrugBank.d434.s16|109-116|resulted|O
DDI-DrugBank.d434.s16|55-63|phenytoin|O
DDI-DrugBank.d434.s16|131-136|levels|O
DDI-DrugBank.d434.s16|138-147|comparable|O
DDI-DrugBank.d434.s16|158-162|prior|O
DDI-DrugBank.d434.s16|91-98|Felbatol|O
DDI-DrugBank.d434.s16|177-190|administration|O
DDI-DrugBank.d434.s16|191-191|.|O
DDI-DrugBank.d434.s17|0-12|Carbamazepine|O
DDI-DrugBank.d434.s17|15-22|Felbatol|O
DDI-DrugBank.d434.s17|25-30|causes|O
DDI-DrugBank.d434.s17|34-41|decrease|O
DDI-DrugBank.d434.s17|50-61|steady-state|O
DDI-DrugBank.d434.s17|63-75|carbamazepine|O
DDI-DrugBank.d434.s17|77-82|plasma|O
DDI-DrugBank.d434.s17|84-97|concentrations|O
DDI-DrugBank.d434.s17|106-113|increase|O
DDI-DrugBank.d434.s17|50-61|steady-state|O
DDI-DrugBank.d434.s17|63-75|carbamazepine|O
DDI-DrugBank.d434.s17|149-155|epoxide|O
DDI-DrugBank.d434.s17|77-82|plasma|O
DDI-DrugBank.d434.s17|84-96|concentration|O
DDI-DrugBank.d434.s17|177-177|.|O
DDI-DrugBank.d434.s18|0-1|In|O
DDI-DrugBank.d434.s18|3-6|nine|O
DDI-DrugBank.d434.s18|8-16|otherwise|O
DDI-DrugBank.d434.s18|18-24|healthy|O
DDI-DrugBank.d434.s18|26-33|subjects|O
DDI-DrugBank.d434.s18|40-47|epilepsy|O
DDI-DrugBank.d434.s18|49-57|ingesting|O
DDI-DrugBank.d434.s18|59-71|carbamazepine|O
DDI-DrugBank.d434.s18|78-89|steady-state|O
DDI-DrugBank.d434.s18|91-96|trough|O
DDI-DrugBank.d434.s18|99-102|Cmin|O
DDI-DrugBank.d434.s18|59-71|carbamazepine|O
DDI-DrugBank.d434.s18|119-131|concentration|O
DDI-DrugBank.d434.s18|137-137|8|O
DDI-DrugBank.d434.s18|139-139|2|O
DDI-DrugBank.d434.s18|141-153|micrograms/mL|O
DDI-DrugBank.d434.s18|154-154|.|O
DDI-DrugBank.d434.s19|0-2|The|O
DDI-DrugBank.d434.s19|4-16|carbamazepine|O
DDI-DrugBank.d434.s19|18-29|steady-state|O
DDI-DrugBank.d434.s19|31-34|Cmin|O
DDI-DrugBank.d434.s19|36-44|decreased|O
DDI-DrugBank.d434.s19|46-47|31|O
DDI-DrugBank.d434.s19|48-48|%|O
DDI-DrugBank.d434.s19|53-53|5|O
DDI-DrugBank.d434.s19|47-47|1|O
DDI-DrugBank.d434.s19|57-69|micrograms/mL|O
DDI-DrugBank.d434.s19|76-84|felbamate|O
DDI-DrugBank.d434.s19|87-90|3000|O
DDI-DrugBank.d434.s19|92-97|mg/day|O
DDI-DrugBank.d434.s19|100-106|divided|O
DDI-DrugBank.d434.s19|113-117|three|O
DDI-DrugBank.d434.s19|119-123|doses|O
DDI-DrugBank.d434.s19|130-143|coadministered|O
DDI-DrugBank.d434.s19|144-144|.|O
DDI-DrugBank.d434.s20|0-12|Carbamazepine|O
DDI-DrugBank.d434.s20|14-20|epoxide|O
DDI-DrugBank.d434.s20|22-33|steady-state|O
DDI-DrugBank.d434.s20|35-38|Cmin|O
DDI-DrugBank.d434.s20|40-53|concentrations|O
DDI-DrugBank.d434.s20|55-63|increased|O
DDI-DrugBank.d434.s20|65-66|57|O
DDI-DrugBank.d434.s20|67-67|%|O
DDI-DrugBank.d434.s20|74-76|1.0|O
DDI-DrugBank.d434.s20|78-80|0.3|O
DDI-DrugBank.d434.s20|85-87|1.6|O
DDI-DrugBank.d434.s20|89-91|0.4|O
DDI-DrugBank.d434.s20|93-105|micrograms/mL|O
DDI-DrugBank.d434.s20|116-123|addition|O
DDI-DrugBank.d434.s20|128-136|felbamate|O
DDI-DrugBank.d434.s20|75-75|.|O
DDI-DrugBank.d434.s21|0-1|In|O
DDI-DrugBank.d434.s21|3-10|clinical|O
DDI-DrugBank.d434.s21|12-17|trials|O
DDI-DrugBank.d434.s21|20-26|similar|O
DDI-DrugBank.d434.s21|28-34|changes|O
DDI-DrugBank.d434.s21|39-51|carbamazepine|O
DDI-DrugBank.d434.s21|39-51|carbamazepine|O
DDI-DrugBank.d434.s21|71-77|epoxide|O
DDI-DrugBank.d434.s21|84-87|seen|O
DDI-DrugBank.d434.s21|88-88|.|O
DDI-DrugBank.d434.s22|0-8|Valproate|O
DDI-DrugBank.d434.s22|11-18|Felbatol|O
DDI-DrugBank.d434.s22|21-26|causes|O
DDI-DrugBank.d434.s22|31-38|increase|O
DDI-DrugBank.d434.s22|43-54|steady-state|O
DDI-DrugBank.d434.s22|56-64|valproate|O
DDI-DrugBank.d434.s22|66-79|concentrations|O
DDI-DrugBank.d434.s22|80-80|.|O
DDI-DrugBank.d434.s23|0-1|In|O
DDI-DrugBank.d434.s23|3-6|four|O
DDI-DrugBank.d434.s23|8-15|subjects|O
DDI-DrugBank.d434.s23|22-29|epilepsy|O
DDI-DrugBank.d434.s23|31-39|ingesting|O
DDI-DrugBank.d434.s23|41-49|valproate|O
DDI-DrugBank.d434.s23|56-67|steady-state|O
DDI-DrugBank.d434.s23|69-74|trough|O
DDI-DrugBank.d434.s23|77-80|Cmin|O
DDI-DrugBank.d434.s23|41-49|valproate|O
DDI-DrugBank.d434.s23|93-98|plasma|O
DDI-DrugBank.d434.s23|100-112|concentration|O
DDI-DrugBank.d434.s23|118-119|63|O
DDI-DrugBank.d434.s23|121-122|16|O
DDI-DrugBank.d434.s23|124-136|micrograms/mL|O
DDI-DrugBank.d434.s23|137-137|.|O
DDI-DrugBank.d434.s24|0-2|The|O
DDI-DrugBank.d434.s24|4-15|steady-state|O
DDI-DrugBank.d434.s24|17-20|Cmin|O
DDI-DrugBank.d434.s24|22-30|increased|O
DDI-DrugBank.d434.s24|35-36|78|O
DDI-DrugBank.d434.s24|38-39|14|O
DDI-DrugBank.d434.s24|41-53|micrograms/mL|O
DDI-DrugBank.d434.s24|60-63|1200|O
DDI-DrugBank.d434.s24|65-70|mg/day|O
DDI-DrugBank.d434.s24|75-83|felbamate|O
DDI-DrugBank.d434.s24|89-102|coadministered|O
DDI-DrugBank.d434.s24|103-103|.|O
DDI-DrugBank.d434.s25|0-9|Increasing|O
DDI-DrugBank.d434.s25|15-23|felbamate|O
DDI-DrugBank.d434.s25|25-28|dose|O
DDI-DrugBank.d434.s25|33-36|2400|O
DDI-DrugBank.d434.s25|38-43|mg/day|O
DDI-DrugBank.d434.s25|45-53|increased|O
DDI-DrugBank.d434.s25|59-69|steadystate|O
DDI-DrugBank.d434.s25|71-79|valproate|O
DDI-DrugBank.d434.s25|81-84|Cmin|O
DDI-DrugBank.d434.s25|89-90|96|O
DDI-DrugBank.d434.s25|92-93|25|O
DDI-DrugBank.d434.s25|95-107|micrograms/mL|O
DDI-DrugBank.d434.s25|108-108|.|O
DDI-DrugBank.d434.s26|0-12|Corresponding|O
DDI-DrugBank.d434.s26|14-19|values|O
DDI-DrugBank.d434.s26|25-28|free|O
DDI-DrugBank.d434.s26|30-38|valproate|O
DDI-DrugBank.d434.s26|40-43|Cmin|O
DDI-DrugBank.d434.s26|45-58|concentrations|O
DDI-DrugBank.d434.s26|65-65|7|O
DDI-DrugBank.d434.s26|67-67|3|O
DDI-DrugBank.d434.s26|70-70|9|O
DDI-DrugBank.d434.s26|72-72|4|O
DDI-DrugBank.d434.s26|79-80|11|O
DDI-DrugBank.d434.s26|82-82|6|O
DDI-DrugBank.d434.s26|84-96|micrograms/mL|O
DDI-DrugBank.d434.s26|102-102|0|O
DDI-DrugBank.d434.s26|105-108|1200|O
DDI-DrugBank.d434.s26|115-118|2400|O
DDI-DrugBank.d434.s26|120-125|mg/day|O
DDI-DrugBank.d434.s26|127-134|Felbatol|O
DDI-DrugBank.d434.s26|138-149|respectively|O
DDI-DrugBank.d434.s26|150-150|.|O
DDI-DrugBank.d434.s27|0-2|The|O
DDI-DrugBank.d434.s27|4-9|ratios|O
DDI-DrugBank.d434.s27|18-21|AUCs|O
DDI-DrugBank.d434.s27|26-32|unbound|O
DDI-DrugBank.d434.s27|34-42|valproate|O
DDI-DrugBank.d434.s27|18-21|AUCs|O
DDI-DrugBank.d434.s27|63-67|total|O
DDI-DrugBank.d434.s27|34-42|valproate|O
DDI-DrugBank.d434.s27|84-87|11.1|O
DDI-DrugBank.d434.s27|89-89|%|O
DDI-DrugBank.d434.s27|92-95|13.0|O
DDI-DrugBank.d434.s27|89-89|%|O
DDI-DrugBank.d434.s27|103-106|11.5|O
DDI-DrugBank.d434.s27|89-89|%|O
DDI-DrugBank.d434.s27|115-130|coadministration|O
DDI-DrugBank.d434.s27|95-95|0|O
DDI-DrugBank.d434.s27|138-141|1200|O
DDI-DrugBank.d434.s27|148-151|2400|O
DDI-DrugBank.d434.s27|153-158|mg/day|O
DDI-DrugBank.d434.s27|163-170|Felbatol|O
DDI-DrugBank.d434.s27|174-185|respectively|O
DDI-DrugBank.d434.s27|86-86|.|O
DDI-DrugBank.d434.s28|0-12|Phenobarbital|O
DDI-DrugBank.d434.s28|15-30|Coadministration|O
DDI-DrugBank.d434.s28|35-43|felbamate|O
DDI-DrugBank.d434.s28|50-62|phenobarbital|O
DDI-DrugBank.d434.s28|64-69|causes|O
DDI-DrugBank.d434.s28|74-81|increase|O
DDI-DrugBank.d434.s28|50-62|phenobarbital|O
DDI-DrugBank.d434.s28|100-105|plasma|O
DDI-DrugBank.d434.s28|107-120|concentrations|O
DDI-DrugBank.d434.s28|123-124|In|O
DDI-DrugBank.d434.s28|126-127|12|O
DDI-DrugBank.d434.s28|129-137|otherwise|O
DDI-DrugBank.d434.s28|139-145|healthy|O
DDI-DrugBank.d434.s28|147-150|male|O
DDI-DrugBank.d434.s28|152-161|volunteers|O
DDI-DrugBank.d434.s28|163-171|ingesting|O
DDI-DrugBank.d434.s28|50-62|phenobarbital|O
DDI-DrugBank.d434.s28|192-203|steady-state|O
DDI-DrugBank.d434.s28|205-210|trough|O
DDI-DrugBank.d434.s28|213-216|Cmin|O
DDI-DrugBank.d434.s28|50-62|phenobarbital|O
DDI-DrugBank.d434.s28|107-119|concentration|O
DDI-DrugBank.d434.s28|251-254|14.2|O
DDI-DrugBank.d434.s28|256-268|micrograms/mL|O
DDI-DrugBank.d434.s29|0-2|The|O
DDI-DrugBank.d434.s29|4-15|steady-state|O
DDI-DrugBank.d434.s29|17-20|Cmin|O
DDI-DrugBank.d434.s29|22-34|concentration|O
DDI-DrugBank.d434.s29|36-44|increased|O
DDI-DrugBank.d434.s29|49-52|17.8|O
DDI-DrugBank.d434.s29|54-66|micrograms/mL|O
DDI-DrugBank.d434.s29|73-76|2400|O
DDI-DrugBank.d434.s29|78-83|mg/day|O
DDI-DrugBank.d434.s29|88-96|felbamate|O
DDI-DrugBank.d434.s29|102-115|coadministered|O
DDI-DrugBank.d434.s29|121-123|one|O
DDI-DrugBank.d434.s29|125-128|week|O
DDI-DrugBank.d434.s29|51-51|.|O
DDI-DrugBank.d434.s30|0-6|Effects|O
DDI-DrugBank.d434.s30|11-15|Other|O
DDI-DrugBank.d434.s30|17-29|Antiepileptic|O
DDI-DrugBank.d434.s30|31-35|Drugs|O
DDI-DrugBank.d434.s30|40-47|Felbatol|O
DDI-DrugBank.d434.s30|50-58|Phenytoin|O
DDI-DrugBank.d434.s30|50-58|Phenytoin|O
DDI-DrugBank.d434.s30|71-76|causes|O
DDI-DrugBank.d434.s30|81-91|approximate|O
DDI-DrugBank.d434.s30|93-100|doubling|O
DDI-DrugBank.d434.s30|109-117|clearance|O
DDI-DrugBank.d434.s30|40-47|Felbatol|O
DDI-DrugBank.d434.s30|133-141|felbamate|O
DDI-DrugBank.d434.s30|147-152|steady|O
DDI-DrugBank.d434.s30|154-158|state|O
DDI-DrugBank.d434.s30|165-173|therefore|O
DDI-DrugBank.d434.s30|180-187|addition|O
DDI-DrugBank.d434.s30|192-200|phenytoin|O
DDI-DrugBank.d434.s30|71-76|causes|O
DDI-DrugBank.d434.s30|81-91|approximate|O
DDI-DrugBank.d434.s30|224-225|45|O
DDI-DrugBank.d434.s30|226-226|%|O
DDI-DrugBank.d434.s30|228-235|decrease|O
DDI-DrugBank.d434.s30|244-255|steady-state|O
DDI-DrugBank.d434.s30|257-262|trough|O
DDI-DrugBank.d434.s30|264-277|concentrations|O
DDI-DrugBank.d434.s30|40-47|Felbatol|O
DDI-DrugBank.d434.s30|295-302|compared|O
DDI-DrugBank.d434.s30|316-319|dose|O
DDI-DrugBank.d434.s30|40-47|Felbatol|O
DDI-DrugBank.d434.s30|334-338|given|O
DDI-DrugBank.d434.s30|343-353|monotherapy|O
DDI-DrugBank.d434.s30|354-354|.|O
DDI-DrugBank.d434.s31|0-12|Carbamazepine|O
DDI-DrugBank.d434.s31|0-12|Carbamazepine|O
DDI-DrugBank.d434.s31|29-34|causes|O
DDI-DrugBank.d434.s31|39-49|approximate|O
DDI-DrugBank.d434.s31|51-52|50|O
DDI-DrugBank.d434.s31|53-53|%|O
DDI-DrugBank.d434.s31|55-62|increase|O
DDI-DrugBank.d434.s31|71-79|clearance|O
DDI-DrugBank.d434.s31|84-91|Felbatol|O
DDI-DrugBank.d434.s31|97-102|steady|O
DDI-DrugBank.d434.s31|104-108|state|O
DDI-DrugBank.d434.s31|115-123|therefore|O
DDI-DrugBank.d434.s31|130-137|addition|O
DDI-DrugBank.d434.s31|142-154|carbamazepine|O
DDI-DrugBank.d434.s31|156-162|results|O
DDI-DrugBank.d434.s31|39-49|approximate|O
DDI-DrugBank.d434.s31|182-183|40|O
DDI-DrugBank.d434.s31|53-53|%|O
DDI-DrugBank.d434.s31|186-193|decrease|O
DDI-DrugBank.d434.s31|202-213|steady-state|O
DDI-DrugBank.d434.s31|215-220|trough|O
DDI-DrugBank.d434.s31|222-235|concentrations|O
DDI-DrugBank.d434.s31|84-91|Felbatol|O
DDI-DrugBank.d434.s31|253-260|compared|O
DDI-DrugBank.d434.s31|274-277|dose|O
DDI-DrugBank.d434.s31|84-91|Felbatol|O
DDI-DrugBank.d434.s31|292-296|given|O
DDI-DrugBank.d434.s31|301-311|monotherapy|O
DDI-DrugBank.d434.s31|312-312|.|O
DDI-DrugBank.d434.s32|0-8|Valproate|O
DDI-DrugBank.d434.s32|11-19|Available|O
DDI-DrugBank.d434.s32|21-24|data|O
DDI-DrugBank.d434.s32|26-32|suggest|O
DDI-DrugBank.d434.s32|51-61|significant|O
DDI-DrugBank.d434.s32|63-68|effect|O
DDI-DrugBank.d434.s32|73-81|valproate|O
DDI-DrugBank.d434.s32|90-98|clearance|O
DDI-DrugBank.d434.s32|103-110|Felbatol|O
DDI-DrugBank.d434.s32|116-121|steady|O
DDI-DrugBank.d434.s32|123-127|state|O
DDI-DrugBank.d434.s32|130-138|Therefore|O
DDI-DrugBank.d434.s32|145-152|addition|O
DDI-DrugBank.d434.s32|73-81|valproate|O
DDI-DrugBank.d434.s32|174-181|expected|O
DDI-DrugBank.d434.s32|186-190|cause|O
DDI-DrugBank.d434.s32|194-203|clinically|O
DDI-DrugBank.d434.s32|205-213|important|O
DDI-DrugBank.d434.s32|63-68|effect|O
DDI-DrugBank.d434.s32|103-110|Felbatol|O
DDI-DrugBank.d434.s32|236-244|felbamate|O
DDI-DrugBank.d434.s32|247-252|plasma|O
DDI-DrugBank.d434.s32|254-267|concentrations|O
DDI-DrugBank.d434.s32|268-268|.|O
DDI-DrugBank.d434.s33|0-12|Phenobarbital|O
DDI-DrugBank.d434.s33|15-16|It|O
DDI-DrugBank.d434.s33|18-24|appears|O
DDI-DrugBank.d434.s33|31-43|phenobarbital|O
DDI-DrugBank.d434.s33|45-47|may|O
DDI-DrugBank.d434.s33|49-54|reduce|O
DDI-DrugBank.d434.s33|56-61|plasma|O
DDI-DrugBank.d434.s33|63-71|felbamate|O
DDI-DrugBank.d434.s33|73-86|concentrations|O
DDI-DrugBank.d434.s33|87-87|.|O
DDI-DrugBank.d434.s34|0-11|Steady-state|O
DDI-DrugBank.d434.s34|13-18|plasma|O
DDI-DrugBank.d434.s34|20-28|felbamate|O
DDI-DrugBank.d434.s34|30-43|concentrations|O
DDI-DrugBank.d434.s34|50-54|found|O
DDI-DrugBank.d434.s34|62-63|29|O
DDI-DrugBank.d434.s34|64-64|%|O
DDI-DrugBank.d434.s34|66-70|lower|O
DDI-DrugBank.d434.s34|81-84|mean|O
DDI-DrugBank.d434.s34|30-43|concentrations|O
DDI-DrugBank.d434.s34|106-110|group|O
DDI-DrugBank.d434.s34|115-119|newly|O
DDI-DrugBank.d434.s34|121-129|diagnosed|O
DDI-DrugBank.d434.s34|131-138|subjects|O
DDI-DrugBank.d434.s34|145-152|epilepsy|O
DDI-DrugBank.d434.s34|154-157|also|O
DDI-DrugBank.d434.s34|159-167|receiving|O
DDI-DrugBank.d434.s34|169-172|2400|O
DDI-DrugBank.d434.s34|174-175|mg|O
DDI-DrugBank.d434.s34|20-28|felbamate|O
DDI-DrugBank.d434.s34|192-194|day|O
DDI-DrugBank.d434.s34|195-195|.|O
DDI-DrugBank.d434.s35|0-6|Effects|O
DDI-DrugBank.d434.s35|11-18|Antacids|O
DDI-DrugBank.d434.s35|23-30|Felbatol|O
DDI-DrugBank.d434.s35|33-35|The|O
DDI-DrugBank.d434.s35|37-40|rate|O
DDI-DrugBank.d434.s35|46-51|extent|O
DDI-DrugBank.d434.s35|56-65|absorption|O
DDI-DrugBank.d434.s35|72-75|2400|O
DDI-DrugBank.d434.s35|77-78|mg|O
DDI-DrugBank.d434.s35|80-83|dose|O
DDI-DrugBank.d434.s35|23-30|Felbatol|O
DDI-DrugBank.d434.s35|101-111|monotherapy|O
DDI-DrugBank.d434.s35|113-117|given|O
DDI-DrugBank.d434.s35|122-128|tablets|O
DDI-DrugBank.d434.s35|138-145|affected|O
DDI-DrugBank.d434.s35|152-165|coadministered|O
DDI-DrugBank.d434.s35|172-179|antacids|O
DDI-DrugBank.d434.s35|180-180|.|O
DDI-DrugBank.d434.s36|0-6|Effects|O
DDI-DrugBank.d434.s36|11-22|Erythromycin|O
DDI-DrugBank.d434.s36|27-34|Felbatol|O
DDI-DrugBank.d434.s36|37-39|The|O
DDI-DrugBank.d434.s36|41-56|coadministration|O
DDI-DrugBank.d434.s36|61-72|erythromycin|O
DDI-DrugBank.d434.s36|75-78|1000|O
DDI-DrugBank.d434.s36|80-85|mg/day|O
DDI-DrugBank.d434.s36|75-76|10|O
DDI-DrugBank.d434.s36|95-98|days|O
DDI-DrugBank.d434.s36|108-112|alter|O
DDI-DrugBank.d434.s36|118-132|pharmacokinetic|O
DDI-DrugBank.d434.s36|134-143|parameters|O
DDI-DrugBank.d434.s36|148-151|Cmax|O
DDI-DrugBank.d434.s36|154-157|Cmin|O
DDI-DrugBank.d434.s36|160-162|AUC|O
DDI-DrugBank.d434.s36|165-169|CI/kg|O
DDI-DrugBank.d434.s36|174-177|tmax|O
DDI-DrugBank.d434.s36|182-190|felbamate|O
DDI-DrugBank.d434.s36|192-196|daily|O
DDI-DrugBank.d434.s36|198-202|doses|O
DDI-DrugBank.d434.s36|207-210|3000|O
DDI-DrugBank.d434.s36|215-218|3600|O
DDI-DrugBank.d434.s36|80-85|mg/day|O
DDI-DrugBank.d434.s36|75-76|10|O
DDI-DrugBank.d434.s36|233-241|otherwise|O
DDI-DrugBank.d434.s36|243-249|healthy|O
DDI-DrugBank.d434.s36|251-258|subjects|O
DDI-DrugBank.d434.s36|265-272|epilepsy|O
DDI-DrugBank.d434.s36|273-273|.|O
DDI-DrugBank.d434.s37|0-6|Effects|O
DDI-DrugBank.d434.s37|11-18|Felbatol|O
DDI-DrugBank.d434.s37|24-31|Low-Dose|O
DDI-DrugBank.d434.s37|33-43|Combination|O
DDI-DrugBank.d434.s37|45-48|Oral|O
DDI-DrugBank.d434.s37|50-63|Contraceptives|O
DDI-DrugBank.d434.s37|65-65|A|O
DDI-DrugBank.d434.s37|67-71|group|O
DDI-DrugBank.d434.s37|76-77|24|O
DDI-DrugBank.d434.s37|79-88|nonsmoking|O
DDI-DrugBank.d434.s37|91-97|healthy|O
DDI-DrugBank.d434.s37|99-103|white|O
DDI-DrugBank.d434.s37|105-110|female|O
DDI-DrugBank.d434.s37|112-121|volunteers|O
DDI-DrugBank.d434.s37|123-133|established|O
DDI-DrugBank.d434.s37|141-144|oral|O
DDI-DrugBank.d434.s37|146-158|contraceptive|O
DDI-DrugBank.d434.s37|160-166|regimen|O
DDI-DrugBank.d434.s37|168-177|containing|O
DDI-DrugBank.d434.s37|179-180|30|O
DDI-DrugBank.d434.s37|182-183|mg|O
DDI-DrugBank.d434.s37|185-191|ethinyl|O
DDI-DrugBank.d434.s37|193-201|estradiol|O
DDI-DrugBank.d434.s37|207-208|75|O
DDI-DrugBank.d434.s37|182-183|mg|O
DDI-DrugBank.d434.s37|213-221|gestodene|O
DDI-DrugBank.d434.s37|230-234|least|O
DDI-DrugBank.d434.s37|179-179|3|O
DDI-DrugBank.d434.s37|238-243|months|O
DDI-DrugBank.d434.s37|245-252|received|O
DDI-DrugBank.d434.s37|254-257|2400|O
DDI-DrugBank.d434.s37|259-264|mg/day|O
DDI-DrugBank.d434.s37|269-277|felbamate|O
DDI-DrugBank.d434.s37|284-291|midcycle|O
DDI-DrugBank.d434.s37|262-264|day|O
DDI-DrugBank.d434.s37|298-299|15|O
DDI-DrugBank.d434.s37|284-291|midcycle|O
DDI-DrugBank.d434.s37|262-264|day|O
DDI-DrugBank.d434.s37|319-320|14|O
DDI-DrugBank.d434.s37|326-328|two|O
DDI-DrugBank.d434.s37|330-340|consecutive|O
DDI-DrugBank.d434.s37|141-144|oral|O
DDI-DrugBank.d434.s37|146-158|contraceptive|O
DDI-DrugBank.d434.s37|361-366|cycles|O
DDI-DrugBank.d434.s37|367-367|.|O
DDI-DrugBank.d434.s38|0-8|Felbamate|O
DDI-DrugBank.d434.s38|10-18|treatment|O
DDI-DrugBank.d434.s38|20-27|resulted|O
DDI-DrugBank.d434.s38|34-35|42|O
DDI-DrugBank.d434.s38|36-36|%|O
DDI-DrugBank.d434.s38|38-45|decrease|O
DDI-DrugBank.d434.s38|54-62|gestodene|O
DDI-DrugBank.d434.s38|64-66|AUC|O
DDI-DrugBank.d434.s38|68-71|0-24|O
DDI-DrugBank.d434.s38|81-90|clinically|O
DDI-DrugBank.d434.s38|92-99|relevant|O
DDI-DrugBank.d434.s38|101-106|effect|O
DDI-DrugBank.d434.s38|112-119|observed|O
DDI-DrugBank.d434.s38|128-142|pharmacokinetic|O
DDI-DrugBank.d434.s38|144-153|parameters|O
DDI-DrugBank.d434.s38|158-164|ethinyl|O
DDI-DrugBank.d434.s38|166-174|estradiol|O
DDI-DrugBank.d434.s38|175-175|.|O
DDI-DrugBank.d434.s39|0-1|No|O
DDI-DrugBank.d434.s39|3-11|volunteer|O
DDI-DrugBank.d434.s39|13-18|showed|O
DDI-DrugBank.d434.s39|20-27|hormonal|O
DDI-DrugBank.d434.s39|29-36|evidence|O
DDI-DrugBank.d434.s39|41-49|ovulation|O
DDI-DrugBank.d434.s39|56-58|one|O
DDI-DrugBank.d434.s39|3-11|volunteer|O
DDI-DrugBank.d434.s39|70-77|reported|O
DDI-DrugBank.d434.s39|79-92|intermenstrual|O
DDI-DrugBank.d434.s39|94-101|bleeding|O
DDI-DrugBank.d434.s39|110-118|felbamate|O
DDI-DrugBank.d434.s39|120-128|treatment|O
DDI-DrugBank.d434.s39|129-129|.|O
DDI-DrugBank.d552.s0|0-7|Nabilone|O
DDI-DrugBank.d552.s0|19-30|administered|O
DDI-DrugBank.d552.s0|37-43|caution|O
DDI-DrugBank.d552.s0|48-55|patients|O
DDI-DrugBank.d552.s0|65-70|taking|O
DDI-DrugBank.d552.s0|78-89|psychoactive|O
DDI-DrugBank.d552.s0|91-95|drugs|O
DDI-DrugBank.d552.s0|100-102|CNS|O
DDI-DrugBank.d552.s0|104-114|depressants|O
DDI-DrugBank.d552.s0|117-125|including|O
DDI-DrugBank.d552.s0|127-133|alcohol|O
DDI-DrugBank.d552.s0|136-147|barbiturates|O
DDI-DrugBank.d552.s0|153-160|narcotic|O
DDI-DrugBank.d552.s0|162-171|analgesics|O
DDI-DrugBank.d552.s0|193-199|history|O
DDI-DrugBank.d552.s0|204-214|psychiatric|O
DDI-DrugBank.d552.s0|216-223|disorder|O
DDI-DrugBank.d552.s0|117-125|including|O
DDI-DrugBank.d552.s0|236-251|manic-depressive|O
DDI-DrugBank.d552.s0|253-259|illness|O
DDI-DrugBank.d552.s0|265-277|schizophrenia|O
DDI-DrugBank.d552.s0|279-279|.|O
DDI-DrugBank.d552.s1|0-7|Nabilone|O
DDI-DrugBank.d552.s1|18-22|shown|O
DDI-DrugBank.d552.s1|35-42|additive|O
DDI-DrugBank.d552.s1|44-46|CNS|O
DDI-DrugBank.d552.s1|48-57|depressant|O
DDI-DrugBank.d552.s1|59-64|effect|O
DDI-DrugBank.d552.s1|71-75|given|O
DDI-DrugBank.d552.s1|82-87|either|O
DDI-DrugBank.d552.s1|89-96|diazepam|O
DDI-DrugBank.d552.s1|99-111|secobarbitone|O
DDI-DrugBank.d552.s1|113-118|sodium|O
DDI-DrugBank.d552.s1|121-127|alcohol|O
DDI-DrugBank.d552.s1|132-138|codeine|O
DDI-DrugBank.d552.s1|139-139|.|O
DDI-DrugBank.d524.s0|0-8|Albuterol|O
DDI-DrugBank.d524.s0|11-24|Antihistamines|O
DDI-DrugBank.d524.s0|27-38|antidiabetic|O
DDI-DrugBank.d524.s0|40-44|drugs|O
DDI-DrugBank.d524.s0|47-55|diuretics|O
DDI-DrugBank.d524.s0|58-66|digitalis|O
DDI-DrugBank.d524.s0|67-67|.|O
DDI-DrugBank.d488.s0|0-3|Drug|O
DDI-DrugBank.d488.s0|5-16|Interactions|O
DDI-DrugBank.d488.s0|20-20|.|O
DDI-DrugBank.d488.s0|22-26|Drugs|O
DDI-DrugBank.d488.s0|28-36|Enhancing|O
DDI-DrugBank.d488.s0|38-44|Heparin|O
DDI-DrugBank.d488.s0|46-51|Effect|O
DDI-DrugBank.d488.s0|54-57|Oral|O
DDI-DrugBank.d488.s0|59-72|anticoagulants|O
DDI-DrugBank.d488.s0|38-44|Heparin|O
DDI-DrugBank.d488.s0|83-88|sodium|O
DDI-DrugBank.d488.s0|90-92|may|O
DDI-DrugBank.d488.s0|94-100|prolong|O
DDI-DrugBank.d488.s0|106-114|one-stage|O
DDI-DrugBank.d488.s0|116-126|prothrombin|O
DDI-DrugBank.d488.s0|128-131|time|O
DDI-DrugBank.d488.s0|20-20|.|O
DDI-DrugBank.d488.s1|0-8|Therefore|O
DDI-DrugBank.d488.s1|16-22|heparin|O
DDI-DrugBank.d488.s1|24-29|sodium|O
DDI-DrugBank.d488.s1|34-38|given|O
DDI-DrugBank.d488.s1|45-53|dicumarol|O
DDI-DrugBank.d488.s1|58-65|warfarin|O
DDI-DrugBank.d488.s1|24-29|sodium|O
DDI-DrugBank.d488.s1|77-82|period|O
DDI-DrugBank.d488.s1|90-94|least|O
DDI-DrugBank.d488.s1|96-96|5|O
DDI-DrugBank.d488.s1|98-102|hours|O
DDI-DrugBank.d488.s1|114-117|last|O
DDI-DrugBank.d488.s1|119-129|intravenous|O
DDI-DrugBank.d488.s1|131-134|dose|O
DDI-DrugBank.d488.s1|139-140|24|O
DDI-DrugBank.d488.s1|98-102|hours|O
DDI-DrugBank.d488.s1|114-117|last|O
DDI-DrugBank.d488.s1|163-174|subcutaneous|O
DDI-DrugBank.d488.s1|131-134|dose|O
DDI-DrugBank.d488.s1|188-193|elapse|O
DDI-DrugBank.d488.s1|202-206|blood|O
DDI-DrugBank.d488.s1|211-215|drawn|O
DDI-DrugBank.d488.s1|222-226|valid|O
DDI-DrugBank.d488.s1|228-238|prothrombin|O
DDI-DrugBank.d488.s1|240-243|time|O
DDI-DrugBank.d488.s1|254-261|obtained|O
DDI-DrugBank.d488.s1|262-262|.|O
DDI-DrugBank.d488.s2|0-7|Platelet|O
DDI-DrugBank.d488.s2|9-18|inhibitors|O
DDI-DrugBank.d488.s2|21-25|Drugs|O
DDI-DrugBank.d488.s2|35-49|acetylsalicylic|O
DDI-DrugBank.d488.s2|51-54|acid|O
DDI-DrugBank.d488.s2|57-63|dextran|O
DDI-DrugBank.d488.s2|66-79|phenylbutazone|O
DDI-DrugBank.d488.s2|82-90|ibuprofen|O
DDI-DrugBank.d488.s2|93-104|indomethacin|O
DDI-DrugBank.d488.s2|107-118|dipyridamole|O
DDI-DrugBank.d488.s2|121-138|hydroxychloroquine|O
DDI-DrugBank.d488.s2|144-149|others|O
DDI-DrugBank.d488.s2|156-164|interfere|O
DDI-DrugBank.d488.s2|171-190|platelet-aggregation|O
DDI-DrugBank.d488.s2|192-200|reactions|O
DDI-DrugBank.d488.s2|207-210|main|O
DDI-DrugBank.d488.s2|212-221|hemostatic|O
DDI-DrugBank.d488.s2|223-229|defense|O
DDI-DrugBank.d488.s2|234-244|heparinized|O
DDI-DrugBank.d488.s2|246-253|patients|O
DDI-DrugBank.d488.s2|256-258|may|O
DDI-DrugBank.d488.s2|260-265|induce|O
DDI-DrugBank.d488.s2|267-274|bleeding|O
DDI-DrugBank.d488.s2|290-293|used|O
DDI-DrugBank.d488.s2|300-306|caution|O
DDI-DrugBank.d488.s2|246-253|patients|O
DDI-DrugBank.d488.s2|320-328|receiving|O
DDI-DrugBank.d488.s2|234-240|heparin|O
DDI-DrugBank.d488.s2|338-343|sodium|O
DDI-DrugBank.d488.s2|344-344|.|O
DDI-DrugBank.d488.s3|0-2|The|O
DDI-DrugBank.d488.s3|4-16|anticoagulant|O
DDI-DrugBank.d488.s3|18-23|effect|O
DDI-DrugBank.d488.s3|28-34|heparin|O
DDI-DrugBank.d488.s3|39-46|enhanced|O
DDI-DrugBank.d488.s3|51-60|concurrent|O
DDI-DrugBank.d488.s3|62-70|treatment|O
DDI-DrugBank.d488.s3|77-88|antithrombin|O
DDI-DrugBank.d488.s3|90-92|III|O
DDI-DrugBank.d488.s3|95-99|human|O
DDI-DrugBank.d488.s3|105-112|patients|O
DDI-DrugBank.d488.s3|119-128|hereditary|O
DDI-DrugBank.d488.s3|77-88|antithrombin|O
DDI-DrugBank.d488.s3|90-92|III|O
DDI-DrugBank.d488.s3|147-156|deficiency|O
DDI-DrugBank.d488.s4|0-3|Thus|O
DDI-DrugBank.d488.s4|8-12|order|O
DDI-DrugBank.d488.s4|17-21|avoid|O
DDI-DrugBank.d488.s4|23-30|bleeding|O
DDI-DrugBank.d488.s4|33-39|reduced|O
DDI-DrugBank.d488.s4|41-46|dosage|O
DDI-DrugBank.d488.s4|51-57|heparin|O
DDI-DrugBank.d488.s4|62-72|recommended|O
DDI-DrugBank.d488.s4|81-89|treatment|O
DDI-DrugBank.d488.s4|96-107|antithrombin|O
DDI-DrugBank.d488.s4|109-111|III|O
DDI-DrugBank.d488.s4|114-118|human|O
DDI-DrugBank.d488.s4|120-120|.|O
DDI-DrugBank.d488.s5|0-0|b|O
DDI-DrugBank.d488.s5|1-1|.|O
DDI-DrugBank.d488.s6|0-4|Drugs|O
DDI-DrugBank.d488.s6|6-15|Decreasing|O
DDI-DrugBank.d488.s6|17-23|Heparin|O
DDI-DrugBank.d488.s6|25-30|Effect|O
DDI-DrugBank.d488.s6|33-41|Digitalis|O
DDI-DrugBank.d488.s6|44-56|tetracyclines|O
DDI-DrugBank.d488.s6|59-66|nicotine|O
DDI-DrugBank.d488.s6|72-85|antihistamines|O
DDI-DrugBank.d488.s6|87-89|may|O
DDI-DrugBank.d488.s6|91-99|partially|O
DDI-DrugBank.d488.s6|101-110|counteract|O
DDI-DrugBank.d488.s6|116-128|anticoagulant|O
DDI-DrugBank.d488.s6|130-135|action|O
DDI-DrugBank.d488.s6|140-146|heparin|O
DDI-DrugBank.d488.s6|148-153|sodium|O
DDI-DrugBank.d488.s6|154-154|.|O
DDI-DrugBank.d488.s7|0-6|Heparin|O
DDI-DrugBank.d488.s7|8-13|Sodium|O
DDI-DrugBank.d488.s7|15-23|Injection|O
DDI-DrugBank.d488.s7|39-43|mixed|O
DDI-DrugBank.d488.s7|50-60|doxorubicin|O
DDI-DrugBank.d488.s7|63-72|droperidol|O
DDI-DrugBank.d488.s7|75-87|ciprofloxacin|O
DDI-DrugBank.d488.s7|93-104|mitoxantrone|O
DDI-DrugBank.d488.s7|107-111|since|O
DDI-DrugBank.d488.s7|125-132|reported|O
DDI-DrugBank.d488.s7|145-149|drugs|O
DDI-DrugBank.d488.s7|155-166|incompatible|O
DDI-DrugBank.d488.s7|173-179|heparin|O
DDI-DrugBank.d488.s7|187-197|precipitate|O
DDI-DrugBank.d488.s7|199-201|may|O
DDI-DrugBank.d488.s7|203-206|form|O
DDI-DrugBank.d488.s7|207-207|.|O
DDI-DrugBank.d488.s8|0-4|Drug/|O
DDI-DrugBank.d488.s8|6-15|Laboratory|O
DDI-DrugBank.d488.s8|17-21|Tests|O
DDI-DrugBank.d488.s8|23-34|Interactions|O
DDI-DrugBank.d488.s8|36-59|Hyperaminotransferasemia|O
DDI-DrugBank.d488.s8|62-72|Significant|O
DDI-DrugBank.d488.s8|74-83|elevations|O
DDI-DrugBank.d488.s8|41-56|aminotransferase|O
DDI-DrugBank.d488.s8|106-109|SGOT|O
DDI-DrugBank.d488.s8|111-111|[|O
DDI-DrugBank.d488.s8|112-116|S-AST|O
DDI-DrugBank.d488.s8|117-117|]|O
DDI-DrugBank.d488.s8|123-126|SGPT|O
DDI-DrugBank.d488.s8|111-111|[|O
DDI-DrugBank.d488.s8|129-133|S-ALT|O
DDI-DrugBank.d488.s8|117-117|]|O
DDI-DrugBank.d488.s8|137-142|levels|O
DDI-DrugBank.d488.s8|149-156|occurred|O
DDI-DrugBank.d488.s8|163-166|high|O
DDI-DrugBank.d488.s8|168-177|percentage|O
DDI-DrugBank.d488.s8|182-189|patients|O
DDI-DrugBank.d488.s8|196-202|healthy|O
DDI-DrugBank.d488.s8|204-211|subjects|O
DDI-DrugBank.d488.s8|223-230|received|O
DDI-DrugBank.d488.s8|232-238|heparin|O
DDI-DrugBank.d488.s8|240-245|sodium|O
DDI-DrugBank.d488.s8|246-246|.|O
DDI-DrugBank.d488.s9|0-4|Since|O
DDI-DrugBank.d488.s9|6-21|aminotransferase|O
DDI-DrugBank.d488.s9|23-36|determinations|O
DDI-DrugBank.d488.s9|42-50|important|O
DDI-DrugBank.d488.s9|59-70|differential|O
DDI-DrugBank.d488.s9|72-80|diagnosis|O
DDI-DrugBank.d488.s9|85-94|myocardial|O
DDI-DrugBank.d488.s9|96-105|infarction|O
DDI-DrugBank.d488.s9|108-112|liver|O
DDI-DrugBank.d488.s9|114-120|disease|O
DDI-DrugBank.d488.s9|126-134|pulmonary|O
DDI-DrugBank.d488.s9|136-141|emboli|O
DDI-DrugBank.d488.s9|144-148|rises|O
DDI-DrugBank.d488.s9|155-159|might|O
DDI-DrugBank.d488.s9|164-169|caused|O
DDI-DrugBank.d488.s9|174-178|drugs|O
DDI-DrugBank.d488.s9|181-187|heparin|O
DDI-DrugBank.d488.s9|189-194|sodium|O
DDI-DrugBank.d488.s9|207-217|interpreted|O
DDI-DrugBank.d488.s9|224-230|caution|O
DDI-DrugBank.d488.s9|231-231|.|O
DDI-DrugBank.d495.s0|0-5|Tablet|O
DDI-DrugBank.d495.s0|7-8|If|O
DDI-DrugBank.d495.s0|12-18|patient|O
DDI-DrugBank.d495.s0|20-28|receiving|O
DDI-DrugBank.d495.s0|30-38|clonidine|O
DDI-DrugBank.d495.s0|40-52|hydrochloride|O
DDI-DrugBank.d495.s0|57-60|also|O
DDI-DrugBank.d495.s0|62-67|taking|O
DDI-DrugBank.d495.s0|69-77|tricyclic|O
DDI-DrugBank.d495.s0|79-93|antidepressants|O
DDI-DrugBank.d495.s0|100-105|effect|O
DDI-DrugBank.d495.s0|30-38|clonidine|O
DDI-DrugBank.d495.s0|120-122|may|O
DDI-DrugBank.d495.s0|127-133|reduced|O
DDI-DrugBank.d495.s0|136-139|thus|O
DDI-DrugBank.d495.s0|141-153|necessitating|O
DDI-DrugBank.d495.s0|158-165|increase|O
DDI-DrugBank.d495.s0|170-175|dosage|O
DDI-DrugBank.d495.s0|176-176|.|O
DDI-DrugBank.d495.s1|0-8|Clonidine|O
DDI-DrugBank.d495.s1|10-22|hydrochloride|O
DDI-DrugBank.d495.s1|24-26|may|O
DDI-DrugBank.d495.s1|28-34|enhance|O
DDI-DrugBank.d495.s1|40-53|CNS-depressive|O
DDI-DrugBank.d495.s1|55-61|effects|O
DDI-DrugBank.d495.s1|66-72|alcohol|O
DDI-DrugBank.d495.s1|75-86|barbiturates|O
DDI-DrugBank.d495.s1|97-105|sedatives|O
DDI-DrugBank.d495.s1|106-106|.|O
DDI-DrugBank.d495.s2|0-12|Amitriptyline|O
DDI-DrugBank.d495.s2|17-27|combination|O
DDI-DrugBank.d495.s2|34-42|clonidine|O
DDI-DrugBank.d495.s2|44-51|enhances|O
DDI-DrugBank.d495.s2|57-69|manifestation|O
DDI-DrugBank.d495.s2|74-80|corneal|O
DDI-DrugBank.d495.s2|82-88|lesions|O
DDI-DrugBank.d495.s2|93-96|rats|O
DDI-DrugBank.d495.s2|98-105|Epidural|O
DDI-DrugBank.d495.s2|107-115|Injection|O
DDI-DrugBank.d495.s2|117-125|Clonidine|O
DDI-DrugBank.d495.s2|127-129|may|O
DDI-DrugBank.d495.s2|131-140|potentiate|O
DDI-DrugBank.d495.s2|146-159|CNS-depressive|O
DDI-DrugBank.d495.s2|161-166|effect|O
DDI-DrugBank.d495.s2|171-177|alcohol|O
DDI-DrugBank.d495.s2|180-191|barbiturates|O
DDI-DrugBank.d495.s2|202-209|sedating|O
DDI-DrugBank.d495.s2|211-215|drugs|O
DDI-DrugBank.d495.s2|216-216|.|O
DDI-DrugBank.d495.s3|0-7|Narcotic|O
DDI-DrugBank.d495.s3|9-18|analgesics|O
DDI-DrugBank.d495.s3|20-22|may|O
DDI-DrugBank.d495.s3|24-33|potentiate|O
DDI-DrugBank.d495.s3|39-49|hypotensive|O
DDI-DrugBank.d495.s3|51-57|effects|O
DDI-DrugBank.d495.s3|62-70|clonidine|O
DDI-DrugBank.d495.s3|71-71|.|O
DDI-DrugBank.d495.s4|0-8|Tricyclic|O
DDI-DrugBank.d495.s4|10-24|antidepressants|O
DDI-DrugBank.d495.s4|26-28|may|O
DDI-DrugBank.d495.s4|30-39|antagonize|O
DDI-DrugBank.d495.s4|45-55|hypotensive|O
DDI-DrugBank.d495.s4|57-63|effects|O
DDI-DrugBank.d495.s4|68-76|clonidine|O
DDI-DrugBank.d495.s4|77-77|.|O
DDI-DrugBank.d495.s5|0-2|The|O
DDI-DrugBank.d495.s5|4-10|effects|O
DDI-DrugBank.d495.s5|15-23|tricyclic|O
DDI-DrugBank.d495.s5|25-39|antidepressants|O
DDI-DrugBank.d495.s5|44-53|clonidines|O
DDI-DrugBank.d495.s5|55-63|analgesic|O
DDI-DrugBank.d495.s5|65-71|actions|O
DDI-DrugBank.d495.s5|81-85|known|O
DDI-DrugBank.d495.s5|86-86|.|O
DDI-DrugBank.d495.s6|0-3|Beta|O
DDI-DrugBank.d495.s6|5-12|blockers|O
DDI-DrugBank.d495.s6|14-16|may|O
DDI-DrugBank.d495.s6|18-27|exacerbate|O
DDI-DrugBank.d495.s6|33-44|hypertensive|O
DDI-DrugBank.d495.s6|46-53|response|O
DDI-DrugBank.d495.s6|55-58|seen|O
DDI-DrugBank.d495.s6|65-73|clonidine|O
DDI-DrugBank.d495.s6|75-83|withdrawl|O
DDI-DrugBank.d495.s6|84-84|.|O
DDI-DrugBank.d495.s7|0-3|Also|O
DDI-DrugBank.d495.s7|6-8|due|O
DDI-DrugBank.d495.s7|17-25|potential|O
DDI-DrugBank.d495.s7|31-38|additive|O
DDI-DrugBank.d495.s7|40-46|effects|O
DDI-DrugBank.d495.s7|56-66|bradycardia|O
DDI-DrugBank.d495.s7|72-73|AV|O
DDI-DrugBank.d495.s7|75-79|block|O
DDI-DrugBank.d495.s7|82-88|caution|O
DDI-DrugBank.d495.s7|93-101|warranted|O
DDI-DrugBank.d495.s7|106-113|patients|O
DDI-DrugBank.d495.s7|115-123|receiving|O
DDI-DrugBank.d495.s7|125-133|clonidine|O
DDI-DrugBank.d495.s7|140-145|agents|O
DDI-DrugBank.d495.s7|147-151|known|O
DDI-DrugBank.d495.s7|156-161|affect|O
DDI-DrugBank.d495.s7|163-167|sinus|O
DDI-DrugBank.d495.s7|169-172|node|O
DDI-DrugBank.d495.s7|174-181|function|O
DDI-DrugBank.d495.s7|72-73|AV|O
DDI-DrugBank.d495.s7|189-193|nodal|O
DDI-DrugBank.d495.s7|195-204|conduction|O
DDI-DrugBank.d495.s7|207-210|e.g.|O
DDI-DrugBank.d495.s7|213-221|digitalis|O
DDI-DrugBank.d495.s7|224-230|calcium|O
DDI-DrugBank.d495.s7|232-238|channel|O
DDI-DrugBank.d495.s7|240-247|blockers|O
DDI-DrugBank.d495.s7|254-266|beta-blockers|O
DDI-DrugBank.d495.s7|208-208|.|O
DDI-DrugBank.d495.s8|0-4|There|O
DDI-DrugBank.d495.s8|9-11|one|O
DDI-DrugBank.d495.s8|13-20|reported|O
DDI-DrugBank.d495.s8|22-25|case|O
DDI-DrugBank.d495.s8|32-38|patient|O
DDI-DrugBank.d495.s8|45-49|acute|O
DDI-DrugBank.d495.s8|51-58|delirium|O
DDI-DrugBank.d495.s8|60-69|associated|O
DDI-DrugBank.d495.s8|80-91|simultaneous|O
DDI-DrugBank.d495.s8|93-95|use|O
DDI-DrugBank.d495.s8|100-111|fluphenazine|O
DDI-DrugBank.d495.s8|117-120|oral|O
DDI-DrugBank.d495.s8|122-130|clonidine|O
DDI-DrugBank.d495.s8|131-131|.|O
DDI-DrugBank.d495.s9|0-7|Symptoms|O
DDI-DrugBank.d495.s9|9-16|resolved|O
DDI-DrugBank.d495.s9|23-31|clonidine|O
DDI-DrugBank.d495.s9|37-45|withdrawn|O
DDI-DrugBank.d495.s9|51-58|recurred|O
DDI-DrugBank.d495.s9|69-75|patient|O
DDI-DrugBank.d495.s9|81-92|rechallenged|O
DDI-DrugBank.d495.s9|23-31|clonidine|O
DDI-DrugBank.d495.s10|0-7|Epidural|O
DDI-DrugBank.d495.s10|9-17|clonidine|O
DDI-DrugBank.d495.s10|19-21|may|O
DDI-DrugBank.d495.s10|23-29|prolong|O
DDI-DrugBank.d495.s10|35-42|duration|O
DDI-DrugBank.d495.s10|47-59|pharmacologic|O
DDI-DrugBank.d495.s10|61-67|effects|O
DDI-DrugBank.d495.s10|72-79|epidural|O
DDI-DrugBank.d495.s10|81-85|local|O
DDI-DrugBank.d495.s10|87-97|anesthetics|O
DDI-DrugBank.d495.s10|100-108|including|O
DDI-DrugBank.d495.s10|115-121|sensory|O
DDI-DrugBank.d495.s10|127-131|motor|O
DDI-DrugBank.d495.s10|133-140|blockade|O
DDI-DrugBank.d495.s10|141-141|.|O
DDI-DrugBank.d504.s0|0-4|There|O
DDI-DrugBank.d504.s0|16-19|rare|O
DDI-DrugBank.d504.s0|21-27|reports|O
DDI-DrugBank.d504.s0|32-42|significant|O
DDI-DrugBank.d504.s0|44-54|respiratory|O
DDI-DrugBank.d504.s0|56-65|depression|O
DDI-DrugBank.d504.s0|68-73|stupor|O
DDI-DrugBank.d504.s0|75-80|and/or|O
DDI-DrugBank.d504.s0|82-92|hypotension|O
DDI-DrugBank.d504.s0|103-113|concomitant|O
DDI-DrugBank.d504.s0|115-117|use|O
DDI-DrugBank.d504.s0|122-129|loxapine|O
DDI-DrugBank.d504.s0|135-143|lorazepam|O
DDI-DrugBank.d504.s0|144-144|.|O
DDI-DrugBank.d504.s1|0-2|The|O
DDI-DrugBank.d504.s1|4-7|risk|O
DDI-DrugBank.d504.s1|12-16|using|O
DDI-DrugBank.d504.s1|18-25|loxapine|O
DDI-DrugBank.d504.s1|30-40|combination|O
DDI-DrugBank.d504.s1|47-56|CNS-active|O
DDI-DrugBank.d504.s1|58-62|drugs|O
DDI-DrugBank.d504.s1|77-90|systematically|O
DDI-DrugBank.d504.s1|92-100|evaluated|O
DDI-DrugBank.d504.s1|101-101|.|O
DDI-DrugBank.d504.s2|0-8|Therefore|O
DDI-DrugBank.d504.s2|11-17|caution|O
DDI-DrugBank.d504.s2|22-28|advised|O
DDI-DrugBank.d504.s2|37-47|concomitant|O
DDI-DrugBank.d504.s2|49-62|administration|O
DDI-DrugBank.d504.s2|67-74|loxapine|O
DDI-DrugBank.d504.s2|80-89|CNS-active|O
DDI-DrugBank.d504.s2|91-95|drugs|O
DDI-DrugBank.d504.s2|100-107|required|O
DDI-DrugBank.d504.s2|108-108|.|O
DDI-DrugBank.d693.s0|0-6|Reduced|O
DDI-DrugBank.d693.s0|8-17|absorption|O
DDI-DrugBank.d693.s0|22-26|folic|O
DDI-DrugBank.d693.s0|28-31|acid|O
DDI-DrugBank.d693.s0|37-43|digoxin|O
DDI-DrugBank.d693.s0|55-62|reported|O
DDI-DrugBank.d693.s0|75-80|agents|O
DDI-DrugBank.d693.s0|87-98|administered|O
DDI-DrugBank.d693.s0|100-112|concomitantly|O
DDI-DrugBank.d693.s0|119-131|sulfasalazine|O
DDI-DrugBank.d693.s0|132-132|.|O
DDI-DrugBank.d693.s1|0-3|When|O
DDI-DrugBank.d693.s1|5-9|daily|O
DDI-DrugBank.d693.s1|11-15|doses|O
DDI-DrugBank.d693.s1|20-32|sulfasalazine|O
DDI-DrugBank.d693.s1|34-34|2|O
DDI-DrugBank.d693.s1|36-36|g|O
DDI-DrugBank.d693.s1|42-47|weekly|O
DDI-DrugBank.d693.s1|11-15|doses|O
DDI-DrugBank.d693.s1|58-69|methotrexate|O
DDI-DrugBank.d693.s1|71-73|7.5|O
DDI-DrugBank.d693.s1|75-76|mg|O
DDI-DrugBank.d693.s1|83-96|coadministered|O
DDI-DrugBank.d693.s1|101-102|15|O
DDI-DrugBank.d693.s1|104-113|rheumatoid|O
DDI-DrugBank.d693.s1|115-123|arthritis|O
DDI-DrugBank.d693.s1|125-132|patients|O
DDI-DrugBank.d693.s1|139-147|drug-drug|O
DDI-DrugBank.d693.s1|149-159|interaction|O
DDI-DrugBank.d693.s1|161-165|study|O
DDI-DrugBank.d693.s1|172-186|pharmacokinetic|O
DDI-DrugBank.d693.s1|188-198|disposition|O
DDI-DrugBank.d693.s1|207-211|drugs|O
DDI-DrugBank.d693.s1|221-227|altered|O
DDI-DrugBank.d693.s1|72-72|.|O
DDI-DrugBank.d693.s2|0-4|Daily|O
DDI-DrugBank.d693.s2|6-10|doses|O
DDI-DrugBank.d693.s2|15-27|sulfasalazine|O
DDI-DrugBank.d693.s2|29-29|2|O
DDI-DrugBank.d693.s2|31-31|g|O
DDI-DrugBank.d693.s2|34-40|maximum|O
DDI-DrugBank.d693.s2|42-42|3|O
DDI-DrugBank.d693.s2|31-31|g|O
DDI-DrugBank.d693.s2|51-56|weekly|O
DDI-DrugBank.d693.s2|6-10|doses|O
DDI-DrugBank.d693.s2|67-78|methotrexate|O
DDI-DrugBank.d693.s2|80-82|7.5|O
DDI-DrugBank.d693.s2|84-85|mg|O
DDI-DrugBank.d693.s2|34-40|maximum|O
DDI-DrugBank.d693.s2|96-97|15|O
DDI-DrugBank.d693.s2|84-85|mg|O
DDI-DrugBank.d693.s2|108-119|administered|O
DDI-DrugBank.d693.s2|121-125|alone|O
DDI-DrugBank.d693.s2|133-143|combination|O
DDI-DrugBank.d693.s2|148-150|310|O
DDI-DrugBank.d693.s2|152-161|rheumatoid|O
DDI-DrugBank.d693.s2|163-171|arthritis|O
DDI-DrugBank.d693.s2|173-180|patients|O
DDI-DrugBank.d693.s2|185-187|two|O
DDI-DrugBank.d693.s2|189-198|controlled|O
DDI-DrugBank.d693.s2|200-206|52-week|O
DDI-DrugBank.d693.s2|208-215|clinical|O
DDI-DrugBank.d693.s2|217-223|studies|O
DDI-DrugBank.d693.s2|81-81|.|O
DDI-DrugBank.d693.s3|0-2|The|O
DDI-DrugBank.d693.s3|4-10|overall|O
DDI-DrugBank.d693.s3|12-19|toxicity|O
DDI-DrugBank.d693.s3|21-27|profile|O
DDI-DrugBank.d693.s3|36-46|combination|O
DDI-DrugBank.d693.s3|48-55|revealed|O
DDI-DrugBank.d693.s3|60-68|increased|O
DDI-DrugBank.d693.s3|70-78|incidence|O
DDI-DrugBank.d693.s3|83-98|gastrointestinal|O
DDI-DrugBank.d693.s3|100-106|adverse|O
DDI-DrugBank.d693.s3|108-113|events|O
DDI-DrugBank.d693.s3|116-125|especially|O
DDI-DrugBank.d693.s3|127-132|nausea|O
DDI-DrugBank.d693.s3|140-147|compared|O
DDI-DrugBank.d693.s3|70-78|incidence|O
DDI-DrugBank.d693.s3|166-175|associated|O
DDI-DrugBank.d693.s3|182-187|either|O
DDI-DrugBank.d693.s3|189-192|drug|O
DDI-DrugBank.d693.s3|194-205|administered|O
DDI-DrugBank.d693.s3|207-211|alone|O
DDI-DrugBank.d693.s3|212-212|.|O
DDI-DrugBank.d693.s4|0-14|Drug/Laboratory|O
DDI-DrugBank.d693.s4|16-19|Test|O
DDI-DrugBank.d693.s4|21-32|Interactions|O
DDI-DrugBank.d693.s4|35-37|The|O
DDI-DrugBank.d693.s4|39-46|presence|O
DDI-DrugBank.d693.s4|51-63|sulfasalazine|O
DDI-DrugBank.d693.s4|72-82|metabolites|O
DDI-DrugBank.d693.s4|87-90|body|O
DDI-DrugBank.d693.s4|92-97|fluids|O
DDI-DrugBank.d693.s4|112-119|reported|O
DDI-DrugBank.d693.s4|124-132|interfere|O
DDI-DrugBank.d693.s4|139-148|laboratory|O
DDI-DrugBank.d693.s4|150-153|test|O
DDI-DrugBank.d693.s4|155-164|procedures|O
DDI-DrugBank.d693.s4|165-165|.|O
DDI-DrugBank.d693.s5|0-9|REFERENCES|O
DDI-DrugBank.d693.s5|11-16|7.Farr|O
DDI-DrugBank.d693.s5|18-18|M|O
DDI-DrugBank.d693.s5|21-22|et|O
DDI-DrugBank.d693.s5|24-25|al|O
DDI-DrugBank.d693.s5|12-12|.|O
DDI-DrugBank.d693.s6|0-17|Immunodeficiencies|O
DDI-DrugBank.d693.s6|19-28|associated|O
DDI-DrugBank.d693.s6|35-48|sulphasalazine|O
DDI-DrugBank.d693.s6|50-56|therapy|O
DDI-DrugBank.d693.s6|61-72|inflammatory|O
DDI-DrugBank.d693.s6|74-82|arthritis|O
DDI-DrugBank.d693.s6|83-83|.|O
DDI-DrugBank.d693.s7|0-6|British|O
DDI-DrugBank.d693.s7|8-10|Jnl|O
DDI-DrugBank.d693.s7|12-16|Rheum|O
DDI-DrugBank.d693.s7|18-21|1991|O
DDI-DrugBank.d693.s7|23-32|30:413-417|O
DDI-DrugBank.d693.s7|33-33|.|O
DDI-MedLine.d141.s0|0-7|Toxicity|O
DDI-MedLine.d141.s0|12-18|cadmium|O
DDI-MedLine.d141.s0|24-27|zinc|O
DDI-MedLine.d141.s0|32-41|encystment|O
DDI-MedLine.d141.s0|50-54|vitro|O
DDI-MedLine.d141.s0|56-65|excystment|O
DDI-MedLine.d141.s0|70-78|Parorchis|O
DDI-MedLine.d141.s0|80-87|acanthus|O
DDI-MedLine.d141.s0|90-96|Digenea|O
DDI-MedLine.d141.s0|99-114|Philophthalmidae|O
DDI-MedLine.d141.s1|0-2|The|O
DDI-MedLine.d141.s1|4-11|toxicity|O
DDI-MedLine.d141.s1|16-22|cadmium|O
DDI-MedLine.d141.s1|25-28|zinc|O
DDI-MedLine.d141.s1|34-45|cadmium/zinc|O
DDI-MedLine.d141.s1|47-54|mixtures|O
DDI-MedLine.d141.s1|59-72|concentrations|O
DDI-MedLine.d141.s1|74-80|ranging|O
DDI-MedLine.d141.s1|87-90|1000|O
DDI-MedLine.d141.s1|95-99|50000|O
DDI-MedLine.d141.s1|101-108|microg/l|O
DDI-MedLine.d141.s1|115-126|investigated|O
DDI-MedLine.d141.s1|136-144|cercariae|O
DDI-MedLine.d141.s1|150-162|metacercariae|O
DDI-MedLine.d141.s1|167-175|Parorchis|O
DDI-MedLine.d141.s1|177-184|acanthus|O
DDI-MedLine.d141.s1|186-193|obtained|O
DDI-MedLine.d141.s1|204-206|dog|O
DDI-MedLine.d141.s1|208-212|whelk|O
DDI-MedLine.d141.s1|214-220|Nucella|O
DDI-MedLine.d141.s1|222-229|lapillus|O
DDI-MedLine.d141.s2|0-8|Cercarial|O
DDI-MedLine.d141.s2|10-19|encystment|O
DDI-MedLine.d141.s2|24-37|concentrations|O
DDI-MedLine.d141.s2|42-46|25000|O
DDI-MedLine.d141.s2|48-55|microg/l|O
DDI-MedLine.d141.s2|60-65|higher|O
DDI-MedLine.d141.s2|71-83|significantly|O
DDI-MedLine.d141.s2|85-92|impaired|O
DDI-MedLine.d141.s2|101-104|test|O
DDI-MedLine.d141.s2|106-111|metals|O
DDI-MedLine.d141.s3|0-6|however|O
DDI-MedLine.d141.s3|12-16|lower|O
DDI-MedLine.d141.s3|18-31|concentrations|O
DDI-MedLine.d141.s3|38-41|zinc|O
DDI-MedLine.d141.s3|43-54|demonstrated|O
DDI-MedLine.d141.s3|56-63|toxicity|O
DDI-MedLine.d141.s3|64-64|.|O
DDI-MedLine.d141.s4|0-7|Mixtures|O
DDI-MedLine.d141.s4|12-18|cadmium|O
DDI-MedLine.d141.s4|24-27|zinc|O
DDI-MedLine.d141.s4|35-45|synergistic|O
DDI-MedLine.d141.s4|47-52|effect|O
DDI-MedLine.d141.s4|54-61|compared|O
DDI-MedLine.d141.s4|68-73|single|O
DDI-MedLine.d141.s4|75-79|metal|O
DDI-MedLine.d141.s4|81-88|toxicity|O
DDI-MedLine.d141.s4|102-106|50000|O
DDI-MedLine.d141.s4|108-115|microg/l|O
DDI-MedLine.d141.s4|116-116|.|O
DDI-MedLine.d141.s5|0-9|Excystment|O
DDI-MedLine.d141.s5|14-18|vitro|O
DDI-MedLine.d141.s5|29-41|significantly|O
DDI-MedLine.d141.s5|43-50|affected|O
DDI-MedLine.d141.s5|55-63|cercariae|O
DDI-MedLine.d141.s5|65-71|exposed|O
DDI-MedLine.d141.s5|76-87|cadmium/zinc|O
DDI-MedLine.d141.s5|89-96|mixtures|O
DDI-MedLine.d141.s5|98-103|whilst|O
DDI-MedLine.d141.s5|105-113|encysting|O
DDI-MedLine.d141.s6|0-10|Twenty-four|O
DDI-MedLine.d141.s6|12-12|h|O
DDI-MedLine.d141.s6|14-22|exposures|O
DDI-MedLine.d141.s6|27-31|fully|O
DDI-MedLine.d141.s6|33-38|formed|O
DDI-MedLine.d141.s6|40-44|cysts|O
DDI-MedLine.d141.s6|53-58|effect|O
DDI-MedLine.d141.s6|63-72|excystment|O
DDI-MedLine.d141.s6|77-81|vitro|O
DDI-MedLine.d141.s7|0-6|Effects|O
DDI-MedLine.d141.s7|14-18|vitro|O
DDI-MedLine.d141.s7|20-29|excystment|O
DDI-MedLine.d141.s7|31-35|rates|O
DDI-MedLine.d141.s7|44-44|2|O
DDI-MedLine.d141.s7|46-46|h|O
DDI-MedLine.d141.s7|48-53|period|O
DDI-MedLine.d141.s7|55-66|demonstrated|O
DDI-MedLine.d141.s7|68-77|widespread|O
DDI-MedLine.d141.s7|79-85|effects|O
DDI-MedLine.d141.s7|91-107|cercariae-exposed|O
DDI-MedLine.d141.s7|109-109|P|O
DDI-MedLine.d141.s7|110-110|.|O
DDI-MedLine.d141.s8|0-7|acanthus|O
DDI-MedLine.d141.s8|8-8|.|O
DDI-MedLine.d141.s9|0-1|No|O
DDI-MedLine.d141.s9|3-9|effects|O
DDI-MedLine.d141.s9|16-22|evident|O
DDI-MedLine.d141.s9|27-36|excystment|O
DDI-MedLine.d141.s9|38-42|rates|O
DDI-MedLine.d141.s9|47-58|cyst-exposed|O
DDI-MedLine.d141.s9|60-68|parasites|O
DDI-MedLine.d141.s9|69-69|.|O
DDI-MedLine.d102.s0|0-8|Influence|O
DDI-MedLine.d102.s0|13-21|estradiol|O
DDI-MedLine.d102.s0|27-38|progesterone|O
DDI-MedLine.d102.s0|47-57|sensitivity|O
DDI-MedLine.d102.s0|62-64|rat|O
DDI-MedLine.d102.s0|66-73|thoracic|O
DDI-MedLine.d102.s0|75-79|aorta|O
DDI-MedLine.d102.s0|84-96|noradrenaline|O
DDI-MedLine.d102.s0|97-97|.|O
DDI-MedLine.d102.s1|0-2|The|O
DDI-MedLine.d102.s1|4-6|aim|O
DDI-MedLine.d102.s1|16-20|study|O
DDI-MedLine.d102.s1|29-39|investigate|O
DDI-MedLine.d102.s1|45-51|effects|O
DDI-MedLine.d102.s1|56-58|low|O
DDI-MedLine.d102.s1|64-67|high|O
DDI-MedLine.d102.s1|69-73|doses|O
DDI-MedLine.d102.s1|78-86|estradiol|O
DDI-MedLine.d102.s1|96-107|progesterone|O
DDI-MedLine.d102.s1|116-123|response|O
DDI-MedLine.d102.s1|128-140|noradrenaline|O
DDI-MedLine.d102.s1|145-147|rat|O
DDI-MedLine.d102.s1|149-156|thoracic|O
DDI-MedLine.d102.s1|158-162|aorta|O
DDI-MedLine.d102.s1|163-163|.|O
DDI-MedLine.d102.s2|0-2|Two|O
DDI-MedLine.d102.s2|4-8|weeks|O
DDI-MedLine.d102.s2|16-24|bilateral|O
DDI-MedLine.d102.s2|26-36|ovariectomy|O
DDI-MedLine.d102.s2|39-44|female|O
DDI-MedLine.d102.s2|46-49|rats|O
DDI-MedLine.d102.s2|51-58|received|O
DDI-MedLine.d102.s2|62-64|s.c|O
DDI-MedLine.d102.s2|63-63|.|O
DDI-MedLine.d102.s3|0-8|injection|O
DDI-MedLine.d102.s3|13-19|vehicle|O
DDI-MedLine.d102.s3|22-25|corn|O
DDI-MedLine.d102.s3|27-29|oil|O
DDI-MedLine.d102.s3|32-34|0.1|O
DDI-MedLine.d102.s3|36-41|mL/day|O
DDI-MedLine.d102.s3|45-53|estradiol|O
DDI-MedLine.d102.s3|56-57|10|O
DDI-MedLine.d102.s3|59-71|microg/kg/day|O
DDI-MedLine.d102.s3|76-76|4|O
DDI-MedLine.d102.s3|78-86|mg/kg/day|O
DDI-MedLine.d102.s3|89-94|and/or|O
DDI-MedLine.d102.s3|96-107|progesterone|O
DDI-MedLine.d102.s3|110-111|20|O
DDI-MedLine.d102.s3|78-86|mg/kg/day|O
DDI-MedLine.d102.s3|129-133|eight|O
DDI-MedLine.d102.s3|135-138|days|O
DDI-MedLine.d102.s3|33-33|.|O
DDI-MedLine.d102.s4|0-1|On|O
DDI-MedLine.d102.s4|7-11|ninth|O
DDI-MedLine.d102.s4|13-15|day|O
DDI-MedLine.d102.s4|22-25|rats|O
DDI-MedLine.d102.s4|32-41|sacrificed|O
DDI-MedLine.d102.s4|47-52|aortic|O
DDI-MedLine.d102.s4|54-58|rings|O
DDI-MedLine.d102.s4|69-75|without|O
DDI-MedLine.d102.s4|77-87|endothelium|O
DDI-MedLine.d102.s4|95-98|used|O
DDI-MedLine.d102.s4|103-110|generate|O
DDI-MedLine.d102.s4|112-133|concentration-response|O
DDI-MedLine.d102.s4|135-140|curves|O
DDI-MedLine.d102.s4|145-157|noradrenaline|O
DDI-MedLine.d102.s4|158-158|.|O
DDI-MedLine.d102.s5|0-5|Aortic|O
DDI-MedLine.d102.s5|7-11|rings|O
DDI-MedLine.d102.s5|18-23|intact|O
DDI-MedLine.d102.s5|25-35|endothelium|O
DDI-MedLine.d102.s5|46-54|high-dose|O
DDI-MedLine.d102.s5|57-57|4|O
DDI-MedLine.d102.s5|59-67|mg/kg/day|O
DDI-MedLine.d102.s5|70-78|estradiol|O
DDI-MedLine.d102.s5|80-84|group|O
DDI-MedLine.d102.s5|91-104|supersensitive|O
DDI-MedLine.d102.s5|109-121|noradrenaline|O
DDI-MedLine.d102.s5|123-130|compared|O
DDI-MedLine.d102.s5|139-145|vehicle|O
DDI-MedLine.d102.s5|150-157|low-dose|O
DDI-MedLine.d102.s5|160-161|10|O
DDI-MedLine.d102.s5|163-175|microg/kg/day|O
DDI-MedLine.d102.s5|70-78|estradiol|O
DDI-MedLine.d102.s5|188-193|groups|O
DDI-MedLine.d102.s5|196-198|pD2|O
DDI-MedLine.d102.s5|200-205|values|O
DDI-MedLine.d102.s5|207-207|=|O
DDI-MedLine.d102.s5|209-219|7.86+/-0.09|O
DDI-MedLine.d102.s5|222-232|7.30+/-0.11|O
DDI-MedLine.d102.s5|238-248|7.35+/-0.04|O
DDI-MedLine.d102.s5|251-262|respectively|O
DDI-MedLine.d102.s6|0-17|Endothelium-intact|O
DDI-MedLine.d102.s6|19-24|aortic|O
DDI-MedLine.d102.s6|26-30|rings|O
DDI-MedLine.d102.s6|37-50|high-estradiol|O
DDI-MedLine.d102.s6|52-55|rats|O
DDI-MedLine.d102.s6|62-75|supersensitive|O
DDI-MedLine.d102.s6|80-92|noradrenaline|O
DDI-MedLine.d102.s6|99-106|compared|O
DDI-MedLine.d102.s6|111-118|vehicle-|O
DDI-MedLine.d102.s6|121-133|progesterone-|O
DDI-MedLine.d102.s6|121-132|progesterone|O
DDI-MedLine.d102.s6|152-152|+|O
DDI-MedLine.d102.s6|154-175|high-estradiol-treated|O
DDI-MedLine.d102.s6|52-55|rats|O
DDI-MedLine.d102.s6|183-185|pD2|O
DDI-MedLine.d102.s6|187-192|values|O
DDI-MedLine.d102.s6|194-194|=|O
DDI-MedLine.d102.s6|196-206|7.77+/-0.12|O
DDI-MedLine.d102.s6|209-219|7.21+/-0.13|O
DDI-MedLine.d102.s6|222-232|6.93+/-0.04|O
DDI-MedLine.d102.s6|238-248|7.22+/-0.18|O
DDI-MedLine.d102.s6|251-262|respectively|O
DDI-MedLine.d102.s7|0-4|There|O
DDI-MedLine.d102.s7|14-24|significant|O
DDI-MedLine.d102.s7|26-36|differences|O
DDI-MedLine.d102.s7|38-42|among|O
DDI-MedLine.d102.s7|48-50|pD2|O
DDI-MedLine.d102.s7|52-57|values|O
DDI-MedLine.d102.s7|63-75|noradrenaline|O
DDI-MedLine.d102.s7|80-85|aortic|O
DDI-MedLine.d102.s7|87-91|rings|O
DDI-MedLine.d102.s7|93-99|without|O
DDI-MedLine.d102.s7|101-111|endothelium|O
DDI-MedLine.d102.s7|112-112|.|O
DDI-MedLine.d102.s8|0-3|Both|O
DDI-MedLine.d102.s8|14-20|effects|O
DDI-MedLine.d102.s8|27-47|endothelium-dependent|O
DDI-MedLine.d102.s8|48-48|.|O
DDI-DrugBank.d321.s0|0-12|Dexamethasone|O
DDI-DrugBank.d321.s0|15-26|Steady-state|O
DDI-DrugBank.d321.s0|28-33|trough|O
DDI-DrugBank.d321.s0|35-48|concentrations|O
DDI-DrugBank.d321.s0|53-63|albendazole|O
DDI-DrugBank.d321.s0|65-73|sulfoxide|O
DDI-DrugBank.d321.s0|86-87|56|O
DDI-DrugBank.d321.s0|88-88|%|O
DDI-DrugBank.d321.s0|90-95|higher|O
DDI-DrugBank.d321.s0|102-102|8|O
DDI-DrugBank.d321.s0|104-105|mg|O
DDI-DrugBank.d321.s0|107-119|dexamethasone|O
DDI-DrugBank.d321.s0|125-138|coadministered|O
DDI-DrugBank.d321.s0|150-153|dose|O
DDI-DrugBank.d321.s0|53-63|albendazole|O
DDI-DrugBank.d321.s0|171-172|15|O
DDI-DrugBank.d321.s0|174-182|mg/kg/day|O
DDI-DrugBank.d321.s0|188-192|eight|O
DDI-DrugBank.d321.s0|194-211|neurocysticercosis|O
DDI-DrugBank.d321.s0|213-220|patients|O
DDI-DrugBank.d321.s0|221-221|.|O
DDI-DrugBank.d321.s1|0-11|Praziquantel|O
DDI-DrugBank.d321.s1|14-15|In|O
DDI-DrugBank.d321.s1|21-23|fed|O
DDI-DrugBank.d321.s1|25-29|state|O
DDI-DrugBank.d321.s1|32-43|praziquantel|O
DDI-DrugBank.d321.s1|46-47|40|O
DDI-DrugBank.d321.s1|49-53|mg/kg|O
DDI-DrugBank.d321.s1|56-64|increased|O
DDI-DrugBank.d321.s1|66-69|mean|O
DDI-DrugBank.d321.s1|71-77|maximum|O
DDI-DrugBank.d321.s1|79-84|plasma|O
DDI-DrugBank.d321.s1|86-98|concentration|O
DDI-DrugBank.d321.s1|104-107|area|O
DDI-DrugBank.d321.s1|119-123|curve|O
DDI-DrugBank.d321.s1|128-138|albendazole|O
DDI-DrugBank.d321.s1|140-148|sulfoxide|O
DDI-DrugBank.d321.s1|159-160|50|O
DDI-DrugBank.d321.s1|161-161|%|O
DDI-DrugBank.d321.s1|166-172|healthy|O
DDI-DrugBank.d321.s1|174-181|subjects|O
DDI-DrugBank.d321.s1|184-187|n=10|O
DDI-DrugBank.d321.s1|190-197|compared|O
DDI-DrugBank.d321.s1|206-213|separate|O
DDI-DrugBank.d321.s1|215-219|group|O
DDI-DrugBank.d321.s1|174-181|subjects|O
DDI-DrugBank.d321.s1|234-236|n=6|O
DDI-DrugBank.d321.s1|239-243|given|O
DDI-DrugBank.d321.s1|128-138|albendazole|O
DDI-DrugBank.d321.s1|257-261|alone|O
DDI-DrugBank.d321.s1|262-262|.|O
DDI-DrugBank.d321.s2|0-3|Mean|O
DDI-DrugBank.d321.s2|5-5|T|O
DDI-DrugBank.d321.s2|7-9|max|O
DDI-DrugBank.d321.s2|15-18|mean|O
DDI-DrugBank.d321.s2|20-25|plasma|O
DDI-DrugBank.d321.s2|27-37|elimination|O
DDI-DrugBank.d321.s2|39-47|half-life|O
DDI-DrugBank.d321.s2|52-62|albendazole|O
DDI-DrugBank.d321.s2|64-72|sulfoxide|O
DDI-DrugBank.d321.s2|79-87|unchanged|O
DDI-DrugBank.d321.s2|88-88|.|O
DDI-DrugBank.d321.s3|0-2|The|O
DDI-DrugBank.d321.s3|4-19|pharmacokinetics|O
DDI-DrugBank.d321.s3|24-35|praziquantel|O
DDI-DrugBank.d321.s3|42-50|unchanged|O
DDI-DrugBank.d321.s3|52-60|following|O
DDI-DrugBank.d321.s3|62-77|coadministration|O
DDI-DrugBank.d321.s3|84-94|albendazole|O
DDI-DrugBank.d321.s3|97-99|400|O
DDI-DrugBank.d321.s3|101-102|mg|O
DDI-DrugBank.d321.s3|104-104|.|O
DDI-DrugBank.d321.s4|0-9|Cimetidine|O
DDI-DrugBank.d321.s4|12-22|Albendazole|O
DDI-DrugBank.d321.s4|24-32|sulfoxide|O
DDI-DrugBank.d321.s4|34-47|concentrations|O
DDI-DrugBank.d321.s4|52-55|bile|O
DDI-DrugBank.d321.s4|61-66|cystic|O
DDI-DrugBank.d321.s4|68-72|fluid|O
DDI-DrugBank.d321.s4|79-87|increased|O
DDI-DrugBank.d321.s4|96-101|2-fold|O
DDI-DrugBank.d321.s4|107-113|hydatid|O
DDI-DrugBank.d321.s4|61-64|cyst|O
DDI-DrugBank.d321.s4|120-127|patients|O
DDI-DrugBank.d321.s4|129-135|treated|O
DDI-DrugBank.d321.s4|142-151|cimetidine|O
DDI-DrugBank.d321.s4|154-155|10|O
DDI-DrugBank.d321.s4|157-165|mg/kg/day|O
DDI-DrugBank.d321.s4|169-171|n=7|O
DDI-DrugBank.d321.s4|174-181|compared|O
DDI-DrugBank.d321.s4|188-198|albendazole|O
DDI-DrugBank.d321.s4|201-202|20|O
DDI-DrugBank.d321.s4|157-165|mg/kg/day|O
DDI-DrugBank.d321.s4|215-219|alone|O
DDI-DrugBank.d321.s4|222-225|n=12|O
DDI-DrugBank.d321.s4|227-227|.|O
DDI-DrugBank.d321.s5|0-10|Albendazole|O
DDI-DrugBank.d321.s5|12-20|sulfoxide|O
DDI-DrugBank.d321.s5|22-27|plasma|O
DDI-DrugBank.d321.s5|29-42|concentrations|O
DDI-DrugBank.d321.s5|49-57|unchanged|O
DDI-DrugBank.d321.s5|59-59|4|O
DDI-DrugBank.d321.s5|61-65|hours|O
DDI-DrugBank.d321.s5|73-78|dosing|O
DDI-DrugBank.d321.s5|79-79|.|O
DDI-DrugBank.d321.s6|0-11|Theophylline|O
DDI-DrugBank.d321.s6|0-2|The|O
DDI-DrugBank.d321.s6|18-33|pharmacokinetics|O
DDI-DrugBank.d321.s6|38-49|theophylline|O
DDI-DrugBank.d321.s6|52-64|aminophylline|O
DDI-DrugBank.d321.s6|66-68|5.8|O
DDI-DrugBank.d321.s6|70-74|mg/kg|O
DDI-DrugBank.d321.s6|76-82|infused|O
DDI-DrugBank.d321.s6|89-90|20|O
DDI-DrugBank.d321.s6|92-98|minutes|O
DDI-DrugBank.d321.s6|106-114|unchanged|O
DDI-DrugBank.d321.s6|116-124|following|O
DDI-DrugBank.d321.s6|128-133|single|O
DDI-DrugBank.d321.s6|135-138|oral|O
DDI-DrugBank.d321.s6|140-143|dose|O
DDI-DrugBank.d321.s6|148-158|albendazole|O
DDI-DrugBank.d321.s6|161-163|400|O
DDI-DrugBank.d321.s6|70-71|mg|O
DDI-DrugBank.d321.s6|172-172|6|O
DDI-DrugBank.d321.s6|174-180|healthy|O
DDI-DrugBank.d321.s6|182-189|subjects|O
DDI-DrugBank.d321.s6|67-67|.|O
DDI-DrugBank.d597.s0|0-2|ACE|O
DDI-DrugBank.d597.s0|4-13|inhibitors|O
DDI-DrugBank.d597.s0|15-21|Reports|O
DDI-DrugBank.d597.s0|23-29|suggest|O
DDI-DrugBank.d597.s0|36-41|NSAIDs|O
DDI-DrugBank.d597.s0|43-45|may|O
DDI-DrugBank.d597.s0|47-54|diminish|O
DDI-DrugBank.d597.s0|60-75|antihypertensive|O
DDI-DrugBank.d597.s0|77-82|effect|O
DDI-DrugBank.d597.s0|87-108|angiotensin-converting|O
DDI-DrugBank.d597.s0|110-115|enzyme|O
DDI-DrugBank.d597.s0|0-2|ACE|O
DDI-DrugBank.d597.s0|4-13|inhibitors|O
DDI-DrugBank.d597.s0|133-133|.|O
DDI-DrugBank.d597.s1|0-3|This|O
DDI-DrugBank.d597.s1|5-15|interaction|O
DDI-DrugBank.d597.s1|27-31|given|O
DDI-DrugBank.d597.s1|33-45|consideration|O
DDI-DrugBank.d597.s1|50-57|patients|O
DDI-DrugBank.d597.s1|59-64|taking|O
DDI-DrugBank.d597.s1|66-71|NSAIDs|O
DDI-DrugBank.d597.s1|73-85|concomitantly|O
DDI-DrugBank.d597.s1|92-94|ACE|O
DDI-DrugBank.d597.s1|96-105|inhibitors|O
DDI-DrugBank.d597.s1|106-106|.|O
DDI-DrugBank.d597.s2|0-6|Aspirin|O
DDI-DrugBank.d597.s2|9-19|Concomitant|O
DDI-DrugBank.d597.s2|21-34|administration|O
DDI-DrugBank.d597.s2|39-45|aspirin|O
DDI-DrugBank.d597.s2|48-51|1000|O
DDI-DrugBank.d597.s2|53-54|mg|O
DDI-DrugBank.d597.s2|56-58|TID|O
DDI-DrugBank.d597.s2|64-70|healthy|O
DDI-DrugBank.d597.s2|72-81|volunteers|O
DDI-DrugBank.d597.s2|83-88|tended|O
DDI-DrugBank.d597.s2|93-100|increase|O
DDI-DrugBank.d597.s2|106-108|AUC|O
DDI-DrugBank.d597.s2|48-49|10|O
DDI-DrugBank.d597.s2|113-113|%|O
DDI-DrugBank.d597.s2|120-123|Cmax|O
DDI-DrugBank.d597.s2|126-127|24|O
DDI-DrugBank.d597.s2|113-113|%|O
DDI-DrugBank.d597.s2|134-142|meloxicam|O
DDI-DrugBank.d597.s2|143-143|.|O
DDI-DrugBank.d597.s3|0-2|The|O
DDI-DrugBank.d597.s3|4-11|clinical|O
DDI-DrugBank.d597.s3|13-24|significance|O
DDI-DrugBank.d597.s3|34-44|interaction|O
DDI-DrugBank.d597.s3|53-57|known|O
DDI-DrugBank.d597.s4|0-6|however|O
DDI-DrugBank.d597.s4|23-28|NSAIDs|O
DDI-DrugBank.d597.s4|31-41|concomitant|O
DDI-DrugBank.d597.s4|43-56|administration|O
DDI-DrugBank.d597.s4|61-69|meloxicam|O
DDI-DrugBank.d597.s4|75-81|aspirin|O
DDI-DrugBank.d597.s4|90-98|generally|O
DDI-DrugBank.d597.s4|100-110|recommended|O
DDI-DrugBank.d597.s4|127-135|potential|O
DDI-DrugBank.d597.s4|141-149|increased|O
DDI-DrugBank.d597.s4|151-157|adverse|O
DDI-DrugBank.d597.s4|159-165|effects|O
DDI-DrugBank.d597.s4|166-166|.|O
DDI-DrugBank.d597.s5|0-10|Concomitant|O
DDI-DrugBank.d597.s5|12-25|administration|O
DDI-DrugBank.d597.s5|30-37|low-dose|O
DDI-DrugBank.d597.s5|39-45|aspirin|O
DDI-DrugBank.d597.s5|52-56|MOBIC|O
DDI-DrugBank.d597.s5|58-60|may|O
DDI-DrugBank.d597.s5|62-67|result|O
DDI-DrugBank.d597.s5|75-83|increased|O
DDI-DrugBank.d597.s5|85-88|rate|O
DDI-DrugBank.d597.s5|93-94|GI|O
DDI-DrugBank.d597.s5|96-105|ulceration|O
DDI-DrugBank.d597.s5|116-128|complications|O
DDI-DrugBank.d597.s5|131-138|compared|O
DDI-DrugBank.d597.s5|143-145|use|O
DDI-DrugBank.d597.s5|52-56|MOBIC|O
DDI-DrugBank.d597.s5|156-160|alone|O
DDI-DrugBank.d597.s5|161-161|.|O
DDI-DrugBank.d597.s6|0-4|MOBIC|O
DDI-DrugBank.d597.s6|15-24|substitute|O
DDI-DrugBank.d597.s6|30-36|aspirin|O
DDI-DrugBank.d597.s6|42-55|cardiovascular|O
DDI-DrugBank.d597.s6|57-67|prophylaxis|O
DDI-DrugBank.d597.s6|68-68|.|O
DDI-DrugBank.d597.s7|0-13|Cholestyramine|O
DDI-DrugBank.d597.s7|16-27|Pretreatment|O
DDI-DrugBank.d597.s7|33-36|four|O
DDI-DrugBank.d597.s7|38-41|days|O
DDI-DrugBank.d597.s7|48-61|cholestyramine|O
DDI-DrugBank.d597.s7|63-75|significantly|O
DDI-DrugBank.d597.s7|77-85|increased|O
DDI-DrugBank.d597.s7|91-99|clearance|O
DDI-DrugBank.d597.s7|104-112|meloxicam|O
DDI-DrugBank.d597.s7|117-118|50|O
DDI-DrugBank.d597.s7|119-119|%|O
DDI-DrugBank.d597.s7|120-120|.|O
DDI-DrugBank.d597.s8|0-3|This|O
DDI-DrugBank.d597.s8|5-12|resulted|O
DDI-DrugBank.d597.s8|19-26|decrease|O
DDI-DrugBank.d597.s8|31-34|t1/2|O
DDI-DrugBank.d597.s8|42-45|19.2|O
DDI-DrugBank.d597.s8|47-51|hours|O
DDI-DrugBank.d597.s8|56-59|12.5|O
DDI-DrugBank.d597.s8|47-51|hours|O
DDI-DrugBank.d597.s8|74-75|35|O
DDI-DrugBank.d597.s8|76-76|%|O
DDI-DrugBank.d597.s8|78-86|reduction|O
DDI-DrugBank.d597.s8|91-93|AUC|O
DDI-DrugBank.d597.s8|44-44|.|O
DDI-DrugBank.d597.s9|0-3|This|O
DDI-DrugBank.d597.s9|5-12|suggests|O
DDI-DrugBank.d597.s9|18-26|existence|O
DDI-DrugBank.d597.s9|33-45|recirculation|O
DDI-DrugBank.d597.s9|47-53|pathway|O
DDI-DrugBank.d597.s9|59-67|meloxicam|O
DDI-DrugBank.d597.s9|76-91|gastrointestinal|O
DDI-DrugBank.d597.s9|93-97|tract|O
DDI-DrugBank.d597.s9|98-98|.|O
DDI-DrugBank.d597.s10|0-2|The|O
DDI-DrugBank.d597.s10|4-11|clinical|O
DDI-DrugBank.d597.s10|13-21|relevance|O
DDI-DrugBank.d597.s10|31-41|interaction|O
DDI-DrugBank.d597.s10|56-66|established|O
DDI-DrugBank.d597.s10|67-67|.|O
DDI-DrugBank.d597.s11|0-9|Cimetidine|O
DDI-DrugBank.d597.s11|12-22|Concomitant|O
DDI-DrugBank.d597.s11|24-37|administration|O
DDI-DrugBank.d597.s11|42-44|200|O
DDI-DrugBank.d597.s11|46-47|mg|O
DDI-DrugBank.d597.s11|49-58|cimetidine|O
DDI-DrugBank.d597.s11|60-62|QID|O
DDI-DrugBank.d597.s11|72-76|alter|O
DDI-DrugBank.d597.s11|82-92|single-dose|O
DDI-DrugBank.d597.s11|94-109|pharmacokinetics|O
DDI-DrugBank.d597.s11|114-115|30|O
DDI-DrugBank.d597.s11|46-47|mg|O
DDI-DrugBank.d597.s11|120-128|meloxicam|O
DDI-DrugBank.d597.s11|129-129|.|O
DDI-DrugBank.d597.s12|0-6|Digoxin|O
DDI-DrugBank.d597.s12|9-17|Meloxicam|O
DDI-DrugBank.d597.s12|19-20|15|O
DDI-DrugBank.d597.s12|22-23|mg|O
DDI-DrugBank.d597.s12|30-34|daily|O
DDI-DrugBank.d597.s12|40-40|7|O
DDI-DrugBank.d597.s12|42-45|days|O
DDI-DrugBank.d597.s12|55-59|alter|O
DDI-DrugBank.d597.s12|65-70|plasma|O
DDI-DrugBank.d597.s12|72-84|concentration|O
DDI-DrugBank.d597.s12|86-92|profile|O
DDI-DrugBank.d597.s12|97-103|digoxin|O
DDI-DrugBank.d597.s12|111-125|b-acetyldigoxin|O
DDI-DrugBank.d597.s12|127-140|administration|O
DDI-DrugBank.d597.s12|40-40|7|O
DDI-DrugBank.d597.s12|42-45|days|O
DDI-DrugBank.d597.s12|156-163|clinical|O
DDI-DrugBank.d597.s12|165-169|doses|O
DDI-DrugBank.d597.s12|170-170|.|O
DDI-DrugBank.d597.s13|0-1|In|O
DDI-DrugBank.d597.s13|3-7|vitro|O
DDI-DrugBank.d597.s13|9-15|testing|O
DDI-DrugBank.d597.s13|17-21|found|O
DDI-DrugBank.d597.s13|26-32|protein|O
DDI-DrugBank.d597.s13|34-40|binding|O
DDI-DrugBank.d597.s13|42-45|drug|O
DDI-DrugBank.d597.s13|47-57|interaction|O
DDI-DrugBank.d597.s13|67-73|digoxin|O
DDI-DrugBank.d597.s13|79-87|meloxicam|O
DDI-DrugBank.d597.s13|88-88|.|O
DDI-DrugBank.d597.s14|0-9|Furosemide|O
DDI-DrugBank.d597.s14|12-19|Clinical|O
DDI-DrugBank.d597.s14|21-27|studies|O
DDI-DrugBank.d597.s14|33-36|well|O
DDI-DrugBank.d597.s14|41-54|post-marketing|O
DDI-DrugBank.d597.s14|56-67|observations|O
DDI-DrugBank.d597.s14|75-79|shown|O
DDI-DrugBank.d597.s14|86-91|NSAIDs|O
DDI-DrugBank.d597.s14|97-102|reduce|O
DDI-DrugBank.d597.s14|108-118|natriuretic|O
DDI-DrugBank.d597.s14|120-125|effect|O
DDI-DrugBank.d597.s14|130-139|furosemide|O
DDI-DrugBank.d597.s14|145-152|thiazide|O
DDI-DrugBank.d597.s14|154-162|diuretics|O
DDI-DrugBank.d597.s14|172-179|patients|O
DDI-DrugBank.d597.s14|180-180|.|O
DDI-DrugBank.d597.s15|0-3|This|O
DDI-DrugBank.d597.s15|5-10|effect|O
DDI-DrugBank.d597.s15|21-30|attributed|O
DDI-DrugBank.d597.s15|35-44|inhibition|O
DDI-DrugBank.d597.s15|49-53|renal|O
DDI-DrugBank.d597.s15|55-67|prostaglandin|O
DDI-DrugBank.d597.s15|69-77|synthesis|O
DDI-DrugBank.d597.s15|78-78|.|O
DDI-DrugBank.d597.s16|0-6|Studies|O
DDI-DrugBank.d597.s16|13-22|furosemide|O
DDI-DrugBank.d597.s16|24-29|agents|O
DDI-DrugBank.d597.s16|35-43|meloxicam|O
DDI-DrugBank.d597.s16|54-65|demonstrated|O
DDI-DrugBank.d597.s16|69-77|reduction|O
DDI-DrugBank.d597.s16|82-92|natriuretic|O
DDI-DrugBank.d597.s16|94-99|effect|O
DDI-DrugBank.d597.s16|100-100|.|O
DDI-DrugBank.d597.s17|0-9|Furosemide|O
DDI-DrugBank.d597.s17|12-17|single|O
DDI-DrugBank.d597.s17|23-30|multiple|O
DDI-DrugBank.d597.s17|32-35|dose|O
DDI-DrugBank.d597.s17|37-52|pharmacodynamics|O
DDI-DrugBank.d597.s17|58-73|pharmacokinetics|O
DDI-DrugBank.d597.s17|83-90|affected|O
DDI-DrugBank.d597.s17|23-30|multiple|O
DDI-DrugBank.d597.s17|104-108|doses|O
DDI-DrugBank.d597.s17|113-121|meloxicam|O
DDI-DrugBank.d597.s17|122-122|.|O
DDI-DrugBank.d597.s18|0-11|Nevertheless|O
DDI-DrugBank.d597.s18|21-31|concomitant|O
DDI-DrugBank.d597.s18|33-39|therapy|O
DDI-DrugBank.d597.s18|46-55|furosemide|O
DDI-DrugBank.d597.s18|61-65|MOBIC|O
DDI-DrugBank.d597.s18|68-75|patients|O
DDI-DrugBank.d597.s18|87-94|observed|O
DDI-DrugBank.d597.s18|96-102|closely|O
DDI-DrugBank.d597.s18|108-112|signs|O
DDI-DrugBank.d597.s18|117-125|declining|O
DDI-DrugBank.d597.s18|127-131|renal|O
DDI-DrugBank.d597.s18|133-140|function|O
DDI-DrugBank.d597.s18|146-149|well|O
DDI-DrugBank.d597.s18|157-162|assure|O
DDI-DrugBank.d597.s18|164-171|diuretic|O
DDI-DrugBank.d597.s18|173-180|efficacy|O
DDI-DrugBank.d597.s18|181-181|.|O
DDI-DrugBank.d597.s19|0-6|Lithium|O
DDI-DrugBank.d597.s19|9-10|In|O
DDI-DrugBank.d597.s19|12-19|clinical|O
DDI-DrugBank.d597.s19|21-26|trials|O
DDI-DrugBank.d597.s19|29-34|NSAIDs|O
DDI-DrugBank.d597.s19|41-48|produced|O
DDI-DrugBank.d597.s19|53-61|elevation|O
DDI-DrugBank.d597.s19|66-71|plasma|O
DDI-DrugBank.d597.s19|73-79|lithium|O
DDI-DrugBank.d597.s19|81-86|levels|O
DDI-DrugBank.d597.s19|94-102|reduction|O
DDI-DrugBank.d597.s19|107-111|renal|O
DDI-DrugBank.d597.s19|73-79|lithium|O
DDI-DrugBank.d597.s19|121-129|clearance|O
DDI-DrugBank.d597.s19|130-130|.|O
DDI-DrugBank.d597.s20|0-1|In|O
DDI-DrugBank.d597.s20|5-9|study|O
DDI-DrugBank.d597.s20|11-19|conducted|O
DDI-DrugBank.d597.s20|24-30|healthy|O
DDI-DrugBank.d597.s20|32-39|subjects|O
DDI-DrugBank.d597.s20|42-45|mean|O
DDI-DrugBank.d597.s20|47-54|pre-dose|O
DDI-DrugBank.d597.s20|56-62|lithium|O
DDI-DrugBank.d597.s20|64-76|concentration|O
DDI-DrugBank.d597.s20|82-84|AUC|O
DDI-DrugBank.d597.s20|91-99|increased|O
DDI-DrugBank.d597.s20|104-105|21|O
DDI-DrugBank.d597.s20|106-106|%|O
DDI-DrugBank.d597.s20|32-39|subjects|O
DDI-DrugBank.d597.s20|120-128|receiving|O
DDI-DrugBank.d597.s20|56-62|lithium|O
DDI-DrugBank.d597.s20|138-142|doses|O
DDI-DrugBank.d597.s20|144-150|ranging|O
DDI-DrugBank.d597.s20|157-159|804|O
DDI-DrugBank.d597.s20|164-167|1072|O
DDI-DrugBank.d597.s20|169-170|mg|O
DDI-DrugBank.d597.s20|172-174|BID|O
DDI-DrugBank.d597.s20|181-189|meloxicam|O
DDI-DrugBank.d597.s20|191-192|15|O
DDI-DrugBank.d597.s20|169-170|mg|O
DDI-DrugBank.d597.s20|197-198|QD|O
DDI-DrugBank.d597.s20|203-210|compared|O
DDI-DrugBank.d597.s20|32-39|subjects|O
DDI-DrugBank.d597.s20|120-128|receiving|O
DDI-DrugBank.d597.s20|56-62|lithium|O
DDI-DrugBank.d597.s20|242-246|alone|O
DDI-DrugBank.d597.s20|247-247|.|O
DDI-DrugBank.d597.s21|0-4|These|O
DDI-DrugBank.d597.s21|6-12|effects|O
DDI-DrugBank.d597.s21|24-33|attributed|O
DDI-DrugBank.d597.s21|38-47|inhibition|O
DDI-DrugBank.d597.s21|52-56|renal|O
DDI-DrugBank.d597.s21|58-70|prostaglandin|O
DDI-DrugBank.d597.s21|72-80|synthesis|O
DDI-DrugBank.d597.s21|85-89|MOBIC|O
DDI-DrugBank.d597.s21|90-90|.|O
DDI-DrugBank.d597.s22|0-7|Patients|O
DDI-DrugBank.d597.s22|12-18|lithium|O
DDI-DrugBank.d597.s22|20-28|treatment|O
DDI-DrugBank.d597.s22|40-46|closely|O
DDI-DrugBank.d597.s22|48-56|monitored|O
DDI-DrugBank.d597.s22|63-67|MOBIC|O
DDI-DrugBank.d597.s22|72-81|introduced|O
DDI-DrugBank.d597.s22|86-94|withdrawn|O
DDI-DrugBank.d597.s22|95-95|.|O
DDI-DrugBank.d597.s23|0-11|Methotrexate|O
DDI-DrugBank.d597.s23|14-14|A|O
DDI-DrugBank.d597.s23|16-20|study|O
DDI-DrugBank.d597.s23|25-26|13|O
DDI-DrugBank.d597.s23|28-37|rheumatoid|O
DDI-DrugBank.d597.s23|39-47|arthritis|O
DDI-DrugBank.d597.s23|50-51|RA|O
DDI-DrugBank.d597.s23|54-61|patients|O
DDI-DrugBank.d597.s23|63-71|evaluated|O
DDI-DrugBank.d597.s23|77-83|effects|O
DDI-DrugBank.d597.s23|88-95|multiple|O
DDI-DrugBank.d597.s23|97-101|doses|O
DDI-DrugBank.d597.s23|106-114|meloxicam|O
DDI-DrugBank.d597.s23|123-138|pharmacokinetics|O
DDI-DrugBank.d597.s23|143-154|methotrexate|O
DDI-DrugBank.d597.s23|156-160|taken|O
DDI-DrugBank.d597.s23|167-172|weekly|O
DDI-DrugBank.d597.s24|0-8|Meloxicam|O
DDI-DrugBank.d597.s24|25-35|significant|O
DDI-DrugBank.d597.s24|37-42|effect|O
DDI-DrugBank.d597.s24|51-66|pharmacokinetics|O
DDI-DrugBank.d597.s24|71-76|single|O
DDI-DrugBank.d597.s24|78-82|doses|O
DDI-DrugBank.d597.s24|87-98|methotrexate|O
DDI-DrugBank.d597.s24|99-99|.|O
DDI-DrugBank.d597.s25|0-1|In|O
DDI-DrugBank.d597.s25|3-7|vitro|O
DDI-DrugBank.d597.s25|10-21|methotrexate|O
DDI-DrugBank.d597.s25|31-38|displace|O
DDI-DrugBank.d597.s25|40-48|meloxicam|O
DDI-DrugBank.d597.s25|59-63|human|O
DDI-DrugBank.d597.s25|65-69|serum|O
DDI-DrugBank.d597.s25|71-77|binding|O
DDI-DrugBank.d597.s25|79-83|sites|O
DDI-DrugBank.d597.s25|84-84|.|O
DDI-DrugBank.d597.s26|0-7|Warfarin|O
DDI-DrugBank.d597.s26|10-22|Anticoagulant|O
DDI-DrugBank.d597.s26|24-31|activity|O
DDI-DrugBank.d597.s26|43-51|monitored|O
DDI-DrugBank.d597.s26|54-65|particularly|O
DDI-DrugBank.d597.s26|74-78|first|O
DDI-DrugBank.d597.s26|84-87|days|O
DDI-DrugBank.d597.s26|95-104|initiating|O
DDI-DrugBank.d597.s26|109-116|changing|O
DDI-DrugBank.d597.s26|118-122|MOBIC|O
DDI-DrugBank.d597.s26|124-130|therapy|O
DDI-DrugBank.d597.s26|135-142|patients|O
DDI-DrugBank.d597.s26|144-152|receiving|O
DDI-DrugBank.d597.s26|154-161|warfarin|O
DDI-DrugBank.d597.s26|166-172|similar|O
DDI-DrugBank.d597.s26|174-179|agents|O
DDI-DrugBank.d597.s26|182-186|since|O
DDI-DrugBank.d597.s26|135-142|patients|O
DDI-DrugBank.d597.s26|213-221|increased|O
DDI-DrugBank.d597.s26|223-226|risk|O
DDI-DrugBank.d597.s26|231-238|bleeding|O
DDI-DrugBank.d597.s26|239-239|.|O
DDI-DrugBank.d597.s27|0-2|The|O
DDI-DrugBank.d597.s27|4-9|effect|O
DDI-DrugBank.d597.s27|14-22|meloxicam|O
DDI-DrugBank.d597.s27|31-43|anticoagulant|O
DDI-DrugBank.d597.s27|4-9|effect|O
DDI-DrugBank.d597.s27|55-62|warfarin|O
DDI-DrugBank.d597.s27|68-74|studied|O
DDI-DrugBank.d597.s27|81-85|group|O
DDI-DrugBank.d597.s27|90-96|healthy|O
DDI-DrugBank.d597.s27|98-105|subjects|O
DDI-DrugBank.d597.s27|107-115|receiving|O
DDI-DrugBank.d597.s27|117-121|daily|O
DDI-DrugBank.d597.s27|123-127|doses|O
DDI-DrugBank.d597.s27|55-62|warfarin|O
DDI-DrugBank.d597.s27|146-153|produced|O
DDI-DrugBank.d597.s27|158-160|INR|O
DDI-DrugBank.d597.s27|163-175|International|O
DDI-DrugBank.d597.s27|177-186|Normalized|O
DDI-DrugBank.d597.s27|188-192|Ratio|O
DDI-DrugBank.d597.s27|203-205|1.2|O
DDI-DrugBank.d597.s27|211-213|1.8|O
DDI-DrugBank.d597.s27|204-204|.|O
DDI-DrugBank.d597.s28|0-1|In|O
DDI-DrugBank.d597.s28|9-16|subjects|O
DDI-DrugBank.d597.s28|19-27|meloxicam|O
DDI-DrugBank.d597.s28|37-41|alter|O
DDI-DrugBank.d597.s28|43-50|warfarin|O
DDI-DrugBank.d597.s28|52-67|pharmacokinetics|O
DDI-DrugBank.d597.s28|77-83|average|O
DDI-DrugBank.d597.s28|85-97|anticoagulant|O
DDI-DrugBank.d597.s28|99-104|effect|O
DDI-DrugBank.d597.s28|43-50|warfarin|O
DDI-DrugBank.d597.s28|121-130|determined|O
DDI-DrugBank.d597.s28|135-145|prothrombin|O
DDI-DrugBank.d597.s28|147-150|time|O
DDI-DrugBank.d597.s28|151-151|.|O
DDI-DrugBank.d597.s29|0-6|However|O
DDI-DrugBank.d597.s29|9-11|one|O
DDI-DrugBank.d597.s29|13-19|subject|O
DDI-DrugBank.d597.s29|21-26|showed|O
DDI-DrugBank.d597.s29|31-38|increase|O
DDI-DrugBank.d597.s29|43-45|INR|O
DDI-DrugBank.d597.s29|52-54|1.5|O
DDI-DrugBank.d597.s29|59-61|2.1|O
DDI-DrugBank.d597.s29|53-53|.|O
DDI-DrugBank.d597.s30|0-6|Caution|O
DDI-DrugBank.d597.s30|18-21|used|O
DDI-DrugBank.d597.s30|28-40|administering|O
DDI-DrugBank.d597.s30|42-46|MOBIC|O
DDI-DrugBank.d597.s30|53-60|warfarin|O
DDI-DrugBank.d597.s30|62-66|since|O
DDI-DrugBank.d597.s30|68-75|patients|O
DDI-DrugBank.d597.s30|53-60|warfarin|O
DDI-DrugBank.d597.s30|89-91|may|O
DDI-DrugBank.d597.s30|93-102|experience|O
DDI-DrugBank.d597.s30|104-110|changes|O
DDI-DrugBank.d597.s30|115-117|INR|O
DDI-DrugBank.d597.s30|126-134|increased|O
DDI-DrugBank.d597.s30|136-139|risk|O
DDI-DrugBank.d597.s30|144-151|bleeding|O
DDI-DrugBank.d597.s30|153-165|complications|O
DDI-DrugBank.d597.s30|174-176|new|O
DDI-DrugBank.d597.s30|178-187|medication|O
DDI-DrugBank.d597.s30|192-201|introduced|O
DDI-DrugBank.d597.s30|202-202|.|O
DDI-DrugBank.d258.s0|0-9|Loratadine|O
DDI-DrugBank.d258.s0|12-13|10|O
DDI-DrugBank.d258.s0|15-16|mg|O
DDI-DrugBank.d258.s0|23-27|daily|O
DDI-DrugBank.d258.s0|39-52|coadministered|O
DDI-DrugBank.d258.s0|59-69|therapeutic|O
DDI-DrugBank.d258.s0|71-75|doses|O
DDI-DrugBank.d258.s0|80-91|erythromycin|O
DDI-DrugBank.d258.s0|94-103|cimetidine|O
DDI-DrugBank.d258.s0|110-121|ketoconazole|O
DDI-DrugBank.d258.s0|126-135|controlled|O
DDI-DrugBank.d258.s0|137-144|clinical|O
DDI-DrugBank.d258.s0|146-157|pharmacology|O
DDI-DrugBank.d258.s0|159-165|studies|O
DDI-DrugBank.d258.s0|170-174|adult|O
DDI-DrugBank.d258.s0|176-185|volunteers|O
DDI-DrugBank.d258.s0|186-186|.|O
DDI-DrugBank.d258.s1|0-7|Although|O
DDI-DrugBank.d258.s1|9-17|increased|O
DDI-DrugBank.d258.s1|19-24|plasma|O
DDI-DrugBank.d258.s1|26-39|concentrations|O
DDI-DrugBank.d258.s1|42-44|AUC|O
DDI-DrugBank.d258.s1|46-49|0-24|O
DDI-DrugBank.d258.s1|51-53|hrs|O
DDI-DrugBank.d258.s1|59-68|loratadine|O
DDI-DrugBank.d258.s1|70-75|and/or|O
DDI-DrugBank.d258.s1|77-100|descarboethoxyloratadine|O
DDI-DrugBank.d258.s1|107-114|observed|O
DDI-DrugBank.d258.s1|116-124|following|O
DDI-DrugBank.d258.s1|126-141|coadministration|O
DDI-DrugBank.d258.s1|59-68|loratadine|O
DDI-DrugBank.d258.s1|176-180|drugs|O
DDI-DrugBank.d258.s1|185-190|normal|O
DDI-DrugBank.d258.s1|192-201|volunteers|O
DDI-DrugBank.d258.s1|10-10|n|O
DDI-DrugBank.d258.s1|206-206|=|O
DDI-DrugBank.d258.s1|48-49|24|O
DDI-DrugBank.d258.s1|219-223|study|O
DDI-DrugBank.d258.s1|241-250|clinically|O
DDI-DrugBank.d258.s1|252-259|relevant|O
DDI-DrugBank.d258.s1|261-267|changes|O
DDI-DrugBank.d258.s1|276-281|safety|O
DDI-DrugBank.d258.s1|283-289|profile|O
DDI-DrugBank.d258.s1|59-68|loratadine|O
DDI-DrugBank.d258.s1|309-316|assessed|O
DDI-DrugBank.d258.s1|321-340|electrocardiographic|O
DDI-DrugBank.d258.s1|342-351|parameters|O
DDI-DrugBank.d258.s1|241-248|clinical|O
DDI-DrugBank.d258.s1|363-372|laboratory|O
DDI-DrugBank.d258.s1|374-378|tests|O
DDI-DrugBank.d258.s1|381-385|vital|O
DDI-DrugBank.d258.s1|387-391|signs|O
DDI-DrugBank.d258.s1|398-404|adverse|O
DDI-DrugBank.d258.s1|406-411|events|O
DDI-DrugBank.d258.s1|412-412|.|O
DDI-DrugBank.d258.s2|0-4|There|O
DDI-DrugBank.d258.s2|14-24|significant|O
DDI-DrugBank.d258.s2|26-32|effects|O
DDI-DrugBank.d258.s2|37-39|QTc|O
DDI-DrugBank.d258.s2|41-49|intervals|O
DDI-DrugBank.d258.s2|59-65|reports|O
DDI-DrugBank.d258.s2|70-77|sedation|O
DDI-DrugBank.d258.s2|82-88|syncope|O
DDI-DrugBank.d258.s2|89-89|.|O
DDI-DrugBank.d258.s3|0-1|No|O
DDI-DrugBank.d258.s3|3-9|effects|O
DDI-DrugBank.d258.s3|14-19|plasma|O
DDI-DrugBank.d258.s3|21-34|concentrations|O
DDI-DrugBank.d258.s3|39-48|cimetidine|O
DDI-DrugBank.d258.s3|53-64|ketoconazole|O
DDI-DrugBank.d258.s3|71-78|observed|O
DDI-DrugBank.d258.s3|79-79|.|O
DDI-DrugBank.d258.s4|0-5|Plasma|O
DDI-DrugBank.d258.s4|7-20|concentrations|O
DDI-DrugBank.d258.s4|23-25|AUC|O
DDI-DrugBank.d258.s4|27-30|0-24|O
DDI-DrugBank.d258.s4|32-34|hrs|O
DDI-DrugBank.d258.s4|40-51|erythromycin|O
DDI-DrugBank.d258.s4|53-61|decreased|O
DDI-DrugBank.d258.s4|63-64|15|O
DDI-DrugBank.d258.s4|65-65|%|O
DDI-DrugBank.d258.s4|72-87|coadministration|O
DDI-DrugBank.d258.s4|92-101|loratadine|O
DDI-DrugBank.d258.s4|103-110|relative|O
DDI-DrugBank.d258.s4|120-127|observed|O
DDI-DrugBank.d258.s4|40-51|erythromycin|O
DDI-DrugBank.d258.s4|147-151|alone|O
DDI-DrugBank.d258.s4|152-152|.|O
DDI-DrugBank.d258.s5|0-2|The|O
DDI-DrugBank.d258.s5|4-11|clinical|O
DDI-DrugBank.d258.s5|13-21|relevance|O
DDI-DrugBank.d258.s5|31-40|difference|O
DDI-DrugBank.d258.s5|45-51|unknown|O
DDI-DrugBank.d258.s5|52-52|.|O
DDI-DrugBank.d258.s6|0-4|These|O
DDI-DrugBank.d258.s6|12-19|findings|O
DDI-DrugBank.d258.s6|25-34|summarized|O
DDI-DrugBank.d258.s6|39-43|TABLE|O
DDI-DrugBank.d258.s6|45-45|1|O
DDI-DrugBank.d258.s6|46-46|.|O
DDI-DrugBank.d258.s7|0-4|TABLE|O
DDI-DrugBank.d258.s7|6-6|1|O
DDI-DrugBank.d258.s7|8-14|Effects|O
DDI-DrugBank.d258.s7|19-24|Plasma|O
DDI-DrugBank.d258.s7|26-39|Concentrations|O
DDI-DrugBank.d258.s7|42-44|AUC|O
DDI-DrugBank.d258.s7|46-49|0-24|O
DDI-DrugBank.d258.s7|51-53|hrs|O
DDI-DrugBank.d258.s7|59-68|Loratadine|O
DDI-DrugBank.d258.s7|74-97|Descarboethoxyloratadine|O
DDI-DrugBank.d258.s7|99-103|After|O
DDI-DrugBank.d258.s7|105-106|10|O
DDI-DrugBank.d258.s7|108-111|Days|O
DDI-DrugBank.d258.s7|116-131|Coadministration|O
DDI-DrugBank.d258.s7|59-68|Loratadine|O
DDI-DrugBank.d258.s7|105-106|10|O
DDI-DrugBank.d258.s7|148-149|mg|O
DDI-DrugBank.d258.s7|155-160|Normal|O
DDI-DrugBank.d258.s7|162-171|Volunteers|O
DDI-DrugBank.d258.s8|0-9|Loratadine|O
DDI-DrugBank.d258.s8|11-34|Descarboethoxyloratadine|O
DDI-DrugBank.d258.s9|0-11|Erythromycin|O
DDI-DrugBank.d258.s9|14-16|500|O
DDI-DrugBank.d258.s9|18-19|mg|O
DDI-DrugBank.d258.s9|21-23|q8h|O
DDI-DrugBank.d258.s9|26-26|+|O
DDI-DrugBank.d258.s9|28-29|40|O
DDI-DrugBank.d258.s9|30-30|%|O
DDI-DrugBank.d258.s9|32-34|+46|O
DDI-DrugBank.d258.s9|30-30|%|O
DDI-DrugBank.d258.s10|0-9|Cimetidine|O
DDI-DrugBank.d258.s10|12-14|300|O
DDI-DrugBank.d258.s10|16-17|mg|O
DDI-DrugBank.d258.s10|19-21|qid|O
DDI-DrugBank.d258.s10|24-27|+103|O
DDI-DrugBank.d258.s10|28-28|%|O
DDI-DrugBank.d258.s10|24-24|+|O
DDI-DrugBank.d258.s10|32-32|6|O
DDI-DrugBank.d258.s10|28-28|%|O
DDI-DrugBank.d258.s11|0-11|Ketoconazole|O
DDI-DrugBank.d258.s11|14-16|200|O
DDI-DrugBank.d258.s11|18-19|mg|O
DDI-DrugBank.d258.s11|21-24|q12h|O
DDI-DrugBank.d258.s11|27-30|+307|O
DDI-DrugBank.d258.s11|31-31|%|O
DDI-DrugBank.d258.s11|33-35|+73|O
DDI-DrugBank.d258.s11|31-31|%|O
DDI-DrugBank.d258.s12|0-4|There|O
DDI-DrugBank.d258.s12|15-20|appear|O
DDI-DrugBank.d258.s12|31-38|increase|O
DDI-DrugBank.d258.s12|43-49|adverse|O
DDI-DrugBank.d258.s12|51-56|events|O
DDI-DrugBank.d258.s12|61-68|subjects|O
DDI-DrugBank.d258.s12|74-81|received|O
DDI-DrugBank.d258.s12|83-86|oral|O
DDI-DrugBank.d258.s12|88-101|contraceptives|O
DDI-DrugBank.d258.s12|107-116|loratadine|O
DDI-DrugBank.d258.s12|117-117|.|O
DDI-DrugBank.d323.s0|0-16|Co-administration|O
DDI-DrugBank.d323.s0|21-27|MYOBLOC|O
DDI-DrugBank.d323.s0|33-47|aminoglycosides|O
DDI-DrugBank.d323.s0|58-63|agents|O
DDI-DrugBank.d323.s0|65-75|interfering|O
DDI-DrugBank.d323.s0|82-94|neuromuscular|O
DDI-DrugBank.d323.s0|96-107|transmission|O
DDI-DrugBank.d323.s0|110-113|e.g.|O
DDI-DrugBank.d323.s0|116-126|curare-like|O
DDI-DrugBank.d323.s0|128-136|compounds|O
DDI-DrugBank.d323.s0|154-162|performed|O
DDI-DrugBank.d323.s0|169-175|caution|O
DDI-DrugBank.d323.s0|184-189|effect|O
DDI-DrugBank.d323.s0|198-202|toxin|O
DDI-DrugBank.d323.s0|204-206|may|O
DDI-DrugBank.d323.s0|211-221|potentiated|O
DDI-DrugBank.d323.s0|111-111|.|O
DDI-DrugBank.d323.s1|0-2|The|O
DDI-DrugBank.d323.s1|4-9|effect|O
DDI-DrugBank.d323.s1|14-26|administering|O
DDI-DrugBank.d323.s1|28-36|different|O
DDI-DrugBank.d323.s1|38-46|botulinum|O
DDI-DrugBank.d323.s1|48-57|neurotoxin|O
DDI-DrugBank.d323.s1|59-67|serotypes|O
DDI-DrugBank.d323.s1|81-84|time|O
DDI-DrugBank.d323.s1|89-94|within|O
DDI-DrugBank.d323.s1|96-99|less|O
DDI-DrugBank.d323.s1|106-106|4|O
DDI-DrugBank.d323.s1|108-113|months|O
DDI-DrugBank.d323.s1|132-138|unknown|O
DDI-DrugBank.d323.s1|139-139|.|O
DDI-DrugBank.d323.s2|0-6|However|O
DDI-DrugBank.d323.s2|9-21|neuromuscular|O
DDI-DrugBank.d323.s2|23-31|paralysis|O
DDI-DrugBank.d323.s2|33-35|may|O
DDI-DrugBank.d323.s2|40-50|potentiated|O
DDI-DrugBank.d323.s2|55-71|co-administration|O
DDI-DrugBank.d323.s2|76-86|overlapping|O
DDI-DrugBank.d323.s2|58-71|administration|O
DDI-DrugBank.d323.s2|106-114|different|O
DDI-DrugBank.d323.s2|116-124|botulinum|O
DDI-DrugBank.d323.s2|126-130|toxin|O
DDI-DrugBank.d323.s2|132-140|serotypes|O
DDI-DrugBank.d323.s2|141-141|.|O
DDI-DrugBank.d506.s0|0-1|If|O
DDI-DrugBank.d506.s0|3-11|phenytoin|O
DDI-DrugBank.d506.s0|22-28|hepatic|O
DDI-DrugBank.d506.s0|30-35|enzyme|O
DDI-DrugBank.d506.s0|37-44|inducers|O
DDI-DrugBank.d506.s0|50-54|taken|O
DDI-DrugBank.d506.s0|56-67|concurrently|O
DDI-DrugBank.d506.s0|74-80|Norpace|O
DDI-DrugBank.d506.s0|74-80|Norpace|O
DDI-DrugBank.d506.s0|93-94|CR|O
DDI-DrugBank.d506.s0|97-101|lower|O
DDI-DrugBank.d506.s0|103-108|plasma|O
DDI-DrugBank.d506.s0|110-115|levels|O
DDI-DrugBank.d506.s0|120-131|disopyramide|O
DDI-DrugBank.d506.s0|133-135|may|O
DDI-DrugBank.d506.s0|137-141|occur|O
DDI-DrugBank.d506.s0|142-142|.|O
DDI-DrugBank.d506.s1|0-9|Monitoring|O
DDI-DrugBank.d506.s1|14-25|disopyramide|O
DDI-DrugBank.d506.s1|27-32|plasma|O
DDI-DrugBank.d506.s1|34-39|levels|O
DDI-DrugBank.d506.s1|44-54|recommended|O
DDI-DrugBank.d506.s1|64-73|concurrent|O
DDI-DrugBank.d506.s1|75-77|use|O
DDI-DrugBank.d506.s1|82-86|avoid|O
DDI-DrugBank.d506.s1|88-98|ineffective|O
DDI-DrugBank.d506.s1|100-106|therapy|O
DDI-DrugBank.d506.s1|107-107|.|O
DDI-DrugBank.d506.s2|0-4|Other|O
DDI-DrugBank.d506.s2|6-19|antiarrhythmic|O
DDI-DrugBank.d506.s2|21-25|drugs|O
DDI-DrugBank.d506.s2|28-29|eg|O
DDI-DrugBank.d506.s2|32-40|quinidine|O
DDI-DrugBank.d506.s2|43-54|procainamide|O
DDI-DrugBank.d506.s2|57-65|lidocaine|O
DDI-DrugBank.d506.s2|68-78|propranolol|O
DDI-DrugBank.d506.s2|86-97|occasionally|O
DDI-DrugBank.d506.s2|104-107|used|O
DDI-DrugBank.d506.s2|109-120|concurrently|O
DDI-DrugBank.d506.s2|127-133|Norpace|O
DDI-DrugBank.d506.s2|134-134|.|O
DDI-DrugBank.d506.s3|0-8|Excessive|O
DDI-DrugBank.d506.s3|10-17|widening|O
DDI-DrugBank.d506.s3|26-28|QRS|O
DDI-DrugBank.d506.s3|30-36|complex|O
DDI-DrugBank.d506.s3|38-43|and/or|O
DDI-DrugBank.d506.s3|45-56|prolongation|O
DDI-DrugBank.d506.s3|65-67|Q-T|O
DDI-DrugBank.d506.s3|69-76|interval|O
DDI-DrugBank.d506.s3|78-80|may|O
DDI-DrugBank.d506.s3|82-86|occur|O
DDI-DrugBank.d506.s3|97-106|situations|O
DDI-DrugBank.d506.s3|107-107|.|O
DDI-DrugBank.d506.s4|0-1|In|O
DDI-DrugBank.d506.s4|3-9|healthy|O
DDI-DrugBank.d506.s4|11-18|subjects|O
DDI-DrugBank.d506.s4|24-34|significant|O
DDI-DrugBank.d506.s4|36-44|drug-drug|O
DDI-DrugBank.d506.s4|46-56|interaction|O
DDI-DrugBank.d506.s4|62-69|observed|O
DDI-DrugBank.d506.s4|76-82|Norpace|O
DDI-DrugBank.d506.s4|88-101|coadministered|O
DDI-DrugBank.d506.s4|108-113|either|O
DDI-DrugBank.d506.s4|115-125|propranolol|O
DDI-DrugBank.d506.s4|130-137|diazepam|O
DDI-DrugBank.d506.s4|138-138|.|O
DDI-DrugBank.d506.s5|0-10|Concomitant|O
DDI-DrugBank.d506.s5|12-25|administration|O
DDI-DrugBank.d506.s5|30-36|Norpace|O
DDI-DrugBank.d506.s5|42-50|quinidine|O
DDI-DrugBank.d506.s5|52-59|resulted|O
DDI-DrugBank.d506.s5|64-69|slight|O
DDI-DrugBank.d506.s5|71-79|increases|O
DDI-DrugBank.d506.s5|84-89|plasma|O
DDI-DrugBank.d506.s5|91-102|disopyramide|O
DDI-DrugBank.d506.s5|104-109|levels|O
DDI-DrugBank.d506.s5|64-69|slight|O
DDI-DrugBank.d506.s5|122-130|decreases|O
DDI-DrugBank.d506.s5|84-89|plasma|O
DDI-DrugBank.d506.s5|42-50|quinidine|O
DDI-DrugBank.d506.s5|104-109|levels|O
DDI-DrugBank.d506.s5|158-158|.|O
DDI-DrugBank.d506.s6|0-6|Norpace|O
DDI-DrugBank.d506.s6|17-24|increase|O
DDI-DrugBank.d506.s6|26-30|serum|O
DDI-DrugBank.d506.s6|32-38|digoxin|O
DDI-DrugBank.d506.s6|40-45|levels|O
DDI-DrugBank.d506.s6|46-46|.|O
DDI-DrugBank.d506.s7|0-7|Patients|O
DDI-DrugBank.d506.s7|9-14|taking|O
DDI-DrugBank.d506.s7|16-27|disopyramide|O
DDI-DrugBank.d506.s7|29-37|phosphate|O
DDI-DrugBank.d506.s7|43-54|erythromycin|O
DDI-DrugBank.d506.s7|56-68|concomitantly|O
DDI-DrugBank.d506.s7|70-72|may|O
DDI-DrugBank.d506.s7|74-80|develop|O
DDI-DrugBank.d506.s7|82-90|increased|O
DDI-DrugBank.d506.s7|92-96|serum|O
DDI-DrugBank.d506.s7|98-111|concentrations|O
DDI-DrugBank.d506.s7|16-27|disopyramide|O
DDI-DrugBank.d506.s7|129-137|resulting|O
DDI-DrugBank.d506.s7|142-150|excessive|O
DDI-DrugBank.d506.s7|152-159|widening|O
DDI-DrugBank.d506.s7|168-170|QRS|O
DDI-DrugBank.d506.s7|172-178|complex|O
DDI-DrugBank.d506.s7|180-185|and/or|O
DDI-DrugBank.d506.s7|187-198|prolongation|O
DDI-DrugBank.d506.s7|207-209|Q-T|O
DDI-DrugBank.d506.s7|211-218|interval|O
DDI-DrugBank.d506.s7|219-219|.|O
DDI-DrugBank.d506.s8|0-7|Patients|O
DDI-DrugBank.d506.s8|9-14|taking|O
DDI-DrugBank.d506.s8|16-27|disopyramide|O
DDI-DrugBank.d506.s8|29-37|phosphate|O
DDI-DrugBank.d506.s8|43-49|hepatic|O
DDI-DrugBank.d506.s8|51-56|enzyme|O
DDI-DrugBank.d506.s8|58-67|inhibitors|O
DDI-DrugBank.d506.s8|69-81|concomitantly|O
DDI-DrugBank.d506.s8|93-99|closely|O
DDI-DrugBank.d506.s8|101-109|monitored|O
DDI-DrugBank.d506.s8|110-110|.|O
DDI-DrugBank.d506.s9|0-4|Until|O
DDI-DrugBank.d506.s9|6-9|data|O
DDI-DrugBank.d506.s9|14-21|possible|O
DDI-DrugBank.d506.s9|23-34|interactions|O
DDI-DrugBank.d506.s9|44-52|verapamil|O
DDI-DrugBank.d506.s9|58-69|disopyramide|O
DDI-DrugBank.d506.s9|71-79|phosphate|O
DDI-DrugBank.d506.s9|85-92|obtained|O
DDI-DrugBank.d506.s9|58-69|disopyramide|O
DDI-DrugBank.d506.s9|122-133|administered|O
DDI-DrugBank.d506.s9|135-140|within|O
DDI-DrugBank.d506.s9|142-143|48|O
DDI-DrugBank.d506.s9|145-149|hours|O
DDI-DrugBank.d506.s9|161-162|24|O
DDI-DrugBank.d506.s9|145-149|hours|O
DDI-DrugBank.d506.s9|44-52|verapamil|O
DDI-DrugBank.d506.s9|186-199|administration|O
DDI-DrugBank.d506.s9|200-200|.|O
DDI-DrugBank.d450.s0|0-18|Potassium-depleting|O
DDI-DrugBank.d450.s0|20-28|diuretics|O
DDI-DrugBank.d450.s0|36-40|major|O
DDI-DrugBank.d450.s0|42-53|contributing|O
DDI-DrugBank.d450.s0|55-60|factor|O
DDI-DrugBank.d450.s0|65-73|digitalis|O
DDI-DrugBank.d450.s0|75-82|toxicity|O
DDI-DrugBank.d450.s0|83-83|.|O
DDI-DrugBank.d450.s1|0-6|Calcium|O
DDI-DrugBank.d450.s1|9-20|particularly|O
DDI-DrugBank.d450.s1|25-36|administered|O
DDI-DrugBank.d450.s1|38-44|rapidly|O
DDI-DrugBank.d450.s1|53-63|intravenous|O
DDI-DrugBank.d450.s1|65-69|route|O
DDI-DrugBank.d450.s1|72-74|may|O
DDI-DrugBank.d450.s1|76-82|produce|O
DDI-DrugBank.d450.s1|84-90|serious|O
DDI-DrugBank.d450.s1|92-102|arrhythmias|O
DDI-DrugBank.d450.s1|107-117|digitalized|O
DDI-DrugBank.d450.s1|119-126|patients|O
DDI-DrugBank.d450.s1|127-127|.|O
DDI-DrugBank.d450.s2|0-8|Quinidine|O
DDI-DrugBank.d450.s2|11-19|verapamil|O
DDI-DrugBank.d450.s2|22-31|amiodarone|O
DDI-DrugBank.d450.s2|34-44|propafenone|O
DDI-DrugBank.d450.s2|47-58|indomethacin|O
DDI-DrugBank.d450.s2|61-72|itraconazole|O
DDI-DrugBank.d450.s2|75-84|alprazolam|O
DDI-DrugBank.d450.s2|91-104|spironolactone|O
DDI-DrugBank.d450.s2|106-110|raise|O
DDI-DrugBank.d450.s2|116-120|serum|O
DDI-DrugBank.d450.s2|122-128|digoxin|O
DDI-DrugBank.d450.s2|130-142|concentration|O
DDI-DrugBank.d450.s2|144-146|due|O
DDI-DrugBank.d450.s2|153-161|reduction|O
DDI-DrugBank.d450.s2|166-174|clearance|O
DDI-DrugBank.d450.s2|176-181|and/or|O
DDI-DrugBank.d450.s2|186-191|volume|O
DDI-DrugBank.d450.s2|196-207|distribution|O
DDI-DrugBank.d450.s2|216-219|drug|O
DDI-DrugBank.d450.s2|231-241|implication|O
DDI-DrugBank.d450.s2|248-256|digitalis|O
DDI-DrugBank.d450.s2|258-269|intoxication|O
DDI-DrugBank.d450.s2|271-273|may|O
DDI-DrugBank.d450.s2|275-280|result|O
DDI-DrugBank.d450.s2|281-281|.|O
DDI-DrugBank.d450.s3|0-11|Erythromycin|O
DDI-DrugBank.d450.s3|17-30|clarithromycin|O
DDI-DrugBank.d450.s3|37-44|possibly|O
DDI-DrugBank.d450.s3|52-60|macrolide|O
DDI-DrugBank.d450.s3|62-72|antibiotics|O
DDI-DrugBank.d450.s3|79-90|tetracycline|O
DDI-DrugBank.d450.s3|92-94|may|O
DDI-DrugBank.d450.s3|96-103|increase|O
DDI-DrugBank.d450.s3|105-111|digoxin|O
DDI-DrugBank.d450.s3|113-122|absorption|O
DDI-DrugBank.d450.s3|127-134|patients|O
DDI-DrugBank.d450.s3|140-149|inactivate|O
DDI-DrugBank.d450.s3|105-111|digoxin|O
DDI-DrugBank.d450.s3|162-170|bacterial|O
DDI-DrugBank.d450.s3|172-181|metabolism|O
DDI-DrugBank.d450.s3|190-194|lower|O
DDI-DrugBank.d450.s3|196-204|intestine|O
DDI-DrugBank.d450.s3|215-223|digitalis|O
DDI-DrugBank.d450.s3|225-236|intoxication|O
DDI-DrugBank.d450.s3|92-94|may|O
DDI-DrugBank.d450.s3|242-247|result|O
DDI-DrugBank.d450.s3|248-248|.|O
DDI-DrugBank.d450.s4|0-2|The|O
DDI-DrugBank.d450.s4|4-7|risk|O
DDI-DrugBank.d450.s4|17-27|interaction|O
DDI-DrugBank.d450.s4|29-31|may|O
DDI-DrugBank.d450.s4|36-42|reduced|O
DDI-DrugBank.d450.s4|47-53|digoxin|O
DDI-DrugBank.d450.s4|58-62|given|O
DDI-DrugBank.d450.s4|67-74|capsules|O
DDI-DrugBank.d450.s4|75-75|.|O
DDI-DrugBank.d450.s5|0-12|Propantheline|O
DDI-DrugBank.d450.s5|18-30|diphenoxylate|O
DDI-DrugBank.d450.s5|36-45|decreasing|O
DDI-DrugBank.d450.s5|47-49|gut|O
DDI-DrugBank.d450.s5|51-58|motility|O
DDI-DrugBank.d450.s5|61-63|may|O
DDI-DrugBank.d450.s5|65-72|increase|O
DDI-DrugBank.d450.s5|74-80|digoxin|O
DDI-DrugBank.d450.s5|82-91|absorption|O
DDI-DrugBank.d450.s5|92-92|.|O
DDI-DrugBank.d450.s6|0-7|Antacids|O
DDI-DrugBank.d450.s6|10-22|kaolin-pectin|O
DDI-DrugBank.d450.s6|25-37|sulfasalazine|O
DDI-DrugBank.d450.s6|40-47|neomycin|O
DDI-DrugBank.d450.s6|50-63|cholestyramine|O
DDI-DrugBank.d450.s6|66-72|certain|O
DDI-DrugBank.d450.s6|74-83|anticancer|O
DDI-DrugBank.d450.s6|85-89|drugs|O
DDI-DrugBank.d450.s6|96-109|metoclopramide|O
DDI-DrugBank.d450.s6|111-113|may|O
DDI-DrugBank.d450.s6|115-123|interfere|O
DDI-DrugBank.d450.s6|130-139|intestinal|O
DDI-DrugBank.d450.s6|141-147|digoxin|O
DDI-DrugBank.d450.s6|149-158|absorption|O
DDI-DrugBank.d450.s6|161-169|resulting|O
DDI-DrugBank.d450.s6|174-185|unexpectedly|O
DDI-DrugBank.d450.s6|187-189|low|O
DDI-DrugBank.d450.s6|191-195|serum|O
DDI-DrugBank.d450.s6|197-210|concentrations|O
DDI-DrugBank.d450.s6|211-211|.|O
DDI-DrugBank.d450.s7|0-7|Rifampin|O
DDI-DrugBank.d450.s7|9-11|may|O
DDI-DrugBank.d450.s7|13-20|decrease|O
DDI-DrugBank.d450.s7|22-26|serum|O
DDI-DrugBank.d450.s7|28-34|digoxin|O
DDI-DrugBank.d450.s7|36-48|concentration|O
DDI-DrugBank.d450.s7|51-60|especially|O
DDI-DrugBank.d450.s7|65-72|patients|O
DDI-DrugBank.d450.s7|79-83|renal|O
DDI-DrugBank.d450.s7|85-95|dysfunction|O
DDI-DrugBank.d450.s7|101-110|increasing|O
DDI-DrugBank.d450.s7|116-124|non-renal|O
DDI-DrugBank.d450.s7|126-134|clearance|O
DDI-DrugBank.d450.s7|28-34|digoxin|O
DDI-DrugBank.d450.s7|146-146|.|O
DDI-DrugBank.d450.s8|0-4|There|O
DDI-DrugBank.d450.s8|16-27|inconsistent|O
DDI-DrugBank.d450.s8|29-35|reports|O
DDI-DrugBank.d450.s8|37-45|regarding|O
DDI-DrugBank.d450.s8|51-57|effects|O
DDI-DrugBank.d450.s8|68-72|drugs|O
DDI-DrugBank.d450.s8|75-78|e.g.|O
DDI-DrugBank.d450.s8|81-87|quinine|O
DDI-DrugBank.d450.s8|90-102|penicillamine|O
DDI-DrugBank.d450.s8|108-112|serum|O
DDI-DrugBank.d450.s8|114-120|digoxin|O
DDI-DrugBank.d450.s8|122-134|concentration|O
DDI-DrugBank.d450.s8|76-76|.|O
DDI-DrugBank.d450.s9|0-6|Thyroid|O
DDI-DrugBank.d450.s9|8-21|administration|O
DDI-DrugBank.d450.s9|28-38|digitalized|O
DDI-DrugBank.d450.s9|41-51|hypothyroid|O
DDI-DrugBank.d450.s9|53-59|patient|O
DDI-DrugBank.d450.s9|61-63|may|O
DDI-DrugBank.d450.s9|65-72|increase|O
DDI-DrugBank.d450.s9|78-81|dose|O
DDI-DrugBank.d450.s9|83-93|requirement|O
DDI-DrugBank.d450.s9|98-104|digoxin|O
DDI-DrugBank.d450.s9|105-105|.|O
DDI-DrugBank.d450.s10|0-10|Concomitant|O
DDI-DrugBank.d450.s10|12-14|use|O
DDI-DrugBank.d450.s10|19-25|digoxin|O
DDI-DrugBank.d450.s10|31-46|sympathomimetics|O
DDI-DrugBank.d450.s10|48-56|increases|O
DDI-DrugBank.d450.s10|62-65|risk|O
DDI-DrugBank.d450.s10|70-76|cardiac|O
DDI-DrugBank.d450.s10|78-88|arrhythmias|O
DDI-DrugBank.d450.s10|89-89|.|O
DDI-DrugBank.d450.s11|0-14|Succinylcholine|O
DDI-DrugBank.d450.s11|16-18|may|O
DDI-DrugBank.d450.s11|20-24|cause|O
DDI-DrugBank.d450.s11|28-33|sudden|O
DDI-DrugBank.d450.s11|35-43|extrusion|O
DDI-DrugBank.d450.s11|48-56|potassium|O
DDI-DrugBank.d450.s11|63-68|muscle|O
DDI-DrugBank.d450.s11|70-74|cells|O
DDI-DrugBank.d450.s11|16-18|may|O
DDI-DrugBank.d450.s11|85-91|thereby|O
DDI-DrugBank.d450.s11|20-24|cause|O
DDI-DrugBank.d450.s11|99-109|arrhythmias|O
DDI-DrugBank.d450.s11|114-124|digitalized|O
DDI-DrugBank.d450.s11|126-133|patients|O
DDI-DrugBank.d450.s11|134-134|.|O
DDI-DrugBank.d450.s12|0-7|Although|O
DDI-DrugBank.d450.s12|9-23|beta-adrenergic|O
DDI-DrugBank.d450.s12|25-32|blockers|O
DDI-DrugBank.d450.s12|37-43|calcium|O
DDI-DrugBank.d450.s12|45-51|channel|O
DDI-DrugBank.d450.s12|25-32|blockers|O
DDI-DrugBank.d450.s12|66-72|digoxin|O
DDI-DrugBank.d450.s12|74-76|may|O
DDI-DrugBank.d450.s12|81-86|useful|O
DDI-DrugBank.d450.s12|91-101|combination|O
DDI-DrugBank.d450.s12|106-112|control|O
DDI-DrugBank.d450.s12|114-119|atrial|O
DDI-DrugBank.d450.s12|121-132|fibrillation|O
DDI-DrugBank.d450.s12|141-148|additive|O
DDI-DrugBank.d450.s12|150-156|effects|O
DDI-DrugBank.d450.s12|161-162|AV|O
DDI-DrugBank.d450.s12|164-167|node|O
DDI-DrugBank.d450.s12|169-178|conduction|O
DDI-DrugBank.d450.s12|184-189|result|O
DDI-DrugBank.d450.s12|194-201|advanced|O
DDI-DrugBank.d450.s12|206-213|complete|O
DDI-DrugBank.d450.s12|215-219|heart|O
DDI-DrugBank.d450.s12|25-29|block|O
DDI-DrugBank.d450.s12|226-226|.|O
DDI-DrugBank.d450.s13|0-2|Due|O
DDI-DrugBank.d450.s13|11-22|considerable|O
DDI-DrugBank.d450.s13|24-34|variability|O
DDI-DrugBank.d450.s13|45-56|interactions|O
DDI-DrugBank.d450.s13|63-68|dosage|O
DDI-DrugBank.d450.s13|73-79|digoxin|O
DDI-DrugBank.d450.s13|91-104|individualized|O
DDI-DrugBank.d450.s13|111-118|patients|O
DDI-DrugBank.d450.s13|120-126|receive|O
DDI-DrugBank.d450.s13|134-144|medications|O
DDI-DrugBank.d450.s13|146-157|concurrently|O
DDI-DrugBank.d450.s13|158-158|.|O
DDI-DrugBank.d450.s14|0-10|Furthermore|O
DDI-DrugBank.d450.s14|13-19|caution|O
DDI-DrugBank.d450.s14|31-39|exercised|O
DDI-DrugBank.d450.s14|46-54|combining|O
DDI-DrugBank.d450.s14|56-62|digoxin|O
DDI-DrugBank.d450.s14|73-76|drug|O
DDI-DrugBank.d450.s14|83-85|may|O
DDI-DrugBank.d450.s14|87-91|cause|O
DDI-DrugBank.d450.s14|95-105|significant|O
DDI-DrugBank.d450.s14|107-119|deterioration|O
DDI-DrugBank.d450.s14|124-128|renal|O
DDI-DrugBank.d450.s14|130-137|function|O
DDI-DrugBank.d450.s14|140-144|since|O
DDI-DrugBank.d450.s14|148-154|decline|O
DDI-DrugBank.d450.s14|159-168|glomerular|O
DDI-DrugBank.d450.s14|170-179|filtration|O
DDI-DrugBank.d450.s14|184-190|tubular|O
DDI-DrugBank.d450.s14|192-200|secretion|O
DDI-DrugBank.d450.s14|83-85|may|O
DDI-DrugBank.d450.s14|206-211|impair|O
DDI-DrugBank.d450.s14|217-225|excretion|O
DDI-DrugBank.d450.s14|56-62|digoxin|O
DDI-DrugBank.d450.s14|237-237|.|O
DDI-DrugBank.d378.s0|0-4|Renal|O
DDI-DrugBank.d378.s0|6-13|function|O
DDI-DrugBank.d378.s0|25-33|monitored|O
DDI-DrugBank.d378.s0|35-43|carefully|O
DDI-DrugBank.d378.s0|48-51|high|O
DDI-DrugBank.d378.s0|53-57|doses|O
DDI-DrugBank.d378.s0|62-76|aminoglycosides|O
DDI-DrugBank.d378.s0|88-99|administered|O
DDI-DrugBank.d378.s0|106-113|MAXIPIME|O
DDI-DrugBank.d378.s0|130-138|increased|O
DDI-DrugBank.d378.s0|140-148|potential|O
DDI-DrugBank.d378.s0|153-166|nephrotoxicity|O
DDI-DrugBank.d378.s0|172-182|ototoxicity|O
DDI-DrugBank.d378.s0|62-75|aminoglycoside|O
DDI-DrugBank.d378.s0|202-212|antibiotics|O
DDI-DrugBank.d378.s0|213-213|.|O
DDI-DrugBank.d378.s1|0-13|Nephrotoxicity|O
DDI-DrugBank.d378.s1|24-31|reported|O
DDI-DrugBank.d378.s1|33-41|following|O
DDI-DrugBank.d378.s1|43-53|concomitant|O
DDI-DrugBank.d378.s1|55-68|administration|O
DDI-DrugBank.d378.s1|79-92|cephalosporins|O
DDI-DrugBank.d378.s1|99-104|potent|O
DDI-DrugBank.d378.s1|106-114|diuretics|O
DDI-DrugBank.d378.s1|124-133|furosemide|O
DDI-DrugBank.d378.s1|134-134|.|O
DDI-DrugBank.d378.s2|0-14|Drug/Laboratory|O
DDI-DrugBank.d378.s2|16-19|Test|O
DDI-DrugBank.d378.s2|21-32|Interactions|O
DDI-DrugBank.d378.s2|34-36|The|O
DDI-DrugBank.d378.s2|38-51|administration|O
DDI-DrugBank.d378.s2|56-63|cefepime|O
DDI-DrugBank.d378.s2|65-67|may|O
DDI-DrugBank.d378.s2|69-74|result|O
DDI-DrugBank.d378.s2|81-94|false-positive|O
DDI-DrugBank.d378.s2|96-103|reaction|O
DDI-DrugBank.d378.s2|109-115|glucose|O
DDI-DrugBank.d378.s2|124-128|urine|O
DDI-DrugBank.d378.s2|135-139|using|O
DDI-DrugBank.d378.s2|141-149|Clinitest|O
DDI-DrugBank.d378.s2|152-158|tablets|O
DDI-DrugBank.d378.s2|159-159|.|O
DDI-DrugBank.d378.s3|0-1|It|O
DDI-DrugBank.d378.s3|6-16|recommended|O
DDI-DrugBank.d378.s3|23-29|glucose|O
DDI-DrugBank.d378.s3|31-35|tests|O
DDI-DrugBank.d378.s3|37-41|based|O
DDI-DrugBank.d378.s3|46-54|enzymatic|O
DDI-DrugBank.d378.s3|23-29|glucose|O
DDI-DrugBank.d378.s3|64-70|oxidase|O
DDI-DrugBank.d378.s3|72-80|reactions|O
DDI-DrugBank.d378.s3|91-99|Clinistix|O
DDI-DrugBank.d378.s3|105-112|Tes-Tape|O
DDI-DrugBank.d378.s3|120-123|used|O
DDI-DrugBank.d378.s3|124-124|.|O
DDI-DrugBank.d119.s0|0-2|The|O
DDI-DrugBank.d119.s0|4-12|following|O
DDI-DrugBank.d119.s0|14-17|drug|O
DDI-DrugBank.d119.s0|19-30|interactions|O
DDI-DrugBank.d119.s0|42-49|reported|O
DDI-DrugBank.d119.s0|56-64|etomidate|O
DDI-DrugBank.d119.s0|65-65|.|O
DDI-DrugBank.d119.s1|0-3|Drug|O
DDI-DrugBank.d119.s1|5-10|Effect|O
DDI-DrugBank.d119.s2|0-9|Probenecid|O
DDI-DrugBank.d119.s2|14-22|Prolonged|O
DDI-DrugBank.d119.s2|24-29|action|O
DDI-DrugBank.d119.s2|34-42|etomidate|O
DDI-DrugBank.d119.s3|0-8|Diazoxide|O
DDI-DrugBank.d119.s3|13-23|Hypotension|O
DDI-DrugBank.d119.s4|0-9|Zimelidine|O
DDI-DrugBank.d119.s4|14-22|etomidate|O
DDI-DrugBank.d119.s4|24-33|antagonism|O
DDI-DrugBank.d119.s5|0-5|Opioid|O
DDI-DrugBank.d119.s5|7-16|analgesics|O
DDI-DrugBank.d119.s5|21-29|Decreased|O
DDI-DrugBank.d119.s5|31-45|antinociceptive|O
DDI-DrugBank.d119.s5|47-52|action|O
DDI-DrugBank.d119.s6|0-12|Aminophylline|O
DDI-DrugBank.d119.s6|18-26|Etomidate|O
DDI-DrugBank.d119.s6|28-37|antagonism|O
DDI-DrugBank.d119.s7|0-8|Midazolam|O
DDI-DrugBank.d119.s7|13-21|Synergism|O
DDI-MedLine.d201.s0|0-8|Antitumor|O
DDI-MedLine.d201.s0|10-16|effects|O
DDI-MedLine.d201.s0|21-26|CRM197|O
DDI-MedLine.d201.s0|31-38|specific|O
DDI-MedLine.d201.s0|40-48|inhibitor|O
DDI-MedLine.d201.s0|53-58|HB-EGF|O
DDI-MedLine.d201.s0|64-69|T-cell|O
DDI-MedLine.d201.s0|71-75|acute|O
DDI-MedLine.d201.s0|77-89|lymphoblastic|O
DDI-MedLine.d201.s0|91-98|leukemia|O
DDI-MedLine.d201.s0|99-99|.|O
DDI-MedLine.d201.s1|0-2|The|O
DDI-MedLine.d201.s1|4-14|therapeutic|O
DDI-MedLine.d201.s1|16-22|outcome|O
DDI-MedLine.d201.s1|28-33|T-cell|O
DDI-MedLine.d201.s1|35-39|acute|O
DDI-MedLine.d201.s1|41-53|lymphoblastic|O
DDI-MedLine.d201.s1|55-62|leukemia|O
DDI-MedLine.d201.s1|65-69|T-ALL|O
DDI-MedLine.d201.s1|72-78|remains|O
DDI-MedLine.d201.s1|80-83|poor|O
DDI-MedLine.d201.s2|0-3|thus|O
DDI-MedLine.d201.s2|6-10|novel|O
DDI-MedLine.d201.s2|13-20|targeted|O
DDI-MedLine.d201.s2|22-30|therapies|O
DDI-MedLine.d201.s2|36-43|urgently|O
DDI-MedLine.d201.s2|45-50|needed|O
DDI-MedLine.d201.s2|51-51|.|O
DDI-MedLine.d201.s3|0-7|Recently|O
DDI-MedLine.d201.s3|13-18|showed|O
DDI-MedLine.d201.s3|25-39|heparin-binding|O
DDI-MedLine.d201.s3|41-49|epidermal|O
DDI-MedLine.d201.s3|51-56|growth|O
DDI-MedLine.d201.s3|58-68|factor-like|O
DDI-MedLine.d201.s3|51-56|growth|O
DDI-MedLine.d201.s3|58-63|factor|O
DDI-MedLine.d201.s3|85-90|HB-EGF|O
DDI-MedLine.d201.s3|96-101|member|O
DDI-MedLine.d201.s3|88-90|EGF|O
DDI-MedLine.d201.s3|114-119|family|O
DDI-MedLine.d201.s3|127-135|promising|O
DDI-MedLine.d201.s3|137-142|target|O
DDI-MedLine.d201.s3|152-160|treatment|O
DDI-MedLine.d201.s3|165-171|various|O
DDI-MedLine.d201.s3|173-177|types|O
DDI-MedLine.d201.s3|182-187|cancer|O
DDI-MedLine.d201.s3|188-188|.|O
DDI-MedLine.d201.s4|0-2|The|O
DDI-MedLine.d201.s4|4-6|aim|O
DDI-MedLine.d201.s4|15-21|present|O
DDI-MedLine.d201.s4|23-27|study|O
DDI-MedLine.d201.s4|36-46|investigate|O
DDI-MedLine.d201.s4|48-54|whether|O
DDI-MedLine.d201.s4|56-61|HB-EGF|O
DDI-MedLine.d201.s4|68-78|therapeutic|O
DDI-MedLine.d201.s4|80-85|target|O
DDI-MedLine.d201.s4|91-95|T-ALL|O
DDI-MedLine.d201.s4|113-121|elucidate|O
DDI-MedLine.d201.s4|127-135|antitumor|O
DDI-MedLine.d201.s4|137-143|effects|O
DDI-MedLine.d201.s4|150-157|specific|O
DDI-MedLine.d201.s4|159-167|inhibitor|O
DDI-MedLine.d201.s4|56-61|HB-EGF|O
DDI-MedLine.d201.s4|180-193|cross-reacting|O
DDI-MedLine.d201.s4|195-202|material|O
DDI-MedLine.d201.s4|204-206|197|O
DDI-MedLine.d201.s4|209-214|CRM197|O
DDI-MedLine.d201.s4|216-216|.|O
DDI-MedLine.d201.s5|0-1|We|O
DDI-MedLine.d201.s5|3-12|elucidated|O
DDI-MedLine.d201.s5|18-27|expression|O
DDI-MedLine.d201.s5|32-37|HB-EGF|O
DDI-MedLine.d201.s5|42-46|T-ALL|O
DDI-MedLine.d201.s5|48-51|cell|O
DDI-MedLine.d201.s5|53-57|lines|O
DDI-MedLine.d201.s5|64-72|evaluated|O
DDI-MedLine.d201.s5|78-83|effect|O
DDI-MedLine.d201.s5|88-93|CRM197|O
DDI-MedLine.d201.s5|104-108|cells|O
DDI-MedLine.d201.s5|110-114|alone|O
DDI-MedLine.d201.s5|122-132|combination|O
DDI-MedLine.d201.s5|139-148|anticancer|O
DDI-MedLine.d201.s5|150-154|agent|O
DDI-MedLine.d201.s6|0-2|The|O
DDI-MedLine.d201.s6|4-13|expression|O
DDI-MedLine.d201.s6|18-21|EGFR|O
DDI-MedLine.d201.s6|18-21|EGFR|O
DDI-MedLine.d201.s6|32-38|ligands|O
DDI-MedLine.d201.s6|44-53|determined|O
DDI-MedLine.d201.s6|58-61|flow|O
DDI-MedLine.d201.s6|63-71|cytometry|O
DDI-MedLine.d201.s6|74-79|RT-PCR|O
DDI-MedLine.d201.s6|85-93|real-time|O
DDI-MedLine.d201.s6|95-106|quantitative|O
DDI-MedLine.d201.s6|77-79|PCR|O
DDI-MedLine.d201.s6|111-111|.|O
DDI-MedLine.d201.s7|0-8|Induction|O
DDI-MedLine.d201.s7|13-21|apoptosis|O
DDI-MedLine.d201.s7|27-34|assessed|O
DDI-MedLine.d201.s7|39-43|TUNEL|O
DDI-MedLine.d201.s7|45-49|assay|O
DDI-MedLine.d201.s7|50-50|.|O
DDI-MedLine.d201.s8|0-5|HB-EGF|O
DDI-MedLine.d201.s8|11-18|strongly|O
DDI-MedLine.d201.s8|20-28|expressed|O
DDI-MedLine.d201.s8|33-37|T-ALL|O
DDI-MedLine.d201.s8|39-42|cell|O
DDI-MedLine.d201.s8|44-48|lines|O
DDI-MedLine.d201.s8|59-68|expression|O
DDI-MedLine.d201.s8|0-5|HB-EGF|O
DDI-MedLine.d201.s8|89-92|EGFR|O
DDI-MedLine.d201.s8|98-105|enhanced|O
DDI-MedLine.d201.s8|110-120|doxorubicin|O
DDI-MedLine.d201.s8|121-121|.|O
DDI-MedLine.d201.s9|0-5|CRM197|O
DDI-MedLine.d201.s9|7-13|induced|O
DDI-MedLine.d201.s9|15-23|apoptosis|O
DDI-MedLine.d201.s9|30-40|furthermore|O
DDI-MedLine.d201.s9|47-57|combination|O
DDI-MedLine.d201.s9|0-5|CRM197|O
DDI-MedLine.d201.s9|69-72|plus|O
DDI-MedLine.d201.s9|74-84|doxorubicin|O
DDI-MedLine.d201.s9|86-93|enhanced|O
DDI-MedLine.d201.s9|95-106|cytotoxicity|O
DDI-MedLine.d201.s9|113-117|T-ALL|O
DDI-MedLine.d201.s9|119-122|cell|O
DDI-MedLine.d201.s9|124-127|line|O
DDI-MedLine.d201.s9|128-128|.|O
DDI-MedLine.d201.s10|0-4|These|O
DDI-MedLine.d201.s10|6-12|results|O
DDI-MedLine.d201.s10|14-20|suggest|O
DDI-MedLine.d201.s10|27-32|HB-EGF|O
DDI-MedLine.d201.s10|39-47|promising|O
DDI-MedLine.d201.s10|49-59|therapeutic|O
DDI-MedLine.d201.s10|61-66|target|O
DDI-MedLine.d201.s10|72-76|T-ALL|O
DDI-MedLine.d201.s10|77-77|.|O
DDI-DrugBank.d573.s0|0-10|Interaction|O
DDI-DrugBank.d573.s0|17-28|Guanethidine|O
DDI-DrugBank.d573.s0|31-38|Although|O
DDI-DrugBank.d573.s0|40-48|minoxidil|O
DDI-DrugBank.d573.s0|66-70|cause|O
DDI-DrugBank.d573.s0|72-82|orthostatic|O
DDI-DrugBank.d573.s0|84-94|hypotension|O
DDI-DrugBank.d573.s0|101-114|administration|O
DDI-DrugBank.d573.s0|119-126|patients|O
DDI-DrugBank.d573.s0|128-134|already|O
DDI-DrugBank.d573.s0|136-144|receiving|O
DDI-DrugBank.d573.s0|146-157|guanethidine|O
DDI-DrugBank.d573.s0|163-168|result|O
DDI-DrugBank.d573.s0|173-180|profound|O
DDI-DrugBank.d573.s0|72-82|orthostatic|O
DDI-DrugBank.d573.s0|194-200|effects|O
DDI-DrugBank.d573.s0|201-201|.|O
DDI-DrugBank.d573.s1|0-1|If|O
DDI-DrugBank.d573.s1|10-17|possible|O
DDI-DrugBank.d573.s1|19-30|guanethidine|O
DDI-DrugBank.d573.s1|42-53|discontinued|O
DDI-DrugBank.d573.s1|55-58|well|O
DDI-DrugBank.d573.s1|67-75|minoxidil|O
DDI-DrugBank.d573.s1|80-84|begun|O
DDI-DrugBank.d573.s1|85-85|.|O
DDI-DrugBank.d573.s2|0-4|Where|O
DDI-DrugBank.d573.s2|18-25|possible|O
DDI-DrugBank.d573.s2|28-36|minoxidil|O
DDI-DrugBank.d573.s2|38-44|therapy|O
DDI-DrugBank.d573.s2|56-62|started|O
DDI-DrugBank.d573.s2|71-78|hospital|O
DDI-DrugBank.d573.s2|88-94|patient|O
DDI-DrugBank.d573.s2|103-108|remain|O
DDI-DrugBank.d573.s2|110-126|institutionalized|O
DDI-DrugBank.d573.s2|134-139|severe|O
DDI-DrugBank.d573.s2|141-151|orthostatic|O
DDI-DrugBank.d573.s2|153-159|effects|O
DDI-DrugBank.d573.s2|168-173|longer|O
DDI-DrugBank.d573.s2|175-181|present|O
DDI-DrugBank.d573.s2|88-94|patient|O
DDI-DrugBank.d573.s2|202-208|learned|O
DDI-DrugBank.d573.s2|213-217|avoid|O
DDI-DrugBank.d573.s2|219-228|activities|O
DDI-DrugBank.d573.s2|235-241|provoke|O
DDI-DrugBank.d573.s2|247-247|.|O
DDI-DrugBank.d591.s0|0-10|Ropivacaine|O
DDI-DrugBank.d591.s0|22-25|used|O
DDI-DrugBank.d591.s0|32-38|caution|O
DDI-DrugBank.d591.s0|43-50|patients|O
DDI-DrugBank.d591.s0|52-60|receiving|O
DDI-DrugBank.d591.s0|68-72|local|O
DDI-DrugBank.d591.s0|74-84|anesthetics|O
DDI-DrugBank.d591.s0|89-94|agents|O
DDI-DrugBank.d591.s0|96-107|structurally|O
DDI-DrugBank.d591.s0|109-115|related|O
DDI-DrugBank.d591.s0|120-129|amide-type|O
DDI-DrugBank.d591.s0|68-72|local|O
DDI-DrugBank.d591.s0|74-84|anesthetics|O
DDI-DrugBank.d591.s0|150-154|since|O
DDI-DrugBank.d591.s0|160-164|toxic|O
DDI-DrugBank.d591.s0|166-172|effects|O
DDI-DrugBank.d591.s0|183-187|drugs|O
DDI-DrugBank.d591.s0|193-200|additive|O
DDI-DrugBank.d591.s0|201-201|.|O
DDI-DrugBank.d591.s1|0-9|Cytochrome|O
DDI-DrugBank.d591.s1|11-17|P4501A2|O
DDI-DrugBank.d591.s1|22-29|involved|O
DDI-DrugBank.d591.s1|38-46|formation|O
DDI-DrugBank.d591.s1|51-59|3-hydroxy|O
DDI-DrugBank.d591.s1|61-71|ropivacaine|O
DDI-DrugBank.d591.s1|78-82|major|O
DDI-DrugBank.d591.s1|84-93|metabolite|O
DDI-DrugBank.d591.s1|94-94|.|O
DDI-DrugBank.d591.s2|0-1|In|O
DDI-DrugBank.d591.s2|3-6|vivo|O
DDI-DrugBank.d591.s2|13-18|plasma|O
DDI-DrugBank.d591.s2|20-28|clearance|O
DDI-DrugBank.d591.s2|33-43|ropivacaine|O
DDI-DrugBank.d591.s2|49-55|reduced|O
DDI-DrugBank.d591.s2|60-61|70|O
DDI-DrugBank.d591.s2|62-62|%|O
DDI-DrugBank.d591.s2|71-86|coadministration|O
DDI-DrugBank.d591.s2|91-101|fluvoxamine|O
DDI-DrugBank.d591.s2|104-105|25|O
DDI-DrugBank.d591.s2|107-108|mg|O
DDI-DrugBank.d591.s2|110-112|bid|O
DDI-DrugBank.d591.s2|104-104|2|O
DDI-DrugBank.d591.s2|120-123|days|O
DDI-DrugBank.d591.s2|129-137|selective|O
DDI-DrugBank.d591.s2|143-148|potent|O
DDI-DrugBank.d591.s2|150-155|CYP1A2|O
DDI-DrugBank.d591.s2|157-165|inhibitor|O
DDI-DrugBank.d591.s2|166-166|.|O
DDI-DrugBank.d591.s3|0-3|Thus|O
DDI-DrugBank.d591.s3|5-10|strong|O
DDI-DrugBank.d591.s3|12-21|inhibitors|O
DDI-DrugBank.d591.s3|26-35|cytochrome|O
DDI-DrugBank.d591.s3|37-43|P4501A2|O
DDI-DrugBank.d591.s3|54-64|fluvoxamine|O
DDI-DrugBank.d591.s3|67-71|given|O
DDI-DrugBank.d591.s3|73-85|concomitantly|O
DDI-DrugBank.d591.s3|94-107|administration|O
DDI-DrugBank.d591.s3|112-122|Ropivacaine|O
DDI-DrugBank.d591.s3|129-136|interact|O
DDI-DrugBank.d591.s3|112-122|Ropivacaine|O
DDI-DrugBank.d591.s3|155-161|leading|O
DDI-DrugBank.d591.s3|166-174|increased|O
DDI-DrugBank.d591.s3|176-186|ropivacaine|O
DDI-DrugBank.d591.s3|188-193|plasma|O
DDI-DrugBank.d591.s3|195-200|levels|O
DDI-DrugBank.d591.s3|201-201|.|O
DDI-DrugBank.d591.s4|0-6|Caution|O
DDI-DrugBank.d591.s4|18-26|exercised|O
DDI-DrugBank.d591.s4|33-38|CYP1A2|O
DDI-DrugBank.d591.s4|40-49|inhibitors|O
DDI-DrugBank.d591.s4|55-68|coadministered|O
DDI-DrugBank.d591.s4|69-69|.|O
DDI-DrugBank.d591.s5|0-7|Possible|O
DDI-DrugBank.d591.s5|9-20|interactions|O
DDI-DrugBank.d591.s5|27-31|drugs|O
DDI-DrugBank.d591.s5|33-37|known|O
DDI-DrugBank.d591.s5|45-55|metabolized|O
DDI-DrugBank.d591.s5|60-65|CYP1A2|O
DDI-DrugBank.d591.s5|67-69|via|O
DDI-DrugBank.d591.s5|71-81|competitive|O
DDI-DrugBank.d591.s5|83-92|inhibition|O
DDI-DrugBank.d591.s5|102-113|theophylline|O
DDI-DrugBank.d591.s5|119-128|imipramine|O
DDI-DrugBank.d591.s5|130-132|may|O
DDI-DrugBank.d591.s5|134-137|also|O
DDI-DrugBank.d591.s5|139-143|occur|O
DDI-DrugBank.d591.s5|144-144|.|O
DDI-DrugBank.d591.s6|0-15|Coadministration|O
DDI-DrugBank.d591.s6|22-30|selective|O
DDI-DrugBank.d591.s6|36-41|potent|O
DDI-DrugBank.d591.s6|43-51|inhibitor|O
DDI-DrugBank.d591.s6|56-61|CYP3A4|O
DDI-DrugBank.d591.s6|64-75|ketoconazole|O
DDI-DrugBank.d591.s6|78-80|100|O
DDI-DrugBank.d591.s6|82-83|mg|O
DDI-DrugBank.d591.s6|85-87|bid|O
DDI-DrugBank.d591.s6|93-93|2|O
DDI-DrugBank.d591.s6|95-98|days|O
DDI-DrugBank.d591.s6|105-115|ropivacaine|O
DDI-DrugBank.d591.s6|117-124|infusion|O
DDI-DrugBank.d591.s6|126-137|administered|O
DDI-DrugBank.d591.s6|78-78|1|O
DDI-DrugBank.d591.s6|141-144|hour|O
DDI-DrugBank.d591.s6|64-75|ketoconazole|O
DDI-DrugBank.d591.s6|166-171|caused|O
DDI-DrugBank.d591.s6|175-176|15|O
DDI-DrugBank.d591.s6|177-177|%|O
DDI-DrugBank.d591.s6|179-187|reduction|O
DDI-DrugBank.d591.s6|192-198|in-vivo|O
DDI-DrugBank.d591.s6|200-205|plasma|O
DDI-DrugBank.d591.s6|207-215|clearance|O
DDI-DrugBank.d591.s6|105-115|ropivacaine|O
DDI-DrugBank.d591.s6|231-231|.|O
DDI-DrugBank.d89.s0|0-9|Cytochrome|O
DDI-DrugBank.d89.s0|11-14|P450|O
DDI-DrugBank.d89.s0|16-18|1A2|O
DDI-DrugBank.d89.s0|21-26|CYP1A2|O
DDI-DrugBank.d89.s0|32-36|known|O
DDI-DrugBank.d89.s0|48-52|major|O
DDI-DrugBank.d89.s0|54-59|enzyme|O
DDI-DrugBank.d89.s0|61-68|involved|O
DDI-DrugBank.d89.s0|77-86|metabolism|O
DDI-DrugBank.d89.s0|91-98|caffeine|O
DDI-DrugBank.d89.s0|99-99|.|O
DDI-DrugBank.d89.s1|0-8|Therefore|O
DDI-DrugBank.d89.s1|11-18|caffeine|O
DDI-DrugBank.d89.s1|28-36|potential|O
DDI-DrugBank.d89.s1|41-48|interact|O
DDI-DrugBank.d89.s1|55-59|drugs|O
DDI-DrugBank.d89.s1|70-79|substrates|O
DDI-DrugBank.d89.s1|85-90|CYP1A2|O
DDI-DrugBank.d89.s1|93-99|inhibit|O
DDI-DrugBank.d89.s1|85-90|CYP1A2|O
DDI-DrugBank.d89.s1|112-117|induce|O
DDI-DrugBank.d89.s1|85-90|CYP1A2|O
DDI-DrugBank.d89.s1|125-125|.|O
DDI-DrugBank.d89.s2|0-2|Few|O
DDI-DrugBank.d89.s2|4-7|data|O
DDI-DrugBank.d89.s2|9-13|exist|O
DDI-DrugBank.d89.s2|18-21|drug|O
DDI-DrugBank.d89.s2|23-34|interactions|O
DDI-DrugBank.d89.s2|41-48|caffeine|O
DDI-DrugBank.d89.s2|53-59|preterm|O
DDI-DrugBank.d89.s2|61-68|neonates|O
DDI-DrugBank.d89.s2|69-69|.|O
DDI-DrugBank.d89.s3|0-4|Based|O
DDI-DrugBank.d89.s3|9-13|adult|O
DDI-DrugBank.d89.s3|15-18|data|O
DDI-DrugBank.d89.s3|21-25|lower|O
DDI-DrugBank.d89.s3|27-31|doses|O
DDI-DrugBank.d89.s3|36-43|caffeine|O
DDI-DrugBank.d89.s3|45-47|may|O
DDI-DrugBank.d89.s3|52-57|needed|O
DDI-DrugBank.d89.s3|59-67|following|O
DDI-DrugBank.d89.s3|69-84|coadministration|O
DDI-DrugBank.d89.s3|89-93|drugs|O
DDI-DrugBank.d89.s3|105-112|reported|O
DDI-DrugBank.d89.s3|117-124|decrease|O
DDI-DrugBank.d89.s3|36-43|caffeine|O
DDI-DrugBank.d89.s3|135-145|elimination|O
DDI-DrugBank.d89.s3|148-151|e.g.|O
DDI-DrugBank.d89.s3|154-163|cimetidine|O
DDI-DrugBank.d89.s3|169-180|ketoconazole|O
DDI-DrugBank.d89.s3|187-192|higher|O
DDI-DrugBank.d89.s3|36-43|caffeine|O
DDI-DrugBank.d89.s3|27-31|doses|O
DDI-DrugBank.d89.s3|45-47|may|O
DDI-DrugBank.d89.s3|52-57|needed|O
DDI-DrugBank.d89.s3|59-67|following|O
DDI-DrugBank.d89.s3|69-84|coadministration|O
DDI-DrugBank.d89.s3|89-93|drugs|O
DDI-DrugBank.d89.s3|264-271|increase|O
DDI-DrugBank.d89.s3|36-43|caffeine|O
DDI-DrugBank.d89.s3|135-145|elimination|O
DDI-DrugBank.d89.s3|148-151|e.g.|O
DDI-DrugBank.d89.s3|301-313|phenobarbital|O
DDI-DrugBank.d89.s3|319-327|phenytoin|O
DDI-DrugBank.d89.s3|149-149|.|O
DDI-DrugBank.d89.s4|0-7|Caffeine|O
DDI-DrugBank.d89.s4|9-20|administered|O
DDI-DrugBank.d89.s4|22-33|concurrently|O
DDI-DrugBank.d89.s4|40-49|ketoprofen|O
DDI-DrugBank.d89.s4|51-57|reduced|O
DDI-DrugBank.d89.s4|63-67|urine|O
DDI-DrugBank.d89.s4|69-74|volume|O
DDI-DrugBank.d89.s4|79-79|4|O
DDI-DrugBank.d89.s4|81-87|healthy|O
DDI-DrugBank.d89.s4|89-98|volunteers|O
DDI-DrugBank.d89.s4|99-99|.|O
DDI-DrugBank.d89.s5|0-2|The|O
DDI-DrugBank.d89.s5|4-11|clinical|O
DDI-DrugBank.d89.s5|13-24|significance|O
DDI-DrugBank.d89.s5|34-44|interaction|O
DDI-DrugBank.d89.s5|49-55|preterm|O
DDI-DrugBank.d89.s5|57-64|neonates|O
DDI-DrugBank.d89.s5|73-77|known|O
DDI-DrugBank.d89.s5|78-78|.|O
DDI-DrugBank.d89.s6|0-14|Interconversion|O
DDI-DrugBank.d89.s6|24-31|caffeine|O
DDI-DrugBank.d89.s6|37-48|theophylline|O
DDI-DrugBank.d89.s6|59-66|reported|O
DDI-DrugBank.d89.s6|71-77|preterm|O
DDI-DrugBank.d89.s6|79-86|neonates|O
DDI-DrugBank.d89.s6|87-87|.|O
DDI-DrugBank.d89.s7|0-2|The|O
DDI-DrugBank.d89.s7|4-13|concurrent|O
DDI-DrugBank.d89.s7|15-17|use|O
DDI-DrugBank.d89.s7|28-32|drugs|O
DDI-DrugBank.d89.s7|41-51|recommended|O
DDI-DrugBank.d89.s7|52-52|.|O
DDI-MedLine.d81.s0|0-10|Hypothermia|O
DDI-MedLine.d81.s0|18-22|index|O
DDI-MedLine.d81.s0|31-48|disulfiram-ethanol|O
DDI-MedLine.d81.s0|50-57|reaction|O
DDI-MedLine.d81.s0|66-68|rat|O
DDI-MedLine.d81.s0|69-69|.|O
DDI-MedLine.d81.s1|0-8|Decreased|O
DDI-MedLine.d81.s1|10-13|core|O
DDI-MedLine.d81.s1|15-25|temperature|O
DDI-MedLine.d81.s1|30-35|female|O
DDI-MedLine.d81.s1|37-40|rats|O
DDI-MedLine.d81.s1|46-57|investigated|O
DDI-MedLine.d81.s1|62-64|one|O
DDI-MedLine.d81.s1|66-73|possible|O
DDI-MedLine.d81.s1|75-79|index|O
DDI-MedLine.d81.s1|88-105|disulfiram-ethanol|O
DDI-MedLine.d81.s1|107-114|reaction|O
DDI-MedLine.d81.s1|117-119|DER|O
DDI-MedLine.d81.s1|121-121|.|O
DDI-MedLine.d81.s2|0-3|Core|O
DDI-MedLine.d81.s2|5-15|temperature|O
DDI-MedLine.d81.s2|21-29|decreased|O
DDI-MedLine.d81.s2|34-37|rats|O
DDI-MedLine.d81.s2|44-57|dose-dependent|O
DDI-MedLine.d81.s2|59-64|manner|O
DDI-MedLine.d81.s2|71-77|ethanol|O
DDI-MedLine.d81.s2|83-94|administered|O
DDI-MedLine.d81.s2|34-37|rats|O
DDI-MedLine.d81.s2|104-110|treated|O
DDI-MedLine.d81.s2|117-126|disulfiram|O
DDI-MedLine.d81.s2|128-128|8|O
DDI-MedLine.d81.s2|130-134|hours|O
DDI-MedLine.d81.s2|71-77|ethanol|O
DDI-MedLine.d81.s2|155-163|challenge|O
DDI-MedLine.d81.s2|164-164|.|O
DDI-MedLine.d81.s3|0-2|The|O
DDI-MedLine.d81.s3|4-11|decrease|O
DDI-MedLine.d81.s3|16-26|temperature|O
DDI-MedLine.d81.s3|28-32|began|O
DDI-MedLine.d81.s3|34-39|within|O
DDI-MedLine.d81.s3|41-42|20|O
DDI-MedLine.d81.s3|44-50|minutes|O
DDI-MedLine.d81.s3|58-64|ethanol|O
DDI-MedLine.d81.s3|66-79|administration|O
DDI-MedLine.d81.s3|82-89|reaching|O
DDI-MedLine.d81.s3|93-99|maximal|O
DDI-MedLine.d81.s3|4-11|decrease|O
DDI-MedLine.d81.s3|118-119|60|O
DDI-MedLine.d81.s3|125-127|120|O
DDI-MedLine.d81.s3|44-50|minutes|O
DDI-MedLine.d81.s3|137-140|post|O
DDI-MedLine.d81.s3|58-64|ethanol|O
DDI-MedLine.d81.s3|149-149|.|O
DDI-MedLine.d81.s4|0-2|The|O
DDI-MedLine.d81.s4|4-7|core|O
DDI-MedLine.d81.s4|9-19|temperature|O
DDI-MedLine.d81.s4|21-28|returned|O
DDI-MedLine.d81.s4|33-38|normal|O
DDI-MedLine.d81.s4|40-42|300|O
DDI-MedLine.d81.s4|44-50|minutes|O
DDI-MedLine.d81.s4|58-64|ethanol|O
DDI-MedLine.d81.s4|65-65|.|O
DDI-MedLine.d81.s5|0-2|The|O
DDI-MedLine.d81.s5|4-8|blood|O
DDI-MedLine.d81.s5|10-17|pressure|O
DDI-MedLine.d81.s5|20-26|carotid|O
DDI-MedLine.d81.s5|28-38|cannulation|O
DDI-MedLine.d81.s5|41-49|decreased|O
DDI-MedLine.d81.s5|51-55|along|O
DDI-MedLine.d81.s5|66-69|core|O
DDI-MedLine.d81.s5|71-81|temperature|O
DDI-MedLine.d81.s5|82-82|.|O
DDI-MedLine.d81.s6|0-6|Maximal|O
DDI-MedLine.d81.s6|8-18|hypotension|O
DDI-MedLine.d81.s6|24-28|found|O
DDI-MedLine.d81.s6|30-32|120|O
DDI-MedLine.d81.s6|34-40|minutes|O
DDI-MedLine.d81.s6|42-45|post|O
DDI-MedLine.d81.s6|47-53|ethanol|O
DDI-MedLine.d81.s6|60-67|returned|O
DDI-MedLine.d81.s6|72-77|normal|O
DDI-MedLine.d81.s6|79-81|300|O
DDI-MedLine.d81.s6|34-40|minutes|O
DDI-MedLine.d81.s6|47-53|ethanol|O
DDI-MedLine.d81.s6|104-104|.|O
DDI-MedLine.d81.s7|0-4|Heart|O
DDI-MedLine.d81.s7|6-9|rate|O
DDI-MedLine.d81.s7|11-19|increased|O
DDI-MedLine.d81.s7|21-29|initially|O
DDI-MedLine.d81.s7|35-42|returned|O
DDI-MedLine.d81.s7|47-52|normal|O
DDI-MedLine.d81.s7|54-55|40|O
DDI-MedLine.d81.s7|57-63|minutes|O
DDI-MedLine.d81.s7|71-77|ethanol|O
DDI-MedLine.d81.s7|79-87|challenge|O
DDI-MedLine.d81.s7|88-88|.|O
DDI-DrugBank.d276.s0|0-7|Antacids|O
DDI-DrugBank.d276.s0|9-18|containing|O
DDI-DrugBank.d276.s0|20-28|magnesium|O
DDI-DrugBank.d276.s0|30-40|trisilicate|O
DDI-DrugBank.d276.s0|48-59|administered|O
DDI-DrugBank.d276.s0|61-73|concomitantly|O
DDI-DrugBank.d276.s0|80-93|nitrofurantoin|O
DDI-DrugBank.d276.s0|96-101|reduce|O
DDI-DrugBank.d276.s0|112-115|rate|O
DDI-DrugBank.d276.s0|121-126|extent|O
DDI-DrugBank.d276.s0|131-140|absorption|O
DDI-DrugBank.d276.s0|141-141|.|O
DDI-DrugBank.d276.s1|0-2|The|O
DDI-DrugBank.d276.s1|4-12|mechanism|O
DDI-DrugBank.d276.s1|23-33|interaction|O
DDI-DrugBank.d276.s1|35-42|probably|O
DDI-DrugBank.d276.s1|47-56|adsorption|O
DDI-DrugBank.d276.s1|61-74|nitrofurantoin|O
DDI-DrugBank.d276.s1|76-79|onto|O
DDI-DrugBank.d276.s1|85-91|surface|O
DDI-DrugBank.d276.s1|96-104|magnesium|O
DDI-DrugBank.d276.s1|106-116|trisilicate|O
DDI-DrugBank.d276.s1|117-117|.|O
DDI-DrugBank.d276.s2|0-9|Uricosuric|O
DDI-DrugBank.d276.s2|11-15|drugs|O
DDI-DrugBank.d276.s2|26-35|probenecid|O
DDI-DrugBank.d276.s2|41-54|sulfinpyrazone|O
DDI-DrugBank.d276.s2|61-67|inhibit|O
DDI-DrugBank.d276.s2|69-73|renal|O
DDI-DrugBank.d276.s2|75-81|tubular|O
DDI-DrugBank.d276.s2|83-91|secretion|O
DDI-DrugBank.d276.s2|96-109|nitrofurantoin|O
DDI-DrugBank.d276.s2|110-110|.|O
DDI-DrugBank.d276.s3|0-2|The|O
DDI-DrugBank.d276.s3|4-12|resulting|O
DDI-DrugBank.d276.s3|14-21|increase|O
DDI-DrugBank.d276.s3|26-39|nitrofurantoin|O
DDI-DrugBank.d276.s3|41-45|serum|O
DDI-DrugBank.d276.s3|47-52|levels|O
DDI-DrugBank.d276.s3|54-56|may|O
DDI-DrugBank.d276.s3|14-21|increase|O
DDI-DrugBank.d276.s3|67-74|toxicity|O
DDI-DrugBank.d276.s3|85-93|decreased|O
DDI-DrugBank.d276.s3|95-101|urinary|O
DDI-DrugBank.d276.s3|47-52|levels|O
DDI-DrugBank.d276.s3|110-114|could|O
DDI-DrugBank.d276.s3|116-121|lessen|O
DDI-DrugBank.d276.s3|127-134|efficacy|O
DDI-DrugBank.d276.s3|95-101|urinary|O
DDI-DrugBank.d276.s3|149-153|tract|O
DDI-DrugBank.d276.s3|155-167|antibacterial|O
DDI-DrugBank.d276.s3|168-168|.|O
DDI-DrugBank.d276.s4|0-14|Drug/Laboratory|O
DDI-DrugBank.d276.s4|16-19|Test|O
DDI-DrugBank.d276.s4|21-32|Interactions|O
DDI-DrugBank.d276.s4|34-35|As|O
DDI-DrugBank.d276.s4|39-44|result|O
DDI-DrugBank.d276.s4|53-60|presence|O
DDI-DrugBank.d276.s4|65-78|nitrofurantoin|O
DDI-DrugBank.d276.s4|83-96|false-positive|O
DDI-DrugBank.d276.s4|98-105|reaction|O
DDI-DrugBank.d276.s4|111-117|glucose|O
DDI-DrugBank.d276.s4|126-130|urine|O
DDI-DrugBank.d276.s4|132-134|may|O
DDI-DrugBank.d276.s4|136-140|occur|O
DDI-DrugBank.d276.s4|141-141|.|O
DDI-DrugBank.d276.s5|0-3|This|O
DDI-DrugBank.d276.s5|14-21|observed|O
DDI-DrugBank.d276.s5|28-35|Benedict|O
DDI-DrugBank.d276.s5|43-49|Fehling|O
DDI-DrugBank.d276.s5|53-61|solutions|O
DDI-DrugBank.d276.s5|80-86|glucose|O
DDI-DrugBank.d276.s5|88-96|enzymatic|O
DDI-DrugBank.d276.s5|98-101|test|O
DDI-DrugBank.d276.s5|102-102|.|O
DDI-DrugBank.d71.s0|0-9|Lamivudine|O
DDI-DrugBank.d71.s0|14-26|predominantly|O
DDI-DrugBank.d71.s0|28-37|eliminated|O
DDI-DrugBank.d71.s0|46-50|urine|O
DDI-DrugBank.d71.s0|55-60|active|O
DDI-DrugBank.d71.s0|62-68|organic|O
DDI-DrugBank.d71.s0|70-77|cationic|O
DDI-DrugBank.d71.s0|79-87|secretion|O
DDI-DrugBank.d71.s0|88-88|.|O
DDI-DrugBank.d71.s1|0-2|The|O
DDI-DrugBank.d71.s1|4-14|possibility|O
DDI-DrugBank.d71.s1|19-30|interactions|O
DDI-DrugBank.d71.s1|43-47|drugs|O
DDI-DrugBank.d71.s1|49-60|administered|O
DDI-DrugBank.d71.s1|62-73|concurrently|O
DDI-DrugBank.d71.s1|85-94|considered|O
DDI-DrugBank.d71.s1|97-108|particularly|O
DDI-DrugBank.d71.s1|121-124|main|O
DDI-DrugBank.d71.s1|126-130|route|O
DDI-DrugBank.d71.s1|135-145|elimination|O
DDI-DrugBank.d71.s1|150-155|active|O
DDI-DrugBank.d71.s1|157-161|renal|O
DDI-DrugBank.d71.s1|163-171|secretion|O
DDI-DrugBank.d71.s1|173-175|via|O
DDI-DrugBank.d71.s1|181-187|organic|O
DDI-DrugBank.d71.s1|189-196|cationic|O
DDI-DrugBank.d71.s1|198-206|transport|O
DDI-DrugBank.d71.s1|208-213|system|O
DDI-DrugBank.d71.s1|216-219|e.g.|O
DDI-DrugBank.d71.s1|222-233|trimethoprim|O
DDI-DrugBank.d71.s1|217-217|.|O
DDI-DrugBank.d71.s2|0-1|No|O
DDI-DrugBank.d71.s2|3-8|change|O
DDI-DrugBank.d71.s2|13-16|dose|O
DDI-DrugBank.d71.s2|21-26|either|O
DDI-DrugBank.d71.s2|28-31|drug|O
DDI-DrugBank.d71.s2|36-46|recommended|O
DDI-DrugBank.d71.s2|47-47|.|O
DDI-DrugBank.d71.s3|0-4|There|O
DDI-DrugBank.d71.s3|12-22|information|O
DDI-DrugBank.d71.s3|24-32|regarding|O
DDI-DrugBank.d71.s3|38-43|effect|O
DDI-DrugBank.d71.s3|48-57|lamivudine|O
DDI-DrugBank.d71.s3|59-74|pharmacokinetics|O
DDI-DrugBank.d71.s3|79-84|higher|O
DDI-DrugBank.d71.s3|86-90|doses|O
DDI-DrugBank.d71.s3|95-101|TMP/SMX|O
DDI-DrugBank.d71.s3|117-120|used|O
DDI-DrugBank.d71.s3|125-129|treat|O
DDI-DrugBank.d71.s3|131-142|Pneumocystis|O
DDI-DrugBank.d71.s3|144-150|carinii|O
DDI-DrugBank.d71.s3|152-160|pneumonia|O
DDI-DrugBank.d71.s3|161-161|.|O
DDI-DrugBank.d71.s4|0-1|No|O
DDI-DrugBank.d71.s4|3-6|data|O
DDI-DrugBank.d71.s4|12-20|available|O
DDI-DrugBank.d71.s4|22-30|regarding|O
DDI-DrugBank.d71.s4|32-43|interactions|O
DDI-DrugBank.d71.s4|56-60|drugs|O
DDI-DrugBank.d71.s4|72-76|renal|O
DDI-DrugBank.d71.s4|78-86|clearance|O
DDI-DrugBank.d71.s4|88-97|mechanisms|O
DDI-DrugBank.d71.s4|99-105|similar|O
DDI-DrugBank.d71.s4|118-127|lamivudine|O
DDI-DrugBank.d71.s4|128-128|.|O
DDI-DrugBank.d71.s5|0-9|Lamivudine|O
DDI-DrugBank.d71.s5|15-25|zalcitabine|O
DDI-DrugBank.d71.s5|27-29|may|O
DDI-DrugBank.d71.s5|31-37|inhibit|O
DDI-DrugBank.d71.s5|43-55|intracellular|O
DDI-DrugBank.d71.s5|57-71|phosphorylation|O
DDI-DrugBank.d71.s5|76-78|one|O
DDI-DrugBank.d71.s5|80-86|another|O
DDI-DrugBank.d71.s5|87-87|.|O
DDI-DrugBank.d71.s6|0-8|Therefore|O
DDI-DrugBank.d71.s6|11-13|use|O
DDI-DrugBank.d71.s6|18-27|lamivudine|O
DDI-DrugBank.d71.s6|32-42|combination|O
DDI-DrugBank.d71.s6|49-59|zalcitabine|O
DDI-DrugBank.d71.s6|68-78|recommended|O
DDI-DrugBank.d71.s7|0-0|.|O
DDI-DrugBank.d149.s0|0-7|Possible|O
DDI-DrugBank.d149.s0|9-12|drug|O
DDI-DrugBank.d149.s0|14-25|interactions|O
DDI-DrugBank.d149.s0|30-37|HUMORSOL|O
DDI-DrugBank.d149.s0|44-58|succinylcholine|O
DDI-DrugBank.d149.s0|74-91|anticholinesterase|O
DDI-DrugBank.d149.s0|93-98|agents|O
DDI-DrugBank.d149.s0|99-99|.|O
DDI-DrugBank.d70.s0|0-10|Fulvestrant|O
DDI-DrugBank.d70.s0|15-25|metabolized|O
DDI-DrugBank.d70.s0|30-32|CYP|O
DDI-DrugBank.d70.s0|34-36|3A4|O
DDI-DrugBank.d70.s0|41-45|vitro|O
DDI-DrugBank.d70.s0|46-46|.|O
DDI-DrugBank.d70.s1|0-7|Clinical|O
DDI-DrugBank.d70.s1|9-15|studies|O
DDI-DrugBank.d70.s1|24-29|effect|O
DDI-DrugBank.d70.s1|34-39|strong|O
DDI-DrugBank.d70.s1|41-43|CYP|O
DDI-DrugBank.d70.s1|45-47|3A4|O
DDI-DrugBank.d70.s1|49-58|inhibitors|O
DDI-DrugBank.d70.s1|67-82|pharmacokinetics|O
DDI-DrugBank.d70.s1|87-97|fulvestrant|O
DDI-DrugBank.d70.s1|113-121|performed|O
DDI-DrugBank.d70.s1|122-122|.|O
DDI-DrugBank.d70.s2|0-13|Carcinogenesis|O
DDI-DrugBank.d70.s2|16-26|Mutagenesis|O
DDI-DrugBank.d70.s2|32-41|Impairment|O
DDI-DrugBank.d70.s2|46-54|Fertility|O
DDI-DrugBank.d70.s2|56-56|A|O
DDI-DrugBank.d70.s2|58-65|two-year|O
DDI-DrugBank.d70.s2|67-80|carcinogenesis|O
DDI-DrugBank.d70.s2|82-86|study|O
DDI-DrugBank.d70.s2|92-100|conducted|O
DDI-DrugBank.d70.s2|105-110|female|O
DDI-DrugBank.d70.s2|107-110|male|O
DDI-DrugBank.d70.s2|121-124|rats|O
DDI-DrugBank.d70.s2|130-142|intramuscular|O
DDI-DrugBank.d70.s2|144-148|doses|O
DDI-DrugBank.d70.s2|153-154|15|O
DDI-DrugBank.d70.s2|156-163|mg/kg/30|O
DDI-DrugBank.d70.s2|165-168|days|O
DDI-DrugBank.d70.s2|171-172|10|O
DDI-DrugBank.d70.s2|174-182|mg/rat/30|O
DDI-DrugBank.d70.s2|165-168|days|O
DDI-DrugBank.d70.s2|171-172|10|O
DDI-DrugBank.d70.s2|196-204|mg/rat/15|O
DDI-DrugBank.d70.s2|165-168|days|O
DDI-DrugBank.d70.s2|210-210|.|O
DDI-DrugBank.d70.s3|0-4|These|O
DDI-DrugBank.d70.s3|6-10|doses|O
DDI-DrugBank.d70.s3|12-21|correspond|O
DDI-DrugBank.d70.s3|26-38|approximately|O
DDI-DrugBank.d70.s3|40-41|1-|O
DDI-DrugBank.d70.s3|44-45|3-|O
DDI-DrugBank.d70.s3|52-57|5-fold|O
DDI-DrugBank.d70.s3|63-69|females|O
DDI-DrugBank.d70.s3|76-79|1.3-|O
DDI-DrugBank.d70.s3|76-79|1.3-|O
DDI-DrugBank.d70.s3|92-99|1.6-fold|O
DDI-DrugBank.d70.s3|65-69|males|O
DDI-DrugBank.d70.s3|116-123|systemic|O
DDI-DrugBank.d70.s3|125-132|exposure|O
DDI-DrugBank.d70.s3|134-134|[|O
DDI-DrugBank.d70.s3|135-141|AUC0-30|O
DDI-DrugBank.d70.s3|143-146|days|O
DDI-DrugBank.d70.s3|147-147|]|O
DDI-DrugBank.d70.s3|147-147|]|O
DDI-DrugBank.d70.s3|150-157|achieved|O
DDI-DrugBank.d70.s3|162-166|women|O
DDI-DrugBank.d70.s3|168-176|receiving|O
DDI-DrugBank.d70.s3|182-192|recommended|O
DDI-DrugBank.d70.s3|6-9|dose|O
DDI-DrugBank.d70.s3|202-204|250|O
DDI-DrugBank.d70.s3|206-213|mg/month|O
DDI-DrugBank.d70.s3|77-77|.|O
DDI-DrugBank.d70.s4|0-1|An|O
DDI-DrugBank.d70.s4|3-11|increased|O
DDI-DrugBank.d70.s4|13-21|incidence|O
DDI-DrugBank.d70.s4|26-31|benign|O
DDI-DrugBank.d70.s4|33-39|ovarian|O
DDI-DrugBank.d70.s4|41-49|granulosa|O
DDI-DrugBank.d70.s4|51-54|cell|O
DDI-DrugBank.d70.s4|56-61|tumors|O
DDI-DrugBank.d70.s4|67-76|testicular|O
DDI-DrugBank.d70.s4|78-83|Leydig|O
DDI-DrugBank.d70.s4|51-54|cell|O
DDI-DrugBank.d70.s4|56-61|tumors|O
DDI-DrugBank.d70.s4|101-107|evident|O
DDI-DrugBank.d70.s4|113-119|females|O
DDI-DrugBank.d70.s4|121-125|dosed|O
DDI-DrugBank.d70.s4|130-131|10|O
DDI-DrugBank.d70.s4|133-141|mg/rat/15|O
DDI-DrugBank.d70.s4|143-146|days|O
DDI-DrugBank.d70.s4|115-119|males|O
DDI-DrugBank.d70.s4|121-125|dosed|O
DDI-DrugBank.d70.s4|140-141|15|O
DDI-DrugBank.d70.s4|170-178|mg/rat/30|O
DDI-DrugBank.d70.s4|143-146|days|O
DDI-DrugBank.d70.s4|186-197|respectively|O
DDI-DrugBank.d70.s4|198-198|.|O
DDI-DrugBank.d70.s5|0-8|Induction|O
DDI-DrugBank.d70.s5|18-23|tumors|O
DDI-DrugBank.d70.s5|28-37|consistent|O
DDI-DrugBank.d70.s5|48-67|pharmacology-related|O
DDI-DrugBank.d70.s5|69-77|endocrine|O
DDI-DrugBank.d70.s5|79-86|feedback|O
DDI-DrugBank.d70.s5|88-98|alterations|O
DDI-DrugBank.d70.s5|103-114|gonadotropin|O
DDI-DrugBank.d70.s5|116-121|levels|O
DDI-DrugBank.d70.s5|123-128|caused|O
DDI-DrugBank.d70.s5|136-147|antiestrogen|O
DDI-DrugBank.d70.s5|148-148|.|O
DDI-DrugBank.d70.s6|0-10|Fulvestrant|O
DDI-DrugBank.d70.s6|20-28|mutagenic|O
DDI-DrugBank.d70.s6|33-43|clastogenic|O
DDI-DrugBank.d70.s6|48-55|multiple|O
DDI-DrugBank.d70.s6|60-64|vitro|O
DDI-DrugBank.d70.s6|66-70|tests|O
DDI-DrugBank.d70.s6|81-87|without|O
DDI-DrugBank.d70.s6|93-100|addition|O
DDI-DrugBank.d70.s6|107-115|mammalian|O
DDI-DrugBank.d70.s6|117-121|liver|O
DDI-DrugBank.d70.s6|123-131|metabolic|O
DDI-DrugBank.d70.s6|133-142|activation|O
DDI-DrugBank.d70.s6|144-149|factor|O
DDI-DrugBank.d70.s6|152-160|bacterial|O
DDI-DrugBank.d70.s6|162-169|mutation|O
DDI-DrugBank.d70.s6|171-175|assay|O
DDI-DrugBank.d70.s6|180-186|strains|O
DDI-DrugBank.d70.s6|191-200|Salmonella|O
DDI-DrugBank.d70.s6|202-212|typhimurium|O
DDI-DrugBank.d70.s6|218-228|Escherichia|O
DDI-DrugBank.d70.s6|230-233|coli|O
DDI-DrugBank.d70.s6|60-64|vitro|O
DDI-DrugBank.d70.s6|245-256|cytogenetics|O
DDI-DrugBank.d70.s6|258-262|study|O
DDI-DrugBank.d70.s6|267-271|human|O
DDI-DrugBank.d70.s6|273-283|lymphocytes|O
DDI-DrugBank.d70.s6|107-115|mammalian|O
DDI-DrugBank.d70.s6|296-299|cell|O
DDI-DrugBank.d70.s6|162-169|mutation|O
DDI-DrugBank.d70.s6|171-175|assay|O
DDI-DrugBank.d70.s6|319-323|mouse|O
DDI-DrugBank.d70.s6|325-332|lymphoma|O
DDI-DrugBank.d70.s6|334-338|cells|O
DDI-DrugBank.d70.s6|347-350|vivo|O
DDI-DrugBank.d70.s6|352-363|micronucleus|O
DDI-DrugBank.d70.s6|66-69|test|O
DDI-DrugBank.d70.s6|373-375|rat|O
DDI-DrugBank.d70.s6|376-376|.|O
DDI-DrugBank.d70.s7|0-1|In|O
DDI-DrugBank.d70.s7|3-8|female|O
DDI-DrugBank.d70.s7|10-13|rats|O
DDI-DrugBank.d70.s7|16-26|fulvestrant|O
DDI-DrugBank.d70.s7|28-39|administered|O
DDI-DrugBank.d70.s7|44-48|doses|O
DDI-DrugBank.d70.s7|52-55|0.01|O
DDI-DrugBank.d70.s7|57-65|mg/kg/day|O
DDI-DrugBank.d70.s7|68-80|approximately|O
DDI-DrugBank.d70.s7|82-94|one-hundredth|O
DDI-DrugBank.d70.s7|103-107|human|O
DDI-DrugBank.d70.s7|109-119|recommended|O
DDI-DrugBank.d70.s7|44-47|dose|O
DDI-DrugBank.d70.s7|126-130|based|O
DDI-DrugBank.d70.s7|135-138|body|O
DDI-DrugBank.d70.s7|140-146|surface|O
DDI-DrugBank.d70.s7|148-151|area|O
DDI-DrugBank.d70.s7|153-153|[|O
DDI-DrugBank.d70.s7|154-156|BSA|O
DDI-DrugBank.d70.s7|157-157|]|O
DDI-DrugBank.d70.s7|164-164|2|O
DDI-DrugBank.d70.s7|166-170|weeks|O
DDI-DrugBank.d70.s7|172-176|prior|O
DDI-DrugBank.d70.s7|55-55|1|O
DDI-DrugBank.d70.s7|166-169|week|O
DDI-DrugBank.d70.s7|196-204|following|O
DDI-DrugBank.d70.s7|206-211|mating|O
DDI-DrugBank.d70.s7|214-219|caused|O
DDI-DrugBank.d70.s7|223-231|reduction|O
DDI-DrugBank.d70.s7|236-244|fertility|O
DDI-DrugBank.d70.s7|250-258|embryonic|O
DDI-DrugBank.d70.s7|260-267|survival|O
DDI-DrugBank.d70.s7|53-53|.|O
DDI-DrugBank.d70.s8|0-1|No|O
DDI-DrugBank.d70.s8|3-9|adverse|O
DDI-DrugBank.d70.s8|11-17|effects|O
DDI-DrugBank.d70.s8|22-27|female|O
DDI-DrugBank.d70.s8|29-37|fertility|O
DDI-DrugBank.d70.s8|43-51|embryonic|O
DDI-DrugBank.d70.s8|53-60|survival|O
DDI-DrugBank.d70.s8|67-73|evident|O
DDI-DrugBank.d70.s8|22-27|female|O
DDI-DrugBank.d70.s8|85-91|animals|O
DDI-DrugBank.d70.s8|93-97|dosed|O
DDI-DrugBank.d70.s8|102-106|0.001|O
DDI-DrugBank.d70.s8|108-116|mg/kg/day|O
DDI-DrugBank.d70.s8|119-131|approximately|O
DDI-DrugBank.d70.s8|133-146|one-thousandth|O
DDI-DrugBank.d70.s8|155-159|human|O
DDI-DrugBank.d70.s8|93-96|dose|O
DDI-DrugBank.d70.s8|166-170|based|O
DDI-DrugBank.d70.s8|175-177|BSA|O
DDI-DrugBank.d70.s8|103-103|.|O
DDI-DrugBank.d70.s9|0-10|Restoration|O
DDI-DrugBank.d70.s9|15-20|female|O
DDI-DrugBank.d70.s9|22-30|fertility|O
DDI-DrugBank.d70.s9|35-40|values|O
DDI-DrugBank.d70.s9|42-48|similar|O
DDI-DrugBank.d70.s9|53-60|controls|O
DDI-DrugBank.d70.s9|66-72|evident|O
DDI-DrugBank.d70.s9|74-82|following|O
DDI-DrugBank.d70.s9|86-91|29-day|O
DDI-DrugBank.d70.s9|93-102|withdrawal|O
DDI-DrugBank.d70.s9|104-109|period|O
DDI-DrugBank.d70.s9|117-122|dosing|O
DDI-DrugBank.d70.s9|86-86|2|O
DDI-DrugBank.d70.s9|129-137|mg/kg/day|O
DDI-DrugBank.d70.s9|140-144|twice|O
DDI-DrugBank.d70.s9|150-154|human|O
DDI-DrugBank.d70.s9|156-159|dose|O
DDI-DrugBank.d70.s9|161-165|based|O
DDI-DrugBank.d70.s9|170-172|BSA|O
DDI-DrugBank.d70.s9|174-174|.|O
DDI-DrugBank.d70.s10|0-2|The|O
DDI-DrugBank.d70.s10|4-10|effects|O
DDI-DrugBank.d70.s10|15-25|fulvestrant|O
DDI-DrugBank.d70.s10|34-42|fertility|O
DDI-DrugBank.d70.s10|47-52|female|O
DDI-DrugBank.d70.s10|54-57|rats|O
DDI-DrugBank.d70.s10|59-64|appear|O
DDI-DrugBank.d70.s10|72-81|consistent|O
DDI-DrugBank.d70.s10|92-106|anti-estrogenic|O
DDI-DrugBank.d70.s10|108-115|activity|O
DDI-DrugBank.d70.s10|116-116|.|O
DDI-DrugBank.d70.s11|0-2|The|O
DDI-DrugBank.d70.s11|4-12|potential|O
DDI-DrugBank.d70.s11|14-20|effects|O
DDI-DrugBank.d70.s11|25-35|fulvestrant|O
DDI-DrugBank.d70.s11|44-52|fertility|O
DDI-DrugBank.d70.s11|57-60|male|O
DDI-DrugBank.d70.s11|62-68|animals|O
DDI-DrugBank.d70.s11|79-85|studied|O
DDI-DrugBank.d70.s11|96-102|6-month|O
DDI-DrugBank.d70.s11|104-113|toxicology|O
DDI-DrugBank.d70.s11|115-119|study|O
DDI-DrugBank.d70.s11|57-60|male|O
DDI-DrugBank.d70.s11|127-130|rats|O
DDI-DrugBank.d70.s11|132-138|treated|O
DDI-DrugBank.d70.s11|145-157|intramuscular|O
DDI-DrugBank.d70.s11|159-163|doses|O
DDI-DrugBank.d70.s11|168-169|15|O
DDI-DrugBank.d70.s11|171-178|mg/kg/30|O
DDI-DrugBank.d70.s11|180-183|days|O
DDI-DrugBank.d70.s11|186-187|10|O
DDI-DrugBank.d70.s11|189-197|mg/rat/30|O
DDI-DrugBank.d70.s11|180-183|days|O
DDI-DrugBank.d70.s11|186-187|10|O
DDI-DrugBank.d70.s11|211-219|mg/rat/15|O
DDI-DrugBank.d70.s11|180-183|days|O
DDI-DrugBank.d70.s11|25-35|fulvestrant|O
DDI-DrugBank.d70.s11|238-243|showed|O
DDI-DrugBank.d70.s11|247-250|loss|O
DDI-DrugBank.d70.s11|255-265|spermatozoa|O
DDI-DrugBank.d70.s11|276-287|seminiferous|O
DDI-DrugBank.d70.s11|289-295|tubules|O
DDI-DrugBank.d70.s11|276-287|seminiferous|O
DDI-DrugBank.d70.s11|311-317|tubular|O
DDI-DrugBank.d70.s11|319-325|atrophy|O
DDI-DrugBank.d70.s11|332-343|degenerative|O
DDI-DrugBank.d70.s11|345-351|changes|O
DDI-DrugBank.d70.s11|360-371|epididymides|O
DDI-DrugBank.d70.s11|372-372|.|O
DDI-DrugBank.d70.s12|0-6|Changes|O
DDI-DrugBank.d70.s12|15-20|testes|O
DDI-DrugBank.d70.s12|26-37|epididymides|O
DDI-DrugBank.d70.s12|47-55|recovered|O
DDI-DrugBank.d70.s12|57-58|20|O
DDI-DrugBank.d70.s12|60-64|weeks|O
DDI-DrugBank.d70.s12|72-80|cessation|O
DDI-DrugBank.d70.s12|85-90|dosing|O
DDI-DrugBank.d70.s12|91-91|.|O
DDI-DrugBank.d70.s13|0-4|These|O
DDI-DrugBank.d70.s13|6-16|fulvestrant|O
DDI-DrugBank.d70.s13|18-22|doses|O
DDI-DrugBank.d70.s13|24-33|correspond|O
DDI-DrugBank.d70.s13|38-50|approximately|O
DDI-DrugBank.d70.s13|52-53|2-|O
DDI-DrugBank.d70.s13|56-57|3-|O
DDI-DrugBank.d70.s13|64-69|3-fold|O
DDI-DrugBank.d70.s13|75-82|systemic|O
DDI-DrugBank.d70.s13|84-91|exposure|O
DDI-DrugBank.d70.s13|93-93|[|O
DDI-DrugBank.d70.s13|94-100|AUC0-30|O
DDI-DrugBank.d70.s13|102-105|days|O
DDI-DrugBank.d70.s13|106-106|]|O
DDI-DrugBank.d70.s13|108-115|achieved|O
DDI-DrugBank.d70.s13|120-124|women|O
DDI-DrugBank.d70.s13|125-125|.|O
DDI-DrugBank.d70.s14|0-8|Pregnancy|O
DDI-DrugBank.d70.s14|0-8|Pregnancy|O
DDI-DrugBank.d70.s14|20-27|Category|O
DDI-DrugBank.d70.s14|29-29|D|O
DDI-DrugBank.d70.s14|32-32|.|O
DDI-DrugBank.d70.s15|0-1|In|O
DDI-DrugBank.d70.s15|3-9|studies|O
DDI-DrugBank.d70.s15|14-19|female|O
DDI-DrugBank.d70.s15|21-24|rats|O
DDI-DrugBank.d70.s15|29-33|doses|O
DDI-DrugBank.d70.s15|37-40|0.01|O
DDI-DrugBank.d70.s15|42-50|mg/kg/day|O
DDI-DrugBank.d70.s15|53-54|IM|O
DDI-DrugBank.d70.s16|0-12|approximately|O
DDI-DrugBank.d70.s16|14-26|one-hundredth|O
DDI-DrugBank.d70.s16|35-39|human|O
DDI-DrugBank.d70.s16|41-51|recommended|O
DDI-DrugBank.d70.s16|53-56|dose|O
DDI-DrugBank.d70.s16|58-62|based|O
DDI-DrugBank.d70.s16|67-70|body|O
DDI-DrugBank.d70.s16|72-78|surface|O
DDI-DrugBank.d70.s16|80-83|area|O
DDI-DrugBank.d70.s16|85-85|[|O
DDI-DrugBank.d70.s16|86-88|BSA|O
DDI-DrugBank.d70.s16|89-89|]|O
DDI-DrugBank.d70.s16|93-103|fulvestrant|O
DDI-DrugBank.d70.s16|105-110|caused|O
DDI-DrugBank.d70.s16|114-123|reversible|O
DDI-DrugBank.d70.s16|125-133|reduction|O
DDI-DrugBank.d70.s16|138-143|female|O
DDI-DrugBank.d70.s16|145-153|fertility|O
DDI-DrugBank.d70.s16|159-162|well|O
DDI-DrugBank.d70.s16|167-173|effects|O
DDI-DrugBank.d70.s16|178-189|embryo/fetal|O
DDI-DrugBank.d70.s16|191-201|development|O
DDI-DrugBank.d70.s16|203-212|consistent|O
DDI-DrugBank.d70.s16|223-237|anti-estrogenic|O
DDI-DrugBank.d70.s16|239-246|activity|O
DDI-DrugBank.d70.s16|247-247|.|O
DDI-DrugBank.d70.s17|0-10|Fulvestrant|O
DDI-DrugBank.d70.s17|12-17|caused|O
DDI-DrugBank.d70.s17|22-30|increased|O
DDI-DrugBank.d70.s17|32-40|incidence|O
DDI-DrugBank.d70.s17|45-49|fetal|O
DDI-DrugBank.d70.s17|51-63|abnormalities|O
DDI-DrugBank.d70.s17|68-71|rats|O
DDI-DrugBank.d70.s17|74-79|tarsal|O
DDI-DrugBank.d70.s17|81-87|flexure|O
DDI-DrugBank.d70.s17|96-99|hind|O
DDI-DrugBank.d70.s17|101-103|paw|O
DDI-DrugBank.d70.s17|108-108|2|O
DDI-DrugBank.d70.s17|110-118|mg/kg/day|O
DDI-DrugBank.d70.s17|120-121|IM|O
DDI-DrugBank.d70.s18|0-4|twice|O
DDI-DrugBank.d70.s18|10-14|human|O
DDI-DrugBank.d70.s18|16-19|dose|O
DDI-DrugBank.d70.s18|24-26|BSA|O
DDI-DrugBank.d70.s18|33-48|non-ossification|O
DDI-DrugBank.d70.s18|57-64|odontoid|O
DDI-DrugBank.d70.s18|70-76|ventral|O
DDI-DrugBank.d70.s18|78-85|tubercle|O
DDI-DrugBank.d70.s18|94-98|first|O
DDI-DrugBank.d70.s18|100-107|cervical|O
DDI-DrugBank.d70.s18|109-116|vertebra|O
DDI-DrugBank.d70.s18|121-125|doses|O
DDI-DrugBank.d70.s18|129-131|0.1|O
DDI-DrugBank.d70.s18|133-141|mg/kg/day|O
DDI-DrugBank.d70.s18|143-144|IM|O
DDI-DrugBank.d70.s18|147-159|approximately|O
DDI-DrugBank.d70.s18|161-169|one-tenth|O
DDI-DrugBank.d70.s18|10-14|human|O
DDI-DrugBank.d70.s18|16-19|dose|O
DDI-DrugBank.d70.s18|24-26|BSA|O
DDI-DrugBank.d70.s18|202-213|administered|O
DDI-DrugBank.d70.s18|226-231|period|O
DDI-DrugBank.d70.s18|236-248|organogenesis|O
DDI-DrugBank.d70.s18|130-130|.|O
DDI-DrugBank.d70.s19|0-6|Rabbits|O
DDI-DrugBank.d70.s19|8-13|failed|O
DDI-DrugBank.d70.s19|18-25|maintain|O
DDI-DrugBank.d70.s19|27-35|pregnancy|O
DDI-DrugBank.d70.s19|42-46|dosed|O
DDI-DrugBank.d70.s19|53-53|1|O
DDI-DrugBank.d70.s19|55-63|mg/kg/day|O
DDI-DrugBank.d70.s19|65-75|fulvestrant|O
DDI-DrugBank.d70.s19|77-78|IM|O
DDI-DrugBank.d70.s19|81-85|twice|O
DDI-DrugBank.d70.s19|91-95|human|O
DDI-DrugBank.d70.s19|42-45|dose|O
DDI-DrugBank.d70.s19|105-107|BSA|O
DDI-DrugBank.d70.s19|121-126|period|O
DDI-DrugBank.d70.s19|131-143|organogenesis|O
DDI-DrugBank.d70.s19|144-144|.|O
DDI-DrugBank.d70.s20|0-6|Further|O
DDI-DrugBank.d70.s20|12-18|rabbits|O
DDI-DrugBank.d70.s20|20-24|dosed|O
DDI-DrugBank.d70.s20|29-32|0.25|O
DDI-DrugBank.d70.s20|34-42|mg/kg/day|O
DDI-DrugBank.d70.s20|51-58|one-half|O
DDI-DrugBank.d70.s20|64-68|human|O
DDI-DrugBank.d70.s20|20-23|dose|O
DDI-DrugBank.d70.s20|78-80|BSA|O
DDI-DrugBank.d70.s20|84-92|increases|O
DDI-DrugBank.d70.s20|97-105|placental|O
DDI-DrugBank.d70.s20|107-112|weight|O
DDI-DrugBank.d70.s20|118-134|post-implantation|O
DDI-DrugBank.d70.s20|136-139|loss|O
DDI-DrugBank.d70.s20|146-153|observed|O
DDI-DrugBank.d70.s20|146-153|observed|O
DDI-DrugBank.d70.s20|183-189|effects|O
DDI-DrugBank.d70.s20|194-198|fetal|O
DDI-DrugBank.d70.s20|200-210|development|O
DDI-DrugBank.d70.s20|30-30|.|O
DDI-DrugBank.d70.s21|0-10|Fulvestrant|O
DDI-DrugBank.d70.s21|16-25|associated|O
DDI-DrugBank.d70.s21|35-43|increased|O
DDI-DrugBank.d70.s21|45-53|incidence|O
DDI-DrugBank.d70.s21|58-62|fetal|O
DDI-DrugBank.d70.s21|64-73|variations|O
DDI-DrugBank.d70.s21|78-84|rabbits|O
DDI-DrugBank.d70.s21|87-95|backwards|O
DDI-DrugBank.d70.s21|97-108|displacement|O
DDI-DrugBank.d70.s21|117-122|pelvic|O
DDI-DrugBank.d70.s21|124-129|girdle|O
DDI-DrugBank.d70.s21|136-137|27|O
DDI-DrugBank.d70.s21|139-148|pre-sacral|O
DDI-DrugBank.d70.s21|150-158|vertebrae|O
DDI-DrugBank.d70.s21|163-166|0.25|O
DDI-DrugBank.d70.s21|168-176|mg/kg/day|O
DDI-DrugBank.d70.s21|178-179|IM|O
DDI-DrugBank.d70.s22|0-7|one-half|O
DDI-DrugBank.d70.s22|13-17|human|O
DDI-DrugBank.d70.s22|19-22|dose|O
DDI-DrugBank.d70.s22|27-29|BSA|O
DDI-DrugBank.d70.s22|37-48|administered|O
DDI-DrugBank.d70.s22|61-66|period|O
DDI-DrugBank.d70.s22|71-83|organogenesis|O
DDI-DrugBank.d70.s22|84-84|.|O
DDI-DrugBank.d70.s23|0-6|Because|O
DDI-DrugBank.d70.s23|8-16|pregnancy|O
DDI-DrugBank.d70.s23|18-22|could|O
DDI-DrugBank.d70.s23|31-40|maintained|O
DDI-DrugBank.d70.s23|49-54|rabbit|O
DDI-DrugBank.d70.s23|56-64|following|O
DDI-DrugBank.d70.s23|66-70|doses|O
DDI-DrugBank.d70.s23|75-85|fulvestrant|O
DDI-DrugBank.d70.s23|90-90|1|O
DDI-DrugBank.d70.s23|92-100|mg/kg/day|O
DDI-DrugBank.d70.s23|118-122|study|O
DDI-DrugBank.d70.s23|128-137|inadequate|O
DDI-DrugBank.d70.s23|142-146|fully|O
DDI-DrugBank.d70.s23|148-153|define|O
DDI-DrugBank.d70.s23|159-166|possible|O
DDI-DrugBank.d70.s23|168-174|adverse|O
DDI-DrugBank.d70.s23|176-182|effects|O
DDI-DrugBank.d70.s23|187-191|fetal|O
DDI-DrugBank.d70.s23|193-203|development|O
DDI-DrugBank.d70.s23|208-217|clinically|O
DDI-DrugBank.d70.s23|219-226|relevant|O
DDI-DrugBank.d70.s23|228-236|exposures|O
DDI-DrugBank.d70.s23|237-237|.|O
DDI-DrugBank.d70.s24|0-6|Nursing|O
DDI-DrugBank.d70.s24|8-14|Mothers|O
DDI-DrugBank.d70.s24|16-26|Fulvestrant|O
DDI-DrugBank.d70.s24|31-35|found|O
DDI-DrugBank.d70.s24|40-42|rat|O
DDI-DrugBank.d70.s24|44-47|milk|O
DDI-DrugBank.d70.s24|52-57|levels|O
DDI-DrugBank.d70.s24|59-71|significantly|O
DDI-DrugBank.d70.s24|73-78|higher|O
DDI-DrugBank.d70.s24|81-93|approximately|O
DDI-DrugBank.d70.s24|95-101|12-fold|O
DDI-DrugBank.d70.s24|109-114|plasma|O
DDI-DrugBank.d70.s24|122-135|administration|O
DDI-DrugBank.d70.s24|96-96|2|O
DDI-DrugBank.d70.s24|142-146|mg/kg|O
DDI-DrugBank.d70.s24|147-147|.|O
DDI-DrugBank.d70.s25|0-3|Drug|O
DDI-DrugBank.d70.s25|5-12|exposure|O
DDI-DrugBank.d70.s25|17-22|rodent|O
DDI-DrugBank.d70.s25|24-27|pups|O
DDI-DrugBank.d70.s25|34-52|fulvestrant-treated|O
DDI-DrugBank.d70.s25|54-62|lactating|O
DDI-DrugBank.d70.s25|64-67|dams|O
DDI-DrugBank.d70.s25|73-81|estimated|O
DDI-DrugBank.d70.s25|86-87|10|O
DDI-DrugBank.d70.s25|88-88|%|O
DDI-DrugBank.d70.s25|97-108|administered|O
DDI-DrugBank.d70.s25|110-113|dose|O
DDI-DrugBank.d70.s25|114-114|.|O
DDI-DrugBank.d70.s26|0-1|It|O
DDI-DrugBank.d70.s26|10-14|known|O
DDI-DrugBank.d70.s26|19-29|fulvestrant|O
DDI-DrugBank.d70.s26|34-41|excreted|O
DDI-DrugBank.d70.s26|46-50|human|O
DDI-DrugBank.d70.s26|52-55|milk|O
DDI-DrugBank.d70.s26|56-56|.|O
DDI-DrugBank.d70.s27|0-6|Because|O
DDI-DrugBank.d70.s27|8-11|many|O
DDI-DrugBank.d70.s27|13-17|drugs|O
DDI-DrugBank.d70.s27|23-30|excreted|O
DDI-DrugBank.d70.s27|35-39|human|O
DDI-DrugBank.d70.s27|41-44|milk|O
DDI-DrugBank.d70.s27|66-74|potential|O
DDI-DrugBank.d70.s27|80-86|serious|O
DDI-DrugBank.d70.s27|88-94|adverse|O
DDI-DrugBank.d70.s27|96-104|reactions|O
DDI-DrugBank.d70.s27|111-118|FASLODEX|O
DDI-DrugBank.d70.s27|123-129|nursing|O
DDI-DrugBank.d70.s27|131-137|infants|O
DDI-DrugBank.d70.s27|142-149|decision|O
DDI-DrugBank.d70.s27|161-164|made|O
DDI-DrugBank.d70.s27|166-172|whether|O
DDI-DrugBank.d70.s27|177-187|discontinue|O
DDI-DrugBank.d70.s27|123-129|nursing|O
DDI-DrugBank.d70.s27|177-187|discontinue|O
DDI-DrugBank.d70.s27|13-16|drug|O
DDI-DrugBank.d70.s27|224-229|taking|O
DDI-DrugBank.d70.s27|236-242|account|O
DDI-DrugBank.d70.s27|248-257|importance|O
DDI-DrugBank.d70.s27|13-16|drug|O
DDI-DrugBank.d70.s27|278-283|mother|O
DDI-DrugBank.d70.s27|284-284|.|O
DDI-DrugBank.d70.s28|0-8|Pediatric|O
DDI-DrugBank.d70.s28|10-12|Use|O
DDI-DrugBank.d70.s28|14-16|The|O
DDI-DrugBank.d70.s28|18-23|safety|O
DDI-DrugBank.d70.s28|29-36|efficacy|O
DDI-DrugBank.d70.s28|41-48|FASLODEX|O
DDI-DrugBank.d70.s28|53-61|pediatric|O
DDI-DrugBank.d70.s28|63-70|patients|O
DDI-DrugBank.d70.s28|86-96|established|O
DDI-DrugBank.d70.s28|97-97|.|O
DDI-DrugBank.d70.s29|0-8|Geriatric|O
DDI-DrugBank.d70.s29|10-12|Use|O
DDI-DrugBank.d70.s29|14-17|When|O
DDI-DrugBank.d70.s29|19-23|tumor|O
DDI-DrugBank.d70.s29|25-32|response|O
DDI-DrugBank.d70.s29|38-47|considered|O
DDI-DrugBank.d70.s29|52-54|age|O
DDI-DrugBank.d70.s29|57-65|objective|O
DDI-DrugBank.d70.s29|67-75|responses|O
DDI-DrugBank.d70.s29|82-85|seen|O
DDI-DrugBank.d70.s29|90-91|24|O
DDI-DrugBank.d70.s29|92-92|%|O
DDI-DrugBank.d70.s29|98-99|22|O
DDI-DrugBank.d70.s29|92-92|%|O
DDI-DrugBank.d70.s29|105-112|patients|O
DDI-DrugBank.d70.s29|120-121|65|O
DDI-DrugBank.d70.s29|123-127|years|O
DDI-DrugBank.d70.s29|52-54|age|O
DDI-DrugBank.d70.s29|143-144|16|O
DDI-DrugBank.d70.s29|92-92|%|O
DDI-DrugBank.d70.s29|151-152|11|O
DDI-DrugBank.d70.s29|92-92|%|O
DDI-DrugBank.d70.s29|105-112|patients|O
DDI-DrugBank.d70.s29|120-121|65|O
DDI-DrugBank.d70.s29|123-127|years|O
DDI-DrugBank.d70.s29|52-54|age|O
DDI-DrugBank.d70.s29|187-191|older|O
DDI-DrugBank.d70.s29|203-209|treated|O
DDI-DrugBank.d70.s29|216-223|FASLODEX|O
DDI-DrugBank.d70.s29|232-239|European|O
DDI-DrugBank.d70.s29|245-249|North|O
DDI-DrugBank.d70.s29|251-258|American|O
DDI-DrugBank.d70.s29|260-265|trials|O
DDI-DrugBank.d70.s29|268-279|respectively|O
DDI-DrugBank.d710.s0|0-9|Cimetidine|O
DDI-DrugBank.d710.s0|12-14|The|O
DDI-DrugBank.d710.s0|16-22|effects|O
DDI-DrugBank.d710.s0|27-33|chronic|O
DDI-DrugBank.d710.s0|35-44|cimetidine|O
DDI-DrugBank.d710.s0|46-48|use|O
DDI-DrugBank.d710.s0|57-66|metabolism|O
DDI-DrugBank.d710.s0|71-81|rimantadine|O
DDI-DrugBank.d710.s0|91-95|known|O
DDI-DrugBank.d710.s0|96-96|.|O
DDI-DrugBank.d710.s1|0-3|When|O
DDI-DrugBank.d710.s1|7-12|single|O
DDI-DrugBank.d710.s1|14-16|100|O
DDI-DrugBank.d710.s1|18-19|mg|O
DDI-DrugBank.d710.s1|21-24|dose|O
DDI-DrugBank.d710.s1|29-39|rimantadine|O
DDI-DrugBank.d710.s1|41-43|HCl|O
DDI-DrugBank.d710.s1|49-60|administered|O
DDI-DrugBank.d710.s1|62-64|one|O
DDI-DrugBank.d710.s1|66-69|hour|O
DDI-DrugBank.d710.s1|81-90|initiation|O
DDI-DrugBank.d710.s1|95-104|Cimetidine|O
DDI-DrugBank.d710.s1|107-109|300|O
DDI-DrugBank.d710.s1|18-19|mg|O
DDI-DrugBank.d710.s1|114-117|four|O
DDI-DrugBank.d710.s1|119-123|times|O
DDI-DrugBank.d710.s1|127-129|day|O
DDI-DrugBank.d710.s1|137-144|apparent|O
DDI-DrugBank.d710.s1|146-150|total|O
DDI-DrugBank.d710.s1|29-39|rimantadine|O
DDI-DrugBank.d710.s1|164-172|clearance|O
DDI-DrugBank.d710.s1|7-12|single|O
DDI-DrugBank.d710.s1|21-24|dose|O
DDI-DrugBank.d710.s1|197-202|normal|O
DDI-DrugBank.d710.s1|204-210|healthy|O
DDI-DrugBank.d710.s1|212-217|adults|O
DDI-DrugBank.d710.s1|223-229|reduced|O
DDI-DrugBank.d710.s1|234-235|18|O
DDI-DrugBank.d710.s1|236-236|%|O
DDI-DrugBank.d710.s1|239-246|compared|O
DDI-DrugBank.d710.s1|137-144|apparent|O
DDI-DrugBank.d710.s1|146-150|total|O
DDI-DrugBank.d710.s1|29-39|rimantadine|O
DDI-DrugBank.d710.s1|164-172|clearance|O
DDI-DrugBank.d710.s1|304-311|subjects|O
DDI-DrugBank.d710.s1|320-326|absence|O
DDI-DrugBank.d710.s1|331-340|cimetidine|O
DDI-DrugBank.d710.s1|342-342|.|O
DDI-DrugBank.d710.s2|0-12|Acetaminophen|O
DDI-DrugBank.d710.s2|15-25|Rimantadine|O
DDI-DrugBank.d710.s2|27-29|HCl|O
DDI-DrugBank.d710.s2|32-34|100|O
DDI-DrugBank.d710.s2|36-37|mg|O
DDI-DrugBank.d710.s2|44-48|given|O
DDI-DrugBank.d710.s2|50-54|twice|O
DDI-DrugBank.d710.s2|56-60|daily|O
DDI-DrugBank.d710.s2|66-67|13|O
DDI-DrugBank.d710.s2|69-72|days|O
DDI-DrugBank.d710.s2|77-78|12|O
DDI-DrugBank.d710.s2|80-86|healthy|O
DDI-DrugBank.d710.s2|88-97|volunteers|O
DDI-DrugBank.d710.s2|98-98|.|O
DDI-DrugBank.d710.s3|0-1|On|O
DDI-DrugBank.d710.s3|3-5|day|O
DDI-DrugBank.d710.s3|7-8|11|O
DDI-DrugBank.d710.s3|11-23|acetaminophen|O
DDI-DrugBank.d710.s3|26-28|650|O
DDI-DrugBank.d710.s3|30-31|mg|O
DDI-DrugBank.d710.s3|33-36|four|O
DDI-DrugBank.d710.s3|38-42|times|O
DDI-DrugBank.d710.s3|44-48|daily|O
DDI-DrugBank.d710.s3|55-61|started|O
DDI-DrugBank.d710.s3|67-75|continued|O
DDI-DrugBank.d710.s3|81-81|8|O
DDI-DrugBank.d710.s3|83-86|days|O
DDI-DrugBank.d710.s3|87-87|.|O
DDI-DrugBank.d710.s4|0-2|The|O
DDI-DrugBank.d710.s4|4-19|pharmacokinetics|O
DDI-DrugBank.d710.s4|24-34|rimantadine|O
DDI-DrugBank.d710.s4|41-48|assessed|O
DDI-DrugBank.d710.s4|53-56|days|O
DDI-DrugBank.d710.s4|58-59|11|O
DDI-DrugBank.d710.s4|65-66|13|O
DDI-DrugBank.d710.s4|67-67|.|O
DDI-DrugBank.d710.s5|0-15|Coadministration|O
DDI-DrugBank.d710.s5|22-34|acetaminophen|O
DDI-DrugBank.d710.s5|36-42|reduced|O
DDI-DrugBank.d710.s5|48-51|peak|O
DDI-DrugBank.d710.s5|53-65|concentration|O
DDI-DrugBank.d710.s5|71-73|AUC|O
DDI-DrugBank.d710.s5|75-80|values|O
DDI-DrugBank.d710.s5|86-96|rimantadine|O
DDI-DrugBank.d710.s5|101-113|approximately|O
DDI-DrugBank.d710.s5|115-116|11|O
DDI-DrugBank.d710.s5|117-117|%|O
DDI-DrugBank.d710.s5|118-118|.|O
DDI-DrugBank.d710.s6|0-6|Aspirin|O
DDI-DrugBank.d710.s6|9-19|Rimantadine|O
DDI-DrugBank.d710.s6|21-23|HCl|O
DDI-DrugBank.d710.s6|26-28|100|O
DDI-DrugBank.d710.s6|30-31|mg|O
DDI-DrugBank.d710.s6|38-42|given|O
DDI-DrugBank.d710.s6|44-48|twice|O
DDI-DrugBank.d710.s6|50-54|daily|O
DDI-DrugBank.d710.s6|56-58|fro|O
DDI-DrugBank.d710.s6|60-61|13|O
DDI-DrugBank.d710.s6|63-66|days|O
DDI-DrugBank.d710.s6|71-72|12|O
DDI-DrugBank.d710.s6|74-80|healthy|O
DDI-DrugBank.d710.s6|82-91|volunteers|O
DDI-DrugBank.d710.s6|92-92|.|O
DDI-DrugBank.d710.s7|0-1|On|O
DDI-DrugBank.d710.s7|3-5|day|O
DDI-DrugBank.d710.s7|7-8|11|O
DDI-DrugBank.d710.s7|11-17|aspirin|O
DDI-DrugBank.d710.s7|20-22|650|O
DDI-DrugBank.d710.s7|24-25|mg|O
DDI-DrugBank.d710.s7|28-31|four|O
DDI-DrugBank.d710.s7|33-37|times|O
DDI-DrugBank.d710.s7|39-43|daily|O
DDI-DrugBank.d710.s7|50-56|started|O
DDI-DrugBank.d710.s7|62-70|continued|O
DDI-DrugBank.d710.s7|76-76|8|O
DDI-DrugBank.d710.s7|78-81|days|O
DDI-DrugBank.d710.s7|82-82|.|O
DDI-DrugBank.d710.s8|0-2|The|O
DDI-DrugBank.d710.s8|4-19|pharmacokinetics|O
DDI-DrugBank.d710.s8|24-34|rimantadine|O
DDI-DrugBank.d710.s8|41-48|assessed|O
DDI-DrugBank.d710.s8|53-56|days|O
DDI-DrugBank.d710.s8|58-59|11|O
DDI-DrugBank.d710.s8|65-66|13|O
DDI-DrugBank.d710.s8|67-67|.|O
DDI-DrugBank.d710.s9|0-3|Peak|O
DDI-DrugBank.d710.s9|5-10|plasma|O
DDI-DrugBank.d710.s9|12-25|concentrations|O
DDI-DrugBank.d710.s9|31-33|AUC|O
DDI-DrugBank.d710.s9|38-48|rimantadine|O
DDI-DrugBank.d710.s9|55-61|reduced|O
DDI-DrugBank.d710.s9|63-75|approximately|O
DDI-DrugBank.d710.s9|77-78|10|O
DDI-DrugBank.d710.s9|79-79|%|O
DDI-DrugBank.d710.s9|88-95|presence|O
DDI-DrugBank.d710.s9|100-106|aspirin|O
DDI-DrugBank.d710.s9|107-107|.|O
DDI-MedLine.d61.s0|0-14|Pharmacokinetic|O
DDI-MedLine.d61.s0|16-25|evaluation|O
DDI-MedLine.d61.s0|34-51|digoxin-amiodarone|O
DDI-MedLine.d61.s0|53-63|interaction|O
DDI-MedLine.d61.s0|64-64|.|O
DDI-MedLine.d61.s1|0-9|Amiodarone|O
DDI-MedLine.d61.s1|14-18|known|O
DDI-MedLine.d61.s1|23-27|raise|O
DDI-MedLine.d61.s1|29-33|serum|O
DDI-MedLine.d61.s1|35-41|digoxin|O
DDI-MedLine.d61.s1|43-48|levels|O
DDI-MedLine.d61.s1|49-49|.|O
DDI-MedLine.d61.s2|0-3|This|O
DDI-MedLine.d61.s2|5-9|study|O
DDI-MedLine.d61.s2|15-22|designed|O
DDI-MedLine.d61.s2|27-34|evaluate|O
DDI-MedLine.d61.s2|40-54|pharmacokinetic|O
DDI-MedLine.d61.s2|56-60|basis|O
DDI-MedLine.d61.s2|70-80|interaction|O
DDI-MedLine.d61.s2|85-86|10|O
DDI-MedLine.d61.s2|88-93|normal|O
DDI-MedLine.d61.s2|95-102|subjects|O
DDI-MedLine.d61.s2|103-103|.|O
DDI-MedLine.d61.s3|0-2|The|O
DDI-MedLine.d61.s3|4-18|pharmacokinetic|O
DDI-MedLine.d61.s3|20-28|variables|O
DDI-MedLine.d61.s3|34-40|digoxin|O
DDI-MedLine.d61.s3|47-56|determined|O
DDI-MedLine.d61.s3|66-68|1.0|O
DDI-MedLine.d61.s3|70-71|mg|O
DDI-MedLine.d61.s3|73-83|intravenous|O
DDI-MedLine.d61.s3|85-88|dose|O
DDI-MedLine.d61.s3|34-40|digoxin|O
DDI-MedLine.d61.s3|109-115|subject|O
DDI-MedLine.d61.s3|135-138|oral|O
DDI-MedLine.d61.s3|140-149|amiodarone|O
DDI-MedLine.d61.s3|152-154|400|O
DDI-MedLine.d61.s3|70-71|mg|O
DDI-MedLine.d61.s3|159-163|daily|O
DDI-MedLine.d61.s3|169-169|3|O
DDI-MedLine.d61.s3|171-175|weeks|O
DDI-MedLine.d61.s3|67-67|.|O
DDI-MedLine.d61.s4|0-5|During|O
DDI-MedLine.d61.s4|7-16|amiodarone|O
DDI-MedLine.d61.s4|18-31|administration|O
DDI-MedLine.d61.s4|34-41|systemic|O
DDI-MedLine.d61.s4|43-51|clearance|O
DDI-MedLine.d61.s4|56-62|digoxin|O
DDI-MedLine.d61.s4|68-74|reduced|O
DDI-MedLine.d61.s4|81-83|234|O
DDI-MedLine.d61.s4|85-87|+/-|O
DDI-MedLine.d61.s4|89-90|72|O
DDI-MedLine.d61.s4|92-97|ml/min|O
DDI-MedLine.d61.s4|100-103|mean|O
DDI-MedLine.d61.s4|85-87|+/-|O
DDI-MedLine.d61.s4|109-116|standard|O
DDI-MedLine.d61.s4|118-126|deviation|O
DDI-MedLine.d61.s4|132-134|172|O
DDI-MedLine.d61.s4|85-87|+/-|O
DDI-MedLine.d61.s4|140-141|33|O
DDI-MedLine.d61.s4|92-97|ml/min|O
DDI-MedLine.d61.s4|151-151|p|O
DDI-MedLine.d61.s4|153-156|less|O
DDI-MedLine.d61.s4|163-166|0.01|O
DDI-MedLine.d61.s4|164-164|.|O
DDI-MedLine.d61.s5|0-3|This|O
DDI-MedLine.d61.s5|9-11|due|O
DDI-MedLine.d61.s5|16-25|reductions|O
DDI-MedLine.d61.s5|35-39|renal|O
DDI-MedLine.d61.s5|41-49|clearance|O
DDI-MedLine.d61.s5|57-59|105|O
DDI-MedLine.d61.s5|61-63|+/-|O
DDI-MedLine.d61.s5|65-66|39|O
DDI-MedLine.d61.s5|71-72|84|O
DDI-MedLine.d61.s5|61-63|+/-|O
DDI-MedLine.d61.s5|78-79|15|O
DDI-MedLine.d61.s5|81-86|ml/min|O
DDI-MedLine.d61.s5|90-90|p|O
DDI-MedLine.d61.s5|92-95|less|O
DDI-MedLine.d61.s5|102-105|0.05|O
DDI-MedLine.d61.s5|112-119|nonrenal|O
DDI-MedLine.d61.s5|41-49|clearance|O
DDI-MedLine.d61.s5|137-139|130|O
DDI-MedLine.d61.s5|61-63|+/-|O
DDI-MedLine.d61.s5|145-146|38|O
DDI-MedLine.d61.s5|151-152|88|O
DDI-MedLine.d61.s5|61-63|+/-|O
DDI-MedLine.d61.s5|158-159|20|O
DDI-MedLine.d61.s5|81-86|ml/min|O
DDI-MedLine.d61.s5|90-90|p|O
DDI-MedLine.d61.s5|92-95|less|O
DDI-MedLine.d61.s5|182-185|0.01|O
DDI-MedLine.d61.s5|103-103|.|O
DDI-MedLine.d61.s6|0-6|Digoxin|O
DDI-MedLine.d61.s6|8-16|half-life|O
DDI-MedLine.d61.s6|21-31|elimination|O
DDI-MedLine.d61.s6|37-45|prolonged|O
DDI-MedLine.d61.s6|52-53|34|O
DDI-MedLine.d61.s6|55-57|+/-|O
DDI-MedLine.d61.s6|59-60|13|O
DDI-MedLine.d61.s6|65-66|40|O
DDI-MedLine.d61.s6|55-57|+/-|O
DDI-MedLine.d61.s6|72-73|16|O
DDI-MedLine.d61.s6|75-79|hours|O
DDI-MedLine.d61.s6|37-37|p|O
DDI-MedLine.d61.s6|84-87|less|O
DDI-MedLine.d61.s6|94-97|0.05|O
DDI-MedLine.d61.s6|95-95|.|O
DDI-MedLine.d61.s7|0-6|Digoxin|O
DDI-MedLine.d61.s7|8-13|volume|O
DDI-MedLine.d61.s7|18-29|distribution|O
DDI-MedLine.d61.s7|39-51|significantly|O
DDI-MedLine.d61.s7|53-59|changed|O
DDI-MedLine.d61.s7|60-60|.|O
DDI-MedLine.d61.s8|0-9|Amiodarone|O
DDI-MedLine.d61.s8|11-16|caused|O
DDI-MedLine.d61.s8|20-25|three-|O
DDI-MedLine.d61.s8|30-37|fivefold|O
DDI-MedLine.d61.s8|39-46|increase|O
DDI-MedLine.d61.s8|51-55|serum|O
DDI-MedLine.d61.s8|57-63|reverse|O
DDI-MedLine.d61.s8|65-80|triiodothyronine|O
DDI-MedLine.d61.s8|82-87|levels|O
DDI-MedLine.d61.s8|94-100|changes|O
DDI-MedLine.d61.s8|105-111|thyroid|O
DDI-MedLine.d61.s8|113-120|function|O
DDI-MedLine.d61.s8|131-144|quantitatively|O
DDI-MedLine.d61.s8|146-152|related|O
DDI-MedLine.d61.s8|94-100|changes|O
DDI-MedLine.d61.s8|172-178|digoxin|O
DDI-MedLine.d61.s8|180-195|pharmacokinetics|O
DDI-MedLine.d61.s8|196-196|.|O
DDI-MedLine.d61.s9|0-4|These|O
DDI-MedLine.d61.s9|6-16|alterations|O
DDI-MedLine.d61.s9|21-27|digoxin|O
DDI-MedLine.d61.s9|29-44|pharmacokinetics|O
DDI-MedLine.d61.s9|46-53|produced|O
DDI-MedLine.d61.s9|58-67|amiodarone|O
DDI-MedLine.d61.s9|69-75|explain|O
DDI-MedLine.d61.s9|81-88|increase|O
DDI-MedLine.d61.s9|93-97|serum|O
DDI-MedLine.d61.s9|21-27|digoxin|O
DDI-MedLine.d61.s9|107-111|level|O
DDI-MedLine.d61.s9|127-134|observed|O
DDI-MedLine.d61.s9|146-149|drug|O
DDI-MedLine.d61.s9|151-161|combination|O
DDI-MedLine.d61.s9|172-175|used|O
DDI-MedLine.d61.s9|177-186|clinically|O
DDI-MedLine.d61.s9|187-187|.|O
DDI-DrugBank.d189.s0|0-1|No|O
DDI-DrugBank.d189.s0|3-11|Important|O
DDI-DrugBank.d189.s0|13-24|Interactions|O
DDI-DrugBank.d189.s0|26-27|To|O
DDI-DrugBank.d189.s0|29-32|Date|O
DDI-DrugBank.d189.s0|34-45|Levosimendan|O
DDI-DrugBank.d189.s0|61-70|clinically|O
DDI-DrugBank.d189.s0|72-80|important|O
DDI-DrugBank.d189.s0|82-96|pharmacokinetic|O
DDI-DrugBank.d189.s0|98-109|interactions|O
DDI-DrugBank.d189.s0|116-124|captopril|O
DDI-DrugBank.d189.s0|127-139|beta-blockers|O
DDI-DrugBank.d189.s0|142-151|felodipine|O
DDI-DrugBank.d189.s0|154-160|digoxin|O
DDI-DrugBank.d189.s0|163-170|warfarin|O
DDI-DrugBank.d189.s0|173-182|isosorbide|O
DDI-DrugBank.d189.s0|184-194|mononitrate|O
DDI-DrugBank.d189.s0|197-206|carvedilol|O
DDI-DrugBank.d189.s0|209-215|ethanol|O
DDI-DrugBank.d189.s0|220-231|itraconazole|O
DDI-DrugBank.d330.s0|0-6|Caution|O
DDI-DrugBank.d330.s0|18-22|taken|O
DDI-DrugBank.d330.s0|27-36|concurrent|O
DDI-DrugBank.d330.s0|41-46|serial|O
DDI-DrugBank.d330.s0|48-50|use|O
DDI-DrugBank.d330.s0|61-70|neurotoxic|O
DDI-DrugBank.d330.s0|72-75|and/|O
DDI-DrugBank.d330.s0|80-90|nephrotoxic|O
DDI-DrugBank.d330.s0|92-96|drugs|O
DDI-DrugBank.d330.s0|109-116|possible|O
DDI-DrugBank.d330.s0|118-128|enhancement|O
DDI-DrugBank.d330.s0|137-150|nephrotoxicity|O
DDI-DrugBank.d330.s0|152-157|and/or|O
DDI-DrugBank.d330.s0|159-169|ototoxicity|O
DDI-DrugBank.d330.s0|174-181|neomycin|O
DDI-DrugBank.d330.s0|182-182|.|O
DDI-DrugBank.d330.s1|0-6|Caution|O
DDI-DrugBank.d330.s1|15-18|also|O
DDI-DrugBank.d330.s1|23-27|taken|O
DDI-DrugBank.d330.s1|32-41|concurrent|O
DDI-DrugBank.d330.s1|46-51|serial|O
DDI-DrugBank.d330.s1|53-55|use|O
DDI-DrugBank.d330.s1|66-80|aminoglycosides|O
DDI-DrugBank.d330.s1|86-95|polymyxins|O
DDI-DrugBank.d330.s1|110-112|may|O
DDI-DrugBank.d330.s1|114-120|enhance|O
DDI-DrugBank.d330.s1|122-129|neomycin|O
DDI-DrugBank.d330.s1|133-146|nephrotoxicity|O
DDI-DrugBank.d330.s1|148-153|and/or|O
DDI-DrugBank.d330.s1|155-165|ototoxicity|O
DDI-DrugBank.d330.s1|171-180|potentiate|O
DDI-DrugBank.d330.s1|122-129|neomycin|O
DDI-DrugBank.d330.s1|191-197|sulfate|O
DDI-DrugBank.d330.s1|199-211|neuromuscular|O
DDI-DrugBank.d330.s1|213-220|blocking|O
DDI-DrugBank.d330.s1|222-228|effects|O
DDI-DrugBank.d330.s1|229-229|.|O
DDI-DrugBank.d330.s2|0-3|Oral|O
DDI-DrugBank.d330.s2|5-12|neomycin|O
DDI-DrugBank.d330.s2|14-21|inhibits|O
DDI-DrugBank.d330.s2|27-42|gastrointestinal|O
DDI-DrugBank.d330.s2|44-53|absorption|O
DDI-DrugBank.d330.s2|58-67|penicillin|O
DDI-DrugBank.d330.s2|69-69|V|O
DDI-DrugBank.d330.s2|72-75|oral|O
DDI-DrugBank.d330.s2|77-83|vitamin|O
DDI-DrugBank.d330.s2|85-88|B-12|O
DDI-DrugBank.d330.s2|91-102|methotrexate|O
DDI-DrugBank.d330.s2|108-121|5-fluorouracil|O
DDI-DrugBank.d330.s2|122-122|.|O
DDI-DrugBank.d330.s3|0-2|The|O
DDI-DrugBank.d330.s3|4-19|gastrointestinal|O
DDI-DrugBank.d330.s3|21-30|absorption|O
DDI-DrugBank.d330.s3|35-41|digoxin|O
DDI-DrugBank.d330.s3|43-46|also|O
DDI-DrugBank.d330.s3|48-54|appears|O
DDI-DrugBank.d330.s3|62-70|inhibited|O
DDI-DrugBank.d330.s3|71-71|.|O
DDI-DrugBank.d330.s4|0-8|Therefore|O
DDI-DrugBank.d330.s4|11-17|digoxin|O
DDI-DrugBank.d330.s4|19-23|serum|O
DDI-DrugBank.d330.s4|25-30|levels|O
DDI-DrugBank.d330.s4|42-50|monitored|O
DDI-DrugBank.d330.s4|51-51|.|O
DDI-DrugBank.d330.s5|0-3|Oral|O
DDI-DrugBank.d330.s5|5-12|neomycin|O
DDI-DrugBank.d330.s5|14-20|sulfate|O
DDI-DrugBank.d330.s5|22-24|may|O
DDI-DrugBank.d330.s5|26-32|enhance|O
DDI-DrugBank.d330.s5|38-43|effect|O
DDI-DrugBank.d330.s5|48-55|coumarin|O
DDI-DrugBank.d330.s5|60-73|anticoagulants|O
DDI-DrugBank.d330.s5|78-87|decreasing|O
DDI-DrugBank.d330.s5|89-95|vitamin|O
DDI-DrugBank.d330.s5|97-97|K|O
DDI-DrugBank.d330.s5|99-110|availability|O
DDI-DrugBank.d330.s5|111-111|.|O
DDI-DrugBank.d599.s0|0-8|Excessive|O
DDI-DrugBank.d599.s0|10-23|glucocorticoid|O
DDI-DrugBank.d599.s0|25-31|therapy|O
DDI-DrugBank.d599.s0|38-44|inhibit|O
DDI-DrugBank.d599.s0|50-65|growth-promoting|O
DDI-DrugBank.d599.s0|67-72|effect|O
DDI-DrugBank.d599.s0|77-81|human|O
DDI-DrugBank.d599.s0|83-84|GH|O
DDI-DrugBank.d599.s0|85-85|.|O
DDI-DrugBank.d599.s1|0-7|Patients|O
DDI-DrugBank.d599.s1|14-17|ACTH|O
DDI-DrugBank.d599.s1|19-28|deficiency|O
DDI-DrugBank.d599.s1|48-73|glucocorticoid-replacement|O
DDI-DrugBank.d599.s1|75-78|dose|O
DDI-DrugBank.d599.s1|80-88|carefully|O
DDI-DrugBank.d599.s1|90-97|adjusted|O
DDI-DrugBank.d599.s1|102-106|avoid|O
DDI-DrugBank.d599.s1|111-120|inhibitory|O
DDI-DrugBank.d599.s1|122-127|effect|O
DDI-DrugBank.d599.s1|132-137|growth|O
DDI-DrugBank.d599.s1|138-138|.|O
DDI-DrugBank.d599.s2|0-2|The|O
DDI-DrugBank.d599.s2|4-6|use|O
DDI-DrugBank.d599.s2|11-18|Nutropin|O
DDI-DrugBank.d599.s2|23-30|patients|O
DDI-DrugBank.d599.s2|37-43|chronic|O
DDI-DrugBank.d599.s2|45-49|renal|O
DDI-DrugBank.d599.s2|51-63|insufficiency|O
DDI-DrugBank.d599.s2|65-73|receiving|O
DDI-DrugBank.d599.s2|75-88|glucocorticoid|O
DDI-DrugBank.d599.s2|90-96|therapy|O
DDI-DrugBank.d599.s2|111-119|evaluated|O
DDI-DrugBank.d599.s2|120-120|.|O
DDI-DrugBank.d599.s3|0-10|Concomitant|O
DDI-DrugBank.d599.s3|12-25|glucocorticoid|O
DDI-DrugBank.d599.s3|27-33|therapy|O
DDI-DrugBank.d599.s3|35-37|may|O
DDI-DrugBank.d599.s3|39-45|inhibit|O
DDI-DrugBank.d599.s3|51-66|growth-promoting|O
DDI-DrugBank.d599.s3|68-73|effect|O
DDI-DrugBank.d599.s3|78-85|Nutropin|O
DDI-DrugBank.d599.s3|86-86|.|O
DDI-DrugBank.d599.s4|0-1|If|O
DDI-DrugBank.d599.s4|3-16|glucocorticoid|O
DDI-DrugBank.d599.s4|18-28|replacement|O
DDI-DrugBank.d599.s4|33-40|required|O
DDI-DrugBank.d599.s4|3-16|glucocorticoid|O
DDI-DrugBank.d599.s4|62-65|dose|O
DDI-DrugBank.d599.s4|77-85|carefully|O
DDI-DrugBank.d599.s4|87-94|adjusted|O
DDI-DrugBank.d599.s5|0-4|There|O
DDI-DrugBank.d599.s5|13-20|evidence|O
DDI-DrugBank.d599.s5|29-38|controlled|O
DDI-DrugBank.d599.s5|40-46|studies|O
DDI-DrugBank.d599.s5|51-58|Nutropin|O
DDI-DrugBank.d599.s5|64-74|interaction|O
DDI-DrugBank.d599.s5|81-85|drugs|O
DDI-DrugBank.d599.s5|87-94|commonly|O
DDI-DrugBank.d599.s5|96-99|used|O
DDI-DrugBank.d599.s5|104-110|chronic|O
DDI-DrugBank.d599.s5|112-116|renal|O
DDI-DrugBank.d599.s5|118-130|insufficiency|O
DDI-DrugBank.d599.s5|132-139|patients|O
DDI-DrugBank.d599.s5|140-140|.|O
DDI-DrugBank.d599.s6|0-6|Limited|O
DDI-DrugBank.d599.s6|8-16|published|O
DDI-DrugBank.d599.s6|18-21|data|O
DDI-DrugBank.d599.s6|23-30|indicate|O
DDI-DrugBank.d599.s6|37-38|GH|O
DDI-DrugBank.d599.s6|40-48|treatment|O
DDI-DrugBank.d599.s6|50-58|increases|O
DDI-DrugBank.d599.s6|60-69|cytochrome|O
DDI-DrugBank.d599.s6|71-74|P450|O
DDI-DrugBank.d599.s6|77-81|CP450|O
DDI-DrugBank.d599.s6|84-91|mediated|O
DDI-DrugBank.d599.s6|93-102|antipyrine|O
DDI-DrugBank.d599.s6|104-112|clearance|O
DDI-DrugBank.d599.s6|117-119|man|O
DDI-DrugBank.d599.s6|120-120|.|O
DDI-DrugBank.d599.s7|0-4|These|O
DDI-DrugBank.d599.s7|6-9|data|O
DDI-DrugBank.d599.s7|11-17|suggest|O
DDI-DrugBank.d599.s7|24-25|GH|O
DDI-DrugBank.d599.s7|27-40|administration|O
DDI-DrugBank.d599.s7|42-44|may|O
DDI-DrugBank.d599.s7|46-50|alter|O
DDI-DrugBank.d599.s7|56-64|clearance|O
DDI-DrugBank.d599.s7|69-77|compounds|O
DDI-DrugBank.d599.s7|79-83|known|O
DDI-DrugBank.d599.s7|91-101|metabolized|O
DDI-DrugBank.d599.s7|106-110|CP450|O
DDI-DrugBank.d599.s7|112-116|liver|O
DDI-DrugBank.d599.s7|118-124|enzymes|O
DDI-DrugBank.d599.s7|127-130|e.g.|O
DDI-DrugBank.d599.s7|133-147|corticosteroids|O
DDI-DrugBank.d599.s7|150-152|sex|O
DDI-DrugBank.d599.s7|140-147|steroids|O
DDI-DrugBank.d599.s7|164-178|anticonvulsants|O
DDI-DrugBank.d599.s7|181-191|cyclosporin|O
DDI-DrugBank.d599.s7|128-128|.|O
DDI-DrugBank.d599.s8|0-6|Careful|O
DDI-DrugBank.d599.s8|8-17|monitoring|O
DDI-DrugBank.d599.s8|22-30|advisable|O
DDI-DrugBank.d599.s8|37-38|GH|O
DDI-DrugBank.d599.s8|43-54|administered|O
DDI-DrugBank.d599.s8|59-69|combination|O
DDI-DrugBank.d599.s8|82-86|drugs|O
DDI-DrugBank.d599.s8|88-92|known|O
DDI-DrugBank.d599.s8|100-110|metabolized|O
DDI-DrugBank.d599.s8|115-119|CP450|O
DDI-DrugBank.d599.s8|121-125|liver|O
DDI-DrugBank.d599.s8|127-133|enzymes|O
DDI-DrugBank.d599.s8|134-134|.|O
DDI-DrugBank.d576.s0|0-10|Salicylates|O
DDI-DrugBank.d576.s0|12-21|antagonize|O
DDI-DrugBank.d576.s0|27-36|uricosuric|O
DDI-DrugBank.d576.s0|38-43|action|O
DDI-DrugBank.d576.s0|48-48|.|O
DDI-DrugBank.d576.s0|50-54|drugs|O
DDI-DrugBank.d576.s0|56-59|used|O
DDI-DrugBank.d576.s0|64-68|treat|O
DDI-DrugBank.d576.s0|70-73|gout|O
DDI-DrugBank.d576.s1|0-6|ASPIRIN|O
DDI-DrugBank.d576.s1|8-10|AND|O
DDI-DrugBank.d576.s1|12-16|OTHER|O
DDI-DrugBank.d576.s1|18-27|SALICYLATE|O
DDI-DrugBank.d576.s1|29-33|DRUGS|O
DDI-DrugBank.d576.s1|35-38|WILL|O
DDI-DrugBank.d576.s1|40-41|BE|O
DDI-DrugBank.d576.s1|43-50|ADDITIVE|O
DDI-DrugBank.d576.s1|52-53|TO|O
DDI-DrugBank.d576.s1|55-62|DISALCID|O
DDI-DrugBank.d576.s1|8-10|AND|O
DDI-DrugBank.d576.s1|68-70|MAY|O
DDI-DrugBank.d576.s1|72-79|INCREASE|O
DDI-DrugBank.d576.s1|81-86|PLASMA|O
DDI-DrugBank.d576.s1|88-101|CONCENTRATIONS|O
DDI-DrugBank.d576.s1|103-104|OF|O
DDI-DrugBank.d576.s1|106-114|SALICYLIC|O
DDI-DrugBank.d576.s1|116-119|ACID|O
DDI-DrugBank.d576.s1|52-53|TO|O
DDI-DrugBank.d576.s1|124-128|TOXIC|O
DDI-DrugBank.d576.s1|130-135|LEVELS|O
DDI-DrugBank.d576.s1|136-136|.|O
DDI-DrugBank.d576.s2|0-4|Drugs|O
DDI-DrugBank.d576.s2|10-14|foods|O
DDI-DrugBank.d576.s2|21-25|raise|O
DDI-DrugBank.d576.s2|27-31|urine|O
DDI-DrugBank.d576.s2|33-34|pH|O
DDI-DrugBank.d576.s2|41-48|increase|O
DDI-DrugBank.d576.s2|50-54|renal|O
DDI-DrugBank.d576.s2|56-64|clearance|O
DDI-DrugBank.d576.s2|70-76|urinary|O
DDI-DrugBank.d576.s2|78-86|excretion|O
DDI-DrugBank.d576.s2|91-99|salicylic|O
DDI-DrugBank.d576.s2|101-104|acid|O
DDI-DrugBank.d576.s2|107-110|thus|O
DDI-DrugBank.d576.s2|112-119|lowering|O
DDI-DrugBank.d576.s2|121-126|plasma|O
DDI-DrugBank.d576.s2|128-133|levels|O
DDI-DrugBank.d576.s3|0-9|acidifying|O
DDI-DrugBank.d576.s3|11-15|drugs|O
DDI-DrugBank.d576.s3|20-24|foods|O
DDI-DrugBank.d576.s3|31-38|decrease|O
DDI-DrugBank.d576.s3|40-46|urinary|O
DDI-DrugBank.d576.s3|48-56|excretion|O
DDI-DrugBank.d576.s3|62-69|increase|O
DDI-DrugBank.d576.s3|71-76|plasma|O
DDI-DrugBank.d576.s3|78-83|levels|O
DDI-DrugBank.d576.s3|84-84|.|O
DDI-DrugBank.d576.s4|0-10|Salicylates|O
DDI-DrugBank.d576.s4|12-16|given|O
DDI-DrugBank.d576.s4|18-30|concomitantly|O
DDI-DrugBank.d576.s4|37-49|anticoagulant|O
DDI-DrugBank.d576.s4|51-55|drugs|O
DDI-DrugBank.d576.s4|57-59|may|O
DDI-DrugBank.d576.s4|61-70|predispose|O
DDI-DrugBank.d576.s4|75-82|systemic|O
DDI-DrugBank.d576.s4|84-91|bleeding|O
DDI-DrugBank.d576.s4|92-92|.|O
DDI-DrugBank.d576.s5|0-10|Salicylates|O
DDI-DrugBank.d576.s5|12-14|may|O
DDI-DrugBank.d576.s5|16-22|enhance|O
DDI-DrugBank.d576.s5|28-39|hypoglycemic|O
DDI-DrugBank.d576.s5|41-46|effect|O
DDI-DrugBank.d576.s5|51-54|oral|O
DDI-DrugBank.d576.s5|56-67|antidiabetic|O
DDI-DrugBank.d576.s5|69-73|drugs|O
DDI-DrugBank.d576.s5|82-93|sulfonylurea|O
DDI-DrugBank.d576.s5|95-99|class|O
DDI-DrugBank.d576.s5|100-100|.|O
DDI-DrugBank.d576.s6|0-9|Salicylate|O
DDI-DrugBank.d576.s6|11-18|competes|O
DDI-DrugBank.d576.s6|27-32|number|O
DDI-DrugBank.d576.s6|37-41|drugs|O
DDI-DrugBank.d576.s6|47-53|protein|O
DDI-DrugBank.d576.s6|55-61|binding|O
DDI-DrugBank.d576.s6|63-67|sites|O
DDI-DrugBank.d576.s6|70-76|notably|O
DDI-DrugBank.d576.s6|78-87|penicillin|O
DDI-DrugBank.d576.s6|90-99|thiopental|O
DDI-DrugBank.d576.s6|102-110|thyroxine|O
DDI-DrugBank.d576.s6|113-128|triiodothyronine|O
DDI-DrugBank.d576.s6|131-139|phenytoin|O
DDI-DrugBank.d576.s6|142-155|sulfinpyrazone|O
DDI-DrugBank.d576.s6|158-165|naproxen|O
DDI-DrugBank.d576.s6|168-175|warfarin|O
DDI-DrugBank.d576.s6|178-189|methotrexate|O
DDI-DrugBank.d576.s6|196-203|possibly|O
DDI-DrugBank.d576.s6|205-219|corticosteroids|O
DDI-DrugBank.d576.s6|220-220|.|O
DDI-DrugBank.d576.s7|0-4|Drug/|O
DDI-DrugBank.d576.s7|6-15|Laboratory|O
DDI-DrugBank.d576.s7|17-20|Test|O
DDI-DrugBank.d576.s7|22-33|Interactions|O
DDI-DrugBank.d576.s7|35-44|Salicylate|O
DDI-DrugBank.d576.s7|46-53|competes|O
DDI-DrugBank.d576.s7|60-66|thyroid|O
DDI-DrugBank.d576.s7|68-74|hormone|O
DDI-DrugBank.d576.s7|80-86|binding|O
DDI-DrugBank.d576.s7|91-96|plasma|O
DDI-DrugBank.d576.s7|98-105|proteins|O
DDI-DrugBank.d576.s7|114-116|may|O
DDI-DrugBank.d576.s7|121-129|reflected|O
DDI-DrugBank.d576.s7|136-144|depressed|O
DDI-DrugBank.d576.s7|91-96|plasma|O
DDI-DrugBank.d576.s7|153-154|T4|O
DDI-DrugBank.d576.s7|156-160|value|O
DDI-DrugBank.d576.s7|170-177|patients|O
DDI-DrugBank.d576.s8|0-6|thyroid|O
DDI-DrugBank.d576.s8|8-15|function|O
DDI-DrugBank.d576.s8|21-25|basal|O
DDI-DrugBank.d576.s8|27-36|metabolism|O
DDI-DrugBank.d576.s8|42-51|unaffected|O
DDI-DrugBank.d576.s8|52-52|.|O
DDI-DrugBank.d322.s0|0-9|Amantadine|O
DDI-DrugBank.d322.s0|12-20|tricyclic|O
DDI-DrugBank.d322.s0|22-36|antidepressants|O
DDI-DrugBank.d322.s0|43-47|MAOIs|O
DDI-DrugBank.d322.s0|49-51|may|O
DDI-DrugBank.d322.s0|53-60|increase|O
DDI-DrugBank.d322.s0|62-76|anticholinergic|O
DDI-DrugBank.d322.s0|78-83|effect|O
DDI-DrugBank.d322.s0|88-96|clidinium|O
DDI-DrugBank.d322.s0|97-97|.|O
DDI-DrugBank.d322.s1|0-8|Clidinium|O
DDI-DrugBank.d322.s1|10-12|may|O
DDI-DrugBank.d322.s1|14-21|decrease|O
DDI-DrugBank.d322.s1|27-32|effect|O
DDI-DrugBank.d322.s1|37-50|phenothiazines|O
DDI-DrugBank.d322.s1|53-60|levodopa|O
DDI-DrugBank.d322.s1|67-78|ketoconazole|O
DDI-DrugBank.d322.s1|79-79|.|O
DDI-MedLine.d115.s0|0-10|Concomitant|O
DDI-MedLine.d115.s0|12-27|cyclophosphamide|O
DDI-MedLine.d115.s0|30-40|doxorubicin|O
DDI-MedLine.d115.s0|43-53|vincristine|O
DDI-MedLine.d115.s0|60-69|prednisone|O
DDI-MedLine.d115.s0|71-82|chemotherapy|O
DDI-MedLine.d115.s0|84-87|plus|O
DDI-MedLine.d115.s0|89-94|highly|O
DDI-MedLine.d115.s0|96-101|active|O
DDI-MedLine.d115.s0|103-116|antiretroviral|O
DDI-MedLine.d115.s0|76-82|therapy|O
DDI-MedLine.d115.s0|129-136|patients|O
DDI-MedLine.d115.s0|143-147|human|O
DDI-MedLine.d115.s0|149-164|immunodeficiency|O
DDI-MedLine.d115.s0|166-178|virus-related|O
DDI-MedLine.d115.s0|181-191|non-Hodgkin|O
DDI-MedLine.d115.s0|193-200|lymphoma|O
DDI-MedLine.d115.s0|201-201|.|O
DDI-MedLine.d115.s1|0-9|BACKGROUND|O
DDI-MedLine.d115.s1|12-14|The|O
DDI-MedLine.d115.s1|16-26|feasibility|O
DDI-MedLine.d115.s1|32-39|efficacy|O
DDI-MedLine.d115.s1|44-54|concomitant|O
DDI-MedLine.d115.s1|56-67|chemotherapy|O
DDI-MedLine.d115.s1|73-78|highly|O
DDI-MedLine.d115.s1|80-85|active|O
DDI-MedLine.d115.s1|87-100|antiretroviral|O
DDI-MedLine.d115.s1|61-67|therapy|O
DDI-MedLine.d115.s1|111-115|HAART|O
DDI-MedLine.d115.s1|121-125|still|O
DDI-MedLine.d115.s1|127-133|unknown|O
DDI-MedLine.d115.s1|138-145|patients|O
DDI-MedLine.d115.s1|152-156|human|O
DDI-MedLine.d115.s1|158-173|immunodeficiency|O
DDI-MedLine.d115.s1|175-179|virus|O
DDI-MedLine.d115.s1|182-184|HIV|O
DDI-MedLine.d115.s1|186-193|-related|O
DDI-MedLine.d115.s1|195-206|malignancies|O
DDI-MedLine.d115.s1|207-207|.|O
DDI-MedLine.d115.s2|0-1|To|O
DDI-MedLine.d115.s2|3-10|evaluate|O
DDI-MedLine.d115.s2|16-21|impact|O
DDI-MedLine.d115.s2|26-37|chemotherapy|O
DDI-MedLine.d115.s2|39-42|plus|O
DDI-MedLine.d115.s2|44-48|HAART|O
DDI-MedLine.d115.s2|57-64|clinical|O
DDI-MedLine.d115.s2|66-71|course|O
DDI-MedLine.d115.s2|76-83|patients|O
DDI-MedLine.d115.s2|90-100|HIV-related|O
DDI-MedLine.d115.s2|103-110|systemic|O
DDI-MedLine.d115.s2|113-123|non-Hodgkin|O
DDI-MedLine.d115.s2|125-132|lymphoma|O
DDI-MedLine.d115.s2|135-141|HIV-NHL|O
DDI-MedLine.d115.s2|149-155|authors|O
DDI-MedLine.d115.s2|157-164|compared|O
DDI-MedLine.d115.s2|166-180|retrospectively|O
DDI-MedLine.d115.s2|184-188|group|O
DDI-MedLine.d115.s2|193-194|24|O
DDI-MedLine.d115.s2|76-83|patients|O
DDI-MedLine.d115.s2|135-141|HIV-NHL|O
DDI-MedLine.d115.s2|227-233|treated|O
DDI-MedLine.d115.s2|244-259|cyclophosphamide|O
DDI-MedLine.d115.s2|262-272|doxorubicin|O
DDI-MedLine.d115.s2|275-285|vincristine|O
DDI-MedLine.d115.s2|292-301|prednisone|O
DDI-MedLine.d115.s2|304-307|CHOP|O
DDI-MedLine.d115.s2|26-37|chemotherapy|O
DDI-MedLine.d115.s2|323-329|regimen|O
DDI-MedLine.d115.s2|39-42|plus|O
DDI-MedLine.d115.s2|44-48|HAART|O
DDI-MedLine.d115.s2|184-188|group|O
DDI-MedLine.d115.s2|358-359|80|O
DDI-MedLine.d115.s2|76-83|patients|O
DDI-MedLine.d115.s2|227-233|treated|O
DDI-MedLine.d115.s2|304-307|CHOP|O
DDI-MedLine.d115.s2|26-37|chemotherapy|O
DDI-MedLine.d115.s2|415-423|CHOP-like|O
DDI-MedLine.d115.s2|323-329|regimen|O
DDI-MedLine.d115.s2|434-437|i.e.|O
DDI-MedLine.d115.s2|244-259|cyclophosphamide|O
DDI-MedLine.d115.s2|262-272|doxorubicin|O
DDI-MedLine.d115.s2|471-480|teniposide|O
DDI-MedLine.d115.s2|292-301|prednisone|O
DDI-MedLine.d115.s2|275-285|vincristine|O
DDI-MedLine.d115.s2|39-42|plus|O
DDI-MedLine.d115.s2|520-528|bleomycin|O
DDI-MedLine.d115.s2|531-537|without|O
DDI-MedLine.d115.s2|539-547|receiving|O
DDI-MedLine.d115.s2|549-562|antiretroviral|O
DDI-MedLine.d115.s2|31-37|therapy|O
DDI-MedLine.d115.s3|0-6|METHODS|O
DDI-MedLine.d115.s3|9-11|All|O
DDI-MedLine.d115.s3|13-20|patients|O
DDI-MedLine.d115.s3|27-34|enrolled|O
DDI-MedLine.d115.s3|39-41|two|O
DDI-MedLine.d115.s3|43-52|sequential|O
DDI-MedLine.d115.s3|54-59|trials|O
DDI-MedLine.d115.s3|61-69|performed|O
DDI-MedLine.d115.s3|78-83|Aviano|O
DDI-MedLine.d115.s3|85-90|Cancer|O
DDI-MedLine.d115.s3|92-97|Center|O
DDI-MedLine.d115.s3|100-104|Italy|O
DDI-MedLine.d115.s3|112-116|April|O
DDI-MedLine.d115.s3|118-121|1988|O
DDI-MedLine.d115.s3|126-133|December|O
DDI-MedLine.d115.s3|135-138|1998|O
DDI-MedLine.d115.s3|139-139|.|O
DDI-MedLine.d115.s4|0-4|HAART|O
DDI-MedLine.d115.s4|10-17|included|O
DDI-MedLine.d115.s4|24-34|combination|O
DDI-MedLine.d115.s4|36-42|therapy|O
DDI-MedLine.d115.s4|49-55|January|O
DDI-MedLine.d115.s4|57-60|1997|O
DDI-MedLine.d115.s4|61-61|.|O
DDI-MedLine.d115.s5|0-13|Antiretroviral|O
DDI-MedLine.d115.s5|15-22|regimens|O
DDI-MedLine.d115.s5|24-32|consisted|O
DDI-MedLine.d115.s5|37-39|two|O
DDI-MedLine.d115.s5|41-47|reverse|O
DDI-MedLine.d115.s5|49-61|transcriptase|O
DDI-MedLine.d115.s5|63-72|inhibitors|O
DDI-MedLine.d115.s5|78-80|one|O
DDI-MedLine.d115.s5|82-89|protease|O
DDI-MedLine.d115.s5|63-71|inhibitor|O
DDI-MedLine.d115.s5|100-100|.|O
DDI-MedLine.d115.s6|0-6|RESULTS|O
DDI-MedLine.d115.s6|9-11|The|O
DDI-MedLine.d115.s6|13-15|two|O
DDI-MedLine.d115.s6|17-25|treatment|O
DDI-MedLine.d115.s6|27-32|groups|O
DDI-MedLine.d115.s6|39-42|well|O
DDI-MedLine.d115.s6|44-50|matched|O
DDI-MedLine.d115.s6|57-62|regard|O
DDI-MedLine.d115.s6|67-73|patient|O
DDI-MedLine.d115.s6|75-86|demographics|O
DDI-MedLine.d115.s6|89-91|NHL|O
DDI-MedLine.d115.s6|93-107|characteristics|O
DDI-MedLine.d115.s6|110-112|HIV|O
DDI-MedLine.d115.s6|114-119|status|O
DDI-MedLine.d115.s6|17-25|treatment|O
DDI-MedLine.d115.s6|137-140|i.e.|O
DDI-MedLine.d115.s6|147-152|number|O
DDI-MedLine.d115.s6|157-162|cycles|O
DDI-MedLine.d115.s6|168-179|chemotherapy|O
DDI-MedLine.d115.s6|181-184|dose|O
DDI-MedLine.d115.s6|138-138|.|O
DDI-MedLine.d115.s7|0-2|The|O
DDI-MedLine.d115.s7|4-11|response|O
DDI-MedLine.d115.s7|13-17|rates|O
DDI-MedLine.d115.s7|24-30|similar|O
DDI-MedLine.d115.s7|44-46|two|O
DDI-MedLine.d115.s7|48-53|groups|O
DDI-MedLine.d115.s7|54-54|.|O
DDI-MedLine.d115.s8|0-5|Severe|O
DDI-MedLine.d115.s8|7-12|anemia|O
DDI-MedLine.d115.s8|15-19|Grade|O
DDI-MedLine.d115.s8|21-23|3-4|O
DDI-MedLine.d115.s8|25-33|according|O
DDI-MedLine.d115.s8|42-46|World|O
DDI-MedLine.d115.s8|48-53|Health|O
DDI-MedLine.d115.s8|55-66|Organization|O
DDI-MedLine.d115.s8|68-75|criteria|O
DDI-MedLine.d115.s8|82-94|significantly|O
DDI-MedLine.d115.s8|96-102|greater|O
DDI-MedLine.d115.s8|111-118|patients|O
DDI-MedLine.d115.s8|124-131|received|O
DDI-MedLine.d115.s8|133-142|CHOP-HAART|O
DDI-MedLine.d115.s8|144-151|compared|O
DDI-MedLine.d115.s8|111-118|patients|O
DDI-MedLine.d115.s8|124-131|received|O
DDI-MedLine.d115.s8|133-136|CHOP|O
DDI-MedLine.d115.s8|189-193|alone|O
DDI-MedLine.d115.s8|196-197|33|O
DDI-MedLine.d115.s8|198-198|%|O
DDI-MedLine.d115.s8|200-202|vs.|O
DDI-MedLine.d115.s8|204-204|7|O
DDI-MedLine.d115.s8|198-198|%|O
DDI-MedLine.d115.s8|208-219|respectively|O
DDI-MedLine.d115.s8|136-136|P|O
DDI-MedLine.d115.s8|224-224|=|O
DDI-MedLine.d115.s8|226-230|0.001|O
DDI-MedLine.d115.s8|202-202|.|O
DDI-MedLine.d115.s9|0-9|Leukopenia|O
DDI-MedLine.d115.s9|15-21|similar|O
DDI-MedLine.d115.s9|35-37|two|O
DDI-MedLine.d115.s9|39-44|groups|O
DDI-MedLine.d115.s9|51-56|colony|O
DDI-MedLine.d115.s9|58-68|stimulating|O
DDI-MedLine.d115.s9|70-75|factor|O
DDI-MedLine.d115.s9|77-83|support|O
DDI-MedLine.d115.s9|89-101|significantly|O
DDI-MedLine.d115.s9|103-109|greater|O
DDI-MedLine.d115.s9|118-127|CHOP-HAART|O
DDI-MedLine.d115.s9|39-43|group|O
DDI-MedLine.d115.s9|147-153|control|O
DDI-MedLine.d115.s9|39-43|group|O
DDI-MedLine.d115.s9|162-163|92|O
DDI-MedLine.d115.s9|164-164|%|O
DDI-MedLine.d115.s9|166-168|vs.|O
DDI-MedLine.d115.s9|170-171|66|O
DDI-MedLine.d115.s9|164-164|%|O
DDI-MedLine.d115.s9|175-186|respectively|O
DDI-MedLine.d115.s9|121-121|P|O
DDI-MedLine.d115.s9|191-191|=|O
DDI-MedLine.d115.s9|193-196|0.03|O
DDI-MedLine.d115.s9|168-168|.|O
DDI-MedLine.d115.s10|0-8|Seventeen|O
DDI-MedLine.d115.s10|10-16|percent|O
DDI-MedLine.d115.s10|21-30|CHOP-HAART|O
DDI-MedLine.d115.s10|32-39|patients|O
DDI-MedLine.d115.s10|41-49|developed|O
DDI-MedLine.d115.s10|51-56|severe|O
DDI-MedLine.d115.s10|58-66|autonomic|O
DDI-MedLine.d115.s10|68-80|neurotoxicity|O
DDI-MedLine.d115.s10|83-89|whereas|O
DDI-MedLine.d115.s10|91-94|none|O
DDI-MedLine.d115.s10|21-24|CHOP|O
DDI-MedLine.d115.s10|32-39|patients|O
DDI-MedLine.d115.s10|41-49|developed|O
DDI-MedLine.d115.s10|68-80|neurotoxicity|O
DDI-MedLine.d115.s10|24-24|P|O
DDI-MedLine.d115.s10|144-144|=|O
DDI-MedLine.d115.s10|146-150|0.002|O
DDI-MedLine.d115.s10|147-147|.|O
DDI-MedLine.d115.s11|0-1|At|O
DDI-MedLine.d115.s11|3-9|similar|O
DDI-MedLine.d115.s11|11-16|median|O
DDI-MedLine.d115.s11|18-26|follow-up|O
DDI-MedLine.d115.s11|29-41|opportunistic|O
DDI-MedLine.d115.s11|43-51|infection|O
DDI-MedLine.d115.s11|54-55|OI|O
DDI-MedLine.d115.s11|58-62|rates|O
DDI-MedLine.d115.s11|68-76|mortality|O
DDI-MedLine.d115.s11|83-95|significantly|O
DDI-MedLine.d115.s11|97-101|lower|O
DDI-MedLine.d115.s11|110-119|CHOP-HAART|O
DDI-MedLine.d115.s11|121-128|patients|O
DDI-MedLine.d115.s11|110-113|CHOP|O
DDI-MedLine.d115.s11|121-128|patients|O
DDI-MedLine.d115.s11|157-158|18|O
DDI-MedLine.d115.s11|159-159|%|O
DDI-MedLine.d115.s11|161-163|vs.|O
DDI-MedLine.d115.s11|165-166|52|O
DDI-MedLine.d115.s11|159-159|%|O
DDI-MedLine.d115.s11|170-181|respectively|O
DDI-MedLine.d115.s11|113-113|P|O
DDI-MedLine.d115.s11|186-186|=|O
DDI-MedLine.d115.s11|188-191|0.05|O
DDI-MedLine.d115.s11|198-199|38|O
DDI-MedLine.d115.s11|159-159|%|O
DDI-MedLine.d115.s11|161-163|vs.|O
DDI-MedLine.d115.s11|206-207|85|O
DDI-MedLine.d115.s11|159-159|%|O
DDI-MedLine.d115.s11|170-181|respectively|O
DDI-MedLine.d115.s11|113-113|P|O
DDI-MedLine.d115.s11|186-186|=|O
DDI-MedLine.d115.s11|229-233|0.001|O
DDI-MedLine.d115.s11|163-163|.|O
DDI-MedLine.d115.s12|0-2|The|O
DDI-MedLine.d115.s12|4-9|median|O
DDI-MedLine.d115.s12|11-18|survival|O
DDI-MedLine.d115.s12|24-33|CHOP-HAART|O
DDI-MedLine.d115.s12|35-42|patients|O
DDI-MedLine.d115.s12|52-58|reached|O
DDI-MedLine.d115.s12|61-67|whereas|O
DDI-MedLine.d115.s12|73-78|medial|O
DDI-MedLine.d115.s12|11-18|survival|O
DDI-MedLine.d115.s12|24-27|CHOP|O
DDI-MedLine.d115.s12|35-42|patients|O
DDI-MedLine.d115.s12|110-110|7|O
DDI-MedLine.d115.s12|112-117|months|O
DDI-MedLine.d115.s12|27-27|P|O
DDI-MedLine.d115.s12|122-122|=|O
DDI-MedLine.d115.s12|124-127|0.03|O
DDI-MedLine.d115.s12|125-125|.|O
DDI-MedLine.d115.s13|0-10|CONCLUSIONS|O
DDI-MedLine.d115.s13|13-15|The|O
DDI-MedLine.d115.s13|17-27|combination|O
DDI-MedLine.d115.s13|32-35|CHOP|O
DDI-MedLine.d115.s13|37-40|plus|O
DDI-MedLine.d115.s13|42-46|HAART|O
DDI-MedLine.d115.s13|51-58|feasible|O
DDI-MedLine.d115.s13|64-66|may|O
DDI-MedLine.d115.s13|68-73|reduce|O
DDI-MedLine.d115.s13|79-87|morbidity|O
DDI-MedLine.d115.s13|94-96|OIs|O
DDI-MedLine.d115.s13|101-107|HIV-NHL|O
DDI-MedLine.d115.s13|109-116|patients|O
DDI-MedLine.d115.s13|117-117|.|O
DDI-MedLine.d115.s14|0-6|However|O
DDI-MedLine.d115.s14|9-15|careful|O
DDI-MedLine.d115.s14|17-25|attention|O
DDI-MedLine.d115.s14|27-30|must|O
DDI-MedLine.d115.s14|35-42|directed|O
DDI-MedLine.d115.s14|47-51|cross|O
DDI-MedLine.d115.s14|53-60|toxicity|O
DDI-MedLine.d115.s14|66-73|possible|O
DDI-MedLine.d115.s14|75-89|pharmacokinetic|O
DDI-MedLine.d115.s14|91-102|interactions|O
DDI-MedLine.d115.s14|112-125|antiretroviral|O
DDI-MedLine.d115.s14|131-144|antineoplastic|O
DDI-MedLine.d115.s14|146-150|drugs|O
DDI-MedLine.d115.s14|151-151|.|O
DDI-MedLine.d115.s15|0-2|The|O
DDI-MedLine.d115.s15|4-9|impact|O
DDI-MedLine.d115.s15|18-25|combined|O
DDI-MedLine.d115.s15|27-38|chemotherapy|O
DDI-MedLine.d115.s15|40-43|plus|O
DDI-MedLine.d115.s15|45-49|HAART|O
DDI-MedLine.d115.s15|51-59|treatment|O
DDI-MedLine.d115.s15|64-70|patient|O
DDI-MedLine.d115.s15|72-79|survival|O
DDI-MedLine.d115.s15|81-85|needs|O
DDI-MedLine.d115.s15|87-94|urgently|O
DDI-MedLine.d115.s15|102-110|evaluated|O
DDI-MedLine.d115.s15|115-125|prospective|O
DDI-MedLine.d115.s15|127-133|studies|O
DDI-MedLine.d115.s15|134-134|.|O
DDI-DrugBank.d29.s0|0-11|Esomeprazole|O
DDI-DrugBank.d29.s0|16-26|extensively|O
DDI-DrugBank.d29.s0|28-38|metabolized|O
DDI-DrugBank.d29.s0|47-51|liver|O
DDI-DrugBank.d29.s0|56-62|CYP2C19|O
DDI-DrugBank.d29.s0|68-73|CYP3A4|O
DDI-DrugBank.d29.s0|74-74|.|O
DDI-DrugBank.d29.s1|0-1|In|O
DDI-DrugBank.d29.s1|3-7|vitro|O
DDI-DrugBank.d29.s1|16-19|vivo|O
DDI-DrugBank.d29.s1|21-27|studies|O
DDI-DrugBank.d29.s1|34-38|shown|O
DDI-DrugBank.d29.s1|45-56|esomeprazole|O
DDI-DrugBank.d29.s1|65-70|likely|O
DDI-DrugBank.d29.s1|75-81|inhibit|O
DDI-DrugBank.d29.s1|83-86|CYPs|O
DDI-DrugBank.d29.s1|88-90|1A2|O
DDI-DrugBank.d29.s1|93-95|2A6|O
DDI-DrugBank.d29.s1|98-100|2C9|O
DDI-DrugBank.d29.s1|103-105|2D6|O
DDI-DrugBank.d29.s1|108-110|2E1|O
DDI-DrugBank.d29.s1|116-118|3A4|O
DDI-DrugBank.d29.s1|119-119|.|O
DDI-DrugBank.d29.s2|0-1|No|O
DDI-DrugBank.d29.s2|3-12|clinically|O
DDI-DrugBank.d29.s2|14-21|relevant|O
DDI-DrugBank.d29.s2|23-34|interactions|O
DDI-DrugBank.d29.s2|41-45|drugs|O
DDI-DrugBank.d29.s2|47-57|metabolized|O
DDI-DrugBank.d29.s2|68-70|CYP|O
DDI-DrugBank.d29.s2|72-78|enzymes|O
DDI-DrugBank.d29.s2|80-84|would|O
DDI-DrugBank.d29.s2|89-96|expected|O
DDI-DrugBank.d29.s2|97-97|.|O
DDI-DrugBank.d29.s3|0-3|Drug|O
DDI-DrugBank.d29.s3|5-15|interaction|O
DDI-DrugBank.d29.s3|17-23|studies|O
DDI-DrugBank.d29.s3|30-34|shown|O
DDI-DrugBank.d29.s3|41-52|esomeprazole|O
DDI-DrugBank.d29.s3|72-81|clinically|O
DDI-DrugBank.d29.s3|83-93|significant|O
DDI-DrugBank.d29.s3|95-106|interactions|O
DDI-DrugBank.d29.s3|113-121|phenytoin|O
DDI-DrugBank.d29.s3|124-131|warfarin|O
DDI-DrugBank.d29.s3|134-142|quinidine|O
DDI-DrugBank.d29.s3|145-158|clarithromycin|O
DDI-DrugBank.d29.s3|163-173|amoxicillin|O
DDI-DrugBank.d29.s3|174-174|.|O
DDI-DrugBank.d29.s4|0-13|Post-marketing|O
DDI-DrugBank.d29.s4|15-21|reports|O
DDI-DrugBank.d29.s4|26-32|changes|O
DDI-DrugBank.d29.s4|37-47|prothrombin|O
DDI-DrugBank.d29.s4|49-56|measures|O
DDI-DrugBank.d29.s4|68-75|received|O
DDI-DrugBank.d29.s4|77-81|among|O
DDI-DrugBank.d29.s4|83-90|patients|O
DDI-DrugBank.d29.s4|95-105|concomitant|O
DDI-DrugBank.d29.s4|107-114|warfarin|O
DDI-DrugBank.d29.s4|120-131|esomeprazole|O
DDI-DrugBank.d29.s4|133-139|therapy|O
DDI-DrugBank.d29.s4|140-140|.|O
DDI-DrugBank.d29.s5|0-8|Increases|O
DDI-DrugBank.d29.s5|13-15|INR|O
DDI-DrugBank.d29.s5|21-31|prothrombin|O
DDI-DrugBank.d29.s5|33-36|time|O
DDI-DrugBank.d29.s5|38-40|may|O
DDI-DrugBank.d29.s5|42-45|lead|O
DDI-DrugBank.d29.s5|50-57|abnormal|O
DDI-DrugBank.d29.s5|59-66|bleeding|O
DDI-DrugBank.d29.s5|72-75|even|O
DDI-DrugBank.d29.s5|77-81|death|O
DDI-DrugBank.d29.s5|82-82|.|O
DDI-DrugBank.d29.s6|0-7|Patients|O
DDI-DrugBank.d29.s6|9-15|treated|O
DDI-DrugBank.d29.s6|22-27|proton|O
DDI-DrugBank.d29.s6|29-32|pump|O
DDI-DrugBank.d29.s6|34-43|inhibitors|O
DDI-DrugBank.d29.s6|49-56|warfarin|O
DDI-DrugBank.d29.s6|58-70|concomitantly|O
DDI-DrugBank.d29.s6|72-74|may|O
DDI-DrugBank.d29.s6|76-79|need|O
DDI-DrugBank.d29.s6|87-95|monitored|O
DDI-DrugBank.d29.s6|101-109|increases|O
DDI-DrugBank.d29.s6|114-116|INR|O
DDI-DrugBank.d29.s6|122-132|prothrombin|O
DDI-DrugBank.d29.s6|134-137|time|O
DDI-DrugBank.d29.s6|138-138|.|O
DDI-DrugBank.d29.s7|0-11|Esomeprazole|O
DDI-DrugBank.d29.s7|13-15|may|O
DDI-DrugBank.d29.s7|17-27|potentially|O
DDI-DrugBank.d29.s7|29-37|interfere|O
DDI-DrugBank.d29.s7|44-50|CYP2C19|O
DDI-DrugBank.d29.s7|57-61|major|O
DDI-DrugBank.d29.s7|63-74|esomeprazole|O
DDI-DrugBank.d29.s7|76-87|metabolizing|O
DDI-DrugBank.d29.s7|89-94|enzyme|O
DDI-DrugBank.d29.s7|95-95|.|O
DDI-DrugBank.d29.s8|0-15|Coadministration|O
DDI-DrugBank.d29.s8|20-31|esomeprazole|O
DDI-DrugBank.d29.s8|33-34|30|O
DDI-DrugBank.d29.s8|36-37|mg|O
DDI-DrugBank.d29.s8|43-50|diazepam|O
DDI-DrugBank.d29.s8|55-61|CYP2C19|O
DDI-DrugBank.d29.s8|63-71|substrate|O
DDI-DrugBank.d29.s8|74-81|resulted|O
DDI-DrugBank.d29.s8|88-89|45|O
DDI-DrugBank.d29.s8|90-90|%|O
DDI-DrugBank.d29.s8|92-99|decrease|O
DDI-DrugBank.d29.s8|104-112|clearance|O
DDI-DrugBank.d29.s8|43-50|diazepam|O
DDI-DrugBank.d29.s8|125-125|.|O
DDI-DrugBank.d29.s9|0-8|Increased|O
DDI-DrugBank.d29.s9|10-15|plasma|O
DDI-DrugBank.d29.s9|17-22|levels|O
DDI-DrugBank.d29.s9|27-34|diazepam|O
DDI-DrugBank.d29.s9|41-48|observed|O
DDI-DrugBank.d29.s9|50-51|12|O
DDI-DrugBank.d29.s9|53-57|hours|O
DDI-DrugBank.d29.s9|65-70|dosing|O
DDI-DrugBank.d29.s9|76-82|onwards|O
DDI-DrugBank.d29.s9|83-83|.|O
DDI-DrugBank.d29.s10|0-6|However|O
DDI-DrugBank.d29.s10|17-20|time|O
DDI-DrugBank.d29.s10|27-32|plasma|O
DDI-DrugBank.d29.s10|34-39|levels|O
DDI-DrugBank.d29.s10|44-51|diazepam|O
DDI-DrugBank.d29.s10|68-78|therapeutic|O
DDI-DrugBank.d29.s10|80-87|interval|O
DDI-DrugBank.d29.s10|94-97|thus|O
DDI-DrugBank.d29.s10|104-114|interaction|O
DDI-DrugBank.d29.s10|119-126|unlikely|O
DDI-DrugBank.d29.s10|137-144|clinical|O
DDI-DrugBank.d29.s10|146-154|relevance|O
DDI-DrugBank.d29.s10|155-155|.|O
DDI-DrugBank.d29.s11|0-11|Esomeprazole|O
DDI-DrugBank.d29.s11|13-20|inhibits|O
DDI-DrugBank.d29.s11|22-28|gastric|O
DDI-DrugBank.d29.s11|30-33|acid|O
DDI-DrugBank.d29.s11|35-43|secretion|O
DDI-DrugBank.d29.s11|44-44|.|O
DDI-DrugBank.d29.s12|0-8|Therefore|O
DDI-DrugBank.d29.s12|11-22|esomeprazole|O
DDI-DrugBank.d29.s12|24-26|may|O
DDI-DrugBank.d29.s12|28-36|interfere|O
DDI-DrugBank.d29.s12|47-56|absorption|O
DDI-DrugBank.d29.s12|61-65|drugs|O
DDI-DrugBank.d29.s12|73-79|gastric|O
DDI-DrugBank.d29.s12|81-82|pH|O
DDI-DrugBank.d29.s12|90-98|important|O
DDI-DrugBank.d29.s12|100-110|determinant|O
DDI-DrugBank.d29.s12|115-129|bioavailability|O
DDI-DrugBank.d29.s12|132-133|eg|O
DDI-DrugBank.d29.s12|136-147|ketoconazole|O
DDI-DrugBank.d29.s12|150-153|iron|O
DDI-DrugBank.d29.s12|155-159|salts|O
DDI-DrugBank.d29.s12|165-171|digoxin|O
DDI-DrugBank.d29.s12|173-173|.|O
DDI-DrugBank.d29.s13|0-15|Coadministration|O
DDI-DrugBank.d29.s13|20-23|oral|O
DDI-DrugBank.d29.s13|25-38|contraceptives|O
DDI-DrugBank.d29.s13|41-48|diazepam|O
DDI-DrugBank.d29.s13|51-59|phenytoin|O
DDI-DrugBank.d29.s13|65-73|quinidine|O
DDI-DrugBank.d29.s13|83-86|seem|O
DDI-DrugBank.d29.s13|91-96|change|O
DDI-DrugBank.d29.s13|102-116|pharmacokinetic|O
DDI-DrugBank.d29.s13|118-124|profile|O
DDI-DrugBank.d29.s13|129-140|esomeprazole|O
DDI-DrugBank.d29.s13|141-141|.|O
DDI-DrugBank.d29.s14|0-10|Concomitant|O
DDI-DrugBank.d29.s14|12-25|administration|O
DDI-DrugBank.d29.s14|30-43|clarithromycin|O
DDI-DrugBank.d29.s14|50-57|pimozide|O
DDI-DrugBank.d29.s14|62-76|contraindicated|O
DDI-DrugBank.d29.s14|77-77|.|O
DDI-DrugBank.d557.s0|0-14|Drug/Laboratory|O
DDI-DrugBank.d557.s0|16-19|Test|O
DDI-DrugBank.d557.s0|21-32|Interactions|O
DDI-DrugBank.d557.s0|34-41|Positive|O
DDI-DrugBank.d557.s0|43-48|direct|O
DDI-DrugBank.d557.s0|50-55|Coombs|O
DDI-DrugBank.d557.s0|58-62|tests|O
DDI-DrugBank.d557.s0|74-81|reported|O
DDI-DrugBank.d557.s0|90-98|treatment|O
DDI-DrugBank.d557.s0|109-121|cephalosporin|O
DDI-DrugBank.d557.s0|123-133|antibiotics|O
DDI-DrugBank.d557.s0|134-134|.|O
DDI-DrugBank.d557.s1|0-1|In|O
DDI-DrugBank.d557.s1|3-13|hematologic|O
DDI-DrugBank.d557.s1|15-21|studies|O
DDI-DrugBank.d557.s1|29-39|transfusion|O
DDI-DrugBank.d557.s1|41-54|cross-matching|O
DDI-DrugBank.d557.s1|56-65|procedures|O
DDI-DrugBank.d557.s1|72-84|anti-globulin|O
DDI-DrugBank.d557.s1|86-90|tests|O
DDI-DrugBank.d557.s1|96-104|performed|O
DDI-DrugBank.d557.s1|113-117|minor|O
DDI-DrugBank.d557.s1|119-122|side|O
DDI-DrugBank.d557.s1|130-135|Coombs|O
DDI-DrugBank.d557.s1|138-144|testing|O
DDI-DrugBank.d557.s1|149-156|newborns|O
DDI-DrugBank.d557.s1|158-162|whose|O
DDI-DrugBank.d557.s1|164-170|mothers|O
DDI-DrugBank.d557.s1|177-184|received|O
DDI-DrugBank.d557.s1|186-198|cephalosporin|O
DDI-DrugBank.d557.s1|200-210|antibiotics|O
DDI-DrugBank.d557.s1|219-229|parturition|O
DDI-DrugBank.d557.s1|245-254|recognized|O
DDI-DrugBank.d557.s1|263-270|positive|O
DDI-DrugBank.d557.s1|130-135|Coombs|O
DDI-DrugBank.d557.s1|86-89|test|O
DDI-DrugBank.d557.s1|285-287|may|O
DDI-DrugBank.d557.s1|292-294|due|O
DDI-DrugBank.d557.s1|303-306|drug|O
DDI-DrugBank.d557.s1|307-307|.|O
DDI-DrugBank.d195.s0|0-10|Anastrozole|O
DDI-DrugBank.d195.s0|12-20|inhibited|O
DDI-DrugBank.d195.s0|25-29|vitro|O
DDI-DrugBank.d195.s0|31-39|metabolic|O
DDI-DrugBank.d195.s0|41-49|reactions|O
DDI-DrugBank.d195.s0|51-59|catalyzed|O
DDI-DrugBank.d195.s0|64-74|cytochromes|O
DDI-DrugBank.d195.s0|76-79|P450|O
DDI-DrugBank.d195.s0|81-83|1A2|O
DDI-DrugBank.d195.s0|86-90|2C8/9|O
DDI-DrugBank.d195.s0|97-99|3A4|O
DDI-DrugBank.d195.s0|113-122|relatively|O
DDI-DrugBank.d195.s0|124-127|high|O
DDI-DrugBank.d195.s0|129-142|concentrations|O
DDI-DrugBank.d195.s0|143-143|.|O
DDI-DrugBank.d195.s1|0-10|Anastrozole|O
DDI-DrugBank.d195.s1|20-26|inhibit|O
DDI-DrugBank.d195.s1|28-31|P450|O
DDI-DrugBank.d195.s1|33-35|2A6|O
DDI-DrugBank.d195.s1|44-54|polymorphic|O
DDI-DrugBank.d195.s1|28-31|P450|O
DDI-DrugBank.d195.s1|61-63|2D6|O
DDI-DrugBank.d195.s1|68-72|human|O
DDI-DrugBank.d195.s1|74-78|liver|O
DDI-DrugBank.d195.s1|80-89|microsomes|O
DDI-DrugBank.d195.s1|90-90|.|O
DDI-DrugBank.d195.s2|0-10|Anastrozole|O
DDI-DrugBank.d195.s2|20-24|alter|O
DDI-DrugBank.d195.s2|30-45|pharmacokinetics|O
DDI-DrugBank.d195.s2|50-59|antipyrine|O
DDI-DrugBank.d195.s2|60-60|.|O
DDI-DrugBank.d195.s3|0-7|Although|O
DDI-DrugBank.d195.s3|28-33|formal|O
DDI-DrugBank.d195.s3|35-45|interaction|O
DDI-DrugBank.d195.s3|47-53|studies|O
DDI-DrugBank.d195.s3|71-80|antipyrine|O
DDI-DrugBank.d195.s3|83-87|based|O
DDI-DrugBank.d195.s3|101-104|vivo|O
DDI-DrugBank.d195.s3|113-117|vitro|O
DDI-DrugBank.d195.s3|47-53|studies|O
DDI-DrugBank.d195.s3|134-141|unlikely|O
DDI-DrugBank.d195.s3|148-164|co-administration|O
DDI-DrugBank.d195.s3|171-171|1|O
DDI-DrugBank.d195.s3|173-174|mg|O
DDI-DrugBank.d195.s3|176-179|dose|O
DDI-DrugBank.d195.s3|184-191|ARIMIDEX|O
DDI-DrugBank.d195.s3|204-208|drugs|O
DDI-DrugBank.d195.s3|215-220|result|O
DDI-DrugBank.d195.s3|225-234|clinically|O
DDI-DrugBank.d195.s3|236-246|significant|O
DDI-DrugBank.d195.s3|204-207|drug|O
DDI-DrugBank.d195.s3|253-262|inhibition|O
DDI-DrugBank.d195.s3|267-276|cytochrome|O
DDI-DrugBank.d195.s3|278-290|P450-mediated|O
DDI-DrugBank.d195.s3|292-301|metabolism|O
DDI-DrugBank.d195.s3|204-208|drugs|O
DDI-DrugBank.d195.s3|321-321|.|O
DDI-DrugBank.d195.s4|0-1|An|O
DDI-DrugBank.d195.s4|3-13|interaction|O
DDI-DrugBank.d195.s4|15-19|study|O
DDI-DrugBank.d195.s4|26-33|warfarin|O
DDI-DrugBank.d195.s4|35-40|showed|O
DDI-DrugBank.d195.s4|45-54|clinically|O
DDI-DrugBank.d195.s4|56-66|significant|O
DDI-DrugBank.d195.s4|68-73|effect|O
DDI-DrugBank.d195.s4|78-88|anastrozole|O
DDI-DrugBank.d195.s4|26-33|warfarin|O
DDI-DrugBank.d195.s4|102-117|pharmacokinetics|O
DDI-DrugBank.d195.s4|122-134|anticoagulant|O
DDI-DrugBank.d195.s4|136-143|activity|O
DDI-DrugBank.d195.s4|144-144|.|O
DDI-DrugBank.d195.s5|0-1|At|O
DDI-DrugBank.d195.s5|5-10|median|O
DDI-DrugBank.d195.s5|12-20|follow-up|O
DDI-DrugBank.d195.s5|25-26|33|O
DDI-DrugBank.d195.s5|28-33|months|O
DDI-DrugBank.d195.s5|40-50|combination|O
DDI-DrugBank.d195.s5|55-62|ARIMIDEX|O
DDI-DrugBank.d195.s5|68-76|tamoxifen|O
DDI-DrugBank.d195.s5|86-96|demonstrate|O
DDI-DrugBank.d195.s5|102-109|efficacy|O
DDI-DrugBank.d195.s5|111-117|benefit|O
DDI-DrugBank.d195.s5|124-131|compared|O
DDI-DrugBank.d195.s5|68-76|tamoxifen|O
DDI-DrugBank.d195.s5|155-162|patients|O
DDI-DrugBank.d195.s5|167-170|well|O
DDI-DrugBank.d195.s5|182-188|hormone|O
DDI-DrugBank.d195.s5|190-206|receptor-positive|O
DDI-DrugBank.d195.s5|208-220|subpopulation|O
DDI-DrugBank.d195.s5|221-221|.|O
DDI-DrugBank.d195.s6|0-3|This|O
DDI-DrugBank.d195.s6|5-13|treatment|O
DDI-DrugBank.d195.s6|15-17|arm|O
DDI-DrugBank.d195.s6|23-34|discontinued|O
DDI-DrugBank.d195.s6|45-49|trial|O
DDI-DrugBank.d195.s6|50-50|.|O
DDI-DrugBank.d195.s7|0-4|Based|O
DDI-DrugBank.d195.s7|9-16|clinical|O
DDI-DrugBank.d195.s7|22-36|pharmacokinetic|O
DDI-DrugBank.d195.s7|38-44|results|O
DDI-DrugBank.d195.s7|55-58|ATAC|O
DDI-DrugBank.d195.s7|60-64|trial|O
DDI-DrugBank.d195.s7|67-75|tamoxifen|O
DDI-DrugBank.d195.s7|91-102|administered|O
DDI-DrugBank.d195.s7|109-119|anastrozole|O
DDI-DrugBank.d195.s7|122-124|see|O
DDI-DrugBank.d195.s7|126-133|CLINICAL|O
DDI-DrugBank.d195.s7|135-146|PHARMACOLOGY|O
DDI-DrugBank.d195.s7|150-153|Drug|O
DDI-DrugBank.d195.s7|155-166|Interactions|O
DDI-DrugBank.d195.s7|126-133|CLINICAL|O
DDI-DrugBank.d195.s7|135-146|PHARMACOLOGY|O
DDI-DrugBank.d195.s7|194-194|-|O
DDI-DrugBank.d195.s7|196-203|Clinical|O
DDI-DrugBank.d195.s7|205-211|Studies|O
DDI-DrugBank.d195.s7|194-194|-|O
DDI-DrugBank.d195.s7|215-222|Adjuvant|O
DDI-DrugBank.d195.s7|224-232|Treatment|O
DDI-DrugBank.d195.s7|237-242|Breast|O
DDI-DrugBank.d195.s7|244-249|Cancer|O
DDI-DrugBank.d195.s7|254-267|Postmenopausal|O
DDI-DrugBank.d195.s7|269-273|Women|O
DDI-DrugBank.d195.s7|275-285|subsections|O
DDI-DrugBank.d195.s7|287-287|.|O
DDI-DrugBank.d195.s8|0-16|Co-administration|O
DDI-DrugBank.d195.s8|21-31|anastrozole|O
DDI-DrugBank.d195.s8|37-45|tamoxifen|O
DDI-DrugBank.d195.s8|47-54|resulted|O
DDI-DrugBank.d195.s8|61-69|reduction|O
DDI-DrugBank.d195.s8|21-31|anastrozole|O
DDI-DrugBank.d195.s8|86-91|plasma|O
DDI-DrugBank.d195.s8|93-98|levels|O
DDI-DrugBank.d195.s8|103-104|27|O
DDI-DrugBank.d195.s8|105-105|%|O
DDI-DrugBank.d195.s8|107-114|compared|O
DDI-DrugBank.d195.s8|127-134|achieved|O
DDI-DrugBank.d195.s8|21-31|anastrozole|O
DDI-DrugBank.d195.s8|153-157|alone|O
DDI-DrugBank.d195.s8|158-158|.|O
DDI-DrugBank.d195.s9|0-18|Estrogen-containing|O
DDI-DrugBank.d195.s9|20-28|therapies|O
DDI-DrugBank.d195.s9|44-47|used|O
DDI-DrugBank.d195.s9|54-61|ARIMIDEX|O
DDI-DrugBank.d195.s9|71-73|may|O
DDI-DrugBank.d195.s9|75-82|diminish|O
DDI-DrugBank.d195.s9|88-100|pharmacologic|O
DDI-DrugBank.d195.s9|102-107|action|O
DDI-DrugBank.d195.s9|108-108|.|O
DDI-DrugBank.d195.s10|0-14|Drug/Laboratory|O
DDI-DrugBank.d195.s10|16-19|Test|O
DDI-DrugBank.d195.s10|21-32|Interactions|O
DDI-DrugBank.d195.s10|34-35|No|O
DDI-DrugBank.d195.s10|37-46|clinically|O
DDI-DrugBank.d195.s10|48-58|significant|O
DDI-DrugBank.d195.s10|60-66|changes|O
DDI-DrugBank.d195.s10|75-81|results|O
DDI-DrugBank.d195.s10|37-44|clinical|O
DDI-DrugBank.d195.s10|95-104|laboratory|O
DDI-DrugBank.d195.s10|106-110|tests|O
DDI-DrugBank.d195.s10|122-129|observed|O
DDI-DrugBank.d195.s11|0-0|.|O
DDI-DrugBank.d732.s0|0-5|CHEMET|O
DDI-DrugBank.d732.s0|14-18|known|O
DDI-DrugBank.d732.s0|23-30|interact|O
DDI-DrugBank.d732.s0|43-47|drugs|O
DDI-DrugBank.d732.s0|49-57|including|O
DDI-DrugBank.d732.s0|59-62|iron|O
DDI-DrugBank.d732.s0|64-74|supplements|O
DDI-DrugBank.d732.s1|0-11|interactions|O
DDI-DrugBank.d732.s1|27-40|systematically|O
DDI-DrugBank.d732.s1|42-48|studied|O
DDI-DrugBank.d732.s1|49-49|.|O
DDI-DrugBank.d732.s2|0-10|Concomitant|O
DDI-DrugBank.d732.s2|12-25|administration|O
DDI-DrugBank.d732.s2|30-35|CHEMET|O
DDI-DrugBank.d732.s2|48-56|chelation|O
DDI-DrugBank.d732.s2|58-64|therapy|O
DDI-DrugBank.d732.s2|75-78|CaNa|O
DDI-DrugBank.d732.s2|80-80|2|O
DDI-DrugBank.d732.s2|82-85|EDTA|O
DDI-DrugBank.d732.s2|94-104|recommended|O
DDI-DrugBank.d732.s2|105-105|.|O
DDI-DrugBank.d732.s3|0-14|Drug/Laboratory|O
DDI-DrugBank.d732.s3|16-20|Tests|O
DDI-DrugBank.d732.s3|22-32|Interaction|O
DDI-DrugBank.d732.s3|35-42|Succimer|O
DDI-DrugBank.d732.s3|44-46|may|O
DDI-DrugBank.d732.s3|48-56|interfere|O
DDI-DrugBank.d732.s3|63-67|serum|O
DDI-DrugBank.d732.s3|73-79|urinary|O
DDI-DrugBank.d732.s3|81-90|laboratory|O
DDI-DrugBank.d732.s3|92-96|tests|O
DDI-DrugBank.d732.s3|97-97|.|O
DDI-DrugBank.d732.s4|0-1|In|O
DDI-DrugBank.d732.s4|3-7|vitro|O
DDI-DrugBank.d732.s4|9-15|studies|O
DDI-DrugBank.d732.s4|22-26|shown|O
DDI-DrugBank.d732.s4|28-35|succimer|O
DDI-DrugBank.d732.s4|40-44|cause|O
DDI-DrugBank.d732.s4|46-50|false|O
DDI-DrugBank.d732.s4|52-59|positive|O
DDI-DrugBank.d732.s4|61-67|results|O
DDI-DrugBank.d732.s4|73-79|ketones|O
DDI-DrugBank.d732.s4|84-88|urine|O
DDI-DrugBank.d732.s4|90-94|using|O
DDI-DrugBank.d732.s4|96-108|nitroprusside|O
DDI-DrugBank.d732.s4|110-117|reagents|O
DDI-DrugBank.d732.s4|127-134|Ketostix|O
DDI-DrugBank.d732.s4|143-149|falsely|O
DDI-DrugBank.d732.s4|151-159|decreased|O
DDI-DrugBank.d732.s4|161-172|measurements|O
DDI-DrugBank.d732.s4|177-181|serum|O
DDI-DrugBank.d732.s4|183-186|uric|O
DDI-DrugBank.d732.s4|188-191|acid|O
DDI-DrugBank.d732.s4|197-199|CPK|O
DDI-DrugBank.d732.s4|200-200|.|O
DDI-DrugBank.d623.s0|0-1|No|O
DDI-DrugBank.d623.s0|3-11|drug-drug|O
DDI-DrugBank.d623.s0|13-23|interaction|O
DDI-DrugBank.d623.s0|25-31|studies|O
DDI-DrugBank.d623.s0|43-51|conducted|O
DDI-DrugBank.d623.s0|58-66|depo-subQ|O
DDI-DrugBank.d623.s0|68-74|provera|O
DDI-DrugBank.d623.s0|76-78|104|O
DDI-DrugBank.d623.s0|79-79|.|O
DDI-DrugBank.d623.s1|0-16|Aminoglutethimide|O
DDI-DrugBank.d623.s1|18-29|administered|O
DDI-DrugBank.d623.s1|31-43|concomitantly|O
DDI-DrugBank.d623.s1|50-58|depo-subQ|O
DDI-DrugBank.d623.s1|60-66|provera|O
DDI-DrugBank.d623.s1|68-70|104|O
DDI-DrugBank.d623.s1|72-74|may|O
DDI-DrugBank.d623.s1|76-88|significantly|O
DDI-DrugBank.d623.s1|90-97|decrease|O
DDI-DrugBank.d623.s1|103-107|serum|O
DDI-DrugBank.d623.s1|109-122|concentrations|O
DDI-DrugBank.d623.s1|127-129|MPA|O
DDI-DrugBank.d623.s1|130-130|.|O
DDI-DrugBank.d623.s2|0-9|Laboratory|O
DDI-DrugBank.d623.s2|11-15|Tests|O
DDI-DrugBank.d623.s2|17-19|The|O
DDI-DrugBank.d623.s2|21-31|pathologist|O
DDI-DrugBank.d623.s2|43-49|advised|O
DDI-DrugBank.d623.s2|54-62|progestin|O
DDI-DrugBank.d623.s2|64-70|therapy|O
DDI-DrugBank.d623.s2|77-84|relevant|O
DDI-DrugBank.d623.s2|86-94|specimens|O
DDI-DrugBank.d623.s2|100-108|submitted|O
DDI-DrugBank.d623.s2|109-109|.|O
DDI-DrugBank.d623.s3|0-2|The|O
DDI-DrugBank.d623.s3|4-12|physician|O
DDI-DrugBank.d623.s3|24-31|informed|O
DDI-DrugBank.d623.s3|38-44|certain|O
DDI-DrugBank.d623.s3|46-54|endocrine|O
DDI-DrugBank.d623.s3|60-64|liver|O
DDI-DrugBank.d623.s3|66-73|function|O
DDI-DrugBank.d623.s3|75-79|tests|O
DDI-DrugBank.d623.s3|86-90|blood|O
DDI-DrugBank.d623.s3|92-101|components|O
DDI-DrugBank.d623.s3|103-105|may|O
DDI-DrugBank.d623.s3|110-117|affected|O
DDI-DrugBank.d623.s3|122-130|progestin|O
DDI-DrugBank.d623.s3|132-138|therapy|O
DDI-DrugBank.d623.s3|145-150|Plasma|O
DDI-DrugBank.d623.s3|156-162|urinary|O
DDI-DrugBank.d623.s3|164-170|steroid|O
DDI-DrugBank.d623.s3|172-177|levels|O
DDI-DrugBank.d623.s3|183-191|decreased|O
DDI-DrugBank.d623.s3|194-197|e.g.|O
DDI-DrugBank.d623.s3|200-211|progesterone|O
DDI-DrugBank.d623.s3|214-222|estradiol|O
DDI-DrugBank.d623.s3|225-236|pregnanediol|O
DDI-DrugBank.d623.s3|239-250|testosterone|O
DDI-DrugBank.d623.s3|253-260|cortisol|O
DDI-DrugBank.d623.s3|195-195|.|O
DDI-DrugBank.d623.s4|1-1|b|O
DDI-DrugBank.d623.s4|4-9|Plasma|O
DDI-DrugBank.d623.s4|15-21|urinary|O
DDI-DrugBank.d623.s4|23-34|gonadotropin|O
DDI-DrugBank.d623.s4|36-41|levels|O
DDI-DrugBank.d623.s4|47-55|decreased|O
DDI-DrugBank.d623.s4|58-61|e.g.|O
DDI-DrugBank.d623.s4|64-65|LH|O
DDI-DrugBank.d623.s4|68-70|FSH|O
DDI-DrugBank.d623.s4|59-59|.|O
DDI-DrugBank.d623.s5|1-1|c|O
DDI-DrugBank.d623.s5|4-7|SHBG|O
DDI-DrugBank.d623.s5|9-22|concentrations|O
DDI-DrugBank.d623.s5|28-36|decreased|O
DDI-DrugBank.d623.s5|37-37|.|O
DDI-DrugBank.d623.s6|4-12|T3-uptake|O
DDI-DrugBank.d623.s6|14-19|values|O
DDI-DrugBank.d623.s6|21-23|may|O
DDI-DrugBank.d623.s6|25-32|decrease|O
DDI-DrugBank.d623.s6|33-33|.|O
DDI-DrugBank.d623.s7|1-1|e|O
DDI-DrugBank.d623.s7|4-8|There|O
DDI-DrugBank.d623.s7|10-12|may|O
DDI-DrugBank.d623.s7|17-21|small|O
DDI-DrugBank.d623.s7|23-29|changes|O
DDI-DrugBank.d623.s7|34-44|coagulation|O
DDI-DrugBank.d623.s7|46-52|factors|O
DDI-DrugBank.d623.s7|53-53|.|O
DDI-DrugBank.d623.s8|1-1|f|O
DDI-DrugBank.d623.s8|4-22|Sulfobromophthalein|O
DDI-DrugBank.d623.s8|34-38|liver|O
DDI-DrugBank.d623.s8|40-47|function|O
DDI-DrugBank.d623.s8|49-52|test|O
DDI-DrugBank.d623.s8|54-59|values|O
DDI-DrugBank.d623.s8|61-63|may|O
DDI-DrugBank.d623.s8|68-76|increased|O
DDI-DrugBank.d623.s8|78-85|slightly|O
DDI-DrugBank.d623.s8|86-86|.|O
DDI-DrugBank.d623.s9|1-1|g|O
DDI-DrugBank.d623.s9|4-8|There|O
DDI-DrugBank.d623.s9|10-12|may|O
DDI-DrugBank.d623.s9|17-21|small|O
DDI-DrugBank.d623.s9|23-29|changes|O
DDI-DrugBank.d623.s9|34-38|lipid|O
DDI-DrugBank.d623.s9|40-47|profiles|O
DDI-DrugBank.d623.s9|48-48|.|O
DDI-DrugBank.d231.s0|0-9|Furosemide|O
DDI-DrugBank.d231.s0|11-13|may|O
DDI-DrugBank.d231.s0|15-22|increase|O
DDI-DrugBank.d231.s0|28-35|ototoxic|O
DDI-DrugBank.d231.s0|37-45|potential|O
DDI-DrugBank.d231.s0|50-63|aminoglycoside|O
DDI-DrugBank.d231.s0|65-75|antibiotics|O
DDI-DrugBank.d231.s0|78-87|especially|O
DDI-DrugBank.d231.s0|96-103|presence|O
DDI-DrugBank.d231.s0|108-115|impaired|O
DDI-DrugBank.d231.s0|117-121|renal|O
DDI-DrugBank.d231.s0|123-130|function|O
DDI-DrugBank.d231.s0|131-131|.|O
DDI-DrugBank.d231.s1|0-5|Except|O
DDI-DrugBank.d231.s1|10-25|life-threatening|O
DDI-DrugBank.d231.s1|27-36|situations|O
DDI-DrugBank.d231.s1|39-43|avoid|O
DDI-DrugBank.d231.s1|50-60|combination|O
DDI-DrugBank.d231.s1|61-61|.|O
DDI-DrugBank.d231.s2|0-9|Furosemide|O
DDI-DrugBank.d231.s2|25-28|used|O
DDI-DrugBank.d231.s2|30-42|concomitantly|O
DDI-DrugBank.d231.s2|49-58|ethacrynic|O
DDI-DrugBank.d231.s2|60-63|acid|O
DDI-DrugBank.d231.s2|80-90|possibility|O
DDI-DrugBank.d231.s2|95-105|ototoxicity|O
DDI-DrugBank.d231.s2|106-106|.|O
DDI-DrugBank.d231.s3|0-7|Patients|O
DDI-DrugBank.d231.s3|9-17|receiving|O
DDI-DrugBank.d231.s3|19-22|high|O
DDI-DrugBank.d231.s3|24-28|doses|O
DDI-DrugBank.d231.s3|33-43|salicylates|O
DDI-DrugBank.d231.s3|45-57|concomitantly|O
DDI-DrugBank.d231.s3|64-73|furosemide|O
DDI-DrugBank.d231.s3|82-90|rheumatic|O
DDI-DrugBank.d231.s3|92-98|disease|O
DDI-DrugBank.d231.s3|101-103|may|O
DDI-DrugBank.d231.s3|105-114|experience|O
DDI-DrugBank.d231.s3|33-42|salicylate|O
DDI-DrugBank.d231.s3|127-134|toxicity|O
DDI-DrugBank.d231.s3|139-143|lower|O
DDI-DrugBank.d231.s3|24-28|doses|O
DDI-DrugBank.d231.s3|162-172|competitive|O
DDI-DrugBank.d231.s3|174-178|renal|O
DDI-DrugBank.d231.s3|180-188|excretory|O
DDI-DrugBank.d231.s3|190-194|sites|O
DDI-DrugBank.d231.s3|195-195|.|O
DDI-DrugBank.d231.s4|0-9|Furosemide|O
DDI-DrugBank.d231.s4|17-24|tendency|O
DDI-DrugBank.d231.s4|29-38|antagonize|O
DDI-DrugBank.d231.s4|44-51|skeletal|O
DDI-DrugBank.d231.s4|53-58|muscle|O
DDI-DrugBank.d231.s4|60-67|relaxing|O
DDI-DrugBank.d231.s4|69-74|effect|O
DDI-DrugBank.d231.s4|79-90|tubocurarine|O
DDI-DrugBank.d231.s4|96-98|may|O
DDI-DrugBank.d231.s4|100-109|potentiate|O
DDI-DrugBank.d231.s4|115-120|action|O
DDI-DrugBank.d231.s4|125-139|succinylcholine|O
DDI-DrugBank.d231.s4|140-140|.|O
DDI-DrugBank.d231.s5|0-6|Lithium|O
DDI-DrugBank.d231.s5|8-16|generally|O
DDI-DrugBank.d231.s5|32-36|given|O
DDI-DrugBank.d231.s5|43-51|diuretics|O
DDI-DrugBank.d231.s5|66-71|reduce|O
DDI-DrugBank.d231.s5|73-80|lithiums|O
DDI-DrugBank.d231.s5|82-86|renal|O
DDI-DrugBank.d231.s5|88-96|clearance|O
DDI-DrugBank.d231.s5|102-104|add|O
DDI-DrugBank.d231.s5|108-111|high|O
DDI-DrugBank.d231.s5|113-116|risk|O
DDI-DrugBank.d231.s5|73-79|lithium|O
DDI-DrugBank.d231.s5|129-136|toxicity|O
DDI-DrugBank.d231.s5|137-137|.|O
DDI-DrugBank.d231.s6|0-9|Furosemide|O
DDI-DrugBank.d231.s6|11-13|may|O
DDI-DrugBank.d231.s6|15-17|add|O
DDI-DrugBank.d231.s6|25-34|potentiate|O
DDI-DrugBank.d231.s6|40-50|therapeutic|O
DDI-DrugBank.d231.s6|52-57|effect|O
DDI-DrugBank.d231.s6|68-83|antihypertensive|O
DDI-DrugBank.d231.s6|85-89|drugs|O
DDI-DrugBank.d231.s6|90-90|.|O
DDI-DrugBank.d231.s7|0-11|Potentiation|O
DDI-DrugBank.d231.s7|13-18|occurs|O
DDI-DrugBank.d231.s7|25-34|ganglionic|O
DDI-DrugBank.d231.s7|39-48|peripheral|O
DDI-DrugBank.d231.s7|50-59|adrenergic|O
DDI-DrugBank.d231.s7|61-68|blocking|O
DDI-DrugBank.d231.s7|70-74|drugs|O
DDI-DrugBank.d231.s7|75-75|.|O
DDI-DrugBank.d231.s8|0-9|Furosemide|O
DDI-DrugBank.d231.s8|11-13|may|O
DDI-DrugBank.d231.s8|15-22|decrease|O
DDI-DrugBank.d231.s8|24-31|arterial|O
DDI-DrugBank.d231.s8|33-46|responsiveness|O
DDI-DrugBank.d231.s8|51-64|norepinephrine|O
DDI-DrugBank.d231.s8|65-65|.|O
DDI-DrugBank.d231.s9|0-6|However|O
DDI-DrugBank.d231.s9|9-22|norepinephrine|O
DDI-DrugBank.d231.s9|24-26|may|O
DDI-DrugBank.d231.s9|28-32|still|O
DDI-DrugBank.d231.s9|37-40|used|O
DDI-DrugBank.d231.s9|42-52|effectively|O
DDI-DrugBank.d231.s9|53-53|.|O
DDI-DrugBank.d231.s10|0-6|Tablets|O
DDI-DrugBank.d231.s10|8-19|Simultaneous|O
DDI-DrugBank.d231.s10|21-34|administration|O
DDI-DrugBank.d231.s10|39-48|sucralfate|O
DDI-DrugBank.d231.s10|54-63|furosemide|O
DDI-DrugBank.d231.s10|65-71|tablets|O
DDI-DrugBank.d231.s10|73-75|may|O
DDI-DrugBank.d231.s10|77-82|reduce|O
DDI-DrugBank.d231.s10|88-98|natriuretic|O
DDI-DrugBank.d231.s10|104-119|antihypertensive|O
DDI-DrugBank.d231.s10|121-127|effects|O
DDI-DrugBank.d231.s10|54-63|furosemide|O
DDI-DrugBank.d231.s10|142-142|.|O
DDI-DrugBank.d231.s11|0-7|Patients|O
DDI-DrugBank.d231.s11|9-17|receiving|O
DDI-DrugBank.d231.s11|24-28|drugs|O
DDI-DrugBank.d231.s11|40-47|observed|O
DDI-DrugBank.d231.s11|49-55|closely|O
DDI-DrugBank.d231.s11|60-68|determine|O
DDI-DrugBank.d231.s11|77-83|desired|O
DDI-DrugBank.d231.s11|85-92|diuretic|O
DDI-DrugBank.d231.s11|94-99|and/or|O
DDI-DrugBank.d231.s11|101-116|antihypertensive|O
DDI-DrugBank.d231.s11|118-123|effect|O
DDI-DrugBank.d231.s11|128-137|furosemide|O
DDI-DrugBank.d231.s11|142-149|achieved|O
DDI-DrugBank.d231.s11|150-150|.|O
DDI-DrugBank.d231.s12|0-2|The|O
DDI-DrugBank.d231.s12|4-9|intake|O
DDI-DrugBank.d231.s12|14-23|furosemide|O
DDI-DrugBank.d231.s12|29-38|sucralfate|O
DDI-DrugBank.d231.s12|50-58|separated|O
DDI-DrugBank.d231.s12|66-70|least|O
DDI-DrugBank.d231.s12|72-74|two|O
DDI-DrugBank.d231.s12|76-80|hours|O
DDI-DrugBank.d231.s12|81-81|.|O
DDI-DrugBank.d231.s13|0-6|Tablets|O
DDI-DrugBank.d231.s13|9-17|Injection|O
DDI-DrugBank.d231.s13|24-27|Oral|O
DDI-DrugBank.d231.s13|29-36|Solution|O
DDI-DrugBank.d231.s13|38-40|One|O
DDI-DrugBank.d231.s13|42-46|study|O
DDI-DrugBank.d231.s13|51-53|six|O
DDI-DrugBank.d231.s13|55-62|subjects|O
DDI-DrugBank.d231.s13|64-75|demonstrated|O
DDI-DrugBank.d231.s13|86-96|combination|O
DDI-DrugBank.d231.s13|101-110|furosemide|O
DDI-DrugBank.d231.s13|116-130|acetylsalicylic|O
DDI-DrugBank.d231.s13|132-135|acid|O
DDI-DrugBank.d231.s13|137-147|temporarily|O
DDI-DrugBank.d231.s13|149-155|reduced|O
DDI-DrugBank.d231.s13|157-166|creatinine|O
DDI-DrugBank.d231.s13|168-176|clearance|O
DDI-DrugBank.d231.s13|181-188|patients|O
DDI-DrugBank.d231.s13|195-201|chronic|O
DDI-DrugBank.d231.s13|203-207|renal|O
DDI-DrugBank.d231.s13|209-221|insufficiency|O
DDI-DrugBank.d231.s13|222-222|.|O
DDI-DrugBank.d231.s14|0-4|There|O
DDI-DrugBank.d231.s14|10-13|case|O
DDI-DrugBank.d231.s14|15-21|reports|O
DDI-DrugBank.d231.s14|26-33|patients|O
DDI-DrugBank.d231.s14|39-47|developed|O
DDI-DrugBank.d231.s14|49-57|increased|O
DDI-DrugBank.d231.s14|59-61|BUN|O
DDI-DrugBank.d231.s14|64-68|serum|O
DDI-DrugBank.d231.s14|70-79|creatinine|O
DDI-DrugBank.d231.s14|64-68|serum|O
DDI-DrugBank.d231.s14|91-99|potassium|O
DDI-DrugBank.d231.s14|101-106|levels|O
DDI-DrugBank.d231.s14|113-118|weight|O
DDI-DrugBank.d231.s14|120-123|gain|O
DDI-DrugBank.d231.s14|130-139|furosemide|O
DDI-DrugBank.d231.s14|145-148|used|O
DDI-DrugBank.d231.s14|153-163|conjunction|O
DDI-DrugBank.d231.s14|170-175|NSAIDs|O
DDI-DrugBank.d231.s14|176-176|.|O
DDI-DrugBank.d231.s15|0-9|Literature|O
DDI-DrugBank.d231.s15|11-17|reports|O
DDI-DrugBank.d231.s15|19-26|indicate|O
DDI-DrugBank.d231.s15|33-48|coadministration|O
DDI-DrugBank.d231.s15|53-64|indomethacin|O
DDI-DrugBank.d231.s15|66-68|may|O
DDI-DrugBank.d231.s15|70-75|reduce|O
DDI-DrugBank.d231.s15|81-91|natriuretic|O
DDI-DrugBank.d231.s15|97-112|antihypertensive|O
DDI-DrugBank.d231.s15|114-120|effects|O
DDI-DrugBank.d231.s15|125-134|furosemide|O
DDI-DrugBank.d231.s15|144-151|patients|O
DDI-DrugBank.d231.s15|156-165|inhibiting|O
DDI-DrugBank.d231.s15|167-179|prostaglandin|O
DDI-DrugBank.d231.s15|181-189|synthesis|O
DDI-DrugBank.d231.s16|0-11|Indomethacin|O
DDI-DrugBank.d231.s16|13-15|may|O
DDI-DrugBank.d231.s16|17-20|also|O
DDI-DrugBank.d231.s16|22-27|affect|O
DDI-DrugBank.d231.s16|29-34|plasma|O
DDI-DrugBank.d231.s16|36-40|renin|O
DDI-DrugBank.d231.s16|42-47|levels|O
DDI-DrugBank.d231.s16|50-60|aldosterone|O
DDI-DrugBank.d231.s16|62-70|excretion|O
DDI-DrugBank.d231.s16|36-40|renin|O
DDI-DrugBank.d231.s16|83-89|profile|O
DDI-DrugBank.d231.s16|91-100|evaluation|O
DDI-DrugBank.d231.s16|101-101|.|O
DDI-DrugBank.d231.s17|0-7|Patients|O
DDI-DrugBank.d231.s17|9-17|receiving|O
DDI-DrugBank.d231.s17|24-35|indomethacin|O
DDI-DrugBank.d231.s17|41-50|furosemide|O
DDI-DrugBank.d231.s17|62-69|observed|O
DDI-DrugBank.d231.s17|71-77|closely|O
DDI-DrugBank.d231.s17|82-90|determine|O
DDI-DrugBank.d231.s17|99-105|desired|O
DDI-DrugBank.d231.s17|107-114|diuretic|O
DDI-DrugBank.d231.s17|116-121|and/or|O
DDI-DrugBank.d231.s17|123-138|antihypertensive|O
DDI-DrugBank.d231.s17|140-145|effect|O
DDI-DrugBank.d231.s17|41-50|furosemide|O
DDI-DrugBank.d231.s17|164-171|achieved|O
DDI-DrugBank.d231.s17|172-172|.|O
DDI-DrugBank.d526.s0|0-3|When|O
DDI-DrugBank.d526.s0|5-16|administered|O
DDI-DrugBank.d526.s0|18-29|concurrently|O
DDI-DrugBank.d526.s0|36-44|following|O
DDI-DrugBank.d526.s0|46-50|drugs|O
DDI-DrugBank.d526.s0|52-54|may|O
DDI-DrugBank.d526.s0|56-63|interact|O
DDI-DrugBank.d526.s0|70-76|adrenal|O
DDI-DrugBank.d526.s0|78-92|corticosteroids|O
DDI-DrugBank.d526.s0|93-93|.|O
DDI-DrugBank.d526.s1|0-11|Amphotericin|O
DDI-DrugBank.d526.s1|13-13|B|O
DDI-DrugBank.d526.s1|18-36|potassium-depleting|O
DDI-DrugBank.d526.s1|38-46|diuretics|O
DDI-DrugBank.d526.s1|49-65|benzothiadiazines|O
DDI-DrugBank.d526.s1|71-77|related|O
DDI-DrugBank.d526.s1|79-83|drugs|O
DDI-DrugBank.d526.s1|86-95|ethacrynic|O
DDI-DrugBank.d526.s1|97-100|acid|O
DDI-DrugBank.d526.s1|106-115|furosemide|O
DDI-DrugBank.d526.s1|118-125|enhanced|O
DDI-DrugBank.d526.s1|127-137|hypokalemia|O
DDI-DrugBank.d526.s1|138-138|.|O
DDI-DrugBank.d526.s2|0-4|Check|O
DDI-DrugBank.d526.s2|6-10|serum|O
DDI-DrugBank.d526.s2|12-20|potassium|O
DDI-DrugBank.d526.s2|22-27|levels|O
DDI-DrugBank.d526.s2|32-39|frequent|O
DDI-DrugBank.d526.s2|41-49|intervals|O
DDI-DrugBank.d526.s3|0-2|use|O
DDI-DrugBank.d526.s3|4-12|potassium|O
DDI-DrugBank.d526.s3|14-24|supplements|O
DDI-DrugBank.d526.s3|29-37|necessary|O
DDI-DrugBank.d526.s3|39-39|.|O
DDI-DrugBank.d526.s4|0-8|Digitalis|O
DDI-DrugBank.d526.s4|10-19|glycosides|O
DDI-DrugBank.d526.s4|21-28|enhanced|O
DDI-DrugBank.d526.s4|30-40|possibility|O
DDI-DrugBank.d526.s4|45-55|arrhythmias|O
DDI-DrugBank.d526.s4|60-68|digitalis|O
DDI-DrugBank.d526.s4|70-77|toxicity|O
DDI-DrugBank.d526.s4|79-88|associated|O
DDI-DrugBank.d526.s4|95-105|hypokalemia|O
DDI-DrugBank.d526.s4|106-106|.|O
DDI-DrugBank.d526.s5|0-6|Monitor|O
DDI-DrugBank.d526.s5|8-12|serum|O
DDI-DrugBank.d526.s5|14-22|potassium|O
DDI-DrugBank.d526.s5|24-29|levels|O
DDI-DrugBank.d526.s6|0-2|use|O
DDI-DrugBank.d526.s6|4-12|potassium|O
DDI-DrugBank.d526.s6|14-24|supplements|O
DDI-DrugBank.d526.s6|29-37|necessary|O
DDI-DrugBank.d526.s6|38-38|.|O
DDI-DrugBank.d526.s7|0-3|Oral|O
DDI-DrugBank.d526.s7|5-18|anticoagulants|O
DDI-DrugBank.d526.s7|20-28|decreased|O
DDI-DrugBank.d526.s7|30-40|prothrombin|O
DDI-DrugBank.d526.s7|42-45|time|O
DDI-DrugBank.d526.s7|47-54|response|O
DDI-DrugBank.d526.s7|55-55|.|O
DDI-DrugBank.d526.s8|0-6|Monitor|O
DDI-DrugBank.d526.s8|8-18|prothrombin|O
DDI-DrugBank.d526.s8|20-25|levels|O
DDI-DrugBank.d526.s8|31-36|adjust|O
DDI-DrugBank.d526.s8|38-50|anticoagulant|O
DDI-DrugBank.d526.s8|52-57|dosage|O
DDI-DrugBank.d526.s8|59-69|accordingly|O
DDI-DrugBank.d526.s8|70-70|.|O
DDI-DrugBank.d526.s9|0-11|Antidiabetic|O
DDI-DrugBank.d526.s9|13-17|drugs|O
DDI-DrugBank.d526.s9|20-23|oral|O
DDI-DrugBank.d526.s9|25-30|agents|O
DDI-DrugBank.d526.s9|36-42|insulin|O
DDI-DrugBank.d526.s9|45-54|diminished|O
DDI-DrugBank.d526.s9|56-67|antidiabetic|O
DDI-DrugBank.d526.s9|69-74|effect|O
DDI-DrugBank.d526.s9|75-75|.|O
DDI-DrugBank.d526.s10|0-6|Monitor|O
DDI-DrugBank.d526.s10|12-19|symptoms|O
DDI-DrugBank.d526.s10|24-36|hyperglycemia|O
DDI-DrugBank.d526.s11|0-5|adjust|O
DDI-DrugBank.d526.s11|7-12|dosage|O
DDI-DrugBank.d526.s11|17-28|antidiabetic|O
DDI-DrugBank.d526.s11|30-33|drug|O
DDI-DrugBank.d526.s11|35-40|upward|O
DDI-DrugBank.d526.s11|45-53|necessary|O
DDI-DrugBank.d526.s11|54-54|.|O
DDI-DrugBank.d526.s12|0-6|Aspirin|O
DDI-DrugBank.d526.s12|8-16|increased|O
DDI-DrugBank.d526.s12|18-28|ulcerogenic|O
DDI-DrugBank.d526.s12|30-35|effect|O
DDI-DrugBank.d526.s13|0-8|decreased|O
DDI-DrugBank.d526.s13|10-22|pharmacologic|O
DDI-DrugBank.d526.s13|24-29|effect|O
DDI-DrugBank.d526.s13|34-40|aspirin|O
DDI-DrugBank.d526.s13|41-41|.|O
DDI-DrugBank.d526.s14|0-5|Rarely|O
DDI-DrugBank.d526.s14|7-16|salicylate|O
DDI-DrugBank.d526.s14|18-25|toxicity|O
DDI-DrugBank.d526.s14|27-29|may|O
DDI-DrugBank.d526.s14|31-35|occur|O
DDI-DrugBank.d526.s14|40-47|patients|O
DDI-DrugBank.d526.s14|53-63|discontinue|O
DDI-DrugBank.d526.s14|65-72|steroids|O
DDI-DrugBank.d526.s14|80-89|concurrent|O
DDI-DrugBank.d526.s14|91-99|high-dose|O
DDI-DrugBank.d526.s14|101-107|aspirin|O
DDI-DrugBank.d526.s14|109-115|therapy|O
DDI-DrugBank.d526.s14|116-116|.|O
DDI-DrugBank.d526.s15|0-6|Monitor|O
DDI-DrugBank.d526.s15|8-17|salicylate|O
DDI-DrugBank.d526.s15|19-24|levels|O
DDI-DrugBank.d526.s15|33-43|therapeutic|O
DDI-DrugBank.d526.s15|45-50|effect|O
DDI-DrugBank.d526.s15|62-68|aspirin|O
DDI-DrugBank.d526.s15|73-77|given|O
DDI-DrugBank.d526.s16|0-5|adjust|O
DDI-DrugBank.d526.s16|7-16|salicylate|O
DDI-DrugBank.d526.s16|18-23|dosage|O
DDI-DrugBank.d526.s16|25-35|accordingly|O
DDI-DrugBank.d526.s16|40-45|effect|O
DDI-DrugBank.d526.s16|50-56|altered|O
DDI-DrugBank.d526.s16|57-57|.|O
DDI-DrugBank.d526.s17|0-11|Barbiturates|O
DDI-DrugBank.d526.s17|14-22|phenytoin|O
DDI-DrugBank.d526.s17|28-35|rifampin|O
DDI-DrugBank.d526.s17|37-45|increased|O
DDI-DrugBank.d526.s17|47-55|metabolic|O
DDI-DrugBank.d526.s17|57-65|clearance|O
DDI-DrugBank.d526.s17|70-84|fludrocortisone|O
DDI-DrugBank.d526.s17|86-92|acetate|O
DDI-DrugBank.d526.s17|109-117|induction|O
DDI-DrugBank.d526.s17|122-128|hepatic|O
DDI-DrugBank.d526.s17|130-136|enzymes|O
DDI-DrugBank.d526.s17|137-137|.|O
DDI-DrugBank.d526.s18|0-6|Observe|O
DDI-DrugBank.d526.s18|12-18|patient|O
DDI-DrugBank.d526.s18|24-31|possible|O
DDI-DrugBank.d526.s18|33-42|diminished|O
DDI-DrugBank.d526.s18|44-49|effect|O
DDI-DrugBank.d526.s18|54-60|steroid|O
DDI-DrugBank.d526.s18|66-73|increase|O
DDI-DrugBank.d526.s18|54-60|steroid|O
DDI-DrugBank.d526.s18|87-92|dosage|O
DDI-DrugBank.d526.s18|94-104|accordingly|O
DDI-DrugBank.d526.s18|105-105|.|O
DDI-DrugBank.d526.s19|0-7|Anabolic|O
DDI-DrugBank.d526.s19|9-16|steroids|O
DDI-DrugBank.d526.s19|19-30|particularly|O
DDI-DrugBank.d526.s19|32-35|C-17|O
DDI-DrugBank.d526.s19|37-45|alkylated|O
DDI-DrugBank.d526.s19|47-55|androgens|O
DDI-DrugBank.d526.s19|65-76|oxymetholone|O
DDI-DrugBank.d526.s19|79-96|methandrostenolone|O
DDI-DrugBank.d526.s19|99-113|norethandrolone|O
DDI-DrugBank.d526.s19|120-126|similar|O
DDI-DrugBank.d526.s19|128-136|compounds|O
DDI-DrugBank.d526.s19|139-146|enhanced|O
DDI-DrugBank.d526.s19|148-155|tendency|O
DDI-DrugBank.d526.s19|157-162|toward|O
DDI-DrugBank.d526.s19|164-168|edema|O
DDI-DrugBank.d526.s19|169-169|.|O
DDI-DrugBank.d526.s20|0-2|Use|O
DDI-DrugBank.d526.s20|4-10|caution|O
DDI-DrugBank.d526.s20|17-22|giving|O
DDI-DrugBank.d526.s20|30-34|drugs|O
DDI-DrugBank.d526.s20|36-43|together|O
DDI-DrugBank.d526.s20|46-55|especially|O
DDI-DrugBank.d526.s20|60-67|patients|O
DDI-DrugBank.d526.s20|74-80|hepatic|O
DDI-DrugBank.d526.s20|85-91|cardiac|O
DDI-DrugBank.d526.s20|93-99|disease|O
DDI-DrugBank.d526.s20|100-100|.|O
DDI-DrugBank.d526.s21|0-7|Vaccines|O
DDI-DrugBank.d526.s21|9-20|neurological|O
DDI-DrugBank.d526.s21|22-34|complications|O
DDI-DrugBank.d526.s21|40-43|lack|O
DDI-DrugBank.d526.s21|48-55|antibody|O
DDI-DrugBank.d526.s21|57-64|response|O
DDI-DrugBank.d526.s21|66-66|.|O
DDI-DrugBank.d526.s22|0-7|Estrogen|O
DDI-DrugBank.d526.s22|9-17|increased|O
DDI-DrugBank.d526.s22|19-24|levels|O
DDI-DrugBank.d526.s22|29-50|corticosteroid-binding|O
DDI-DrugBank.d526.s22|52-59|globulin|O
DDI-DrugBank.d526.s22|62-68|thereby|O
DDI-DrugBank.d526.s22|70-79|increasing|O
DDI-DrugBank.d526.s22|85-89|bound|O
DDI-DrugBank.d526.s22|92-99|inactive|O
DDI-DrugBank.d526.s22|102-109|fraction|O
DDI-DrugBank.d526.s23|5-10|effect|O
DDI-DrugBank.d526.s23|18-22|least|O
DDI-DrugBank.d526.s23|24-31|balanced|O
DDI-DrugBank.d526.s23|36-44|decreased|O
DDI-DrugBank.d526.s23|46-55|metabolism|O
DDI-DrugBank.d526.s23|60-74|corticosteroids|O
DDI-DrugBank.d526.s23|75-75|.|O
DDI-DrugBank.d526.s24|0-3|When|O
DDI-DrugBank.d526.s24|5-12|estrogen|O
DDI-DrugBank.d526.s24|14-20|therapy|O
DDI-DrugBank.d526.s24|25-33|initiated|O
DDI-DrugBank.d526.s24|38-46|reduction|O
DDI-DrugBank.d526.s24|51-64|corticosteroid|O
DDI-DrugBank.d526.s24|66-71|dosage|O
DDI-DrugBank.d526.s24|73-75|may|O
DDI-DrugBank.d526.s24|80-87|required|O
DDI-DrugBank.d526.s24|94-102|increased|O
DDI-DrugBank.d526.s24|104-110|amounts|O
DDI-DrugBank.d526.s24|73-75|may|O
DDI-DrugBank.d526.s24|80-87|required|O
DDI-DrugBank.d526.s24|5-12|estrogen|O
DDI-DrugBank.d526.s24|145-154|terminated|O
DDI-DrugBank.d526.s25|0-14|Drug/Laboratory|O
DDI-DrugBank.d526.s25|16-19|Test|O
DDI-DrugBank.d526.s25|21-32|Interactions|O
DDI-DrugBank.d526.s25|34-48|Corticosteroids|O
DDI-DrugBank.d526.s25|50-52|may|O
DDI-DrugBank.d526.s25|54-59|affect|O
DDI-DrugBank.d526.s25|65-84|nitrobluetetrazolium|O
DDI-DrugBank.d526.s25|86-89|test|O
DDI-DrugBank.d526.s25|95-103|bacterial|O
DDI-DrugBank.d526.s25|105-113|infection|O
DDI-DrugBank.d526.s25|119-125|produce|O
DDI-DrugBank.d526.s25|127-140|false-negative|O
DDI-DrugBank.d526.s25|142-148|results|O
DDI-DrugBank.d526.s26|0-0|.|O
DDI-DrugBank.d66.s0|0-4|Human|O
DDI-DrugBank.d66.s0|6-11|growth|O
DDI-DrugBank.d66.s0|13-19|hormone|O
DDI-DrugBank.d66.s0|21-21|-|O
DDI-DrugBank.d66.s0|23-33|Concomitant|O
DDI-DrugBank.d66.s0|35-37|use|O
DDI-DrugBank.d66.s0|42-52|L-glutamine|O
DDI-DrugBank.d66.s0|58-62|human|O
DDI-DrugBank.d66.s0|6-11|growth|O
DDI-DrugBank.d66.s0|13-19|hormone|O
DDI-DrugBank.d66.s0|79-81|may|O
DDI-DrugBank.d66.s0|83-89|enhance|O
DDI-DrugBank.d66.s0|91-98|nutrient|O
DDI-DrugBank.d66.s0|100-109|absorption|O
DDI-DrugBank.d66.s0|125-130|severe|O
DDI-DrugBank.d66.s0|132-136|short|O
DDI-DrugBank.d66.s0|138-142|bowel|O
DDI-DrugBank.d66.s0|144-151|syndrome|O
DDI-DrugBank.d66.s0|152-152|.|O
DDI-DrugBank.d66.s1|0-10|L-glutamine|O
DDI-DrugBank.d66.s1|16-21|orphan|O
DDI-DrugBank.d66.s1|23-26|drug|O
DDI-DrugBank.d66.s1|28-33|status|O
DDI-DrugBank.d66.s1|44-53|indication|O
DDI-DrugBank.d66.s1|54-54|.|O
DDI-DrugBank.d66.s2|0-11|Indomethacin|O
DDI-DrugBank.d66.s2|13-13|-|O
DDI-DrugBank.d66.s2|15-25|Concomitant|O
DDI-DrugBank.d66.s2|27-29|use|O
DDI-DrugBank.d66.s2|34-44|L-glutamine|O
DDI-DrugBank.d66.s2|50-61|indomethacin|O
DDI-DrugBank.d66.s2|63-65|may|O
DDI-DrugBank.d66.s2|67-76|ameliorate|O
DDI-DrugBank.d66.s2|78-86|increased|O
DDI-DrugBank.d66.s2|88-97|intestinal|O
DDI-DrugBank.d66.s2|99-110|permeability|O
DDI-DrugBank.d66.s2|112-117|caused|O
DDI-DrugBank.d66.s2|50-61|indomethacin|O
DDI-DrugBank.d66.s2|134-134|.|O
DDI-DrugBank.d66.s3|0-2|The|O
DDI-DrugBank.d66.s3|4-11|reported|O
DDI-DrugBank.d66.s3|13-16|dose|O
DDI-DrugBank.d66.s3|18-21|used|O
DDI-DrugBank.d66.s3|27-37|L-glutamine|O
DDI-DrugBank.d66.s3|43-44|21|O
DDI-DrugBank.d66.s3|46-50|grams|O
DDI-DrugBank.d66.s3|52-56|daily|O
DDI-DrugBank.d66.s3|58-62|taken|O
DDI-DrugBank.d66.s3|67-73|divided|O
DDI-DrugBank.d66.s3|75-79|doses|O
DDI-DrugBank.d66.s3|81-85|three|O
DDI-DrugBank.d66.s3|87-91|times|O
DDI-DrugBank.d66.s3|95-97|day|O
DDI-DrugBank.d66.s3|98-98|.|O
DDI-DrugBank.d66.s4|0-6|Further|O
DDI-DrugBank.d66.s4|9-19|misoprostol|O
DDI-DrugBank.d66.s4|24-31|reported|O
DDI-DrugBank.d66.s4|43-53|synergistic|O
DDI-DrugBank.d66.s4|55-60|effect|O
DDI-DrugBank.d66.s4|72-82|combination|O
DDI-DrugBank.d66.s4|87-98|ameliorating|O
DDI-DrugBank.d66.s4|100-109|intestinal|O
DDI-DrugBank.d66.s4|111-122|permeability|O
DDI-DrugBank.d66.s4|123-123|.|O
DDI-DrugBank.d66.s5|0-11|Methotrexate|O
DDI-DrugBank.d66.s5|13-13|-|O
DDI-DrugBank.d66.s5|15-19|There|O
DDI-DrugBank.d66.s5|24-26|one|O
DDI-DrugBank.d66.s5|28-33|report|O
DDI-DrugBank.d66.s5|40-51|methotrexate|O
DDI-DrugBank.d66.s5|53-55|may|O
DDI-DrugBank.d66.s5|57-64|decrease|O
DDI-DrugBank.d66.s5|70-77|possible|O
DDI-DrugBank.d66.s5|79-91|effectiveness|O
DDI-DrugBank.d66.s5|96-107|supplemental|O
DDI-DrugBank.d66.s5|109-119|L-glutamine|O
DDI-DrugBank.d66.s5|125-144|chemotherapy-induced|O
DDI-DrugBank.d66.s5|146-154|mucositis|O
DDI-DrugBank.d66.s5|155-155|.|O
DDI-DrugBank.d66.s6|0-1|In|O
DDI-DrugBank.d66.s6|3-9|another|O
DDI-DrugBank.d66.s6|11-16|report|O
DDI-DrugBank.d66.s6|19-22|nine|O
DDI-DrugBank.d66.s6|24-31|patients|O
DDI-DrugBank.d66.s6|38-43|breast|O
DDI-DrugBank.d66.s6|45-50|cancer|O
DDI-DrugBank.d66.s6|57-64|reported|O
DDI-DrugBank.d66.s6|74-82|decreased|O
DDI-DrugBank.d66.s6|84-91|symptoms|O
DDI-DrugBank.d66.s6|96-115|methotrexate-related|O
DDI-DrugBank.d66.s6|117-124|toxicity|O
DDI-DrugBank.d66.s6|131-135|given|O
DDI-DrugBank.d66.s6|137-148|supplemental|O
DDI-DrugBank.d66.s6|150-160|L-glutamine|O
DDI-DrugBank.d66.s6|167-170|dose|O
DDI-DrugBank.d66.s6|175-177|0.5|O
DDI-DrugBank.d66.s6|179-195|gram/kilogram/day|O
DDI-DrugBank.d66.s6|176-176|.|O
DDI-DrugBank.d66.s7|0-9|Paclitaxel|O
DDI-DrugBank.d66.s7|11-11|-|O
DDI-DrugBank.d66.s7|13-14|In|O
DDI-DrugBank.d66.s7|16-18|one|O
DDI-DrugBank.d66.s7|20-25|report|O
DDI-DrugBank.d66.s7|28-38|L-glutamine|O
DDI-DrugBank.d66.s7|45-48|dose|O
DDI-DrugBank.d66.s7|53-54|10|O
DDI-DrugBank.d66.s7|56-60|grams|O
DDI-DrugBank.d66.s7|62-66|three|O
DDI-DrugBank.d66.s7|68-72|times|O
DDI-DrugBank.d66.s7|74-78|daily|O
DDI-DrugBank.d66.s7|81-85|given|O
DDI-DrugBank.d66.s7|87-88|24|O
DDI-DrugBank.d66.s7|90-94|hours|O
DDI-DrugBank.d66.s7|102-110|receiving|O
DDI-DrugBank.d66.s7|112-121|paclitaxel|O
DDI-DrugBank.d66.s7|124-131|appeared|O
DDI-DrugBank.d66.s7|136-142|prevent|O
DDI-DrugBank.d66.s7|148-158|development|O
DDI-DrugBank.d66.s7|163-169|myalgia|O
DDI-DrugBank.d66.s7|175-184|arthralgia|O
DDI-DrugBank.d66.s7|187-193|adverse|O
DDI-DrugBank.d66.s7|195-203|reactions|O
DDI-DrugBank.d66.s7|112-121|paclitaxel|O
DDI-DrugBank.d66.s7|218-218|.|O
DDI-DrugBank.d204.s0|0-3|When|O
DDI-DrugBank.d204.s0|5-16|administered|O
DDI-DrugBank.d204.s0|18-29|concurrently|O
DDI-DrugBank.d204.s0|36-44|following|O
DDI-DrugBank.d204.s0|46-50|drugs|O
DDI-DrugBank.d204.s0|52-54|may|O
DDI-DrugBank.d204.s0|56-63|interact|O
DDI-DrugBank.d204.s0|70-84|beta-adrenergic|O
DDI-DrugBank.d204.s0|86-93|receptor|O
DDI-DrugBank.d204.s0|95-102|blocking|O
DDI-DrugBank.d204.s0|104-109|agents|O
DDI-DrugBank.d204.s0|112-122|Anesthetics|O
DDI-DrugBank.d204.s0|125-131|general|O
DDI-DrugBank.d204.s0|134-145|exaggeration|O
DDI-DrugBank.d204.s0|154-164|hypotension|O
DDI-DrugBank.d204.s0|166-172|induced|O
DDI-DrugBank.d204.s0|125-131|general|O
DDI-DrugBank.d204.s0|185-195|anesthetics|O
DDI-DrugBank.d204.s0|196-196|.|O
DDI-DrugBank.d204.s1|0-11|Antidiabetic|O
DDI-DrugBank.d204.s1|13-17|drugs|O
DDI-DrugBank.d204.s1|20-23|oral|O
DDI-DrugBank.d204.s1|25-30|agents|O
DDI-DrugBank.d204.s1|36-42|insulin|O
DDI-DrugBank.d204.s1|46-57|hypoglycemia|O
DDI-DrugBank.d204.s1|62-74|hyperglycemia|O
DDI-DrugBank.d204.s2|0-5|adjust|O
DDI-DrugBank.d204.s2|7-12|dosage|O
DDI-DrugBank.d204.s2|17-28|antidiabetic|O
DDI-DrugBank.d204.s2|30-33|drug|O
DDI-DrugBank.d204.s2|35-45|accordingly|O
DDI-DrugBank.d204.s2|46-46|.|O
DDI-DrugBank.d204.s3|0-22|Catecholamine-depleting|O
DDI-DrugBank.d204.s3|24-28|drugs|O
DDI-DrugBank.d204.s3|31-34|e.g.|O
DDI-DrugBank.d204.s3|37-45|reserpine|O
DDI-DrugBank.d204.s3|49-56|additive|O
DDI-DrugBank.d204.s3|58-63|effect|O
DDI-DrugBank.d204.s4|0-6|monitor|O
DDI-DrugBank.d204.s4|8-14|closely|O
DDI-DrugBank.d204.s4|20-27|evidence|O
DDI-DrugBank.d204.s4|32-42|hypotension|O
DDI-DrugBank.d204.s4|44-49|and/or|O
DDI-DrugBank.d204.s4|51-59|excessive|O
DDI-DrugBank.d204.s4|61-71|bradycardia|O
DDI-DrugBank.d204.s4|74-77|e.g.|O
DDI-DrugBank.d204.s4|80-86|vertigo|O
DDI-DrugBank.d204.s4|89-95|syncope|O
DDI-DrugBank.d204.s4|98-105|postural|O
DDI-DrugBank.d204.s4|32-42|hypotension|O
DDI-DrugBank.d204.s4|75-75|.|O
DDI-DrugBank.d204.s5|0-7|Response|O
DDI-DrugBank.d204.s5|12-20|Treatment|O
DDI-DrugBank.d204.s5|26-37|Anaphylactic|O
DDI-DrugBank.d204.s5|39-46|Reaction|O
DDI-DrugBank.d204.s5|49-53|While|O
DDI-DrugBank.d204.s5|55-60|taking|O
DDI-DrugBank.d204.s5|62-74|beta-blockers|O
DDI-DrugBank.d204.s5|77-84|patients|O
DDI-DrugBank.d204.s5|93-99|history|O
DDI-DrugBank.d204.s5|104-109|severe|O
DDI-DrugBank.d204.s5|111-122|anaphylactic|O
DDI-DrugBank.d204.s5|124-131|reaction|O
DDI-DrugBank.d204.s5|138-144|variety|O
DDI-DrugBank.d204.s5|149-157|allergens|O
DDI-DrugBank.d204.s5|159-161|may|O
DDI-DrugBank.d204.s5|171-178|reactive|O
DDI-DrugBank.d204.s5|183-190|repeated|O
DDI-DrugBank.d204.s5|192-200|challenge|O
DDI-DrugBank.d204.s5|203-208|either|O
DDI-DrugBank.d204.s5|210-219|accidental|O
DDI-DrugBank.d204.s5|222-231|diagnostic|O
DDI-DrugBank.d204.s5|237-247|therapeutic|O
DDI-DrugBank.d204.s5|248-248|.|O
DDI-DrugBank.d204.s6|0-3|Such|O
DDI-DrugBank.d204.s6|5-12|patients|O
DDI-DrugBank.d204.s6|14-16|may|O
DDI-DrugBank.d204.s6|21-32|unresponsive|O
DDI-DrugBank.d204.s6|41-45|usual|O
DDI-DrugBank.d204.s6|47-51|doses|O
DDI-DrugBank.d204.s6|56-66|epinephrine|O
DDI-DrugBank.d204.s6|68-71|used|O
DDI-DrugBank.d204.s6|76-80|treat|O
DDI-DrugBank.d204.s6|82-89|allergic|O
DDI-DrugBank.d204.s6|91-98|reaction|O
DDI-DrugBank.d204.s6|99-99|.|O
DDI-DrugBank.d774.s0|0-9|Trilostane|O
DDI-DrugBank.d774.s0|11-13|may|O
DDI-DrugBank.d774.s0|15-22|interact|O
DDI-DrugBank.d774.s0|29-45|aminoglutethimide|O
DDI-DrugBank.d774.s0|50-57|mitotane|O
DDI-DrugBank.d774.s0|60-66|causing|O
DDI-DrugBank.d774.s0|72-76|great|O
DDI-DrugBank.d774.s0|80-87|decrease|O
DDI-DrugBank.d774.s0|92-98|adrenal|O
DDI-DrugBank.d774.s0|100-107|function|O
DDI-DrugBank.d774.s0|109-109|.|O
DDI-DrugBank.d285.s0|0-6|Reduced|O
DDI-DrugBank.d285.s0|8-15|efficacy|O
DDI-DrugBank.d285.s0|21-29|increased|O
DDI-DrugBank.d285.s0|31-39|incidence|O
DDI-DrugBank.d285.s0|44-55|breakthrough|O
DDI-DrugBank.d285.s0|57-64|bleeding|O
DDI-DrugBank.d285.s0|70-78|menstrual|O
DDI-DrugBank.d285.s0|80-93|irregularities|O
DDI-DrugBank.d285.s0|105-114|associated|O
DDI-DrugBank.d285.s0|121-131|concomitant|O
DDI-DrugBank.d285.s0|133-135|use|O
DDI-DrugBank.d285.s0|140-147|rifampin|O
DDI-DrugBank.d285.s0|148-148|.|O
DDI-DrugBank.d285.s1|0-0|A|O
DDI-DrugBank.d285.s1|2-8|similar|O
DDI-DrugBank.d285.s1|10-20|association|O
DDI-DrugBank.d285.s1|23-28|though|O
DDI-DrugBank.d285.s1|30-33|less|O
DDI-DrugBank.d285.s1|35-40|marked|O
DDI-DrugBank.d285.s1|52-60|suggested|O
DDI-DrugBank.d285.s1|67-78|barbiturates|O
DDI-DrugBank.d285.s1|81-95|phenyl-butazone|O
DDI-DrugBank.d285.s1|98-106|phenytoin|O
DDI-DrugBank.d285.s1|108-113|sodium|O
DDI-DrugBank.d285.s1|116-128|carbamazepine|O
DDI-DrugBank.d285.s1|134-141|possibly|O
DDI-DrugBank.d285.s1|148-159|griseofulvin|O
DDI-DrugBank.d285.s1|162-171|ampicillin|O
DDI-DrugBank.d285.s1|178-190|tetracyclines|O
DDI-DrugBank.d285.s1|193-194|72|O
DDI-DrugBank.d285.s2|0-0|.|O
DDI-MedLine.d27.s0|0-0|[|O
DDI-MedLine.d27.s0|1-3|The|O
DDI-MedLine.d27.s0|5-14|GABA-ergic|O
DDI-MedLine.d27.s0|16-21|system|O
DDI-MedLine.d27.s0|27-31|brain|O
DDI-MedLine.d27.s0|33-37|edema|O
DDI-MedLine.d27.s0|38-38|]|O
DDI-MedLine.d27.s0|41-42|It|O
DDI-MedLine.d27.s0|53-57|shown|O
DDI-MedLine.d27.s0|62-65|rats|O
DDI-MedLine.d27.s0|72-83|experimental|O
DDI-MedLine.d27.s0|85-89|toxic|O
DDI-MedLine.d27.s0|95-103|traumatic|O
DDI-MedLine.d27.s0|105-110|edemas|O
DDI-MedLine.d27.s0|117-126|picrotoxin|O
DDI-MedLine.d27.s0|129-129|1|O
DDI-MedLine.d27.s0|131-135|mg/kg|O
DDI-MedLine.d27.s0|138-144|removes|O
DDI-MedLine.d27.s0|150-162|antiedematous|O
DDI-MedLine.d27.s0|164-169|action|O
DDI-MedLine.d27.s0|174-181|diazepam|O
DDI-MedLine.d27.s0|184-193|phenazepam|O
DDI-MedLine.d27.s0|196-203|phenibut|O
DDI-MedLine.d27.s0|209-214|amizyl|O
DDI-MedLine.d27.s0|220-226|reduces|O
DDI-MedLine.d27.s0|164-169|action|O
DDI-MedLine.d27.s0|242-253|phentolamine|O
DDI-MedLine.d27.s0|254-254|.|O
DDI-MedLine.d27.s1|0-3|When|O
DDI-MedLine.d27.s1|9-12|dose|O
DDI-MedLine.d27.s1|17-26|picrotoxin|O
DDI-MedLine.d27.s1|31-39|minimized|O
DDI-MedLine.d27.s1|44-46|0.5|O
DDI-MedLine.d27.s1|48-52|mg/kg|O
DDI-MedLine.d27.s1|62-67|effect|O
DDI-MedLine.d27.s1|76-83|observed|O
DDI-MedLine.d27.s1|45-45|.|O
DDI-MedLine.d27.s2|0-8|Prolonged|O
DDI-MedLine.d27.s2|10-14|daily|O
DDI-MedLine.d27.s2|16-29|administration|O
DDI-MedLine.d27.s2|34-43|picrotoxin|O
DDI-MedLine.d27.s2|50-53|dose|O
DDI-MedLine.d27.s2|58-58|1|O
DDI-MedLine.d27.s2|60-64|mg/kg|O
DDI-MedLine.d27.s2|66-72|results|O
DDI-MedLine.d27.s2|81-91|development|O
DDI-MedLine.d27.s2|96-100|brain|O
DDI-MedLine.d27.s2|102-106|edema|O
DDI-MedLine.d27.s2|107-107|.|O
DDI-MedLine.d27.s3|0-1|It|O
DDI-MedLine.d27.s3|6-16|recommended|O
DDI-MedLine.d27.s3|23-35|GABA-positive|O
DDI-MedLine.d27.s3|37-41|drugs|O
DDI-MedLine.d27.s3|46-53|included|O
DDI-MedLine.d27.s3|62-68|complex|O
DDI-MedLine.d27.s3|73-81|treatment|O
DDI-MedLine.d27.s3|83-90|measures|O
DDI-MedLine.d27.s3|96-100|edema|O
DDI-MedLine.d27.s3|101-101|.|O
DDI-DrugBank.d751.s0|0-8|AGGRASTAT|O
DDI-DrugBank.d751.s0|19-25|studied|O
DDI-DrugBank.d751.s0|32-41|background|O
DDI-DrugBank.d751.s0|46-52|aspirin|O
DDI-DrugBank.d751.s0|58-64|heparin|O
DDI-DrugBank.d751.s0|65-65|.|O
DDI-DrugBank.d751.s1|0-2|The|O
DDI-DrugBank.d751.s1|4-6|use|O
DDI-DrugBank.d751.s1|11-19|AGGRASTAT|O
DDI-DrugBank.d751.s1|25-35|combination|O
DDI-DrugBank.d751.s1|42-48|heparin|O
DDI-DrugBank.d751.s1|54-60|aspirin|O
DDI-DrugBank.d751.s1|72-81|associated|O
DDI-DrugBank.d751.s1|91-98|increase|O
DDI-DrugBank.d751.s1|103-110|bleeding|O
DDI-DrugBank.d751.s1|112-119|compared|O
DDI-DrugBank.d751.s1|42-48|heparin|O
DDI-DrugBank.d751.s1|54-60|aspirin|O
DDI-DrugBank.d751.s1|144-148|alone|O
DDI-DrugBank.d751.s1|151-153|see|O
DDI-DrugBank.d558.s0|0-14|Drug/Laboratory|O
DDI-DrugBank.d558.s0|16-19|Test|O
DDI-DrugBank.d558.s0|21-32|Interactions|O
DDI-DrugBank.d558.s0|34-37|None|O
DDI-DrugBank.d558.s0|39-43|known|O
DDI-DrugBank.d558.s0|44-44|.|O
DDI-DrugBank.d558.s1|0-8|Drug-Drug|O
DDI-DrugBank.d558.s1|10-21|Interactions|O
DDI-DrugBank.d558.s1|23-32|Cimetidine|O
DDI-DrugBank.d558.s1|35-45|Concomitant|O
DDI-DrugBank.d558.s1|47-49|use|O
DDI-DrugBank.d558.s1|54-63|cimetidine|O
DDI-DrugBank.d558.s1|68-82|contraindicated|O
DDI-DrugBank.d558.s1|83-83|.|O
DDI-DrugBank.d558.s2|0-9|Cimetidine|O
DDI-DrugBank.d558.s2|14-16|400|O
DDI-DrugBank.d558.s2|18-19|mg|O
DDI-DrugBank.d558.s2|21-23|BID|O
DDI-DrugBank.d558.s2|30-34|usual|O
DDI-DrugBank.d558.s2|36-47|prescription|O
DDI-DrugBank.d558.s2|49-52|dose|O
DDI-DrugBank.d558.s2|55-69|co-administered|O
DDI-DrugBank.d558.s2|76-82|TIKOSYN|O
DDI-DrugBank.d558.s2|85-87|500|O
DDI-DrugBank.d558.s2|89-91|mcg|O
DDI-DrugBank.d558.s2|21-23|BID|O
DDI-DrugBank.d558.s2|102-102|7|O
DDI-DrugBank.d558.s2|104-107|days|O
DDI-DrugBank.d558.s2|118-122|shown|O
DDI-DrugBank.d558.s2|127-134|increase|O
DDI-DrugBank.d558.s2|136-145|dofetilide|O
DDI-DrugBank.d558.s2|147-152|plasma|O
DDI-DrugBank.d558.s2|154-159|levels|O
DDI-DrugBank.d558.s2|164-165|58|O
DDI-DrugBank.d558.s2|166-166|%|O
DDI-DrugBank.d558.s2|167-167|.|O
DDI-DrugBank.d558.s3|0-9|Cimetidine|O
DDI-DrugBank.d558.s3|14-18|doses|O
DDI-DrugBank.d558.s3|23-25|100|O
DDI-DrugBank.d558.s3|27-28|mg|O
DDI-DrugBank.d558.s3|30-32|BID|O
DDI-DrugBank.d558.s3|35-37|OTC|O
DDI-DrugBank.d558.s3|14-17|dose|O
DDI-DrugBank.d558.s3|45-52|resulted|O
DDI-DrugBank.d558.s3|59-60|13|O
DDI-DrugBank.d558.s3|61-61|%|O
DDI-DrugBank.d558.s3|63-70|increase|O
DDI-DrugBank.d558.s3|75-84|dofetilide|O
DDI-DrugBank.d558.s3|86-91|plasma|O
DDI-DrugBank.d558.s3|93-98|levels|O
DDI-DrugBank.d558.s3|101-103|500|O
DDI-DrugBank.d558.s3|105-107|mcg|O
DDI-DrugBank.d558.s3|109-114|single|O
DDI-DrugBank.d558.s3|14-17|dose|O
DDI-DrugBank.d558.s3|121-121|.|O
DDI-DrugBank.d558.s4|0-1|No|O
DDI-DrugBank.d558.s4|3-9|studies|O
DDI-DrugBank.d558.s4|21-29|conducted|O
DDI-DrugBank.d558.s4|34-45|intermediate|O
DDI-DrugBank.d558.s4|47-51|doses|O
DDI-DrugBank.d558.s4|56-65|cimetidine|O
DDI-DrugBank.d558.s4|66-66|.|O
DDI-DrugBank.d558.s5|0-1|If|O
DDI-DrugBank.d558.s5|5-11|patient|O
DDI-DrugBank.d558.s5|13-20|requires|O
DDI-DrugBank.d558.s5|22-28|TIKOSYN|O
DDI-DrugBank.d558.s5|34-43|anti-ulcer|O
DDI-DrugBank.d558.s5|45-51|therapy|O
DDI-DrugBank.d558.s5|60-68|suggested|O
DDI-DrugBank.d558.s5|75-84|omeprazole|O
DDI-DrugBank.d558.s5|87-96|ranitidine|O
DDI-DrugBank.d558.s5|102-109|antacids|O
DDI-DrugBank.d558.s5|112-119|aluminum|O
DDI-DrugBank.d558.s5|125-133|magnesium|O
DDI-DrugBank.d558.s5|135-144|hydroxides|O
DDI-DrugBank.d558.s5|150-153|used|O
DDI-DrugBank.d558.s5|158-169|alternatives|O
DDI-DrugBank.d558.s5|174-183|cimetidine|O
DDI-DrugBank.d558.s5|195-200|agents|O
DDI-DrugBank.d558.s5|210-215|effect|O
DDI-DrugBank.d558.s5|224-238|pharmacokinetic|O
DDI-DrugBank.d558.s5|240-246|profile|O
DDI-DrugBank.d558.s5|22-28|TIKOSYN|O
DDI-DrugBank.d558.s5|258-258|.|O
DDI-DrugBank.d558.s6|0-8|Verapamil|O
DDI-DrugBank.d558.s6|11-21|Concomitant|O
DDI-DrugBank.d558.s6|23-25|use|O
DDI-DrugBank.d558.s6|30-38|verapamil|O
DDI-DrugBank.d558.s6|43-57|contraindicated|O
DDI-DrugBank.d558.s6|58-58|.|O
DDI-DrugBank.d558.s7|0-16|Co-administration|O
DDI-DrugBank.d558.s7|21-27|TIKOSYN|O
DDI-DrugBank.d558.s7|34-42|verapamil|O
DDI-DrugBank.d558.s7|44-51|resulted|O
DDI-DrugBank.d558.s7|56-64|increases|O
DDI-DrugBank.d558.s7|69-78|dofetilide|O
DDI-DrugBank.d558.s7|80-83|peak|O
DDI-DrugBank.d558.s7|85-90|plasma|O
DDI-DrugBank.d558.s7|92-97|levels|O
DDI-DrugBank.d558.s7|102-103|42|O
DDI-DrugBank.d558.s7|104-104|%|O
DDI-DrugBank.d558.s7|107-114|although|O
DDI-DrugBank.d558.s7|116-122|overall|O
DDI-DrugBank.d558.s7|124-131|exposure|O
DDI-DrugBank.d558.s7|69-78|dofetilide|O
DDI-DrugBank.d558.s7|155-167|significantly|O
DDI-DrugBank.d558.s7|169-177|increased|O
DDI-DrugBank.d558.s7|178-178|.|O
DDI-DrugBank.d558.s8|0-1|In|O
DDI-DrugBank.d558.s8|6-13|analysis|O
DDI-DrugBank.d558.s8|22-37|supraventricular|O
DDI-DrugBank.d558.s8|39-48|arrhythmia|O
DDI-DrugBank.d558.s8|54-60|DIAMOND|O
DDI-DrugBank.d558.s8|62-68|patient|O
DDI-DrugBank.d558.s8|70-80|populations|O
DDI-DrugBank.d558.s8|87-97|concomitant|O
DDI-DrugBank.d558.s8|99-112|administration|O
DDI-DrugBank.d558.s8|117-125|verapamil|O
DDI-DrugBank.d558.s8|132-141|dofetilide|O
DDI-DrugBank.d558.s8|147-156|associated|O
DDI-DrugBank.d558.s8|165-170|higher|O
DDI-DrugBank.d558.s8|172-181|occurrence|O
DDI-DrugBank.d558.s8|186-192|torsade|O
DDI-DrugBank.d558.s8|140-141|de|O
DDI-DrugBank.d558.s8|197-203|pointes|O
DDI-DrugBank.d558.s8|204-204|.|O
DDI-DrugBank.d558.s9|0-11|Ketoconazole|O
DDI-DrugBank.d558.s9|14-24|Concomitant|O
DDI-DrugBank.d558.s9|26-28|use|O
DDI-DrugBank.d558.s9|33-44|ketoconazole|O
DDI-DrugBank.d558.s9|49-63|contraindicated|O
DDI-DrugBank.d558.s9|64-64|.|O
DDI-DrugBank.d558.s10|0-11|Ketoconazole|O
DDI-DrugBank.d558.s10|16-18|400|O
DDI-DrugBank.d558.s10|20-21|mg|O
DDI-DrugBank.d558.s10|23-27|daily|O
DDI-DrugBank.d558.s10|34-40|maximum|O
DDI-DrugBank.d558.s10|42-49|approved|O
DDI-DrugBank.d558.s10|51-62|prescription|O
DDI-DrugBank.d558.s10|64-67|dose|O
DDI-DrugBank.d558.s10|70-84|co-administered|O
DDI-DrugBank.d558.s10|91-97|TIKOSYN|O
DDI-DrugBank.d558.s10|100-102|500|O
DDI-DrugBank.d558.s10|104-106|mcg|O
DDI-DrugBank.d558.s10|108-110|BID|O
DDI-DrugBank.d558.s10|117-117|7|O
DDI-DrugBank.d558.s10|119-122|days|O
DDI-DrugBank.d558.s10|133-137|shown|O
DDI-DrugBank.d558.s10|142-149|increase|O
DDI-DrugBank.d558.s10|151-160|dofetilide|O
DDI-DrugBank.d558.s10|162-165|Cmax|O
DDI-DrugBank.d558.s10|170-171|53|O
DDI-DrugBank.d558.s10|172-172|%|O
DDI-DrugBank.d558.s10|177-181|males|O
DDI-DrugBank.d558.s10|187-188|97|O
DDI-DrugBank.d558.s10|172-172|%|O
DDI-DrugBank.d558.s10|194-200|females|O
DDI-DrugBank.d558.s10|207-209|AUC|O
DDI-DrugBank.d558.s10|214-215|41|O
DDI-DrugBank.d558.s10|172-172|%|O
DDI-DrugBank.d558.s10|177-181|males|O
DDI-DrugBank.d558.s10|231-232|69|O
DDI-DrugBank.d558.s10|172-172|%|O
DDI-DrugBank.d558.s10|194-200|females|O
DDI-DrugBank.d558.s10|245-245|.|O
DDI-DrugBank.d558.s11|0-11|Trimethoprim|O
DDI-DrugBank.d558.s11|13-17|Alone|O
DDI-DrugBank.d558.s11|25-35|Combination|O
DDI-DrugBank.d558.s11|42-57|Sulfamethoxazole|O
DDI-DrugBank.d558.s11|60-70|Concomitant|O
DDI-DrugBank.d558.s11|72-74|use|O
DDI-DrugBank.d558.s11|79-90|trimethoprim|O
DDI-DrugBank.d558.s11|92-96|alone|O
DDI-DrugBank.d558.s11|104-114|combination|O
DDI-DrugBank.d558.s11|121-136|sulfamethoxazole|O
DDI-DrugBank.d558.s11|141-155|contraindicated|O
DDI-DrugBank.d558.s11|156-156|.|O
DDI-DrugBank.d558.s12|0-18|Hydrochlorothiazide|O
DDI-DrugBank.d558.s12|21-24|HCTZ|O
DDI-DrugBank.d558.s12|27-31|Alone|O
DDI-DrugBank.d558.s12|39-49|Combination|O
DDI-DrugBank.d558.s12|56-66|Triamterene|O
DDI-DrugBank.d558.s12|69-79|Concomitant|O
DDI-DrugBank.d558.s12|81-83|use|O
DDI-DrugBank.d558.s12|21-24|HCTZ|O
DDI-DrugBank.d558.s12|93-97|alone|O
DDI-DrugBank.d558.s12|105-115|combination|O
DDI-DrugBank.d558.s12|122-132|triamterene|O
DDI-DrugBank.d558.s12|137-151|contraindicated|O
DDI-DrugBank.d558.s12|152-152|.|O
DDI-DrugBank.d558.s13|0-3|HCTZ|O
DDI-DrugBank.d558.s13|5-6|50|O
DDI-DrugBank.d558.s13|8-9|mg|O
DDI-DrugBank.d558.s13|11-12|QD|O
DDI-DrugBank.d558.s13|17-32|HCTZ/triamterene|O
DDI-DrugBank.d558.s13|34-39|50/100|O
DDI-DrugBank.d558.s13|8-9|mg|O
DDI-DrugBank.d558.s13|11-12|QD|O
DDI-DrugBank.d558.s13|51-65|co-administered|O
DDI-DrugBank.d558.s13|72-78|TIKOSYN|O
DDI-DrugBank.d558.s13|81-83|500|O
DDI-DrugBank.d558.s13|85-87|mcg|O
DDI-DrugBank.d558.s13|89-91|BID|O
DDI-DrugBank.d558.s13|5-5|5|O
DDI-DrugBank.d558.s13|100-103|days|O
DDI-DrugBank.d558.s13|106-114|following|O
DDI-DrugBank.d558.s13|116-116|2|O
DDI-DrugBank.d558.s13|100-103|days|O
DDI-DrugBank.d558.s13|126-133|diuretic|O
DDI-DrugBank.d558.s13|135-137|use|O
DDI-DrugBank.d558.s13|142-145|half|O
DDI-DrugBank.d558.s13|147-150|dose|O
DDI-DrugBank.d558.s13|152-152|.|O
DDI-DrugBank.d558.s14|0-1|In|O
DDI-DrugBank.d558.s14|3-10|patients|O
DDI-DrugBank.d558.s14|12-20|receiving|O
DDI-DrugBank.d558.s14|22-25|HCTZ|O
DDI-DrugBank.d558.s14|27-31|alone|O
DDI-DrugBank.d558.s14|34-43|dofetilide|O
DDI-DrugBank.d558.s14|45-47|AUC|O
DDI-DrugBank.d558.s14|49-57|increased|O
DDI-DrugBank.d558.s14|62-63|27|O
DDI-DrugBank.d558.s14|64-64|%|O
DDI-DrugBank.d558.s14|70-73|Cmax|O
DDI-DrugBank.d558.s14|78-79|21|O
DDI-DrugBank.d558.s14|64-64|%|O
DDI-DrugBank.d558.s14|81-81|.|O
DDI-DrugBank.d558.s15|0-6|However|O
DDI-DrugBank.d558.s15|13-27|pharmacodynamic|O
DDI-DrugBank.d558.s15|29-34|effect|O
DDI-DrugBank.d558.s15|36-44|increased|O
DDI-DrugBank.d558.s15|49-51|197|O
DDI-DrugBank.d558.s15|52-52|%|O
DDI-DrugBank.d558.s15|55-57|QTc|O
DDI-DrugBank.d558.s15|36-43|increase|O
DDI-DrugBank.d558.s15|73-76|time|O
DDI-DrugBank.d558.s15|86-87|95|O
DDI-DrugBank.d558.s15|52-52|%|O
DDI-DrugBank.d558.s15|91-97|maximum|O
DDI-DrugBank.d558.s15|55-57|QTc|O
DDI-DrugBank.d558.s15|36-43|increase|O
DDI-DrugBank.d558.s15|112-112|.|O
DDI-DrugBank.d558.s16|0-6|However|O
DDI-DrugBank.d558.s16|13-27|pharmacodynamic|O
DDI-DrugBank.d558.s16|29-34|effect|O
DDI-DrugBank.d558.s16|36-44|increased|O
DDI-DrugBank.d558.s16|49-51|190|O
DDI-DrugBank.d558.s16|52-52|%|O
DDI-DrugBank.d558.s16|55-57|QTc|O
DDI-DrugBank.d558.s16|36-43|increase|O
DDI-DrugBank.d558.s16|73-76|time|O
DDI-DrugBank.d558.s16|86-87|84|O
DDI-DrugBank.d558.s16|52-52|%|O
DDI-DrugBank.d558.s16|91-97|Maximum|O
DDI-DrugBank.d558.s16|55-57|QTc|O
DDI-DrugBank.d558.s16|36-43|increase|O
DDI-DrugBank.d558.s16|112-112|.|O
DDI-DrugBank.d558.s17|0-2|The|O
DDI-DrugBank.d558.s17|4-18|pharmacodynamic|O
DDI-DrugBank.d558.s17|20-26|effects|O
DDI-DrugBank.d558.s17|35-43|explained|O
DDI-DrugBank.d558.s17|50-60|combination|O
DDI-DrugBank.d558.s17|69-76|increase|O
DDI-DrugBank.d558.s17|81-90|dofetilide|O
DDI-DrugBank.d558.s17|92-99|exposure|O
DDI-DrugBank.d558.s17|109-118|reductions|O
DDI-DrugBank.d558.s17|123-127|serum|O
DDI-DrugBank.d558.s17|129-137|potassium|O
DDI-DrugBank.d558.s17|138-138|.|O
DDI-DrugBank.d558.s18|0-1|In|O
DDI-DrugBank.d558.s18|7-13|DIAMOND|O
DDI-DrugBank.d558.s18|15-20|trials|O
DDI-DrugBank.d558.s18|23-26|1252|O
DDI-DrugBank.d558.s18|28-35|patients|O
DDI-DrugBank.d558.s18|42-48|treated|O
DDI-DrugBank.d558.s18|55-61|TIKOSYN|O
DDI-DrugBank.d558.s18|67-75|diuretics|O
DDI-DrugBank.d558.s18|77-89|concomitantly|O
DDI-DrugBank.d558.s18|99-101|493|O
DDI-DrugBank.d558.s18|103-106|died|O
DDI-DrugBank.d558.s18|108-115|compared|O
DDI-DrugBank.d558.s18|120-122|508|O
DDI-DrugBank.d558.s18|124-129|deaths|O
DDI-DrugBank.d558.s18|131-135|among|O
DDI-DrugBank.d558.s18|141-144|1248|O
DDI-DrugBank.d558.s18|28-35|patients|O
DDI-DrugBank.d558.s18|155-163|receiving|O
DDI-DrugBank.d558.s18|165-171|placebo|O
DDI-DrugBank.d558.s18|67-75|diuretics|O
DDI-DrugBank.d558.s18|186-186|.|O
DDI-DrugBank.d558.s19|0-1|Of|O
DDI-DrugBank.d558.s19|7-9|229|O
DDI-DrugBank.d558.s19|11-18|patients|O
DDI-DrugBank.d558.s19|28-36|potassium|O
DDI-DrugBank.d558.s19|38-46|depleting|O
DDI-DrugBank.d558.s19|48-56|diuretics|O
DDI-DrugBank.d558.s19|58-62|added|O
DDI-DrugBank.d558.s19|73-83|concomitant|O
DDI-DrugBank.d558.s19|85-95|medications|O
DDI-DrugBank.d558.s19|104-110|DIAMOND|O
DDI-DrugBank.d558.s19|112-117|trials|O
DDI-DrugBank.d558.s19|11-18|patients|O
DDI-DrugBank.d558.s19|136-142|TIKOSYN|O
DDI-DrugBank.d558.s19|150-166|non-significantly|O
DDI-DrugBank.d558.s19|168-174|reduced|O
DDI-DrugBank.d558.s19|176-183|relative|O
DDI-DrugBank.d558.s19|185-188|risk|O
DDI-DrugBank.d558.s19|194-198|death|O
DDI-DrugBank.d558.s19|203-206|0.68|O
DDI-DrugBank.d558.s19|209-210|95|O
DDI-DrugBank.d558.s19|211-211|%|O
DDI-DrugBank.d558.s19|213-214|CI|O
DDI-DrugBank.d558.s19|216-220|0.376|O
DDI-DrugBank.d558.s19|223-227|1.230|O
DDI-DrugBank.d558.s20|0-8|Potential|O
DDI-DrugBank.d558.s20|10-13|Drug|O
DDI-DrugBank.d558.s20|15-26|Interactions|O
DDI-DrugBank.d558.s20|28-37|Dofetilide|O
DDI-DrugBank.d558.s20|42-51|eliminated|O
DDI-DrugBank.d558.s20|60-65|kidney|O
DDI-DrugBank.d558.s20|70-77|cationic|O
DDI-DrugBank.d558.s20|79-87|secretion|O
DDI-DrugBank.d558.s20|88-88|.|O
DDI-DrugBank.d558.s21|0-9|Inhibitors|O
DDI-DrugBank.d558.s21|14-18|renal|O
DDI-DrugBank.d558.s21|20-27|cationic|O
DDI-DrugBank.d558.s21|29-37|secretion|O
DDI-DrugBank.d558.s21|43-57|contraindicated|O
DDI-DrugBank.d558.s21|64-70|TIKOSYN|O
DDI-DrugBank.d558.s21|71-71|.|O
DDI-DrugBank.d558.s22|0-1|In|O
DDI-DrugBank.d558.s22|3-10|addition|O
DDI-DrugBank.d558.s22|13-17|drugs|O
DDI-DrugBank.d558.s22|28-35|actively|O
DDI-DrugBank.d558.s22|37-44|secreted|O
DDI-DrugBank.d558.s22|46-48|via|O
DDI-DrugBank.d558.s22|55-59|route|O
DDI-DrugBank.d558.s22|62-65|e.g.|O
DDI-DrugBank.d558.s22|68-78|triamterene|O
DDI-DrugBank.d558.s22|81-89|metformin|O
DDI-DrugBank.d558.s22|95-103|amiloride|O
DDI-DrugBank.d558.s22|116-130|co-administered|O
DDI-DrugBank.d558.s22|137-140|care|O
DDI-DrugBank.d558.s22|150-154|might|O
DDI-DrugBank.d558.s22|156-163|increase|O
DDI-DrugBank.d558.s22|165-174|dofetilide|O
DDI-DrugBank.d558.s22|176-181|levels|O
DDI-DrugBank.d558.s22|63-63|.|O
DDI-DrugBank.d558.s23|0-9|Dofetilide|O
DDI-DrugBank.d558.s23|14-24|metabolized|O
DDI-DrugBank.d558.s23|31-35|small|O
DDI-DrugBank.d558.s23|37-42|extent|O
DDI-DrugBank.d558.s23|51-56|CYP3A4|O
DDI-DrugBank.d558.s23|58-66|isoenzyme|O
DDI-DrugBank.d558.s23|75-84|cytochrome|O
DDI-DrugBank.d558.s23|86-89|P450|O
DDI-DrugBank.d558.s23|91-96|system|O
DDI-DrugBank.d558.s23|97-97|.|O
DDI-DrugBank.d558.s24|0-9|Inhibitors|O
DDI-DrugBank.d558.s24|18-23|CYP3A4|O
DDI-DrugBank.d558.s24|25-33|isoenzyme|O
DDI-DrugBank.d558.s24|35-39|could|O
DDI-DrugBank.d558.s24|41-48|increase|O
DDI-DrugBank.d558.s24|50-57|systemic|O
DDI-DrugBank.d558.s24|59-68|dofetilide|O
DDI-DrugBank.d558.s24|70-77|exposure|O
DDI-DrugBank.d558.s24|78-78|.|O
DDI-DrugBank.d558.s25|0-9|Inhibitors|O
DDI-DrugBank.d558.s25|19-27|isoenzyme|O
DDI-DrugBank.d558.s25|30-33|e.g.|O
DDI-DrugBank.d558.s25|36-44|macrolide|O
DDI-DrugBank.d558.s25|46-56|antibiotics|O
DDI-DrugBank.d558.s25|59-63|azole|O
DDI-DrugBank.d558.s25|65-74|antifungal|O
DDI-DrugBank.d558.s25|76-81|agents|O
DDI-DrugBank.d558.s25|84-91|protease|O
DDI-DrugBank.d558.s25|93-102|inhibitors|O
DDI-DrugBank.d558.s25|105-113|serotonin|O
DDI-DrugBank.d558.s25|115-122|reuptake|O
DDI-DrugBank.d558.s25|93-102|inhibitors|O
DDI-DrugBank.d558.s25|136-145|amiodarone|O
DDI-DrugBank.d558.s25|148-159|cannabinoids|O
DDI-DrugBank.d558.s25|162-170|diltiazem|O
DDI-DrugBank.d558.s25|173-182|grapefruit|O
DDI-DrugBank.d558.s25|184-188|juice|O
DDI-DrugBank.d558.s25|191-200|nefazadone|O
DDI-DrugBank.d558.s25|203-213|norfloxacin|O
DDI-DrugBank.d558.s25|216-222|quinine|O
DDI-DrugBank.d558.s25|225-235|zafirlukast|O
DDI-DrugBank.d558.s25|248-257|cautiously|O
DDI-DrugBank.d558.s25|259-272|coadministered|O
DDI-DrugBank.d558.s25|279-285|TIKOSYN|O
DDI-DrugBank.d558.s25|299-309|potentially|O
DDI-DrugBank.d558.s25|311-318|increase|O
DDI-DrugBank.d558.s25|320-329|dofetilide|O
DDI-DrugBank.d558.s25|331-336|levels|O
DDI-DrugBank.d558.s25|31-31|.|O
DDI-DrugBank.d558.s26|0-9|Dofetilide|O
DDI-DrugBank.d558.s26|21-29|inhibitor|O
DDI-DrugBank.d558.s26|34-39|CYP3A4|O
DDI-DrugBank.d558.s26|54-63|cytochrome|O
DDI-DrugBank.d558.s26|65-68|P450|O
DDI-DrugBank.d558.s26|70-79|isoenzymes|O
DDI-DrugBank.d558.s26|82-85|e.g.|O
DDI-DrugBank.d558.s26|88-93|CYP2C9|O
DDI-DrugBank.d558.s26|96-101|CYP2D6|O
DDI-DrugBank.d558.s26|115-122|expected|O
DDI-DrugBank.d558.s26|127-134|increase|O
DDI-DrugBank.d558.s26|136-141|levels|O
DDI-DrugBank.d558.s26|146-150|drugs|O
DDI-DrugBank.d558.s26|152-162|metabolized|O
DDI-DrugBank.d558.s26|34-39|CYP3A4|O
DDI-DrugBank.d558.s26|83-83|.|O
DDI-DrugBank.d558.s27|0-4|Other|O
DDI-DrugBank.d558.s27|6-9|Drug|O
DDI-DrugBank.d558.s27|11-21|Interaction|O
DDI-DrugBank.d558.s27|23-33|Information|O
DDI-DrugBank.d558.s27|35-41|Digoxin|O
DDI-DrugBank.d558.s27|44-50|Studies|O
DDI-DrugBank.d558.s27|55-61|healthy|O
DDI-DrugBank.d558.s27|63-72|volunteers|O
DDI-DrugBank.d558.s27|79-83|shown|O
DDI-DrugBank.d558.s27|90-96|TIKOSYN|O
DDI-DrugBank.d558.s27|107-112|affect|O
DDI-DrugBank.d558.s27|118-133|pharmacokinetics|O
DDI-DrugBank.d558.s27|138-144|digoxin|O
DDI-DrugBank.d558.s27|145-145|.|O
DDI-DrugBank.d558.s28|0-1|In|O
DDI-DrugBank.d558.s28|3-10|patients|O
DDI-DrugBank.d558.s28|17-27|concomitant|O
DDI-DrugBank.d558.s28|29-42|administration|O
DDI-DrugBank.d558.s28|47-53|digoxin|O
DDI-DrugBank.d558.s28|60-69|dofetilide|O
DDI-DrugBank.d558.s28|75-84|associated|O
DDI-DrugBank.d558.s28|93-98|higher|O
DDI-DrugBank.d558.s28|100-109|occurrence|O
DDI-DrugBank.d558.s28|114-120|torsade|O
DDI-DrugBank.d558.s28|68-69|de|O
DDI-DrugBank.d558.s28|125-131|pointes|O
DDI-DrugBank.d558.s28|132-132|.|O
DDI-DrugBank.d558.s29|0-1|It|O
DDI-DrugBank.d558.s29|10-14|clear|O
DDI-DrugBank.d558.s29|16-22|whether|O
DDI-DrugBank.d558.s29|29-38|represents|O
DDI-DrugBank.d558.s29|43-53|interaction|O
DDI-DrugBank.d558.s29|60-66|TIKOSYN|O
DDI-DrugBank.d558.s29|75-82|presence|O
DDI-DrugBank.d558.s29|92-97|severe|O
DDI-DrugBank.d558.s29|99-108|structural|O
DDI-DrugBank.d558.s29|110-114|heart|O
DDI-DrugBank.d558.s29|116-122|disease|O
DDI-DrugBank.d558.s29|127-134|patients|O
DDI-DrugBank.d558.s29|139-145|digoxin|O
DDI-DrugBank.d558.s30|0-9|structural|O
DDI-DrugBank.d558.s30|11-15|heart|O
DDI-DrugBank.d558.s30|17-23|disease|O
DDI-DrugBank.d558.s30|30-34|known|O
DDI-DrugBank.d558.s30|36-39|risk|O
DDI-DrugBank.d558.s30|41-46|factor|O
DDI-DrugBank.d558.s30|52-61|arrhythmia|O
DDI-DrugBank.d558.s30|62-62|.|O
DDI-DrugBank.d558.s31|0-1|No|O
DDI-DrugBank.d558.s31|3-10|increase|O
DDI-DrugBank.d558.s31|15-23|mortality|O
DDI-DrugBank.d558.s31|29-36|observed|O
DDI-DrugBank.d558.s31|41-48|patients|O
DDI-DrugBank.d558.s31|50-55|taking|O
DDI-DrugBank.d558.s31|57-63|digoxin|O
DDI-DrugBank.d558.s31|68-78|concomitant|O
DDI-DrugBank.d558.s31|80-89|medication|O
DDI-DrugBank.d558.s31|90-90|.|O
DDI-DrugBank.d558.s32|0-4|Other|O
DDI-DrugBank.d558.s32|6-10|Drugs|O
DDI-DrugBank.d558.s32|13-14|In|O
DDI-DrugBank.d558.s32|16-22|healthy|O
DDI-DrugBank.d558.s32|24-33|volunteers|O
DDI-DrugBank.d558.s32|36-45|amlodipine|O
DDI-DrugBank.d558.s32|48-56|phenytoin|O
DDI-DrugBank.d558.s32|59-67|glyburide|O
DDI-DrugBank.d558.s32|70-79|ranitidine|O
DDI-DrugBank.d558.s32|82-91|omeprazole|O
DDI-DrugBank.d558.s32|94-100|hormone|O
DDI-DrugBank.d558.s32|102-112|replacement|O
DDI-DrugBank.d558.s32|114-120|therapy|O
DDI-DrugBank.d558.s32|125-135|combination|O
DDI-DrugBank.d558.s32|140-149|conjugated|O
DDI-DrugBank.d558.s32|151-159|estrogens|O
DDI-DrugBank.d558.s32|165-183|medroxyprogesterone|O
DDI-DrugBank.d558.s32|187-193|antacid|O
DDI-DrugBank.d558.s32|196-203|aluminum|O
DDI-DrugBank.d558.s32|209-217|magnesium|O
DDI-DrugBank.d558.s32|219-228|hydroxides|O
DDI-DrugBank.d558.s32|235-246|theophylline|O
DDI-DrugBank.d558.s32|256-261|affect|O
DDI-DrugBank.d558.s32|267-282|pharmacokinetics|O
DDI-DrugBank.d558.s32|287-293|TIKOSYN|O
DDI-DrugBank.d558.s33|0-1|In|O
DDI-DrugBank.d558.s33|3-10|addition|O
DDI-DrugBank.d558.s33|13-19|studies|O
DDI-DrugBank.d558.s33|24-30|healthy|O
DDI-DrugBank.d558.s33|32-41|volunteers|O
DDI-DrugBank.d558.s33|48-52|shown|O
DDI-DrugBank.d558.s33|59-65|TIKOSYN|O
DDI-DrugBank.d558.s33|76-81|affect|O
DDI-DrugBank.d558.s33|87-102|pharmacokinetics|O
DDI-DrugBank.d558.s33|107-122|pharmacodynamics|O
DDI-DrugBank.d558.s33|127-134|warfarin|O
DDI-DrugBank.d558.s33|87-102|pharmacokinetics|O
DDI-DrugBank.d558.s33|164-174|propranolol|O
DDI-DrugBank.d558.s33|177-178|40|O
DDI-DrugBank.d558.s33|180-181|mg|O
DDI-DrugBank.d558.s33|183-187|twice|O
DDI-DrugBank.d558.s33|189-193|daily|O
DDI-DrugBank.d558.s33|197-205|phenytoin|O
DDI-DrugBank.d558.s33|208-219|theophylline|O
DDI-DrugBank.d558.s33|225-228|oral|O
DDI-DrugBank.d558.s33|230-243|contraceptives|O
DDI-DrugBank.d558.s33|244-244|.|O
DDI-DrugBank.d558.s34|0-9|Population|O
DDI-DrugBank.d558.s34|11-25|pharmacokinetic|O
DDI-DrugBank.d558.s34|27-34|analyses|O
DDI-DrugBank.d558.s34|41-49|conducted|O
DDI-DrugBank.d558.s34|54-59|plasma|O
DDI-DrugBank.d558.s34|61-73|concentration|O
DDI-DrugBank.d558.s34|75-78|data|O
DDI-DrugBank.d558.s34|85-88|1445|O
DDI-DrugBank.d558.s34|90-97|patients|O
DDI-DrugBank.d558.s34|102-109|clinical|O
DDI-DrugBank.d558.s34|111-116|trials|O
DDI-DrugBank.d558.s34|121-127|examine|O
DDI-DrugBank.d558.s34|133-139|effects|O
DDI-DrugBank.d558.s34|144-154|concomitant|O
DDI-DrugBank.d558.s34|156-166|medications|O
DDI-DrugBank.d558.s34|171-179|clearance|O
DDI-DrugBank.d558.s34|184-189|volume|O
DDI-DrugBank.d558.s34|194-205|distribution|O
DDI-DrugBank.d558.s34|210-219|dofetilide|O
DDI-DrugBank.d558.s34|220-220|.|O
DDI-DrugBank.d558.s35|0-10|Concomitant|O
DDI-DrugBank.d558.s35|12-22|medications|O
DDI-DrugBank.d558.s35|29-35|grouped|O
DDI-DrugBank.d558.s35|40-42|ACE|O
DDI-DrugBank.d558.s35|44-53|inhibitors|O
DDI-DrugBank.d558.s35|56-59|oral|O
DDI-DrugBank.d558.s35|61-74|anticoagulants|O
DDI-DrugBank.d558.s35|77-83|calcium|O
DDI-DrugBank.d558.s35|85-91|channel|O
DDI-DrugBank.d558.s35|93-100|blockers|O
DDI-DrugBank.d558.s35|103-106|beta|O
DDI-DrugBank.d558.s35|93-100|blockers|O
DDI-DrugBank.d558.s35|118-124|cardiac|O
DDI-DrugBank.d558.s35|126-135|glycosides|O
DDI-DrugBank.d558.s35|138-145|inducers|O
DDI-DrugBank.d558.s35|150-155|CYP3A4|O
DDI-DrugBank.d558.s35|158-167|substrates|O
DDI-DrugBank.d558.s35|44-53|inhibitors|O
DDI-DrugBank.d558.s35|150-155|CYP3A4|O
DDI-DrugBank.d558.s35|158-167|substrates|O
DDI-DrugBank.d558.s35|44-53|inhibitors|O
DDI-DrugBank.d558.s35|224-237|P-glycoprotein|O
DDI-DrugBank.d558.s35|240-247|nitrates|O
DDI-DrugBank.d558.s35|250-263|sulphonylureas|O
DDI-DrugBank.d558.s35|266-269|loop|O
DDI-DrugBank.d558.s35|271-279|diuretics|O
DDI-DrugBank.d558.s35|282-290|potassium|O
DDI-DrugBank.d558.s35|292-298|sparing|O
DDI-DrugBank.d558.s35|271-279|diuretics|O
DDI-DrugBank.d558.s35|311-318|thiazide|O
DDI-DrugBank.d558.s35|271-279|diuretics|O
DDI-DrugBank.d558.s35|158-167|substrates|O
DDI-DrugBank.d558.s35|44-53|inhibitors|O
DDI-DrugBank.d558.s35|360-366|tubular|O
DDI-DrugBank.d558.s35|368-374|organic|O
DDI-DrugBank.d558.s35|16-21|cation|O
DDI-DrugBank.d558.s35|383-391|transport|O
DDI-DrugBank.d558.s35|398-411|QTc-prolonging|O
DDI-DrugBank.d558.s35|413-417|drugs|O
DDI-DrugBank.d558.s35|418-418|.|O
DDI-DrugBank.d558.s36|0-10|Differences|O
DDI-DrugBank.d558.s36|15-23|clearance|O
DDI-DrugBank.d558.s36|33-40|patients|O
DDI-DrugBank.d558.s36|51-61|medications|O
DDI-DrugBank.d558.s36|71-78|occasion|O
DDI-DrugBank.d558.s36|87-91|study|O
DDI-DrugBank.d558.s36|51-61|medications|O
DDI-DrugBank.d558.s36|120-125|varied|O
DDI-DrugBank.d558.s36|135-137|-16|O
DDI-DrugBank.d558.s36|138-138|%|O
DDI-DrugBank.d558.s36|144-145|+3|O
DDI-DrugBank.d558.s36|138-138|%|O
DDI-DrugBank.d558.s36|147-147|.|O
DDI-DrugBank.d558.s37|0-2|The|O
DDI-DrugBank.d558.s37|4-7|mean|O
DDI-DrugBank.d558.s37|9-18|clearances|O
DDI-DrugBank.d558.s37|23-32|dofetilide|O
DDI-DrugBank.d558.s37|39-40|16|O
DDI-DrugBank.d558.s37|41-41|%|O
DDI-DrugBank.d558.s37|47-48|15|O
DDI-DrugBank.d558.s37|41-41|%|O
DDI-DrugBank.d558.s37|51-55|lower|O
DDI-DrugBank.d558.s37|60-67|patients|O
DDI-DrugBank.d558.s37|72-79|thiazide|O
DDI-DrugBank.d558.s37|81-89|diuretics|O
DDI-DrugBank.d558.s37|95-104|inhibitors|O
DDI-DrugBank.d558.s37|109-115|tubular|O
DDI-DrugBank.d558.s37|117-123|organic|O
DDI-DrugBank.d558.s37|125-130|cation|O
DDI-DrugBank.d558.s37|132-140|transport|O
DDI-DrugBank.d558.s37|143-154|respectively|O
DDI-DrugBank.d558.s37|155-155|.|O
DDI-MedLine.d79.s0|0-1|If|O
DDI-MedLine.d79.s0|3-7|taken|O
DDI-MedLine.d79.s0|9-9|1|O
DDI-MedLine.d79.s0|11-14|hour|O
DDI-MedLine.d79.s0|23-31|indinavir|O
DDI-MedLine.d79.s0|34-36|IDV|O
DDI-MedLine.d79.s0|40-49|didanosine|O
DDI-MedLine.d79.s0|60-65|affect|O
DDI-MedLine.d79.s0|34-36|IDV|O
DDI-MedLine.d79.s0|71-78|exposure|O
DDI-MedLine.d79.s0|81-87|despite|O
DDI-MedLine.d79.s0|89-98|persistent|O
DDI-MedLine.d79.s0|100-108|buffering|O
DDI-MedLine.d79.s0|110-116|effects|O
DDI-MedLine.d79.s1|0-9|Concurrent|O
DDI-MedLine.d79.s1|11-24|administration|O
DDI-MedLine.d79.s1|29-37|indinavir|O
DDI-MedLine.d79.s1|43-52|didanosine|O
DDI-MedLine.d79.s1|54-66|significantly|O
DDI-MedLine.d79.s1|68-74|reduces|O
DDI-MedLine.d79.s1|80-84|level|O
DDI-MedLine.d79.s1|89-96|exposure|O
DDI-MedLine.d79.s1|29-37|indinavir|O
DDI-MedLine.d79.s1|122-128|unclear|O
DDI-MedLine.d79.s1|134-137|soon|O
DDI-MedLine.d79.s1|43-52|didanosine|O
DDI-MedLine.d79.s1|11-24|administration|O
DDI-MedLine.d79.s1|29-37|indinavir|O
DDI-MedLine.d79.s1|181-183|may|O
DDI-MedLine.d79.s1|188-192|given|O
DDI-MedLine.d79.s1|194-199|safely|O
DDI-MedLine.d79.s1|200-200|.|O
DDI-MedLine.d79.s2|0-1|We|O
DDI-MedLine.d79.s2|3-10|compared|O
DDI-MedLine.d79.s2|12-20|indinavir|O
DDI-MedLine.d79.s2|22-37|pharmacokinetics|O
DDI-MedLine.d79.s2|43-49|gastric|O
DDI-MedLine.d79.s2|51-52|pH|O
DDI-MedLine.d79.s2|57-58|12|O
DDI-MedLine.d79.s2|60-64|human|O
DDI-MedLine.d79.s2|66-81|immunodeficiency|O
DDI-MedLine.d79.s2|83-96|virus-positive|O
DDI-MedLine.d79.s2|98-105|patients|O
DDI-MedLine.d79.s2|110-112|use|O
DDI-MedLine.d79.s2|117-119|800|O
DDI-MedLine.d79.s2|121-122|mg|O
DDI-MedLine.d79.s2|12-20|indinavir|O
DDI-MedLine.d79.s2|137-141|alone|O
DDI-MedLine.d79.s2|143-148|versus|O
DDI-MedLine.d79.s2|117-119|800|O
DDI-MedLine.d79.s2|121-122|mg|O
DDI-MedLine.d79.s2|12-20|indinavir|O
DDI-MedLine.d79.s2|170-181|administered|O
DDI-MedLine.d79.s2|57-57|1|O
DDI-MedLine.d79.s2|23-23|h|O
DDI-MedLine.d79.s2|193-202|didanosine|O
DDI-MedLine.d79.s2|204-217|administration|O
DDI-MedLine.d79.s2|218-218|.|O
DDI-MedLine.d79.s3|0-5|Median|O
DDI-MedLine.d79.s3|7-13|gastric|O
DDI-MedLine.d79.s3|15-16|pH|O
DDI-MedLine.d79.s3|22-34|significantly|O
DDI-MedLine.d79.s3|36-41|higher|O
DDI-MedLine.d79.s3|48-56|indinavir|O
DDI-MedLine.d79.s3|62-66|taken|O
DDI-MedLine.d79.s3|74-83|didanosine|O
DDI-MedLine.d79.s3|85-98|administration|O
DDI-MedLine.d79.s4|0-6|however|O
DDI-MedLine.d79.s4|12-22|significant|O
DDI-MedLine.d79.s4|24-33|difference|O
DDI-MedLine.d79.s4|42-48|maximum|O
DDI-MedLine.d79.s4|50-62|concentration|O
DDI-MedLine.d79.s4|67-72|plasma|O
DDI-MedLine.d79.s4|81-84|area|O
DDI-MedLine.d79.s4|96-113|concentration-time|O
DDI-MedLine.d79.s4|115-119|curve|O
DDI-MedLine.d79.s4|110-113|time|O
DDI-MedLine.d79.s4|131-134|zero|O
DDI-MedLine.d79.s4|139-139|8|O
DDI-MedLine.d79.s4|0-0|h|O
DDI-MedLine.d79.s4|147-154|observed|O
DDI-MedLine.d79.s4|155-155|.|O
DDI-MedLine.d79.s5|0-8|Indinavir|O
DDI-MedLine.d79.s5|10-12|may|O
DDI-MedLine.d79.s5|17-21|taken|O
DDI-MedLine.d79.s5|30-34|light|O
DDI-MedLine.d79.s5|36-39|meal|O
DDI-MedLine.d79.s5|41-41|1|O
DDI-MedLine.d79.s5|26-26|h|O
DDI-MedLine.d79.s5|45-53|following|O
DDI-MedLine.d79.s5|59-72|administration|O
DDI-MedLine.d79.s5|77-79|400|O
DDI-MedLine.d79.s5|81-82|mg|O
DDI-MedLine.d79.s5|87-96|didanosine|O
DDI-MedLine.d79.s5|97-97|.|O
DDI-DrugBank.d747.s0|0-11|Tetracycline|O
DDI-DrugBank.d747.s0|16-29|bacteriostatic|O
DDI-DrugBank.d747.s0|31-40|antibiotic|O
DDI-DrugBank.d747.s0|43-45|may|O
DDI-DrugBank.d747.s0|47-56|antagonize|O
DDI-DrugBank.d747.s0|62-73|bactericidal|O
DDI-DrugBank.d747.s0|75-80|effect|O
DDI-DrugBank.d747.s0|85-94|penicillin|O
DDI-DrugBank.d747.s0|100-109|concurrent|O
DDI-DrugBank.d747.s0|111-113|use|O
DDI-DrugBank.d747.s0|124-128|drugs|O
DDI-DrugBank.d747.s0|140-146|avoided|O
DDI-DrugBank.d747.s0|147-147|.|O
DDI-DrugBank.d443.s0|0-9|Uricosuric|O
DDI-DrugBank.d443.s0|11-16|Agents|O
DDI-DrugBank.d443.s0|19-25|Aspirin|O
DDI-DrugBank.d443.s0|27-29|may|O
DDI-DrugBank.d443.s0|31-38|decrease|O
DDI-DrugBank.d443.s0|44-50|effects|O
DDI-DrugBank.d443.s0|55-64|probenecid|O
DDI-DrugBank.d443.s0|67-80|sulfinpyrazone|O
DDI-DrugBank.d443.s0|87-100|phenylbutazone|O
DDI-DrugBank.d443.s0|101-101|.|O
DDI-DrugBank.d443.s1|0-6|Alcohol|O
DDI-DrugBank.d443.s1|9-11|Has|O
DDI-DrugBank.d443.s1|15-25|synergistic|O
DDI-DrugBank.d443.s1|27-32|effect|O
DDI-DrugBank.d443.s1|39-45|aspirin|O
DDI-DrugBank.d443.s1|50-56|causing|O
DDI-DrugBank.d443.s1|58-73|gastrointestinal|O
DDI-DrugBank.d443.s1|75-82|bleeding|O
DDI-DrugBank.d443.s1|83-83|.|O
DDI-DrugBank.d443.s2|0-14|Corticosteroids|O
DDI-DrugBank.d443.s2|17-27|Concomitant|O
DDI-DrugBank.d443.s2|29-42|administration|O
DDI-DrugBank.d443.s2|49-55|aspirin|O
DDI-DrugBank.d443.s2|57-59|may|O
DDI-DrugBank.d443.s2|61-68|increase|O
DDI-DrugBank.d443.s2|74-77|risk|O
DDI-DrugBank.d443.s2|82-97|gastrointestinal|O
DDI-DrugBank.d443.s2|99-108|ulceration|O
DDI-DrugBank.d443.s2|57-59|may|O
DDI-DrugBank.d443.s2|118-123|reduce|O
DDI-DrugBank.d443.s2|125-129|serum|O
DDI-DrugBank.d443.s2|131-140|salicylate|O
DDI-DrugBank.d443.s2|142-147|levels|O
DDI-DrugBank.d443.s2|148-148|.|O
DDI-DrugBank.d443.s3|0-9|Pyrazolone|O
DDI-DrugBank.d443.s3|11-21|Derivatives|O
DDI-DrugBank.d443.s3|24-37|phenylbutazone|O
DDI-DrugBank.d443.s3|40-54|oxyphenbutazone|O
DDI-DrugBank.d443.s3|61-68|possibly|O
DDI-DrugBank.d443.s3|70-77|dipyrone|O
DDI-DrugBank.d443.s3|81-91|Concomitant|O
DDI-DrugBank.d443.s3|93-106|administration|O
DDI-DrugBank.d443.s3|113-119|aspirin|O
DDI-DrugBank.d443.s3|121-123|may|O
DDI-DrugBank.d443.s3|125-132|increase|O
DDI-DrugBank.d443.s3|138-141|risk|O
DDI-DrugBank.d443.s3|146-161|gastrointestinal|O
DDI-DrugBank.d443.s3|163-172|ulceration|O
DDI-DrugBank.d443.s3|173-173|.|O
DDI-DrugBank.d443.s4|0-11|Nonsteroidal|O
DDI-DrugBank.d443.s4|13-28|Antiinflammatory|O
DDI-DrugBank.d443.s4|30-35|Agents|O
DDI-DrugBank.d443.s4|38-44|Aspirin|O
DDI-DrugBank.d443.s4|49-63|contraindicated|O
DDI-DrugBank.d443.s4|68-75|patients|O
DDI-DrugBank.d443.s4|85-98|hypersensitive|O
DDI-DrugBank.d443.s4|103-114|nonsteroidal|O
DDI-DrugBank.d443.s4|116-132|anti-inflammatory|O
DDI-DrugBank.d443.s4|134-139|agents|O
DDI-DrugBank.d443.s4|140-140|.|O
DDI-DrugBank.d443.s5|0-6|Urinary|O
DDI-DrugBank.d443.s5|8-19|Alkalinizers|O
DDI-DrugBank.d443.s5|22-29|Decrease|O
DDI-DrugBank.d443.s5|31-37|aspirin|O
DDI-DrugBank.d443.s5|39-51|effectiveness|O
DDI-DrugBank.d443.s5|56-65|increasing|O
DDI-DrugBank.d443.s5|71-74|rate|O
DDI-DrugBank.d443.s5|79-88|salicylate|O
DDI-DrugBank.d443.s5|90-94|renal|O
DDI-DrugBank.d443.s5|96-104|excretion|O
DDI-DrugBank.d443.s5|105-105|.|O
DDI-DrugBank.d443.s6|0-12|Phenobarbital|O
DDI-DrugBank.d443.s6|15-23|Decreases|O
DDI-DrugBank.d443.s6|25-31|aspirin|O
DDI-DrugBank.d443.s6|33-45|effectiveness|O
DDI-DrugBank.d443.s6|50-55|enzyme|O
DDI-DrugBank.d443.s6|57-65|induction|O
DDI-DrugBank.d443.s6|66-66|.|O
DDI-DrugBank.d443.s7|0-8|Phenytoin|O
DDI-DrugBank.d443.s7|11-15|Serum|O
DDI-DrugBank.d443.s7|17-25|phenytoin|O
DDI-DrugBank.d443.s7|27-32|levels|O
DDI-DrugBank.d443.s7|34-36|may|O
DDI-DrugBank.d443.s7|41-49|increased|O
DDI-DrugBank.d443.s7|54-60|aspirin|O
DDI-DrugBank.d443.s7|61-61|.|O
DDI-DrugBank.d443.s8|0-10|Propranolol|O
DDI-DrugBank.d443.s8|13-15|May|O
DDI-DrugBank.d443.s8|17-24|decrease|O
DDI-DrugBank.d443.s8|26-33|aspirins|O
DDI-DrugBank.d443.s8|35-51|anti-inflammatory|O
DDI-DrugBank.d443.s8|53-58|action|O
DDI-DrugBank.d443.s8|63-71|competing|O
DDI-DrugBank.d443.s8|86-94|receptors|O
DDI-DrugBank.d443.s8|95-95|.|O
DDI-DrugBank.d443.s9|0-7|Antacids|O
DDI-DrugBank.d443.s9|10-16|Enteric|O
DDI-DrugBank.d443.s9|18-23|Coated|O
DDI-DrugBank.d443.s9|25-31|Aspirin|O
DDI-DrugBank.d443.s9|47-51|given|O
DDI-DrugBank.d443.s9|53-64|concurrently|O
DDI-DrugBank.d443.s9|71-78|antacids|O
DDI-DrugBank.d443.s9|81-85|since|O
DDI-DrugBank.d443.s9|90-97|increase|O
DDI-DrugBank.d443.s9|106-107|pH|O
DDI-DrugBank.d443.s9|116-122|stomach|O
DDI-DrugBank.d443.s9|124-126|may|O
DDI-DrugBank.d443.s9|128-133|effect|O
DDI-DrugBank.d443.s9|139-145|enteric|O
DDI-DrugBank.d443.s9|147-153|coating|O
DDI-DrugBank.d443.s9|162-168|tablets|O
DDI-DrugBank.d443.s9|169-169|.|O
DDI-DrugBank.d161.s0|0-1|No|O
DDI-DrugBank.d161.s0|3-10|specific|O
DDI-DrugBank.d161.s0|12-15|drug|O
DDI-DrugBank.d161.s0|17-27|interaction|O
DDI-DrugBank.d161.s0|29-35|studies|O
DDI-DrugBank.d161.s0|47-55|conducted|O
DDI-DrugBank.d161.s0|56-56|.|O
DDI-DrugBank.d161.s1|0-2|For|O
DDI-DrugBank.d161.s1|4-14|information|O
DDI-DrugBank.d161.s1|23-38|pharmacokinetics|O
DDI-DrugBank.d161.s1|43-48|Gemzar|O
DDI-DrugBank.d161.s1|54-62|cisplatin|O
DDI-DrugBank.d161.s1|67-77|combination|O
DDI-DrugBank.d161.s1|80-82|see|O
DDI-DrugBank.d161.s1|84-87|Drug|O
DDI-DrugBank.d161.s1|89-100|Interactions|O
DDI-DrugBank.d161.s1|108-115|CLINICAL|O
DDI-DrugBank.d161.s1|117-128|PHARMACOLOGY|O
DDI-DrugBank.d161.s1|130-136|section|O
DDI-DrugBank.d161.s1|137-137|.|O
DDI-DrugBank.d758.s0|0-2|The|O
DDI-DrugBank.d758.s0|4-6|CNS|O
DDI-DrugBank.d758.s0|8-17|depressant|O
DDI-DrugBank.d758.s0|19-25|effects|O
DDI-DrugBank.d758.s0|30-38|oxycodone|O
DDI-DrugBank.d758.s0|40-52|hydrochloride|O
DDI-DrugBank.d758.s0|54-56|may|O
DDI-DrugBank.d758.s0|61-68|additive|O
DDI-DrugBank.d758.s0|4-6|CNS|O
DDI-DrugBank.d758.s0|93-103|depressants|O
DDI-DrugBank.d758.s0|104-105|..|O
DDI-DrugBank.d703.s0|0-10|Interaction|O
DDI-DrugBank.d703.s0|17-21|Other|O
DDI-DrugBank.d703.s0|23-29|Central|O
DDI-DrugBank.d703.s0|31-37|Nervous|O
DDI-DrugBank.d703.s0|39-44|System|O
DDI-DrugBank.d703.s0|46-56|Depressants|O
DDI-DrugBank.d703.s0|59-68|MEPERIDINE|O
DDI-DrugBank.d703.s0|70-75|SHOULD|O
DDI-DrugBank.d703.s0|77-78|BE|O
DDI-DrugBank.d703.s0|80-83|USED|O
DDI-DrugBank.d703.s0|85-88|WITH|O
DDI-DrugBank.d703.s0|90-94|GREAT|O
DDI-DrugBank.d703.s0|96-102|CAUTION|O
DDI-DrugBank.d703.s0|104-106|AND|O
DDI-DrugBank.d703.s0|66-67|IN|O
DDI-DrugBank.d703.s0|111-117|REDUCED|O
DDI-DrugBank.d703.s0|119-124|DOSAGE|O
DDI-DrugBank.d703.s0|66-67|IN|O
DDI-DrugBank.d703.s0|129-136|PATIENTS|O
DDI-DrugBank.d703.s0|138-140|WHO|O
DDI-DrugBank.d703.s0|142-144|ARE|O
DDI-DrugBank.d703.s0|146-157|CONCURRENTLY|O
DDI-DrugBank.d703.s0|159-167|RECEIVING|O
DDI-DrugBank.d703.s0|169-173|OTHER|O
DDI-DrugBank.d703.s0|175-182|NARCOTIC|O
DDI-DrugBank.d703.s0|184-193|ANALGESICS|O
DDI-DrugBank.d703.s0|196-202|GENERAL|O
DDI-DrugBank.d703.s0|204-214|ANESTHETICS|O
DDI-DrugBank.d703.s0|217-230|PHENOTHIAZINES|O
DDI-DrugBank.d703.s0|169-173|OTHER|O
DDI-DrugBank.d703.s0|239-251|TRANQUILIZERS|O
DDI-DrugBank.d703.s0|254-271|SEDATIVE-HYPNOTICS|O
DDI-DrugBank.d703.s0|274-282|INCLUDING|O
DDI-DrugBank.d703.s0|284-295|BARBITURATES|O
DDI-DrugBank.d703.s0|299-307|TRICYCLIC|O
DDI-DrugBank.d703.s0|309-323|ANTIDEPRESSANTS|O
DDI-DrugBank.d703.s0|104-106|AND|O
DDI-DrugBank.d703.s0|169-173|OTHER|O
DDI-DrugBank.d703.s0|335-337|CNS|O
DDI-DrugBank.d703.s0|313-323|DEPRESSANTS|O
DDI-DrugBank.d703.s0|274-282|INCLUDING|O
DDI-DrugBank.d703.s0|362-368|ALCOHOL|O
DDI-DrugBank.d703.s0|370-370|.|O
DDI-DrugBank.d703.s1|0-10|RESPIRATORY|O
DDI-DrugBank.d703.s1|12-21|DEPRESSION|O
DDI-DrugBank.d703.s1|24-34|HYPOTENSION|O
DDI-DrugBank.d703.s1|37-39|AND|O
DDI-DrugBank.d703.s1|41-48|PROFOUND|O
DDI-DrugBank.d703.s1|50-57|SEDATION|O
DDI-DrugBank.d703.s1|8-9|OR|O
DDI-DrugBank.d703.s1|62-65|COMA|O
DDI-DrugBank.d703.s1|67-69|MAY|O
DDI-DrugBank.d703.s1|71-76|RESULT|O
DDI-DrugBank.d703.s1|77-77|.|O
DDI-DrugBank.d361.s0|0-10|Combination|O
DDI-DrugBank.d361.s0|12-18|Therapy|O
DDI-DrugBank.d361.s0|21-23|Any|O
DDI-DrugBank.d361.s0|25-28|form|O
DDI-DrugBank.d361.s0|33-39|therapy|O
DDI-DrugBank.d361.s0|47-50|adds|O
DDI-DrugBank.d361.s0|59-64|stress|O
DDI-DrugBank.d361.s0|73-79|patient|O
DDI-DrugBank.d361.s0|82-91|interferes|O
DDI-DrugBank.d361.s0|98-106|nutrition|O
DDI-DrugBank.d361.s0|111-119|depresses|O
DDI-DrugBank.d361.s0|121-124|bone|O
DDI-DrugBank.d361.s0|126-131|marrow|O
DDI-DrugBank.d361.s0|133-140|function|O
DDI-DrugBank.d361.s0|147-154|increase|O
DDI-DrugBank.d361.s0|160-167|toxicity|O
DDI-DrugBank.d361.s0|172-182|Floxuridine|O
DDI-DrugBank.d361.s0|183-183|.|O
DDI-MedLine.d64.s0|0-14|Pharmacological|O
DDI-MedLine.d64.s0|16-24|treatment|O
DDI-MedLine.d64.s0|29-38|depression|O
DDI-MedLine.d64.s0|45-48|role|O
DDI-MedLine.d64.s0|53-62|paroxetine|O
DDI-MedLine.d64.s0|63-63|.|O
DDI-MedLine.d64.s1|0-9|Depression|O
DDI-MedLine.d64.s1|14-21|reaching|O
DDI-MedLine.d64.s1|23-30|epidemic|O
DDI-MedLine.d64.s1|32-42|proportions|O
DDI-MedLine.d64.s1|51-57|western|O
DDI-MedLine.d64.s1|59-63|world|O
DDI-MedLine.d64.s1|64-64|.|O
DDI-MedLine.d64.s2|0-3|With|O
DDI-MedLine.d64.s2|10-19|successive|O
DDI-MedLine.d64.s2|21-30|generation|O
DDI-MedLine.d64.s2|37-42|people|O
DDI-MedLine.d64.s2|48-55|becoming|O
DDI-MedLine.d64.s2|62-69|severely|O
DDI-MedLine.d64.s2|71-79|depressed|O
DDI-MedLine.d64.s2|86-92|younger|O
DDI-MedLine.d64.s2|94-96|age|O
DDI-MedLine.d64.s2|97-97|.|O
DDI-DrugBank.d469.s0|0-4|Drugs|O
DDI-DrugBank.d469.s0|12-14|may|O
DDI-DrugBank.d469.s0|16-22|enhance|O
DDI-DrugBank.d469.s0|28-40|neuromuscular|O
DDI-DrugBank.d469.s0|42-49|blocking|O
DDI-DrugBank.d469.s0|51-56|action|O
DDI-DrugBank.d469.s0|61-68|TRACRIUM|O
DDI-DrugBank.d469.s0|70-76|include|O
DDI-DrugBank.d469.s0|79-87|enflurane|O
DDI-DrugBank.d469.s1|0-9|isoflurane|O
DDI-DrugBank.d469.s2|0-8|halothane|O
DDI-DrugBank.d469.s3|0-6|certain|O
DDI-DrugBank.d469.s3|8-18|antibiotics|O
DDI-DrugBank.d469.s3|21-30|especially|O
DDI-DrugBank.d469.s3|36-50|aminoglycosides|O
DDI-DrugBank.d469.s3|56-65|polymyxins|O
DDI-DrugBank.d469.s4|0-6|lithium|O
DDI-DrugBank.d469.s5|0-8|magnesium|O
DDI-DrugBank.d469.s5|10-14|salts|O
DDI-DrugBank.d469.s6|0-11|procainamide|O
DDI-DrugBank.d469.s7|0-4|Drugs|O
DDI-DrugBank.d469.s7|12-14|may|O
DDI-DrugBank.d469.s7|16-22|enhance|O
DDI-DrugBank.d469.s7|28-40|neuromuscular|O
DDI-DrugBank.d469.s7|42-49|blocking|O
DDI-DrugBank.d469.s7|51-56|action|O
DDI-DrugBank.d469.s7|61-68|TRACRIUM|O
DDI-DrugBank.d469.s7|70-76|include|O
DDI-DrugBank.d469.s7|79-87|enflurane|O
DDI-DrugBank.d469.s7|89-98|isoflurane|O
DDI-DrugBank.d469.s7|100-108|halothane|O
DDI-DrugBank.d469.s7|110-116|certain|O
DDI-DrugBank.d469.s7|118-128|antibiotics|O
DDI-DrugBank.d469.s7|131-140|especially|O
DDI-DrugBank.d469.s7|146-160|aminoglycosides|O
DDI-DrugBank.d469.s7|166-175|polymyxins|O
DDI-DrugBank.d469.s7|177-183|lithium|O
DDI-DrugBank.d469.s7|185-193|magnesium|O
DDI-DrugBank.d469.s7|195-199|salts|O
DDI-DrugBank.d469.s7|201-212|procainamide|O
DDI-DrugBank.d469.s7|218-226|quinidine|O
DDI-DrugBank.d469.s7|227-227|.|O
DDI-DrugBank.d469.s8|0-1|If|O
DDI-DrugBank.d469.s8|9-14|muscle|O
DDI-DrugBank.d469.s8|16-24|relaxants|O
DDI-DrugBank.d469.s8|30-33|used|O
DDI-DrugBank.d469.s8|51-59|procedure|O
DDI-DrugBank.d469.s8|66-76|possibility|O
DDI-DrugBank.d469.s8|83-93|synergistic|O
DDI-DrugBank.d469.s8|98-107|antagonist|O
DDI-DrugBank.d469.s8|109-114|effect|O
DDI-DrugBank.d469.s8|126-135|considered|O
DDI-DrugBank.d469.s8|136-136|.|O
DDI-DrugBank.d469.s9|0-2|The|O
DDI-DrugBank.d469.s9|4-8|prior|O
DDI-DrugBank.d469.s9|10-23|administration|O
DDI-DrugBank.d469.s9|28-42|succinylcholine|O
DDI-DrugBank.d469.s9|53-59|enhance|O
DDI-DrugBank.d469.s9|65-72|duration|O
DDI-DrugBank.d469.s9|79-86|quickens|O
DDI-DrugBank.d469.s9|92-96|onset|O
DDI-DrugBank.d469.s9|102-104|may|O
DDI-DrugBank.d469.s9|106-113|increase|O
DDI-DrugBank.d469.s9|119-123|depth|O
DDI-DrugBank.d469.s9|129-141|neuromuscular|O
DDI-DrugBank.d469.s9|143-147|block|O
DDI-DrugBank.d469.s9|149-155|induced|O
DDI-DrugBank.d469.s9|160-167|TRACRIUM|O
DDI-DrugBank.d469.s9|168-168|.|O
DDI-DrugBank.d469.s10|0-7|TRACRIUM|O
DDI-DrugBank.d469.s10|23-34|administered|O
DDI-DrugBank.d469.s10|44-50|patient|O
DDI-DrugBank.d469.s10|56-64|recovered|O
DDI-DrugBank.d469.s10|71-93|succinylcholine-induced|O
DDI-DrugBank.d469.s10|95-107|neuromuscular|O
DDI-DrugBank.d469.s10|109-113|block|O
DDI-DrugBank.d469.s10|114-114|.|O
DDI-MedLine.d9.s0|0-15|Pharmacokinetics|O
DDI-MedLine.d9.s0|20-32|calcium-entry|O
DDI-MedLine.d9.s0|34-41|blockers|O
DDI-MedLine.d9.s0|42-42|.|O
DDI-MedLine.d9.s1|0-8|Effective|O
DDI-MedLine.d9.s1|10-12|use|O
DDI-MedLine.d9.s1|17-21|drugs|O
DDI-MedLine.d9.s1|26-32|therapy|O
DDI-MedLine.d9.s1|34-40|depends|O
DDI-MedLine.d9.s1|54-61|clinical|O
DDI-MedLine.d9.s1|63-68|acumen|O
DDI-MedLine.d9.s1|74-77|also|O
DDI-MedLine.d9.s1|86-97|availability|O
DDI-MedLine.d9.s1|102-109|relevant|O
DDI-MedLine.d9.s1|111-125|pharmacokinetic|O
DDI-MedLine.d9.s1|131-145|pharmacodynamic|O
DDI-MedLine.d9.s1|147-150|data|O
DDI-MedLine.d9.s1|151-151|.|O
DDI-MedLine.d9.s2|0-3|Such|O
DDI-MedLine.d9.s2|5-15|information|O
DDI-MedLine.d9.s2|17-23|assists|O
DDI-MedLine.d9.s2|28-38|development|O
DDI-MedLine.d9.s2|43-46|safe|O
DDI-MedLine.d9.s2|48-53|dosing|O
DDI-MedLine.d9.s2|55-62|regimens|O
DDI-MedLine.d9.s2|65-74|prediction|O
DDI-MedLine.d9.s2|79-86|abnormal|O
DDI-MedLine.d9.s2|88-95|handling|O
DDI-MedLine.d9.s2|100-104|drugs|O
DDI-MedLine.d9.s2|109-114|states|O
DDI-MedLine.d9.s2|119-125|disease|O
DDI-MedLine.d9.s2|131-138|disorder|O
DDI-MedLine.d9.s2|144-155|anticipation|O
DDI-MedLine.d9.s2|100-103|drug|O
DDI-MedLine.d9.s2|165-176|interactions|O
DDI-MedLine.d9.s2|177-177|.|O
DDI-MedLine.d9.s3|0-2|For|O
DDI-MedLine.d9.s3|8-20|calcium-entry|O
DDI-MedLine.d9.s3|22-29|blocking|O
DDI-MedLine.d9.s3|31-36|agents|O
DDI-MedLine.d9.s3|42-50|available|O
DDI-MedLine.d9.s3|59-64|United|O
DDI-MedLine.d9.s3|66-71|States|O
DDI-MedLine.d9.s3|74-82|verapamil|O
DDI-MedLine.d9.s3|85-94|nifedipine|O
DDI-MedLine.d9.s3|100-108|diltiazem|O
DDI-MedLine.d9.s3|118-121|data|O
DDI-MedLine.d9.s3|123-130|appeared|O
DDI-MedLine.d9.s3|132-135|well|O
DDI-MedLine.d9.s3|143-150|clinical|O
DDI-MedLine.d9.s3|152-159|patterns|O
DDI-MedLine.d9.s3|164-166|use|O
DDI-MedLine.d9.s3|168-174|evolved|O
DDI-MedLine.d9.s3|175-175|.|O
DDI-MedLine.d9.s4|0-10|Nonetheless|O
DDI-MedLine.d9.s4|19-27|relevance|O
DDI-MedLine.d9.s4|29-37|continues|O
DDI-MedLine.d9.s4|45-56|demonstrated|O
DDI-MedLine.d9.s4|65-74|dependence|O
DDI-MedLine.d9.s4|84-88|agent|O
DDI-MedLine.d9.s4|93-98|intact|O
DDI-MedLine.d9.s4|100-104|liver|O
DDI-MedLine.d9.s4|106-110|blood|O
DDI-MedLine.d9.s4|112-115|flow|O
DDI-MedLine.d9.s4|121-128|function|O
DDI-MedLine.d9.s4|134-139|normal|O
DDI-MedLine.d9.s4|141-145|rates|O
DDI-MedLine.d9.s4|150-160|elimination|O
DDI-MedLine.d9.s5|7-15|nonlinear|O
DDI-MedLine.d9.s5|17-23|kinetic|O
DDI-MedLine.d9.s5|25-39|characteristics|O
DDI-MedLine.d9.s5|45-53|verapamil|O
DDI-MedLine.d9.s5|59-67|diltiazem|O
DDI-MedLine.d9.s5|74-81|probably|O
DDI-MedLine.d9.s5|87-96|nifedipine|O
DDI-MedLine.d9.s5|102-105|well|O
DDI-MedLine.d9.s5|116-125|derivative|O
DDI-MedLine.d9.s5|127-138|implications|O
DDI-MedLine.d9.s5|144-152|decreased|O
DDI-MedLine.d9.s5|154-159|dosing|O
DDI-MedLine.d9.s5|161-169|frequency|O
DDI-MedLine.d9.s5|171-182|requirements|O
DDI-MedLine.d9.s6|7-18|observations|O
DDI-MedLine.d9.s6|24-32|appearing|O
DDI-MedLine.d9.s6|41-48|relation|O
DDI-MedLine.d9.s6|58-63|plasma|O
DDI-MedLine.d9.s6|65-68|drug|O
DDI-MedLine.d9.s6|70-75|levels|O
DDI-MedLine.d9.s6|65-68|drug|O
DDI-MedLine.d9.s6|86-92|effects|O
DDI-MedLine.d9.s6|100-110|therapeutic|O
DDI-MedLine.d9.s6|116-120|toxic|O
DDI-MedLine.d9.s6|121-121|.|O
DDI-MedLine.d9.s7|0-3|Such|O
DDI-MedLine.d9.s7|5-8|data|O
DDI-MedLine.d9.s7|14-22|discussed|O
DDI-MedLine.d9.s7|24-29|herein|O
DDI-MedLine.d9.s7|37-44|emphasis|O
DDI-MedLine.d9.s7|55-61|aspects|O
DDI-MedLine.d9.s7|68-73|impact|O
DDI-MedLine.d9.s7|82-89|clinical|O
DDI-MedLine.d9.s7|91-93|use|O
DDI-MedLine.d9.s7|102-114|calcium-entry|O
DDI-MedLine.d9.s7|116-126|antagonists|O
DDI-MedLine.d9.s7|127-127|.|O
DDI-DrugBank.d345.s0|0-4|Since|O
DDI-DrugBank.d345.s0|6-15|colestipol|O
DDI-DrugBank.d345.s0|17-29|hydrochloride|O
DDI-DrugBank.d345.s0|37-41|anion|O
DDI-DrugBank.d345.s0|43-50|exchange|O
DDI-DrugBank.d345.s0|52-56|resin|O
DDI-DrugBank.d345.s0|62-64|may|O
DDI-DrugBank.d345.s0|73-78|strong|O
DDI-DrugBank.d345.s0|80-87|affinity|O
DDI-DrugBank.d345.s0|93-98|anions|O
DDI-DrugBank.d345.s0|115-118|bile|O
DDI-DrugBank.d345.s0|120-124|acids|O
DDI-DrugBank.d345.s0|125-125|.|O
DDI-DrugBank.d345.s1|0-1|In|O
DDI-DrugBank.d345.s1|3-7|vitro|O
DDI-DrugBank.d345.s1|9-15|studies|O
DDI-DrugBank.d345.s1|22-30|indicated|O
DDI-DrugBank.d345.s1|37-46|colestipol|O
DDI-DrugBank.d345.s1|48-60|hydrochloride|O
DDI-DrugBank.d345.s1|62-66|binds|O
DDI-DrugBank.d345.s1|70-75|number|O
DDI-DrugBank.d345.s1|80-84|drugs|O
DDI-DrugBank.d345.s1|85-85|.|O
DDI-DrugBank.d345.s2|0-8|Therefore|O
DDI-DrugBank.d345.s2|11-18|COLESTlD|O
DDI-DrugBank.d345.s2|20-26|Tablets|O
DDI-DrugBank.d345.s2|28-30|may|O
DDI-DrugBank.d345.s2|32-36|delay|O
DDI-DrugBank.d345.s2|41-46|reduce|O
DDI-DrugBank.d345.s2|52-61|absorption|O
DDI-DrugBank.d345.s2|66-76|concomitant|O
DDI-DrugBank.d345.s2|78-81|oral|O
DDI-DrugBank.d345.s2|83-92|medication|O
DDI-DrugBank.d345.s2|93-93|.|O
DDI-DrugBank.d345.s3|0-2|The|O
DDI-DrugBank.d345.s3|4-11|interval|O
DDI-DrugBank.d345.s3|25-38|administration|O
DDI-DrugBank.d345.s3|43-50|COLESTID|O
DDI-DrugBank.d345.s3|52-58|Tablets|O
DDI-DrugBank.d345.s3|74-83|medication|O
DDI-DrugBank.d345.s3|98-101|long|O
DDI-DrugBank.d345.s3|106-113|possible|O
DDI-DrugBank.d345.s3|114-114|.|O
DDI-DrugBank.d345.s4|0-7|Patients|O
DDI-DrugBank.d345.s4|16-19|take|O
DDI-DrugBank.d345.s4|27-31|drugs|O
DDI-DrugBank.d345.s4|36-40|least|O
DDI-DrugBank.d345.s4|42-44|one|O
DDI-DrugBank.d345.s4|46-49|hour|O
DDI-DrugBank.d345.s4|61-64|four|O
DDI-DrugBank.d345.s4|66-70|hours|O
DDI-DrugBank.d345.s4|78-85|COLESTID|O
DDI-DrugBank.d345.s4|87-93|Tablets|O
DDI-DrugBank.d345.s4|98-102|avoid|O
DDI-DrugBank.d345.s4|104-111|impeding|O
DDI-DrugBank.d345.s4|119-128|absorption|O
DDI-DrugBank.d345.s4|129-129|.|O
DDI-DrugBank.d345.s5|0-7|Repeated|O
DDI-DrugBank.d345.s5|9-13|doses|O
DDI-DrugBank.d345.s5|18-27|colestipol|O
DDI-DrugBank.d345.s5|29-41|hydrochloride|O
DDI-DrugBank.d345.s5|43-47|given|O
DDI-DrugBank.d345.s5|49-53|prior|O
DDI-DrugBank.d345.s5|60-65|single|O
DDI-DrugBank.d345.s5|9-12|dose|O
DDI-DrugBank.d345.s5|75-85|propranolol|O
DDI-DrugBank.d345.s5|90-94|human|O
DDI-DrugBank.d345.s5|96-101|trials|O
DDI-DrugBank.d345.s5|113-120|reported|O
DDI-DrugBank.d345.s5|125-132|decrease|O
DDI-DrugBank.d345.s5|75-85|propranolol|O
DDI-DrugBank.d345.s5|146-155|absorption|O
DDI-DrugBank.d345.s5|156-156|.|O
DDI-DrugBank.d345.s6|0-6|However|O
DDI-DrugBank.d345.s6|14-22|follow-up|O
DDI-DrugBank.d345.s6|24-28|study|O
DDI-DrugBank.d345.s6|33-38|normal|O
DDI-DrugBank.d345.s6|40-47|subjects|O
DDI-DrugBank.d345.s6|50-60|single-dose|O
DDI-DrugBank.d345.s6|62-75|administration|O
DDI-DrugBank.d345.s6|80-89|colestipol|O
DDI-DrugBank.d345.s6|91-103|hydrochloride|O
DDI-DrugBank.d345.s6|109-119|propranolol|O
DDI-DrugBank.d345.s6|125-135|twice-a-day|O
DDI-DrugBank.d345.s6|62-75|administration|O
DDI-DrugBank.d345.s6|156-156|5|O
DDI-DrugBank.d345.s6|158-161|days|O
DDI-DrugBank.d345.s6|171-176|agents|O
DDI-DrugBank.d345.s6|186-191|affect|O
DDI-DrugBank.d345.s6|197-202|extent|O
DDI-DrugBank.d345.s6|109-119|propranolol|O
DDI-DrugBank.d345.s6|219-228|absorption|O
DDI-DrugBank.d345.s6|241-245|small|O
DDI-DrugBank.d345.s6|247-249|yet|O
DDI-DrugBank.d345.s6|251-263|statistically|O
DDI-DrugBank.d345.s6|265-275|significant|O
DDI-DrugBank.d345.s6|277-282|effect|O
DDI-DrugBank.d345.s6|291-294|rate|O
DDI-DrugBank.d345.s6|219-228|absorption|O
DDI-DrugBank.d345.s7|4-7|time|O
DDI-DrugBank.d345.s7|12-16|reach|O
DDI-DrugBank.d345.s7|18-24|maximum|O
DDI-DrugBank.d345.s7|26-38|concentration|O
DDI-DrugBank.d345.s7|44-50|delayed|O
DDI-DrugBank.d345.s7|52-64|approximately|O
DDI-DrugBank.d345.s7|66-67|30|O
DDI-DrugBank.d345.s7|69-75|minutes|O
DDI-DrugBank.d345.s7|76-76|.|O
DDI-DrugBank.d345.s8|0-6|Effects|O
DDI-DrugBank.d345.s8|15-24|absorption|O
DDI-DrugBank.d345.s8|35-47|beta-blockers|O
DDI-DrugBank.d345.s8|63-72|determined|O
DDI-DrugBank.d345.s8|73-73|.|O
DDI-DrugBank.d345.s9|0-8|Therefore|O
DDI-DrugBank.d345.s9|11-18|patients|O
DDI-DrugBank.d345.s9|23-33|propranolol|O
DDI-DrugBank.d345.s9|45-52|observed|O
DDI-DrugBank.d345.s9|59-66|COLESTID|O
DDI-DrugBank.d345.s9|68-74|Tablets|O
DDI-DrugBank.d345.s9|80-85|either|O
DDI-DrugBank.d345.s9|87-91|added|O
DDI-DrugBank.d345.s9|96-102|deleted|O
DDI-DrugBank.d345.s9|111-121|therapeutic|O
DDI-DrugBank.d345.s9|123-129|regimen|O
DDI-DrugBank.d345.s9|130-130|.|O
DDI-DrugBank.d345.s10|0-6|Studies|O
DDI-DrugBank.d345.s10|11-16|humans|O
DDI-DrugBank.d345.s10|18-21|show|O
DDI-DrugBank.d345.s10|32-41|absorption|O
DDI-DrugBank.d345.s10|46-59|chlorothiazide|O
DDI-DrugBank.d345.s10|64-72|reflected|O
DDI-DrugBank.d345.s10|77-83|urinary|O
DDI-DrugBank.d345.s10|85-93|excretion|O
DDI-DrugBank.d345.s10|98-105|markedly|O
DDI-DrugBank.d345.s10|107-115|decreased|O
DDI-DrugBank.d345.s10|117-120|even|O
DDI-DrugBank.d345.s10|127-138|administered|O
DDI-DrugBank.d345.s10|140-142|one|O
DDI-DrugBank.d345.s10|144-147|hour|O
DDI-DrugBank.d345.s10|156-165|colestipol|O
DDI-DrugBank.d345.s10|167-179|hydrochloride|O
DDI-DrugBank.d345.s10|180-180|.|O
DDI-DrugBank.d345.s11|0-2|The|O
DDI-DrugBank.d345.s11|4-13|absorption|O
DDI-DrugBank.d345.s11|18-29|tetracycline|O
DDI-DrugBank.d345.s11|32-41|furosemide|O
DDI-DrugBank.d345.s11|44-53|penicillin|O
DDI-DrugBank.d345.s11|55-55|G|O
DDI-DrugBank.d345.s11|58-76|hydrochlorothiazide|O
DDI-DrugBank.d345.s11|83-93|gemfibrozil|O
DDI-DrugBank.d345.s11|99-111|significantly|O
DDI-DrugBank.d345.s11|113-121|decreased|O
DDI-DrugBank.d345.s11|128-132|given|O
DDI-DrugBank.d345.s11|134-147|simultaneously|O
DDI-DrugBank.d345.s11|154-163|colestipol|O
DDI-DrugBank.d345.s11|165-177|hydrochloride|O
DDI-DrugBank.d345.s12|6-10|drugs|O
DDI-DrugBank.d345.s12|21-26|tested|O
DDI-DrugBank.d345.s12|31-39|determine|O
DDI-DrugBank.d345.s12|45-50|effect|O
DDI-DrugBank.d345.s12|55-68|administration|O
DDI-DrugBank.d345.s12|70-72|one|O
DDI-DrugBank.d345.s12|74-77|hour|O
DDI-DrugBank.d345.s12|86-95|colestipol|O
DDI-DrugBank.d345.s12|97-109|hydrochloride|O
DDI-DrugBank.d345.s12|110-110|.|O
DDI-DrugBank.d345.s13|0-1|No|O
DDI-DrugBank.d345.s13|3-12|depressant|O
DDI-DrugBank.d345.s13|14-19|effect|O
DDI-DrugBank.d345.s13|24-28|blood|O
DDI-DrugBank.d345.s13|30-35|levels|O
DDI-DrugBank.d345.s13|40-45|humans|O
DDI-DrugBank.d345.s13|51-55|noted|O
DDI-DrugBank.d345.s13|62-71|colestipol|O
DDI-DrugBank.d345.s13|73-85|hydrochloride|O
DDI-DrugBank.d345.s13|91-102|administered|O
DDI-DrugBank.d345.s13|120-128|following|O
DDI-DrugBank.d345.s13|130-134|drugs|O
DDI-DrugBank.d345.s13|137-143|aspirin|O
DDI-DrugBank.d345.s13|146-156|clindamycin|O
DDI-DrugBank.d345.s13|159-168|clofibrate|O
DDI-DrugBank.d345.s13|171-180|methyldopa|O
DDI-DrugBank.d345.s13|183-191|nicotinic|O
DDI-DrugBank.d345.s13|193-196|acid|O
DDI-DrugBank.d345.s13|199-204|niacin|O
DDI-DrugBank.d345.s13|208-218|tolbutamide|O
DDI-DrugBank.d345.s13|221-229|phenytoin|O
DDI-DrugBank.d345.s13|234-241|warfarin|O
DDI-DrugBank.d345.s13|242-242|.|O
DDI-DrugBank.d345.s14|0-9|Particular|O
DDI-DrugBank.d345.s14|11-17|caution|O
DDI-DrugBank.d345.s14|29-36|observed|O
DDI-DrugBank.d345.s14|43-51|digitalis|O
DDI-DrugBank.d345.s14|53-64|preparations|O
DDI-DrugBank.d345.s14|66-70|since|O
DDI-DrugBank.d345.s14|82-92|conflicting|O
DDI-DrugBank.d345.s14|94-100|results|O
DDI-DrugBank.d345.s14|110-115|effect|O
DDI-DrugBank.d345.s14|120-129|colestipol|O
DDI-DrugBank.d345.s14|131-143|hydrochloride|O
DDI-DrugBank.d345.s14|152-163|availability|O
DDI-DrugBank.d345.s14|168-174|digoxin|O
DDI-DrugBank.d345.s14|180-188|digitoxin|O
DDI-DrugBank.d345.s14|189-189|.|O
DDI-DrugBank.d345.s15|0-2|The|O
DDI-DrugBank.d345.s15|4-12|potential|O
DDI-DrugBank.d345.s15|18-24|binding|O
DDI-DrugBank.d345.s15|35-39|drugs|O
DDI-DrugBank.d345.s15|44-48|given|O
DDI-DrugBank.d345.s15|50-62|concomitantly|O
DDI-DrugBank.d345.s15|67-73|present|O
DDI-DrugBank.d345.s15|74-74|.|O
DDI-DrugBank.d345.s16|0-12|Discontinuing|O
DDI-DrugBank.d345.s16|14-23|colestipol|O
DDI-DrugBank.d345.s16|25-37|hydrochloride|O
DDI-DrugBank.d345.s16|39-43|could|O
DDI-DrugBank.d345.s16|45-48|pose|O
DDI-DrugBank.d345.s16|52-57|hazard|O
DDI-DrugBank.d345.s16|62-67|health|O
DDI-DrugBank.d345.s16|74-84|potentially|O
DDI-DrugBank.d345.s16|86-90|toxic|O
DDI-DrugBank.d345.s16|92-95|drug|O
DDI-DrugBank.d345.s16|105-117|significantly|O
DDI-DrugBank.d345.s16|119-123|bound|O
DDI-DrugBank.d345.s16|132-136|resin|O
DDI-DrugBank.d345.s16|147-154|titrated|O
DDI-DrugBank.d345.s16|161-171|maintenance|O
DDI-DrugBank.d345.s16|173-177|level|O
DDI-DrugBank.d345.s16|189-195|patient|O
DDI-DrugBank.d345.s16|201-206|taking|O
DDI-DrugBank.d345.s16|14-23|colestipol|O
DDI-DrugBank.d345.s16|25-37|hydrochloride|O
DDI-DrugBank.d345.s16|232-232|.|O
DDI-DrugBank.d345.s17|0-3|Bile|O
DDI-DrugBank.d345.s17|5-8|acid|O
DDI-DrugBank.d345.s17|10-16|binding|O
DDI-DrugBank.d345.s17|18-23|resins|O
DDI-DrugBank.d345.s17|25-27|may|O
DDI-DrugBank.d345.s17|29-32|also|O
DDI-DrugBank.d345.s17|34-42|interfere|O
DDI-DrugBank.d345.s17|53-62|absorption|O
DDI-DrugBank.d345.s17|67-70|oral|O
DDI-DrugBank.d345.s17|72-80|phosphate|O
DDI-DrugBank.d345.s17|82-92|supplements|O
DDI-DrugBank.d345.s17|98-111|hydrocortisone|O
DDI-DrugBank.d345.s17|112-112|.|O
DDI-DrugBank.d11.s0|0-8|Drug-Drug|O
DDI-DrugBank.d11.s0|10-21|Interactions|O
DDI-DrugBank.d11.s0|23-31|Albuterol|O
DDI-DrugBank.d11.s0|4-4|-|O
DDI-DrugBank.d11.s0|35-43|STRATTERA|O
DDI-DrugBank.d11.s0|55-66|administered|O
DDI-DrugBank.d11.s0|73-79|caution|O
DDI-DrugBank.d11.s0|84-91|patients|O
DDI-DrugBank.d11.s0|99-105|treated|O
DDI-DrugBank.d11.s0|112-136|systemically-administered|O
DDI-DrugBank.d11.s0|139-142|oral|O
DDI-DrugBank.d11.s0|147-157|intravenous|O
DDI-DrugBank.d11.s0|160-168|albuterol|O
DDI-DrugBank.d11.s0|180-184|beta2|O
DDI-DrugBank.d11.s0|186-193|agonists|O
DDI-DrugBank.d11.s0|15-20|action|O
DDI-DrugBank.d11.s0|160-168|albuterol|O
DDI-DrugBank.d11.s0|235-248|cardiovascular|O
DDI-DrugBank.d11.s0|112-117|system|O
DDI-DrugBank.d11.s0|264-274|potentiated|O
DDI-DrugBank.d11.s0|276-284|resulting|O
DDI-DrugBank.d11.s0|289-297|increases|O
DDI-DrugBank.d11.s0|302-306|heart|O
DDI-DrugBank.d11.s0|308-311|rate|O
DDI-DrugBank.d11.s0|317-321|blood|O
DDI-DrugBank.d11.s0|323-330|pressure|O
DDI-DrugBank.d11.s0|331-331|.|O
DDI-DrugBank.d11.s1|0-5|CYP2D6|O
DDI-DrugBank.d11.s1|7-16|inhibitors|O
DDI-DrugBank.d11.s1|18-18|-|O
DDI-DrugBank.d11.s1|20-30|Atomoxetine|O
DDI-DrugBank.d11.s1|35-43|primarily|O
DDI-DrugBank.d11.s1|45-55|metabolized|O
DDI-DrugBank.d11.s1|0-5|CYP2D6|O
DDI-DrugBank.d11.s1|71-77|pathway|O
DDI-DrugBank.d11.s1|82-101|4-hydroxyatomoxetine|O
DDI-DrugBank.d11.s1|102-102|.|O
DDI-DrugBank.d11.s2|0-1|In|O
DDI-DrugBank.d11.s2|3-5|EMs|O
DDI-DrugBank.d11.s2|8-16|selective|O
DDI-DrugBank.d11.s2|18-27|inhibitors|O
DDI-DrugBank.d11.s2|32-37|CYP2D6|O
DDI-DrugBank.d11.s2|39-46|increase|O
DDI-DrugBank.d11.s2|48-58|atomoxetine|O
DDI-DrugBank.d11.s2|60-71|steady-state|O
DDI-DrugBank.d11.s2|73-78|plasma|O
DDI-DrugBank.d11.s2|80-93|concentrations|O
DDI-DrugBank.d11.s2|98-106|exposures|O
DDI-DrugBank.d11.s2|108-114|similar|O
DDI-DrugBank.d11.s2|125-132|observed|O
DDI-DrugBank.d11.s2|137-139|PMs|O
DDI-DrugBank.d11.s2|140-140|.|O
DDI-DrugBank.d11.s3|0-5|Dosage|O
DDI-DrugBank.d11.s3|7-16|adjustment|O
DDI-DrugBank.d11.s3|21-29|STRATTERA|O
DDI-DrugBank.d11.s3|31-33|may|O
DDI-DrugBank.d11.s3|38-46|necessary|O
DDI-DrugBank.d11.s3|53-66|coadministered|O
DDI-DrugBank.d11.s3|73-78|CYP2D6|O
DDI-DrugBank.d11.s3|80-89|inhibitors|O
DDI-DrugBank.d11.s3|92-95|e.g.|O
DDI-DrugBank.d11.s3|98-107|paroxetine|O
DDI-DrugBank.d11.s3|110-119|fluoxetine|O
DDI-DrugBank.d11.s3|126-134|quinidine|O
DDI-DrugBank.d11.s3|93-93|.|O
DDI-DrugBank.d11.s4|0-1|In|O
DDI-DrugBank.d11.s4|3-4|EM|O
DDI-DrugBank.d11.s4|6-16|individuals|O
DDI-DrugBank.d11.s4|18-24|treated|O
DDI-DrugBank.d11.s4|31-40|paroxetine|O
DDI-DrugBank.d11.s4|45-54|fluoxetine|O
DDI-DrugBank.d11.s4|61-63|AUC|O
DDI-DrugBank.d11.s4|68-78|atomoxetine|O
DDI-DrugBank.d11.s4|83-95|approximately|O
DDI-DrugBank.d11.s4|97-98|6-|O
DDI-DrugBank.d11.s4|103-108|8-fold|O
DDI-DrugBank.d11.s4|114-116|Css|O
DDI-DrugBank.d11.s4|118-120|max|O
DDI-DrugBank.d11.s4|131-132|3-|O
DDI-DrugBank.d11.s4|137-142|4-fold|O
DDI-DrugBank.d11.s4|144-150|greater|O
DDI-DrugBank.d11.s4|68-78|atomoxetine|O
DDI-DrugBank.d11.s4|169-173|alone|O
DDI-DrugBank.d11.s5|0-1|In|O
DDI-DrugBank.d11.s5|3-7|vitro|O
DDI-DrugBank.d11.s5|9-15|studies|O
DDI-DrugBank.d11.s5|17-23|suggest|O
DDI-DrugBank.d11.s5|30-45|coadministration|O
DDI-DrugBank.d11.s5|50-59|cytochrome|O
DDI-DrugBank.d11.s5|61-64|P450|O
DDI-DrugBank.d11.s5|66-75|inhibitors|O
DDI-DrugBank.d11.s5|80-82|PMs|O
DDI-DrugBank.d11.s5|93-100|increase|O
DDI-DrugBank.d11.s5|106-111|plasma|O
DDI-DrugBank.d11.s5|113-126|concentrations|O
DDI-DrugBank.d11.s5|131-141|atomoxetine|O
DDI-DrugBank.d11.s5|142-142|.|O
DDI-DrugBank.d11.s6|0-6|Pressor|O
DDI-DrugBank.d11.s6|8-13|agents|O
DDI-DrugBank.d11.s6|15-15|-|O
DDI-DrugBank.d11.s6|17-23|Because|O
DDI-DrugBank.d11.s6|28-35|possible|O
DDI-DrugBank.d11.s6|37-43|effects|O
DDI-DrugBank.d11.s6|48-52|blood|O
DDI-DrugBank.d11.s6|54-61|pressure|O
DDI-DrugBank.d11.s6|64-72|STRATTERA|O
DDI-DrugBank.d11.s6|84-87|used|O
DDI-DrugBank.d11.s6|89-98|cautiously|O
DDI-DrugBank.d11.s6|105-111|pressor|O
DDI-DrugBank.d11.s6|8-13|agents|O
DDI-DrugBank.d11.s6|119-119|.|O
DDI-DrugBank.d511.s0|0-0|A|O
DDI-DrugBank.d511.s0|2-9|possible|O
DDI-DrugBank.d511.s0|11-14|drug|O
DDI-DrugBank.d511.s0|16-26|interaction|O
DDI-DrugBank.d511.s0|31-38|FOSCAVIR|O
DDI-DrugBank.d511.s0|44-54|intravenous|O
DDI-DrugBank.d511.s0|56-66|pentamidine|O
DDI-DrugBank.d511.s0|77-85|described|O
DDI-DrugBank.d511.s0|86-86|.|O
DDI-DrugBank.d511.s1|0-10|Concomitant|O
DDI-DrugBank.d511.s1|12-20|treatment|O
DDI-DrugBank.d511.s1|25-28|four|O
DDI-DrugBank.d511.s1|30-37|patients|O
DDI-DrugBank.d511.s1|46-51|United|O
DDI-DrugBank.d511.s1|53-59|Kingdom|O
DDI-DrugBank.d511.s1|66-73|FOSCAVIR|O
DDI-DrugBank.d511.s1|79-89|intravenous|O
DDI-DrugBank.d511.s1|91-101|pentamidine|O
DDI-DrugBank.d511.s1|103-105|may|O
DDI-DrugBank.d511.s1|112-117|caused|O
DDI-DrugBank.d511.s1|119-130|hypocalcemia|O
DDI-DrugBank.d511.s2|0-2|one|O
DDI-DrugBank.d511.s2|4-10|patient|O
DDI-DrugBank.d511.s2|12-15|died|O
DDI-DrugBank.d511.s2|22-27|severe|O
DDI-DrugBank.d511.s2|29-40|hypocalcemia|O
DDI-DrugBank.d511.s2|41-41|.|O
DDI-DrugBank.d511.s3|0-7|Toxicity|O
DDI-DrugBank.d511.s3|9-18|associated|O
DDI-DrugBank.d511.s3|25-35|concomitant|O
DDI-DrugBank.d511.s3|37-39|use|O
DDI-DrugBank.d511.s3|44-54|aerosolized|O
DDI-DrugBank.d511.s3|56-66|pentamidine|O
DDI-DrugBank.d511.s3|81-88|reported|O
DDI-DrugBank.d511.s3|89-89|.|O
DDI-DrugBank.d511.s4|0-6|Because|O
DDI-DrugBank.d511.s4|11-20|foscarnets|O
DDI-DrugBank.d511.s4|22-29|tendency|O
DDI-DrugBank.d511.s4|2-6|cause|O
DDI-DrugBank.d511.s4|40-44|renal|O
DDI-DrugBank.d511.s4|46-55|impairment|O
DDI-DrugBank.d511.s4|4-6|use|O
DDI-DrugBank.d511.s4|69-76|FOSCAVIR|O
DDI-DrugBank.d511.s4|88-94|avoided|O
DDI-DrugBank.d511.s4|99-109|combination|O
DDI-DrugBank.d511.s4|116-126|potentially|O
DDI-DrugBank.d511.s4|128-138|nephrotoxic|O
DDI-DrugBank.d511.s4|140-144|drugs|O
DDI-DrugBank.d511.s4|154-168|aminoglycosides|O
DDI-DrugBank.d511.s4|171-182|amphotericin|O
DDI-DrugBank.d511.s4|0-0|B|O
DDI-DrugBank.d511.s4|190-200|intravenous|O
DDI-DrugBank.d511.s4|202-212|pentamidine|O
DDI-DrugBank.d511.s4|214-219|unless|O
DDI-DrugBank.d511.s4|116-124|potential|O
DDI-DrugBank.d511.s4|235-242|benefits|O
DDI-DrugBank.d511.s4|244-251|outweigh|O
DDI-DrugBank.d511.s4|257-261|risks|O
DDI-DrugBank.d511.s4|270-276|patient|O
DDI-DrugBank.d511.s4|277-277|.|O
DDI-DrugBank.d511.s5|0-4|Since|O
DDI-DrugBank.d511.s5|6-13|FOSCAVIR|O
DDI-DrugBank.d511.s5|15-23|decreases|O
DDI-DrugBank.d511.s5|25-29|serum|O
DDI-DrugBank.d511.s5|31-44|concentrations|O
DDI-DrugBank.d511.s5|49-55|ionized|O
DDI-DrugBank.d511.s5|57-63|calcium|O
DDI-DrugBank.d511.s5|66-75|concurrent|O
DDI-DrugBank.d511.s5|77-85|treatment|O
DDI-DrugBank.d511.s5|98-102|drugs|O
DDI-DrugBank.d511.s5|104-108|known|O
DDI-DrugBank.d511.s5|113-121|influence|O
DDI-DrugBank.d511.s5|25-29|serum|O
DDI-DrugBank.d511.s5|57-63|calcium|O
DDI-DrugBank.d511.s5|31-44|concentrations|O
DDI-DrugBank.d511.s5|162-165|used|O
DDI-DrugBank.d511.s5|172-181|particular|O
DDI-DrugBank.d511.s5|183-189|caution|O
DDI-DrugBank.d511.s5|190-190|.|O
DDI-DrugBank.d511.s6|0-10|Ganciclovir|O
DDI-DrugBank.d511.s6|13-15|The|O
DDI-DrugBank.d511.s6|17-32|pharmacokinetics|O
DDI-DrugBank.d511.s6|37-45|foscarnet|O
DDI-DrugBank.d511.s6|51-61|ganciclovir|O
DDI-DrugBank.d511.s6|72-78|altered|O
DDI-DrugBank.d511.s6|83-84|13|O
DDI-DrugBank.d511.s6|86-93|patients|O
DDI-DrugBank.d511.s6|95-103|receiving|O
DDI-DrugBank.d511.s6|105-110|either|O
DDI-DrugBank.d511.s6|112-122|concomitant|O
DDI-DrugBank.d511.s6|124-130|therapy|O
DDI-DrugBank.d511.s6|135-139|daily|O
DDI-DrugBank.d511.s6|141-151|alternating|O
DDI-DrugBank.d511.s6|124-130|therapy|O
DDI-DrugBank.d511.s6|165-175|maintenance|O
DDI-DrugBank.d511.s6|180-182|CMV|O
DDI-DrugBank.d511.s6|184-190|disease|O
DDI-DrugBank.d511.s6|191-191|.|O
DDI-MedLine.d85.s0|0-11|Misonidazole|O
DDI-MedLine.d85.s0|13-20|protects|O
DDI-MedLine.d85.s0|22-26|mouse|O
DDI-MedLine.d85.s0|28-33|tumour|O
DDI-MedLine.d85.s0|39-44|normal|O
DDI-MedLine.d85.s0|46-52|tissues|O
DDI-MedLine.d85.s0|63-70|toxicity|O
DDI-MedLine.d85.s0|75-78|oral|O
DDI-MedLine.d85.s0|80-83|CCNU|O
DDI-MedLine.d85.s0|84-84|.|O
DDI-MedLine.d85.s1|0-6|Because|O
DDI-MedLine.d85.s1|12-22|nitrosourea|O
DDI-MedLine.d85.s1|24-27|CCNU|O
DDI-MedLine.d85.s1|32-36|given|O
DDI-MedLine.d85.s1|38-48|exclusively|O
DDI-MedLine.d85.s1|57-60|oral|O
DDI-MedLine.d85.s1|62-66|route|O
DDI-MedLine.d85.s1|71-73|man|O
DDI-MedLine.d85.s1|84-90|carried|O
DDI-MedLine.d85.s1|96-102|studies|O
DDI-MedLine.d85.s1|107-110|mice|O
DDI-MedLine.d85.s1|119-128|antitumour|O
DDI-MedLine.d85.s1|130-137|activity|O
DDI-MedLine.d85.s1|140-144|acute|O
DDI-MedLine.d85.s1|146-153|toxicity|O
DDI-MedLine.d85.s1|159-174|pharmacokinetics|O
DDI-MedLine.d85.s1|57-60|oral|O
DDI-MedLine.d85.s1|24-27|CCNU|O
DDI-MedLine.d85.s1|190-195|either|O
DDI-MedLine.d85.s1|197-201|alone|O
DDI-MedLine.d85.s1|209-219|combination|O
DDI-MedLine.d85.s1|230-244|chemosensitizer|O
DDI-MedLine.d85.s1|246-257|misonidazole|O
DDI-MedLine.d85.s2|0-1|In|O
DDI-MedLine.d85.s2|8-13|plasma|O
DDI-MedLine.d85.s2|19-21|KHT|O
DDI-MedLine.d85.s2|23-28|tumour|O
DDI-MedLine.d85.s2|34-37|peak|O
DDI-MedLine.d85.s2|39-51|concentration|O
DDI-MedLine.d85.s2|-1-0|``|O
DDI-MedLine.d85.s2|58-62|early|O
DDI-MedLine.d85.s2|-1-0|''|O
DDI-MedLine.d85.s3|0-2|AUC|O
DDI-MedLine.d85.s3|8-12|total|O
DDI-MedLine.d85.s3|14-25|nitrosoureas|O
DDI-MedLine.d85.s3|38-44|1.4-1.5|O
DDI-MedLine.d85.s3|46-49|fold|O
DDI-MedLine.d85.s3|51-57|greater|O
DDI-MedLine.d85.s3|67-70|oral|O
DDI-MedLine.d85.s3|72-79|compared|O
DDI-MedLine.d85.s3|88-90|i.p|O
DDI-MedLine.d85.s3|39-39|.|O
DDI-MedLine.d85.s4|0-4|route|O
DDI-MedLine.d85.s4|5-5|.|O
DDI-MedLine.d85.s5|0-4|These|O
DDI-MedLine.d85.s5|6-16|differences|O
DDI-MedLine.d85.s5|23-31|reflected|O
DDI-MedLine.d85.s5|40-46|roughly|O
DDI-MedLine.d85.s5|48-54|twofold|O
DDI-MedLine.d85.s5|56-62|greater|O
DDI-MedLine.d85.s5|64-73|antitumour|O
DDI-MedLine.d85.s5|75-82|activity|O
DDI-MedLine.d85.s5|92-95|oral|O
DDI-MedLine.d85.s5|97-101|route|O
DDI-MedLine.d85.s5|102-102|.|O
DDI-MedLine.d85.s6|0-1|In|O
DDI-MedLine.d85.s6|3-10|contrast|O
DDI-MedLine.d85.s6|13-17|acute|O
DDI-MedLine.d85.s6|19-26|toxicity|O
DDI-MedLine.d85.s6|28-32|tests|O
DDI-MedLine.d85.s6|34-39|showed|O
DDI-MedLine.d85.s6|46-49|oral|O
DDI-MedLine.d85.s6|51-54|CCNU|O
DDI-MedLine.d85.s6|60-63|1.45|O
DDI-MedLine.d85.s6|65-69|times|O
DDI-MedLine.d85.s6|71-74|less|O
DDI-MedLine.d85.s6|19-23|toxic|O
DDI-MedLine.d85.s6|85-90|normal|O
DDI-MedLine.d85.s6|92-97|tissue|O
DDI-MedLine.d85.s6|100-107|although|O
DDI-MedLine.d85.s6|113-125|dose-limiting|O
DDI-MedLine.d85.s6|127-131|organ|O
DDI-MedLine.d85.s6|133-135|may|O
DDI-MedLine.d85.s6|140-148|different|O
DDI-MedLine.d85.s6|158-160|two|O
DDI-MedLine.d85.s6|162-167|routes|O
DDI-MedLine.d85.s6|61-61|.|O
DDI-MedLine.d85.s7|0-11|Misonidazole|O
DDI-MedLine.d85.s7|13-19|reduced|O
DDI-MedLine.d85.s7|25-34|antitumour|O
DDI-MedLine.d85.s7|36-43|activity|O
DDI-MedLine.d85.s7|48-51|oral|O
DDI-MedLine.d85.s7|53-56|CCNU|O
DDI-MedLine.d85.s7|61-64|dose|O
DDI-MedLine.d85.s7|66-74|modifying|O
DDI-MedLine.d85.s7|76-82|factors|O
DDI-MedLine.d85.s7|85-87|DMF|O
DDI-MedLine.d85.s7|93-101|0.58-0.71|O
DDI-MedLine.d85.s7|94-94|.|O
DDI-MedLine.d85.s8|0-8|Similarly|O
DDI-MedLine.d85.s8|15-19|acute|O
DDI-MedLine.d85.s8|21-28|toxicity|O
DDI-MedLine.d85.s8|34-37|also|O
DDI-MedLine.d85.s8|39-48|diminished|O
DDI-MedLine.d85.s8|55-57|DMF|O
DDI-MedLine.d85.s8|62-65|0.74|O
DDI-MedLine.d85.s8|63-63|.|O
DDI-MedLine.d85.s9|0-11|Misonidazole|O
DDI-MedLine.d85.s9|19-25|complex|O
DDI-MedLine.d85.s9|27-32|effect|O
DDI-MedLine.d85.s9|37-40|oral|O
DDI-MedLine.d85.s9|42-45|CCNU|O
DDI-MedLine.d85.s9|47-62|pharmacokinetics|O
DDI-MedLine.d85.s9|63-63|.|O
DDI-MedLine.d85.s10|0-2|The|O
DDI-MedLine.d85.s10|4-9|plasma|O
DDI-MedLine.d85.s10|15-20|tumour|O
DDI-MedLine.d85.s10|22-26|total|O
DDI-MedLine.d85.s10|28-38|nitrosourea|O
DDI-MedLine.d85.s10|40-43|peak|O
DDI-MedLine.d85.s10|45-58|concentrations|O
DDI-MedLine.d85.s10|65-71|reduced|O
DDI-MedLine.d85.s10|76-78|1.5|O
DDI-MedLine.d85.s10|84-86|1.7|O
DDI-MedLine.d85.s10|88-91|fold|O
DDI-MedLine.d85.s10|93-104|respectively|O
DDI-MedLine.d85.s10|77-77|.|O
DDI-MedLine.d85.s11|0-11|Misonidazole|O
DDI-MedLine.d85.s11|13-16|also|O
DDI-MedLine.d85.s11|18-24|reduced|O
DDI-MedLine.d85.s11|-1-0|``|O
DDI-MedLine.d85.s11|31-35|early|O
DDI-MedLine.d85.s11|-1-0|''|O
DDI-MedLine.d85.s12|0-10|nitrosourea|O
DDI-MedLine.d85.s12|12-14|AUC|O
DDI-MedLine.d85.s12|26-31|extent|O
DDI-MedLine.d85.s12|40-48|reduction|O
DDI-MedLine.d85.s12|50-58|depending|O
DDI-MedLine.d85.s12|67-73|minimum|O
DDI-MedLine.d85.s12|75-83|effective|O
DDI-MedLine.d85.s12|85-97|concentration|O
DDI-MedLine.d85.s12|100-102|MEC|O
DDI-MedLine.d85.s12|105-110|chosen|O
DDI-MedLine.d85.s12|111-111|.|O
DDI-MedLine.d85.s13|0-2|For|O
DDI-MedLine.d85.s13|4-10|example|O
DDI-MedLine.d85.s13|17-22|plasma|O
DDI-MedLine.d85.s13|24-34|nitrosourea|O
DDI-MedLine.d85.s13|36-38|AUC|O
DDI-MedLine.d85.s13|44-50|reduced|O
DDI-MedLine.d85.s13|55-61|factors|O
DDI-MedLine.d85.s13|66-69|1.05|O
DDI-MedLine.d85.s13|75-77|9.6|O
DDI-MedLine.d85.s13|83-85|MEC|O
DDI-MedLine.d85.s13|87-92|values|O
DDI-MedLine.d85.s13|66-66|1|O
DDI-MedLine.d85.s13|103-103|2|O
DDI-MedLine.d85.s13|105-114|micrograms|O
DDI-MedLine.d85.s13|116-119|ml-1|O
DDI-MedLine.d85.s13|121-132|respectively|O
DDI-MedLine.d85.s13|67-67|.|O
DDI-MedLine.d85.s14|0-1|We|O
DDI-MedLine.d85.s14|3-9|propose|O
DDI-MedLine.d85.s14|17-31|pharmacokinetic|O
DDI-MedLine.d85.s14|33-39|changes|O
DDI-MedLine.d85.s14|51-60|underlying|O
DDI-MedLine.d85.s14|62-70|mechanism|O
DDI-MedLine.d85.s14|80-88|reduction|O
DDI-MedLine.d85.s14|93-96|oral|O
DDI-MedLine.d85.s14|98-101|CCNU|O
DDI-MedLine.d85.s14|103-114|cytotoxicity|O
DDI-MedLine.d85.s14|119-130|misonidazole|O
DDI-MedLine.d85.s14|131-131|.|O
DDI-MedLine.d85.s15|0-7|Clinical|O
DDI-MedLine.d85.s15|9-14|trials|O
DDI-MedLine.d85.s15|24-35|combinations|O
DDI-MedLine.d85.s15|47-57|accompanied|O
DDI-MedLine.d85.s15|62-69|detailed|O
DDI-MedLine.d85.s15|71-85|pharmacokinetic|O
DDI-MedLine.d85.s15|87-96|evaluation|O
DDI-MedLine.d85.s15|97-97|.|O
DDI-DrugBank.d678.s0|0-4|Drugs|O
DDI-DrugBank.d678.s0|6-14|affecting|O
DDI-DrugBank.d678.s0|16-24|pituitary|O
DDI-DrugBank.d678.s0|29-42|adrenocortical|O
DDI-DrugBank.d678.s0|44-51|function|O
DDI-DrugBank.d678.s0|54-62|including|O
DDI-DrugBank.d678.s0|68-81|corticosteroid|O
DDI-DrugBank.d678.s0|83-89|therapy|O
DDI-DrugBank.d678.s0|92-95|must|O
DDI-DrugBank.d678.s0|100-111|discontinued|O
DDI-DrugBank.d678.s0|113-117|prior|O
DDI-DrugBank.d678.s0|133-139|testing|O
DDI-DrugBank.d678.s0|146-155|Metopirone|O
DDI-DrugBank.d678.s0|156-156|.|O
DDI-DrugBank.d678.s1|0-2|The|O
DDI-DrugBank.d678.s1|4-13|metabolism|O
DDI-DrugBank.d678.s1|18-27|Metopirone|O
DDI-DrugBank.d678.s1|32-42|accelerated|O
DDI-DrugBank.d678.s1|47-55|phenytoin|O
DDI-DrugBank.d678.s2|0-8|therefore|O
DDI-DrugBank.d678.s2|11-17|results|O
DDI-DrugBank.d678.s2|26-29|test|O
DDI-DrugBank.d678.s2|31-33|may|O
DDI-DrugBank.d678.s2|38-47|inaccurate|O
DDI-DrugBank.d678.s2|52-59|patients|O
DDI-DrugBank.d678.s2|61-66|taking|O
DDI-DrugBank.d678.s2|68-76|phenytoin|O
DDI-DrugBank.d678.s2|78-83|within|O
DDI-DrugBank.d678.s2|85-87|two|O
DDI-DrugBank.d678.s2|89-93|weeks|O
DDI-DrugBank.d678.s2|101-101|.|O
DDI-DrugBank.d678.s3|0-9|Asubnormal|O
DDI-DrugBank.d678.s3|11-18|response|O
DDI-DrugBank.d678.s3|20-22|may|O
DDI-DrugBank.d678.s3|24-28|occur|O
DDI-DrugBank.d678.s3|33-40|patients|O
DDI-DrugBank.d678.s3|45-52|estrogen|O
DDI-DrugBank.d678.s3|54-60|therapy|O
DDI-DrugBank.d678.s3|61-61|.|O
DDI-DrugBank.d678.s4|0-9|Metopirone|O
DDI-DrugBank.d678.s4|11-18|inhibits|O
DDI-DrugBank.d678.s4|24-38|glucuronidation|O
DDI-DrugBank.d678.s4|43-55|acetaminophen|O
DDI-DrugBank.d678.s4|61-65|could|O
DDI-DrugBank.d678.s4|67-74|possibly|O
DDI-DrugBank.d678.s4|76-85|potentiate|O
DDI-DrugBank.d678.s4|43-55|acetaminophen|O
DDI-DrugBank.d678.s4|101-108|toxicity|O
DDI-DrugBank.d678.s4|109-109|.|O
DDI-DrugBank.d529.s0|0-7|Antacids|O
DDI-DrugBank.d529.s0|10-23|Administration|O
DDI-DrugBank.d529.s0|28-39|flurbiprofen|O
DDI-DrugBank.d529.s0|44-53|volunteers|O
DDI-DrugBank.d529.s0|61-67|fasting|O
DDI-DrugBank.d529.s0|69-78|conditions|O
DDI-DrugBank.d529.s0|89-95|antacid|O
DDI-DrugBank.d529.s0|97-106|suspension|O
DDI-DrugBank.d529.s0|108-114|yielded|O
DDI-DrugBank.d529.s0|116-122|similar|O
DDI-DrugBank.d529.s0|124-128|serum|O
DDI-DrugBank.d529.s0|28-39|flurbiprofen|O
DDI-DrugBank.d529.s0|143-146|time|O
DDI-DrugBank.d529.s0|148-155|profiles|O
DDI-DrugBank.d529.s0|160-164|young|O
DDI-DrugBank.d529.s0|166-173|subjects|O
DDI-DrugBank.d529.s0|176-179|n=12|O
DDI-DrugBank.d529.s0|181-181|.|O
DDI-DrugBank.d529.s1|0-1|In|O
DDI-DrugBank.d529.s1|3-11|geriatric|O
DDI-DrugBank.d529.s1|13-20|subjects|O
DDI-DrugBank.d529.s1|23-25|n=7|O
DDI-DrugBank.d529.s1|40-48|reduction|O
DDI-DrugBank.d529.s1|57-60|rate|O
DDI-DrugBank.d529.s1|74-79|extent|O
DDI-DrugBank.d529.s1|84-95|flurbiprofen|O
DDI-DrugBank.d529.s1|97-106|absorption|O
DDI-DrugBank.d529.s1|107-107|.|O
DDI-DrugBank.d529.s2|0-13|Anticoagulants|O
DDI-DrugBank.d529.s2|16-27|Flurbiprofen|O
DDI-DrugBank.d529.s2|29-32|like|O
DDI-DrugBank.d529.s2|40-51|nonsteroidal|O
DDI-DrugBank.d529.s2|53-69|anti-inflammatory|O
DDI-DrugBank.d529.s2|71-75|drugs|O
DDI-DrugBank.d529.s2|87-91|shown|O
DDI-DrugBank.d529.s2|96-101|affect|O
DDI-DrugBank.d529.s2|103-110|bleeding|O
DDI-DrugBank.d529.s2|112-121|parameters|O
DDI-DrugBank.d529.s2|126-133|patients|O
DDI-DrugBank.d529.s2|135-143|receiving|O
DDI-DrugBank.d529.s2|145-159|anti-coagulants|O
DDI-DrugBank.d529.s2|166-172|serious|O
DDI-DrugBank.d529.s2|174-181|clinical|O
DDI-DrugBank.d529.s2|103-110|bleeding|O
DDI-DrugBank.d529.s2|201-208|reported|O
DDI-DrugBank.d529.s2|209-209|.|O
DDI-DrugBank.d529.s3|0-2|The|O
DDI-DrugBank.d529.s3|4-12|physician|O
DDI-DrugBank.d529.s3|24-31|cautious|O
DDI-DrugBank.d529.s3|38-50|administering|O
DDI-DrugBank.d529.s3|52-63|flurbiprofen|O
DDI-DrugBank.d529.s3|68-75|patients|O
DDI-DrugBank.d529.s3|77-82|taking|O
DDI-DrugBank.d529.s3|84-97|anticoagulants|O
DDI-DrugBank.d529.s3|98-98|.|O
DDI-DrugBank.d529.s4|0-6|Aspirin|O
DDI-DrugBank.d529.s4|9-18|Concurrent|O
DDI-DrugBank.d529.s4|20-33|administration|O
DDI-DrugBank.d529.s4|38-44|aspirin|O
DDI-DrugBank.d529.s4|50-61|flurbiprofen|O
DDI-DrugBank.d529.s4|63-70|resulted|O
DDI-DrugBank.d529.s4|75-76|50|O
DDI-DrugBank.d529.s4|77-77|%|O
DDI-DrugBank.d529.s4|79-83|lower|O
DDI-DrugBank.d529.s4|85-89|serum|O
DDI-DrugBank.d529.s4|50-61|flurbiprofen|O
DDI-DrugBank.d529.s4|104-117|concentrations|O
DDI-DrugBank.d529.s4|118-118|.|O
DDI-DrugBank.d529.s5|0-3|This|O
DDI-DrugBank.d529.s5|5-10|effect|O
DDI-DrugBank.d529.s5|15-21|aspirin|O
DDI-DrugBank.d529.s5|30-33|also|O
DDI-DrugBank.d529.s5|35-40|lowers|O
DDI-DrugBank.d529.s5|42-46|serum|O
DDI-DrugBank.d529.s5|48-61|concentrations|O
DDI-DrugBank.d529.s5|72-83|nonsteroidal|O
DDI-DrugBank.d529.s5|85-101|anti-inflammatory|O
DDI-DrugBank.d529.s5|103-107|drugs|O
DDI-DrugBank.d529.s5|109-113|given|O
DDI-DrugBank.d529.s5|133-144|demonstrated|O
DDI-DrugBank.d529.s5|149-156|patients|O
DDI-DrugBank.d529.s5|163-172|rheumatoid|O
DDI-DrugBank.d529.s5|174-182|arthritis|O
DDI-DrugBank.d529.s5|185-186|n=|O
DDI-DrugBank.d529.s5|188-189|15|O
DDI-DrugBank.d529.s5|195-198|well|O
DDI-DrugBank.d529.s5|203-208|normal|O
DDI-DrugBank.d529.s5|210-219|volunteers|O
DDI-DrugBank.d529.s5|185-186|n=|O
DDI-DrugBank.d529.s5|225-226|16|O
DDI-DrugBank.d529.s5|228-228|.|O
DDI-DrugBank.d529.s6|0-9|Concurrent|O
DDI-DrugBank.d529.s6|11-13|use|O
DDI-DrugBank.d529.s6|18-29|flurbiprofen|O
DDI-DrugBank.d529.s6|35-41|aspirin|O
DDI-DrugBank.d529.s6|46-54|therefore|O
DDI-DrugBank.d529.s6|60-70|recommended|O
DDI-DrugBank.d529.s6|71-71|.|O
DDI-DrugBank.d529.s7|0-14|Beta-adrenergic|O
DDI-DrugBank.d529.s7|16-23|Blocking|O
DDI-DrugBank.d529.s7|25-30|Agents|O
DDI-DrugBank.d529.s7|33-35|The|O
DDI-DrugBank.d529.s7|37-42|effect|O
DDI-DrugBank.d529.s7|47-58|flurbiprofen|O
DDI-DrugBank.d529.s7|63-67|blood|O
DDI-DrugBank.d529.s7|69-76|pressure|O
DDI-DrugBank.d529.s7|78-85|response|O
DDI-DrugBank.d529.s7|90-100|propranolol|O
DDI-DrugBank.d529.s7|106-113|atenolol|O
DDI-DrugBank.d529.s7|119-127|evaluated|O
DDI-DrugBank.d529.s7|132-134|men|O
DDI-DrugBank.d529.s7|141-144|mild|O
DDI-DrugBank.d529.s7|146-158|uncomplicated|O
DDI-DrugBank.d529.s7|160-171|hypertension|O
DDI-DrugBank.d529.s7|9-9|n|O
DDI-DrugBank.d529.s7|176-176|=|O
DDI-DrugBank.d529.s7|178-179|10|O
DDI-DrugBank.d529.s7|181-181|.|O
DDI-DrugBank.d529.s8|0-11|Flurbiprofen|O
DDI-DrugBank.d529.s8|13-24|pretreatment|O
DDI-DrugBank.d529.s8|26-35|attenuated|O
DDI-DrugBank.d529.s8|41-51|hypotensive|O
DDI-DrugBank.d529.s8|53-58|effect|O
DDI-DrugBank.d529.s8|65-70|single|O
DDI-DrugBank.d529.s8|72-75|dose|O
DDI-DrugBank.d529.s8|80-90|propranolol|O
DDI-DrugBank.d529.s8|100-107|atenolol|O
DDI-DrugBank.d529.s8|108-108|.|O
DDI-DrugBank.d529.s9|0-11|Flurbiprofen|O
DDI-DrugBank.d529.s9|21-26|appear|O
DDI-DrugBank.d529.s9|31-36|affect|O
DDI-DrugBank.d529.s9|42-62|beta-blocker-mediated|O
DDI-DrugBank.d529.s9|64-72|reduction|O
DDI-DrugBank.d529.s9|77-81|heart|O
DDI-DrugBank.d529.s9|83-86|rate|O
DDI-DrugBank.d529.s9|87-87|.|O
DDI-DrugBank.d529.s10|0-11|Flurbiprofen|O
DDI-DrugBank.d529.s10|21-26|affect|O
DDI-DrugBank.d529.s10|32-46|pharmacokinetic|O
DDI-DrugBank.d529.s10|48-54|profile|O
DDI-DrugBank.d529.s10|59-64|either|O
DDI-DrugBank.d529.s10|66-69|drug|O
DDI-DrugBank.d529.s10|80-88|mechanism|O
DDI-DrugBank.d529.s10|96-100|lying|O
DDI-DrugBank.d529.s10|106-117|interference|O
DDI-DrugBank.d529.s10|124-135|propranolols|O
DDI-DrugBank.d529.s10|137-147|hypotensive|O
DDI-DrugBank.d529.s10|149-154|effect|O
DDI-DrugBank.d529.s10|159-165|unknown|O
DDI-DrugBank.d529.s11|0-7|Patients|O
DDI-DrugBank.d529.s11|9-14|taking|O
DDI-DrugBank.d529.s11|21-32|flurbiprofen|O
DDI-DrugBank.d529.s11|40-51|beta-blocker|O
DDI-DrugBank.d529.s11|63-71|monitored|O
DDI-DrugBank.d529.s11|76-81|ensure|O
DDI-DrugBank.d529.s11|90-101|satisfactory|O
DDI-DrugBank.d529.s11|103-113|hypotensive|O
DDI-DrugBank.d529.s11|115-120|effect|O
DDI-DrugBank.d529.s11|125-132|achieved|O
DDI-DrugBank.d529.s11|133-133|.|O
DDI-DrugBank.d529.s12|0-9|Cimetidine|O
DDI-DrugBank.d529.s12|12-21|Ranitidine|O
DDI-DrugBank.d529.s12|24-25|In|O
DDI-DrugBank.d529.s12|27-32|normal|O
DDI-DrugBank.d529.s12|34-43|volunteers|O
DDI-DrugBank.d529.s12|46-48|n=9|O
DDI-DrugBank.d529.s12|52-63|pretreatment|O
DDI-DrugBank.d529.s12|70-79|cimetidine|O
DDI-DrugBank.d529.s12|84-93|ranitidine|O
DDI-DrugBank.d529.s12|103-108|affect|O
DDI-DrugBank.d529.s12|110-121|flurbiprofen|O
DDI-DrugBank.d529.s12|123-138|pharmacokinetics|O
DDI-DrugBank.d529.s12|140-145|except|O
DDI-DrugBank.d529.s12|154-158|small|O
DDI-DrugBank.d529.s12|161-162|13|O
DDI-DrugBank.d529.s12|164-164|%|O
DDI-DrugBank.d529.s12|171-183|statistically|O
DDI-DrugBank.d529.s12|185-195|significant|O
DDI-DrugBank.d529.s12|197-204|increase|O
DDI-DrugBank.d529.s12|213-216|area|O
DDI-DrugBank.d529.s12|228-232|serum|O
DDI-DrugBank.d529.s12|234-246|concentration|O
DDI-DrugBank.d529.s12|248-252|curve|O
DDI-DrugBank.d529.s12|110-121|flurbiprofen|O
DDI-DrugBank.d529.s12|270-277|resulted|O
DDI-DrugBank.d529.s12|70-79|cimetidine|O
DDI-DrugBank.d529.s12|294-294|.|O
DDI-DrugBank.d529.s13|0-6|Digoxin|O
DDI-DrugBank.d529.s13|9-15|Studies|O
DDI-DrugBank.d529.s13|20-30|concomitant|O
DDI-DrugBank.d529.s13|32-45|administration|O
DDI-DrugBank.d529.s13|50-61|flurbiprofen|O
DDI-DrugBank.d529.s13|67-73|digoxin|O
DDI-DrugBank.d529.s13|78-84|healthy|O
DDI-DrugBank.d529.s13|86-88|men|O
DDI-DrugBank.d529.s13|91-92|n=|O
DDI-DrugBank.d529.s13|94-95|14|O
DDI-DrugBank.d529.s13|106-109|show|O
DDI-DrugBank.d529.s13|113-118|change|O
DDI-DrugBank.d529.s13|127-132|steady|O
DDI-DrugBank.d529.s13|134-138|state|O
DDI-DrugBank.d529.s13|140-144|serum|O
DDI-DrugBank.d529.s13|146-151|levels|O
DDI-DrugBank.d529.s13|156-161|either|O
DDI-DrugBank.d529.s13|163-166|drug|O
DDI-DrugBank.d529.s13|167-167|.|O
DDI-DrugBank.d529.s14|0-8|Diuretics|O
DDI-DrugBank.d529.s14|11-17|Studies|O
DDI-DrugBank.d529.s14|22-27|normal|O
DDI-DrugBank.d529.s14|29-38|volunteers|O
DDI-DrugBank.d529.s14|45-49|shown|O
DDI-DrugBank.d529.s14|56-67|flurbiprofen|O
DDI-DrugBank.d529.s14|69-72|like|O
DDI-DrugBank.d529.s14|80-91|nonsteroidal|O
DDI-DrugBank.d529.s14|93-109|anti-inflammatory|O
DDI-DrugBank.d529.s14|111-115|drugs|O
DDI-DrugBank.d529.s14|122-130|interfere|O
DDI-DrugBank.d529.s14|141-147|effects|O
DDI-DrugBank.d529.s14|152-161|furosemide|O
DDI-DrugBank.d529.s14|162-162|.|O
DDI-DrugBank.d529.s15|0-7|Although|O
DDI-DrugBank.d529.s15|9-15|results|O
DDI-DrugBank.d529.s15|22-27|varied|O
DDI-DrugBank.d529.s15|34-38|study|O
DDI-DrugBank.d529.s15|34-38|study|O
DDI-DrugBank.d529.s15|50-56|effects|O
DDI-DrugBank.d529.s15|68-72|shown|O
DDI-DrugBank.d529.s15|77-97|furosemide-stimulated|O
DDI-DrugBank.d529.s15|99-106|diuresis|O
DDI-DrugBank.d529.s15|109-119|natriuresis|O
DDI-DrugBank.d529.s15|126-135|kaliuresis|O
DDI-DrugBank.d529.s15|136-136|.|O
DDI-DrugBank.d529.s16|0-4|Other|O
DDI-DrugBank.d529.s16|6-17|nonsteroidal|O
DDI-DrugBank.d529.s16|19-35|anti-inflammatory|O
DDI-DrugBank.d529.s16|37-41|drugs|O
DDI-DrugBank.d529.s16|48-54|inhibit|O
DDI-DrugBank.d529.s16|56-68|prostaglandin|O
DDI-DrugBank.d529.s16|70-78|synthesis|O
DDI-DrugBank.d529.s16|90-94|shown|O
DDI-DrugBank.d529.s16|99-107|interfere|O
DDI-DrugBank.d529.s16|114-121|thiazide|O
DDI-DrugBank.d529.s16|123-131|diuretics|O
DDI-DrugBank.d529.s16|141-147|studies|O
DDI-DrugBank.d529.s16|158-174|potassium-sparing|O
DDI-DrugBank.d529.s16|123-131|diuretics|O
DDI-DrugBank.d529.s16|185-185|.|O
DDI-DrugBank.d529.s17|0-7|Patients|O
DDI-DrugBank.d529.s17|9-17|receiving|O
DDI-DrugBank.d529.s17|19-30|flurbiprofen|O
DDI-DrugBank.d529.s17|36-45|furosemide|O
DDI-DrugBank.d529.s17|56-64|diuretics|O
DDI-DrugBank.d529.s17|76-83|observed|O
DDI-DrugBank.d529.s17|85-91|closely|O
DDI-DrugBank.d529.s17|96-104|determine|O
DDI-DrugBank.d529.s17|113-119|desired|O
DDI-DrugBank.d529.s17|121-126|effect|O
DDI-DrugBank.d529.s17|131-138|obtained|O
DDI-DrugBank.d529.s17|139-139|.|O
DDI-DrugBank.d529.s18|0-3|Oral|O
DDI-DrugBank.d529.s18|5-16|Hypoglycemic|O
DDI-DrugBank.d529.s18|18-23|Agents|O
DDI-DrugBank.d529.s18|26-27|In|O
DDI-DrugBank.d529.s18|29-31|one|O
DDI-DrugBank.d529.s18|33-37|study|O
DDI-DrugBank.d529.s18|40-51|flurbiprofen|O
DDI-DrugBank.d529.s18|57-61|given|O
DDI-DrugBank.d529.s18|66-70|adult|O
DDI-DrugBank.d529.s18|72-80|diabetics|O
DDI-DrugBank.d529.s18|91-97|already|O
DDI-DrugBank.d529.s18|99-107|receiving|O
DDI-DrugBank.d529.s18|109-117|glyburide|O
DDI-DrugBank.d529.s18|120-122|n=4|O
DDI-DrugBank.d529.s18|126-134|metformin|O
DDI-DrugBank.d529.s18|137-139|n=2|O
DDI-DrugBank.d529.s18|142-155|chlorpropamide|O
DDI-DrugBank.d529.s18|162-171|phenformin|O
DDI-DrugBank.d529.s18|120-121|n=|O
DDI-DrugBank.d529.s18|177-177|3|O
DDI-DrugBank.d529.s18|109-117|glyburide|O
DDI-DrugBank.d529.s18|162-171|phenformin|O
DDI-DrugBank.d529.s18|210-212|n=6|O
DDI-DrugBank.d529.s18|214-214|.|O
DDI-DrugBank.d529.s19|0-7|Although|O
DDI-DrugBank.d529.s19|21-26|slight|O
DDI-DrugBank.d529.s19|28-36|reduction|O
DDI-DrugBank.d529.s19|41-45|blood|O
DDI-DrugBank.d529.s19|47-51|sugar|O
DDI-DrugBank.d529.s19|53-66|concentrations|O
DDI-DrugBank.d529.s19|75-85|concomitant|O
DDI-DrugBank.d529.s19|87-100|administration|O
DDI-DrugBank.d529.s19|105-116|flurbiprofen|O
DDI-DrugBank.d529.s19|122-133|hypoglycemic|O
DDI-DrugBank.d529.s19|135-140|agents|O
DDI-DrugBank.d529.s19|157-161|signs|O
DDI-DrugBank.d529.s19|166-173|symptoms|O
DDI-DrugBank.d529.s19|178-189|hypoglycemia|O
DDI-DrugBank.d529.s19|190-190|.|O
DDI-DrugBank.d136.s0|0-6|Alcohol|O
DDI-DrugBank.d136.s0|9-17|increases|O
DDI-DrugBank.d136.s0|19-33|bioavailability|O
DDI-DrugBank.d136.s0|38-39|50|O
DDI-DrugBank.d136.s0|40-40|%|O
DDI-DrugBank.d136.s0|44-53|cimetidine|O
DDI-DrugBank.d136.s0|60-69|valproates|O
DDI-DrugBank.d136.s0|70-70|.|O
DDI-DrugBank.d46.s0|0-3|When|O
DDI-DrugBank.d46.s0|5-9|given|O
DDI-DrugBank.d46.s0|11-22|concurrently|O
DDI-DrugBank.d46.s0|28-36|following|O
DDI-DrugBank.d46.s0|38-42|drugs|O
DDI-DrugBank.d46.s0|44-46|may|O
DDI-DrugBank.d46.s0|48-55|interact|O
DDI-DrugBank.d46.s0|62-69|thiazide|O
DDI-DrugBank.d46.s0|71-79|diuretics|O
DDI-DrugBank.d46.s0|80-80|.|O
DDI-DrugBank.d46.s1|0-0|-|O
DDI-DrugBank.d46.s1|2-8|Alcohol|O
DDI-DrugBank.d46.s1|11-22|barbiturates|O
DDI-DrugBank.d46.s1|28-36|narcotics|O
DDI-DrugBank.d46.s1|39-50|Potentiation|O
DDI-DrugBank.d46.s1|55-65|otthostatic|O
DDI-DrugBank.d46.s1|67-77|hypotension|O
DDI-DrugBank.d46.s1|79-81|may|O
DDI-DrugBank.d46.s1|83-87|occur|O
DDI-DrugBank.d46.s2|0-0|.|O
DDI-DrugBank.d46.s3|0-0|-|O
DDI-DrugBank.d46.s3|2-13|Antidiabetic|O
DDI-DrugBank.d46.s3|15-19|drugs|O
DDI-DrugBank.d46.s3|23-26|Oral|O
DDI-DrugBank.d46.s3|28-33|agents|O
DDI-DrugBank.d46.s3|39-45|insulin|O
DDI-DrugBank.d46.s3|48-53|Dosage|O
DDI-DrugBank.d46.s3|55-64|adjustment|O
DDI-DrugBank.d46.s3|73-84|antidiabetic|O
DDI-DrugBank.d46.s3|15-18|drug|O
DDI-DrugBank.d46.s3|91-93|may|O
DDI-DrugBank.d46.s3|98-105|required|O
DDI-DrugBank.d46.s4|0-0|.|O
DDI-DrugBank.d46.s5|0-0|-|O
DDI-DrugBank.d46.s5|2-6|Other|O
DDI-DrugBank.d46.s5|8-23|antihypertensive|O
DDI-DrugBank.d46.s5|25-29|drugs|O
DDI-DrugBank.d46.s5|32-39|Additive|O
DDI-DrugBank.d46.s5|41-46|effect|O
DDI-DrugBank.d46.s5|51-62|potentiation|O
DDI-DrugBank.d46.s6|0-0|.|O
DDI-DrugBank.d46.s7|0-0|-|O
DDI-DrugBank.d46.s7|2-15|Cholestyramine|O
DDI-DrugBank.d46.s7|21-30|colestipol|O
DDI-DrugBank.d46.s7|32-37|resins|O
DDI-DrugBank.d46.s7|40-53|Cholestytamine|O
DDI-DrugBank.d46.s7|21-30|colestipol|O
DDI-DrugBank.d46.s7|32-37|resins|O
DDI-DrugBank.d46.s7|86-94|potential|O
DDI-DrugBank.d46.s7|99-105|binding|O
DDI-DrugBank.d46.s7|107-114|thiazide|O
DDI-DrugBank.d46.s7|116-124|diuretics|O
DDI-DrugBank.d46.s7|130-137|reducing|O
DDI-DrugBank.d46.s7|116-123|diuretic|O
DDI-DrugBank.d46.s7|148-157|absorption|O
DDI-DrugBank.d46.s7|168-183|gastrointestinal|O
DDI-DrugBank.d46.s7|185-189|tract|O
DDI-DrugBank.d46.s8|0-0|.|O
DDI-DrugBank.d46.s9|0-0|-|O
DDI-DrugBank.d46.s9|2-16|Corticosteroids|O
DDI-DrugBank.d46.s9|19-22|ACTH|O
DDI-DrugBank.d46.s9|25-35|Intensified|O
DDI-DrugBank.d46.s9|37-47|electrolyte|O
DDI-DrugBank.d46.s9|49-57|depletion|O
DDI-DrugBank.d46.s9|60-71|particularly|O
DDI-DrugBank.d46.s9|73-83|hypokalemia|O
DDI-DrugBank.d46.s10|0-0|.|O
DDI-DrugBank.d46.s11|0-0|-|O
DDI-DrugBank.d46.s11|2-8|Pressor|O
DDI-DrugBank.d46.s11|10-15|amines|O
DDI-DrugBank.d46.s11|18-21|e.g.|O
DDI-DrugBank.d46.s11|24-37|norepinephrine|O
DDI-DrugBank.d46.s11|41-48|Possible|O
DDI-DrugBank.d46.s11|50-58|decreased|O
DDI-DrugBank.d46.s11|60-67|response|O
DDI-DrugBank.d46.s11|72-78|pressor|O
DDI-DrugBank.d46.s11|10-15|amines|O
DDI-DrugBank.d46.s11|95-104|sufficient|O
DDI-DrugBank.d46.s11|109-116|preclude|O
DDI-DrugBank.d46.s11|124-126|use|O
DDI-DrugBank.d46.s12|0-0|.|O
DDI-DrugBank.d46.s13|0-0|-|O
DDI-DrugBank.d46.s13|2-9|Skeletal|O
DDI-DrugBank.d46.s13|11-16|muscle|O
DDI-DrugBank.d46.s13|18-26|relaxants|O
DDI-DrugBank.d46.s13|29-43|nondepolarizing|O
DDI-DrugBank.d46.s13|46-49|e.g.|O
DDI-DrugBank.d46.s13|52-63|tubocurarine|O
DDI-DrugBank.d46.s13|67-74|Possible|O
DDI-DrugBank.d46.s13|76-84|increased|O
DDI-DrugBank.d46.s13|86-99|responsiveness|O
DDI-DrugBank.d46.s13|11-16|muscle|O
DDI-DrugBank.d46.s13|18-25|relaxant|O
DDI-DrugBank.d46.s14|0-0|.|O
DDI-DrugBank.d46.s15|0-0|-|O
DDI-DrugBank.d46.s15|2-8|Lithium|O
DDI-DrugBank.d46.s15|11-19|Generally|O
DDI-DrugBank.d46.s15|35-39|given|O
DDI-DrugBank.d46.s15|46-54|diuretics|O
DDI-DrugBank.d46.s15|55-55|.|O
DDI-DrugBank.d46.s16|0-7|Diuretic|O
DDI-DrugBank.d46.s16|9-14|agents|O
DDI-DrugBank.d46.s16|16-21|reduce|O
DDI-DrugBank.d46.s16|27-31|renal|O
DDI-DrugBank.d46.s16|33-41|clearance|O
DDI-DrugBank.d46.s16|46-52|lithium|O
DDI-DrugBank.d46.s16|58-60|add|O
DDI-DrugBank.d46.s16|64-67|high|O
DDI-DrugBank.d46.s16|69-72|risk|O
DDI-DrugBank.d46.s16|46-52|lithium|O
DDI-DrugBank.d46.s16|85-92|toxicity|O
DDI-DrugBank.d46.s16|93-93|.|O
DDI-DrugBank.d46.s17|0-4|Refer|O
DDI-DrugBank.d46.s17|13-19|package|O
DDI-DrugBank.d46.s17|21-26|insert|O
DDI-DrugBank.d46.s17|32-38|lithium|O
DDI-DrugBank.d46.s17|40-51|preparations|O
DDI-DrugBank.d46.s17|60-62|use|O
DDI-DrugBank.d46.s17|40-51|preparations|O
DDI-DrugBank.d46.s17|90-103|chlorothiazide|O
DDI-DrugBank.d46.s18|0-0|.|O
DDI-DrugBank.d46.s19|0-0|-|O
DDI-DrugBank.d46.s19|2-14|Non-steroidal|O
DDI-DrugBank.d46.s19|16-32|Anti-inflammatory|O
DDI-DrugBank.d46.s19|34-38|Drugs|O
DDI-DrugBank.d46.s19|41-42|In|O
DDI-DrugBank.d46.s19|49-56|patients|O
DDI-DrugBank.d46.s19|63-76|administration|O
DDI-DrugBank.d46.s19|83-95|non-steroidal|O
DDI-DrugBank.d46.s19|97-113|anti-inflammatory|O
DDI-DrugBank.d46.s19|115-119|agent|O
DDI-DrugBank.d46.s19|125-130|reduce|O
DDI-DrugBank.d46.s19|136-143|diuretic|O
DDI-DrugBank.d46.s19|146-156|natriuretic|O
DDI-DrugBank.d46.s19|163-178|antihypertensive|O
DDI-DrugBank.d46.s19|180-186|effects|O
DDI-DrugBank.d46.s19|191-194|loop|O
DDI-DrugBank.d46.s19|197-213|potassium-sparing|O
DDI-DrugBank.d46.s19|219-226|thiazide|O
DDI-DrugBank.d46.s19|228-236|diuretics|O
DDI-DrugBank.d46.s19|237-237|.|O
DDI-DrugBank.d46.s20|0-8|Therefore|O
DDI-DrugBank.d46.s20|16-29|chlorothiazide|O
DDI-DrugBank.d46.s20|35-47|non-steroidal|O
DDI-DrugBank.d46.s20|49-65|anti-inflammatory|O
DDI-DrugBank.d46.s20|67-72|agents|O
DDI-DrugBank.d46.s20|78-81|used|O
DDI-DrugBank.d46.s20|83-95|concomitantly|O
DDI-DrugBank.d46.s20|102-108|patient|O
DDI-DrugBank.d46.s20|120-127|observed|O
DDI-DrugBank.d46.s20|129-135|closely|O
DDI-DrugBank.d46.s20|140-148|determine|O
DDI-DrugBank.d46.s20|157-163|desired|O
DDI-DrugBank.d46.s20|165-170|effect|O
DDI-DrugBank.d46.s20|179-186|diuretic|O
DDI-DrugBank.d46.s20|191-198|obtained|O
DDI-DrugBank.d46.s21|0-0|.|O
DDI-DrugBank.d46.s22|0-0|-|O
DDI-DrugBank.d46.s22|2-16|Drug/Laboratory|O
DDI-DrugBank.d46.s22|18-21|Test|O
DDI-DrugBank.d46.s22|23-34|Interactions|O
DDI-DrugBank.d46.s22|37-45|Thiazides|O
DDI-DrugBank.d46.s22|57-68|discontinued|O
DDI-DrugBank.d46.s22|77-84|carrying|O
DDI-DrugBank.d46.s22|90-94|tests|O
DDI-DrugBank.d46.s22|100-110|parathyroid|O
DDI-DrugBank.d46.s22|112-119|function|O
DDI-DrugBank.d46.s22|120-120|.|O
DDI-MedLine.d108.s0|0-13|Administration|O
DDI-MedLine.d108.s0|18-24|lithium|O
DDI-MedLine.d108.s0|26-36|prophylaxis|O
DDI-MedLine.d108.s0|37-37|.|O
DDI-MedLine.d108.s1|0-9|Successful|O
DDI-MedLine.d108.s1|11-21|prophylaxis|O
DDI-MedLine.d108.s1|26-41|manic-depressive|O
DDI-MedLine.d108.s1|43-50|disorder|O
DDI-MedLine.d108.s1|52-59|requires|O
DDI-MedLine.d108.s1|75-86|prescription|O
DDI-MedLine.d108.s1|91-97|lithium|O
DDI-MedLine.d108.s1|99-107|carbonate|O
DDI-MedLine.d108.s1|108-108|.|O
DDI-MedLine.d108.s2|0-2|The|O
DDI-MedLine.d108.s2|4-17|administrative|O
DDI-MedLine.d108.s2|19-30|arrangements|O
DDI-MedLine.d108.s2|38-41|area|O
DDI-MedLine.d108.s2|46-53|Scotland|O
DDI-MedLine.d108.s2|60-70|accompanied|O
DDI-MedLine.d108.s2|77-79|300|O
DDI-MedLine.d108.s2|80-80|%|O
DDI-MedLine.d108.s2|82-89|increase|O
DDI-MedLine.d108.s2|98-106|frequency|O
DDI-MedLine.d108.s2|111-120|admissions|O
DDI-MedLine.d108.s2|126-130|mania|O
DDI-MedLine.d108.s2|133-139|whereas|O
DDI-MedLine.d108.s2|38-41|area|O
DDI-MedLine.d108.s2|159-162|West|O
DDI-MedLine.d108.s2|164-171|Midlands|O
DDI-MedLine.d108.s2|176-180|large|O
DDI-MedLine.d108.s2|182-189|decrease|O
DDI-MedLine.d108.s2|195-202|achieved|O
DDI-MedLine.d108.s2|203-203|.|O
DDI-DrugBank.d499.s0|0-2|The|O
DDI-DrugBank.d499.s0|4-12|following|O
DDI-DrugBank.d499.s0|14-17|drug|O
DDI-DrugBank.d499.s0|19-30|interactions|O
DDI-DrugBank.d499.s0|37-43|studied|O
DDI-DrugBank.d499.s0|50-59|ketoprofen|O
DDI-DrugBank.d499.s0|61-65|doses|O
DDI-DrugBank.d499.s0|70-72|200|O
DDI-DrugBank.d499.s0|74-79|mg/day|O
DDI-DrugBank.d499.s0|80-80|.|O
DDI-DrugBank.d499.s1|0-2|The|O
DDI-DrugBank.d499.s1|4-14|possibility|O
DDI-DrugBank.d499.s1|19-27|increased|O
DDI-DrugBank.d499.s1|29-39|interaction|O
DDI-DrugBank.d499.s1|51-54|kept|O
DDI-DrugBank.d499.s1|59-62|mind|O
DDI-DrugBank.d499.s1|69-74|Orudis|O
DDI-DrugBank.d499.s1|76-80|doses|O
DDI-DrugBank.d499.s1|82-88|greater|O
DDI-DrugBank.d499.s1|95-96|50|O
DDI-DrugBank.d499.s1|98-99|mg|O
DDI-DrugBank.d499.s1|106-111|single|O
DDI-DrugBank.d499.s1|76-79|dose|O
DDI-DrugBank.d499.s1|121-123|200|O
DDI-DrugBank.d499.s1|98-99|mg|O
DDI-DrugBank.d499.s1|131-140|ketoprofen|O
DDI-DrugBank.d499.s1|142-144|per|O
DDI-DrugBank.d499.s1|146-148|day|O
DDI-DrugBank.d499.s1|154-157|used|O
DDI-DrugBank.d499.s1|159-171|concomitantly|O
DDI-DrugBank.d499.s1|178-183|highly|O
DDI-DrugBank.d499.s1|185-189|bound|O
DDI-DrugBank.d499.s1|191-195|drugs|O
DDI-DrugBank.d499.s1|196-196|.|O
DDI-DrugBank.d499.s2|0-0|1|O
DDI-DrugBank.d499.s2|1-1|.|O
DDI-DrugBank.d499.s3|0-7|Antacids|O
DDI-DrugBank.d499.s3|10-20|Concomitant|O
DDI-DrugBank.d499.s3|22-35|administration|O
DDI-DrugBank.d499.s3|40-48|magnesium|O
DDI-DrugBank.d499.s3|50-58|hydroxide|O
DDI-DrugBank.d499.s3|64-71|aluminum|O
DDI-DrugBank.d499.s3|50-58|hydroxide|O
DDI-DrugBank.d499.s3|92-100|interfere|O
DDI-DrugBank.d499.s3|111-114|rate|O
DDI-DrugBank.d499.s3|119-124|extent|O
DDI-DrugBank.d499.s3|133-142|absorption|O
DDI-DrugBank.d499.s3|147-156|ketoprofen|O
DDI-DrugBank.d499.s3|158-169|administered|O
DDI-DrugBank.d499.s3|174-179|Orudis|O
DDI-DrugBank.d499.s3|180-180|.|O
DDI-DrugBank.d499.s4|0-0|2|O
DDI-DrugBank.d499.s4|1-1|.|O
DDI-DrugBank.d499.s5|0-6|Aspirin|O
DDI-DrugBank.d499.s5|9-18|Ketoprofen|O
DDI-DrugBank.d499.s5|29-33|alter|O
DDI-DrugBank.d499.s5|35-41|aspirin|O
DDI-DrugBank.d499.s5|43-52|absorption|O
DDI-DrugBank.d499.s6|0-6|however|O
DDI-DrugBank.d499.s6|14-18|study|O
DDI-DrugBank.d499.s6|23-24|12|O
DDI-DrugBank.d499.s6|26-31|normal|O
DDI-DrugBank.d499.s6|33-40|subjects|O
DDI-DrugBank.d499.s6|43-52|concurrent|O
DDI-DrugBank.d499.s6|54-67|administration|O
DDI-DrugBank.d499.s6|72-78|aspirin|O
DDI-DrugBank.d499.s6|80-88|decreased|O
DDI-DrugBank.d499.s6|90-99|ketoprofen|O
DDI-DrugBank.d499.s6|101-107|protein|O
DDI-DrugBank.d499.s6|109-115|binding|O
DDI-DrugBank.d499.s6|121-129|increased|O
DDI-DrugBank.d499.s6|90-99|ketoprofen|O
DDI-DrugBank.d499.s6|142-147|plasma|O
DDI-DrugBank.d499.s6|149-157|clearance|O
DDI-DrugBank.d499.s6|164-167|0.07|O
DDI-DrugBank.d499.s6|169-174|L/kg/h|O
DDI-DrugBank.d499.s6|176-182|without|O
DDI-DrugBank.d499.s6|72-78|aspirin|O
DDI-DrugBank.d499.s6|195-198|0.11|O
DDI-DrugBank.d499.s6|169-174|L/kg/h|O
DDI-DrugBank.d499.s6|72-78|aspirin|O
DDI-DrugBank.d499.s6|165-165|.|O
DDI-DrugBank.d499.s7|0-2|The|O
DDI-DrugBank.d499.s7|4-11|clinical|O
DDI-DrugBank.d499.s7|13-24|significance|O
DDI-DrugBank.d499.s7|35-41|changes|O
DDI-DrugBank.d499.s7|56-65|adequately|O
DDI-DrugBank.d499.s7|67-73|studied|O
DDI-DrugBank.d499.s7|74-74|.|O
DDI-DrugBank.d499.s8|0-8|Therefore|O
DDI-DrugBank.d499.s8|11-20|concurrent|O
DDI-DrugBank.d499.s8|22-24|use|O
DDI-DrugBank.d499.s8|29-35|aspirin|O
DDI-DrugBank.d499.s8|41-50|ketoprofen|O
DDI-DrugBank.d499.s8|59-69|recommended|O
DDI-DrugBank.d499.s8|70-70|.|O
DDI-DrugBank.d499.s9|0-0|3|O
DDI-DrugBank.d499.s9|1-1|.|O
DDI-DrugBank.d499.s10|0-7|Diuretic|O
DDI-DrugBank.d499.s10|10-28|Hydrochlorothiazide|O
DDI-DrugBank.d499.s10|31-35|given|O
DDI-DrugBank.d499.s10|37-49|concomitantly|O
DDI-DrugBank.d499.s10|56-65|ketoprofen|O
DDI-DrugBank.d499.s10|68-75|produces|O
DDI-DrugBank.d499.s10|79-87|reduction|O
DDI-DrugBank.d499.s10|92-98|urinary|O
DDI-DrugBank.d499.s10|100-108|potassium|O
DDI-DrugBank.d499.s10|114-121|chloride|O
DDI-DrugBank.d499.s10|123-131|excretion|O
DDI-DrugBank.d499.s10|133-140|compared|O
DDI-DrugBank.d499.s10|145-163|hydrochlorothiazide|O
DDI-DrugBank.d499.s10|165-169|alone|O
DDI-DrugBank.d499.s10|170-170|.|O
DDI-DrugBank.d499.s11|0-7|Patients|O
DDI-DrugBank.d499.s11|9-14|taking|O
DDI-DrugBank.d499.s11|16-24|diuretics|O
DDI-DrugBank.d499.s11|35-41|greater|O
DDI-DrugBank.d499.s11|43-46|risk|O
DDI-DrugBank.d499.s11|51-60|developing|O
DDI-DrugBank.d499.s11|62-66|renal|O
DDI-DrugBank.d499.s11|68-74|failure|O
DDI-DrugBank.d499.s11|76-84|secondary|O
DDI-DrugBank.d499.s11|91-98|decrease|O
DDI-DrugBank.d499.s11|62-66|renal|O
DDI-DrugBank.d499.s11|109-113|blood|O
DDI-DrugBank.d499.s11|115-118|flow|O
DDI-DrugBank.d499.s11|120-125|caused|O
DDI-DrugBank.d499.s11|130-142|prostaglandin|O
DDI-DrugBank.d499.s11|144-153|inhibition|O
DDI-DrugBank.d499.s11|154-154|.|O
DDI-DrugBank.d499.s12|0-0|4|O
DDI-DrugBank.d499.s12|1-1|.|O
DDI-DrugBank.d499.s13|0-6|Digoxin|O
DDI-DrugBank.d499.s13|9-10|In|O
DDI-DrugBank.d499.s13|14-18|study|O
DDI-DrugBank.d499.s13|23-24|12|O
DDI-DrugBank.d499.s13|26-33|patients|O
DDI-DrugBank.d499.s13|40-49|congestive|O
DDI-DrugBank.d499.s13|51-55|heart|O
DDI-DrugBank.d499.s13|57-63|failure|O
DDI-DrugBank.d499.s13|71-80|ketoprofen|O
DDI-DrugBank.d499.s13|86-92|digoxin|O
DDI-DrugBank.d499.s13|99-111|concomitantly|O
DDI-DrugBank.d499.s13|113-124|administered|O
DDI-DrugBank.d499.s13|71-80|ketoprofen|O
DDI-DrugBank.d499.s13|146-150|alter|O
DDI-DrugBank.d499.s13|156-160|serum|O
DDI-DrugBank.d499.s13|162-167|levels|O
DDI-DrugBank.d499.s13|86-92|digoxin|O
DDI-DrugBank.d499.s13|179-179|.|O
DDI-DrugBank.d499.s14|0-0|5|O
DDI-DrugBank.d499.s14|1-1|.|O
DDI-DrugBank.d499.s15|0-7|Warfarin|O
DDI-DrugBank.d499.s15|10-11|In|O
DDI-DrugBank.d499.s15|15-24|short-term|O
DDI-DrugBank.d499.s15|26-35|controlled|O
DDI-DrugBank.d499.s15|37-41|study|O
DDI-DrugBank.d499.s15|46-47|14|O
DDI-DrugBank.d499.s15|49-54|normal|O
DDI-DrugBank.d499.s15|56-65|volunteers|O
DDI-DrugBank.d499.s15|68-77|ketoprofen|O
DDI-DrugBank.d499.s15|87-99|significantly|O
DDI-DrugBank.d499.s15|101-109|interfere|O
DDI-DrugBank.d499.s15|120-125|effect|O
DDI-DrugBank.d499.s15|130-137|warfarin|O
DDI-DrugBank.d499.s15|142-152|prothrombin|O
DDI-DrugBank.d499.s15|154-157|time|O
DDI-DrugBank.d499.s15|158-158|.|O
DDI-DrugBank.d499.s16|0-7|Bleeding|O
DDI-DrugBank.d499.s16|16-21|number|O
DDI-DrugBank.d499.s16|26-30|sites|O
DDI-DrugBank.d499.s16|32-34|may|O
DDI-DrugBank.d499.s16|41-52|complication|O
DDI-DrugBank.d499.s16|57-64|warfarin|O
DDI-DrugBank.d499.s16|66-74|treatment|O
DDI-DrugBank.d499.s16|80-81|GI|O
DDI-DrugBank.d499.s16|83-90|bleeding|O
DDI-DrugBank.d499.s16|41-52|complication|O
DDI-DrugBank.d499.s16|110-119|ketoprofen|O
DDI-DrugBank.d499.s16|66-74|treatment|O
DDI-DrugBank.d499.s16|130-130|.|O
DDI-DrugBank.d499.s17|0-6|Because|O
DDI-DrugBank.d499.s17|8-21|prostaglandina|O
DDI-DrugBank.d499.s17|23-26|play|O
DDI-DrugBank.d499.s17|31-39|important|O
DDI-DrugBank.d499.s17|41-44|role|O
DDI-DrugBank.d499.s17|49-58|hemostasis|O
DDI-DrugBank.d499.s17|64-73|ketoprofen|O
DDI-DrugBank.d499.s17|82-87|effect|O
DDI-DrugBank.d499.s17|92-99|platelet|O
DDI-DrugBank.d499.s17|101-108|function|O
DDI-DrugBank.d499.s17|113-116|well|O
DDI-DrugBank.d499.s17|119-127|concurent|O
DDI-DrugBank.d499.s17|129-135|therapy|O
DDI-DrugBank.d499.s17|64-73|ketoprofen|O
DDI-DrugBank.d499.s17|157-164|warfarin|O
DDI-DrugBank.d499.s17|166-173|requires|O
DDI-DrugBank.d499.s17|175-179|close|O
DDI-DrugBank.d499.s17|181-190|monitoring|O
DDI-DrugBank.d499.s17|195-202|patients|O
DDI-DrugBank.d499.s17|212-216|drugs|O
DDI-DrugBank.d499.s17|217-217|.|O
DDI-DrugBank.d499.s18|0-0|6|O
DDI-DrugBank.d499.s18|1-1|.|O
DDI-DrugBank.d499.s19|0-9|Probenecid|O
DDI-DrugBank.d499.s19|0-9|Probenecid|O
DDI-DrugBank.d499.s19|23-31|increases|O
DDI-DrugBank.d499.s19|38-41|free|O
DDI-DrugBank.d499.s19|47-51|bound|O
DDI-DrugBank.d499.s19|53-62|ketoprofen|O
DDI-DrugBank.d499.s19|67-74|reducing|O
DDI-DrugBank.d499.s19|80-85|plasma|O
DDI-DrugBank.d499.s19|87-95|clearance|O
DDI-DrugBank.d499.s19|53-62|ketoprofen|O
DDI-DrugBank.d499.s19|120-128|one-third|O
DDI-DrugBank.d499.s19|134-137|well|O
DDI-DrugBank.d499.s19|142-151|decreasing|O
DDI-DrugBank.d499.s19|157-163|protein|O
DDI-DrugBank.d499.s19|165-171|binding|O
DDI-DrugBank.d499.s19|172-172|.|O
DDI-DrugBank.d499.s20|0-8|Therefore|O
DDI-DrugBank.d499.s20|15-25|combination|O
DDI-DrugBank.d499.s20|30-39|ketoprofen|O
DDI-DrugBank.d499.s20|45-54|probenecid|O
DDI-DrugBank.d499.s20|63-73|recommended|O
DDI-DrugBank.d499.s20|74-74|.|O
DDI-DrugBank.d499.s21|0-0|7|O
DDI-DrugBank.d499.s21|1-1|.|O
DDI-DrugBank.d499.s22|0-11|Methotrexate|O
DDI-DrugBank.d499.s22|14-23|Ketoprofen|O
DDI-DrugBank.d499.s22|26-29|like|O
DDI-DrugBank.d499.s22|37-42|NSAIDs|O
DDI-DrugBank.d499.s22|45-47|may|O
DDI-DrugBank.d499.s22|49-53|cause|O
DDI-DrugBank.d499.s22|55-61|changes|O
DDI-DrugBank.d499.s22|70-80|elimination|O
DDI-DrugBank.d499.s22|85-96|methotrexate|O
DDI-DrugBank.d499.s22|98-104|leading|O
DDI-DrugBank.d499.s22|109-116|elevated|O
DDI-DrugBank.d499.s22|118-122|serum|O
DDI-DrugBank.d499.s22|124-129|levels|O
DDI-DrugBank.d499.s22|138-141|drug|O
DDI-DrugBank.d499.s22|147-155|increased|O
DDI-DrugBank.d499.s22|157-164|toxicity|O
DDI-DrugBank.d499.s22|165-165|.|O
DDI-DrugBank.d499.s23|0-0|8|O
DDI-DrugBank.d499.s23|1-1|.|O
DDI-DrugBank.d499.s24|0-6|Lithium|O
DDI-DrugBank.d499.s24|9-20|Nonsteroidal|O
DDI-DrugBank.d499.s24|22-38|anti-inflammatory|O
DDI-DrugBank.d499.s24|40-45|agents|O
DDI-DrugBank.d499.s24|57-64|reported|O
DDI-DrugBank.d499.s24|69-76|increase|O
DDI-DrugBank.d499.s24|78-88|steadystate|O
DDI-DrugBank.d499.s24|90-95|plasma|O
DDI-DrugBank.d499.s24|97-103|lithium|O
DDI-DrugBank.d499.s24|105-110|levels|O
DDI-DrugBank.d499.s24|111-111|.|O
DDI-DrugBank.d499.s25|0-1|It|O
DDI-DrugBank.d499.s25|6-16|recommended|O
DDI-DrugBank.d499.s25|23-28|plasma|O
DDI-DrugBank.d499.s25|30-36|lithium|O
DDI-DrugBank.d499.s25|38-43|levels|O
DDI-DrugBank.d499.s25|48-56|monitored|O
DDI-DrugBank.d499.s25|63-72|ketoprofen|O
DDI-DrugBank.d499.s25|77-90|coadministered|O
DDI-DrugBank.d499.s25|30-36|lithium|O
DDI-DrugBank.d499.s25|104-104|.|O
DDI-DrugBank.d499.s26|0-14|DRUG/LABORATORY|O
DDI-DrugBank.d499.s26|16-19|TEST|O
DDI-DrugBank.d499.s26|21-32|INTERACTIONS|O
DDI-DrugBank.d499.s26|35-40|EFFECT|O
DDI-DrugBank.d499.s26|30-31|ON|O
DDI-DrugBank.d499.s26|45-49|BLOOD|O
DDI-DrugBank.d499.s26|51-61|COAGULATION|O
DDI-DrugBank.d499.s26|63-72|Ketoprofen|O
DDI-DrugBank.d499.s26|74-82|decreases|O
DDI-DrugBank.d499.s26|84-91|platelet|O
DDI-DrugBank.d499.s26|93-100|adhesion|O
DDI-DrugBank.d499.s26|106-116|aggregation|O
DDI-DrugBank.d499.s26|117-117|.|O
DDI-DrugBank.d499.s27|0-8|Therefore|O
DDI-DrugBank.d499.s27|18-24|prolong|O
DDI-DrugBank.d499.s27|26-33|bleeding|O
DDI-DrugBank.d499.s27|35-38|time|O
DDI-DrugBank.d499.s27|43-55|approximately|O
DDI-DrugBank.d499.s27|57-57|3|O
DDI-DrugBank.d499.s27|62-62|4|O
DDI-DrugBank.d499.s27|64-70|minutes|O
DDI-DrugBank.d499.s27|77-84|baseline|O
DDI-DrugBank.d499.s27|86-91|values|O
DDI-DrugBank.d499.s27|92-92|.|O
DDI-DrugBank.d499.s28|0-4|There|O
DDI-DrugBank.d499.s28|12-22|significant|O
DDI-DrugBank.d499.s28|24-29|change|O
DDI-DrugBank.d499.s28|34-41|platelet|O
DDI-DrugBank.d499.s28|43-47|count|O
DDI-DrugBank.d499.s28|50-60|prothrombin|O
DDI-DrugBank.d499.s28|62-65|time|O
DDI-DrugBank.d499.s28|68-74|partial|O
DDI-DrugBank.d499.s28|76-89|thromboplastin|O
DDI-DrugBank.d499.s28|62-65|time|O
DDI-DrugBank.d499.s28|53-60|thrombin|O
DDI-DrugBank.d499.s28|62-65|time|O
DDI-DrugBank.d499.s28|113-113|.|O
DDI-DrugBank.d194.s0|0-6|Caution|O
DDI-DrugBank.d194.s0|18-26|exercised|O
DDI-DrugBank.d194.s0|33-45|administering|O
DDI-DrugBank.d194.s0|47-55|ETOPOPHOS|O
DDI-DrugBank.d194.s0|62-66|drugs|O
DDI-DrugBank.d194.s0|77-81|known|O
DDI-DrugBank.d194.s0|86-92|inhibit|O
DDI-DrugBank.d194.s0|94-104|phosphatase|O
DDI-DrugBank.d194.s0|106-115|activities|O
DDI-DrugBank.d194.s0|118-121|e.g.|O
DDI-DrugBank.d194.s0|124-133|levamisole|O
DDI-DrugBank.d194.s0|135-147|hydrochloride|O
DDI-DrugBank.d194.s0|119-119|.|O
DDI-DrugBank.d194.s1|0-8|High-dose|O
DDI-DrugBank.d194.s1|10-20|cyclosporin|O
DDI-DrugBank.d194.s1|22-22|A|O
DDI-DrugBank.d194.s1|24-32|resulting|O
DDI-DrugBank.d194.s1|37-50|concentrations|O
DDI-DrugBank.d194.s1|58-61|2000|O
DDI-DrugBank.d194.s1|63-67|ng/mL|O
DDI-DrugBank.d194.s1|69-80|administered|O
DDI-DrugBank.d194.s1|87-90|oral|O
DDI-DrugBank.d194.s1|92-100|etoposide|O
DDI-DrugBank.d194.s1|106-108|led|O
DDI-DrugBank.d194.s1|116-117|80|O
DDI-DrugBank.d194.s1|118-118|%|O
DDI-DrugBank.d194.s1|120-127|increase|O
DDI-DrugBank.d194.s1|92-100|etoposide|O
DDI-DrugBank.d194.s1|142-149|exposure|O
DDI-DrugBank.d194.s1|158-159|38|O
DDI-DrugBank.d194.s1|118-118|%|O
DDI-DrugBank.d194.s1|162-169|decrease|O
DDI-DrugBank.d194.s1|174-178|total|O
DDI-DrugBank.d194.s1|180-183|body|O
DDI-DrugBank.d194.s1|185-193|clearance|O
DDI-DrugBank.d194.s1|92-100|etoposide|O
DDI-DrugBank.d194.s1|208-215|compared|O
DDI-DrugBank.d194.s1|92-100|etoposide|O
DDI-DrugBank.d194.s1|230-234|alone|O
DDI-DrugBank.d194.s1|235-235|.|O
DDI-DrugBank.d473.s0|0-7|Although|O
DDI-DrugBank.d473.s0|12-19|clinical|O
DDI-DrugBank.d473.s0|21-29|drug-drug|O
DDI-DrugBank.d473.s0|31-41|interaction|O
DDI-DrugBank.d473.s0|43-49|studies|O
DDI-DrugBank.d473.s0|61-69|conducted|O
DDI-DrugBank.d473.s0|74-77|date|O
DDI-DrugBank.d473.s0|87-91|basis|O
DDI-DrugBank.d473.s0|103-107|vitro|O
DDI-DrugBank.d473.s0|43-49|studies|O
DDI-DrugBank.d473.s0|118-127|cytochrome|O
DDI-DrugBank.d473.s0|129-132|p450|O
DDI-DrugBank.d473.s0|134-143|inhibitors|O
DDI-DrugBank.d473.s0|149-156|inducers|O
DDI-DrugBank.d473.s0|162-169|unlikely|O
DDI-DrugBank.d473.s0|174-179|affect|O
DDI-DrugBank.d473.s0|185-194|metabolism|O
DDI-DrugBank.d473.s0|199-209|clofarabine|O
DDI-DrugBank.d473.s0|210-210|.|O
DDI-DrugBank.d473.s1|0-2|The|O
DDI-DrugBank.d473.s1|4-9|effect|O
DDI-DrugBank.d473.s1|14-24|clofarabine|O
DDI-DrugBank.d473.s1|33-42|metabolism|O
DDI-DrugBank.d473.s1|47-56|cytochrome|O
DDI-DrugBank.d473.s1|58-61|p450|O
DDI-DrugBank.d473.s1|63-72|substrates|O
DDI-DrugBank.d473.s1|87-93|studied|O
DDI-DrugBank.d473.s1|94-94|.|O
DDI-DrugBank.d473.s2|0-14|Drug/Laboratory|O
DDI-DrugBank.d473.s2|16-20|Tests|O
DDI-DrugBank.d473.s2|22-33|Interactions|O
DDI-DrugBank.d473.s2|35-39|There|O
DDI-DrugBank.d473.s2|48-52|known|O
DDI-DrugBank.d473.s2|54-63|clinically|O
DDI-DrugBank.d473.s2|65-75|significant|O
DDI-DrugBank.d473.s2|77-88|interactions|O
DDI-DrugBank.d473.s2|93-98|CLOLAR|O
DDI-DrugBank.d473.s2|112-122|medications|O
DDI-DrugBank.d473.s2|127-136|laboratory|O
DDI-DrugBank.d473.s2|138-142|tests|O
DDI-DrugBank.d473.s2|143-143|.|O
DDI-DrugBank.d473.s3|0-1|No|O
DDI-DrugBank.d473.s3|3-8|formal|O
DDI-DrugBank.d473.s3|10-24|drug/laboratory|O
DDI-DrugBank.d473.s3|26-29|test|O
DDI-DrugBank.d473.s3|31-41|interaction|O
DDI-DrugBank.d473.s3|43-49|studies|O
DDI-DrugBank.d473.s3|61-69|conducted|O
DDI-DrugBank.d473.s3|76-81|CLOLAR|O
DDI-DrugBank.d473.s3|84-84|.|O
DDI-MedLine.d195.s0|0-8|Influence|O
DDI-MedLine.d195.s0|13-20|piperine|O
DDI-MedLine.d195.s0|25-33|ibuprofen|O
DDI-MedLine.d195.s0|35-41|induced|O
DDI-MedLine.d195.s0|43-57|antinociception|O
DDI-MedLine.d195.s0|67-82|pharmacokinetics|O
DDI-MedLine.d195.s0|83-83|.|O
DDI-MedLine.d195.s1|0-7|Piperine|O
DDI-MedLine.d195.s1|10-12|CAS|O
DDI-MedLine.d195.s1|14-20|94-62-2|O
DDI-MedLine.d195.s1|27-34|alkaloid|O
DDI-MedLine.d195.s1|36-43|obtained|O
DDI-MedLine.d195.s1|0-4|Piper|O
DDI-MedLine.d195.s1|56-61|nigrum|O
DDI-MedLine.d195.s1|0-0|P|O
DDI-MedLine.d195.s1|68-68|.|O
DDI-MedLine.d195.s2|0-5|longum|O
DDI-MedLine.d195.s2|13-17|known|O
DDI-MedLine.d195.s2|19-27|inhibitor|O
DDI-MedLine.d195.s2|32-38|various|O
DDI-MedLine.d195.s2|40-46|enzymes|O
DDI-MedLine.d195.s2|49-51|CYP|O
DDI-MedLine.d195.s2|53-60|isozymes|O
DDI-MedLine.d195.s2|63-73|responsible|O
DDI-MedLine.d195.s2|79-95|biotransformation|O
DDI-MedLine.d195.s2|100-104|drugs|O
DDI-MedLine.d195.s2|105-105|.|O
DDI-MedLine.d195.s3|0-1|By|O
DDI-MedLine.d195.s3|3-12|inhibiting|O
DDI-MedLine.d195.s3|18-27|metabolism|O
DDI-MedLine.d195.s3|32-36|drugs|O
DDI-MedLine.d195.s3|39-46|piperine|O
DDI-MedLine.d195.s3|48-55|improves|O
DDI-MedLine.d195.s3|61-75|bioavailability|O
DDI-MedLine.d195.s3|32-36|drugs|O
DDI-MedLine.d195.s3|85-85|.|O
DDI-MedLine.d195.s4|0-1|In|O
DDI-MedLine.d195.s4|7-13|present|O
DDI-MedLine.d195.s4|15-19|study|O
DDI-MedLine.d195.s4|21-28|piperine|O
DDI-MedLine.d195.s4|31-32|10|O
DDI-MedLine.d195.s4|34-38|mg/kg|O
DDI-MedLine.d195.s4|41-53|significantly|O
DDI-MedLine.d195.s4|55-63|increased|O
DDI-MedLine.d195.s4|69-82|dose-dependent|O
DDI-MedLine.d195.s4|84-98|antinociceptive|O
DDI-MedLine.d195.s4|100-107|activity|O
DDI-MedLine.d195.s4|112-120|ibuprofen|O
DDI-MedLine.d195.s4|122-130|evaluated|O
DDI-MedLine.d195.s4|140-145|acetic|O
DDI-MedLine.d195.s4|147-150|acid|O
DDI-MedLine.d195.s4|152-159|writhing|O
DDI-MedLine.d195.s4|165-172|formalin|O
DDI-MedLine.d195.s4|174-177|test|O
DDI-MedLine.d195.s4|192-203|administered|O
DDI-MedLine.d195.s4|112-120|ibuprofen|O
DDI-MedLine.d195.s4|219-219|.|O
DDI-MedLine.d195.s5|0-8|Ibuprofen|O
DDI-MedLine.d195.s5|10-15|plasma|O
DDI-MedLine.d195.s5|17-29|concentration|O
DDI-MedLine.d195.s5|35-38|also|O
DDI-MedLine.d195.s5|40-48|increased|O
DDI-MedLine.d195.s5|62-73|administered|O
DDI-MedLine.d195.s5|80-87|piperine|O
DDI-MedLine.d195.s5|88-88|.|O
DDI-MedLine.d195.s6|0-2|The|O
DDI-MedLine.d195.s6|4-14|synergistic|O
DDI-MedLine.d195.s6|16-30|antinociception|O
DDI-MedLine.d195.s6|32-39|activity|O
DDI-MedLine.d195.s6|44-52|ibuprofen|O
DDI-MedLine.d195.s6|59-70|administered|O
DDI-MedLine.d195.s6|77-84|piperine|O
DDI-MedLine.d195.s6|93-102|attributed|O
DDI-MedLine.d195.s6|107-115|increased|O
DDI-MedLine.d195.s6|117-122|plasma|O
DDI-MedLine.d195.s6|124-136|concentration|O
DDI-MedLine.d195.s6|44-52|ibuprofen|O
DDI-MedLine.d195.s6|150-150|.|O
DDI-MedLine.d195.s7|0-3|From|O
DDI-MedLine.d195.s7|10-14|study|O
DDI-MedLine.d195.s7|26-34|concluded|O
DDI-MedLine.d195.s7|41-48|piperine|O
DDI-MedLine.d195.s7|57-60|used|O
DDI-MedLine.d195.s7|67-77|bioenhancer|O
DDI-MedLine.d195.s7|79-83|along|O
DDI-MedLine.d195.s7|90-98|ibuprofen|O
DDI-MedLine.d195.s7|99-99|.|O
DDI-MedLine.d14.s0|0-0|[|O
DDI-MedLine.d14.s0|1-1|A|O
DDI-MedLine.d14.s0|3-17|pharmacological|O
DDI-MedLine.d14.s0|19-26|analysis|O
DDI-MedLine.d14.s0|35-40|effect|O
DDI-MedLine.d14.s0|45-55|angiotensin|O
DDI-MedLine.d14.s0|60-69|stimulated|O
DDI-MedLine.d14.s0|71-77|gastric|O
DDI-MedLine.d14.s0|79-87|secretion|O
DDI-MedLine.d14.s0|88-88|]|O
DDI-MedLine.d14.s0|91-97|Chronic|O
DDI-MedLine.d14.s0|99-109|experiments|O
DDI-MedLine.d14.s0|114-117|dogs|O
DDI-MedLine.d14.s0|71-77|gastric|O
DDI-MedLine.d14.s0|132-139|fistulas|O
DDI-MedLine.d14.s0|146-152|carried|O
DDI-MedLine.d14.s0|161-165|study|O
DDI-MedLine.d14.s0|171-179|influence|O
DDI-MedLine.d14.s0|45-55|angiotensin|O
DDI-MedLine.d14.s0|196-196|1|O
DDI-MedLine.d14.s0|45-55|angiotensin|O
DDI-MedLine.d14.s0|214-214|2|O
DDI-MedLine.d14.s0|219-231|pentagastrin-|O
DDI-MedLine.d14.s0|237-253|histamine-induced|O
DDI-MedLine.d14.s0|71-77|gastric|O
DDI-MedLine.d14.s0|263-266|acid|O
DDI-MedLine.d14.s0|79-87|secretion|O
DDI-MedLine.d14.s0|277-277|.|O
DDI-MedLine.d14.s1|0-1|It|O
DDI-MedLine.d14.s1|7-17|established|O
DDI-MedLine.d14.s1|29-40|angiotensins|O
DDI-MedLine.d14.s1|42-50|inhibited|O
DDI-MedLine.d14.s1|52-58|gastric|O
DDI-MedLine.d14.s1|60-63|acid|O
DDI-MedLine.d14.s1|65-73|secretion|O
DDI-MedLine.d14.s1|75-84|stimulated|O
DDI-MedLine.d14.s1|89-100|pentagastrin|O
DDI-MedLine.d14.s1|113-121|histamine|O
DDI-MedLine.d14.s1|122-122|.|O
DDI-MedLine.d14.s2|0-10|Comparative|O
DDI-MedLine.d14.s2|12-19|analysis|O
DDI-MedLine.d14.s2|28-34|effects|O
DDI-MedLine.d14.s2|39-49|stimulation|O
DDI-MedLine.d14.s2|55-64|inhibition|O
DDI-MedLine.d14.s2|69-76|cholino-|O
DDI-MedLine.d14.s2|82-96|adrenoreceptors|O
DDI-MedLine.d14.s2|106-115|inhibitory|O
DDI-MedLine.d14.s2|117-122|action|O
DDI-MedLine.d14.s2|127-138|angiotensins|O
DDI-MedLine.d14.s2|140-148|suggested|O
DDI-MedLine.d14.s2|154-162|mediation|O
DDI-MedLine.d14.s2|127-137|angiotensin|O
DDI-MedLine.d14.s2|179-187|influence|O
DDI-MedLine.d14.s2|201-210|modulation|O
DDI-MedLine.d14.s2|215-225|cholinergic|O
DDI-MedLine.d14.s2|227-235|reactions|O
DDI-MedLine.d14.s2|240-247|parietal|O
DDI-MedLine.d14.s2|249-253|cells|O
DDI-MedLine.d14.s2|262-268|stomach|O
DDI-MedLine.d14.s2|269-269|.|O
DDI-DrugBank.d217.s0|0-7|Elevated|O
DDI-DrugBank.d217.s0|9-14|plasma|O
DDI-DrugBank.d217.s0|16-21|levels|O
DDI-DrugBank.d217.s0|26-37|theophylline|O
DDI-DrugBank.d217.s0|49-56|reported|O
DDI-DrugBank.d217.s0|63-73|concomitant|O
DDI-DrugBank.d217.s0|75-83|quinolone|O
DDI-DrugBank.d217.s0|85-87|use|O
DDI-DrugBank.d217.s0|88-88|.|O
DDI-DrugBank.d217.s1|0-4|There|O
DDI-DrugBank.d217.s1|16-22|reports|O
DDI-DrugBank.d217.s1|27-46|theophylline-related|O
DDI-DrugBank.d217.s1|48-51|side|O
DDI-DrugBank.d217.s1|53-59|effects|O
DDI-DrugBank.d217.s1|64-71|patients|O
DDI-DrugBank.d217.s1|76-86|concomitant|O
DDI-DrugBank.d217.s1|88-94|therapy|O
DDI-DrugBank.d217.s1|101-111|norfloxacin|O
DDI-DrugBank.d217.s1|27-38|theophylline|O
DDI-DrugBank.d217.s1|129-129|.|O
DDI-DrugBank.d217.s2|0-8|Therefore|O
DDI-DrugBank.d217.s2|11-20|monitoring|O
DDI-DrugBank.d217.s2|25-36|theophylline|O
DDI-DrugBank.d217.s2|38-43|plasma|O
DDI-DrugBank.d217.s2|45-50|levels|O
DDI-DrugBank.d217.s2|62-71|considered|O
DDI-DrugBank.d217.s2|77-82|dosage|O
DDI-DrugBank.d217.s2|25-36|theophylline|O
DDI-DrugBank.d217.s2|100-107|adjusted|O
DDI-DrugBank.d217.s2|112-119|required|O
DDI-DrugBank.d217.s2|120-120|.|O
DDI-DrugBank.d217.s3|0-7|Elevated|O
DDI-DrugBank.d217.s3|9-13|serum|O
DDI-DrugBank.d217.s3|15-20|levels|O
DDI-DrugBank.d217.s3|25-36|cyclosporine|O
DDI-DrugBank.d217.s3|48-55|reported|O
DDI-DrugBank.d217.s3|62-72|concomitant|O
DDI-DrugBank.d217.s3|74-76|use|O
DDI-DrugBank.d217.s3|25-36|cyclosporine|O
DDI-DrugBank.d217.s3|99-109|norfloxacin|O
DDI-DrugBank.d217.s3|110-110|.|O
DDI-DrugBank.d217.s4|0-8|Therefore|O
DDI-DrugBank.d217.s4|11-22|cyclosporine|O
DDI-DrugBank.d217.s4|24-28|serum|O
DDI-DrugBank.d217.s4|30-35|levels|O
DDI-DrugBank.d217.s4|47-55|monitored|O
DDI-DrugBank.d217.s4|61-71|appropriate|O
DDI-DrugBank.d217.s4|11-22|cyclosporine|O
DDI-DrugBank.d217.s4|86-91|dosage|O
DDI-DrugBank.d217.s4|93-103|adjustments|O
DDI-DrugBank.d217.s4|105-108|made|O
DDI-DrugBank.d217.s4|121-125|drugs|O
DDI-DrugBank.d217.s4|131-134|used|O
DDI-DrugBank.d217.s4|136-148|concomitantly|O
DDI-DrugBank.d217.s4|149-149|.|O
DDI-DrugBank.d217.s5|0-9|Quinolones|O
DDI-DrugBank.d217.s5|12-20|including|O
DDI-DrugBank.d217.s5|22-32|norfloxacin|O
DDI-DrugBank.d217.s5|35-37|may|O
DDI-DrugBank.d217.s5|39-45|enhance|O
DDI-DrugBank.d217.s5|51-57|effects|O
DDI-DrugBank.d217.s5|62-65|oral|O
DDI-DrugBank.d217.s5|67-80|anticoagulants|O
DDI-DrugBank.d217.s5|12-20|including|O
DDI-DrugBank.d217.s5|93-100|warfarin|O
DDI-DrugBank.d217.s5|109-119|derivatives|O
DDI-DrugBank.d217.s5|124-130|similar|O
DDI-DrugBank.d217.s5|132-137|agents|O
DDI-DrugBank.d217.s5|138-138|.|O
DDI-DrugBank.d217.s6|0-3|When|O
DDI-DrugBank.d217.s6|11-18|products|O
DDI-DrugBank.d217.s6|24-35|administered|O
DDI-DrugBank.d217.s6|37-49|concomitantly|O
DDI-DrugBank.d217.s6|52-62|prothrombin|O
DDI-DrugBank.d217.s6|64-67|time|O
DDI-DrugBank.d217.s6|78-85|suitable|O
DDI-DrugBank.d217.s6|87-97|coagulation|O
DDI-DrugBank.d217.s6|99-103|tests|O
DDI-DrugBank.d217.s6|115-121|closely|O
DDI-DrugBank.d217.s6|123-131|monitored|O
DDI-DrugBank.d217.s6|132-132|.|O
DDI-DrugBank.d217.s7|0-2|The|O
DDI-DrugBank.d217.s7|4-14|concomitant|O
DDI-DrugBank.d217.s7|16-29|administration|O
DDI-DrugBank.d217.s7|34-43|quinolones|O
DDI-DrugBank.d217.s7|45-53|including|O
DDI-DrugBank.d217.s7|55-65|norfloxacin|O
DDI-DrugBank.d217.s7|72-80|glyburide|O
DDI-DrugBank.d217.s7|85-96|sulfonylurea|O
DDI-DrugBank.d217.s7|98-102|agent|O
DDI-DrugBank.d217.s7|113-116|rare|O
DDI-DrugBank.d217.s7|118-126|occasions|O
DDI-DrugBank.d217.s7|129-136|resulted|O
DDI-DrugBank.d217.s7|141-146|severe|O
DDI-DrugBank.d217.s7|148-159|hypoglycemia|O
DDI-DrugBank.d217.s7|160-160|.|O
DDI-DrugBank.d217.s8|0-8|Therefore|O
DDI-DrugBank.d217.s8|11-20|monitoring|O
DDI-DrugBank.d217.s8|25-29|blood|O
DDI-DrugBank.d217.s8|31-37|glucose|O
DDI-DrugBank.d217.s8|42-52|recommended|O
DDI-DrugBank.d217.s8|65-70|agents|O
DDI-DrugBank.d217.s8|76-90|co-administered|O
DDI-DrugBank.d217.s8|91-91|.|O
DDI-DrugBank.d217.s9|0-9|Diminished|O
DDI-DrugBank.d217.s9|11-17|urinary|O
DDI-DrugBank.d217.s9|19-27|excretion|O
DDI-DrugBank.d217.s9|32-42|norfloxacin|O
DDI-DrugBank.d217.s9|53-60|reported|O
DDI-DrugBank.d217.s9|73-83|concomitant|O
DDI-DrugBank.d217.s9|85-98|administration|O
DDI-DrugBank.d217.s9|103-112|probenecid|O
DDI-DrugBank.d217.s9|32-42|norfloxacin|O
DDI-DrugBank.d217.s9|129-129|.|O
DDI-DrugBank.d217.s10|0-2|The|O
DDI-DrugBank.d217.s10|4-14|concomitant|O
DDI-DrugBank.d217.s10|16-18|use|O
DDI-DrugBank.d217.s10|23-36|nitrofurantoin|O
DDI-DrugBank.d217.s10|45-55|recommended|O
DDI-DrugBank.d217.s10|57-61|since|O
DDI-DrugBank.d217.s10|23-36|nitrofurantoin|O
DDI-DrugBank.d217.s10|78-80|may|O
DDI-DrugBank.d217.s10|82-91|antagonize|O
DDI-DrugBank.d217.s10|97-109|antibacterial|O
DDI-DrugBank.d217.s10|111-116|effect|O
DDI-DrugBank.d217.s10|121-131|Norfloxacin|O
DDI-DrugBank.d217.s10|140-146|urinary|O
DDI-DrugBank.d217.s10|148-152|tract|O
DDI-DrugBank.d217.s10|153-153|.|O
DDI-DrugBank.d217.s11|0-12|Multivitamins|O
DDI-DrugBank.d217.s11|24-31|products|O
DDI-DrugBank.d217.s11|33-42|containing|O
DDI-DrugBank.d217.s11|44-47|iron|O
DDI-DrugBank.d217.s11|52-55|zinc|O
DDI-DrugBank.d217.s11|58-65|antacids|O
DDI-DrugBank.d217.s11|70-79|sucralfate|O
DDI-DrugBank.d217.s11|95-106|administered|O
DDI-DrugBank.d217.s11|108-120|concomitantly|O
DDI-DrugBank.d217.s11|131-136|within|O
DDI-DrugBank.d217.s11|138-138|2|O
DDI-DrugBank.d217.s11|140-144|hours|O
DDI-DrugBank.d217.s11|154-167|administration|O
DDI-DrugBank.d217.s11|172-182|norfloxacin|O
DDI-DrugBank.d217.s11|198-200|may|O
DDI-DrugBank.d217.s11|202-210|interfere|O
DDI-DrugBank.d217.s11|217-226|absorption|O
DDI-DrugBank.d217.s11|228-236|resulting|O
DDI-DrugBank.d217.s11|241-245|lower|O
DDI-DrugBank.d217.s11|247-251|serum|O
DDI-DrugBank.d217.s11|257-261|urine|O
DDI-DrugBank.d217.s11|263-268|levels|O
DDI-DrugBank.d217.s11|172-182|norfloxacin|O
DDI-DrugBank.d217.s11|284-284|.|O
DDI-DrugBank.d217.s12|0-4|Videx|O
DDI-DrugBank.d217.s12|7-16|Didanosine|O
DDI-DrugBank.d217.s12|19-35|chewable/buffered|O
DDI-DrugBank.d217.s12|37-43|tablets|O
DDI-DrugBank.d217.s12|52-60|pediatric|O
DDI-DrugBank.d217.s12|62-67|powder|O
DDI-DrugBank.d217.s12|73-76|oral|O
DDI-DrugBank.d217.s12|78-85|solution|O
DDI-DrugBank.d217.s12|101-112|administered|O
DDI-DrugBank.d217.s12|114-126|concomitantly|O
DDI-DrugBank.d217.s12|137-142|within|O
DDI-DrugBank.d217.s12|144-144|2|O
DDI-DrugBank.d217.s12|146-150|hours|O
DDI-DrugBank.d217.s12|160-173|administration|O
DDI-DrugBank.d217.s12|178-188|norfloxacin|O
DDI-DrugBank.d217.s12|205-212|products|O
DDI-DrugBank.d217.s12|214-216|may|O
DDI-DrugBank.d217.s12|218-226|interfere|O
DDI-DrugBank.d217.s12|233-242|absorption|O
DDI-DrugBank.d217.s12|244-252|resulting|O
DDI-DrugBank.d217.s12|257-261|lower|O
DDI-DrugBank.d217.s12|263-267|serum|O
DDI-DrugBank.d217.s12|273-277|urine|O
DDI-DrugBank.d217.s12|279-284|levels|O
DDI-DrugBank.d217.s12|178-188|norfloxacin|O
DDI-DrugBank.d217.s12|300-300|.|O
DDI-DrugBank.d217.s13|0-3|Some|O
DDI-DrugBank.d217.s13|5-14|quinolones|O
DDI-DrugBank.d217.s13|21-24|also|O
DDI-DrugBank.d217.s13|31-35|shown|O
DDI-DrugBank.d217.s13|40-48|interfere|O
DDI-DrugBank.d217.s13|59-68|metabolism|O
DDI-DrugBank.d217.s13|73-80|caffeine|O
DDI-DrugBank.d217.s13|81-81|.|O
DDI-DrugBank.d217.s14|0-3|This|O
DDI-DrugBank.d217.s14|5-7|may|O
DDI-DrugBank.d217.s14|9-12|lead|O
DDI-DrugBank.d217.s14|17-23|reduced|O
DDI-DrugBank.d217.s14|25-33|clearance|O
DDI-DrugBank.d217.s14|38-45|caffeine|O
DDI-DrugBank.d217.s14|53-64|prolongation|O
DDI-DrugBank.d217.s14|73-78|plasma|O
DDI-DrugBank.d217.s14|80-88|half-life|O
DDI-DrugBank.d217.s14|89-89|.|O
DDI-DrugBank.d415.s0|0-12|Coumarin-Type|O
DDI-DrugBank.d415.s0|14-27|Anticoagulants|O
DDI-DrugBank.d415.s0|30-36|Several|O
DDI-DrugBank.d415.s0|38-47|short-term|O
DDI-DrugBank.d415.s0|49-58|controlled|O
DDI-DrugBank.d415.s0|60-66|studies|O
DDI-DrugBank.d415.s0|68-73|failed|O
DDI-DrugBank.d415.s0|78-82|wshow|O
DDI-DrugBank.d415.s0|89-97|ibuprofen|O
DDI-DrugBank.d415.s0|99-111|significantly|O
DDI-DrugBank.d415.s0|113-120|affected|O
DDI-DrugBank.d415.s0|122-132|prothrombin|O
DDI-DrugBank.d415.s0|134-138|times|O
DDI-DrugBank.d415.s0|145-151|variety|O
DDI-DrugBank.d415.s0|162-169|clotting|O
DDI-DrugBank.d415.s0|171-177|factors|O
DDI-DrugBank.d415.s0|184-195|administered|O
DDI-DrugBank.d415.s0|200-210|individuals|O
DDI-DrugBank.d415.s0|215-227|coumarin-type|O
DDI-DrugBank.d415.s0|229-242|anticoagulants|O
DDI-DrugBank.d415.s0|243-243|.|O
DDI-DrugBank.d415.s1|0-6|However|O
DDI-DrugBank.d415.s1|17-24|bleeding|O
DDI-DrugBank.d415.s1|35-42|reported|O
DDI-DrugBank.d415.s1|49-57|ibuprofen|O
DDI-DrugBank.d415.s1|69-80|nonsteroidal|O
DDI-DrugBank.d415.s1|82-98|anti-inflammatory|O
DDI-DrugBank.d415.s1|100-105|agents|O
DDI-DrugBank.d415.s1|117-128|administered|O
DDI-DrugBank.d415.s1|133-140|patients|O
DDI-DrugBank.d415.s1|145-157|coumarin-type|O
DDI-DrugBank.d415.s1|159-172|anticoagulants|O
DDI-DrugBank.d415.s1|179-187|physician|O
DDI-DrugBank.d415.s1|199-206|cautious|O
DDI-DrugBank.d415.s1|213-225|administering|O
DDI-DrugBank.d415.s1|49-57|ibuprofen|O
DDI-DrugBank.d415.s1|133-140|patients|O
DDI-DrugBank.d415.s1|159-172|anticoagulants|O
DDI-DrugBank.d415.s1|266-266|.|O
DDI-DrugBank.d415.s2|0-6|Aspirin|O
DDI-DrugBank.d415.s2|9-14|Animal|O
DDI-DrugBank.d415.s2|16-22|studies|O
DDI-DrugBank.d415.s2|24-28|wshow|O
DDI-DrugBank.d415.s2|35-41|aspirin|O
DDI-DrugBank.d415.s2|43-47|given|O
DDI-DrugBank.d415.s2|54-65|nonsteroidal|O
DDI-DrugBank.d415.s2|67-83|anti-inflammatory|O
DDI-DrugBank.d415.s2|85-90|agents|O
DDI-DrugBank.d415.s2|93-101|including|O
DDI-DrugBank.d415.s2|103-111|ibuprofen|O
DDI-DrugBank.d415.s2|114-119|yields|O
DDI-DrugBank.d415.s2|123-125|net|O
DDI-DrugBank.d415.s2|127-134|decrease|O
DDI-DrugBank.d415.s2|67-83|anti-inflammatory|O
DDI-DrugBank.d415.s2|157-164|activity|O
DDI-DrugBank.d415.s2|171-177|lowered|O
DDI-DrugBank.d415.s2|179-183|blood|O
DDI-DrugBank.d415.s2|185-190|levels|O
DDI-DrugBank.d415.s2|199-209|non-aspirin|O
DDI-DrugBank.d415.s2|211-214|drug|O
DDI-DrugBank.d415.s2|215-215|.|O
DDI-DrugBank.d415.s3|0-5|Single|O
DDI-DrugBank.d415.s3|7-10|dose|O
DDI-DrugBank.d415.s3|12-26|bioavailability|O
DDI-DrugBank.d415.s3|28-34|studies|O
DDI-DrugBank.d415.s3|39-44|normal|O
DDI-DrugBank.d415.s3|46-55|volunteers|O
DDI-DrugBank.d415.s3|62-67|failed|O
DDI-DrugBank.d415.s3|72-76|wshow|O
DDI-DrugBank.d415.s3|81-86|effect|O
DDI-DrugBank.d415.s3|91-97|aspirin|O
DDI-DrugBank.d415.s3|102-110|ibuprofen|O
DDI-DrugBank.d415.s3|112-116|blood|O
DDI-DrugBank.d415.s3|118-123|levels|O
DDI-DrugBank.d415.s3|124-124|.|O
DDI-DrugBank.d415.s4|0-10|Correlative|O
DDI-DrugBank.d415.s4|12-19|clinical|O
DDI-DrugBank.d415.s4|21-27|studies|O
DDI-DrugBank.d415.s4|43-51|performed|O
DDI-DrugBank.d415.s4|52-52|.|O
DDI-DrugBank.d415.s5|0-11|Methotrexate|O
DDI-DrugBank.d415.s5|14-22|Ibuprofen|O
DDI-DrugBank.d415.s5|28-31|well|O
DDI-DrugBank.d415.s5|42-53|nonsteroidal|O
DDI-DrugBank.d415.s5|55-71|anti-inflammatory|O
DDI-DrugBank.d415.s5|73-77|drugs|O
DDI-DrugBank.d415.s5|80-87|probably|O
DDI-DrugBank.d415.s5|89-95|reduces|O
DDI-DrugBank.d415.s5|101-107|tubular|O
DDI-DrugBank.d415.s5|109-117|secretion|O
DDI-DrugBank.d415.s5|122-133|methotrexate|O
DDI-DrugBank.d415.s5|135-139|based|O
DDI-DrugBank.d415.s5|147-151|vitro|O
DDI-DrugBank.d415.s5|153-159|studies|O
DDI-DrugBank.d415.s5|164-169|rabbit|O
DDI-DrugBank.d415.s5|171-176|kidney|O
DDI-DrugBank.d415.s5|178-183|slices|O
DDI-DrugBank.d415.s5|184-184|.|O
DDI-DrugBank.d415.s6|0-3|This|O
DDI-DrugBank.d415.s6|5-7|may|O
DDI-DrugBank.d415.s6|9-16|indicate|O
DDI-DrugBank.d415.s6|23-31|ibuprofen|O
DDI-DrugBank.d415.s6|33-37|could|O
DDI-DrugBank.d415.s6|39-45|enhance|O
DDI-DrugBank.d415.s6|51-58|toxicity|O
DDI-DrugBank.d415.s6|63-74|methotrexate|O
DDI-DrugBank.d415.s6|75-75|.|O
DDI-DrugBank.d415.s7|0-6|Caution|O
DDI-DrugBank.d415.s7|18-21|used|O
DDI-DrugBank.d415.s7|26-34|ibuprofen|O
DDI-DrugBank.d415.s7|39-50|administered|O
DDI-DrugBank.d415.s7|52-64|concomitantly|O
DDI-DrugBank.d415.s7|71-82|methotrexate|O
DDI-DrugBank.d415.s7|83-83|.|O
DDI-DrugBank.d415.s8|0-2|H-2|O
DDI-DrugBank.d415.s8|4-14|Antagonists|O
DDI-DrugBank.d415.s8|17-18|In|O
DDI-DrugBank.d415.s8|20-26|studies|O
DDI-DrugBank.d415.s8|33-37|human|O
DDI-DrugBank.d415.s8|39-48|volunteers|O
DDI-DrugBank.d415.s8|51-67|co-administration|O
DDI-DrugBank.d415.s8|72-81|cimetidine|O
DDI-DrugBank.d415.s8|86-95|ranitidine|O
DDI-DrugBank.d415.s8|102-110|ibuprofen|O
DDI-DrugBank.d415.s8|119-129|substantive|O
DDI-DrugBank.d415.s8|131-136|effect|O
DDI-DrugBank.d415.s8|102-110|ibuprofen|O
DDI-DrugBank.d415.s8|151-155|serum|O
DDI-DrugBank.d415.s8|157-170|concentrations|O
DDI-DrugBank.d415.s8|171-171|.|O
DDI-DrugBank.d415.s9|0-9|Furosemide|O
DDI-DrugBank.d415.s9|12-19|Clinical|O
DDI-DrugBank.d415.s9|21-27|studies|O
DDI-DrugBank.d415.s9|33-36|well|O
DDI-DrugBank.d415.s9|41-46|random|O
DDI-DrugBank.d415.s9|48-59|observations|O
DDI-DrugBank.d415.s9|67-71|shown|O
DDI-DrugBank.d415.s9|78-86|ibuprofen|O
DDI-DrugBank.d415.s9|92-97|reduce|O
DDI-DrugBank.d415.s9|103-113|natriuretic|O
DDI-DrugBank.d415.s9|115-120|effect|O
DDI-DrugBank.d415.s9|125-134|furosemide|O
DDI-DrugBank.d415.s9|140-148|thiazides|O
DDI-DrugBank.d415.s9|158-165|patients|O
DDI-DrugBank.d415.s9|166-166|.|O
DDI-DrugBank.d415.s10|0-3|This|O
DDI-DrugBank.d415.s10|5-12|response|O
DDI-DrugBank.d415.s10|23-32|attributed|O
DDI-DrugBank.d415.s10|37-46|inhibition|O
DDI-DrugBank.d415.s10|51-55|renal|O
DDI-DrugBank.d415.s10|57-69|prostaglandin|O
DDI-DrugBank.d415.s10|71-79|synthesis|O
DDI-DrugBank.d415.s10|80-80|.|O
DDI-DrugBank.d415.s11|0-5|During|O
DDI-DrugBank.d415.s11|7-17|concomitant|O
DDI-DrugBank.d415.s11|19-25|therapy|O
DDI-DrugBank.d415.s11|32-40|ibuprofen|O
DDI-DrugBank.d415.s11|47-53|patient|O
DDI-DrugBank.d415.s11|65-72|observed|O
DDI-DrugBank.d415.s11|74-80|closely|O
DDI-DrugBank.d415.s11|86-90|signs|O
DDI-DrugBank.d415.s11|95-99|renal|O
DDI-DrugBank.d415.s11|101-107|failure|O
DDI-DrugBank.d415.s11|113-116|well|O
DDI-DrugBank.d415.s11|124-129|assure|O
DDI-DrugBank.d415.s11|131-138|diuretic|O
DDI-DrugBank.d415.s11|140-147|efficacy|O
DDI-DrugBank.d415.s11|148-148|.|O
DDI-DrugBank.d415.s12|0-6|Lithium|O
DDI-DrugBank.d415.s12|9-17|Ibuprofen|O
DDI-DrugBank.d415.s12|19-26|produced|O
DDI-DrugBank.d415.s12|31-39|elevation|O
DDI-DrugBank.d415.s12|44-49|plasma|O
DDI-DrugBank.d415.s12|51-57|lithium|O
DDI-DrugBank.d415.s12|59-64|levels|O
DDI-DrugBank.d415.s12|72-80|reduction|O
DDI-DrugBank.d415.s12|85-89|renal|O
DDI-DrugBank.d415.s12|51-57|lithium|O
DDI-DrugBank.d415.s12|99-107|clearance|O
DDI-DrugBank.d415.s12|114-118|study|O
DDI-DrugBank.d415.s12|123-128|eleven|O
DDI-DrugBank.d415.s12|130-135|normal|O
DDI-DrugBank.d415.s12|137-146|volunteers|O
DDI-DrugBank.d415.s12|147-147|.|O
DDI-DrugBank.d415.s13|0-2|The|O
DDI-DrugBank.d415.s13|4-7|mean|O
DDI-DrugBank.d415.s13|9-15|minimum|O
DDI-DrugBank.d415.s13|17-23|lithium|O
DDI-DrugBank.d415.s13|25-37|concentration|O
DDI-DrugBank.d415.s13|39-47|increased|O
DDI-DrugBank.d415.s13|49-50|15|O
DDI-DrugBank.d415.s13|51-51|%|O
DDI-DrugBank.d415.s13|61-65|renal|O
DDI-DrugBank.d415.s13|67-75|clearance|O
DDI-DrugBank.d415.s13|17-23|lithium|O
DDI-DrugBank.d415.s13|92-100|decreased|O
DDI-DrugBank.d415.s13|105-106|19|O
DDI-DrugBank.d415.s13|51-51|%|O
DDI-DrugBank.d415.s13|121-126|period|O
DDI-DrugBank.d415.s13|131-141|concomitant|O
DDI-DrugBank.d415.s13|143-146|drug|O
DDI-DrugBank.d415.s13|148-161|administration|O
DDI-DrugBank.d415.s13|162-162|.|O
DDI-DrugBank.d415.s14|0-3|This|O
DDI-DrugBank.d415.s14|5-10|effect|O
DDI-DrugBank.d415.s14|21-30|attributed|O
DDI-DrugBank.d415.s14|35-44|inhibition|O
DDI-DrugBank.d415.s14|49-53|renal|O
DDI-DrugBank.d415.s14|55-67|prostaglandin|O
DDI-DrugBank.d415.s14|69-77|synthesis|O
DDI-DrugBank.d415.s14|82-90|ibuprofen|O
DDI-DrugBank.d415.s14|91-91|.|O
DDI-DrugBank.d415.s15|0-3|Thus|O
DDI-DrugBank.d415.s15|11-19|ibuprofen|O
DDI-DrugBank.d415.s15|25-31|lithium|O
DDI-DrugBank.d415.s15|37-48|administered|O
DDI-DrugBank.d415.s15|50-61|concurrently|O
DDI-DrugBank.d415.s15|64-71|subjects|O
DDI-DrugBank.d415.s15|83-90|observed|O
DDI-DrugBank.d415.s15|92-100|carefully|O
DDI-DrugBank.d415.s15|106-110|signs|O
DDI-DrugBank.d415.s15|25-31|lithium|O
DDI-DrugBank.d415.s15|123-130|toxicity|O
DDI-DrugBank.d415.s15|131-131|.|O
DDI-DrugBank.d415.s16|1-4|Read|O
DDI-DrugBank.d415.s16|6-14|circulars|O
DDI-DrugBank.d415.s16|20-26|lithium|O
DDI-DrugBank.d415.s16|28-38|preparation|O
DDI-DrugBank.d415.s16|47-49|use|O
DDI-DrugBank.d415.s16|59-68|concurrent|O
DDI-DrugBank.d415.s16|70-76|therapy|O
DDI-DrugBank.d415.s16|78-78|.|O
DDI-MedLine.d216.s0|0-7|Exposure|O
DDI-MedLine.d216.s0|12-15|oral|O
DDI-MedLine.d216.s0|17-26|S-ketamine|O
DDI-MedLine.d216.s0|31-40|unaffected|O
DDI-MedLine.d216.s0|45-56|itraconazole|O
DDI-MedLine.d216.s0|62-68|greatly|O
DDI-MedLine.d216.s0|70-78|increased|O
DDI-MedLine.d216.s0|83-93|ticlopidine|O
DDI-MedLine.d216.s0|94-94|.|O
DDI-MedLine.d216.s1|0-3|This|O
DDI-MedLine.d216.s1|5-9|study|O
DDI-MedLine.d216.s1|11-18|examined|O
DDI-MedLine.d216.s1|20-28|drug-drug|O
DDI-MedLine.d216.s1|30-41|interactions|O
DDI-MedLine.d216.s1|46-49|oral|O
DDI-MedLine.d216.s1|51-60|S-ketamine|O
DDI-MedLine.d216.s1|71-80|cytochrome|O
DDI-MedLine.d216.s1|82-85|P450|O
DDI-MedLine.d216.s1|88-90|CYP|O
DDI-MedLine.d216.s1|93-95|2B6|O
DDI-MedLine.d216.s1|97-105|inhibitor|O
DDI-MedLine.d216.s1|107-117|ticlopidine|O
DDI-MedLine.d216.s1|127-131|CYP3A|O
DDI-MedLine.d216.s1|97-105|inhibitor|O
DDI-MedLine.d216.s1|143-154|itraconazole|O
DDI-MedLine.d216.s1|155-155|.|O
DDI-MedLine.d216.s2|0-1|In|O
DDI-MedLine.d216.s2|8-17|randomized|O
DDI-MedLine.d216.s2|20-26|blinded|O
DDI-MedLine.d216.s2|29-37|crossover|O
DDI-MedLine.d216.s2|39-43|study|O
DDI-MedLine.d216.s2|46-47|11|O
DDI-MedLine.d216.s2|49-55|healthy|O
DDI-MedLine.d216.s2|57-66|volunteers|O
DDI-MedLine.d216.s2|68-75|ingested|O
DDI-MedLine.d216.s2|77-79|0.2|O
DDI-MedLine.d216.s2|81-85|mg/kg|O
DDI-MedLine.d216.s2|87-96|S-ketamine|O
DDI-MedLine.d216.s2|104-116|pretreatments|O
DDI-MedLine.d216.s2|123-126|oral|O
DDI-MedLine.d216.s2|128-138|ticlopidine|O
DDI-MedLine.d216.s2|141-143|250|O
DDI-MedLine.d216.s2|81-82|mg|O
DDI-MedLine.d216.s2|148-152|twice|O
DDI-MedLine.d216.s2|154-158|daily|O
DDI-MedLine.d216.s2|162-173|itraconazole|O
DDI-MedLine.d216.s2|176-178|200|O
DDI-MedLine.d216.s2|81-82|mg|O
DDI-MedLine.d216.s2|154-158|daily|O
DDI-MedLine.d216.s2|199-205|placebo|O
DDI-MedLine.d216.s2|210-214|6-day|O
DDI-MedLine.d216.s2|107-115|treatment|O
DDI-MedLine.d216.s2|226-232|periods|O
DDI-MedLine.d216.s2|237-245|intervals|O
DDI-MedLine.d216.s2|250-250|4|O
DDI-MedLine.d216.s2|252-256|weeks|O
DDI-MedLine.d216.s2|78-78|.|O
DDI-MedLine.d216.s3|0-10|Ticlopidine|O
DDI-MedLine.d216.s3|12-20|treatment|O
DDI-MedLine.d216.s3|22-30|increased|O
DDI-MedLine.d216.s3|36-39|mean|O
DDI-MedLine.d216.s3|41-44|area|O
DDI-MedLine.d216.s3|56-61|plasma|O
DDI-MedLine.d216.s3|63-80|concentration-time|O
DDI-MedLine.d216.s3|82-86|curve|O
DDI-MedLine.d216.s3|88-99|extrapolated|O
DDI-MedLine.d216.s3|104-111|infinity|O
DDI-MedLine.d216.s3|114-116|AUC|O
DDI-MedLine.d216.s3|118-119|0-|O
DDI-MedLine.d216.s3|129-132|oral|O
DDI-MedLine.d216.s3|134-141|ketamine|O
DDI-MedLine.d216.s3|146-153|2.4-fold|O
DDI-MedLine.d216.s3|156-162|whereas|O
DDI-MedLine.d216.s3|164-175|itraconazole|O
DDI-MedLine.d216.s3|12-20|treatment|O
DDI-MedLine.d216.s3|22-29|increase|O
DDI-MedLine.d216.s3|208-215|exposure|O
DDI-MedLine.d216.s3|220-229|S-ketamine|O
DDI-MedLine.d216.s3|147-147|.|O
DDI-MedLine.d216.s4|0-2|The|O
DDI-MedLine.d216.s4|4-8|ratio|O
DDI-MedLine.d216.s4|13-23|norketamine|O
DDI-MedLine.d216.s4|25-27|AUC|O
DDI-MedLine.d216.s4|29-30|0-|O
DDI-MedLine.d216.s4|16-23|ketamine|O
DDI-MedLine.d216.s4|25-27|AUC|O
DDI-MedLine.d216.s4|29-30|0-|O
DDI-MedLine.d216.s4|63-75|significantly|O
DDI-MedLine.d216.s4|77-85|decreased|O
DDI-MedLine.d216.s4|94-104|ticlopidine|O
DDI-MedLine.d216.s4|107-107|P|O
DDI-MedLine.d216.s4|109-109|&|O
DDI-MedLine.d216.s4|110-111|lt|O
DDI-MedLine.d216.s4|114-118|0.001|O
DDI-MedLine.d216.s4|125-136|itraconazole|O
DDI-MedLine.d216.s4|138-143|phases|O
DDI-MedLine.d216.s4|107-107|P|O
DDI-MedLine.d216.s4|148-148|=|O
DDI-MedLine.d216.s4|150-154|0.006|O
DDI-MedLine.d216.s4|160-167|compared|O
DDI-MedLine.d216.s4|172-178|placebo|O
DDI-MedLine.d216.s4|115-115|.|O
DDI-MedLine.d216.s5|0-1|In|O
DDI-MedLine.d216.s5|7-17|ticlopidine|O
DDI-MedLine.d216.s5|23-34|itraconazole|O
DDI-MedLine.d216.s5|36-41|phases|O
DDI-MedLine.d216.s5|48-52|areas|O
DDI-MedLine.d216.s5|64-74|effect-time|O
DDI-MedLine.d216.s5|76-81|curves|O
DDI-MedLine.d216.s5|84-96|self-reported|O
DDI-MedLine.d216.s5|98-107|drowsiness|O
DDI-MedLine.d216.s5|113-123|performance|O
DDI-MedLine.d216.s5|131-143|significantly|O
DDI-MedLine.d216.s5|145-150|higher|O
DDI-MedLine.d216.s5|170-176|placebo|O
DDI-MedLine.d216.s5|36-40|phase|O
DDI-MedLine.d216.s5|185-185|P|O
DDI-MedLine.d216.s5|187-187|<|O
DDI-MedLine.d216.s5|189-192|0.05|O
DDI-MedLine.d216.s5|190-190|.|O
DDI-MedLine.d216.s6|0-2|The|O
DDI-MedLine.d216.s6|4-11|findings|O
DDI-MedLine.d216.s6|13-19|suggest|O
DDI-MedLine.d216.s6|30-35|dosage|O
DDI-MedLine.d216.s6|40-49|S-ketamine|O
DDI-MedLine.d216.s6|61-67|reduced|O
DDI-MedLine.d216.s6|72-79|patients|O
DDI-MedLine.d216.s6|81-89|receiving|O
DDI-MedLine.d216.s6|91-101|ticlopidine|O
DDI-MedLine.d216.s6|102-102|.|O
DDI-DrugBank.d264.s0|0-1|No|O
DDI-DrugBank.d264.s0|3-13|Information|O
DDI-DrugBank.d264.s0|15-22|Provided|O
DDI-MedLine.d11.s0|0-16|Immunosuppressive|O
DDI-MedLine.d11.s0|18-22|drugs|O
DDI-MedLine.d11.s0|34-46|complications|O
DDI-MedLine.d11.s0|47-47|.|O
DDI-MedLine.d11.s1|0-4|Drugs|O
DDI-MedLine.d11.s1|11-18|suppress|O
DDI-MedLine.d11.s1|24-29|immune|O
DDI-MedLine.d11.s1|31-36|system|O
DDI-MedLine.d11.s1|42-47|widely|O
DDI-MedLine.d11.s1|49-52|used|O
DDI-MedLine.d11.s1|53-53|.|O
DDI-MedLine.d11.s2|0-3|They|O
DDI-MedLine.d11.s2|9-12|part|O
DDI-MedLine.d11.s2|21-29|treatment|O
DDI-MedLine.d11.s2|34-41|patients|O
DDI-MedLine.d11.s2|48-52|organ|O
DDI-MedLine.d11.s2|54-64|transplants|O
DDI-MedLine.d11.s2|67-76|malignancy|O
DDI-MedLine.d11.s2|83-94|increasingly|O
DDI-MedLine.d11.s2|107-116|conditions|O
DDI-MedLine.d11.s2|126-134|psoriasis|O
DDI-MedLine.d11.s2|137-146|rheumatoid|O
DDI-MedLine.d11.s2|148-156|arthritis|O
DDI-MedLine.d11.s2|163-167|liver|O
DDI-MedLine.d11.s2|173-177|bowel|O
DDI-MedLine.d11.s2|179-185|disease|O
DDI-MedLine.d11.s2|196-207|inflammation|O
DDI-MedLine.d11.s2|215-226|aetiological|O
DDI-MedLine.d11.s2|228-233|factor|O
DDI-MedLine.d11.s2|234-234|.|O
DDI-MedLine.d11.s3|0-6|Because|O
DDI-MedLine.d11.s3|15-24|broadening|O
DDI-MedLine.d11.s3|26-36|indications|O
DDI-MedLine.d11.s3|42-58|immunosuppressive|O
DDI-MedLine.d11.s3|60-64|drugs|O
DDI-MedLine.d11.s3|75-83|prolonged|O
DDI-MedLine.d11.s3|85-92|survival|O
DDI-MedLine.d11.s3|97-106|conditions|O
DDI-MedLine.d11.s3|133-136|used|O
DDI-MedLine.d11.s3|139-142|many|O
DDI-MedLine.d11.s3|144-151|patients|O
DDI-MedLine.d11.s3|156-172|immunosuppression|O
DDI-MedLine.d11.s3|182-186|cared|O
DDI-MedLine.d11.s3|199-207|community|O
DDI-MedLine.d11.s3|212-215|seen|O
DDI-MedLine.d11.s3|220-233|non-specialist|O
DDI-MedLine.d11.s3|235-243|hospitals|O
DDI-MedLine.d11.s3|246-252|usually|O
DDI-MedLine.d11.s3|257-261|close|O
DDI-MedLine.d11.s3|263-275|collaboration|O
DDI-MedLine.d11.s3|224-233|specialist|O
DDI-MedLine.d11.s4|0-3|This|O
DDI-MedLine.d11.s4|5-11|article|O
DDI-MedLine.d11.s4|13-17|looks|O
DDI-MedLine.d11.s4|22-25|five|O
DDI-MedLine.d11.s4|27-34|commonly|O
DDI-MedLine.d11.s4|36-39|used|O
DDI-MedLine.d11.s4|41-57|immunosuppressive|O
DDI-MedLine.d11.s4|59-63|drugs|O
DDI-MedLine.d11.s4|68-71|turn|O
DDI-MedLine.d11.s4|74-88|corticosteroids|O
DDI-MedLine.d11.s4|91-101|cyclosporin|O
DDI-MedLine.d11.s4|104-115|azathioprine|O
DDI-MedLine.d11.s4|118-129|methotrexate|O
DDI-MedLine.d11.s4|132-147|cyclophosphamide|O
DDI-MedLine.d11.s4|151-160|discussing|O
DDI-MedLine.d11.s4|166-169|main|O
DDI-MedLine.d11.s4|172-184|non-infection|O
DDI-MedLine.d11.s4|187-194|unwanted|O
DDI-MedLine.d11.s4|196-202|effects|O
DDI-MedLine.d11.s4|205-208|ways|O
DDI-MedLine.d11.s4|213-217|avoid|O
DDI-MedLine.d11.s4|242-249|problems|O
DDI-MedLine.d11.s4|251-255|arise|O
DDI-MedLine.d11.s4|256-256|.|O
DDI-MedLine.d11.s5|0-2|The|O
DDI-MedLine.d11.s5|4-13|management|O
DDI-MedLine.d11.s5|18-26|infection|O
DDI-MedLine.d11.s5|31-35|dealt|O
DDI-MedLine.d11.s5|47-54|separate|O
DDI-MedLine.d11.s5|56-62|section|O
DDI-MedLine.d11.s5|63-63|.|O
DDI-DrugBank.d487.s0|0-2|The|O
DDI-DrugBank.d487.s0|4-18|pharmacokinetic|O
DDI-DrugBank.d487.s0|20-31|interactions|O
DDI-DrugBank.d487.s0|33-38|listed|O
DDI-DrugBank.d487.s0|50-60|potentially|O
DDI-DrugBank.d487.s0|62-71|clinically|O
DDI-DrugBank.d487.s0|73-81|important|O
DDI-DrugBank.d487.s0|82-82|.|O
DDI-DrugBank.d487.s1|0-4|Drugs|O
DDI-DrugBank.d487.s1|11-16|induce|O
DDI-DrugBank.d487.s1|18-24|hepatic|O
DDI-DrugBank.d487.s1|26-32|enzymes|O
DDI-DrugBank.d487.s1|42-54|phenobarbital|O
DDI-DrugBank.d487.s1|57-65|phenytoin|O
DDI-DrugBank.d487.s1|71-78|rifampin|O
DDI-DrugBank.d487.s1|80-82|may|O
DDI-DrugBank.d487.s1|84-91|increase|O
DDI-DrugBank.d487.s1|97-105|clearance|O
DDI-DrugBank.d487.s1|110-124|corticosteroids|O
DDI-DrugBank.d487.s1|80-82|may|O
DDI-DrugBank.d487.s1|134-140|require|O
DDI-DrugBank.d487.s1|142-150|increases|O
DDI-DrugBank.d487.s1|110-123|corticosteroid|O
DDI-DrugBank.d487.s1|170-173|dose|O
DDI-DrugBank.d487.s1|178-184|achieve|O
DDI-DrugBank.d487.s1|190-196|desired|O
DDI-DrugBank.d487.s1|198-205|response|O
DDI-DrugBank.d487.s1|206-206|.|O
DDI-DrugBank.d487.s2|0-4|Drugs|O
DDI-DrugBank.d487.s2|14-27|troleandomycin|O
DDI-DrugBank.d487.s2|33-44|ketoconazole|O
DDI-DrugBank.d487.s2|46-48|may|O
DDI-DrugBank.d487.s2|50-56|inhibit|O
DDI-DrugBank.d487.s2|62-71|metabolism|O
DDI-DrugBank.d487.s2|76-90|corticosteroids|O
DDI-DrugBank.d487.s2|96-99|thus|O
DDI-DrugBank.d487.s2|101-108|decrease|O
DDI-DrugBank.d487.s2|116-124|clearance|O
DDI-DrugBank.d487.s2|125-125|.|O
DDI-DrugBank.d487.s3|0-8|Therefore|O
DDI-DrugBank.d487.s3|15-18|dose|O
DDI-DrugBank.d487.s3|23-36|corticosteroid|O
DDI-DrugBank.d487.s3|48-55|titrated|O
DDI-DrugBank.d487.s3|60-64|avoid|O
DDI-DrugBank.d487.s3|30-36|steroid|O
DDI-DrugBank.d487.s3|74-81|toxicity|O
DDI-DrugBank.d487.s3|82-82|.|O
DDI-DrugBank.d487.s4|0-14|Corticosteroids|O
DDI-DrugBank.d487.s4|16-18|may|O
DDI-DrugBank.d487.s4|20-27|increase|O
DDI-DrugBank.d487.s4|33-41|clearance|O
DDI-DrugBank.d487.s4|46-52|chronic|O
DDI-DrugBank.d487.s4|54-57|high|O
DDI-DrugBank.d487.s4|59-62|dose|O
DDI-DrugBank.d487.s4|64-70|aspirin|O
DDI-DrugBank.d487.s4|71-71|.|O
DDI-DrugBank.d487.s5|0-3|This|O
DDI-DrugBank.d487.s5|5-9|could|O
DDI-DrugBank.d487.s5|11-14|lead|O
DDI-DrugBank.d487.s5|19-27|decreased|O
DDI-DrugBank.d487.s5|29-38|salicylate|O
DDI-DrugBank.d487.s5|40-44|serum|O
DDI-DrugBank.d487.s5|46-51|levels|O
DDI-DrugBank.d487.s5|56-63|increase|O
DDI-DrugBank.d487.s5|69-72|risk|O
DDI-DrugBank.d487.s5|29-38|salicylate|O
DDI-DrugBank.d487.s5|88-95|toxicity|O
DDI-DrugBank.d487.s5|102-115|corticosteroid|O
DDI-DrugBank.d487.s5|120-128|withdrawn|O
DDI-DrugBank.d487.s5|129-129|.|O
DDI-DrugBank.d487.s6|0-6|Aspirin|O
DDI-DrugBank.d487.s6|18-21|used|O
DDI-DrugBank.d487.s6|23-32|cautiously|O
DDI-DrugBank.d487.s6|37-47|conjunction|O
DDI-DrugBank.d487.s6|54-69|cortico-steroids|O
DDI-DrugBank.d487.s6|74-81|patients|O
DDI-DrugBank.d487.s6|83-91|suffering|O
DDI-DrugBank.d487.s6|98-117|hypopro-thrombinemia|O
DDI-DrugBank.d487.s6|118-118|.|O
DDI-DrugBank.d487.s7|0-2|The|O
DDI-DrugBank.d487.s7|4-9|effect|O
DDI-DrugBank.d487.s7|14-28|corticosteroids|O
DDI-DrugBank.d487.s7|33-36|oral|O
DDI-DrugBank.d487.s7|38-51|anticoagulants|O
DDI-DrugBank.d487.s7|56-63|variable|O
DDI-DrugBank.d487.s7|64-64|.|O
DDI-DrugBank.d487.s8|0-4|There|O
DDI-DrugBank.d487.s8|10-16|reports|O
DDI-DrugBank.d487.s8|21-28|enhanced|O
DDI-DrugBank.d487.s8|33-36|well|O
DDI-DrugBank.d487.s8|41-50|diminished|O
DDI-DrugBank.d487.s8|52-58|effects|O
DDI-DrugBank.d487.s8|63-76|anticoagulants|O
DDI-DrugBank.d487.s8|83-87|given|O
DDI-DrugBank.d487.s8|89-100|concurrently|O
DDI-DrugBank.d487.s8|107-121|corticosteroids|O
DDI-DrugBank.d487.s8|122-122|.|O
DDI-DrugBank.d487.s9|0-8|Therefore|O
DDI-DrugBank.d487.s9|11-21|coagulation|O
DDI-DrugBank.d487.s9|23-29|indices|O
DDI-DrugBank.d487.s9|41-49|monitored|O
DDI-DrugBank.d487.s9|54-61|maintain|O
DDI-DrugBank.d487.s9|67-73|desired|O
DDI-DrugBank.d487.s9|75-87|anticoagulant|O
DDI-DrugBank.d487.s9|89-94|effect|O
DDI-DrugBank.d487.s9|95-95|.|O
DDI-DrugBank.d721.s0|0-2|The|O
DDI-DrugBank.d721.s0|4-18|bioavailability|O
DDI-DrugBank.d721.s0|23-28|SKELID|O
DDI-DrugBank.d721.s0|33-41|decreased|O
DDI-DrugBank.d721.s0|43-44|80|O
DDI-DrugBank.d721.s0|45-45|%|O
DDI-DrugBank.d721.s0|50-56|calcium|O
DDI-DrugBank.d721.s0|50-56|calcium|O
DDI-DrugBank.d721.s0|23-28|SKELID|O
DDI-DrugBank.d721.s0|87-98|administered|O
DDI-DrugBank.d721.s0|112-115|time|O
DDI-DrugBank.d721.s0|122-123|60|O
DDI-DrugBank.d721.s0|45-45|%|O
DDI-DrugBank.d721.s0|134-142|aluminum-|O
DDI-DrugBank.d721.s0|147-166|magnesium-containing|O
DDI-DrugBank.d721.s0|168-175|antacids|O
DDI-DrugBank.d721.s0|87-98|administered|O
DDI-DrugBank.d721.s0|196-196|1|O
DDI-DrugBank.d721.s0|198-201|hour|O
DDI-DrugBank.d721.s0|23-28|SKELID|O
DDI-DrugBank.d721.s0|216-216|.|O
DDI-DrugBank.d721.s1|0-6|Aspirin|O
DDI-DrugBank.d721.s1|8-10|may|O
DDI-DrugBank.d721.s1|12-19|decrease|O
DDI-DrugBank.d721.s1|21-35|bioavailability|O
DDI-DrugBank.d721.s1|40-45|SKELID|O
DDI-DrugBank.d721.s1|56-57|50|O
DDI-DrugBank.d721.s1|58-58|%|O
DDI-DrugBank.d721.s1|65-69|taken|O
DDI-DrugBank.d721.s1|71-71|2|O
DDI-DrugBank.d721.s1|73-77|hours|O
DDI-DrugBank.d721.s1|40-45|SKELID|O
DDI-DrugBank.d721.s1|91-91|.|O
DDI-DrugBank.d721.s2|0-2|The|O
DDI-DrugBank.d721.s2|4-18|bioavailability|O
DDI-DrugBank.d721.s2|23-28|SKELID|O
DDI-DrugBank.d721.s2|33-41|increased|O
DDI-DrugBank.d721.s2|43-45|2-4|O
DDI-DrugBank.d721.s2|47-50|fold|O
DDI-DrugBank.d721.s2|55-66|indomethacin|O
DDI-DrugBank.d721.s2|79-91|significantly|O
DDI-DrugBank.d721.s2|93-99|altered|O
DDI-DrugBank.d721.s2|104-119|coadministration|O
DDI-DrugBank.d721.s2|124-133|diclofenac|O
DDI-DrugBank.d721.s2|134-134|.|O
DDI-DrugBank.d721.s3|0-2|The|O
DDI-DrugBank.d721.s3|4-18|pharmacokinetic|O
DDI-DrugBank.d721.s3|20-29|parameters|O
DDI-DrugBank.d721.s3|34-40|digoxin|O
DDI-DrugBank.d721.s3|50-62|significantly|O
DDI-DrugBank.d721.s3|64-71|modified|O
DDI-DrugBank.d721.s3|76-81|SKELID|O
DDI-DrugBank.d721.s3|83-98|coadministration|O
DDI-DrugBank.d721.s3|99-99|.|O
DDI-DrugBank.d721.s4|0-1|In|O
DDI-DrugBank.d721.s4|3-7|vitro|O
DDI-DrugBank.d721.s4|9-15|studies|O
DDI-DrugBank.d721.s4|17-20|show|O
DDI-DrugBank.d721.s4|27-37|tiludronate|O
DDI-DrugBank.d721.s4|48-55|displace|O
DDI-DrugBank.d721.s4|57-64|warfarin|O
DDI-DrugBank.d721.s4|75-81|binding|O
DDI-DrugBank.d721.s4|83-86|site|O
DDI-DrugBank.d721.s4|91-97|protein|O
DDI-DrugBank.d721.s4|98-98|.|O
DDI-MedLine.d34.s0|0-11|Interactions|O
DDI-MedLine.d34.s0|16-21|cobalt|O
DDI-MedLine.d34.s0|27-30|iron|O
DDI-MedLine.d34.s0|35-44|absorption|O
DDI-MedLine.d34.s0|50-58|retention|O
DDI-MedLine.d34.s0|59-59|.|O
DDI-MedLine.d34.s1|0-2|The|O
DDI-MedLine.d34.s1|4-10|effects|O
DDI-MedLine.d34.s1|15-27|supplementary|O
DDI-MedLine.d34.s1|29-32|oral|O
DDI-MedLine.d34.s1|34-39|cobalt|O
DDI-MedLine.d34.s1|45-48|iron|O
DDI-MedLine.d34.s1|54-57|well|O
DDI-MedLine.d34.s1|66-76|interaction|O
DDI-MedLine.d34.s1|98-107|absorption|O
DDI-MedLine.d34.s1|109-112|site|O
DDI-MedLine.d34.s1|115-119|fecal|O
DDI-MedLine.d34.s1|125-131|urinary|O
DDI-MedLine.d34.s1|133-141|excretion|O
DDI-MedLine.d34.s1|54-57|well|O
DDI-MedLine.d34.s1|158-166|retention|O
DDI-MedLine.d34.s1|177-181|trace|O
DDI-MedLine.d34.s1|183-190|elements|O
DDI-MedLine.d34.s1|197-206|determined|O
DDI-MedLine.d34.s1|211-215|using|O
DDI-MedLine.d34.s1|217-220|four|O
DDI-MedLine.d34.s1|222-226|diets|O
DDI-MedLine.d34.s1|228-237|containing|O
DDI-MedLine.d34.s1|239-244|either|O
DDI-MedLine.d34.s1|246-246|9|O
DDI-MedLine.d34.s1|251-252|63|O
DDI-MedLine.d34.s1|254-266|micrograms/kg|O
DDI-MedLine.d34.s1|271-272|Co|O
DDI-MedLine.d34.s1|278-279|48|O
DDI-MedLine.d34.s1|284-286|446|O
DDI-MedLine.d34.s1|288-292|mg/kg|O
DDI-MedLine.d34.s1|297-298|Fe|O
DDI-MedLine.d34.s1|307-312|period|O
DDI-MedLine.d34.s1|317-318|19|O
DDI-MedLine.d34.s1|320-323|days|O
DDI-MedLine.d34.s1|330-334|total|O
DDI-MedLine.d34.s1|339-340|24|O
DDI-MedLine.d34.s1|342-345|rats|O
DDI-MedLine.d34.s1|346-346|.|O
DDI-MedLine.d34.s2|0-8|Retention|O
DDI-MedLine.d34.s2|14-23|calculated|O
DDI-MedLine.d34.s2|32-38|balance|O
DDI-MedLine.d34.s2|40-48|technique|O
DDI-MedLine.d34.s2|61-71|comparative|O
DDI-MedLine.d34.s2|73-81|slaughter|O
DDI-MedLine.d34.s2|40-48|technique|O
DDI-MedLine.d34.s2|92-92|.|O
DDI-MedLine.d34.s3|0-4|After|O
DDI-MedLine.d34.s3|6-8|one|O
DDI-MedLine.d34.s3|10-12|day|O
DDI-MedLine.d34.s3|15-19|fecal|O
DDI-MedLine.d34.s3|24-27|well|O
DDI-MedLine.d34.s3|32-38|urinary|O
DDI-MedLine.d34.s3|40-48|excretion|O
DDI-MedLine.d34.s3|58-65|elements|O
DDI-MedLine.d34.s3|71-77|already|O
DDI-MedLine.d34.s3|79-87|responded|O
DDI-MedLine.d34.s3|96-102|dietary|O
DDI-MedLine.d34.s3|104-113|treatments|O
DDI-MedLine.d34.s3|121-128|constant|O
DDI-MedLine.d34.s3|130-135|values|O
DDI-MedLine.d34.s3|143-149|reached|O
DDI-MedLine.d34.s3|157-169|approximately|O
DDI-MedLine.d34.s3|171-175|three|O
DDI-MedLine.d34.s3|177-180|days|O
DDI-MedLine.d34.s3|181-181|.|O
DDI-MedLine.d34.s4|0-5|Cobalt|O
DDI-MedLine.d34.s4|7-15|excretion|O
DDI-MedLine.d34.s4|21-28|enhanced|O
DDI-MedLine.d34.s4|33-45|supplementary|O
DDI-MedLine.d34.s4|47-52|cobalt|O
DDI-MedLine.d34.s5|0-4|fecal|O
DDI-MedLine.d34.s5|6-14|excretion|O
DDI-MedLine.d34.s5|26-34|increased|O
DDI-MedLine.d34.s5|39-51|supplementary|O
DDI-MedLine.d34.s5|53-56|iron|O
DDI-MedLine.d34.s6|0-6|whereas|O
DDI-MedLine.d34.s6|8-14|urinary|O
DDI-MedLine.d34.s6|16-24|excretion|O
DDI-MedLine.d34.s6|30-38|decreased|O
DDI-MedLine.d34.s6|48-52|cases|O
DDI-MedLine.d34.s6|53-53|.|O
DDI-MedLine.d34.s7|0-9|Additional|O
DDI-MedLine.d34.s7|11-14|iron|O
DDI-MedLine.d34.s7|16-28|significantly|O
DDI-MedLine.d34.s7|30-38|inhibited|O
DDI-MedLine.d34.s7|44-53|absorption|O
DDI-MedLine.d34.s7|58-63|cobalt|O
DDI-MedLine.d34.s7|73-79|dietary|O
DDI-MedLine.d34.s7|58-63|cobalt|O
DDI-MedLine.d34.s7|88-97|treatments|O
DDI-MedLine.d34.s7|98-98|.|O
DDI-MedLine.d34.s8|0-2|The|O
DDI-MedLine.d34.s8|4-8|lower|O
DDI-MedLine.d34.s8|10-13|rate|O
DDI-MedLine.d34.s8|18-27|absorption|O
DDI-MedLine.d34.s8|36-41|groups|O
DDI-MedLine.d34.s8|43-51|receiving|O
DDI-MedLine.d34.s8|53-55|446|O
DDI-MedLine.d34.s8|57-58|mg|O
DDI-MedLine.d34.s8|60-61|Fe|O
DDI-MedLine.d34.s8|63-69|instead|O
DDI-MedLine.d34.s8|74-75|48|O
DDI-MedLine.d34.s8|57-58|mg|O
DDI-MedLine.d34.s8|60-61|Fe|O
DDI-MedLine.d34.s8|86-88|per|O
DDI-MedLine.d34.s8|90-91|kg|O
DDI-MedLine.d34.s8|93-96|diet|O
DDI-MedLine.d34.s8|98-105|resulted|O
DDI-MedLine.d34.s8|112-120|decreased|O
DDI-MedLine.d34.s8|122-126|renal|O
DDI-MedLine.d34.s8|128-136|excretion|O
DDI-MedLine.d34.s8|141-146|cobalt|O
DDI-MedLine.d34.s8|147-147|.|O
DDI-MedLine.d34.s9|0-11|Consequently|O
DDI-MedLine.d34.s9|18-23|effect|O
DDI-MedLine.d34.s9|28-31|iron|O
DDI-MedLine.d34.s9|40-48|retention|O
DDI-MedLine.d34.s9|53-58|cobalt|O
DDI-MedLine.d34.s9|64-68|lower|O
DDI-MedLine.d34.s9|78-87|absorption|O
DDI-MedLine.d34.s9|88-88|.|O
DDI-MedLine.d34.s10|0-3|This|O
DDI-MedLine.d34.s10|5-12|suggests|O
DDI-MedLine.d34.s10|19-30|interactions|O
DDI-MedLine.d34.s10|44-46|two|O
DDI-MedLine.d34.s10|48-55|elements|O
DDI-MedLine.d34.s10|62-65|take|O
DDI-MedLine.d34.s10|67-71|place|O
DDI-MedLine.d34.s10|80-83|site|O
DDI-MedLine.d34.s10|88-97|absorption|O
DDI-MedLine.d34.s10|98-98|.|O
DDI-MedLine.d34.s11|0-6|Because|O
DDI-MedLine.d34.s11|15-17|low|O
DDI-MedLine.d34.s11|19-25|dietary|O
DDI-MedLine.d34.s11|27-32|cobalt|O
DDI-MedLine.d34.s11|34-46|concentration|O
DDI-MedLine.d34.s11|51-58|compared|O
DDI-MedLine.d34.s11|67-70|iron|O
DDI-MedLine.d34.s11|72-79|contents|O
DDI-MedLine.d34.s11|88-92|diets|O
DDI-MedLine.d34.s11|98-103|effect|O
DDI-MedLine.d34.s11|27-32|cobalt|O
DDI-MedLine.d34.s11|67-70|iron|O
DDI-MedLine.d34.s11|123-132|absorption|O
DDI-MedLine.d34.s11|138-146|excretion|O
DDI-MedLine.d34.s11|148-155|occurred|O
DDI-MedLine.d34.s11|156-156|.|O
DDI-MedLine.d34.s12|0-10|Differences|O
DDI-MedLine.d34.s12|15-18|iron|O
DDI-MedLine.d34.s12|20-26|balance|O
DDI-MedLine.d34.s12|38-45|observed|O
DDI-MedLine.d34.s12|60-66|dietary|O
DDI-MedLine.d34.s12|68-81|concentrations|O
DDI-MedLine.d34.s12|84-90|showing|O
DDI-MedLine.d34.s12|94-99|higher|O
DDI-MedLine.d34.s12|101-108|absolute|O
DDI-MedLine.d34.s12|116-120|lower|O
DDI-MedLine.d34.s12|122-129|relative|O
DDI-MedLine.d34.s12|131-140|absorption|O
DDI-MedLine.d34.s12|145-148|well|O
DDI-MedLine.d34.s12|153-161|retention|O
DDI-MedLine.d34.s12|170-175|groups|O
DDI-MedLine.d34.s12|177-179|fed|O
DDI-MedLine.d34.s12|189-190|Fe|O
DDI-MedLine.d34.s12|191-191|.|O
DDI-MedLine.d34.s12|219-223|WORDS|O
DDI-DrugBank.d628.s0|0-2|The|O
DDI-DrugBank.d628.s0|4-12|induction|O
DDI-DrugBank.d628.s0|14-17|dose|O
DDI-DrugBank.d628.s0|19-30|requirements|O
DDI-DrugBank.d628.s0|35-42|DIPRIVAN|O
DDI-DrugBank.d628.s0|44-53|Injectable|O
DDI-DrugBank.d628.s0|55-62|Emulsion|O
DDI-DrugBank.d628.s0|64-66|may|O
DDI-DrugBank.d628.s0|71-77|reduced|O
DDI-DrugBank.d628.s0|82-89|patients|O
DDI-DrugBank.d628.s0|96-108|intramuscular|O
DDI-DrugBank.d628.s0|113-123|intravenous|O
DDI-DrugBank.d628.s0|125-137|premedication|O
DDI-DrugBank.d628.s0|140-151|particularly|O
DDI-DrugBank.d628.s0|158-166|narcotics|O
DDI-DrugBank.d628.s0|169-170|eg|O
DDI-DrugBank.d628.s0|173-180|morphine|O
DDI-DrugBank.d628.s0|183-192|meperidine|O
DDI-DrugBank.d628.s0|199-206|fentanyl|O
DDI-DrugBank.d628.s0|209-211|etc|O
DDI-DrugBank.d628.s0|212-212|.|O
DDI-DrugBank.d628.s1|4-15|combinations|O
DDI-DrugBank.d628.s1|20-26|opioids|O
DDI-DrugBank.d628.s1|32-40|sedatives|O
DDI-DrugBank.d628.s1|43-44|eg|O
DDI-DrugBank.d628.s1|47-61|benzodiazepines|O
DDI-DrugBank.d628.s1|64-75|barbiturates|O
DDI-DrugBank.d628.s1|78-84|chloral|O
DDI-DrugBank.d628.s1|86-92|hydrate|O
DDI-DrugBank.d628.s1|95-104|droperidol|O
DDI-DrugBank.d628.s1|107-109|etc|O
DDI-DrugBank.d628.s1|110-110|.|O
DDI-DrugBank.d628.s2|0-4|These|O
DDI-DrugBank.d628.s2|6-11|agents|O
DDI-DrugBank.d628.s2|13-15|may|O
DDI-DrugBank.d628.s2|17-24|increase|O
DDI-DrugBank.d628.s2|30-39|anesthetic|O
DDI-DrugBank.d628.s2|44-51|sedative|O
DDI-DrugBank.d628.s2|53-59|effects|O
DDI-DrugBank.d628.s2|64-71|DIPRIVAN|O
DDI-DrugBank.d628.s2|73-82|Injectable|O
DDI-DrugBank.d628.s2|84-91|Emulsion|O
DDI-DrugBank.d628.s2|13-15|may|O
DDI-DrugBank.d628.s2|101-104|also|O
DDI-DrugBank.d628.s2|106-111|result|O
DDI-DrugBank.d628.s2|121-130|pronounced|O
DDI-DrugBank.d628.s2|132-140|decreases|O
DDI-DrugBank.d628.s2|145-152|systolic|O
DDI-DrugBank.d628.s2|155-163|diastolic|O
DDI-DrugBank.d628.s2|170-173|mean|O
DDI-DrugBank.d628.s2|175-182|arterial|O
DDI-DrugBank.d628.s2|184-192|pressures|O
DDI-DrugBank.d628.s2|198-204|cardiac|O
DDI-DrugBank.d628.s2|206-211|output|O
DDI-DrugBank.d628.s2|212-212|.|O
DDI-DrugBank.d628.s3|0-5|During|O
DDI-DrugBank.d628.s3|7-17|maintenance|O
DDI-DrugBank.d628.s3|22-31|anesthesia|O
DDI-DrugBank.d628.s3|36-43|sedation|O
DDI-DrugBank.d628.s3|50-53|rate|O
DDI-DrugBank.d628.s3|58-65|DIPRIVAN|O
DDI-DrugBank.d628.s3|67-76|Injectable|O
DDI-DrugBank.d628.s3|78-85|Emulsion|O
DDI-DrugBank.d628.s3|87-100|administration|O
DDI-DrugBank.d628.s3|112-119|adjusted|O
DDI-DrugBank.d628.s3|121-129|according|O
DDI-DrugBank.d628.s3|138-144|desired|O
DDI-DrugBank.d628.s3|146-150|level|O
DDI-DrugBank.d628.s3|22-31|anesthesia|O
DDI-DrugBank.d628.s3|36-43|sedation|O
DDI-DrugBank.d628.s3|182-184|may|O
DDI-DrugBank.d628.s3|189-195|reduced|O
DDI-DrugBank.d628.s3|204-211|presence|O
DDI-DrugBank.d628.s3|216-227|supplemental|O
DDI-DrugBank.d628.s3|229-237|analgesic|O
DDI-DrugBank.d628.s3|239-244|agents|O
DDI-DrugBank.d628.s3|247-248|eg|O
DDI-DrugBank.d628.s3|251-257|nitrous|O
DDI-DrugBank.d628.s3|259-263|oxide|O
DDI-DrugBank.d628.s3|268-274|opioids|O
DDI-DrugBank.d628.s3|276-276|.|O
DDI-DrugBank.d628.s4|0-2|The|O
DDI-DrugBank.d628.s4|4-13|concurrent|O
DDI-DrugBank.d628.s4|15-28|administration|O
DDI-DrugBank.d628.s4|33-38|potent|O
DDI-DrugBank.d628.s4|40-51|inhalational|O
DDI-DrugBank.d628.s4|53-58|agents|O
DDI-DrugBank.d628.s4|61-62|eg|O
DDI-DrugBank.d628.s4|65-74|isoflurane|O
DDI-DrugBank.d628.s4|77-85|enflurane|O
DDI-DrugBank.d628.s4|92-100|halothane|O
DDI-DrugBank.d628.s4|110-120|maintenance|O
DDI-DrugBank.d628.s4|127-134|DIPRIVAN|O
DDI-DrugBank.d628.s4|136-145|Injectable|O
DDI-DrugBank.d628.s4|147-154|Emulsion|O
DDI-DrugBank.d628.s4|169-179|extensively|O
DDI-DrugBank.d628.s4|181-189|evaluated|O
DDI-DrugBank.d628.s4|190-190|.|O
DDI-DrugBank.d628.s5|0-4|These|O
DDI-DrugBank.d628.s5|6-17|inhalational|O
DDI-DrugBank.d628.s5|19-24|agents|O
DDI-DrugBank.d628.s5|30-33|also|O
DDI-DrugBank.d628.s5|38-45|expected|O
DDI-DrugBank.d628.s5|50-57|increase|O
DDI-DrugBank.d628.s5|63-72|anesthetic|O
DDI-DrugBank.d628.s5|77-84|sedative|O
DDI-DrugBank.d628.s5|90-106|cardiorespiratory|O
DDI-DrugBank.d628.s5|108-114|effects|O
DDI-DrugBank.d628.s5|119-126|DIPRIVAN|O
DDI-DrugBank.d628.s5|128-137|Injectable|O
DDI-DrugBank.d628.s5|139-146|Emulsion|O
DDI-DrugBank.d628.s5|147-147|.|O
DDI-DrugBank.d628.s6|0-7|DIPRIVAN|O
DDI-DrugBank.d628.s6|9-18|Injectable|O
DDI-DrugBank.d628.s6|20-27|Emulsion|O
DDI-DrugBank.d628.s6|38-42|cause|O
DDI-DrugBank.d628.s6|46-55|clinically|O
DDI-DrugBank.d628.s6|57-67|significant|O
DDI-DrugBank.d628.s6|69-74|change|O
DDI-DrugBank.d628.s6|79-83|onset|O
DDI-DrugBank.d628.s6|86-94|intensity|O
DDI-DrugBank.d628.s6|100-107|duration|O
DDI-DrugBank.d628.s6|112-117|action|O
DDI-DrugBank.d628.s6|126-133|commonly|O
DDI-DrugBank.d628.s6|135-138|used|O
DDI-DrugBank.d628.s6|140-152|neuromuscular|O
DDI-DrugBank.d628.s6|154-161|blocking|O
DDI-DrugBank.d628.s6|163-168|agents|O
DDI-DrugBank.d628.s6|171-172|eg|O
DDI-DrugBank.d628.s6|175-189|succinylcholine|O
DDI-DrugBank.d628.s6|195-209|nondepolarizing|O
DDI-DrugBank.d628.s6|211-216|muscle|O
DDI-DrugBank.d628.s6|218-226|relaxants|O
DDI-DrugBank.d628.s6|228-228|.|O
DDI-DrugBank.d628.s7|0-1|No|O
DDI-DrugBank.d628.s7|3-13|significant|O
DDI-DrugBank.d628.s7|15-21|adverse|O
DDI-DrugBank.d628.s7|23-34|interactions|O
DDI-DrugBank.d628.s7|41-48|commonly|O
DDI-DrugBank.d628.s7|50-53|used|O
DDI-DrugBank.d628.s7|55-68|premedications|O
DDI-DrugBank.d628.s7|73-77|drugs|O
DDI-DrugBank.d628.s7|50-53|used|O
DDI-DrugBank.d628.s7|91-100|anesthesia|O
DDI-DrugBank.d628.s7|105-112|sedation|O
DDI-DrugBank.d628.s7|115-123|including|O
DDI-DrugBank.d628.s7|127-131|range|O
DDI-DrugBank.d628.s7|136-141|muscle|O
DDI-DrugBank.d628.s7|143-151|relaxants|O
DDI-DrugBank.d628.s7|154-165|inhalational|O
DDI-DrugBank.d628.s7|167-172|agents|O
DDI-DrugBank.d628.s7|175-183|analgesic|O
DDI-DrugBank.d628.s7|167-172|agents|O
DDI-DrugBank.d628.s7|197-201|local|O
DDI-DrugBank.d628.s7|203-212|anesthetic|O
DDI-DrugBank.d628.s7|167-172|agents|O
DDI-DrugBank.d628.s7|232-239|observed|O
DDI-DrugBank.d628.s7|240-240|.|O
DDI-DrugBank.d263.s0|0-9|Zidovudine|O
DDI-DrugBank.d263.s0|12-16|There|O
DDI-DrugBank.d263.s0|24-34|significant|O
DDI-DrugBank.d263.s0|36-50|pharmacokinetic|O
DDI-DrugBank.d263.s0|52-62|interaction|O
DDI-DrugBank.d263.s0|72-74|ZDV|O
DDI-DrugBank.d263.s0|80-90|zalcitabine|O
DDI-DrugBank.d263.s0|107-115|confirmed|O
DDI-DrugBank.d263.s0|117-126|clinically|O
DDI-DrugBank.d263.s0|127-127|.|O
DDI-DrugBank.d263.s1|0-10|Zalcitabine|O
DDI-DrugBank.d263.s1|12-15|also|O
DDI-DrugBank.d263.s1|24-34|significant|O
DDI-DrugBank.d263.s1|36-41|effect|O
DDI-DrugBank.d263.s1|50-62|intracellular|O
DDI-DrugBank.d263.s1|64-78|phosphorylation|O
DDI-DrugBank.d263.s1|83-85|ZDV|O
DDI-DrugBank.d263.s1|91-95|shown|O
DDI-DrugBank.d263.s1|100-104|vitro|O
DDI-DrugBank.d263.s1|109-118|peripheral|O
DDI-DrugBank.d263.s1|120-124|blood|O
DDI-DrugBank.d263.s1|126-136|mononuclear|O
DDI-DrugBank.d263.s1|138-142|cells|O
DDI-DrugBank.d263.s1|150-152|two|O
DDI-DrugBank.d263.s1|55-58|cell|O
DDI-DrugBank.d263.s1|165-169|lines|O
DDI-DrugBank.d263.s1|172-175|U937|O
DDI-DrugBank.d263.s1|181-186|Molt-4|O
DDI-DrugBank.d263.s1|188-188|.|O
DDI-DrugBank.d263.s2|0-1|In|O
DDI-DrugBank.d263.s2|12-16|study|O
DDI-DrugBank.d263.s2|25-29|shown|O
DDI-DrugBank.d263.s2|36-45|didanosine|O
DDI-DrugBank.d263.s2|51-59|stavudine|O
DDI-DrugBank.d263.s2|68-78|significant|O
DDI-DrugBank.d263.s2|80-85|effect|O
DDI-DrugBank.d263.s2|94-106|intracellular|O
DDI-DrugBank.d263.s2|108-122|phosphorylation|O
DDI-DrugBank.d263.s2|127-137|zalcitabine|O
DDI-DrugBank.d263.s2|142-151|peripheral|O
DDI-DrugBank.d263.s2|153-157|blood|O
DDI-DrugBank.d263.s2|159-169|mononuclear|O
DDI-DrugBank.d263.s2|171-175|cells|O
DDI-DrugBank.d263.s2|176-176|.|O
DDI-DrugBank.d263.s3|0-9|Lamivudine|O
DDI-DrugBank.d263.s3|12-13|In|O
DDI-DrugBank.d263.s3|15-19|vitro|O
DDI-DrugBank.d263.s3|21-27|studies|O
DDI-DrugBank.d263.s3|32-41|peripheral|O
DDI-DrugBank.d263.s3|43-47|blood|O
DDI-DrugBank.d263.s3|49-59|mononuclear|O
DDI-DrugBank.d263.s3|61-65|cells|O
DDI-DrugBank.d263.s3|68-71|U937|O
DDI-DrugBank.d263.s3|77-82|Molt-4|O
DDI-DrugBank.d263.s3|61-65|cells|O
DDI-DrugBank.d263.s3|90-97|revealed|O
DDI-DrugBank.d263.s3|104-113|lamivudine|O
DDI-DrugBank.d263.s3|115-127|significantly|O
DDI-DrugBank.d263.s3|129-137|inhibited|O
DDI-DrugBank.d263.s3|139-149|zalcitabine|O
DDI-DrugBank.d263.s3|151-165|phosphorylation|O
DDI-DrugBank.d263.s3|172-175|dose|O
DDI-DrugBank.d263.s3|177-185|dependent|O
DDI-DrugBank.d263.s3|187-192|manner|O
DDI-DrugBank.d263.s3|193-193|.|O
DDI-DrugBank.d263.s4|0-6|Effects|O
DDI-DrugBank.d263.s4|13-19|already|O
DDI-DrugBank.d263.s4|21-24|seen|O
DDI-DrugBank.d263.s4|31-35|doses|O
DDI-DrugBank.d263.s4|37-49|corresponding|O
DDI-DrugBank.d263.s4|54-61|relevant|O
DDI-DrugBank.d263.s4|63-68|plasma|O
DDI-DrugBank.d263.s4|70-75|levels|O
DDI-DrugBank.d263.s4|80-85|humans|O
DDI-DrugBank.d263.s4|96-108|intracellular|O
DDI-DrugBank.d263.s4|110-124|phosphorylation|O
DDI-DrugBank.d263.s4|129-139|zalcitabine|O
DDI-DrugBank.d263.s4|148-152|three|O
DDI-DrugBank.d263.s4|154-164|metabolites|O
DDI-DrugBank.d263.s4|167-175|including|O
DDI-DrugBank.d263.s4|181-186|active|O
DDI-DrugBank.d263.s4|129-139|zalcitabine|O
DDI-DrugBank.d263.s4|200-211|triphosphate|O
DDI-DrugBank.d263.s4|154-163|metabolite|O
DDI-DrugBank.d263.s4|229-241|significantly|O
DDI-DrugBank.d263.s4|243-251|inhibited|O
DDI-DrugBank.d263.s4|252-252|.|O
DDI-DrugBank.d263.s5|0-10|Zalcitabine|O
DDI-DrugBank.d263.s5|12-20|inhibited|O
DDI-DrugBank.d263.s5|22-31|lamivudine|O
DDI-DrugBank.d263.s5|33-47|phosphorylation|O
DDI-DrugBank.d263.s5|52-55|high|O
DDI-DrugBank.d263.s5|57-69|concentration|O
DDI-DrugBank.d263.s5|71-76|ratios|O
DDI-DrugBank.d263.s5|79-80|10|O
DDI-DrugBank.d263.s5|86-88|100|O
DDI-DrugBank.d263.s6|0-6|however|O
DDI-DrugBank.d263.s6|15-24|considered|O
DDI-DrugBank.d263.s6|32-39|unlikely|O
DDI-DrugBank.d263.s6|51-58|decrease|O
DDI-DrugBank.d263.s6|63-76|phosphorylated|O
DDI-DrugBank.d263.s6|78-87|lamivudine|O
DDI-DrugBank.d263.s6|89-101|concentration|O
DDI-DrugBank.d263.s6|109-116|clinical|O
DDI-DrugBank.d263.s6|118-129|significance|O
DDI-DrugBank.d263.s6|78-87|lamivudine|O
DDI-DrugBank.d263.s6|156-164|efficient|O
DDI-DrugBank.d263.s6|166-174|substrate|O
DDI-DrugBank.d263.s6|180-192|deoxycytidine|O
DDI-DrugBank.d263.s6|194-199|kinase|O
DDI-DrugBank.d263.s6|206-216|zalcitabine|O
DDI-DrugBank.d263.s7|0-4|These|O
DDI-DrugBank.d263.s7|9-13|vitro|O
DDI-DrugBank.d263.s7|15-21|studies|O
DDI-DrugBank.d263.s7|23-29|suggest|O
DDI-DrugBank.d263.s7|36-46|concomitant|O
DDI-DrugBank.d263.s7|48-61|administration|O
DDI-DrugBank.d263.s7|66-76|zalcitabine|O
DDI-DrugBank.d263.s7|82-91|lamivudine|O
DDI-DrugBank.d263.s7|96-101|humans|O
DDI-DrugBank.d263.s7|103-105|may|O
DDI-DrugBank.d263.s7|107-112|result|O
DDI-DrugBank.d263.s7|117-131|sub-therapeutic|O
DDI-DrugBank.d263.s7|133-146|concentrations|O
DDI-DrugBank.d263.s7|151-156|active|O
DDI-DrugBank.d263.s7|158-171|phosphorylated|O
DDI-DrugBank.d263.s7|66-76|zalcitabine|O
DDI-DrugBank.d263.s7|103-105|may|O
DDI-DrugBank.d263.s7|196-199|lead|O
DDI-DrugBank.d263.s7|206-214|decreased|O
DDI-DrugBank.d263.s7|216-229|antiretroviral|O
DDI-DrugBank.d263.s7|231-236|effect|O
DDI-DrugBank.d263.s7|66-76|zalcitabine|O
DDI-DrugBank.d263.s7|252-252|.|O
DDI-DrugBank.d263.s8|0-1|It|O
DDI-DrugBank.d263.s8|6-12|unknown|O
DDI-DrugBank.d263.s8|22-27|effect|O
DDI-DrugBank.d263.s8|29-32|seen|O
DDI-DrugBank.d263.s8|46-50|vitro|O
DDI-DrugBank.d263.s8|52-58|studies|O
DDI-DrugBank.d263.s8|60-69|translates|O
DDI-DrugBank.d263.s8|76-83|clinical|O
DDI-DrugBank.d263.s8|85-96|consequences|O
DDI-DrugBank.d263.s8|97-97|.|O
DDI-DrugBank.d263.s9|0-10|Concomitant|O
DDI-DrugBank.d263.s9|12-14|use|O
DDI-DrugBank.d263.s9|19-29|zalcitabine|O
DDI-DrugBank.d263.s9|35-44|lamivudine|O
DDI-DrugBank.d263.s9|53-63|recommended|O
DDI-DrugBank.d263.s9|64-64|.|O
DDI-DrugBank.d263.s10|0-9|Saquinavir|O
DDI-DrugBank.d263.s10|12-14|The|O
DDI-DrugBank.d263.s10|16-26|combination|O
DDI-DrugBank.d263.s10|31-35|HIVID|O
DDI-DrugBank.d263.s10|38-47|saquinavir|O
DDI-DrugBank.d263.s10|54-56|ZDV|O
DDI-DrugBank.d263.s10|67-73|studied|O
DDI-DrugBank.d263.s10|79-84|triple|O
DDI-DrugBank.d263.s10|16-26|combination|O
DDI-DrugBank.d263.s10|102-107|adults|O
DDI-DrugBank.d263.s10|108-108|.|O
DDI-DrugBank.d263.s11|0-14|Pharmacokinetic|O
DDI-DrugBank.d263.s11|16-19|data|O
DDI-DrugBank.d263.s11|21-27|suggest|O
DDI-DrugBank.d263.s11|34-43|absorption|O
DDI-DrugBank.d263.s11|46-55|metabolism|O
DDI-DrugBank.d263.s11|62-72|elimination|O
DDI-DrugBank.d263.s11|91-95|drugs|O
DDI-DrugBank.d263.s11|101-109|unchanged|O
DDI-DrugBank.d263.s11|125-128|used|O
DDI-DrugBank.d263.s11|130-137|together|O
DDI-DrugBank.d263.s11|138-138|.|O
DDI-DrugBank.d263.s12|0-4|Drugs|O
DDI-DrugBank.d263.s12|6-15|Associated|O
DDI-DrugBank.d263.s12|17-20|With|O
DDI-DrugBank.d263.s12|22-31|Peripheral|O
DDI-DrugBank.d263.s12|33-42|Neuropathy|O
DDI-DrugBank.d263.s12|45-47|The|O
DDI-DrugBank.d263.s12|49-59|concomitant|O
DDI-DrugBank.d263.s12|61-63|use|O
DDI-DrugBank.d263.s12|68-72|HIVID|O
DDI-DrugBank.d263.s12|79-83|drugs|O
DDI-DrugBank.d263.s12|99-107|potential|O
DDI-DrugBank.d263.s12|112-116|cause|O
DDI-DrugBank.d263.s12|118-127|peripheral|O
DDI-DrugBank.d263.s12|129-138|neuropathy|O
DDI-DrugBank.d263.s12|150-156|avoided|O
DDI-DrugBank.d263.s12|164-171|possible|O
DDI-DrugBank.d263.s12|172-172|.|O
DDI-DrugBank.d263.s13|0-4|Drugs|O
DDI-DrugBank.d263.s13|21-30|associated|O
DDI-DrugBank.d263.s13|37-46|peripheral|O
DDI-DrugBank.d263.s13|48-57|neuropathy|O
DDI-DrugBank.d263.s13|59-65|include|O
DDI-DrugBank.d263.s13|67-80|antiretroviral|O
DDI-DrugBank.d263.s13|82-91|nucleoside|O
DDI-DrugBank.d263.s13|93-101|analogues|O
DDI-DrugBank.d263.s13|104-118|chloramphenicol|O
DDI-DrugBank.d263.s13|121-129|cisplatin|O
DDI-DrugBank.d263.s13|132-138|dapsone|O
DDI-DrugBank.d263.s13|141-150|disulfiram|O
DDI-DrugBank.d263.s13|153-163|ethionamide|O
DDI-DrugBank.d263.s13|166-177|glutethimide|O
DDI-DrugBank.d263.s13|180-183|gold|O
DDI-DrugBank.d263.s13|186-196|hydralazine|O
DDI-DrugBank.d263.s13|199-208|iodoquinol|O
DDI-DrugBank.d263.s13|211-219|isoniazid|O
DDI-DrugBank.d263.s13|222-234|metronidazole|O
DDI-DrugBank.d263.s13|237-250|nitrofurantoin|O
DDI-DrugBank.d263.s13|253-261|phenytoin|O
DDI-DrugBank.d263.s13|264-272|ribavirin|O
DDI-DrugBank.d263.s13|279-289|vincristine|O
DDI-DrugBank.d263.s13|290-290|.|O
DDI-DrugBank.d263.s14|0-10|Concomitant|O
DDI-DrugBank.d263.s14|12-14|use|O
DDI-DrugBank.d263.s14|19-23|HIVID|O
DDI-DrugBank.d263.s14|30-39|didanosine|O
DDI-DrugBank.d263.s14|48-58|recommended|O
DDI-DrugBank.d263.s14|59-59|.|O
DDI-DrugBank.d263.s15|0-10|Intravenous|O
DDI-DrugBank.d263.s15|12-22|Pentamidine|O
DDI-DrugBank.d263.s15|25-33|Treatment|O
DDI-DrugBank.d263.s15|40-44|HIVID|O
DDI-DrugBank.d263.s15|56-66|interrupted|O
DDI-DrugBank.d263.s15|77-79|use|O
DDI-DrugBank.d263.s15|86-89|drug|O
DDI-DrugBank.d263.s15|104-112|potential|O
DDI-DrugBank.d263.s15|117-121|cause|O
DDI-DrugBank.d263.s15|123-134|pancreatitis|O
DDI-DrugBank.d263.s15|139-146|required|O
DDI-DrugBank.d263.s15|147-147|.|O
DDI-DrugBank.d263.s16|0-4|Death|O
DDI-DrugBank.d263.s16|6-8|due|O
DDI-DrugBank.d263.s16|13-21|fulminant|O
DDI-DrugBank.d263.s16|23-34|pancreatitis|O
DDI-DrugBank.d263.s16|36-43|possibly|O
DDI-DrugBank.d263.s16|45-51|related|O
DDI-DrugBank.d263.s16|56-66|intravenous|O
DDI-DrugBank.d263.s16|68-78|pentamidine|O
DDI-DrugBank.d263.s16|84-88|HIVID|O
DDI-DrugBank.d263.s16|99-106|reported|O
DDI-DrugBank.d263.s16|107-107|.|O
DDI-DrugBank.d263.s17|0-1|If|O
DDI-DrugBank.d263.s17|3-13|intravenous|O
DDI-DrugBank.d263.s17|15-25|pentamidine|O
DDI-DrugBank.d263.s17|30-37|required|O
DDI-DrugBank.d263.s17|42-46|treat|O
DDI-DrugBank.d263.s17|48-59|Pneumocystis|O
DDI-DrugBank.d263.s17|61-67|carinii|O
DDI-DrugBank.d263.s17|69-77|pneumonia|O
DDI-DrugBank.d263.s17|80-88|treatment|O
DDI-DrugBank.d263.s17|95-99|HIVID|O
DDI-DrugBank.d263.s17|111-121|interrupted|O
DDI-DrugBank.d263.s17|122-122|.|O
DDI-DrugBank.d263.s18|0-11|Amphotericin|O
DDI-DrugBank.d263.s18|14-22|Foscarnet|O
DDI-DrugBank.d263.s18|29-43|Aminoglycosides|O
DDI-DrugBank.d263.s18|46-50|Drugs|O
DDI-DrugBank.d263.s18|60-71|amphotericin|O
DDI-DrugBank.d263.s18|74-82|foscarnet|O
DDI-DrugBank.d263.s18|89-103|aminoglycosides|O
DDI-DrugBank.d263.s18|105-107|may|O
DDI-DrugBank.d263.s18|109-116|increase|O
DDI-DrugBank.d263.s18|122-125|risk|O
DDI-DrugBank.d263.s18|130-139|developing|O
DDI-DrugBank.d263.s18|141-150|peripheral|O
DDI-DrugBank.d263.s18|152-161|neuropathy|O
DDI-DrugBank.d263.s18|172-187|HIVID-associated|O
DDI-DrugBank.d263.s18|189-195|adverse|O
DDI-DrugBank.d263.s18|197-202|events|O
DDI-DrugBank.d263.s18|207-217|interfering|O
DDI-DrugBank.d263.s18|228-232|renal|O
DDI-DrugBank.d263.s18|234-242|clearance|O
DDI-DrugBank.d263.s18|247-257|zalcitabine|O
DDI-DrugBank.d263.s18|260-266|thereby|O
DDI-DrugBank.d263.s18|268-274|raising|O
DDI-DrugBank.d263.s18|276-283|systemic|O
DDI-DrugBank.d263.s18|285-292|exposure|O
DDI-DrugBank.d263.s18|294-294|.|O
DDI-DrugBank.d263.s19|0-7|Patients|O
DDI-DrugBank.d263.s19|13-19|require|O
DDI-DrugBank.d263.s19|25-27|use|O
DDI-DrugBank.d263.s19|32-34|one|O
DDI-DrugBank.d263.s19|45-49|drugs|O
DDI-DrugBank.d263.s19|56-60|HIVID|O
DDI-DrugBank.d263.s19|74-81|frequent|O
DDI-DrugBank.d263.s19|83-90|clinical|O
DDI-DrugBank.d263.s19|96-105|laboratory|O
DDI-DrugBank.d263.s19|107-116|monitoring|O
DDI-DrugBank.d263.s19|123-128|dosage|O
DDI-DrugBank.d263.s19|130-139|adjustment|O
DDI-DrugBank.d263.s19|149-159|significant|O
DDI-DrugBank.d263.s19|161-166|change|O
DDI-DrugBank.d263.s19|171-175|renal|O
DDI-DrugBank.d263.s19|177-184|function|O
DDI-DrugBank.d263.s19|185-185|.|O
DDI-DrugBank.d263.s20|0-9|Probenecid|O
DDI-DrugBank.d263.s20|14-23|Cimetidine|O
DDI-DrugBank.d263.s20|26-36|Concomitant|O
DDI-DrugBank.d263.s20|38-51|administration|O
DDI-DrugBank.d263.s20|56-65|probenecid|O
DDI-DrugBank.d263.s20|70-79|cimetidine|O
DDI-DrugBank.d263.s20|81-89|decreases|O
DDI-DrugBank.d263.s20|95-105|elimination|O
DDI-DrugBank.d263.s20|110-120|zalcitabine|O
DDI-DrugBank.d263.s20|128-133|likely|O
DDI-DrugBank.d263.s20|138-147|inhibition|O
DDI-DrugBank.d263.s20|152-156|renal|O
DDI-DrugBank.d263.s20|158-164|tubular|O
DDI-DrugBank.d263.s20|166-174|secretion|O
DDI-DrugBank.d263.s20|110-120|zalcitabine|O
DDI-DrugBank.d263.s20|190-190|.|O
DDI-DrugBank.d263.s21|0-7|Patients|O
DDI-DrugBank.d263.s21|9-17|receiving|O
DDI-DrugBank.d263.s21|25-29|drugs|O
DDI-DrugBank.d263.s21|34-44|combination|O
DDI-DrugBank.d263.s21|51-61|zalcitabine|O
DDI-DrugBank.d263.s21|73-81|monitored|O
DDI-DrugBank.d263.s21|87-91|signs|O
DDI-DrugBank.d263.s21|96-103|toxicity|O
DDI-DrugBank.d263.s21|113-116|dose|O
DDI-DrugBank.d263.s21|51-61|zalcitabine|O
DDI-DrugBank.d263.s21|133-139|reduced|O
DDI-DrugBank.d263.s21|144-152|warranted|O
DDI-DrugBank.d263.s21|153-153|.|O
DDI-DrugBank.d263.s22|0-28|Magnesium/Aluminum-containing|O
DDI-DrugBank.d263.s22|30-36|Antacid|O
DDI-DrugBank.d263.s22|38-45|Products|O
DDI-DrugBank.d263.s22|48-57|Absorption|O
DDI-DrugBank.d263.s22|62-72|zalcitabine|O
DDI-DrugBank.d263.s22|77-86|moderately|O
DDI-DrugBank.d263.s22|88-94|reduced|O
DDI-DrugBank.d263.s22|97-109|approximately|O
DDI-DrugBank.d263.s22|111-112|25|O
DDI-DrugBank.d263.s22|113-113|%|O
DDI-DrugBank.d263.s22|121-134|coadministered|O
DDI-DrugBank.d263.s22|141-169|magnesium/aluminum-containing|O
DDI-DrugBank.d263.s22|171-177|antacid|O
DDI-DrugBank.d263.s22|179-186|products|O
DDI-DrugBank.d263.s22|187-187|.|O
DDI-DrugBank.d263.s23|0-2|The|O
DDI-DrugBank.d263.s23|4-11|clinical|O
DDI-DrugBank.d263.s23|13-24|significance|O
DDI-DrugBank.d263.s23|34-42|reduction|O
DDI-DrugBank.d263.s23|51-55|known|O
DDI-DrugBank.d263.s23|58-62|hence|O
DDI-DrugBank.d263.s23|64-74|zalcitabine|O
DDI-DrugBank.d263.s23|83-93|recommended|O
DDI-DrugBank.d263.s23|101-108|ingested|O
DDI-DrugBank.d263.s23|110-123|simultaneously|O
DDI-DrugBank.d263.s23|130-158|magnesium/aluminum-containing|O
DDI-DrugBank.d263.s23|160-167|antacids|O
DDI-DrugBank.d263.s24|0-13|Metoclopramide|O
DDI-DrugBank.d263.s24|16-30|Bioavailability|O
DDI-DrugBank.d263.s24|35-40|mildly|O
DDI-DrugBank.d263.s24|42-48|reduced|O
DDI-DrugBank.d263.s24|51-63|approximately|O
DDI-DrugBank.d263.s24|65-66|10|O
DDI-DrugBank.d263.s24|67-67|%|O
DDI-DrugBank.d263.s24|75-85|zalcitabine|O
DDI-DrugBank.d263.s24|91-104|metoclopramide|O
DDI-DrugBank.d263.s24|110-123|coadministered|O
DDI-DrugBank.d263.s24|124-124|.|O
DDI-DrugBank.d263.s25|0-10|Doxorubicin|O
DDI-DrugBank.d263.s25|0-10|Doxorubicin|O
DDI-DrugBank.d263.s25|25-30|caused|O
DDI-DrugBank.d263.s25|34-41|decrease|O
DDI-DrugBank.d263.s25|46-56|zalcitabine|O
DDI-DrugBank.d263.s25|58-72|phosphorylation|O
DDI-DrugBank.d263.s25|76-77|50|O
DDI-DrugBank.d263.s25|78-78|%|O
DDI-DrugBank.d263.s25|80-89|inhibition|O
DDI-DrugBank.d263.s25|94-98|total|O
DDI-DrugBank.d263.s25|100-108|phosphate|O
DDI-DrugBank.d263.s25|110-118|formation|O
DDI-DrugBank.d263.s25|124-132|U937/Molt|O
DDI-DrugBank.d263.s25|134-134|4|O
DDI-DrugBank.d263.s25|136-140|cells|O
DDI-DrugBank.d263.s25|141-141|.|O
DDI-DrugBank.d263.s26|0-7|Although|O
DDI-DrugBank.d263.s26|15-17|may|O
DDI-DrugBank.d263.s26|22-30|decreased|O
DDI-DrugBank.d263.s26|32-42|zalcitabine|O
DDI-DrugBank.d263.s26|44-51|activity|O
DDI-DrugBank.d263.s26|64-71|lessened|O
DDI-DrugBank.d263.s26|73-78|active|O
DDI-DrugBank.d263.s26|80-89|metabolite|O
DDI-DrugBank.d263.s26|91-99|formation|O
DDI-DrugBank.d263.s26|106-113|clinical|O
DDI-DrugBank.d263.s26|115-123|relevance|O
DDI-DrugBank.d263.s26|137-141|vitro|O
DDI-DrugBank.d263.s26|143-149|results|O
DDI-DrugBank.d263.s26|159-163|known|O
DDI-DrugBank.d263.s26|164-164|.|O
DDI-DrugBank.d92.s0|0-1|No|O
DDI-DrugBank.d92.s0|3-12|well-known|O
DDI-DrugBank.d92.s0|14-17|drug|O
DDI-DrugBank.d92.s0|19-30|interactions|O
DDI-DrugBank.d92.s0|37-44|glutamic|O
DDI-DrugBank.d92.s0|46-49|acid|O
DDI-DrugBank.d57.s0|0-1|In|O
DDI-DrugBank.d57.s0|3-7|vitro|O
DDI-DrugBank.d57.s0|9-14|mixing|O
DDI-DrugBank.d57.s0|22-35|aminoglycoside|O
DDI-DrugBank.d57.s0|42-56|beta-lactamtype|O
DDI-DrugBank.d57.s0|58-68|antibiotics|O
DDI-DrugBank.d57.s0|71-81|penicillins|O
DDI-DrugBank.d57.s0|86-99|cephalosporins|O
DDI-DrugBank.d57.s0|102-104|may|O
DDI-DrugBank.d57.s0|106-111|result|O
DDI-DrugBank.d57.s0|118-128|significant|O
DDI-DrugBank.d57.s0|130-135|mutual|O
DDI-DrugBank.d57.s0|137-148|inactivation|O
DDI-DrugBank.d57.s0|149-149|.|O
DDI-DrugBank.d57.s1|0-3|Even|O
DDI-DrugBank.d57.s1|13-26|aminoglycoside|O
DDI-DrugBank.d57.s1|34-48|penicillin-type|O
DDI-DrugBank.d57.s1|50-53|drug|O
DDI-DrugBank.d57.s1|59-70|administered|O
DDI-DrugBank.d57.s1|72-81|separately|O
DDI-DrugBank.d57.s1|86-94|different|O
DDI-DrugBank.d57.s1|96-101|routes|O
DDI-DrugBank.d57.s1|106-114|reduction|O
DDI-DrugBank.d57.s1|13-26|aminoglycoside|O
DDI-DrugBank.d57.s1|134-138|serum|O
DDI-DrugBank.d57.s1|140-148|half-life|O
DDI-DrugBank.d57.s1|134-138|serum|O
DDI-DrugBank.d57.s1|159-164|levels|O
DDI-DrugBank.d57.s1|175-182|reported|O
DDI-DrugBank.d57.s1|187-194|patients|O
DDI-DrugBank.d57.s1|201-208|impaired|O
DDI-DrugBank.d57.s1|210-214|renal|O
DDI-DrugBank.d57.s1|216-223|function|O
DDI-DrugBank.d57.s1|187-194|patients|O
DDI-DrugBank.d57.s1|251-256|normal|O
DDI-DrugBank.d57.s1|210-214|renal|O
DDI-DrugBank.d57.s1|216-223|function|O
DDI-DrugBank.d57.s1|272-272|.|O
DDI-DrugBank.d57.s2|0-6|Usually|O
DDI-DrugBank.d57.s2|14-25|inactivation|O
DDI-DrugBank.d57.s2|34-47|aminoglycoside|O
DDI-DrugBank.d57.s2|52-61|clinically|O
DDI-DrugBank.d57.s2|63-73|significant|O
DDI-DrugBank.d57.s2|83-90|patients|O
DDI-DrugBank.d57.s2|97-104|severely|O
DDI-DrugBank.d57.s2|106-113|impaired|O
DDI-DrugBank.d57.s2|115-119|renal|O
DDI-DrugBank.d57.s2|121-128|function|O
DDI-DrugBank.d57.s2|129-130|..|O
DDI-DrugBank.d57.s3|0-2|See|O
DDI-DrugBank.d363.s0|0-1|No|O
DDI-DrugBank.d363.s0|3-12|clinically|O
DDI-DrugBank.d363.s0|14-24|significant|O
DDI-DrugBank.d363.s0|26-32|adverse|O
DDI-DrugBank.d363.s0|34-45|interactions|O
DDI-DrugBank.d363.s0|52-59|commonly|O
DDI-DrugBank.d363.s0|61-64|used|O
DDI-DrugBank.d363.s0|66-78|preanesthetic|O
DDI-DrugBank.d363.s0|80-84|drugs|O
DDI-DrugBank.d363.s0|80-84|drugs|O
DDI-DrugBank.d363.s0|61-64|used|O
DDI-DrugBank.d363.s0|108-117|anesthesia|O
DDI-DrugBank.d363.s0|120-125|muscle|O
DDI-DrugBank.d363.s0|127-135|relaxants|O
DDI-DrugBank.d363.s0|138-148|intravenous|O
DDI-DrugBank.d363.s0|150-155|agents|O
DDI-DrugBank.d363.s0|162-166|local|O
DDI-DrugBank.d363.s0|69-78|anesthetic|O
DDI-DrugBank.d363.s0|150-155|agents|O
DDI-DrugBank.d363.s0|192-199|reported|O
DDI-DrugBank.d363.s0|3-10|clinical|O
DDI-DrugBank.d363.s0|213-218|trials|O
DDI-DrugBank.d363.s0|219-219|.|O
DDI-DrugBank.d363.s1|0-2|The|O
DDI-DrugBank.d363.s1|4-9|effect|O
DDI-DrugBank.d363.s1|14-23|desflurane|O
DDI-DrugBank.d363.s1|32-42|disposition|O
DDI-DrugBank.d363.s1|53-57|drugs|O
DDI-DrugBank.d363.s1|72-81|determined|O
DDI-DrugBank.d363.s1|82-82|.|O
DDI-DrugBank.d363.s2|0-3|Like|O
DDI-DrugBank.d363.s2|5-14|isoflurane|O
DDI-DrugBank.d363.s2|17-26|desflurane|O
DDI-DrugBank.d363.s2|37-46|predispose|O
DDI-DrugBank.d363.s2|51-59|premature|O
DDI-DrugBank.d363.s2|61-71|ventricular|O
DDI-DrugBank.d363.s2|73-83|arrhythmias|O
DDI-DrugBank.d363.s2|92-99|presence|O
DDI-DrugBank.d363.s2|104-114|exogenously|O
DDI-DrugBank.d363.s2|116-122|infused|O
DDI-DrugBank.d363.s2|124-134|epinephrine|O
DDI-DrugBank.d363.s2|139-143|swine|O
DDI-DrugBank.d363.s2|144-144|.|O
DDI-DrugBank.d146.s0|0-9|Colchicine|O
DDI-DrugBank.d146.s0|14-22|inhibited|O
DDI-DrugBank.d146.s0|27-36|acidifying|O
DDI-DrugBank.d146.s0|38-43|agents|O
DDI-DrugBank.d146.s0|44-44|.|O
DDI-DrugBank.d146.s1|0-2|The|O
DDI-DrugBank.d146.s1|4-9|action|O
DDI-DrugBank.d146.s1|14-23|colchicine|O
DDI-DrugBank.d146.s1|28-38|potentiated|O
DDI-DrugBank.d146.s1|43-54|alkalinizing|O
DDI-DrugBank.d146.s1|56-61|agents|O
DDI-DrugBank.d146.s1|62-62|.|O
DDI-DrugBank.d146.s2|0-9|Colchicine|O
DDI-DrugBank.d146.s2|11-13|may|O
DDI-DrugBank.d146.s2|15-22|increase|O
DDI-DrugBank.d146.s2|24-34|sensitivity|O
DDI-DrugBank.d146.s2|43-45|CNS|O
DDI-DrugBank.d146.s2|47-57|depressants|O
DDI-DrugBank.d146.s2|58-58|.|O
DDI-DrugBank.d146.s3|0-7|Response|O
DDI-DrugBank.d146.s3|12-26|sympathomimetic|O
DDI-DrugBank.d146.s3|28-33|agents|O
DDI-DrugBank.d146.s3|35-37|may|O
DDI-DrugBank.d146.s3|42-49|enhanced|O
DDI-DrugBank.d146.s3|54-63|colchicine|O
DDI-DrugBank.d146.s3|64-64|.|O
DDI-DrugBank.d366.s0|0-2|May|O
DDI-DrugBank.d366.s0|4-11|interact|O
DDI-DrugBank.d366.s0|18-21|skin|O
DDI-DrugBank.d366.s0|23-30|products|O
DDI-DrugBank.d366.s0|35-42|shampoos|O
DDI-DrugBank.d366.s0|48-55|dandruff|O
DDI-DrugBank.d366.s0|60-68|psoriasis|O
DDI-DrugBank.d366.s0|69-69|.|O
DDI-MedLine.d111.s0|0-5|Effect|O
DDI-MedLine.d111.s0|10-23|coadministered|O
DDI-MedLine.d111.s0|25-29|drugs|O
DDI-MedLine.d111.s0|35-41|ethanol|O
DDI-MedLine.d111.s0|50-56|binding|O
DDI-MedLine.d111.s0|61-71|therapeutic|O
DDI-MedLine.d111.s0|25-29|drugs|O
DDI-MedLine.d111.s0|82-86|human|O
DDI-MedLine.d111.s0|88-92|serum|O
DDI-MedLine.d111.s0|97-101|vitro|O
DDI-MedLine.d111.s0|102-102|.|O
DDI-MedLine.d111.s1|0-2|The|O
DDI-MedLine.d111.s1|4-10|effects|O
DDI-MedLine.d111.s1|15-28|coadministered|O
DDI-MedLine.d111.s1|30-34|drugs|O
DDI-MedLine.d111.s1|40-46|ethanol|O
DDI-MedLine.d111.s1|55-61|binding|O
DDI-MedLine.d111.s1|66-76|therapeutic|O
DDI-MedLine.d111.s1|30-34|drugs|O
DDI-MedLine.d111.s1|87-91|human|O
DDI-MedLine.d111.s1|93-97|serum|O
DDI-MedLine.d111.s1|102-106|vitro|O
DDI-MedLine.d111.s1|112-123|investigated|O
DDI-MedLine.d111.s1|124-124|.|O
DDI-MedLine.d111.s2|0-12|Acetaminophen|O
DDI-MedLine.d111.s2|15-23|lidocaine|O
DDI-MedLine.d111.s2|26-38|phenobarbital|O
DDI-MedLine.d111.s2|41-49|quinidine|O
DDI-MedLine.d111.s2|52-63|theophylline|O
DDI-MedLine.d111.s2|70-77|valproic|O
DDI-MedLine.d111.s2|79-82|acid|O
DDI-MedLine.d111.s2|89-93|added|O
DDI-MedLine.d111.s2|98-103|pooled|O
DDI-MedLine.d111.s2|105-109|human|O
DDI-MedLine.d111.s2|111-115|serum|O
DDI-MedLine.d111.s2|120-130|therapeutic|O
DDI-MedLine.d111.s2|132-145|concentrations|O
DDI-MedLine.d111.s2|146-146|.|O
DDI-MedLine.d111.s3|0-1|To|O
DDI-MedLine.d111.s3|8-18|preparation|O
DDI-MedLine.d111.s3|24-28|added|O
DDI-MedLine.d111.s3|30-32|one|O
DDI-MedLine.d111.s3|34-43|additional|O
DDI-MedLine.d111.s3|45-48|drug|O
DDI-MedLine.d111.s3|53-57|three|O
DDI-MedLine.d111.s3|59-72|concentrations|O
DDI-MedLine.d111.s3|74-80|ranging|O
DDI-MedLine.d111.s3|87-97|therapeutic|O
DDI-MedLine.d111.s3|102-106|toxic|O
DDI-MedLine.d111.s3|107-107|.|O
DDI-MedLine.d111.s4|0-2|The|O
DDI-MedLine.d111.s4|4-12|following|O
DDI-MedLine.d111.s4|14-18|eight|O
DDI-MedLine.d111.s4|20-25|target|O
DDI-MedLine.d111.s4|27-36|drug/added|O
DDI-MedLine.d111.s4|27-30|drug|O
DDI-MedLine.d111.s4|43-54|combinations|O
DDI-MedLine.d111.s4|61-67|studied|O
DDI-MedLine.d111.s4|70-96|acetaminophen/phenobarbital|O
DDI-MedLine.d111.s4|97-97|.|O
DDI-MedLine.d111.s5|0-25|acetaminophen/theophylline|O
DDI-MedLine.d111.s5|28-46|lidocaine/quinidine|O
DDI-MedLine.d111.s5|49-75|phenobarbital/acetaminophen|O
DDI-MedLine.d111.s5|78-99|phenobarbital/valproic|O
DDI-MedLine.d111.s5|101-104|acid|O
DDI-MedLine.d111.s5|107-125|quinidine/lidocaine|O
DDI-MedLine.d111.s5|128-153|theophylline/acetaminophen|O
DDI-MedLine.d111.s5|92-99|valproic|O
DDI-MedLine.d111.s5|169-186|acid/phenobarbital|O
DDI-MedLine.d111.s6|0-3|Each|O
DDI-MedLine.d111.s6|5-9|serum|O
DDI-MedLine.d111.s6|11-17|without|O
DDI-MedLine.d111.s6|29-33|added|O
DDI-MedLine.d111.s6|35-38|drug|O
DDI-MedLine.d111.s6|43-46|well|O
DDI-MedLine.d111.s6|5-9|serum|O
DDI-MedLine.d111.s6|61-72|supplemented|O
DDI-MedLine.d111.s6|35-38|drug|O
DDI-MedLine.d111.s6|101-105|three|O
DDI-MedLine.d111.s6|107-120|concentrations|O
DDI-MedLine.d111.s6|126-133|dialyzed|O
DDI-MedLine.d111.s6|143-151|phosphate|O
DDI-MedLine.d111.s6|153-158|buffer|O
DDI-MedLine.d111.s6|159-159|.|O
DDI-MedLine.d111.s7|0-8|Similarly|O
DDI-MedLine.d111.s7|10-17|dialyzed|O
DDI-MedLine.d111.s7|24-36|phenobarbital|O
DDI-MedLine.d111.s7|39-47|quinidine|O
DDI-MedLine.d111.s7|54-65|theophylline|O
DDI-MedLine.d111.s7|73-77|alone|O
DDI-MedLine.d111.s7|82-92|therapeutic|O
DDI-MedLine.d111.s7|94-107|concentrations|O
DDI-MedLine.d111.s7|112-116|serum|O
DDI-MedLine.d111.s7|127-133|ethanol|O
DDI-MedLine.d111.s7|138-142|three|O
DDI-MedLine.d111.s7|144-152|different|O
DDI-MedLine.d111.s7|94-107|concentrations|O
DDI-MedLine.d111.s7|112-116|serum|O
DDI-MedLine.d111.s7|177-177|.|O
DDI-MedLine.d111.s8|0-2|The|O
DDI-MedLine.d111.s8|4-13|percentage|O
DDI-MedLine.d111.s8|18-21|drug|O
DDI-MedLine.d111.s8|23-29|binding|O
DDI-MedLine.d111.s8|39-49|preparation|O
DDI-MedLine.d111.s8|55-64|calculated|O
DDI-MedLine.d111.s8|65-65|.|O
DDI-MedLine.d111.s9|0-12|Acetaminophen|O
DDI-MedLine.d111.s9|14-23|diminished|O
DDI-MedLine.d111.s9|29-35|binding|O
DDI-MedLine.d111.s9|40-51|theophylline|O
DDI-MedLine.d111.s9|56-60|human|O
DDI-MedLine.d111.s9|62-66|serum|O
DDI-MedLine.d111.s9|73-75|net|O
DDI-MedLine.d111.s9|77-82|change|O
DDI-MedLine.d111.s9|87-89|5.7|O
DDI-MedLine.d111.s9|90-90|%|O
DDI-MedLine.d111.s9|93-102|percentage|O
DDI-MedLine.d111.s9|104-111|increase|O
DDI-MedLine.d111.s9|116-119|free|O
DDI-MedLine.d111.s9|121-124|drug|O
DDI-MedLine.d111.s9|126-133|fraction|O
DDI-MedLine.d111.s9|135-135|[|O
DDI-MedLine.d111.s9|136-138|FDF|O
DDI-MedLine.d111.s9|139-139|]|O
DDI-MedLine.d111.s9|142-145|11.0|O
DDI-MedLine.d111.s9|90-90|%|O
DDI-MedLine.d111.s9|152-154|662|O
DDI-MedLine.d111.s9|156-165|micromol/L|O
DDI-MedLine.d111.s9|73-75|net|O
DDI-MedLine.d111.s9|77-82|change|O
DDI-MedLine.d111.s9|190-192|7.1|O
DDI-MedLine.d111.s9|90-90|%|O
DDI-MedLine.d111.s9|93-102|percentage|O
DDI-MedLine.d111.s9|104-111|increase|O
DDI-MedLine.d111.s9|136-138|FDF|O
DDI-MedLine.d111.s9|224-227|13.7|O
DDI-MedLine.d111.s9|90-90|%|O
DDI-MedLine.d111.s9|234-237|1324|O
DDI-MedLine.d111.s9|156-165|micromol/L|O
DDI-MedLine.d111.s9|88-88|.|O
DDI-MedLine.d111.s10|0-11|Theophylline|O
DDI-MedLine.d111.s10|13-21|decreased|O
DDI-MedLine.d111.s10|27-33|binding|O
DDI-MedLine.d111.s10|38-50|acetaminophen|O
DDI-MedLine.d111.s10|57-59|net|O
DDI-MedLine.d111.s10|61-66|change|O
DDI-MedLine.d111.s10|71-73|6.8|O
DDI-MedLine.d111.s10|74-74|%|O
DDI-MedLine.d111.s10|77-86|percentage|O
DDI-MedLine.d111.s10|88-95|increase|O
DDI-MedLine.d111.s10|100-102|FDF|O
DDI-MedLine.d111.s10|105-107|8.8|O
DDI-MedLine.d111.s10|74-74|%|O
DDI-MedLine.d111.s10|114-118|277.5|O
DDI-MedLine.d111.s10|120-129|micromol/L|O
DDI-MedLine.d111.s11|0-12|phenobarbital|O
DDI-MedLine.d111.s11|14-20|reduced|O
DDI-MedLine.d111.s11|30-32|net|O
DDI-MedLine.d111.s11|34-39|change|O
DDI-MedLine.d111.s11|44-46|6.6|O
DDI-MedLine.d111.s11|47-47|%|O
DDI-MedLine.d111.s11|50-59|percentage|O
DDI-MedLine.d111.s11|61-68|increase|O
DDI-MedLine.d111.s11|73-75|FDF|O
DDI-MedLine.d111.s11|78-80|8.5|O
DDI-MedLine.d111.s11|47-47|%|O
DDI-MedLine.d111.s11|87-89|431|O
DDI-MedLine.d111.s11|91-100|micromol/L|O
DDI-MedLine.d111.s11|45-45|.|O
DDI-MedLine.d111.s12|0-7|Valproic|O
DDI-MedLine.d111.s12|9-12|acid|O
DDI-MedLine.d111.s12|14-23|diminished|O
DDI-MedLine.d111.s12|25-31|binding|O
DDI-MedLine.d111.s12|36-48|phenobarbital|O
DDI-MedLine.d111.s12|55-57|net|O
DDI-MedLine.d111.s12|59-64|change|O
DDI-MedLine.d111.s12|69-71|9.9|O
DDI-MedLine.d111.s12|72-72|%|O
DDI-MedLine.d111.s12|75-84|percentage|O
DDI-MedLine.d111.s12|86-93|increase|O
DDI-MedLine.d111.s12|98-100|FDF|O
DDI-MedLine.d111.s12|103-106|21.2|O
DDI-MedLine.d111.s12|72-72|%|O
DDI-MedLine.d111.s12|113-116|1732|O
DDI-MedLine.d111.s12|118-127|micromol/L|O
DDI-MedLine.d111.s12|70-70|.|O
DDI-MedLine.d111.s13|0-1|No|O
DDI-MedLine.d111.s13|3-13|significant|O
DDI-MedLine.d111.s13|15-21|effects|O
DDI-MedLine.d111.s13|28-32|noted|O
DDI-MedLine.d111.s13|45-48|drug|O
DDI-MedLine.d111.s13|50-61|combinations|O
DDI-MedLine.d111.s13|75-82|addition|O
DDI-MedLine.d111.s13|87-93|ethanol|O
DDI-MedLine.d111.s13|94-94|.|O
DDI-MedLine.d111.s14|0-10|Coingestion|O
DDI-MedLine.d111.s14|15-27|acetaminophen|O
DDI-MedLine.d111.s14|34-45|theophylline|O
DDI-MedLine.d111.s14|48-60|phenobarbital|O
DDI-MedLine.d111.s14|15-27|acetaminophen|O
DDI-MedLine.d111.s14|86-93|valproic|O
DDI-MedLine.d111.s14|95-98|acid|O
DDI-MedLine.d111.s14|48-60|phenobarbital|O
DDI-MedLine.d111.s14|122-125|high|O
DDI-MedLine.d111.s14|130-134|toxic|O
DDI-MedLine.d111.s14|136-149|concentrations|O
DDI-MedLine.d111.s14|151-159|decreases|O
DDI-MedLine.d111.s14|165-171|binding|O
DDI-MedLine.d111.s14|180-185|target|O
DDI-MedLine.d111.s14|187-190|drug|O
DDI-MedLine.d111.s14|191-191|.|O
DDI-MedLine.d111.s15|0-2|The|O
DDI-MedLine.d111.s15|4-12|resulting|O
DDI-MedLine.d111.s15|14-21|increase|O
DDI-MedLine.d111.s15|26-29|free|O
DDI-MedLine.d111.s15|31-34|drug|O
DDI-MedLine.d111.s15|36-48|concentration|O
DDI-MedLine.d111.s15|50-52|may|O
DDI-MedLine.d111.s15|54-57|lead|O
DDI-MedLine.d111.s15|62-69|enhanced|O
DDI-MedLine.d111.s15|31-34|drug|O
DDI-MedLine.d111.s15|76-81|effect|O
DDI-MedLine.d111.s15|86-89|vivo|O
DDI-MedLine.d111.s15|90-90|.|O
DDI-DrugBank.d172.s0|0-6|General|O
DDI-DrugBank.d172.s0|9-19|Significant|O
DDI-DrugBank.d172.s0|21-32|interactions|O
DDI-DrugBank.d172.s0|34-36|may|O
DDI-DrugBank.d172.s0|38-42|occur|O
DDI-DrugBank.d172.s0|49-57|celecoxib|O
DDI-DrugBank.d172.s0|62-73|administered|O
DDI-DrugBank.d172.s0|75-82|together|O
DDI-DrugBank.d172.s0|89-93|drugs|O
DDI-DrugBank.d172.s0|100-106|inhibit|O
DDI-DrugBank.d172.s0|108-111|P450|O
DDI-DrugBank.d172.s0|113-115|2C9|O
DDI-DrugBank.d172.s0|116-116|.|O
DDI-DrugBank.d172.s1|0-8|Celecoxib|O
DDI-DrugBank.d172.s1|10-19|metabolism|O
DDI-DrugBank.d172.s1|24-36|predominantly|O
DDI-DrugBank.d172.s1|38-45|mediated|O
DDI-DrugBank.d172.s1|47-49|via|O
DDI-DrugBank.d172.s1|51-60|cytochrome|O
DDI-DrugBank.d172.s1|62-65|P450|O
DDI-DrugBank.d172.s1|67-69|2C9|O
DDI-DrugBank.d172.s1|78-82|liver|O
DDI-DrugBank.d172.s1|83-83|.|O
DDI-DrugBank.d172.s2|0-16|Co-administration|O
DDI-DrugBank.d172.s2|21-29|celecoxib|O
DDI-DrugBank.d172.s2|36-40|drugs|O
DDI-DrugBank.d172.s2|51-55|known|O
DDI-DrugBank.d172.s2|60-66|inhibit|O
DDI-DrugBank.d172.s2|68-70|2C9|O
DDI-DrugBank.d172.s2|82-85|done|O
DDI-DrugBank.d172.s2|92-98|caution|O
DDI-DrugBank.d172.s2|99-99|.|O
DDI-DrugBank.d172.s3|0-1|In|O
DDI-DrugBank.d172.s3|3-7|vitro|O
DDI-DrugBank.d172.s3|9-15|studies|O
DDI-DrugBank.d172.s3|17-24|indicate|O
DDI-DrugBank.d172.s3|31-39|celecoxib|O
DDI-DrugBank.d172.s3|51-59|inhibitor|O
DDI-DrugBank.d172.s3|64-73|cytochrome|O
DDI-DrugBank.d172.s3|75-78|P450|O
DDI-DrugBank.d172.s3|80-82|2C9|O
DDI-DrugBank.d172.s3|85-88|2C19|O
DDI-DrugBank.d172.s3|93-95|3A4|O
DDI-DrugBank.d172.s3|96-96|.|O
DDI-DrugBank.d172.s4|0-1|In|O
DDI-DrugBank.d172.s4|3-7|vitro|O
DDI-DrugBank.d172.s4|9-15|studies|O
DDI-DrugBank.d172.s4|17-20|also|O
DDI-DrugBank.d172.s4|22-29|indicate|O
DDI-DrugBank.d172.s4|36-44|celecoxib|O
DDI-DrugBank.d172.s4|47-54|although|O
DDI-DrugBank.d172.s4|62-70|substrate|O
DDI-DrugBank.d172.s4|79-87|inhibitor|O
DDI-DrugBank.d172.s4|92-101|cytochrome|O
DDI-DrugBank.d172.s4|103-106|P450|O
DDI-DrugBank.d172.s4|108-110|2D6|O
DDI-DrugBank.d172.s4|111-111|.|O
DDI-DrugBank.d172.s5|0-8|Therefore|O
DDI-DrugBank.d172.s5|22-30|potential|O
DDI-DrugBank.d172.s5|42-45|vivo|O
DDI-DrugBank.d172.s5|47-50|drug|O
DDI-DrugBank.d172.s5|52-62|interaction|O
DDI-DrugBank.d172.s5|69-73|drugs|O
DDI-DrugBank.d172.s5|84-94|metabolized|O
DDI-DrugBank.d172.s5|99-102|P450|O
DDI-DrugBank.d172.s5|104-106|2D6|O
DDI-DrugBank.d172.s5|107-107|.|O
DDI-DrugBank.d172.s6|0-7|Clinical|O
DDI-DrugBank.d172.s6|9-15|studies|O
DDI-DrugBank.d172.s6|22-30|celecoxib|O
DDI-DrugBank.d172.s6|37-46|identified|O
DDI-DrugBank.d172.s6|48-58|potentially|O
DDI-DrugBank.d172.s6|60-70|significant|O
DDI-DrugBank.d172.s6|72-83|interactions|O
DDI-DrugBank.d172.s6|90-100|fluconazole|O
DDI-DrugBank.d172.s6|106-112|lithium|O
DDI-DrugBank.d172.s6|113-113|.|O
DDI-DrugBank.d172.s7|0-9|Experience|O
DDI-DrugBank.d172.s7|16-27|nonsteroidal|O
DDI-DrugBank.d172.s7|29-45|anti-inflammatory|O
DDI-DrugBank.d172.s7|47-51|drugs|O
DDI-DrugBank.d172.s7|54-59|NSAIDs|O
DDI-DrugBank.d172.s7|62-69|suggests|O
DDI-DrugBank.d172.s7|75-83|potential|O
DDI-DrugBank.d172.s7|89-100|interactions|O
DDI-DrugBank.d172.s7|107-116|furosemide|O
DDI-DrugBank.d172.s7|122-124|ACE|O
DDI-DrugBank.d172.s7|126-135|inhibitors|O
DDI-DrugBank.d172.s7|136-136|.|O
DDI-DrugBank.d172.s8|0-2|The|O
DDI-DrugBank.d172.s8|4-10|effects|O
DDI-DrugBank.d172.s8|12-20|celecoxib|O
DDI-DrugBank.d172.s8|29-44|pharmacokinetics|O
DDI-DrugBank.d172.s8|46-51|and/or|O
DDI-DrugBank.d172.s8|53-68|pharmacodynamics|O
DDI-DrugBank.d172.s8|73-81|glyburide|O
DDI-DrugBank.d172.s8|84-95|ketoconazole|O
DDI-DrugBank.d172.s8|98-109|methotrexate|O
DDI-DrugBank.d172.s8|112-120|phenytoin|O
DDI-DrugBank.d172.s8|123-133|tolbutamide|O
DDI-DrugBank.d172.s8|140-147|warfarin|O
DDI-DrugBank.d172.s8|159-165|studied|O
DDI-DrugBank.d172.s8|170-173|vivo|O
DDI-DrugBank.d172.s8|179-188|clinically|O
DDI-DrugBank.d172.s8|190-198|important|O
DDI-DrugBank.d172.s8|200-211|interactions|O
DDI-DrugBank.d172.s8|227-231|found|O
DDI-DrugBank.d172.s8|232-232|.|O
DDI-DrugBank.d172.s9|0-2|ACE|O
DDI-DrugBank.d172.s9|4-13|inhibitors|O
DDI-DrugBank.d172.s9|16-22|Reports|O
DDI-DrugBank.d172.s9|24-30|suggest|O
DDI-DrugBank.d172.s9|37-42|NSAIDs|O
DDI-DrugBank.d172.s9|44-46|may|O
DDI-DrugBank.d172.s9|48-55|diminish|O
DDI-DrugBank.d172.s9|61-76|antihypertensive|O
DDI-DrugBank.d172.s9|78-83|effect|O
DDI-DrugBank.d172.s9|88-98|Angiotensin|O
DDI-DrugBank.d172.s9|100-109|Converting|O
DDI-DrugBank.d172.s9|111-116|Enzyme|O
DDI-DrugBank.d172.s9|0-2|ACE|O
DDI-DrugBank.d172.s9|4-13|inhibitors|O
DDI-DrugBank.d172.s9|134-134|.|O
DDI-DrugBank.d172.s10|0-3|This|O
DDI-DrugBank.d172.s10|5-15|interaction|O
DDI-DrugBank.d172.s10|27-31|given|O
DDI-DrugBank.d172.s10|33-45|consideration|O
DDI-DrugBank.d172.s10|50-57|patients|O
DDI-DrugBank.d172.s10|59-64|taking|O
DDI-DrugBank.d172.s10|66-73|CELEBREX|O
DDI-DrugBank.d172.s10|75-87|concomitantly|O
DDI-DrugBank.d172.s10|94-107|ACE-inhibitors|O
DDI-DrugBank.d172.s10|108-108|.|O
DDI-DrugBank.d172.s11|0-9|Furosemide|O
DDI-DrugBank.d172.s11|12-19|Clinical|O
DDI-DrugBank.d172.s11|21-27|studies|O
DDI-DrugBank.d172.s11|33-36|well|O
DDI-DrugBank.d172.s11|41-44|post|O
DDI-DrugBank.d172.s11|46-54|marketing|O
DDI-DrugBank.d172.s11|56-67|observations|O
DDI-DrugBank.d172.s11|75-79|shown|O
DDI-DrugBank.d172.s11|86-91|NSAIDs|O
DDI-DrugBank.d172.s11|97-102|reduce|O
DDI-DrugBank.d172.s11|108-118|natriuretic|O
DDI-DrugBank.d172.s11|120-125|effect|O
DDI-DrugBank.d172.s11|130-139|furosemide|O
DDI-DrugBank.d172.s11|145-153|thiazides|O
DDI-DrugBank.d172.s11|163-170|patients|O
DDI-DrugBank.d172.s11|171-171|.|O
DDI-DrugBank.d172.s12|0-3|This|O
DDI-DrugBank.d172.s12|5-12|response|O
DDI-DrugBank.d172.s12|23-32|attributed|O
DDI-DrugBank.d172.s12|37-46|inhibition|O
DDI-DrugBank.d172.s12|51-55|renal|O
DDI-DrugBank.d172.s12|57-69|prostaglandin|O
DDI-DrugBank.d172.s12|71-79|synthesis|O
DDI-DrugBank.d172.s12|80-80|.|O
DDI-DrugBank.d172.s13|0-6|Aspirin|O
DDI-DrugBank.d172.s13|9-16|CELEBREX|O
DDI-DrugBank.d172.s13|25-28|used|O
DDI-DrugBank.d172.s13|35-37|low|O
DDI-DrugBank.d172.s13|39-42|dose|O
DDI-DrugBank.d172.s13|44-50|aspirin|O
DDI-DrugBank.d172.s13|51-51|.|O
DDI-DrugBank.d172.s14|0-6|However|O
DDI-DrugBank.d172.s14|9-19|concomitant|O
DDI-DrugBank.d172.s14|21-34|administration|O
DDI-DrugBank.d172.s14|39-45|aspirin|O
DDI-DrugBank.d172.s14|52-59|CELEBREX|O
DDI-DrugBank.d172.s14|61-63|may|O
DDI-DrugBank.d172.s14|65-70|result|O
DDI-DrugBank.d172.s14|78-86|increased|O
DDI-DrugBank.d172.s14|88-91|rate|O
DDI-DrugBank.d172.s14|96-97|GI|O
DDI-DrugBank.d172.s14|99-108|ulceration|O
DDI-DrugBank.d172.s14|119-131|complications|O
DDI-DrugBank.d172.s14|134-141|compared|O
DDI-DrugBank.d172.s14|146-148|use|O
DDI-DrugBank.d172.s14|52-59|CELEBREX|O
DDI-DrugBank.d172.s14|162-166|alone|O
DDI-DrugBank.d172.s14|167-167|.|O
DDI-DrugBank.d172.s15|0-6|Because|O
DDI-DrugBank.d172.s15|15-18|lack|O
DDI-DrugBank.d172.s15|23-30|platelet|O
DDI-DrugBank.d172.s15|32-38|effects|O
DDI-DrugBank.d172.s15|41-48|CELEBREX|O
DDI-DrugBank.d172.s15|59-68|substitute|O
DDI-DrugBank.d172.s15|74-80|aspirin|O
DDI-DrugBank.d172.s15|86-99|cardiovascular|O
DDI-DrugBank.d172.s15|101-111|prophylaxis|O
DDI-DrugBank.d172.s15|112-112|.|O
DDI-DrugBank.d172.s16|0-10|Fluconazole|O
DDI-DrugBank.d172.s16|13-23|Concomitant|O
DDI-DrugBank.d172.s16|25-38|administration|O
DDI-DrugBank.d172.s16|43-53|fluconazole|O
DDI-DrugBank.d172.s16|58-60|200|O
DDI-DrugBank.d172.s16|62-63|mg|O
DDI-DrugBank.d172.s16|65-66|QD|O
DDI-DrugBank.d172.s16|68-75|resulted|O
DDI-DrugBank.d172.s16|82-89|two-fold|O
DDI-DrugBank.d172.s16|91-98|increase|O
DDI-DrugBank.d172.s16|103-111|celecoxib|O
DDI-DrugBank.d172.s16|113-118|plasma|O
DDI-DrugBank.d172.s16|120-132|concentration|O
DDI-DrugBank.d172.s16|133-133|.|O
DDI-DrugBank.d172.s17|0-3|This|O
DDI-DrugBank.d172.s17|5-12|increase|O
DDI-DrugBank.d172.s17|17-19|due|O
DDI-DrugBank.d172.s17|28-37|inhibition|O
DDI-DrugBank.d172.s17|42-50|celecoxib|O
DDI-DrugBank.d172.s17|52-61|metabolism|O
DDI-DrugBank.d172.s17|63-65|via|O
DDI-DrugBank.d172.s17|67-70|P450|O
DDI-DrugBank.d172.s17|72-74|2C9|O
DDI-DrugBank.d172.s17|79-89|fluconazole|O
DDI-DrugBank.d172.s17|92-94|see|O
DDI-DrugBank.d172.s17|96-103|CLINICAL|O
DDI-DrugBank.d172.s17|105-116|PHARMACOLOGY|O
DDI-DrugBank.d172.s17|118-118|-|O
DDI-DrugBank.d172.s17|120-135|Pharmacokinetics|O
DDI-DrugBank.d172.s17|138-147|Metabolism|O
DDI-DrugBank.d172.s17|149-149|.|O
DDI-DrugBank.d172.s18|0-7|CELEBREX|O
DDI-DrugBank.d172.s18|19-28|introduced|O
DDI-DrugBank.d172.s18|37-42|lowest|O
DDI-DrugBank.d172.s18|44-54|recommended|O
DDI-DrugBank.d172.s18|56-59|dose|O
DDI-DrugBank.d172.s18|64-71|patients|O
DDI-DrugBank.d172.s18|73-81|receiving|O
DDI-DrugBank.d172.s18|83-93|fluconazole|O
DDI-DrugBank.d172.s18|94-94|.|O
DDI-DrugBank.d172.s19|0-6|Lithium|O
DDI-DrugBank.d172.s19|9-10|In|O
DDI-DrugBank.d172.s19|14-18|study|O
DDI-DrugBank.d172.s19|20-28|conducted|O
DDI-DrugBank.d172.s19|33-39|healthy|O
DDI-DrugBank.d172.s19|41-48|subjects|O
DDI-DrugBank.d172.s19|51-54|mean|O
DDI-DrugBank.d172.s19|56-67|steady-state|O
DDI-DrugBank.d172.s19|69-75|lithium|O
DDI-DrugBank.d172.s19|77-82|plasma|O
DDI-DrugBank.d172.s19|84-89|levels|O
DDI-DrugBank.d172.s19|91-99|increased|O
DDI-DrugBank.d172.s19|101-113|approximately|O
DDI-DrugBank.d172.s19|115-116|17|O
DDI-DrugBank.d172.s19|117-117|%|O
DDI-DrugBank.d172.s19|41-48|subjects|O
DDI-DrugBank.d172.s19|131-139|receiving|O
DDI-DrugBank.d172.s19|69-75|lithium|O
DDI-DrugBank.d172.s19|149-151|450|O
DDI-DrugBank.d172.s19|153-154|mg|O
DDI-DrugBank.d172.s19|156-158|BID|O
DDI-DrugBank.d172.s19|165-172|CELEBREX|O
DDI-DrugBank.d172.s19|174-176|200|O
DDI-DrugBank.d172.s19|153-154|mg|O
DDI-DrugBank.d172.s19|156-158|BID|O
DDI-DrugBank.d172.s19|188-195|compared|O
DDI-DrugBank.d172.s19|41-48|subjects|O
DDI-DrugBank.d172.s19|131-139|receiving|O
DDI-DrugBank.d172.s19|69-75|lithium|O
DDI-DrugBank.d172.s19|227-231|alone|O
DDI-DrugBank.d172.s19|232-232|.|O
DDI-DrugBank.d172.s20|0-7|Patients|O
DDI-DrugBank.d172.s20|12-18|lithium|O
DDI-DrugBank.d172.s20|20-28|treatment|O
DDI-DrugBank.d172.s20|40-46|closely|O
DDI-DrugBank.d172.s20|48-56|monitored|O
DDI-DrugBank.d172.s20|63-70|CELEBREX|O
DDI-DrugBank.d172.s20|75-84|introduced|O
DDI-DrugBank.d172.s20|89-97|withdrawn|O
DDI-DrugBank.d172.s20|98-98|.|O
DDI-DrugBank.d172.s21|0-11|Methotrexate|O
DDI-DrugBank.d172.s21|14-15|In|O
DDI-DrugBank.d172.s21|20-30|interaction|O
DDI-DrugBank.d172.s21|32-36|study|O
DDI-DrugBank.d172.s21|41-50|rheumatoid|O
DDI-DrugBank.d172.s21|52-60|arthritis|O
DDI-DrugBank.d172.s21|62-69|patients|O
DDI-DrugBank.d172.s21|71-76|taking|O
DDI-DrugBank.d172.s21|78-89|methotrexate|O
DDI-DrugBank.d172.s21|92-99|CELEBREX|O
DDI-DrugBank.d172.s21|116-126|significant|O
DDI-DrugBank.d172.s21|128-133|effect|O
DDI-DrugBank.d172.s21|142-157|pharmacokinetics|O
DDI-DrugBank.d172.s21|78-89|methotrexate|O
DDI-DrugBank.d172.s21|174-174|.|O
DDI-DrugBank.d172.s22|0-7|Warfarin|O
DDI-DrugBank.d172.s22|10-12|The|O
DDI-DrugBank.d172.s22|14-19|effect|O
DDI-DrugBank.d172.s22|24-32|celecoxib|O
DDI-DrugBank.d172.s22|41-54|anti-coagulant|O
DDI-DrugBank.d172.s22|14-19|effect|O
DDI-DrugBank.d172.s22|66-73|warfarin|O
DDI-DrugBank.d172.s22|79-85|studied|O
DDI-DrugBank.d172.s22|92-96|group|O
DDI-DrugBank.d172.s22|101-107|healthy|O
DDI-DrugBank.d172.s22|109-116|subjects|O
DDI-DrugBank.d172.s22|118-126|receiving|O
DDI-DrugBank.d172.s22|128-132|daily|O
DDI-DrugBank.d172.s22|134-138|doses|O
DDI-DrugBank.d172.s22|143-145|2-5|O
DDI-DrugBank.d172.s22|147-148|mg|O
DDI-DrugBank.d172.s22|66-73|warfarin|O
DDI-DrugBank.d172.s22|161-161|.|O
DDI-DrugBank.d172.s23|0-1|In|O
DDI-DrugBank.d172.s23|9-16|subjects|O
DDI-DrugBank.d172.s23|19-27|celecoxib|O
DDI-DrugBank.d172.s23|37-41|alter|O
DDI-DrugBank.d172.s23|47-59|anticoagulant|O
DDI-DrugBank.d172.s23|61-66|effect|O
DDI-DrugBank.d172.s23|71-78|warfarin|O
DDI-DrugBank.d172.s23|83-92|determined|O
DDI-DrugBank.d172.s23|97-107|prothrombin|O
DDI-DrugBank.d172.s23|109-112|time|O
DDI-DrugBank.d172.s23|113-113|.|O
DDI-DrugBank.d172.s24|0-6|However|O
DDI-DrugBank.d172.s24|9-15|caution|O
DDI-DrugBank.d172.s24|27-30|used|O
DDI-DrugBank.d172.s24|37-49|administering|O
DDI-DrugBank.d172.s24|51-58|CELEBREX|O
DDI-DrugBank.d172.s24|65-72|warfarin|O
DDI-DrugBank.d172.s24|74-78|since|O
DDI-DrugBank.d172.s24|86-93|patients|O
DDI-DrugBank.d172.s24|102-110|increased|O
DDI-DrugBank.d172.s24|112-115|risk|O
DDI-DrugBank.d172.s24|120-127|bleeding|O
DDI-DrugBank.d172.s24|129-141|complications|O
DDI-DrugBank.d172.s24|142-142|.|O
DDI-DrugBank.d700.s0|0-7|Antacids|O
DDI-DrugBank.d700.s0|10-19|Absorption|O
DDI-DrugBank.d700.s0|26-31|single|O
DDI-DrugBank.d700.s0|33-36|dose|O
DDI-DrugBank.d700.s0|41-48|Myfortic|O
DDI-DrugBank.d700.s0|54-62|decreased|O
DDI-DrugBank.d700.s0|69-80|administered|O
DDI-DrugBank.d700.s0|85-86|12|O
DDI-DrugBank.d700.s0|88-93|stable|O
DDI-DrugBank.d700.s0|95-99|renal|O
DDI-DrugBank.d700.s0|101-110|transplant|O
DDI-DrugBank.d700.s0|112-119|patients|O
DDI-DrugBank.d700.s0|121-124|also|O
DDI-DrugBank.d700.s0|126-131|taking|O
DDI-DrugBank.d700.s0|133-150|magnesium-aluminum|O
DDI-DrugBank.d700.s0|152-161|containing|O
DDI-DrugBank.d700.s0|163-170|antacids|O
DDI-DrugBank.d700.s0|173-174|30|O
DDI-DrugBank.d700.s0|176-177|mL|O
DDI-DrugBank.d700.s0|185-188|mean|O
DDI-DrugBank.d700.s0|190-193|Cmax|O
DDI-DrugBank.d700.s0|199-201|AUC|O
DDI-DrugBank.d700.s0|203-205|0-t|O
DDI-DrugBank.d700.s0|208-213|values|O
DDI-DrugBank.d700.s0|219-221|MPA|O
DDI-DrugBank.d700.s0|228-229|25|O
DDI-DrugBank.d700.s0|230-230|%|O
DDI-DrugBank.d700.s0|236-237|37|O
DDI-DrugBank.d700.s0|230-230|%|O
DDI-DrugBank.d700.s0|240-244|lower|O
DDI-DrugBank.d700.s0|247-258|respectively|O
DDI-DrugBank.d700.s0|41-48|Myfortic|O
DDI-DrugBank.d700.s0|69-80|administered|O
DDI-DrugBank.d700.s0|297-301|alone|O
DDI-DrugBank.d700.s0|309-315|fasting|O
DDI-DrugBank.d700.s0|317-326|conditions|O
DDI-DrugBank.d700.s1|0-1|It|O
DDI-DrugBank.d700.s1|6-16|recommended|O
DDI-DrugBank.d700.s1|23-30|Myfortic|O
DDI-DrugBank.d700.s1|36-43|antacids|O
DDI-DrugBank.d700.s1|52-63|administered|O
DDI-DrugBank.d700.s1|65-78|simultaneously|O
DDI-DrugBank.d700.s1|79-79|.|O
DDI-DrugBank.d700.s2|0-11|Cyclosporine|O
DDI-DrugBank.d700.s2|14-17|When|O
DDI-DrugBank.d700.s2|19-25|studied|O
DDI-DrugBank.d700.s2|30-35|stable|O
DDI-DrugBank.d700.s2|37-41|renal|O
DDI-DrugBank.d700.s2|43-52|transplant|O
DDI-DrugBank.d700.s2|54-61|patients|O
DDI-DrugBank.d700.s2|64-75|cyclosporine|O
DDI-DrugBank.d700.s2|78-80|USP|O
DDI-DrugBank.d700.s2|83-90|MODIFIED|O
DDI-DrugBank.d700.s2|93-108|pharmacokinetics|O
DDI-DrugBank.d700.s2|115-124|unaffected|O
DDI-DrugBank.d700.s2|129-134|steady|O
DDI-DrugBank.d700.s2|136-140|state|O
DDI-DrugBank.d700.s2|142-147|dosing|O
DDI-DrugBank.d700.s2|152-159|Myfortic|O
DDI-DrugBank.d700.s2|160-160|.|O
DDI-DrugBank.d700.s3|0-20|Acyclovir/Ganciclovir|O
DDI-DrugBank.d700.s3|23-25|may|O
DDI-DrugBank.d700.s3|30-34|taken|O
DDI-DrugBank.d700.s3|41-48|Myfortic|O
DDI-DrugBank.d700.s4|0-6|however|O
DDI-DrugBank.d700.s4|20-25|period|O
DDI-DrugBank.d700.s4|30-38|treatment|O
DDI-DrugBank.d700.s4|41-50|physicians|O
DDI-DrugBank.d700.s4|59-65|monitor|O
DDI-DrugBank.d700.s4|67-71|blood|O
DDI-DrugBank.d700.s4|73-76|cell|O
DDI-DrugBank.d700.s4|78-83|counts|O
DDI-DrugBank.d700.s4|84-84|.|O
DDI-DrugBank.d700.s5|0-3|Both|O
DDI-DrugBank.d700.s5|5-25|acyclovir/ganciclovir|O
DDI-DrugBank.d700.s5|31-34|MPAG|O
DDI-DrugBank.d700.s5|36-49|concentrations|O
DDI-DrugBank.d700.s5|55-63|increased|O
DDI-DrugBank.d700.s5|72-79|presence|O
DDI-DrugBank.d700.s5|84-88|renal|O
DDI-DrugBank.d700.s5|90-99|impairment|O
DDI-DrugBank.d700.s5|108-118|coexistence|O
DDI-DrugBank.d700.s5|120-122|may|O
DDI-DrugBank.d700.s5|124-130|compete|O
DDI-DrugBank.d700.s5|136-142|tubular|O
DDI-DrugBank.d700.s5|144-152|secretion|O
DDI-DrugBank.d700.s5|55-62|increase|O
DDI-DrugBank.d700.s5|36-49|concentrations|O
DDI-DrugBank.d700.s5|204-206|two|O
DDI-DrugBank.d700.s5|207-207|.|O
DDI-DrugBank.d700.s6|0-25|Azathioprine/Mycophenolate|O
DDI-DrugBank.d700.s6|27-33|Mofetil|O
DDI-DrugBank.d700.s6|36-40|Given|O
DDI-DrugBank.d700.s6|47-58|azathioprine|O
DDI-DrugBank.d700.s6|64-76|mycophenolate|O
DDI-DrugBank.d700.s6|78-84|mofetil|O
DDI-DrugBank.d700.s6|86-92|inhibit|O
DDI-DrugBank.d700.s6|94-99|purine|O
DDI-DrugBank.d700.s6|101-110|metabolism|O
DDI-DrugBank.d700.s6|119-129|recommended|O
DDI-DrugBank.d700.s6|136-143|Myfortic|O
DDI-DrugBank.d700.s6|152-163|administered|O
DDI-DrugBank.d700.s6|165-177|concomitantly|O
DDI-DrugBank.d700.s6|47-58|azathioprine|O
DDI-DrugBank.d700.s6|64-76|mycophenolate|O
DDI-DrugBank.d700.s6|78-84|mofetil|O
DDI-DrugBank.d700.s6|221-221|.|O
DDI-DrugBank.d700.s7|0-13|Cholestyramine|O
DDI-DrugBank.d700.s7|19-23|Drugs|O
DDI-DrugBank.d700.s7|30-33|Bind|O
DDI-DrugBank.d700.s7|35-38|Bile|O
DDI-DrugBank.d700.s7|40-44|Acids|O
DDI-DrugBank.d700.s7|47-51|These|O
DDI-DrugBank.d700.s7|53-57|drugs|O
DDI-DrugBank.d700.s7|59-67|interrupt|O
DDI-DrugBank.d700.s7|69-81|enterohepatic|O
DDI-DrugBank.d700.s7|83-95|recirculation|O
DDI-DrugBank.d700.s7|101-106|reduce|O
DDI-DrugBank.d700.s7|108-110|MPA|O
DDI-DrugBank.d700.s7|112-119|exposure|O
DDI-DrugBank.d700.s7|126-139|coadministered|O
DDI-DrugBank.d700.s7|146-158|mycophenolate|O
DDI-DrugBank.d700.s7|160-166|mofetil|O
DDI-DrugBank.d700.s7|167-167|.|O
DDI-DrugBank.d700.s8|0-8|Therefore|O
DDI-DrugBank.d700.s8|18-27|administer|O
DDI-DrugBank.d700.s8|29-36|Myfortic|O
DDI-DrugBank.d700.s8|43-56|cholestyramine|O
DDI-DrugBank.d700.s8|67-72|agents|O
DDI-DrugBank.d700.s8|79-81|may|O
DDI-DrugBank.d700.s8|83-91|interfere|O
DDI-DrugBank.d700.s8|98-110|enterohepatic|O
DDI-DrugBank.d700.s8|112-124|recirculation|O
DDI-DrugBank.d700.s8|129-133|drugs|O
DDI-DrugBank.d700.s8|79-81|may|O
DDI-DrugBank.d700.s8|144-147|bind|O
DDI-DrugBank.d700.s8|149-152|bile|O
DDI-DrugBank.d700.s8|154-158|acids|O
DDI-DrugBank.d700.s8|165-171|example|O
DDI-DrugBank.d700.s8|149-152|bile|O
DDI-DrugBank.d700.s8|154-157|acid|O
DDI-DrugBank.d700.s8|183-194|sequestrates|O
DDI-DrugBank.d700.s8|199-202|oral|O
DDI-DrugBank.d700.s8|204-212|activated|O
DDI-DrugBank.d700.s8|214-221|charcoal|O
DDI-DrugBank.d700.s8|239-247|potential|O
DDI-DrugBank.d700.s8|252-257|reduce|O
DDI-DrugBank.d700.s8|263-270|efficacy|O
DDI-DrugBank.d700.s8|29-36|Myfortic|O
DDI-DrugBank.d700.s8|283-283|.|O
DDI-DrugBank.d700.s9|0-3|Oral|O
DDI-DrugBank.d700.s9|5-18|Contraceptives|O
DDI-DrugBank.d700.s9|21-25|Given|O
DDI-DrugBank.d700.s9|31-39|different|O
DDI-DrugBank.d700.s9|41-50|metabolism|O
DDI-DrugBank.d700.s9|55-62|Myfortic|O
DDI-DrugBank.d700.s9|68-71|oral|O
DDI-DrugBank.d700.s9|73-86|contraceptives|O
DDI-DrugBank.d700.s9|92-95|drug|O
DDI-DrugBank.d700.s9|97-107|interaction|O
DDI-DrugBank.d700.s9|123-125|two|O
DDI-DrugBank.d700.s9|127-133|classes|O
DDI-DrugBank.d700.s9|92-95|drug|O
DDI-DrugBank.d700.s9|146-153|expected|O
DDI-DrugBank.d700.s9|154-154|.|O
DDI-DrugBank.d700.s10|0-6|However|O
DDI-DrugBank.d700.s10|14-22|drug-drug|O
DDI-DrugBank.d700.s10|24-34|interaction|O
DDI-DrugBank.d700.s10|36-40|study|O
DDI-DrugBank.d700.s10|43-46|mean|O
DDI-DrugBank.d700.s10|48-62|levonorgesterol|O
DDI-DrugBank.d700.s10|64-66|AUC|O
DDI-DrugBank.d700.s10|72-80|decreased|O
DDI-DrugBank.d700.s10|85-86|15|O
DDI-DrugBank.d700.s10|87-87|%|O
DDI-DrugBank.d700.s10|94-107|coadministered|O
DDI-DrugBank.d700.s10|114-126|mycophenolate|O
DDI-DrugBank.d700.s10|128-134|mofetil|O
DDI-DrugBank.d700.s10|135-135|.|O
DDI-DrugBank.d700.s11|0-8|Therefore|O
DDI-DrugBank.d700.s11|17-27|recommended|O
DDI-DrugBank.d700.s11|34-37|oral|O
DDI-DrugBank.d700.s11|39-52|contraceptives|O
DDI-DrugBank.d700.s11|58-60|co-|O
DDI-DrugBank.d700.s11|62-73|administered|O
DDI-DrugBank.d700.s11|80-87|Myfortic|O
DDI-DrugBank.d700.s11|94-100|caution|O
DDI-DrugBank.d700.s11|106-115|additional|O
DDI-DrugBank.d700.s11|117-121|birth|O
DDI-DrugBank.d700.s11|123-129|control|O
DDI-DrugBank.d700.s11|131-137|methods|O
DDI-DrugBank.d700.s11|142-151|considered|O
DDI-DrugBank.d700.s11|152-152|.|O
DDI-DrugBank.d700.s12|0-3|Live|O
DDI-DrugBank.d700.s12|5-12|Vaccines|O
DDI-DrugBank.d700.s12|15-20|During|O
DDI-DrugBank.d700.s12|22-30|treatment|O
DDI-DrugBank.d700.s12|37-44|Myfortic|O
DDI-DrugBank.d700.s12|51-53|use|O
DDI-DrugBank.d700.s12|58-61|live|O
DDI-DrugBank.d700.s12|63-72|attenuated|O
DDI-DrugBank.d700.s12|74-81|vaccines|O
DDI-DrugBank.d700.s12|93-99|avoided|O
DDI-DrugBank.d700.s12|105-112|patients|O
DDI-DrugBank.d700.s12|124-130|advised|O
DDI-DrugBank.d700.s12|137-148|vaccinations|O
DDI-DrugBank.d700.s12|150-152|may|O
DDI-DrugBank.d700.s12|157-160|less|O
DDI-DrugBank.d700.s12|162-170|effective|O
DDI-DrugBank.d700.s12|171-171|.|O
DDI-DrugBank.d700.s13|0-8|Influenza|O
DDI-DrugBank.d700.s13|10-20|vaccination|O
DDI-DrugBank.d700.s13|22-24|may|O
DDI-DrugBank.d700.s13|32-36|value|O
DDI-DrugBank.d700.s13|37-37|.|O
DDI-DrugBank.d700.s14|0-10|Prescribers|O
DDI-DrugBank.d700.s14|19-23|refer|O
DDI-DrugBank.d700.s14|28-35|national|O
DDI-DrugBank.d700.s14|37-46|guidelines|O
DDI-DrugBank.d700.s14|52-60|influenza|O
DDI-DrugBank.d700.s14|62-72|vaccination|O
DDI-DrugBank.d700.s14|73-73|.|O
DDI-DrugBank.d700.s15|0-4|Drugs|O
DDI-DrugBank.d700.s15|11-15|alter|O
DDI-DrugBank.d700.s15|21-36|gastrointestinal|O
DDI-DrugBank.d700.s15|38-42|flora|O
DDI-DrugBank.d700.s15|44-46|may|O
DDI-DrugBank.d700.s15|48-55|interact|O
DDI-DrugBank.d700.s15|62-69|Myfortic|O
DDI-DrugBank.d700.s15|74-83|disrupting|O
DDI-DrugBank.d700.s15|85-97|enterohepatic|O
DDI-DrugBank.d700.s15|99-111|recirculation|O
DDI-DrugBank.d700.s15|112-112|.|O
DDI-DrugBank.d700.s16|0-11|Interference|O
DDI-DrugBank.d700.s16|16-19|MPAG|O
DDI-DrugBank.d700.s16|21-30|hydrolysis|O
DDI-DrugBank.d700.s16|32-34|may|O
DDI-DrugBank.d700.s16|36-39|lead|O
DDI-DrugBank.d700.s16|44-47|less|O
DDI-DrugBank.d700.s16|16-18|MPA|O
DDI-DrugBank.d700.s16|53-61|available|O
DDI-DrugBank.d700.s16|67-76|absorption|O
DDI-DrugBank.d103.s0|0-11|Short-Acting|O
DDI-DrugBank.d103.s0|13-26|beta2-agonists|O
DDI-DrugBank.d103.s0|29-35|Aerosol|O
DDI-DrugBank.d103.s0|37-51|bronchodilators|O
DDI-DrugBank.d103.s0|60-71|short-acting|O
DDI-DrugBank.d103.s0|73-82|adrenergic|O
DDI-DrugBank.d103.s0|84-92|stimulant|O
DDI-DrugBank.d103.s0|94-97|type|O
DDI-DrugBank.d103.s0|99-101|may|O
DDI-DrugBank.d103.s0|106-109|used|O
DDI-DrugBank.d103.s0|115-120|relief|O
DDI-DrugBank.d103.s0|125-136|breakthrough|O
DDI-DrugBank.d103.s0|138-145|symptoms|O
DDI-DrugBank.d103.s0|153-157|using|O
DDI-DrugBank.d103.s0|159-168|formoterol|O
DDI-DrugBank.d103.s0|169-169|.|O
DDI-DrugBank.d103.s1|0-6|However|O
DDI-DrugBank.d103.s1|9-18|increasing|O
DDI-DrugBank.d103.s1|20-22|use|O
DDI-DrugBank.d103.s1|32-43|preparations|O
DDI-DrugBank.d103.s1|48-54|control|O
DDI-DrugBank.d103.s1|56-63|symptoms|O
DDI-DrugBank.d103.s1|65-73|indicates|O
DDI-DrugBank.d103.s1|75-87|deterioration|O
DDI-DrugBank.d103.s1|92-97|asthma|O
DDI-DrugBank.d103.s1|48-54|control|O
DDI-DrugBank.d103.s1|115-118|need|O
DDI-DrugBank.d103.s1|123-130|reassess|O
DDI-DrugBank.d103.s1|136-142|patient|O
DDI-DrugBank.d103.s1|146-152|therapy|O
DDI-DrugBank.d103.s1|153-153|.|O
DDI-DrugBank.d103.s2|0-10|Concomitant|O
DDI-DrugBank.d103.s2|12-25|administration|O
DDI-DrugBank.d103.s2|36-50|sympathomimetic|O
DDI-DrugBank.d103.s2|52-57|agents|O
DDI-DrugBank.d103.s2|59-61|may|O
DDI-DrugBank.d103.s2|63-72|potentiate|O
DDI-DrugBank.d103.s2|78-88|undesirable|O
DDI-DrugBank.d103.s2|90-96|effects|O
DDI-DrugBank.d103.s2|101-107|FORADIL|O
DDI-DrugBank.d103.s2|108-108|.|O
DDI-DrugBank.d103.s3|0-8|Monoamine|O
DDI-DrugBank.d103.s3|10-16|Oxidase|O
DDI-DrugBank.d103.s3|18-27|Inhibitors|O
DDI-DrugBank.d103.s3|33-41|Tricyclic|O
DDI-DrugBank.d103.s3|43-57|Antidepressants|O
DDI-DrugBank.d103.s3|60-66|FORADIL|O
DDI-DrugBank.d103.s3|78-89|administered|O
DDI-DrugBank.d103.s3|96-102|extreme|O
DDI-DrugBank.d103.s3|104-110|caution|O
DDI-DrugBank.d103.s3|115-122|patients|O
DDI-DrugBank.d103.s3|130-136|treated|O
DDI-DrugBank.d103.s3|143-151|monoamine|O
DDI-DrugBank.d103.s3|153-159|oxidase|O
DDI-DrugBank.d103.s3|161-170|inhibitors|O
DDI-DrugBank.d103.s3|175-183|tricyclic|O
DDI-DrugBank.d103.s3|185-199|antidepressants|O
DDI-DrugBank.d103.s3|213-218|action|O
DDI-DrugBank.d103.s3|223-232|formoterol|O
DDI-DrugBank.d103.s3|241-254|cardiovascular|O
DDI-DrugBank.d103.s3|256-261|system|O
DDI-DrugBank.d103.s3|263-265|may|O
DDI-DrugBank.d103.s3|270-280|potentiated|O
DDI-DrugBank.d103.s3|291-296|agents|O
DDI-DrugBank.d103.s3|297-297|.|O
DDI-DrugBank.d103.s4|0-14|Corticosteroids|O
DDI-DrugBank.d103.s4|17-31|Methylxanthines|O
DDI-DrugBank.d103.s4|37-45|Diuretics|O
DDI-DrugBank.d103.s4|48-58|Concomitant|O
DDI-DrugBank.d103.s4|60-68|treatment|O
DDI-DrugBank.d103.s4|23-30|xanthine|O
DDI-DrugBank.d103.s4|84-94|derivatives|O
DDI-DrugBank.d103.s4|7-14|steroids|O
DDI-DrugBank.d103.s4|110-118|diuretics|O
DDI-DrugBank.d103.s4|120-122|may|O
DDI-DrugBank.d103.s4|124-133|potentiate|O
DDI-DrugBank.d103.s4|137-144|possible|O
DDI-DrugBank.d103.s4|146-156|hypokalemic|O
DDI-DrugBank.d103.s4|158-163|effect|O
DDI-DrugBank.d103.s4|169-182|beta2-agonists|O
DDI-DrugBank.d103.s4|183-183|.|O
DDI-DrugBank.d103.s5|0-10|Hypokalemia|O
DDI-DrugBank.d103.s5|12-14|may|O
DDI-DrugBank.d103.s5|16-23|increase|O
DDI-DrugBank.d103.s5|25-38|susceptibility|O
DDI-DrugBank.d103.s5|43-49|cardiac|O
DDI-DrugBank.d103.s5|51-61|arrhythmias|O
DDI-DrugBank.d103.s5|66-73|patients|O
DDI-DrugBank.d103.s5|75-81|treated|O
DDI-DrugBank.d103.s5|88-96|digitalis|O
DDI-DrugBank.d103.s5|97-97|.|O
DDI-DrugBank.d103.s6|0-10|-adrenergic|O
DDI-DrugBank.d103.s6|12-19|Blockers|O
DDI-DrugBank.d103.s6|0-10|-adrenergic|O
DDI-DrugBank.d103.s6|35-42|blockers|O
DDI-DrugBank.d103.s6|44-46|may|O
DDI-DrugBank.d103.s6|48-53|weaken|O
DDI-DrugBank.d103.s6|58-67|antagonise|O
DDI-DrugBank.d103.s6|73-78|effect|O
DDI-DrugBank.d103.s6|83-89|FORADIL|O
DDI-DrugBank.d103.s6|90-90|.|O
DDI-DrugBank.d103.s7|0-8|Therefore|O
DDI-DrugBank.d103.s7|10-16|FORADIL|O
DDI-DrugBank.d103.s7|32-36|given|O
DDI-DrugBank.d103.s7|38-45|together|O
DDI-DrugBank.d103.s7|53-63|-adrenergic|O
DDI-DrugBank.d103.s7|65-72|blockers|O
DDI-DrugBank.d103.s7|75-83|including|O
DDI-DrugBank.d103.s7|85-87|eye|O
DDI-DrugBank.d103.s7|89-93|drops|O
DDI-DrugBank.d103.s7|96-101|unless|O
DDI-DrugBank.d103.s7|113-122|compelling|O
DDI-DrugBank.d103.s7|124-130|reasons|O
DDI-DrugBank.d103.s7|142-144|use|O
DDI-DrugBank.d103.s7|145-145|.|O
DDI-DrugBank.d103.s8|0-4|Other|O
DDI-DrugBank.d103.s8|6-10|Drugs|O
DDI-DrugBank.d103.s8|6-10|Drugs|O
DDI-DrugBank.d103.s8|26-34|quinidine|O
DDI-DrugBank.d103.s8|37-48|disopyramide|O
DDI-DrugBank.d103.s8|51-62|procainamide|O
DDI-DrugBank.d103.s8|65-78|phenothiazines|O
DDI-DrugBank.d103.s8|81-94|antihistamines|O
DDI-DrugBank.d103.s8|101-109|tricyclic|O
DDI-DrugBank.d103.s8|111-125|antidepressants|O
DDI-DrugBank.d103.s8|127-129|may|O
DDI-DrugBank.d103.s8|134-143|associated|O
DDI-DrugBank.d103.s8|150-160|QT-interval|O
DDI-DrugBank.d103.s8|162-173|prolongation|O
DDI-DrugBank.d103.s8|182-190|increased|O
DDI-DrugBank.d103.s8|192-195|risk|O
DDI-DrugBank.d103.s8|200-210|ventricular|O
DDI-DrugBank.d103.s8|212-221|arrhythmia|O
DDI-DrugBank.d103.s8|222-222|.|O
DDI-DrugBank.d103.s9|0-10|INFORMATION|O
DDI-DrugBank.d103.s9|12-13|TO|O
DDI-DrugBank.d103.s9|15-16|BE|O
DDI-DrugBank.d103.s9|18-25|PROVIDED|O
DDI-DrugBank.d103.s9|12-13|TO|O
DDI-DrugBank.d103.s9|30-32|THE|O
DDI-DrugBank.d103.s9|34-40|PATIENT|O
DDI-DrugBank.d103.s9|3-4|OR|O
DDI-DrugBank.d103.s9|45-52|GUARDIAN|O
DDI-DrugBank.d103.s9|54-56|See|O
DDI-DrugBank.d103.s9|58-68|illustrated|O
DDI-DrugBank.d103.s9|70-80|Information|O
DDI-DrugBank.d103.s9|82-84|For|O
DDI-DrugBank.d103.s9|86-88|The|O
DDI-DrugBank.d103.s9|90-96|Patient|O
DDI-DrugBank.d103.s9|101-108|Guardian|O
DDI-DrugBank.d103.s9|110-116|section|O
DDI-DrugBank.d103.s9|117-117|.|O
DDI-DrugBank.d103.s10|0-1|It|O
DDI-DrugBank.d103.s10|6-14|important|O
DDI-DrugBank.d103.s10|21-28|patients|O
DDI-DrugBank.d103.s10|30-39|understand|O
DDI-DrugBank.d103.s10|48-50|use|O
DDI-DrugBank.d103.s10|52-58|FORADIL|O
DDI-DrugBank.d103.s10|62-71|formoterol|O
DDI-DrugBank.d103.s10|73-80|fumarate|O
DDI-DrugBank.d103.s10|83-90|capsules|O
DDI-DrugBank.d103.s10|101-108|supplied|O
DDI-DrugBank.d103.s10|110-120|AerolizerTM|O
DDI-DrugBank.d103.s10|122-131|inhalation|O
DDI-DrugBank.d103.s10|133-138|device|O
DDI-DrugBank.d103.s10|161-164|used|O
DDI-DrugBank.d103.s10|169-176|relation|O
DDI-DrugBank.d103.s10|187-192|asthma|O
DDI-DrugBank.d103.s10|197-200|COPD|O
DDI-DrugBank.d103.s10|202-212|medications|O
DDI-DrugBank.d103.s10|223-228|taking|O
DDI-DrugBank.d103.s10|229-229|.|O
DDI-DrugBank.d103.s11|0-17|Patients/Guardians|O
DDI-DrugBank.d103.s11|29-33|given|O
DDI-DrugBank.d103.s11|39-47|following|O
DDI-DrugBank.d103.s11|49-59|information|O
DDI-DrugBank.d103.s11|63-63|.|O
DDI-DrugBank.d103.s12|0-2|The|O
DDI-DrugBank.d103.s12|4-14|recommended|O
DDI-DrugBank.d103.s12|16-21|dosage|O
DDI-DrugBank.d103.s12|24-26|one|O
DDI-DrugBank.d103.s12|31-33|two|O
DDI-DrugBank.d103.s12|35-42|capsules|O
DDI-DrugBank.d103.s12|44-48|twice|O
DDI-DrugBank.d103.s12|50-54|daily|O
DDI-DrugBank.d103.s12|57-63|morning|O
DDI-DrugBank.d103.s12|69-75|evening|O
DDI-DrugBank.d103.s12|92-99|exceeded|O
DDI-DrugBank.d103.s12|100-100|.|O
DDI-DrugBank.d103.s13|0-1|ii|O
DDI-DrugBank.d103.s13|2-2|.|O
DDI-DrugBank.d103.s14|0-6|FORADIL|O
DDI-DrugBank.d103.s14|15-19|meant|O
DDI-DrugBank.d103.s14|24-30|relieve|O
DDI-DrugBank.d103.s14|32-36|acute|O
DDI-DrugBank.d103.s14|38-43|asthma|O
DDI-DrugBank.d103.s14|48-51|COPD|O
DDI-DrugBank.d103.s14|53-60|symptoms|O
DDI-DrugBank.d103.s14|66-70|extra|O
DDI-DrugBank.d103.s14|72-76|doses|O
DDI-DrugBank.d103.s14|92-95|used|O
DDI-DrugBank.d103.s14|106-112|purpose|O
DDI-DrugBank.d103.s14|113-113|.|O
DDI-DrugBank.d103.s15|0-4|Acute|O
DDI-DrugBank.d103.s15|6-13|symptoms|O
DDI-DrugBank.d103.s15|25-31|treated|O
DDI-DrugBank.d103.s15|40-51|short-acting|O
DDI-DrugBank.d103.s15|54-60|inhaled|O
DDI-DrugBank.d103.s15|63-75|beta2-agonist|O
DDI-DrugBank.d103.s15|85-94|salbutamol|O
DDI-DrugBank.d103.s15|101-109|physician|O
DDI-DrugBank.d103.s15|118-124|provide|O
DDI-DrugBank.d103.s15|130-136|patient|O
DDI-DrugBank.d103.s15|148-157|medication|O
DDI-DrugBank.d103.s15|163-170|instruct|O
DDI-DrugBank.d103.s15|130-136|patient|O
DDI-DrugBank.d103.s15|204-207|used|O
DDI-DrugBank.d103.s15|209-209|.|O
DDI-DrugBank.d103.s16|0-2|iii|O
DDI-DrugBank.d103.s16|3-3|.|O
DDI-DrugBank.d103.s17|0-2|The|O
DDI-DrugBank.d103.s17|4-12|physician|O
DDI-DrugBank.d103.s17|24-31|notified|O
DDI-DrugBank.d103.s17|33-43|immediately|O
DDI-DrugBank.d103.s17|59-67|following|O
DDI-DrugBank.d103.s17|69-78|situations|O
DDI-DrugBank.d103.s17|80-84|occur|O
DDI-DrugBank.d103.s17|93-95|may|O
DDI-DrugBank.d103.s17|102-105|sign|O
DDI-DrugBank.d103.s17|110-118|seriously|O
DDI-DrugBank.d103.s17|120-128|worsening|O
DDI-DrugBank.d103.s17|130-135|asthma|O
DDI-DrugBank.d103.s17|140-148|Decreased|O
DDI-DrugBank.d103.s17|150-162|effectiveness|O
DDI-DrugBank.d103.s17|167-178|short-acting|O
DDI-DrugBank.d103.s17|181-187|inhaled|O
DDI-DrugBank.d103.s17|189-202|beta2-agonists|O
DDI-DrugBank.d103.s18|0-3|Need|O
DDI-DrugBank.d103.s18|14-24|inhalations|O
DDI-DrugBank.d103.s18|31-35|usual|O
DDI-DrugBank.d103.s18|40-51|short-acting|O
DDI-DrugBank.d103.s18|54-60|inhaled|O
DDI-DrugBank.d103.s18|62-75|beta2-agonists|O
DDI-DrugBank.d103.s18|76-76|.|O
DDI-DrugBank.d103.s19|0-1|iv|O
DDI-DrugBank.d103.s19|2-2|.|O
DDI-DrugBank.d103.s20|0-6|FORADIL|O
DDI-DrugBank.d103.s20|22-25|used|O
DDI-DrugBank.d103.s20|32-41|substitute|O
DDI-DrugBank.d103.s20|47-50|oral|O
DDI-DrugBank.d103.s20|55-61|inhaled|O
DDI-DrugBank.d103.s20|63-77|corticosteroids|O
DDI-DrugBank.d103.s20|78-78|.|O
DDI-DrugBank.d103.s21|0-2|The|O
DDI-DrugBank.d103.s21|4-9|dosage|O
DDI-DrugBank.d103.s21|20-30|medications|O
DDI-DrugBank.d103.s21|46-52|changed|O
DDI-DrugBank.d103.s21|77-83|stopped|O
DDI-DrugBank.d103.s21|85-91|without|O
DDI-DrugBank.d103.s21|93-102|consulting|O
DDI-DrugBank.d103.s21|108-116|physician|O
DDI-DrugBank.d103.s21|119-122|even|O
DDI-DrugBank.d103.s21|131-137|patient|O
DDI-DrugBank.d103.s21|139-143|feels|O
DDI-DrugBank.d103.s21|145-150|better|O
DDI-DrugBank.d103.s21|158-167|initiating|O
DDI-DrugBank.d103.s21|169-177|treatment|O
DDI-DrugBank.d103.s21|184-190|FORADIL|O
DDI-DrugBank.d103.s21|191-191|.|O
DDI-DrugBank.d103.s22|0-1|v.|O
DDI-DrugBank.d103.s22|3-10|Patients|O
DDI-DrugBank.d103.s22|22-30|cautioned|O
DDI-DrugBank.d103.s22|32-40|regarding|O
DDI-DrugBank.d103.s22|42-50|potential|O
DDI-DrugBank.d103.s22|52-58|adverse|O
DDI-DrugBank.d103.s22|60-73|cardiovascular|O
DDI-DrugBank.d103.s22|75-81|effects|O
DDI-DrugBank.d103.s22|92-103|palpitations|O
DDI-DrugBank.d103.s22|108-112|chest|O
DDI-DrugBank.d103.s22|114-117|pain|O
DDI-DrugBank.d103.s22|1-1|.|O
DDI-DrugBank.d103.s23|0-1|vi|O
DDI-DrugBank.d103.s23|2-2|.|O
DDI-DrugBank.d103.s24|0-1|In|O
DDI-DrugBank.d103.s24|3-10|patients|O
DDI-DrugBank.d103.s24|12-20|receiving|O
DDI-DrugBank.d103.s24|22-28|FORADIL|O
DDI-DrugBank.d103.s24|37-43|inhaled|O
DDI-DrugBank.d103.s24|45-55|medications|O
DDI-DrugBank.d103.s24|67-70|used|O
DDI-DrugBank.d103.s24|80-87|directed|O
DDI-DrugBank.d103.s24|96-104|physician|O
DDI-DrugBank.d103.s24|105-105|.|O
DDI-DrugBank.d103.s25|0-2|vii|O
DDI-DrugBank.d103.s25|3-3|.|O
DDI-DrugBank.d103.s26|0-8|Guardians|O
DDI-DrugBank.d103.s26|13-20|children|O
DDI-DrugBank.d103.s26|36-45|prescribed|O
DDI-DrugBank.d103.s26|47-53|FORADIL|O
DDI-DrugBank.d103.s26|65-71|alerted|O
DDI-DrugBank.d103.s26|80-86|general|O
DDI-DrugBank.d103.s26|88-94|concern|O
DDI-DrugBank.d103.s26|96-104|regarding|O
DDI-DrugBank.d103.s26|106-111|asthma|O
DDI-DrugBank.d103.s26|113-119|therapy|O
DDI-DrugBank.d103.s26|121-130|compliance|O
DDI-DrugBank.d103.s26|133-142|especially|O
DDI-DrugBank.d103.s26|144-150|neglect|O
DDI-DrugBank.d103.s26|155-171|anti-inflammatory|O
DDI-DrugBank.d103.s26|113-119|therapy|O
DDI-DrugBank.d103.s26|185-191|overuse|O
DDI-DrugBank.d103.s26|196-207|short-acting|O
DDI-DrugBank.d103.s26|210-223|beta2-agonists|O
DDI-DrugBank.d103.s26|224-224|.|O
DDI-DrugBank.d55.s0|0-12|Isoproterenol|O
DDI-DrugBank.d55.s0|14-26|hydrochloride|O
DDI-DrugBank.d55.s0|28-36|injection|O
DDI-DrugBank.d55.s0|42-52|epinephrine|O
DDI-DrugBank.d55.s0|68-79|administered|O
DDI-DrugBank.d55.s0|81-94|simultaneously|O
DDI-DrugBank.d55.s0|109-113|drugs|O
DDI-DrugBank.d55.s0|119-124|direct|O
DDI-DrugBank.d55.s0|126-132|cardiac|O
DDI-DrugBank.d55.s0|134-143|stimulants|O
DDI-DrugBank.d55.s0|155-162|combined|O
DDI-DrugBank.d55.s0|164-170|effects|O
DDI-DrugBank.d55.s0|172-174|may|O
DDI-DrugBank.d55.s0|176-181|induce|O
DDI-DrugBank.d55.s0|183-189|serious|O
DDI-DrugBank.d55.s0|191-201|arrhythmias|O
DDI-DrugBank.d55.s0|202-202|.|O
DDI-DrugBank.d55.s1|0-2|The|O
DDI-DrugBank.d55.s1|4-8|drugs|O
DDI-DrugBank.d55.s1|10-12|may|O
DDI-DrugBank.d55.s1|15-21|however|O
DDI-DrugBank.d55.s1|27-38|administered|O
DDI-DrugBank.d55.s1|40-50|alternately|O
DDI-DrugBank.d55.s1|52-59|provided|O
DDI-DrugBank.d55.s1|63-68|proper|O
DDI-DrugBank.d55.s1|70-77|interval|O
DDI-DrugBank.d55.s1|83-89|elapsed|O
DDI-DrugBank.d55.s1|99-103|doses|O
DDI-DrugBank.d55.s1|104-104|.|O
DDI-DrugBank.d55.s2|0-6|ISUPREL|O
DDI-DrugBank.d55.s2|18-21|used|O
DDI-DrugBank.d55.s2|28-34|caution|O
DDI-DrugBank.d55.s2|53-58|potent|O
DDI-DrugBank.d55.s2|60-71|inhalational|O
DDI-DrugBank.d55.s2|73-83|anesthetics|O
DDI-DrugBank.d55.s2|93-101|halothane|O
DDI-DrugBank.d55.s2|107-114|employed|O
DDI-DrugBank.d55.s2|127-135|potential|O
DDI-DrugBank.d55.s2|140-148|sensitize|O
DDI-DrugBank.d55.s2|154-163|myocardium|O
DDI-DrugBank.d55.s2|168-174|effects|O
DDI-DrugBank.d55.s2|179-193|sympathomimetic|O
DDI-DrugBank.d55.s2|195-200|amines|O
DDI-DrugBank.d55.s2|201-201|.|O
DDI-DrugBank.d392.s0|0-7|Patients|O
DDI-DrugBank.d392.s0|17-24|applying|O
DDI-DrugBank.d392.s0|26-33|Panretin|O
DDI-DrugBank.d392.s0|35-37|gel|O
DDI-DrugBank.d392.s0|50-61|concurrently|O
DDI-DrugBank.d392.s0|63-65|use|O
DDI-DrugBank.d392.s0|67-74|products|O
DDI-DrugBank.d392.s0|81-87|contain|O
DDI-DrugBank.d392.s0|89-92|DEET|O
DDI-DrugBank.d392.s0|95-95|N|O
DDI-DrugBank.d392.s0|98-118|N-diethyl-m-toluamide|O
DDI-DrugBank.d392.s0|124-129|common|O
DDI-DrugBank.d392.s0|131-139|component|O
DDI-DrugBank.d392.s0|144-149|insect|O
DDI-DrugBank.d392.s0|151-159|repellent|O
DDI-DrugBank.d392.s0|67-74|products|O
DDI-DrugBank.d392.s0|169-169|.|O
DDI-DrugBank.d392.s1|0-5|Animal|O
DDI-DrugBank.d392.s1|7-16|toxicology|O
DDI-DrugBank.d392.s1|18-24|studies|O
DDI-DrugBank.d392.s1|26-31|showed|O
DDI-DrugBank.d392.s1|33-41|increased|O
DDI-DrugBank.d392.s1|43-46|DEET|O
DDI-DrugBank.d392.s1|48-55|toxicity|O
DDI-DrugBank.d392.s1|43-46|DEET|O
DDI-DrugBank.d392.s1|71-78|included|O
DDI-DrugBank.d392.s1|83-87|proof|O
DDI-DrugBank.d392.s1|96-106|formulation|O
DDI-DrugBank.d392.s1|107-107|.|O
DDI-DrugBank.d392.s2|0-7|Although|O
DDI-DrugBank.d392.s2|22-29|clinical|O
DDI-DrugBank.d392.s2|31-38|evidence|O
DDI-DrugBank.d392.s2|47-64|vehicle-controlled|O
DDI-DrugBank.d392.s2|66-72|studies|O
DDI-DrugBank.d392.s2|77-80|drug|O
DDI-DrugBank.d392.s2|82-93|interactions|O
DDI-DrugBank.d392.s2|100-107|systemic|O
DDI-DrugBank.d392.s2|109-122|antiretroviral|O
DDI-DrugBank.d392.s2|124-129|agents|O
DDI-DrugBank.d392.s2|132-140|including|O
DDI-DrugBank.d392.s2|142-149|protease|O
DDI-DrugBank.d392.s2|151-160|inhibitors|O
DDI-DrugBank.d392.s2|163-171|macrolide|O
DDI-DrugBank.d392.s2|173-183|antibiotics|O
DDI-DrugBank.d392.s2|190-194|azole|O
DDI-DrugBank.d392.s2|196-206|antifungals|O
DDI-DrugBank.d392.s2|213-218|effect|O
DDI-DrugBank.d392.s2|223-230|Panretin|O
DDI-DrugBank.d392.s2|232-234|gel|O
DDI-DrugBank.d392.s2|243-254|steady-state|O
DDI-DrugBank.d392.s2|256-269|concentrations|O
DDI-DrugBank.d392.s2|280-284|drugs|O
DDI-DrugBank.d392.s2|293-297|known|O
DDI-DrugBank.d392.s2|298-298|.|O
DDI-DrugBank.d392.s3|0-1|No|O
DDI-DrugBank.d392.s3|3-6|drug|O
DDI-DrugBank.d392.s3|8-18|interaction|O
DDI-DrugBank.d392.s3|20-23|data|O
DDI-DrugBank.d392.s3|29-37|available|O
DDI-DrugBank.d392.s3|42-52|concomitant|O
DDI-DrugBank.d392.s3|54-67|administration|O
DDI-DrugBank.d392.s3|72-79|Panretin|O
DDI-DrugBank.d392.s3|81-83|gel|O
DDI-DrugBank.d392.s3|89-96|systemic|O
DDI-DrugBank.d392.s3|98-104|anti-KS|O
DDI-DrugBank.d392.s3|106-111|agents|O
DDI-DrugBank.d392.s3|112-112|.|O
DDI-DrugBank.d405.s0|0-8|Dicumarol|O
DDI-DrugBank.d405.s0|14-21|warfarin|O
DDI-DrugBank.d405.s0|23-25|may|O
DDI-DrugBank.d405.s0|27-34|decrease|O
DDI-DrugBank.d405.s0|36-54|hypoprothrombinemic|O
DDI-DrugBank.d405.s0|56-61|effect|O
DDI-DrugBank.d405.s0|62-62|.|O
DDI-DrugBank.d405.s1|0-4|Other|O
DDI-DrugBank.d405.s1|6-17|depressasnts|O
DDI-DrugBank.d405.s1|27-33|alcohol|O
DDI-DrugBank.d405.s1|36-47|barbiturates|O
DDI-DrugBank.d405.s1|54-58|MAOIs|O
DDI-DrugBank.d405.s1|60-62|may|O
DDI-DrugBank.d405.s1|64-70|enhance|O
DDI-DrugBank.d405.s1|72-74|CNS|O
DDI-DrugBank.d405.s1|76-85|depression|O
DDI-DrugBank.d405.s1|92-103|administered|O
DDI-DrugBank.d405.s1|110-122|ethchlorvynol|O
DDI-DrugBank.d405.s1|123-123|.|O
DDI-DrugBank.d352.s0|0-11|Antidiabetic|O
DDI-DrugBank.d352.s0|13-16|drug|O
DDI-DrugBank.d352.s0|18-29|requirements|O
DDI-DrugBank.d352.s0|32-35|i.e.|O
DDI-DrugBank.d352.s0|38-44|insulin|O
DDI-DrugBank.d352.s0|47-49|may|O
DDI-DrugBank.d352.s0|54-60|altered|O
DDI-DrugBank.d352.s0|33-33|.|O
DDI-DrugBank.d352.s1|0-9|Concurrent|O
DDI-DrugBank.d352.s1|11-13|use|O
DDI-DrugBank.d352.s1|20-26|general|O
DDI-DrugBank.d352.s1|28-38|anesthetics|O
DDI-DrugBank.d352.s1|40-42|may|O
DDI-DrugBank.d352.s1|44-49|result|O
DDI-DrugBank.d352.s1|54-64|arrhythmias|O
DDI-DrugBank.d352.s1|65-65|.|O
DDI-DrugBank.d352.s2|0-2|The|O
DDI-DrugBank.d352.s2|4-10|pressor|O
DDI-DrugBank.d352.s2|12-18|effects|O
DDI-DrugBank.d352.s2|23-36|diethylpropion|O
DDI-DrugBank.d352.s2|57-61|drugs|O
DDI-DrugBank.d352.s2|63-65|may|O
DDI-DrugBank.d352.s2|70-77|additive|O
DDI-DrugBank.d352.s2|57-61|drugs|O
DDI-DrugBank.d352.s2|98-101|used|O
DDI-DrugBank.d352.s2|103-115|concomitantly|O
DDI-DrugBank.d352.s3|0-9|conversely|O
DDI-DrugBank.d352.s3|12-25|diethylpropion|O
DDI-DrugBank.d352.s3|27-29|may|O
DDI-DrugBank.d352.s3|31-39|interfere|O
DDI-DrugBank.d352.s3|46-61|antihypertensive|O
DDI-DrugBank.d352.s3|63-67|drugs|O
DDI-DrugBank.d352.s3|70-73|i.e.|O
DDI-DrugBank.d352.s3|76-87|guanethidine|O
DDI-DrugBank.d352.s3|90-101|a-methyldopa|O
DDI-DrugBank.d352.s3|71-71|.|O
DDI-DrugBank.d352.s4|0-9|Concurrent|O
DDI-DrugBank.d352.s4|11-13|use|O
DDI-DrugBank.d352.s4|18-31|phenothiazines|O
DDI-DrugBank.d352.s4|33-35|may|O
DDI-DrugBank.d352.s4|37-46|antagonize|O
DDI-DrugBank.d352.s4|52-60|anorectic|O
DDI-DrugBank.d352.s4|62-67|effect|O
DDI-DrugBank.d352.s4|72-85|diethylpropion|O
DDI-DrugBank.d352.s4|86-86|.|O
DDI-DrugBank.d553.s0|0-3|Drug|O
DDI-DrugBank.d553.s0|5-14|Laboratory|O
DDI-DrugBank.d553.s0|16-19|Test|O
DDI-DrugBank.d553.s0|21-32|Interactions|O
DDI-DrugBank.d553.s0|35-46|Prolongation|O
DDI-DrugBank.d553.s0|55-62|template|O
DDI-DrugBank.d553.s0|64-71|bleeding|O
DDI-DrugBank.d553.s0|73-76|time|O
DDI-DrugBank.d553.s0|87-94|reported|O
DDI-DrugBank.d553.s0|103-112|continuous|O
DDI-DrugBank.d553.s0|114-124|intravenous|O
DDI-DrugBank.d553.s0|126-133|infusion|O
DDI-DrugBank.d553.s0|138-143|AMICAR|O
DDI-DrugBank.d553.s0|148-154|dosages|O
DDI-DrugBank.d553.s0|156-164|exceeding|O
DDI-DrugBank.d553.s0|166-167|24|O
DDI-DrugBank.d553.s0|169-173|g/day|O
DDI-DrugBank.d553.s0|174-174|.|O
DDI-DrugBank.d553.s1|0-7|Platelet|O
DDI-DrugBank.d553.s1|9-16|function|O
DDI-DrugBank.d553.s1|18-24|studies|O
DDI-DrugBank.d553.s1|35-42|patients|O
DDI-DrugBank.d553.s1|53-64|demonstrated|O
DDI-DrugBank.d553.s1|70-80|significant|O
DDI-DrugBank.d553.s1|82-89|platelet|O
DDI-DrugBank.d553.s1|91-101|dysfunction|O
DDI-DrugBank.d553.s1|102-102|.|O
DDI-DrugBank.d553.s2|0-6|However|O
DDI-DrugBank.d553.s2|12-16|vitro|O
DDI-DrugBank.d553.s2|18-24|studies|O
DDI-DrugBank.d553.s2|31-35|shown|O
DDI-DrugBank.d553.s2|45-48|high|O
DDI-DrugBank.d553.s2|50-63|concentrations|O
DDI-DrugBank.d553.s2|66-68|7.4|O
DDI-DrugBank.d553.s2|70-75|mMol/L|O
DDI-DrugBank.d553.s2|80-83|0.97|O
DDI-DrugBank.d553.s2|85-89|mg/mL|O
DDI-DrugBank.d553.s2|95-101|greater|O
DDI-DrugBank.d553.s2|104-107|EACA|O
DDI-DrugBank.d553.s2|109-116|inhibits|O
DDI-DrugBank.d553.s2|118-120|ADP|O
DDI-DrugBank.d553.s2|126-141|collagen-induced|O
DDI-DrugBank.d553.s2|143-150|platelet|O
DDI-DrugBank.d553.s2|152-162|aggregation|O
DDI-DrugBank.d553.s2|169-175|release|O
DDI-DrugBank.d553.s2|180-182|ATP|O
DDI-DrugBank.d553.s2|188-196|serotonin|O
DDI-DrugBank.d553.s2|207-213|binding|O
DDI-DrugBank.d553.s2|218-227|fibrinogen|O
DDI-DrugBank.d553.s2|236-244|platelets|O
DDI-DrugBank.d553.s2|251-272|concentration-response|O
DDI-DrugBank.d553.s2|274-279|manner|O
DDI-DrugBank.d553.s2|67-67|.|O
DDI-DrugBank.d553.s3|0-8|Following|O
DDI-DrugBank.d553.s3|12-13|10|O
DDI-DrugBank.d553.s3|8-8|g|O
DDI-DrugBank.d553.s3|17-21|bolus|O
DDI-DrugBank.d553.s3|26-31|AMICAR|O
DDI-DrugBank.d553.s3|34-42|transient|O
DDI-DrugBank.d553.s3|44-47|peak|O
DDI-DrugBank.d553.s3|49-54|plasma|O
DDI-DrugBank.d553.s3|56-69|concentrations|O
DDI-DrugBank.d553.s3|74-76|4.6|O
DDI-DrugBank.d553.s3|78-83|mMol/L|O
DDI-DrugBank.d553.s3|88-91|0.60|O
DDI-DrugBank.d553.s3|93-97|mg/mL|O
DDI-DrugBank.d553.s3|109-116|obtained|O
DDI-DrugBank.d553.s3|75-75|.|O
DDI-DrugBank.d553.s4|0-2|The|O
DDI-DrugBank.d553.s4|4-16|concentration|O
DDI-DrugBank.d553.s4|21-26|AMICAR|O
DDI-DrugBank.d553.s4|28-36|necessary|O
DDI-DrugBank.d553.s4|41-48|maintain|O
DDI-DrugBank.d553.s4|50-59|inhibition|O
DDI-DrugBank.d553.s4|64-75|fibrinolysis|O
DDI-DrugBank.d553.s4|80-83|0.99|O
DDI-DrugBank.d553.s4|85-90|mMol/L|O
DDI-DrugBank.d553.s4|95-98|0.13|O
DDI-DrugBank.d553.s4|100-104|mg/mL|O
DDI-DrugBank.d553.s4|81-81|.|O
DDI-DrugBank.d553.s5|0-13|Administration|O
DDI-DrugBank.d553.s5|20-20|5|O
DDI-DrugBank.d553.s5|22-22|g|O
DDI-DrugBank.d553.s5|24-28|bolus|O
DDI-DrugBank.d553.s5|30-37|followed|O
DDI-DrugBank.d553.s5|42-42|1|O
DDI-DrugBank.d553.s5|47-50|1.25|O
DDI-DrugBank.d553.s5|52-55|g/hr|O
DDI-DrugBank.d553.s5|64-70|achieve|O
DDI-DrugBank.d553.s5|76-82|sustain|O
DDI-DrugBank.d553.s5|84-89|plasma|O
DDI-DrugBank.d553.s5|91-96|levels|O
DDI-DrugBank.d553.s5|101-104|0.13|O
DDI-DrugBank.d553.s5|106-110|mg/mL|O
DDI-DrugBank.d553.s5|48-48|.|O
DDI-DrugBank.d553.s6|0-3|Thus|O
DDI-DrugBank.d553.s6|6-19|concentrations|O
DDI-DrugBank.d553.s6|37-44|obtained|O
DDI-DrugBank.d553.s6|49-52|vivo|O
DDI-DrugBank.d553.s6|54-63|clinically|O
DDI-DrugBank.d553.s6|68-75|patients|O
DDI-DrugBank.d553.s6|82-87|normal|O
DDI-DrugBank.d553.s6|89-93|renal|O
DDI-DrugBank.d553.s6|95-102|function|O
DDI-DrugBank.d553.s6|108-119|considerably|O
DDI-DrugBank.d553.s6|121-125|lower|O
DDI-DrugBank.d553.s6|139-143|vitro|O
DDI-DrugBank.d553.s6|6-19|concentrations|O
DDI-DrugBank.d553.s6|160-164|found|O
DDI-DrugBank.d553.s6|169-174|induce|O
DDI-DrugBank.d553.s6|176-188|abnormalities|O
DDI-DrugBank.d553.s6|193-200|platelet|O
DDI-DrugBank.d553.s6|95-102|function|O
DDI-DrugBank.d553.s6|211-215|tests|O
DDI-DrugBank.d553.s6|216-216|.|O
DDI-DrugBank.d553.s7|0-6|However|O
DDI-DrugBank.d553.s7|9-14|higher|O
DDI-DrugBank.d553.s7|16-21|plasma|O
DDI-DrugBank.d553.s7|23-36|concentrations|O
DDI-DrugBank.d553.s7|41-46|AMICAR|O
DDI-DrugBank.d553.s7|48-50|may|O
DDI-DrugBank.d553.s7|52-56|occur|O
DDI-DrugBank.d553.s7|61-68|patients|O
DDI-DrugBank.d553.s7|75-80|severe|O
DDI-DrugBank.d553.s7|82-86|renal|O
DDI-DrugBank.d553.s7|88-94|failure|O
DDI-DrugBank.d553.s7|95-95|.|O
DDI-MedLine.d184.s0|0-10|Amphetamine|O
DDI-MedLine.d184.s0|12-20|locomotor|O
DDI-MedLine.d184.s0|22-34|sensitization|O
DDI-MedLine.d184.s0|40-50|conditioned|O
DDI-MedLine.d184.s0|52-56|place|O
DDI-MedLine.d184.s0|58-67|preference|O
DDI-MedLine.d184.s0|72-81|adolescent|O
DDI-MedLine.d184.s0|83-86|male|O
DDI-MedLine.d184.s0|92-97|female|O
DDI-MedLine.d184.s0|99-102|rats|O
DDI-MedLine.d184.s0|104-113|neonatally|O
DDI-MedLine.d184.s0|115-121|treated|O
DDI-MedLine.d184.s0|128-137|quinpirole|O
DDI-MedLine.d184.s0|138-138|.|O
DDI-MedLine.d184.s1|0-7|Neonatal|O
DDI-MedLine.d184.s1|9-18|quinpirole|O
DDI-MedLine.d184.s1|20-28|treatment|O
DDI-MedLine.d184.s1|39-43|shown|O
DDI-MedLine.d184.s1|48-54|produce|O
DDI-MedLine.d184.s1|59-66|increase|O
DDI-MedLine.d184.s1|71-78|dopamine|O
DDI-MedLine.d184.s1|80-86|D2-like|O
DDI-MedLine.d184.s1|88-95|receptor|O
DDI-MedLine.d184.s1|97-107|sensitivity|O
DDI-MedLine.d184.s1|114-121|persists|O
DDI-MedLine.d184.s1|123-132|throughout|O
DDI-MedLine.d184.s1|138-144|subject|O
DDI-MedLine.d184.s1|145-146|'s|O
DDI-MedLine.d184.s1|148-155|lifetime|O
DDI-MedLine.d184.s1|156-156|.|O
DDI-MedLine.d184.s2|0-2|The|O
DDI-MedLine.d184.s2|4-12|objective|O
DDI-MedLine.d184.s2|21-27|analyze|O
DDI-MedLine.d184.s2|33-39|effects|O
DDI-MedLine.d184.s2|44-51|neonatal|O
DDI-MedLine.d184.s2|53-62|quinpirole|O
DDI-MedLine.d184.s2|64-72|treatment|O
DDI-MedLine.d184.s2|33-39|effects|O
DDI-MedLine.d184.s2|88-98|amphetamine|O
DDI-MedLine.d184.s2|103-112|adolescent|O
DDI-MedLine.d184.s2|114-117|rats|O
DDI-MedLine.d184.s2|119-123|using|O
DDI-MedLine.d184.s2|125-133|locomotor|O
DDI-MedLine.d184.s2|135-147|sensitization|O
DDI-MedLine.d184.s2|153-163|conditioned|O
DDI-MedLine.d184.s2|165-169|place|O
DDI-MedLine.d184.s2|171-180|preference|O
DDI-MedLine.d184.s2|182-191|procedures|O
DDI-MedLine.d184.s2|192-192|.|O
DDI-MedLine.d184.s3|0-13|Sprague-Dawley|O
DDI-MedLine.d184.s3|15-18|rats|O
DDI-MedLine.d184.s3|25-31|treated|O
DDI-MedLine.d184.s3|38-47|quinpirole|O
DDI-MedLine.d184.s3|50-50|1|O
DDI-MedLine.d184.s3|52-56|mg/kg|O
DDI-MedLine.d184.s3|62-67|saline|O
DDI-MedLine.d184.s3|74-82|postnatal|O
DDI-MedLine.d184.s3|84-87|days|O
DDI-MedLine.d184.s3|90-90|P|O
DDI-MedLine.d184.s3|50-50|1|O
DDI-MedLine.d184.s3|97-99|P11|O
DDI-MedLine.d184.s3|105-110|raised|O
DDI-MedLine.d184.s3|115-125|adolescence|O
DDI-MedLine.d184.s3|126-126|.|O
DDI-MedLine.d184.s4|0-2|For|O
DDI-MedLine.d184.s4|4-12|locomotor|O
DDI-MedLine.d184.s4|14-26|sensitization|O
DDI-MedLine.d184.s4|29-36|subjects|O
DDI-MedLine.d184.s4|43-47|given|O
DDI-MedLine.d184.s4|49-59|amphetamine|O
DDI-MedLine.d184.s4|62-62|1|O
DDI-MedLine.d184.s4|64-68|mg/kg|O
DDI-MedLine.d184.s4|74-79|saline|O
DDI-MedLine.d184.s4|81-85|every|O
DDI-MedLine.d184.s4|87-92|second|O
DDI-MedLine.d184.s4|94-96|day|O
DDI-MedLine.d184.s4|103-105|P35|O
DDI-MedLine.d184.s4|110-112|P47|O
DDI-MedLine.d184.s4|123-128|placed|O
DDI-MedLine.d184.s4|4-12|locomotor|O
DDI-MedLine.d184.s4|147-151|arena|O
DDI-MedLine.d184.s4|152-152|.|O
DDI-MedLine.d184.s5|0-1|In|O
DDI-MedLine.d184.s5|3-8|female|O
DDI-MedLine.d184.s5|10-13|rats|O
DDI-MedLine.d184.s5|16-23|neonatal|O
DDI-MedLine.d184.s5|25-34|quinpirole|O
DDI-MedLine.d184.s5|36-44|treatment|O
DDI-MedLine.d184.s5|46-53|enhanced|O
DDI-MedLine.d184.s5|55-65|amphetamine|O
DDI-MedLine.d184.s5|67-75|locomotor|O
DDI-MedLine.d184.s5|77-89|sensitization|O
DDI-MedLine.d184.s5|91-98|compared|O
DDI-MedLine.d184.s5|105-119|quinpirole-free|O
DDI-MedLine.d184.s5|121-128|controls|O
DDI-MedLine.d184.s5|130-139|sensitized|O
DDI-MedLine.d184.s5|55-65|amphetamine|O
DDI-MedLine.d184.s5|155-155|.|O
DDI-MedLine.d184.s6|0-3|Male|O
DDI-MedLine.d184.s6|5-8|rats|O
DDI-MedLine.d184.s6|10-21|demonstrated|O
DDI-MedLine.d184.s6|23-35|sensitization|O
DDI-MedLine.d184.s6|40-50|amphetamine|O
DDI-MedLine.d184.s6|53-60|although|O
DDI-MedLine.d184.s6|71-75|muted|O
DDI-MedLine.d184.s6|77-84|compared|O
DDI-MedLine.d184.s6|91-96|female|O
DDI-MedLine.d184.s6|5-8|rats|O
DDI-MedLine.d184.s6|113-122|unaffected|O
DDI-MedLine.d184.s6|127-134|neonatal|O
DDI-MedLine.d184.s6|136-145|quinpirole|O
DDI-MedLine.d184.s6|146-146|.|O
DDI-MedLine.d184.s7|0-2|For|O
DDI-MedLine.d184.s7|4-14|conditioned|O
DDI-MedLine.d184.s7|16-20|place|O
DDI-MedLine.d184.s7|22-31|preference|O
DDI-MedLine.d184.s7|34-41|subjects|O
DDI-MedLine.d184.s7|4-14|conditioned|O
DDI-MedLine.d184.s7|64-64|8|O
DDI-MedLine.d184.s7|66-76|consecutive|O
DDI-MedLine.d184.s7|78-81|days|O
DDI-MedLine.d184.s7|84-89|P32-39|O
DDI-MedLine.d184.s7|97-107|amphetamine|O
DDI-MedLine.d184.s7|110-110|1|O
DDI-MedLine.d184.s7|112-116|mg/kg|O
DDI-MedLine.d184.s7|122-127|saline|O
DDI-MedLine.d184.s7|135-143|drug-free|O
DDI-MedLine.d184.s7|22-31|preference|O
DDI-MedLine.d184.s7|156-159|test|O
DDI-MedLine.d184.s7|165-173|conducted|O
DDI-MedLine.d184.s7|178-180|P40|O
DDI-MedLine.d184.s7|181-181|.|O
DDI-MedLine.d184.s8|0-3|Rats|O
DDI-MedLine.d184.s8|5-11|treated|O
DDI-MedLine.d184.s8|18-25|neonatal|O
DDI-MedLine.d184.s8|27-36|quinpirole|O
DDI-MedLine.d184.s8|38-45|enhanced|O
DDI-MedLine.d184.s8|47-50|time|O
DDI-MedLine.d184.s8|52-56|spent|O
DDI-MedLine.d184.s8|65-82|amphetamine-paired|O
DDI-MedLine.d184.s8|84-90|context|O
DDI-MedLine.d184.s8|92-99|compared|O
DDI-MedLine.d184.s8|106-120|quinpirole-free|O
DDI-MedLine.d184.s8|122-129|controls|O
DDI-MedLine.d184.s8|131-141|conditioned|O
DDI-MedLine.d184.s8|65-75|amphetamine|O
DDI-MedLine.d184.s8|170-175|female|O
DDI-MedLine.d184.s8|122-129|controls|O
DDI-MedLine.d184.s8|131-141|conditioned|O
DDI-MedLine.d184.s8|65-75|amphetamine|O
DDI-MedLine.d184.s8|52-56|spent|O
DDI-MedLine.d184.s8|47-50|time|O
DDI-MedLine.d184.s8|238-248|drug-paired|O
DDI-MedLine.d184.s8|84-90|context|O
DDI-MedLine.d184.s8|92-99|compared|O
DDI-MedLine.d184.s8|272-285|saline-treated|O
DDI-MedLine.d184.s8|122-129|controls|O
DDI-MedLine.d184.s8|295-295|.|O
DDI-MedLine.d184.s9|0-8|Increased|O
DDI-MedLine.d184.s9|10-10|D|O
DDI-MedLine.d184.s9|14-18|-like|O
DDI-MedLine.d184.s9|20-27|receptor|O
DDI-MedLine.d184.s9|29-39|sensitivity|O
DDI-MedLine.d184.s9|41-47|appears|O
DDI-MedLine.d184.s9|57-64|enhanced|O
DDI-MedLine.d184.s9|70-79|behavioral|O
DDI-MedLine.d184.s9|81-87|effects|O
DDI-MedLine.d184.s9|92-102|amphetamine|O
DDI-MedLine.d184.s9|81-87|effects|O
DDI-MedLine.d184.s9|133-141|prevalent|O
DDI-MedLine.d184.s9|146-155|adolescent|O
DDI-MedLine.d184.s9|157-162|female|O
DDI-MedLine.d184.s9|164-167|rats|O
DDI-MedLine.d184.s9|169-176|compared|O
DDI-MedLine.d184.s9|159-162|male|O
DDI-MedLine.d184.s9|164-167|rats|O
DDI-MedLine.d184.s9|192-192|.|O
DDI-MedLine.d189.s0|0-6|Effects|O
DDI-MedLine.d189.s0|11-13|CYP|O
DDI-MedLine.d189.s0|15-24|inhibitors|O
DDI-MedLine.d189.s0|29-37|precocene|O
DDI-MedLine.d189.s0|39-39|I|O
DDI-MedLine.d189.s0|41-50|metabolism|O
DDI-MedLine.d189.s0|56-63|toxicity|O
DDI-MedLine.d189.s0|68-70|rat|O
DDI-MedLine.d189.s0|72-76|liver|O
DDI-MedLine.d189.s0|78-83|slices|O
DDI-MedLine.d189.s0|84-84|.|O
DDI-MedLine.d189.s1|0-1|We|O
DDI-MedLine.d189.s1|3-9|present|O
DDI-MedLine.d189.s1|13-25|comprehensive|O
DDI-MedLine.d189.s1|30-34|vitro|O
DDI-MedLine.d189.s1|36-43|approach|O
DDI-MedLine.d189.s1|48-56|assessing|O
DDI-MedLine.d189.s1|58-76|metabolism-mediated|O
DDI-MedLine.d189.s1|78-91|hepatotoxicity|O
DDI-MedLine.d189.s1|93-97|using|O
DDI-MedLine.d189.s1|99-102|male|O
DDI-MedLine.d189.s1|104-117|Sprague-Dawley|O
DDI-MedLine.d189.s1|119-121|rat|O
DDI-MedLine.d189.s1|123-127|liver|O
DDI-MedLine.d189.s1|129-134|slices|O
DDI-MedLine.d189.s1|136-144|incubated|O
DDI-MedLine.d189.s1|155-158|well|O
DDI-MedLine.d189.s1|160-172|characterized|O
DDI-MedLine.d189.s1|174-187|hepatotoxicant|O
DDI-MedLine.d189.s1|190-198|precocene|O
DDI-MedLine.d189.s1|200-200|I|O
DDI-MedLine.d189.s1|207-216|inhibitors|O
DDI-MedLine.d189.s1|221-230|cytochrome|O
DDI-MedLine.d189.s1|232-235|P450|O
DDI-MedLine.d189.s1|238-240|CYP|O
DDI-MedLine.d189.s1|243-249|enzymes|O
DDI-MedLine.d189.s1|250-250|.|O
DDI-MedLine.d189.s2|0-3|This|O
DDI-MedLine.d189.s2|5-12|approach|O
DDI-MedLine.d189.s2|14-21|combines|O
DDI-MedLine.d189.s2|23-28|liquid|O
DDI-MedLine.d189.s2|30-43|chromatography|O
DDI-MedLine.d189.s2|45-48|mass|O
DDI-MedLine.d189.s2|50-61|spectrometry|O
DDI-MedLine.d189.s2|64-65|LC|O
DDI-MedLine.d189.s2|67-68|MS|O
DDI-MedLine.d189.s2|71-79|detection|O
DDI-MedLine.d189.s2|81-87|methods|O
DDI-MedLine.d189.s2|94-101|multiple|O
DDI-MedLine.d189.s2|103-110|toxicity|O
DDI-MedLine.d189.s2|112-120|endpoints|O
DDI-MedLine.d189.s2|125-130|enable|O
DDI-MedLine.d189.s2|132-145|identification|O
DDI-MedLine.d189.s2|150-157|critical|O
DDI-MedLine.d189.s2|159-167|metabolic|O
DDI-MedLine.d189.s2|169-176|pathways|O
DDI-MedLine.d189.s2|182-195|hepatotoxicity|O
DDI-MedLine.d189.s2|196-196|.|O
DDI-MedLine.d189.s3|0-2|The|O
DDI-MedLine.d189.s3|4-14|incubations|O
DDI-MedLine.d189.s3|21-29|performed|O
DDI-MedLine.d189.s3|38-44|absence|O
DDI-MedLine.d189.s3|50-57|presence|O
DDI-MedLine.d189.s3|66-77|non-specific|O
DDI-MedLine.d189.s3|79-81|CYP|O
DDI-MedLine.d189.s3|83-91|inhibitor|O
DDI-MedLine.d189.s3|94-113|1-aminobenzotriazole|O
DDI-MedLine.d189.s3|116-118|ABT|O
DDI-MedLine.d189.s3|125-140|isoform-specific|O
DDI-MedLine.d189.s3|142-151|inhibitors|O
DDI-MedLine.d189.s3|152-152|.|O
DDI-MedLine.d189.s4|0-2|The|O
DDI-MedLine.d189.s4|4-13|metabolite|O
DDI-MedLine.d189.s4|15-21|profile|O
DDI-MedLine.d189.s4|26-34|precocene|O
DDI-MedLine.d189.s4|36-36|I|O
DDI-MedLine.d189.s4|41-43|rat|O
DDI-MedLine.d189.s4|45-49|liver|O
DDI-MedLine.d189.s4|51-56|slices|O
DDI-MedLine.d189.s4|58-63|shares|O
DDI-MedLine.d189.s4|70-77|features|O
DDI-MedLine.d189.s4|89-92|vivo|O
DDI-MedLine.d189.s4|15-21|profile|O
DDI-MedLine.d189.s4|107-110|also|O
DDI-MedLine.d189.s4|118-122|major|O
DDI-MedLine.d189.s4|124-133|difference|O
DDI-MedLine.d189.s4|143-149|epoxide|O
DDI-MedLine.d189.s4|151-161|dihydrodiol|O
DDI-MedLine.d189.s4|163-172|hydrolysis|O
DDI-MedLine.d189.s4|174-181|products|O
DDI-MedLine.d189.s4|192-199|observed|O
DDI-MedLine.d189.s4|206-215|measurable|O
DDI-MedLine.d189.s4|217-222|extent|O
DDI-MedLine.d189.s4|223-223|.|O
DDI-MedLine.d189.s5|0-1|As|O
DDI-MedLine.d189.s5|3-10|examples|O
DDI-MedLine.d189.s5|19-23|liver|O
DDI-MedLine.d189.s5|25-29|slice|O
DDI-MedLine.d189.s5|31-40|metabolite|O
DDI-MedLine.d189.s5|42-55|identification|O
DDI-MedLine.d189.s5|57-65|procedure|O
DDI-MedLine.d189.s5|70-74|minor|O
DDI-MedLine.d189.s5|76-86|glutathione|O
DDI-MedLine.d189.s5|88-93|adduct|O
DDI-MedLine.d189.s5|99-108|previously|O
DDI-MedLine.d189.s5|110-119|unreported|O
DDI-MedLine.d189.s5|121-133|7-O-desmethyl|O
DDI-MedLine.d189.s5|139-152|glucuronidated|O
DDI-MedLine.d189.s5|154-164|metabolites|O
DDI-MedLine.d189.s5|169-177|precocene|O
DDI-MedLine.d189.s5|179-179|I|O
DDI-MedLine.d189.s5|112-119|reported|O
DDI-MedLine.d189.s5|193-193|.|O
DDI-MedLine.d189.s6|0-8|Precocene|O
DDI-MedLine.d189.s6|10-10|I|O
DDI-MedLine.d189.s6|12-18|induced|O
DDI-MedLine.d189.s6|20-33|hepatocellular|O
DDI-MedLine.d189.s6|35-42|necrosis|O
DDI-MedLine.d189.s6|49-53|dose-|O
DDI-MedLine.d189.s6|59-72|time-dependent|O
DDI-MedLine.d189.s6|74-79|manner|O
DDI-MedLine.d189.s7|0-2|ABT|O
DDI-MedLine.d189.s7|4-12|decreased|O
DDI-MedLine.d189.s7|18-25|toxicity|O
DDI-MedLine.d189.s7|30-38|precocene|O
DDI-MedLine.d189.s7|40-40|I|O
DDI-MedLine.d189.s7|43-51|increased|O
DDI-MedLine.d189.s7|53-60|exposure|O
DDI-MedLine.d189.s7|65-70|parent|O
DDI-MedLine.d189.s7|72-79|compound|O
DDI-MedLine.d189.s7|4-12|decreased|O
DDI-MedLine.d189.s7|96-105|metabolite|O
DDI-MedLine.d189.s7|107-112|levels|O
DDI-MedLine.d189.s7|119-132|dose-dependent|O
DDI-MedLine.d189.s7|134-139|manner|O
DDI-MedLine.d189.s7|140-140|.|O
DDI-MedLine.d189.s8|0-1|Of|O
DDI-MedLine.d189.s8|7-22|isoform-specific|O
DDI-MedLine.d189.s8|24-26|CYP|O
DDI-MedLine.d189.s8|28-37|inhibitors|O
DDI-MedLine.d189.s8|39-44|tested|O
DDI-MedLine.d189.s8|53-58|effect|O
DDI-MedLine.d189.s8|67-75|precocene|O
DDI-MedLine.d189.s8|77-77|I|O
DDI-MedLine.d189.s8|79-88|metabolite|O
DDI-MedLine.d189.s8|90-96|profile|O
DDI-MedLine.d189.s8|104-118|tranylcypromine|O
DDI-MedLine.d189.s8|124-133|noticeably|O
DDI-MedLine.d189.s8|135-143|effective|O
DDI-MedLine.d189.s8|146-155|indicating|O
DDI-MedLine.d189.s8|159-162|role|O
DDI-MedLine.d189.s8|167-170|CYPs|O
DDI-MedLine.d189.s8|172-174|2A6|O
DDI-MedLine.d189.s8|177-179|2C9|O
DDI-MedLine.d189.s8|182-185|2Cl9|O
DDI-MedLine.d189.s8|192-194|2E1|O
DDI-MedLine.d189.s8|195-195|.|O
DDI-MedLine.d189.s9|0-3|With|O
DDI-MedLine.d189.s9|5-11|respect|O
DDI-MedLine.d189.s9|16-23|toxicity|O
DDI-MedLine.d189.s9|30-34|order|O
DDI-MedLine.d189.s9|39-41|CYP|O
DDI-MedLine.d189.s9|43-51|inhibitor|O
DDI-MedLine.d189.s9|53-65|effectiveness|O
DDI-MedLine.d189.s9|71-73|ABT|O
DDI-MedLine.d189.s9|74-74|>|O
DDI-MedLine.d189.s9|75-112|diethyldithiocarbamate~tranylcypromine|O
DDI-MedLine.d189.s9|74-74|>|O
DDI-MedLine.d189.s9|114-125|ketoconazole|O
DDI-MedLine.d189.s9|126-126|.|O
DDI-MedLine.d189.s10|0-10|Furafylline|O
DDI-MedLine.d189.s10|16-29|sulfaphenazole|O
DDI-MedLine.d189.s10|38-43|effect|O
DDI-MedLine.d189.s10|52-60|quinidine|O
DDI-MedLine.d189.s10|62-69|appeared|O
DDI-MedLine.d189.s10|74-80|augment|O
DDI-MedLine.d189.s10|82-90|precocene|O
DDI-MedLine.d189.s10|92-92|I|O
DDI-MedLine.d189.s10|94-101|toxicity|O
DDI-MedLine.d189.s10|102-102|.|O
DDI-MedLine.d189.s11|0-4|These|O
DDI-MedLine.d189.s11|6-12|results|O
DDI-MedLine.d189.s11|14-20|suggest|O
DDI-MedLine.d189.s11|27-29|rat|O
DDI-MedLine.d189.s11|31-35|liver|O
DDI-MedLine.d189.s11|37-42|slices|O
DDI-MedLine.d189.s11|51-59|reproduce|O
DDI-MedLine.d189.s11|65-72|reported|O
DDI-MedLine.d189.s11|77-80|vivo|O
DDI-MedLine.d189.s11|82-98|biotransformation|O
DDI-MedLine.d189.s11|103-111|precocene|O
DDI-MedLine.d189.s11|113-113|I|O
DDI-MedLine.d189.s11|119-127|therefore|O
DDI-MedLine.d189.s11|129-131|may|O
DDI-MedLine.d189.s11|143-153|appropriate|O
DDI-MedLine.d189.s11|155-159|model|O
DDI-MedLine.d189.s11|103-111|precocene|O
DDI-MedLine.d189.s11|113-113|I|O
DDI-MedLine.d189.s11|177-186|metabolism|O
DDI-MedLine.d189.s11|187-187|.|O
DDI-MedLine.d189.s12|0-6|However|O
DDI-MedLine.d189.s12|15-21|results|O
DDI-MedLine.d189.s12|23-29|provide|O
DDI-MedLine.d189.s12|34-40|example|O
DDI-MedLine.d189.s12|49-53|small|O
DDI-MedLine.d189.s12|55-62|molecule|O
DDI-MedLine.d189.s12|64-75|manipulation|O
DDI-MedLine.d189.s12|80-82|CYP|O
DDI-MedLine.d189.s12|84-91|activity|O
DDI-MedLine.d189.s12|102-106|vitro|O
DDI-MedLine.d189.s12|108-112|model|O
DDI-MedLine.d189.s12|121-124|used|O
DDI-MedLine.d189.s12|129-135|confirm|O
DDI-MedLine.d189.s12|137-155|metabolism-mediated|O
DDI-MedLine.d189.s12|157-164|toxicity|O
DDI-MedLine.d189.s12|165-165|.|O
DDI-DrugBank.d164.s0|0-1|No|O
DDI-DrugBank.d164.s0|3-6|drug|O
DDI-DrugBank.d164.s0|8-18|interaction|O
DDI-DrugBank.d164.s0|20-26|studies|O
DDI-DrugBank.d164.s0|33-41|performed|O
DDI-DrugBank.d164.s0|42-42|.|O
DDI-DrugBank.d164.s1|0-1|No|O
DDI-DrugBank.d164.s1|6-10|vitro|O
DDI-DrugBank.d164.s1|12-21|metabolism|O
DDI-DrugBank.d164.s1|23-29|studies|O
DDI-DrugBank.d164.s1|36-44|performed|O
DDI-DrugBank.d164.s1|45-45|.|O
DDI-DrugBank.d279.s0|0-2|The|O
DDI-DrugBank.d279.s0|4-10|adverse|O
DDI-DrugBank.d279.s0|12-18|effects|O
DDI-DrugBank.d279.s0|23-31|CAMPTOSAR|O
DDI-DrugBank.d279.s0|42-57|myelosuppression|O
DDI-DrugBank.d279.s0|63-70|diarrhea|O
DDI-DrugBank.d279.s0|73-77|would|O
DDI-DrugBank.d279.s0|82-89|expected|O
DDI-DrugBank.d279.s0|97-107|exacerbated|O
DDI-DrugBank.d279.s0|118-131|antineoplastic|O
DDI-DrugBank.d279.s0|133-138|agents|O
DDI-DrugBank.d279.s0|147-153|similar|O
DDI-DrugBank.d279.s0|4-10|adverse|O
DDI-DrugBank.d279.s0|12-18|effects|O
DDI-DrugBank.d279.s0|170-170|.|O
DDI-DrugBank.d279.s1|0-7|Patients|O
DDI-DrugBank.d279.s1|18-27|previously|O
DDI-DrugBank.d279.s1|29-36|received|O
DDI-DrugBank.d279.s1|38-44|pelvic/|O
DDI-DrugBank.d279.s1|46-54|abdominal|O
DDI-DrugBank.d279.s1|56-66|irradiation|O
DDI-DrugBank.d279.s1|75-83|increased|O
DDI-DrugBank.d279.s1|85-88|risk|O
DDI-DrugBank.d279.s1|93-98|severe|O
DDI-DrugBank.d279.s1|100-115|myelosuppression|O
DDI-DrugBank.d279.s1|117-125|following|O
DDI-DrugBank.d279.s1|131-144|administration|O
DDI-DrugBank.d279.s1|149-157|CAMPTOSAR|O
DDI-DrugBank.d279.s1|158-158|.|O
DDI-DrugBank.d279.s2|0-2|The|O
DDI-DrugBank.d279.s2|4-13|concurrent|O
DDI-DrugBank.d279.s2|15-28|administration|O
DDI-DrugBank.d279.s2|33-41|CAMPTOSAR|O
DDI-DrugBank.d279.s2|48-58|irradiation|O
DDI-DrugBank.d279.s2|73-82|adequately|O
DDI-DrugBank.d279.s2|84-90|studied|O
DDI-DrugBank.d279.s2|103-113|recommended|O
DDI-DrugBank.d279.s2|114-114|.|O
DDI-DrugBank.d279.s3|0-14|Lymphocytopenia|O
DDI-DrugBank.d279.s3|25-32|reported|O
DDI-DrugBank.d279.s3|37-44|patients|O
DDI-DrugBank.d279.s3|46-54|receiving|O
DDI-DrugBank.d279.s3|56-64|CAMPTOSAR|O
DDI-DrugBank.d279.s3|77-84|possible|O
DDI-DrugBank.d279.s3|95-108|administration|O
DDI-DrugBank.d279.s3|113-125|dexamethasone|O
DDI-DrugBank.d279.s3|130-139|antiemetic|O
DDI-DrugBank.d279.s3|141-151|prophylaxis|O
DDI-DrugBank.d279.s3|153-155|may|O
DDI-DrugBank.d279.s3|162-169|enhanced|O
DDI-DrugBank.d279.s3|175-184|likelihood|O
DDI-DrugBank.d279.s3|194-199|effect|O
DDI-DrugBank.d279.s3|200-200|.|O
DDI-DrugBank.d279.s4|0-6|However|O
DDI-DrugBank.d279.s4|9-15|serious|O
DDI-DrugBank.d279.s4|17-29|opportunistic|O
DDI-DrugBank.d279.s4|31-40|infections|O
DDI-DrugBank.d279.s4|56-63|observed|O
DDI-DrugBank.d279.s4|73-85|complications|O
DDI-DrugBank.d279.s4|92-103|specifically|O
DDI-DrugBank.d279.s4|110-119|attributed|O
DDI-DrugBank.d279.s4|124-138|lymphocytopenia|O
DDI-DrugBank.d279.s5|0-12|Hyperglycemia|O
DDI-DrugBank.d279.s5|18-21|also|O
DDI-DrugBank.d279.s5|28-35|reported|O
DDI-DrugBank.d279.s5|40-47|patients|O
DDI-DrugBank.d279.s5|49-57|receiving|O
DDI-DrugBank.d279.s5|59-67|CAMPTOSAR|O
DDI-DrugBank.d279.s5|68-68|.|O
DDI-DrugBank.d279.s6|0-6|Usually|O
DDI-DrugBank.d279.s6|23-30|observed|O
DDI-DrugBank.d279.s6|35-42|patients|O
DDI-DrugBank.d279.s6|51-57|history|O
DDI-DrugBank.d279.s6|62-69|diabetes|O
DDI-DrugBank.d279.s6|71-78|mellitus|O
DDI-DrugBank.d279.s6|83-90|evidence|O
DDI-DrugBank.d279.s6|95-101|glucose|O
DDI-DrugBank.d279.s6|103-113|intolerance|O
DDI-DrugBank.d279.s6|115-119|prior|O
DDI-DrugBank.d279.s6|124-137|administration|O
DDI-DrugBank.d279.s6|142-150|CAMPTOSAR|O
DDI-DrugBank.d279.s6|151-151|.|O
DDI-DrugBank.d279.s7|0-1|It|O
DDI-DrugBank.d279.s7|6-13|probable|O
DDI-DrugBank.d279.s7|20-32|dexamethasone|O
DDI-DrugBank.d279.s7|35-39|given|O
DDI-DrugBank.d279.s7|44-53|antiemetic|O
DDI-DrugBank.d279.s7|55-65|prophylaxis|O
DDI-DrugBank.d279.s7|68-78|contributed|O
DDI-DrugBank.d279.s7|83-95|hyperglycemia|O
DDI-DrugBank.d279.s7|105-112|patients|O
DDI-DrugBank.d279.s7|113-113|.|O
DDI-DrugBank.d279.s8|0-2|The|O
DDI-DrugBank.d279.s8|4-12|incidence|O
DDI-DrugBank.d279.s8|17-25|akathisia|O
DDI-DrugBank.d279.s8|30-37|clinical|O
DDI-DrugBank.d279.s8|39-44|trials|O
DDI-DrugBank.d279.s8|53-58|weekly|O
DDI-DrugBank.d279.s8|60-65|dosage|O
DDI-DrugBank.d279.s8|67-74|schedule|O
DDI-DrugBank.d279.s8|80-86|greater|O
DDI-DrugBank.d279.s8|89-91|8.5|O
DDI-DrugBank.d279.s8|92-92|%|O
DDI-DrugBank.d279.s8|95-98|4/47|O
DDI-DrugBank.d279.s8|100-107|patients|O
DDI-DrugBank.d279.s8|115-130|prochlorperazine|O
DDI-DrugBank.d279.s8|136-147|administered|O
DDI-DrugBank.d279.s8|161-163|day|O
DDI-DrugBank.d279.s8|168-176|CAMPTOSAR|O
DDI-DrugBank.d279.s8|194-198|drugs|O
DDI-DrugBank.d279.s8|205-209|given|O
DDI-DrugBank.d279.s8|214-221|separate|O
DDI-DrugBank.d279.s8|223-226|days|O
DDI-DrugBank.d279.s8|229-231|1.3|O
DDI-DrugBank.d279.s8|92-92|%|O
DDI-DrugBank.d279.s8|235-238|1/80|O
DDI-DrugBank.d279.s8|100-107|patients|O
DDI-DrugBank.d279.s8|90-90|.|O
DDI-DrugBank.d279.s9|0-2|The|O
DDI-DrugBank.d279.s9|4-6|8.5|O
DDI-DrugBank.d279.s9|7-7|%|O
DDI-DrugBank.d279.s9|9-17|incidence|O
DDI-DrugBank.d279.s9|22-30|akathisia|O
DDI-DrugBank.d279.s9|33-39|however|O
DDI-DrugBank.d279.s9|45-50|within|O
DDI-DrugBank.d279.s9|56-60|range|O
DDI-DrugBank.d279.s9|62-69|reported|O
DDI-DrugBank.d279.s9|75-77|use|O
DDI-DrugBank.d279.s9|82-97|prochlorperazine|O
DDI-DrugBank.d279.s9|104-108|given|O
DDI-DrugBank.d279.s9|115-127|premedication|O
DDI-DrugBank.d279.s9|139-152|chemotherapies|O
DDI-DrugBank.d279.s9|5-5|.|O
DDI-DrugBank.d279.s10|0-1|It|O
DDI-DrugBank.d279.s10|3-7|would|O
DDI-DrugBank.d279.s10|12-19|expected|O
DDI-DrugBank.d279.s10|26-33|laxative|O
DDI-DrugBank.d279.s10|35-37|use|O
DDI-DrugBank.d279.s10|46-52|therapy|O
DDI-DrugBank.d279.s10|59-67|CAMPTOSAR|O
DDI-DrugBank.d279.s10|3-7|would|O
DDI-DrugBank.d279.s10|75-80|worsen|O
DDI-DrugBank.d279.s10|86-94|incidence|O
DDI-DrugBank.d279.s10|99-106|severity|O
DDI-DrugBank.d279.s10|111-118|diarrhea|O
DDI-DrugBank.d279.s10|143-149|studied|O
DDI-DrugBank.d279.s10|150-150|.|O
DDI-DrugBank.d279.s11|0-1|In|O
DDI-DrugBank.d279.s11|3-6|view|O
DDI-DrugBank.d279.s11|15-23|potential|O
DDI-DrugBank.d279.s11|25-28|risk|O
DDI-DrugBank.d279.s11|33-43|dehydration|O
DDI-DrugBank.d279.s11|45-53|secondary|O
DDI-DrugBank.d279.s11|58-65|vomiting|O
DDI-DrugBank.d279.s11|67-72|and/or|O
DDI-DrugBank.d279.s11|74-81|diarrhea|O
DDI-DrugBank.d279.s11|83-89|induced|O
DDI-DrugBank.d279.s11|94-102|CAMPTOSAR|O
DDI-DrugBank.d279.s11|109-117|physician|O
DDI-DrugBank.d279.s11|119-121|may|O
DDI-DrugBank.d279.s11|123-126|wish|O
DDI-DrugBank.d279.s11|131-138|withhold|O
DDI-DrugBank.d279.s11|140-148|diuretics|O
DDI-DrugBank.d279.s11|157-162|dosing|O
DDI-DrugBank.d279.s11|94-102|CAMPTOSAR|O
DDI-DrugBank.d279.s11|184-192|certainly|O
DDI-DrugBank.d279.s11|202-208|periods|O
DDI-DrugBank.d279.s11|213-218|active|O
DDI-DrugBank.d279.s11|58-65|vomiting|O
DDI-DrugBank.d279.s11|74-81|diarrhea|O
DDI-DrugBank.d279.s11|240-240|.|O
DDI-DrugBank.d279.s12|0-14|Drug-Laboratory|O
DDI-DrugBank.d279.s12|16-19|Test|O
DDI-DrugBank.d279.s12|21-32|Interactions|O
DDI-DrugBank.d279.s12|34-38|There|O
DDI-DrugBank.d279.s12|47-51|known|O
DDI-DrugBank.d279.s12|53-64|interactions|O
DDI-DrugBank.d279.s12|74-82|CAMPTOSAR|O
DDI-DrugBank.d279.s12|88-97|laboratory|O
DDI-DrugBank.d279.s12|99-103|tests|O
DDI-DrugBank.d279.s12|104-104|.|O
DDI-DrugBank.d102.s0|0-1|No|O
DDI-DrugBank.d102.s0|3-13|information|O
DDI-DrugBank.d102.s0|15-22|provided|O
DDI-DrugBank.d578.s0|0-2|The|O
DDI-DrugBank.d578.s0|4-18|pharmacokinetic|O
DDI-DrugBank.d578.s0|20-31|interactions|O
DDI-DrugBank.d578.s0|33-38|listed|O
DDI-DrugBank.d578.s0|50-60|potentially|O
DDI-DrugBank.d578.s0|62-71|clinically|O
DDI-DrugBank.d578.s0|73-81|important|O
DDI-DrugBank.d578.s0|82-82|.|O
DDI-DrugBank.d578.s1|0-5|Mutual|O
DDI-DrugBank.d578.s1|7-16|inhibition|O
DDI-DrugBank.d578.s1|21-30|metabolism|O
DDI-DrugBank.d578.s1|32-37|occurs|O
DDI-DrugBank.d578.s1|44-53|concurrent|O
DDI-DrugBank.d578.s1|55-57|use|O
DDI-DrugBank.d578.s1|62-72|cyclosporin|O
DDI-DrugBank.d578.s1|78-95|methylprednisolone|O
DDI-DrugBank.d578.s2|0-8|therefore|O
DDI-DrugBank.d578.s2|17-24|possible|O
DDI-DrugBank.d578.s2|31-37|adverse|O
DDI-DrugBank.d578.s2|39-44|events|O
DDI-DrugBank.d578.s2|46-55|associated|O
DDI-DrugBank.d578.s2|66-75|individual|O
DDI-DrugBank.d578.s2|77-79|use|O
DDI-DrugBank.d578.s2|84-89|either|O
DDI-DrugBank.d578.s2|91-94|drug|O
DDI-DrugBank.d578.s2|96-98|may|O
DDI-DrugBank.d578.s2|108-110|apt|O
DDI-DrugBank.d578.s2|115-119|occur|O
DDI-DrugBank.d578.s2|120-120|.|O
DDI-DrugBank.d578.s3|0-10|convulsions|O
DDI-DrugBank.d578.s3|22-29|reported|O
DDI-DrugBank.d578.s3|36-45|concurrent|O
DDI-DrugBank.d578.s3|47-49|use|O
DDI-DrugBank.d578.s3|54-71|methylprednisolone|O
DDI-DrugBank.d578.s3|77-87|cyclosporin|O
DDI-DrugBank.d578.s3|88-88|.|O
DDI-DrugBank.d578.s4|0-4|Drugs|O
DDI-DrugBank.d578.s4|11-16|induce|O
DDI-DrugBank.d578.s4|18-24|hepatic|O
DDI-DrugBank.d578.s4|26-32|enzymes|O
DDI-DrugBank.d578.s4|42-54|phenobarbital|O
DDI-DrugBank.d578.s4|57-65|phenytoin|O
DDI-DrugBank.d578.s4|72-79|rifampin|O
DDI-DrugBank.d578.s4|81-83|may|O
DDI-DrugBank.d578.s4|85-92|increase|O
DDI-DrugBank.d578.s4|98-106|clearance|O
DDI-DrugBank.d578.s4|111-128|methylprednisolone|O
DDI-DrugBank.d578.s4|81-83|may|O
DDI-DrugBank.d578.s4|138-144|require|O
DDI-DrugBank.d578.s4|146-154|increased|O
DDI-DrugBank.d578.s4|111-128|methylprednisolone|O
DDI-DrugBank.d578.s4|178-181|dose|O
DDI-DrugBank.d578.s4|186-192|achieve|O
DDI-DrugBank.d578.s4|198-204|desired|O
DDI-DrugBank.d578.s4|206-213|response|O
DDI-DrugBank.d578.s4|214-214|.|O
DDI-DrugBank.d578.s5|0-4|Drugs|O
DDI-DrugBank.d578.s5|14-27|troleandomycin|O
DDI-DrugBank.d578.s5|33-44|ketoconazole|O
DDI-DrugBank.d578.s5|46-48|may|O
DDI-DrugBank.d578.s5|50-56|inhibit|O
DDI-DrugBank.d578.s5|62-71|metabolism|O
DDI-DrugBank.d578.s5|76-93|methylprednisolone|O
DDI-DrugBank.d578.s5|99-102|thus|O
DDI-DrugBank.d578.s5|104-111|decrease|O
DDI-DrugBank.d578.s5|117-125|clearance|O
DDI-DrugBank.d578.s5|126-126|.|O
DDI-DrugBank.d578.s6|0-8|Therefore|O
DDI-DrugBank.d578.s6|15-18|dose|O
DDI-DrugBank.d578.s6|23-40|methylprednisolone|O
DDI-DrugBank.d578.s6|52-59|titrated|O
DDI-DrugBank.d578.s6|64-68|avoid|O
DDI-DrugBank.d578.s6|70-76|steroid|O
DDI-DrugBank.d578.s6|78-85|toxicity|O
DDI-DrugBank.d578.s6|86-86|.|O
DDI-DrugBank.d578.s7|0-17|Methylprednisolone|O
DDI-DrugBank.d578.s7|19-21|may|O
DDI-DrugBank.d578.s7|23-30|increase|O
DDI-DrugBank.d578.s7|36-44|clearance|O
DDI-DrugBank.d578.s7|49-55|chronic|O
DDI-DrugBank.d578.s7|57-60|high|O
DDI-DrugBank.d578.s7|62-65|dose|O
DDI-DrugBank.d578.s7|67-73|aspirin|O
DDI-DrugBank.d578.s7|74-74|.|O
DDI-DrugBank.d578.s8|0-3|This|O
DDI-DrugBank.d578.s8|5-9|could|O
DDI-DrugBank.d578.s8|11-14|lead|O
DDI-DrugBank.d578.s8|19-27|decreased|O
DDI-DrugBank.d578.s8|29-38|salicylate|O
DDI-DrugBank.d578.s8|40-44|serum|O
DDI-DrugBank.d578.s8|46-51|levels|O
DDI-DrugBank.d578.s8|56-63|increase|O
DDI-DrugBank.d578.s8|69-72|risk|O
DDI-DrugBank.d578.s8|29-38|salicylate|O
DDI-DrugBank.d578.s8|88-95|toxicity|O
DDI-DrugBank.d578.s8|102-119|methylprednisolone|O
DDI-DrugBank.d578.s8|124-132|withdrawn|O
DDI-DrugBank.d578.s8|133-133|.|O
DDI-DrugBank.d578.s9|0-6|Aspirin|O
DDI-DrugBank.d578.s9|18-21|used|O
DDI-DrugBank.d578.s9|23-32|cautiously|O
DDI-DrugBank.d578.s9|37-47|conjunction|O
DDI-DrugBank.d578.s9|54-68|corticosteroids|O
DDI-DrugBank.d578.s9|73-80|patients|O
DDI-DrugBank.d578.s9|82-90|suffering|O
DDI-DrugBank.d578.s9|97-115|hypoprothrombinemia|O
DDI-DrugBank.d578.s9|116-116|.|O
DDI-DrugBank.d578.s10|0-2|The|O
DDI-DrugBank.d578.s10|4-9|effect|O
DDI-DrugBank.d578.s10|14-31|methylprednisolone|O
DDI-DrugBank.d578.s10|36-39|oral|O
DDI-DrugBank.d578.s10|41-54|anticoagulants|O
DDI-DrugBank.d578.s10|59-66|variable|O
DDI-DrugBank.d578.s10|67-67|.|O
DDI-DrugBank.d578.s11|0-4|There|O
DDI-DrugBank.d578.s11|10-16|reports|O
DDI-DrugBank.d578.s11|21-28|enhanced|O
DDI-DrugBank.d578.s11|33-36|well|O
DDI-DrugBank.d578.s11|41-50|diminished|O
DDI-DrugBank.d578.s11|52-58|effects|O
DDI-DrugBank.d578.s11|63-75|anticoagulant|O
DDI-DrugBank.d578.s11|82-86|given|O
DDI-DrugBank.d578.s11|88-99|concurrently|O
DDI-DrugBank.d578.s11|106-120|corticosteroids|O
DDI-DrugBank.d578.s11|121-121|.|O
DDI-DrugBank.d578.s12|0-8|Therefore|O
DDI-DrugBank.d578.s12|11-21|coagulation|O
DDI-DrugBank.d578.s12|23-29|indices|O
DDI-DrugBank.d578.s12|41-49|monitored|O
DDI-DrugBank.d578.s12|54-61|maintain|O
DDI-DrugBank.d578.s12|67-73|desired|O
DDI-DrugBank.d578.s12|75-87|anticoagulant|O
DDI-DrugBank.d578.s12|89-94|effect|O
DDI-DrugBank.d578.s12|95-95|.|O
DDI-DrugBank.d123.s0|0-3|Some|O
DDI-DrugBank.d123.s0|5-14|quinolones|O
DDI-DrugBank.d123.s0|17-25|including|O
DDI-DrugBank.d123.s0|27-39|ciprofloxacin|O
DDI-DrugBank.d123.s0|47-50|also|O
DDI-DrugBank.d123.s0|57-61|shown|O
DDI-DrugBank.d123.s0|66-74|interfere|O
DDI-DrugBank.d123.s0|85-94|metabolism|O
DDI-DrugBank.d123.s0|99-106|caffeine|O
DDI-DrugBank.d123.s0|107-107|.|O
DDI-DrugBank.d123.s1|0-3|This|O
DDI-DrugBank.d123.s1|5-7|may|O
DDI-DrugBank.d123.s1|9-12|lead|O
DDI-DrugBank.d123.s1|17-23|reduced|O
DDI-DrugBank.d123.s1|25-33|clearance|O
DDI-DrugBank.d123.s1|38-45|caffeine|O
DDI-DrugBank.d123.s1|53-64|prolongation|O
DDI-DrugBank.d123.s1|73-77|serum|O
DDI-DrugBank.d123.s1|79-87|half-life|O
DDI-DrugBank.d123.s1|88-88|.|O
DDI-DrugBank.d123.s2|0-3|Some|O
DDI-DrugBank.d123.s2|5-14|quinolones|O
DDI-DrugBank.d123.s2|17-25|including|O
DDI-DrugBank.d123.s2|27-39|ciprofloxacin|O
DDI-DrugBank.d123.s2|52-61|associated|O
DDI-DrugBank.d123.s2|68-76|transient|O
DDI-DrugBank.d123.s2|78-87|elevations|O
DDI-DrugBank.d123.s2|92-96|serum|O
DDI-DrugBank.d123.s2|98-107|creatinine|O
DDI-DrugBank.d123.s2|112-119|patients|O
DDI-DrugBank.d123.s2|121-129|receiving|O
DDI-DrugBank.d123.s2|131-142|cyclosporine|O
DDI-DrugBank.d123.s2|144-156|concomitantly|O
DDI-DrugBank.d123.s2|157-157|.|O
DDI-DrugBank.d123.s3|0-8|Glyburide|O
DDI-DrugBank.d123.s3|11-13|The|O
DDI-DrugBank.d123.s3|15-25|concomitant|O
DDI-DrugBank.d123.s3|27-40|administration|O
DDI-DrugBank.d123.s3|45-57|ciprofloxacin|O
DDI-DrugBank.d123.s3|68-79|sulfonylurea|O
DDI-DrugBank.d123.s3|81-89|glyburide|O
DDI-DrugBank.d123.s3|99-102|rare|O
DDI-DrugBank.d123.s3|104-112|occasions|O
DDI-DrugBank.d123.s3|115-122|resulted|O
DDI-DrugBank.d123.s3|127-132|severe|O
DDI-DrugBank.d123.s3|134-145|hypoglycemia|O
DDI-DrugBank.d123.s3|146-146|.|O
DDI-DrugBank.d123.s4|0-8|Histamine|O
DDI-DrugBank.d123.s4|10-20|H2-receptor|O
DDI-DrugBank.d123.s4|22-32|antagonists|O
DDI-DrugBank.d123.s4|0-8|Histamine|O
DDI-DrugBank.d123.s4|10-20|H2-receptor|O
DDI-DrugBank.d123.s4|22-32|antagonists|O
DDI-DrugBank.d123.s4|69-74|appear|O
DDI-DrugBank.d123.s4|87-97|significant|O
DDI-DrugBank.d123.s4|99-104|effect|O
DDI-DrugBank.d123.s4|113-127|bioavailability|O
DDI-DrugBank.d123.s4|132-144|ciprofloxacin|O
DDI-DrugBank.d123.s4|145-145|.|O
DDI-DrugBank.d123.s5|0-11|Methotrexate|O
DDI-DrugBank.d123.s5|13-17|Renal|O
DDI-DrugBank.d123.s5|19-25|tubular|O
DDI-DrugBank.d123.s5|27-35|transport|O
DDI-DrugBank.d123.s5|40-51|methotrexate|O
DDI-DrugBank.d123.s5|53-55|may|O
DDI-DrugBank.d123.s5|60-68|inhibited|O
DDI-DrugBank.d123.s5|73-83|concomitant|O
DDI-DrugBank.d123.s5|85-98|administration|O
DDI-DrugBank.d123.s5|103-115|ciprofloxacin|O
DDI-DrugBank.d123.s5|118-128|potentially|O
DDI-DrugBank.d123.s5|130-136|leading|O
DDI-DrugBank.d123.s5|141-149|increased|O
DDI-DrugBank.d123.s5|151-156|plasma|O
DDI-DrugBank.d123.s5|158-163|levels|O
DDI-DrugBank.d123.s5|40-51|methotrexate|O
DDI-DrugBank.d123.s5|180-180|.|O
DDI-DrugBank.d123.s6|0-3|This|O
DDI-DrugBank.d123.s6|5-9|might|O
DDI-DrugBank.d123.s6|11-18|increase|O
DDI-DrugBank.d123.s6|24-27|risk|O
DDI-DrugBank.d123.s6|32-43|methotrexate|O
DDI-DrugBank.d123.s6|45-49|toxic|O
DDI-DrugBank.d123.s6|51-59|reactions|O
DDI-DrugBank.d123.s6|60-60|.|O
DDI-DrugBank.d123.s7|0-8|Therefore|O
DDI-DrugBank.d123.s7|11-18|patients|O
DDI-DrugBank.d123.s7|26-37|methotrexate|O
DDI-DrugBank.d123.s7|39-45|therapy|O
DDI-DrugBank.d123.s7|57-65|carefully|O
DDI-DrugBank.d123.s7|67-75|monitored|O
DDI-DrugBank.d123.s7|82-92|concomitant|O
DDI-DrugBank.d123.s7|94-106|ciprofloxacin|O
DDI-DrugBank.d123.s7|39-45|therapy|O
DDI-DrugBank.d123.s7|119-127|indicated|O
DDI-DrugBank.d123.s7|128-128|.|O
DDI-DrugBank.d123.s8|0-10|Multivalent|O
DDI-DrugBank.d123.s8|12-28|Cation-Containing|O
DDI-DrugBank.d123.s8|30-37|Products|O
DDI-DrugBank.d123.s8|40-49|Concurrent|O
DDI-DrugBank.d123.s8|51-64|administration|O
DDI-DrugBank.d123.s8|71-79|quinolone|O
DDI-DrugBank.d123.s8|82-90|including|O
DDI-DrugBank.d123.s8|92-104|ciprofloxacin|O
DDI-DrugBank.d123.s8|112-122|multivalent|O
DDI-DrugBank.d123.s8|124-140|cation-containing|O
DDI-DrugBank.d123.s8|142-149|products|O
DDI-DrugBank.d123.s8|159-167|magnesium|O
DDI-DrugBank.d123.s8|172-179|aluminum|O
DDI-DrugBank.d123.s8|181-188|antacids|O
DDI-DrugBank.d123.s8|191-200|sucralfate|O
DDI-DrugBank.d123.s8|203-207|VIDEX|O
DDI-DrugBank.d123.s8|209-225|chewable/buffered|O
DDI-DrugBank.d123.s8|227-233|tablets|O
DDI-DrugBank.d123.s8|238-246|pediatric|O
DDI-DrugBank.d123.s8|248-253|powder|O
DDI-DrugBank.d123.s8|142-149|products|O
DDI-DrugBank.d123.s8|131-140|containing|O
DDI-DrugBank.d123.s8|279-285|calcium|O
DDI-DrugBank.d123.s8|288-291|iron|O
DDI-DrugBank.d123.s8|297-300|zinc|O
DDI-DrugBank.d123.s8|302-304|may|O
DDI-DrugBank.d123.s8|306-318|substantially|O
DDI-DrugBank.d123.s8|320-327|decrease|O
DDI-DrugBank.d123.s8|333-342|absorption|O
DDI-DrugBank.d123.s8|92-104|ciprofloxacin|O
DDI-DrugBank.d123.s8|362-370|resulting|O
DDI-DrugBank.d123.s8|375-379|serum|O
DDI-DrugBank.d123.s8|385-389|urine|O
DDI-DrugBank.d123.s8|391-396|levels|O
DDI-DrugBank.d123.s8|398-409|considerably|O
DDI-DrugBank.d123.s8|411-415|lower|O
DDI-DrugBank.d123.s8|422-428|desired|O
DDI-DrugBank.d123.s8|429-429|.|O
DDI-DrugBank.d123.s9|0-6|Proquin|O
DDI-DrugBank.d123.s9|8-9|XR|O
DDI-DrugBank.d123.s9|21-32|administered|O
DDI-DrugBank.d123.s9|37-41|least|O
DDI-DrugBank.d123.s9|43-43|4|O
DDI-DrugBank.d123.s9|45-49|hours|O
DDI-DrugBank.d123.s9|61-61|2|O
DDI-DrugBank.d123.s9|45-49|hours|O
DDI-DrugBank.d123.s9|81-88|products|O
DDI-DrugBank.d123.s9|89-89|.|O
DDI-DrugBank.d123.s10|0-3|This|O
DDI-DrugBank.d123.s10|5-8|time|O
DDI-DrugBank.d123.s10|10-15|window|O
DDI-DrugBank.d123.s10|20-28|different|O
DDI-DrugBank.d123.s10|45-48|oral|O
DDI-DrugBank.d123.s10|50-61|formulations|O
DDI-DrugBank.d123.s10|66-78|ciprofloxacin|O
DDI-DrugBank.d123.s10|91-97|usually|O
DDI-DrugBank.d123.s10|99-110|administered|O
DDI-DrugBank.d123.s10|112-112|2|O
DDI-DrugBank.d123.s10|114-118|hours|O
DDI-DrugBank.d123.s10|130-130|6|O
DDI-DrugBank.d123.s10|114-118|hours|O
DDI-DrugBank.d123.s10|144-151|antacids|O
DDI-DrugBank.d123.s10|152-152|.|O
DDI-DrugBank.d123.s11|0-12|Non-steroidal|O
DDI-DrugBank.d123.s11|14-30|anti-inflammatory|O
DDI-DrugBank.d123.s11|32-36|drugs|O
DDI-DrugBank.d123.s11|47-53|aspirin|O
DDI-DrugBank.d123.s11|57-61|These|O
DDI-DrugBank.d123.s11|32-36|drugs|O
DDI-DrugBank.d123.s11|72-82|combination|O
DDI-DrugBank.d123.s11|94-97|high|O
DDI-DrugBank.d123.s11|99-103|doses|O
DDI-DrugBank.d123.s11|108-117|quinolones|O
DDI-DrugBank.d123.s11|129-133|shown|O
DDI-DrugBank.d123.s11|138-144|provoke|O
DDI-DrugBank.d123.s11|146-156|convulsions|O
DDI-DrugBank.d123.s11|161-172|pre-clinical|O
DDI-DrugBank.d123.s11|174-180|studies|O
DDI-DrugBank.d123.s11|181-181|.|O
DDI-DrugBank.d123.s12|0-9|Omeprazole|O
DDI-DrugBank.d123.s12|12-14|The|O
DDI-DrugBank.d123.s12|16-19|rate|O
DDI-DrugBank.d123.s12|25-30|extent|O
DDI-DrugBank.d123.s12|35-44|absorption|O
DDI-DrugBank.d123.s12|49-61|ciprofloxacin|O
DDI-DrugBank.d123.s12|67-79|bioequivalent|O
DDI-DrugBank.d123.s12|86-92|Proquin|O
DDI-DrugBank.d123.s12|94-95|XR|O
DDI-DrugBank.d123.s12|101-105|given|O
DDI-DrugBank.d123.s12|107-111|alone|O
DDI-DrugBank.d123.s12|86-92|Proquin|O
DDI-DrugBank.d123.s12|94-95|XR|O
DDI-DrugBank.d123.s12|101-105|given|O
DDI-DrugBank.d123.s12|142-142|2|O
DDI-DrugBank.d123.s12|144-148|hours|O
DDI-DrugBank.d123.s12|156-165|omeprazole|O
DDI-DrugBank.d123.s12|174-177|dose|O
DDI-DrugBank.d123.s12|184-192|maximally|O
DDI-DrugBank.d123.s12|194-203|suppresses|O
DDI-DrugBank.d123.s12|205-211|gastric|O
DDI-DrugBank.d123.s12|213-216|acid|O
DDI-DrugBank.d123.s12|218-226|secretion|O
DDI-DrugBank.d123.s12|227-227|.|O
DDI-DrugBank.d123.s13|0-9|Omeprazole|O
DDI-DrugBank.d123.s13|21-25|taken|O
DDI-DrugBank.d123.s13|30-37|directed|O
DDI-DrugBank.d123.s13|43-49|Proquin|O
DDI-DrugBank.d123.s13|51-52|XR|O
DDI-DrugBank.d123.s13|21-25|taken|O
DDI-DrugBank.d123.s13|77-80|main|O
DDI-DrugBank.d123.s13|82-85|meal|O
DDI-DrugBank.d123.s13|94-96|day|O
DDI-DrugBank.d123.s13|99-108|preferably|O
DDI-DrugBank.d123.s13|114-120|evening|O
DDI-DrugBank.d123.s13|82-85|meal|O
DDI-DrugBank.d123.s13|126-127|..|O
DDI-DrugBank.d123.s14|0-8|Phenytoin|O
DDI-DrugBank.d123.s14|11-17|Altered|O
DDI-DrugBank.d123.s14|19-23|serum|O
DDI-DrugBank.d123.s14|25-30|levels|O
DDI-DrugBank.d123.s14|35-43|phenytoin|O
DDI-DrugBank.d123.s14|46-54|increased|O
DDI-DrugBank.d123.s14|60-68|decreased|O
DDI-DrugBank.d123.s14|81-88|reported|O
DDI-DrugBank.d123.s14|93-100|patients|O
DDI-DrugBank.d123.s14|102-110|receiving|O
DDI-DrugBank.d123.s14|112-122|concomitant|O
DDI-DrugBank.d123.s14|124-136|ciprofloxacin|O
DDI-DrugBank.d123.s14|137-137|.|O
DDI-DrugBank.d123.s15|0-9|Probenecid|O
DDI-DrugBank.d123.s15|0-9|Probenecid|O
DDI-DrugBank.d123.s15|23-32|interferes|O
DDI-DrugBank.d123.s15|39-43|renal|O
DDI-DrugBank.d123.s15|45-51|tubular|O
DDI-DrugBank.d123.s15|53-61|secretion|O
DDI-DrugBank.d123.s15|66-78|ciprofloxacin|O
DDI-DrugBank.d123.s15|84-91|produces|O
DDI-DrugBank.d123.s15|96-103|increase|O
DDI-DrugBank.d123.s15|112-116|level|O
DDI-DrugBank.d123.s15|66-78|ciprofloxacin|O
DDI-DrugBank.d123.s15|138-142|serum|O
DDI-DrugBank.d123.s15|143-143|.|O
DDI-DrugBank.d123.s16|0-11|Theophylline|O
DDI-DrugBank.d123.s16|14-15|As|O
DDI-DrugBank.d123.s16|33-42|quinolones|O
DDI-DrugBank.d123.s16|45-54|concurrent|O
DDI-DrugBank.d123.s16|56-69|administration|O
DDI-DrugBank.d123.s16|74-86|ciprofloxacin|O
DDI-DrugBank.d123.s16|93-104|theophylline|O
DDI-DrugBank.d123.s16|106-108|may|O
DDI-DrugBank.d123.s16|110-113|lead|O
DDI-DrugBank.d123.s16|118-125|elevated|O
DDI-DrugBank.d123.s16|127-131|serum|O
DDI-DrugBank.d123.s16|133-146|concentrations|O
DDI-DrugBank.d123.s16|93-104|theophylline|O
DDI-DrugBank.d123.s16|168-179|prolongation|O
DDI-DrugBank.d123.s16|188-198|elimination|O
DDI-DrugBank.d123.s16|200-208|half-life|O
DDI-DrugBank.d123.s16|209-209|.|O
DDI-DrugBank.d123.s17|0-3|This|O
DDI-DrugBank.d123.s17|5-7|may|O
DDI-DrugBank.d123.s17|9-14|result|O
DDI-DrugBank.d123.s17|19-27|increased|O
DDI-DrugBank.d123.s17|29-32|risk|O
DDI-DrugBank.d123.s17|37-56|theophylline-related|O
DDI-DrugBank.d123.s17|58-64|adverse|O
DDI-DrugBank.d123.s17|66-74|reactions|O
DDI-DrugBank.d123.s17|75-75|.|O
DDI-DrugBank.d123.s18|0-1|If|O
DDI-DrugBank.d123.s18|3-13|concomitant|O
DDI-DrugBank.d123.s18|15-17|use|O
DDI-DrugBank.d123.s18|29-35|avoided|O
DDI-DrugBank.d123.s18|38-42|serum|O
DDI-DrugBank.d123.s18|44-49|levels|O
DDI-DrugBank.d123.s18|54-65|theophylline|O
DDI-DrugBank.d123.s18|77-85|monitored|O
DDI-DrugBank.d123.s18|91-96|dosage|O
DDI-DrugBank.d123.s18|98-108|adjustments|O
DDI-DrugBank.d123.s18|110-113|made|O
DDI-DrugBank.d123.s18|118-128|appropriate|O
DDI-DrugBank.d123.s18|129-129|.|O
DDI-DrugBank.d123.s19|0-7|Warfarin|O
DDI-DrugBank.d123.s19|10-19|Quinolones|O
DDI-DrugBank.d123.s19|31-38|reported|O
DDI-DrugBank.d123.s19|43-49|enhance|O
DDI-DrugBank.d123.s19|55-61|effects|O
DDI-DrugBank.d123.s19|70-73|oral|O
DDI-DrugBank.d123.s19|75-87|anticoagulant|O
DDI-DrugBank.d123.s19|89-96|warfarin|O
DDI-DrugBank.d123.s19|105-115|derivatives|O
DDI-DrugBank.d123.s19|116-116|.|O
DDI-DrugBank.d123.s20|0-3|When|O
DDI-DrugBank.d123.s20|11-18|products|O
DDI-DrugBank.d123.s20|24-35|administered|O
DDI-DrugBank.d123.s20|37-49|concomitantly|O
DDI-DrugBank.d123.s20|52-62|prothrombin|O
DDI-DrugBank.d123.s20|64-67|time|O
DDI-DrugBank.d123.s20|78-85|suitable|O
DDI-DrugBank.d123.s20|87-97|coagulation|O
DDI-DrugBank.d123.s20|99-103|tests|O
DDI-DrugBank.d123.s20|115-123|monitored|O
DDI-DrugBank.d123.s20|124-124|.|O
DDI-DrugBank.d407.s0|0-14|Drug/Laboratory|O
DDI-DrugBank.d407.s0|16-27|Interactions|O
DDI-DrugBank.d407.s0|29-30|No|O
DDI-DrugBank.d407.s0|32-37|formal|O
DDI-DrugBank.d407.s0|39-42|drug|O
DDI-DrugBank.d407.s0|44-54|interaction|O
DDI-DrugBank.d407.s0|56-62|studies|O
DDI-DrugBank.d407.s0|74-82|performed|O
DDI-DrugBank.d407.s0|89-95|Campath|O
DDI-DrugBank.d407.s0|96-96|.|O
DDI-DrugBank.d407.s1|0-1|An|O
DDI-DrugBank.d407.s1|3-8|immune|O
DDI-DrugBank.d407.s1|10-17|response|O
DDI-DrugBank.d407.s1|22-28|Campath|O
DDI-DrugBank.d407.s1|30-32|may|O
DDI-DrugBank.d407.s1|34-42|interfere|O
DDI-DrugBank.d407.s1|49-58|subsequent|O
DDI-DrugBank.d407.s1|60-69|diagnostic|O
DDI-DrugBank.d407.s1|71-75|serum|O
DDI-DrugBank.d407.s1|77-81|tests|O
DDI-DrugBank.d407.s1|88-94|utilize|O
DDI-DrugBank.d407.s1|96-105|antibodies|O
DDI-DrugBank.d407.s2|0-0|.|O
DDI-DrugBank.d411.s0|0-2|The|O
DDI-DrugBank.d411.s0|4-12|magnitude|O
DDI-DrugBank.d411.s0|18-25|relative|O
DDI-DrugBank.d411.s0|27-36|importance|O
DDI-DrugBank.d411.s0|45-51|effects|O
DDI-DrugBank.d411.s0|53-57|noted|O
DDI-DrugBank.d411.s0|69-74|likely|O
DDI-DrugBank.d411.s0|82-88|patient|O
DDI-DrugBank.d411.s0|90-97|specific|O
DDI-DrugBank.d411.s0|103-105|may|O
DDI-DrugBank.d411.s0|107-110|vary|O
DDI-DrugBank.d411.s0|120-126|factors|O
DDI-DrugBank.d411.s0|131-133|age|O
DDI-DrugBank.d411.s0|136-141|gender|O
DDI-DrugBank.d411.s0|144-147|race|O
DDI-DrugBank.d411.s0|150-161|intercurrent|O
DDI-DrugBank.d411.s0|163-171|illnesses|O
DDI-DrugBank.d411.s0|174-177|dose|O
DDI-DrugBank.d411.s0|182-187|either|O
DDI-DrugBank.d411.s0|189-193|agent|O
DDI-DrugBank.d411.s0|196-205|additional|O
DDI-DrugBank.d411.s0|207-217|concomitant|O
DDI-DrugBank.d411.s0|219-229|medications|O
DDI-DrugBank.d411.s0|236-241|timing|O
DDI-DrugBank.d411.s0|246-249|drug|O
DDI-DrugBank.d411.s0|251-264|administration|O
DDI-DrugBank.d411.s0|265-265|.|O
DDI-DrugBank.d411.s1|0-2|Any|O
DDI-DrugBank.d411.s1|4-8|agent|O
DDI-DrugBank.d411.s1|15-20|alters|O
DDI-DrugBank.d411.s1|22-28|thyroid|O
DDI-DrugBank.d411.s1|30-36|hormone|O
DDI-DrugBank.d411.s1|38-46|synthesis|O
DDI-DrugBank.d411.s1|49-57|secretion|O
DDI-DrugBank.d411.s1|60-71|distribution|O
DDI-DrugBank.d411.s1|74-79|effect|O
DDI-DrugBank.d411.s1|84-89|target|O
DDI-DrugBank.d411.s1|91-97|tissues|O
DDI-DrugBank.d411.s1|100-109|metabolism|O
DDI-DrugBank.d411.s1|115-125|elimination|O
DDI-DrugBank.d411.s1|127-129|may|O
DDI-DrugBank.d411.s1|15-19|alter|O
DDI-DrugBank.d411.s1|141-147|optimal|O
DDI-DrugBank.d411.s1|149-159|therapeutic|O
DDI-DrugBank.d411.s1|161-164|dose|O
DDI-DrugBank.d411.s1|169-181|levothyroxine|O
DDI-DrugBank.d411.s1|183-188|sodium|O
DDI-DrugBank.d411.s1|189-189|.|O
DDI-DrugBank.d411.s2|0-12|Levothyroxine|O
DDI-DrugBank.d411.s2|14-19|Sodium|O
DDI-DrugBank.d411.s2|21-30|Absorption|O
DDI-DrugBank.d411.s2|33-35|The|O
DDI-DrugBank.d411.s2|37-45|following|O
DDI-DrugBank.d411.s2|47-52|agents|O
DDI-DrugBank.d411.s2|54-56|may|O
DDI-DrugBank.d411.s2|58-61|bind|O
DDI-DrugBank.d411.s2|67-74|decrease|O
DDI-DrugBank.d411.s2|76-85|absorption|O
DDI-DrugBank.d411.s2|90-102|levothyroxine|O
DDI-DrugBank.d411.s2|104-109|sodium|O
DDI-DrugBank.d411.s2|120-135|gastrointestinal|O
DDI-DrugBank.d411.s2|137-141|tract|O
DDI-DrugBank.d411.s2|144-151|aluminum|O
DDI-DrugBank.d411.s2|153-160|hydoxide|O
DDI-DrugBank.d411.s2|163-176|cholestyramine|O
DDI-DrugBank.d411.s2|178-182|resin|O
DDI-DrugBank.d411.s2|185-194|colestipol|O
DDI-DrugBank.d411.s2|196-208|hydrochloride|O
DDI-DrugBank.d411.s2|211-217|ferrous|O
DDI-DrugBank.d411.s2|219-225|sulfate|O
DDI-DrugBank.d411.s2|104-109|sodium|O
DDI-DrugBank.d411.s2|235-245|polystyrene|O
DDI-DrugBank.d411.s2|247-255|sulfonate|O
DDI-DrugBank.d411.s2|258-264|soybean|O
DDI-DrugBank.d411.s2|266-270|flour|O
DDI-DrugBank.d411.s2|273-276|e.g.|O
DDI-DrugBank.d411.s2|279-284|infant|O
DDI-DrugBank.d411.s2|286-292|formula|O
DDI-DrugBank.d411.s2|296-305|sucralfate|O
DDI-DrugBank.d411.s2|274-274|.|O
DDI-DrugBank.d411.s3|0-6|Binding|O
DDI-DrugBank.d411.s3|11-15|Serum|O
DDI-DrugBank.d411.s3|17-24|Proteins|O
DDI-DrugBank.d411.s3|27-29|The|O
DDI-DrugBank.d411.s3|31-39|following|O
DDI-DrugBank.d411.s3|41-46|agents|O
DDI-DrugBank.d411.s3|48-50|may|O
DDI-DrugBank.d411.s3|52-57|either|O
DDI-DrugBank.d411.s3|59-65|inhibit|O
DDI-DrugBank.d411.s3|67-79|levothyroxine|O
DDI-DrugBank.d411.s3|81-86|sodium|O
DDI-DrugBank.d411.s3|88-94|binding|O
DDI-DrugBank.d411.s3|99-103|serum|O
DDI-DrugBank.d411.s3|105-112|proteins|O
DDI-DrugBank.d411.s3|117-121|alter|O
DDI-DrugBank.d411.s3|127-140|concentrations|O
DDI-DrugBank.d411.s3|99-103|serum|O
DDI-DrugBank.d411.s3|88-94|binding|O
DDI-DrugBank.d411.s3|105-112|proteins|O
DDI-DrugBank.d411.s3|169-177|androgens|O
DDI-DrugBank.d411.s3|183-189|related|O
DDI-DrugBank.d411.s3|191-198|anabolic|O
DDI-DrugBank.d411.s3|200-207|hormones|O
DDI-DrugBank.d411.s3|210-221|asparaginase|O
DDI-DrugBank.d411.s3|224-233|clofibrate|O
DDI-DrugBank.d411.s3|236-244|estrogens|O
DDI-DrugBank.d411.s3|250-268|estrogen-containing|O
DDI-DrugBank.d411.s3|270-278|compounds|O
DDI-DrugBank.d411.s3|281-294|5-fluorouracil|O
DDI-DrugBank.d411.s3|297-306|furosemide|O
DDI-DrugBank.d411.s3|309-323|glucocorticoids|O
DDI-DrugBank.d411.s3|326-337|meclofenamic|O
DDI-DrugBank.d411.s3|339-342|acid|O
DDI-DrugBank.d411.s3|345-353|mefenamic|O
DDI-DrugBank.d411.s3|339-342|acid|O
DDI-DrugBank.d411.s3|361-369|methadone|O
DDI-DrugBank.d411.s3|372-383|perphenazine|O
DDI-DrugBank.d411.s3|386-399|phenylbutazone|O
DDI-DrugBank.d411.s3|402-410|phenytoin|O
DDI-DrugBank.d411.s3|413-423|salicylates|O
DDI-DrugBank.d411.s3|426-434|tamoxifen|O
DDI-DrugBank.d411.s3|435-435|.|O
DDI-DrugBank.d411.s4|0-6|Thyroid|O
DDI-DrugBank.d411.s4|8-17|Physiology|O
DDI-DrugBank.d411.s4|20-22|The|O
DDI-DrugBank.d411.s4|24-32|following|O
DDI-DrugBank.d411.s4|34-39|agents|O
DDI-DrugBank.d411.s4|41-43|may|O
DDI-DrugBank.d411.s4|45-49|alter|O
DDI-DrugBank.d411.s4|51-57|thyroid|O
DDI-DrugBank.d411.s4|59-65|hormone|O
DDI-DrugBank.d411.s4|70-72|TSH|O
DDI-DrugBank.d411.s4|74-79|levels|O
DDI-DrugBank.d411.s4|82-90|generally|O
DDI-DrugBank.d411.s4|95-101|effects|O
DDI-DrugBank.d411.s4|51-57|thyroid|O
DDI-DrugBank.d411.s4|59-65|hormone|O
DDI-DrugBank.d411.s4|122-130|synthesis|O
DDI-DrugBank.d411.s4|133-141|secretion|O
DDI-DrugBank.d411.s4|144-155|distribution|O
DDI-DrugBank.d411.s4|158-167|metabolism|O
DDI-DrugBank.d411.s4|59-65|hormone|O
DDI-DrugBank.d411.s4|178-183|action|O
DDI-DrugBank.d411.s4|189-199|elimination|O
DDI-DrugBank.d411.s4|205-211|altered|O
DDI-DrugBank.d411.s4|70-72|TSH|O
DDI-DrugBank.d411.s4|133-141|secretion|O
DDI-DrugBank.d411.s4|228-244|aminoglutethimide|O
DDI-DrugBank.d411.s4|247-262|p-aminosalicylic|O
DDI-DrugBank.d411.s4|264-267|acid|O
DDI-DrugBank.d411.s4|270-279|amiodarone|O
DDI-DrugBank.d411.s4|282-290|androgens|O
DDI-DrugBank.d411.s4|296-302|related|O
DDI-DrugBank.d411.s4|304-311|anabolic|O
DDI-DrugBank.d411.s4|313-320|hormones|O
DDI-DrugBank.d411.s4|323-329|complex|O
DDI-DrugBank.d411.s4|331-336|anions|O
DDI-DrugBank.d411.s4|339-349|thiocyanate|O
DDI-DrugBank.d411.s4|352-362|perchlorate|O
DDI-DrugBank.d411.s4|365-377|pertechnetate|O
DDI-DrugBank.d411.s4|381-391|antithyroid|O
DDI-DrugBank.d411.s4|393-397|drugs|O
DDI-DrugBank.d411.s4|400-411|b-adrenergic|O
DDI-DrugBank.d411.s4|413-420|blocking|O
DDI-DrugBank.d411.s4|34-39|agents|O
DDI-DrugBank.d411.s4|430-442|carbamazepine|O
DDI-DrugBank.d411.s4|445-451|chloral|O
DDI-DrugBank.d411.s4|453-459|hydrate|O
DDI-DrugBank.d411.s4|462-469|diazepam|O
DDI-DrugBank.d411.s4|472-479|dopamine|O
DDI-DrugBank.d411.s4|472-479|dopamine|O
DDI-DrugBank.d411.s4|494-501|agonists|O
DDI-DrugBank.d411.s4|504-514|ethionamide|O
DDI-DrugBank.d411.s4|517-531|glucocorticoids|O
DDI-DrugBank.d411.s4|534-540|heparin|O
DDI-DrugBank.d411.s4|543-549|hepatic|O
DDI-DrugBank.d411.s4|551-556|enzyme|O
DDI-DrugBank.d411.s4|558-565|inducers|O
DDI-DrugBank.d411.s4|568-574|insulin|O
DDI-DrugBank.d411.s4|577-585|iodinated|O
DDI-DrugBank.d411.s4|587-601|cholestographic|O
DDI-DrugBank.d411.s4|34-39|agents|O
DDI-DrugBank.d411.s4|611-627|iodine-containing|O
DDI-DrugBank.d411.s4|629-637|compounds|O
DDI-DrugBank.d411.s4|640-647|levodopa|O
DDI-DrugBank.d411.s4|650-659|lovastatin|O
DDI-DrugBank.d411.s4|662-668|lithium|O
DDI-DrugBank.d411.s4|671-686|6-mercaptopurine|O
DDI-DrugBank.d411.s4|689-702|metoclopramide|O
DDI-DrugBank.d411.s4|705-712|mitotane|O
DDI-DrugBank.d411.s4|715-727|nitroprusside|O
DDI-DrugBank.d411.s4|730-742|phenobarbital|O
DDI-DrugBank.d411.s4|745-753|phenytoin|O
DDI-DrugBank.d411.s4|756-765|resorcinol|O
DDI-DrugBank.d411.s4|768-775|rifampin|O
DDI-DrugBank.d411.s4|778-789|somatostatin|O
DDI-DrugBank.d411.s4|791-797|analogs|O
DDI-DrugBank.d411.s4|800-811|sulfonamides|O
DDI-DrugBank.d411.s4|814-826|sulfonylureas|O
DDI-DrugBank.d411.s4|829-836|thiazide|O
DDI-DrugBank.d411.s4|838-846|diuretics|O
DDI-DrugBank.d411.s4|847-847|.|O
DDI-DrugBank.d411.s5|0-15|Adrenocorticoids|O
DDI-DrugBank.d411.s5|18-26|Metabolic|O
DDI-DrugBank.d411.s5|28-36|clearance|O
DDI-DrugBank.d411.s5|41-56|adrenocorticoids|O
DDI-DrugBank.d411.s5|61-69|decreased|O
DDI-DrugBank.d411.s5|74-84|hypothyroid|O
DDI-DrugBank.d411.s5|86-93|patients|O
DDI-DrugBank.d411.s5|99-107|increased|O
DDI-DrugBank.d411.s5|112-123|hyperthyroid|O
DDI-DrugBank.d411.s5|86-93|patients|O
DDI-DrugBank.d411.s5|139-141|may|O
DDI-DrugBank.d411.s5|143-151|therefore|O
DDI-DrugBank.d411.s5|153-158|change|O
DDI-DrugBank.d411.s5|165-172|changing|O
DDI-DrugBank.d411.s5|78-84|thyroid|O
DDI-DrugBank.d411.s5|182-187|status|O
DDI-DrugBank.d411.s5|188-188|.|O
DDI-DrugBank.d411.s6|0-9|Amiodarone|O
DDI-DrugBank.d411.s6|0-9|Amiodarone|O
DDI-DrugBank.d411.s6|23-29|therapy|O
DDI-DrugBank.d411.s6|31-35|alone|O
DDI-DrugBank.d411.s6|41-45|cause|O
DDI-DrugBank.d411.s6|47-60|hypothyroidism|O
DDI-DrugBank.d411.s6|65-79|hyperthyroidism|O
DDI-DrugBank.d411.s6|80-80|.|O
DDI-DrugBank.d411.s7|0-13|Anticoagulants|O
DDI-DrugBank.d411.s7|16-19|Oral|O
DDI-DrugBank.d411.s7|23-25|The|O
DDI-DrugBank.d411.s7|27-45|hypoprothrombinemic|O
DDI-DrugBank.d411.s7|47-52|effect|O
DDI-DrugBank.d411.s7|57-70|anticoagulants|O
DDI-DrugBank.d411.s7|72-74|may|O
DDI-DrugBank.d411.s7|79-89|potentiated|O
DDI-DrugBank.d411.s7|92-101|apparently|O
DDI-DrugBank.d411.s7|106-114|increased|O
DDI-DrugBank.d411.s7|116-125|catabloism|O
DDI-DrugBank.d411.s7|130-136|vitamin|O
DDI-DrugBank.d411.s7|138-148|K-dependent|O
DDI-DrugBank.d411.s7|150-157|clotting|O
DDI-DrugBank.d411.s7|159-165|factors|O
DDI-DrugBank.d411.s7|166-166|.|O
DDI-DrugBank.d411.s8|0-11|Antidiabetic|O
DDI-DrugBank.d411.s8|13-18|Agents|O
DDI-DrugBank.d411.s8|21-27|Insulin|O
DDI-DrugBank.d411.s8|30-42|Sulfonylureas|O
DDI-DrugBank.d411.s8|46-57|Requirements|O
DDI-DrugBank.d411.s8|63-69|insulin|O
DDI-DrugBank.d411.s8|74-77|oral|O
DDI-DrugBank.d411.s8|79-90|antidiabetic|O
DDI-DrugBank.d411.s8|92-97|agents|O
DDI-DrugBank.d411.s8|99-101|may|O
DDI-DrugBank.d411.s8|106-112|reduced|O
DDI-DrugBank.d411.s8|117-127|hypothyroid|O
DDI-DrugBank.d411.s8|129-136|patients|O
DDI-DrugBank.d411.s8|143-150|diabetes|O
DDI-DrugBank.d411.s8|152-159|mellitus|O
DDI-DrugBank.d411.s8|99-101|may|O
DDI-DrugBank.d411.s8|169-180|subsequently|O
DDI-DrugBank.d411.s8|182-189|increase|O
DDI-DrugBank.d411.s8|200-209|initiation|O
DDI-DrugBank.d411.s8|121-127|thyroid|O
DDI-DrugBank.d411.s8|222-228|hormone|O
DDI-DrugBank.d411.s8|230-240|replacement|O
DDI-DrugBank.d411.s8|242-248|therapy|O
DDI-DrugBank.d411.s8|249-249|.|O
DDI-DrugBank.d411.s9|0-11|b-Adrenergic|O
DDI-DrugBank.d411.s9|13-20|Blocking|O
DDI-DrugBank.d411.s9|22-27|Agents|O
DDI-DrugBank.d411.s9|30-36|Actions|O
DDI-DrugBank.d411.s9|49-61|beta-blocking|O
DDI-DrugBank.d411.s9|63-68|agents|O
DDI-DrugBank.d411.s9|70-72|may|O
DDI-DrugBank.d411.s9|77-84|impaired|O
DDI-DrugBank.d411.s9|91-101|hypothyroid|O
DDI-DrugBank.d411.s9|103-110|patients|O
DDI-DrugBank.d411.s9|112-117|become|O
DDI-DrugBank.d411.s9|119-127|euthyroid|O
DDI-DrugBank.d411.s9|128-128|.|O
DDI-DrugBank.d411.s10|0-8|Cytokines|O
DDI-DrugBank.d411.s10|11-20|interferon|O
DDI-DrugBank.d411.s10|23-33|interleukin|O
DDI-DrugBank.d411.s10|0-8|Cytokines|O
DDI-DrugBank.d411.s10|57-64|reported|O
DDI-DrugBank.d411.s10|69-74|induce|O
DDI-DrugBank.d411.s10|81-95|hyperthyroidism|O
DDI-DrugBank.d411.s10|101-114|hypothyroidism|O
DDI-DrugBank.d411.s10|115-115|.|O
DDI-DrugBank.d411.s11|0-8|Digitalis|O
DDI-DrugBank.d411.s11|10-19|Glycosides|O
DDI-DrugBank.d411.s11|22-32|Therapeutic|O
DDI-DrugBank.d411.s11|34-40|effects|O
DDI-DrugBank.d411.s11|45-53|digitalis|O
DDI-DrugBank.d411.s11|55-64|glycosides|O
DDI-DrugBank.d411.s11|66-68|may|O
DDI-DrugBank.d411.s11|73-79|reduced|O
DDI-DrugBank.d411.s11|80-80|.|O
DDI-DrugBank.d411.s12|0-4|Serum|O
DDI-DrugBank.d411.s12|6-14|digitalis|O
DDI-DrugBank.d411.s12|16-21|levels|O
DDI-DrugBank.d411.s12|23-25|may|O
DDI-DrugBank.d411.s12|30-38|decreased|O
DDI-DrugBank.d411.s12|43-57|hyperthyroidism|O
DDI-DrugBank.d411.s12|69-79|hypothyroid|O
DDI-DrugBank.d411.s12|81-87|patient|O
DDI-DrugBank.d411.s12|89-95|becomes|O
DDI-DrugBank.d411.s12|97-105|euthyroid|O
DDI-DrugBank.d411.s12|106-106|.|O
DDI-DrugBank.d411.s13|0-7|Ketamine|O
DDI-DrugBank.d411.s13|10-15|Marked|O
DDI-DrugBank.d411.s13|17-28|hypertension|O
DDI-DrugBank.d411.s13|34-44|tachycardia|O
DDI-DrugBank.d411.s13|56-63|reported|O
DDI-DrugBank.d411.s13|68-78|association|O
DDI-DrugBank.d411.s13|85-95|concomitant|O
DDI-DrugBank.d411.s13|97-110|administration|O
DDI-DrugBank.d411.s13|115-127|levothyroxine|O
DDI-DrugBank.d411.s13|129-134|sodium|O
DDI-DrugBank.d411.s13|140-147|ketamine|O
DDI-DrugBank.d411.s13|148-148|.|O
DDI-DrugBank.d411.s14|0-10|Maprotiline|O
DDI-DrugBank.d411.s14|13-16|Risk|O
DDI-DrugBank.d411.s14|21-27|cardiac|O
DDI-DrugBank.d411.s14|29-39|arrhythmias|O
DDI-DrugBank.d411.s14|41-43|may|O
DDI-DrugBank.d411.s14|45-52|increase|O
DDI-DrugBank.d411.s14|53-53|.|O
DDI-DrugBank.d411.s15|0-5|Sodium|O
DDI-DrugBank.d411.s15|7-12|Iodide|O
DDI-DrugBank.d411.s15|15-18|123I|O
DDI-DrugBank.d411.s15|24-27|131I|O
DDI-DrugBank.d411.s15|0-5|Sodium|O
DDI-DrugBank.d411.s15|38-50|Pertechnetate|O
DDI-DrugBank.d411.s15|52-56|Tc99m|O
DDI-DrugBank.d411.s15|59-64|Uptake|O
DDI-DrugBank.d411.s15|69-80|radiolabeled|O
DDI-DrugBank.d411.s15|82-85|ions|O
DDI-DrugBank.d411.s15|87-89|may|O
DDI-DrugBank.d411.s15|94-102|decreased|O
DDI-DrugBank.d411.s15|103-103|.|O
DDI-DrugBank.d411.s16|0-18|Somatrem/Somatropin|O
DDI-DrugBank.d411.s16|21-29|Excessive|O
DDI-DrugBank.d411.s16|31-40|concurrent|O
DDI-DrugBank.d411.s16|42-44|use|O
DDI-DrugBank.d411.s16|49-55|thyroid|O
DDI-DrugBank.d411.s16|57-63|hormone|O
DDI-DrugBank.d411.s16|65-67|may|O
DDI-DrugBank.d411.s16|69-78|accelerate|O
DDI-DrugBank.d411.s16|80-89|epiphyseal|O
DDI-DrugBank.d411.s16|91-97|closure|O
DDI-DrugBank.d411.s16|98-98|.|O
DDI-DrugBank.d411.s17|0-8|Untreated|O
DDI-DrugBank.d411.s17|10-23|hypothyroidism|O
DDI-DrugBank.d411.s17|25-27|may|O
DDI-DrugBank.d411.s17|29-37|interfere|O
DDI-DrugBank.d411.s17|48-53|growth|O
DDI-DrugBank.d411.s17|55-62|response|O
DDI-DrugBank.d411.s17|67-74|somatrem|O
DDI-DrugBank.d411.s17|79-88|somatropin|O
DDI-DrugBank.d411.s17|89-89|.|O
DDI-DrugBank.d411.s18|0-11|Theophylline|O
DDI-DrugBank.d411.s18|0-11|Theophylline|O
DDI-DrugBank.d411.s18|27-35|clearance|O
DDI-DrugBank.d411.s18|37-39|may|O
DDI-DrugBank.d411.s18|41-48|decrease|O
DDI-DrugBank.d411.s18|53-63|hypothyroid|O
DDI-DrugBank.d411.s18|65-72|patients|O
DDI-DrugBank.d411.s18|78-83|return|O
DDI-DrugBank.d411.s18|85-90|toward|O
DDI-DrugBank.d411.s18|92-97|normal|O
DDI-DrugBank.d411.s18|106-114|euthyroid|O
DDI-DrugBank.d411.s18|116-120|state|O
DDI-DrugBank.d411.s18|125-132|achieved|O
DDI-DrugBank.d411.s18|133-133|.|O
DDI-DrugBank.d411.s19|0-8|Tricyclic|O
DDI-DrugBank.d411.s19|10-24|Antidepressants|O
DDI-DrugBank.d411.s19|27-36|Concurrent|O
DDI-DrugBank.d411.s19|38-40|use|O
DDI-DrugBank.d411.s19|42-44|may|O
DDI-DrugBank.d411.s19|46-53|increase|O
DDI-DrugBank.d411.s19|59-69|therapeutic|O
DDI-DrugBank.d411.s19|75-79|toxic|O
DDI-DrugBank.d411.s19|81-87|effects|O
DDI-DrugBank.d411.s19|97-101|drugs|O
DDI-DrugBank.d411.s19|104-111|possibly|O
DDI-DrugBank.d411.s19|113-115|due|O
DDI-DrugBank.d411.s19|120-128|increased|O
DDI-DrugBank.d411.s19|130-142|catecholamine|O
DDI-DrugBank.d411.s19|144-154|sensitivity|O
DDI-DrugBank.d411.s19|155-155|.|O
DDI-DrugBank.d411.s20|0-4|Onset|O
DDI-DrugBank.d411.s20|9-14|action|O
DDI-DrugBank.d411.s20|19-28|tricyclics|O
DDI-DrugBank.d411.s20|30-32|may|O
DDI-DrugBank.d411.s20|37-47|accelerated|O
DDI-DrugBank.d411.s20|48-48|.|O
DDI-DrugBank.d411.s21|0-14|Sympathomimetic|O
DDI-DrugBank.d411.s21|16-21|Agents|O
DDI-DrugBank.d411.s21|24-31|Possible|O
DDI-DrugBank.d411.s21|33-41|increased|O
DDI-DrugBank.d411.s21|43-46|risk|O
DDI-DrugBank.d411.s21|51-58|coronary|O
DDI-DrugBank.d411.s21|60-72|insufficiency|O
DDI-DrugBank.d411.s21|77-84|patients|O
DDI-DrugBank.d411.s21|51-58|coronary|O
DDI-DrugBank.d411.s21|100-105|artery|O
DDI-DrugBank.d411.s21|107-113|disease|O
DDI-DrugBank.d411.s21|114-114|.|O
DDI-DrugBank.d130.s0|0-9|Lincomycin|O
DDI-DrugBank.d130.s0|20-24|shown|O
DDI-DrugBank.d130.s0|34-46|neuromuscular|O
DDI-DrugBank.d130.s0|48-55|blocking|O
DDI-DrugBank.d130.s0|57-66|properties|O
DDI-DrugBank.d130.s0|73-75|may|O
DDI-DrugBank.d130.s0|77-83|enhance|O
DDI-DrugBank.d130.s0|89-94|action|O
DDI-DrugBank.d130.s0|34-46|neuromuscular|O
DDI-DrugBank.d130.s0|48-55|blocking|O
DDI-DrugBank.d130.s0|128-133|agents|O
DDI-DrugBank.d130.s0|134-134|.|O
DDI-DrugBank.d130.s1|0-8|Therefore|O
DDI-DrugBank.d130.s1|24-27|used|O
DDI-DrugBank.d130.s1|32-38|caution|O
DDI-DrugBank.d130.s1|43-50|patients|O
DDI-DrugBank.d130.s1|52-60|receiving|O
DDI-DrugBank.d130.s1|67-72|agents|O
DDI-DrugBank.d130.s1|73-73|.|O
DDI-DrugBank.d130.s2|0-9|Antagonism|O
DDI-DrugBank.d130.s2|19-28|lincomycin|O
DDI-DrugBank.d130.s2|34-45|erythromycin|O
DDI-DrugBank.d130.s2|50-54|vitro|O
DDI-DrugBank.d130.s2|65-76|demonstrated|O
DDI-DrugBank.d130.s2|77-77|.|O
DDI-DrugBank.d130.s3|0-6|Because|O
DDI-DrugBank.d130.s3|11-18|possible|O
DDI-DrugBank.d130.s3|20-27|clinical|O
DDI-DrugBank.d130.s3|29-40|significance|O
DDI-DrugBank.d130.s3|47-49|two|O
DDI-DrugBank.d130.s3|51-55|drugs|O
DDI-DrugBank.d130.s3|71-82|administered|O
DDI-DrugBank.d130.s3|84-95|concurrently|O
DDI-DrugBank.d130.s3|96-96|.|O
DDI-DrugBank.d121.s0|0-13|Nephrotoxicity|O
DDI-DrugBank.d121.s0|24-31|reported|O
DDI-DrugBank.d121.s0|33-41|following|O
DDI-DrugBank.d121.s0|43-53|concomitant|O
DDI-DrugBank.d121.s0|55-68|administration|O
DDI-DrugBank.d121.s0|73-86|aminoglycoside|O
DDI-DrugBank.d121.s0|88-98|antibiotics|O
DDI-DrugBank.d121.s0|104-116|cephalosporin|O
DDI-DrugBank.d121.s0|88-98|antibiotics|O
DDI-DrugBank.d121.s0|129-129|.|O
DDI-DrugBank.d121.s1|0-10|Concomitant|O
DDI-DrugBank.d121.s1|12-25|administration|O
DDI-DrugBank.d121.s1|30-39|probenecid|O
DDI-DrugBank.d121.s1|41-47|doubled|O
DDI-DrugBank.d121.s1|53-55|AUC|O
DDI-DrugBank.d121.s1|61-69|cefprozil|O
DDI-DrugBank.d121.s1|70-70|.|O
DDI-DrugBank.d121.s2|0-2|The|O
DDI-DrugBank.d121.s2|4-18|bioavailability|O
DDI-DrugBank.d121.s2|27-33|capsule|O
DDI-DrugBank.d121.s2|35-45|formulation|O
DDI-DrugBank.d121.s2|50-58|cefprozil|O
DDI-DrugBank.d121.s2|68-75|affected|O
DDI-DrugBank.d121.s2|82-93|administered|O
DDI-DrugBank.d121.s2|95-95|5|O
DDI-DrugBank.d121.s2|97-103|minutes|O
DDI-DrugBank.d121.s2|105-113|following|O
DDI-DrugBank.d121.s2|118-124|antacid|O
DDI-DrugBank.d121.s2|125-125|.|O
DDI-DrugBank.d12.s0|0-6|Caution|O
DDI-DrugBank.d12.s0|18-26|exercised|O
DDI-DrugBank.d12.s0|33-46|anticoagulants|O
DDI-DrugBank.d12.s0|52-56|given|O
DDI-DrugBank.d12.s0|61-71|conjunction|O
DDI-DrugBank.d12.s0|78-86|Atromid-S|O
DDI-DrugBank.d12.s0|87-87|.|O
DDI-DrugBank.d12.s1|0-6|Usually|O
DDI-DrugBank.d12.s1|13-18|dosage|O
DDI-DrugBank.d12.s1|27-39|anticoagulant|O
DDI-DrugBank.d12.s1|51-57|reduced|O
DDI-DrugBank.d12.s1|62-69|one-half|O
DDI-DrugBank.d12.s1|72-80|depending|O
DDI-DrugBank.d12.s1|89-98|individual|O
DDI-DrugBank.d12.s1|100-103|case|O
DDI-DrugBank.d12.s1|109-116|maintain|O
DDI-DrugBank.d12.s1|122-132|prothrombin|O
DDI-DrugBank.d12.s1|134-137|time|O
DDI-DrugBank.d12.s1|146-152|desired|O
DDI-DrugBank.d12.s1|154-158|level|O
DDI-DrugBank.d12.s1|163-169|prevent|O
DDI-DrugBank.d12.s1|171-178|bleeding|O
DDI-DrugBank.d12.s1|180-192|complications|O
DDI-DrugBank.d12.s1|193-193|.|O
DDI-DrugBank.d12.s2|0-7|Frequent|O
DDI-DrugBank.d12.s2|9-19|prothrombin|O
DDI-DrugBank.d12.s2|21-34|determinations|O
DDI-DrugBank.d12.s2|40-48|advisable|O
DDI-DrugBank.d12.s2|68-77|determined|O
DDI-DrugBank.d12.s2|79-88|definitely|O
DDI-DrugBank.d12.s2|9-19|prothrombin|O
DDI-DrugBank.d12.s2|111-115|level|O
DDI-DrugBank.d12.s2|126-135|stabilized|O
DDI-DrugBank.d12.s2|136-136|.|O
DDI-DrugBank.d12.s3|0-8|Atromid-S|O
DDI-DrugBank.d12.s3|10-12|may|O
DDI-DrugBank.d12.s3|14-21|displace|O
DDI-DrugBank.d12.s3|23-28|acidic|O
DDI-DrugBank.d12.s3|30-34|drugs|O
DDI-DrugBank.d12.s3|44-52|phenytoin|O
DDI-DrugBank.d12.s3|57-67|tolbutamide|O
DDI-DrugBank.d12.s3|80-86|binding|O
DDI-DrugBank.d12.s3|88-92|sites|O
DDI-DrugBank.d12.s3|93-93|.|O
DDI-DrugBank.d12.s4|0-6|Caution|O
DDI-DrugBank.d12.s4|18-26|exercised|O
DDI-DrugBank.d12.s4|33-40|treating|O
DDI-DrugBank.d12.s4|42-49|patients|O
DDI-DrugBank.d12.s4|56-61|either|O
DDI-DrugBank.d12.s4|72-76|drugs|O
DDI-DrugBank.d12.s4|87-92|highly|O
DDI-DrugBank.d12.s4|94-106|protein-bound|O
DDI-DrugBank.d12.s4|72-76|drugs|O
DDI-DrugBank.d12.s4|118-126|Atromid-S|O
DDI-DrugBank.d12.s4|127-127|.|O
DDI-DrugBank.d12.s5|0-2|The|O
DDI-DrugBank.d12.s5|4-15|hypoglycemic|O
DDI-DrugBank.d12.s5|17-22|effect|O
DDI-DrugBank.d12.s5|27-37|tolbutamide|O
DDI-DrugBank.d12.s5|48-55|reported|O
DDI-DrugBank.d12.s5|60-67|increase|O
DDI-DrugBank.d12.s5|74-82|Atromid-S|O
DDI-DrugBank.d12.s5|87-91|given|O
DDI-DrugBank.d12.s5|93-104|concurrently|O
DDI-DrugBank.d12.s5|105-105|.|O
DDI-DrugBank.d12.s6|0-8|Fulminant|O
DDI-DrugBank.d12.s6|10-23|rhabdomyolysis|O
DDI-DrugBank.d12.s6|34-37|seen|O
DDI-DrugBank.d12.s6|42-46|early|O
DDI-DrugBank.d12.s6|51-55|three|O
DDI-DrugBank.d12.s6|57-61|weeks|O
DDI-DrugBank.d12.s6|69-78|initiation|O
DDI-DrugBank.d12.s6|83-90|combined|O
DDI-DrugBank.d12.s6|92-98|therapy|O
DDI-DrugBank.d12.s6|105-111|another|O
DDI-DrugBank.d12.s6|113-119|fibrate|O
DDI-DrugBank.d12.s6|125-134|lovastatin|O
DDI-DrugBank.d12.s6|140-142|may|O
DDI-DrugBank.d12.s6|34-37|seen|O
DDI-DrugBank.d12.s6|158-164|several|O
DDI-DrugBank.d12.s6|166-171|months|O
DDI-DrugBank.d12.s6|172-172|.|O
DDI-DrugBank.d12.s7|0-2|For|O
DDI-DrugBank.d12.s7|10-16|reasons|O
DDI-DrugBank.d12.s7|25-28|felt|O
DDI-DrugBank.d12.s7|44-51|subjects|O
DDI-DrugBank.d12.s7|69-82|unsatisfactory|O
DDI-DrugBank.d12.s7|84-88|lipid|O
DDI-DrugBank.d12.s7|90-97|response|O
DDI-DrugBank.d12.s7|102-107|either|O
DDI-DrugBank.d12.s7|109-112|drug|O
DDI-DrugBank.d12.s7|114-118|alone|O
DDI-DrugBank.d12.s7|125-132|possible|O
DDI-DrugBank.d12.s7|134-141|benefits|O
DDI-DrugBank.d12.s7|146-153|combined|O
DDI-DrugBank.d12.s7|155-161|therapy|O
DDI-DrugBank.d12.s7|168-177|lovastatin|O
DDI-DrugBank.d12.s7|185-191|fibrate|O
DDI-DrugBank.d12.s7|200-207|outweigh|O
DDI-DrugBank.d12.s7|213-217|risks|O
DDI-DrugBank.d12.s7|222-227|severe|O
DDI-DrugBank.d12.s7|229-236|myopathy|O
DDI-DrugBank.d12.s7|239-252|rhabdomyolysis|O
DDI-DrugBank.d12.s7|259-263|acute|O
DDI-DrugBank.d12.s7|265-269|renal|O
DDI-DrugBank.d12.s7|271-277|failure|O
DDI-DrugBank.d12.s7|278-278|.|O
DDI-DrugBank.d12.s8|0-4|While|O
DDI-DrugBank.d12.s8|16-20|known|O
DDI-DrugBank.d12.s8|22-28|whether|O
DDI-DrugBank.d12.s8|35-45|interaction|O
DDI-DrugBank.d12.s8|47-52|occurs|O
DDI-DrugBank.d12.s8|59-66|fibrates|O
DDI-DrugBank.d12.s8|79-89|gemfibrozil|O
DDI-DrugBank.d12.s8|92-99|myopathy|O
DDI-DrugBank.d12.s8|105-118|rhabdomyolysis|O
DDI-DrugBank.d12.s8|125-136|occasionally|O
DDI-DrugBank.d12.s8|143-152|associated|O
DDI-DrugBank.d12.s8|163-165|use|O
DDI-DrugBank.d12.s8|59-66|fibrates|O
DDI-DrugBank.d12.s8|179-183|alone|O
DDI-DrugBank.d12.s8|186-194|including|O
DDI-DrugBank.d12.s8|196-205|clofibrate|O
DDI-DrugBank.d12.s8|206-206|.|O
DDI-DrugBank.d12.s9|0-8|Therefore|O
DDI-DrugBank.d12.s9|15-22|combined|O
DDI-DrugBank.d12.s9|24-26|use|O
DDI-DrugBank.d12.s9|31-40|lovastatin|O
DDI-DrugBank.d12.s9|47-54|fibrates|O
DDI-DrugBank.d12.s9|63-71|generally|O
DDI-DrugBank.d12.s9|76-82|avoided|O
DDI-DrugBank.d340.s0|0-9|Nelfinavir|O
DDI-DrugBank.d340.s0|17-25|inhibitor|O
DDI-DrugBank.d340.s0|30-34|CYP3A|O
DDI-DrugBank.d340.s0|37-46|cytochrome|O
DDI-DrugBank.d340.s0|48-51|P450|O
DDI-DrugBank.d340.s0|33-34|3A|O
DDI-DrugBank.d340.s0|56-56|.|O
DDI-DrugBank.d340.s1|0-15|Coadministration|O
DDI-DrugBank.d340.s1|20-27|VIRACEPT|O
DDI-DrugBank.d340.s1|33-37|drugs|O
DDI-DrugBank.d340.s1|39-47|primarily|O
DDI-DrugBank.d340.s1|49-59|metabolized|O
DDI-DrugBank.d340.s1|64-68|CYP3A|O
DDI-DrugBank.d340.s1|71-74|e.g.|O
DDI-DrugBank.d340.s1|77-91|dihydropyridine|O
DDI-DrugBank.d340.s1|93-99|calcium|O
DDI-DrugBank.d340.s1|101-107|channel|O
DDI-DrugBank.d340.s1|109-116|blockers|O
DDI-DrugBank.d340.s1|119-121|may|O
DDI-DrugBank.d340.s1|123-128|result|O
DDI-DrugBank.d340.s1|133-141|increased|O
DDI-DrugBank.d340.s1|143-148|plasma|O
DDI-DrugBank.d340.s1|150-163|concentrations|O
DDI-DrugBank.d340.s1|33-36|drug|O
DDI-DrugBank.d340.s1|188-192|could|O
DDI-DrugBank.d340.s1|133-140|increase|O
DDI-DrugBank.d340.s1|206-212|prolong|O
DDI-DrugBank.d340.s1|223-233|therapeutic|O
DDI-DrugBank.d340.s1|239-245|adverse|O
DDI-DrugBank.d340.s1|247-253|effects|O
DDI-DrugBank.d340.s1|72-72|.|O
DDI-DrugBank.d340.s2|0-9|Nelfinavir|O
DDI-DrugBank.d340.s2|14-24|metabolized|O
DDI-DrugBank.d340.s2|29-33|proof|O
DDI-DrugBank.d340.s2|38-42|C.P.A|O
DDI-DrugBank.d340.s2|39-39|.|O
DDI-DrugBank.d340.s3|0-15|Coadministration|O
DDI-DrugBank.d340.s3|20-27|VIRACEPT|O
DDI-DrugBank.d340.s3|33-37|drugs|O
DDI-DrugBank.d340.s3|44-49|induce|O
DDI-DrugBank.d340.s3|51-55|CYP3A|O
DDI-DrugBank.d340.s3|57-59|may|O
DDI-DrugBank.d340.s3|61-68|decrease|O
DDI-DrugBank.d340.s3|70-79|nelfinavir|O
DDI-DrugBank.d340.s3|81-86|plasma|O
DDI-DrugBank.d340.s3|88-101|concentrations|O
DDI-DrugBank.d340.s3|107-112|reduce|O
DDI-DrugBank.d340.s3|118-128|therapeutic|O
DDI-DrugBank.d340.s3|130-135|effect|O
DDI-DrugBank.d340.s3|136-136|.|O
DDI-DrugBank.d340.s4|0-15|Coadministration|O
DDI-DrugBank.d340.s4|20-27|VIRACEPT|O
DDI-DrugBank.d340.s4|33-37|drugs|O
DDI-DrugBank.d340.s4|44-50|inhibit|O
DDI-DrugBank.d340.s4|52-56|CYP3A|O
DDI-DrugBank.d340.s4|58-60|may|O
DDI-DrugBank.d340.s4|62-69|increase|O
DDI-DrugBank.d340.s4|71-80|nelfinavir|O
DDI-DrugBank.d340.s4|82-87|plasma|O
DDI-DrugBank.d340.s4|89-102|concentrations|O
DDI-DrugBank.d340.s4|103-103|.|O
DDI-DrugBank.d340.s5|0-4|Based|O
DDI-DrugBank.d340.s5|9-13|known|O
DDI-DrugBank.d340.s5|15-23|metabolic|O
DDI-DrugBank.d340.s5|25-32|profiles|O
DDI-DrugBank.d340.s5|35-44|clinically|O
DDI-DrugBank.d340.s5|46-56|significant|O
DDI-DrugBank.d340.s5|58-61|drug|O
DDI-DrugBank.d340.s5|63-74|interactions|O
DDI-DrugBank.d340.s5|84-91|expected|O
DDI-DrugBank.d340.s5|101-108|VIRACEPT|O
DDI-DrugBank.d340.s5|114-120|dapsone|O
DDI-DrugBank.d340.s5|123-151|trimethoprim/sulfamethoxazole|O
DDI-DrugBank.d340.s5|154-167|clarithromycin|O
DDI-DrugBank.d340.s5|170-181|erythromycin|O
DDI-DrugBank.d340.s5|184-195|itraconazole|O
DDI-DrugBank.d340.s5|200-210|fluconazole|O
DDI-DrugBank.d340.s5|211-211|.|O
DDI-DrugBank.d340.s6|0-4|Drugs|O
DDI-DrugBank.d340.s6|6-9|That|O
DDI-DrugBank.d340.s6|11-16|Should|O
DDI-DrugBank.d340.s6|18-20|Not|O
DDI-DrugBank.d340.s6|22-23|Be|O
DDI-DrugBank.d340.s6|25-38|Coadministered|O
DDI-DrugBank.d340.s6|40-43|With|O
DDI-DrugBank.d340.s6|45-52|VIRACEPT|O
DDI-DrugBank.d340.s6|54-68|Antiarrhythmics|O
DDI-DrugBank.d340.s6|71-80|amiodarone|O
DDI-DrugBank.d340.s6|83-91|quinidine|O
DDI-DrugBank.d340.s6|93-106|Antihistamines|O
DDI-DrugBank.d340.s6|109-118|astemizole|O
DDI-DrugBank.d340.s6|121-131|terfenadine|O
DDI-DrugBank.d340.s6|133-144|Antimigraine|O
DDI-DrugBank.d340.s6|147-151|ergot|O
DDI-DrugBank.d340.s6|153-163|derivatives|O
DDI-DrugBank.d340.s6|165-181|Antimycobacterial|O
DDI-DrugBank.d340.s6|183-188|agents|O
DDI-DrugBank.d340.s6|191-198|rifampin|O
DDI-DrugBank.d340.s6|200-214|Benzodiazepines|O
DDI-DrugBank.d340.s6|216-224|midazolam|O
DDI-DrugBank.d340.s6|227-235|triazolam|O
DDI-DrugBank.d340.s6|237-238|GI|O
DDI-DrugBank.d340.s6|240-247|motility|O
DDI-DrugBank.d340.s6|183-188|agents|O
DDI-DrugBank.d340.s6|257-265|cisapride|O
DDI-DrugBank.d340.s7|0-4|Drugs|O
DDI-DrugBank.d340.s7|6-10|Which|O
DDI-DrugBank.d340.s7|12-18|Require|O
DDI-DrugBank.d340.s7|22-25|Dose|O
DDI-DrugBank.d340.s7|27-35|Reduction|O
DDI-DrugBank.d340.s7|37-40|When|O
DDI-DrugBank.d340.s7|42-54|Coadminstered|O
DDI-DrugBank.d340.s7|56-59|With|O
DDI-DrugBank.d340.s7|61-68|VIRACEPT|O
DDI-DrugBank.d340.s7|70-86|Antimycobacterial|O
DDI-DrugBank.d340.s7|88-93|agents|O
DDI-DrugBank.d340.s7|96-104|rifabutin|O
DDI-DrugBank.d340.s8|0-0|*|O
DDI-DrugBank.d340.s8|2-5|This|O
DDI-DrugBank.d340.s8|7-11|table|O
DDI-DrugBank.d340.s8|24-32|inclusive|O
DDI-DrugBank.d340.s8|0-0|*|O
DDI-DrugBank.d340.s8|0-0|*|O
DDI-DrugBank.d340.s8|37-44|VIRACEPT|O
DDI-DrugBank.d340.s8|46-48|may|O
DDI-DrugBank.d340.s8|57-65|effective|O
DDI-DrugBank.d340.s8|67-69|due|O
DDI-DrugBank.d340.s8|74-82|decreased|O
DDI-DrugBank.d340.s8|84-93|nelfinavir|O
DDI-DrugBank.d340.s8|95-100|plasma|O
DDI-DrugBank.d340.s8|102-115|concentrations|O
DDI-DrugBank.d340.s8|120-127|patients|O
DDI-DrugBank.d340.s8|129-134|taking|O
DDI-DrugBank.d340.s8|142-147|agents|O
DDI-DrugBank.d340.s8|149-161|concomitantly|O
DDI-DrugBank.d340.s9|0-13|Antihistamines|O
DDI-DrugBank.d340.s10|0-10|Terfenadine|O
DDI-DrugBank.d340.s10|13-26|Administration|O
DDI-DrugBank.d340.s10|31-41|terfenadine|O
DDI-DrugBank.d340.s10|48-55|VIRACEPT|O
DDI-DrugBank.d340.s10|57-64|resulted|O
DDI-DrugBank.d340.s10|73-82|appearance|O
DDI-DrugBank.d340.s10|87-95|unchanged|O
DDI-DrugBank.d340.s10|31-41|terfenadine|O
DDI-DrugBank.d340.s10|112-117|plasma|O
DDI-DrugBank.d340.s11|0-8|therefore|O
DDI-DrugBank.d340.s11|11-18|VIRACEPT|O
DDI-DrugBank.d340.s11|34-45|administered|O
DDI-DrugBank.d340.s11|47-58|concurrently|O
DDI-DrugBank.d340.s11|65-75|terfenadine|O
DDI-DrugBank.d340.s11|92-100|potential|O
DDI-DrugBank.d340.s11|106-112|serious|O
DDI-DrugBank.d340.s11|114-119|and/or|O
DDI-DrugBank.d340.s11|121-136|life-threatening|O
DDI-DrugBank.d340.s11|138-144|cardiac|O
DDI-DrugBank.d340.s11|146-156|arrhythmias|O
DDI-DrugBank.d340.s11|157-157|.|O
DDI-DrugBank.d340.s12|0-6|Because|O
DDI-DrugBank.d340.s12|10-16|similar|O
DDI-DrugBank.d340.s12|18-28|interaction|O
DDI-DrugBank.d340.s12|33-38|likely|O
DDI-DrugBank.d340.s12|41-48|VIRACEPT|O
DDI-DrugBank.d340.s12|57-60|also|O
DDI-DrugBank.d340.s12|69-80|administered|O
DDI-DrugBank.d340.s12|82-93|concurrently|O
DDI-DrugBank.d340.s12|100-109|astemizole|O
DDI-DrugBank.d340.s12|110-110|.|O
DDI-DrugBank.d340.s13|0-7|Anti-HIV|O
DDI-DrugBank.d340.s13|9-16|Protease|O
DDI-DrugBank.d340.s13|18-27|Inhibitors|O
DDI-DrugBank.d340.s14|0-8|Indinavir|O
DDI-DrugBank.d340.s14|11-26|Coadministration|O
DDI-DrugBank.d340.s14|31-39|indinavir|O
DDI-DrugBank.d340.s14|46-53|VIRACEPT|O
DDI-DrugBank.d340.s14|55-62|resulted|O
DDI-DrugBank.d340.s14|70-71|83|O
DDI-DrugBank.d340.s14|72-72|%|O
DDI-DrugBank.d340.s14|74-81|increase|O
DDI-DrugBank.d340.s14|86-95|nelfinavir|O
DDI-DrugBank.d340.s14|97-102|plasma|O
DDI-DrugBank.d340.s14|104-106|AUC|O
DDI-DrugBank.d340.s14|114-115|51|O
DDI-DrugBank.d340.s14|72-72|%|O
DDI-DrugBank.d340.s14|74-81|increase|O
DDI-DrugBank.d340.s14|31-39|indinavir|O
DDI-DrugBank.d340.s14|97-102|plasma|O
DDI-DrugBank.d340.s14|147-149|A.C|O
DDI-DrugBank.d340.s14|148-148|.|O
DDI-DrugBank.d340.s15|0-8|Currently|O
DDI-DrugBank.d340.s15|24-29|safety|O
DDI-DrugBank.d340.s15|35-42|efficacy|O
DDI-DrugBank.d340.s15|44-47|data|O
DDI-DrugBank.d340.s15|49-57|available|O
DDI-DrugBank.d340.s15|68-70|use|O
DDI-DrugBank.d340.s15|80-90|combination|O
DDI-DrugBank.d340.s15|91-91|.|O
DDI-DrugBank.d340.s16|0-8|Ritonavir|O
DDI-DrugBank.d340.s16|11-26|Coadministration|O
DDI-DrugBank.d340.s16|31-39|ritonavir|O
DDI-DrugBank.d340.s16|46-53|VIRACEPT|O
DDI-DrugBank.d340.s16|55-62|resulted|O
DDI-DrugBank.d340.s16|69-71|152|O
DDI-DrugBank.d340.s16|72-72|%|O
DDI-DrugBank.d340.s16|74-81|increase|O
DDI-DrugBank.d340.s16|86-95|nelfinavir|O
DDI-DrugBank.d340.s16|97-102|plasma|O
DDI-DrugBank.d340.s16|104-106|AUC|O
DDI-DrugBank.d340.s16|117-122|little|O
DDI-DrugBank.d340.s16|124-129|change|O
DDI-DrugBank.d340.s16|31-39|ritonavir|O
DDI-DrugBank.d340.s16|97-102|plasma|O
DDI-DrugBank.d340.s16|151-153|A.C|O
DDI-DrugBank.d340.s16|152-152|.|O
DDI-DrugBank.d340.s17|0-8|Currently|O
DDI-DrugBank.d340.s17|24-29|safety|O
DDI-DrugBank.d340.s17|35-42|efficacy|O
DDI-DrugBank.d340.s17|44-47|data|O
DDI-DrugBank.d340.s17|49-57|available|O
DDI-DrugBank.d340.s17|68-70|use|O
DDI-DrugBank.d340.s17|80-90|combination|O
DDI-DrugBank.d340.s17|91-91|.|O
DDI-DrugBank.d340.s18|0-9|Saquinavir|O
DDI-DrugBank.d340.s18|12-27|Coadministration|O
DDI-DrugBank.d340.s18|32-41|saquinavir|O
DDI-DrugBank.d340.s18|44-48|using|O
DDI-DrugBank.d340.s18|53-64|experimental|O
DDI-DrugBank.d340.s18|66-77|soft-gelatin|O
DDI-DrugBank.d340.s18|79-85|capsule|O
DDI-DrugBank.d340.s18|87-97|formulation|O
DDI-DrugBank.d340.s18|32-41|saquinavir|O
DDI-DrugBank.d340.s18|113-118|1200mg|O
DDI-DrugBank.d340.s18|126-133|VIRACEPT|O
DDI-DrugBank.d340.s18|135-142|resulted|O
DDI-DrugBank.d340.s18|150-151|18|O
DDI-DrugBank.d340.s18|152-152|%|O
DDI-DrugBank.d340.s18|154-161|increase|O
DDI-DrugBank.d340.s18|166-175|nelfinavir|O
DDI-DrugBank.d340.s18|177-182|plasma|O
DDI-DrugBank.d340.s18|184-186|AUC|O
DDI-DrugBank.d340.s18|194-199|4-fold|O
DDI-DrugBank.d340.s18|154-161|increase|O
DDI-DrugBank.d340.s18|32-41|saquinavir|O
DDI-DrugBank.d340.s18|177-182|plasma|O
DDI-DrugBank.d340.s18|231-233|A.C|O
DDI-DrugBank.d340.s18|232-232|.|O
DDI-DrugBank.d340.s19|0-1|If|O
DDI-DrugBank.d340.s19|3-6|used|O
DDI-DrugBank.d340.s19|11-21|combination|O
DDI-DrugBank.d340.s19|28-37|saquinavir|O
DDI-DrugBank.d340.s19|39-42|hard|O
DDI-DrugBank.d340.s19|44-50|gelatin|O
DDI-DrugBank.d340.s19|52-59|capsules|O
DDI-DrugBank.d340.s19|68-78|recommended|O
DDI-DrugBank.d340.s19|80-83|dose|O
DDI-DrugBank.d340.s19|88-90|600|O
DDI-DrugBank.d340.s19|92-93|mg|O
DDI-DrugBank.d340.s19|95-97|tid|O
DDI-DrugBank.d340.s19|80-83|dose|O
DDI-DrugBank.d340.s19|108-118|adjustments|O
DDI-DrugBank.d340.s19|124-129|needed|O
DDI-DrugBank.d340.s19|130-130|.|O
DDI-DrugBank.d340.s20|0-8|Currently|O
DDI-DrugBank.d340.s20|24-29|safety|O
DDI-DrugBank.d340.s20|35-42|efficacy|O
DDI-DrugBank.d340.s20|44-47|data|O
DDI-DrugBank.d340.s20|49-57|available|O
DDI-DrugBank.d340.s20|68-70|use|O
DDI-DrugBank.d340.s20|80-90|combination|O
DDI-DrugBank.d340.s20|91-91|.|O
DDI-DrugBank.d340.s21|0-9|Antifungal|O
DDI-DrugBank.d340.s21|11-16|Agents|O
DDI-DrugBank.d340.s22|0-11|Ketoconazole|O
DDI-DrugBank.d340.s22|14-29|Coadministration|O
DDI-DrugBank.d340.s22|34-45|ketoconazole|O
DDI-DrugBank.d340.s22|52-59|VIRACEPT|O
DDI-DrugBank.d340.s22|61-68|resulted|O
DDI-DrugBank.d340.s22|75-76|35|O
DDI-DrugBank.d340.s22|77-77|%|O
DDI-DrugBank.d340.s22|79-86|increase|O
DDI-DrugBank.d340.s22|91-100|nelfinavir|O
DDI-DrugBank.d340.s22|102-107|plasma|O
DDI-DrugBank.d340.s22|109-111|A.C|O
DDI-DrugBank.d340.s22|110-110|.|O
DDI-DrugBank.d340.s23|0-3|This|O
DDI-DrugBank.d340.s23|5-10|change|O
DDI-DrugBank.d340.s23|20-29|considered|O
DDI-DrugBank.d340.s23|31-40|clinically|O
DDI-DrugBank.d340.s23|42-52|significant|O
DDI-DrugBank.d340.s23|61-64|dose|O
DDI-DrugBank.d340.s23|66-75|adjustment|O
DDI-DrugBank.d340.s23|80-85|needed|O
DDI-DrugBank.d340.s23|92-103|ketoconazole|O
DDI-DrugBank.d340.s23|109-116|VIRACEPT|O
DDI-DrugBank.d340.s23|122-135|coadministered|O
DDI-DrugBank.d340.s23|136-136|.|O
DDI-DrugBank.d340.s24|0-7|Anti-HIV|O
DDI-DrugBank.d340.s24|9-15|Reverse|O
DDI-DrugBank.d340.s24|17-29|Transcriptase|O
DDI-DrugBank.d340.s24|31-40|Inhibitors|O
DDI-DrugBank.d340.s25|0-9|Didanosine|O
DDI-DrugBank.d340.s25|12-13|It|O
DDI-DrugBank.d340.s25|18-28|recommended|O
DDI-DrugBank.d340.s25|35-44|didanosine|O
DDI-DrugBank.d340.s25|49-60|administered|O
DDI-DrugBank.d340.s25|68-72|empty|O
DDI-DrugBank.d340.s25|74-80|stomach|O
DDI-DrugBank.d340.s26|0-8|therefore|O
DDI-DrugBank.d340.s26|11-20|nelfinavir|O
DDI-DrugBank.d340.s26|32-43|administered|O
DDI-DrugBank.d340.s26|51-54|food|O
DDI-DrugBank.d340.s26|57-59|one|O
DDI-DrugBank.d340.s26|61-64|hour|O
DDI-DrugBank.d340.s26|85-87|two|O
DDI-DrugBank.d340.s26|89-93|hours|O
DDI-DrugBank.d340.s26|102-111|didanosine|O
DDI-DrugBank.d340.s26|112-112|.|O
DDI-DrugBank.d340.s27|0-0|A|O
DDI-DrugBank.d340.s27|2-5|dose|O
DDI-DrugBank.d340.s27|7-16|adjustment|O
DDI-DrugBank.d340.s27|25-30|needed|O
DDI-DrugBank.d340.s27|37-46|zidovudine|O
DDI-DrugBank.d340.s27|51-62|administered|O
DDI-DrugBank.d340.s27|69-76|VIRACEPT|O
DDI-DrugBank.d340.s27|77-77|.|O
DDI-DrugBank.d340.s28|0-5|Little|O
DDI-DrugBank.d340.s28|13-18|change|O
DDI-DrugBank.d340.s28|27-42|pharmacokinetics|O
DDI-DrugBank.d340.s28|47-52|either|O
DDI-DrugBank.d340.s28|54-57|drug|O
DDI-DrugBank.d340.s28|63-70|observed|O
DDI-DrugBank.d340.s28|77-84|VIRACEPT|O
DDI-DrugBank.d340.s28|90-103|coadministered|O
DDI-DrugBank.d340.s28|110-119|lamivudine|O
DDI-DrugBank.d340.s28|124-132|stavudine|O
DDI-DrugBank.d340.s28|133-133|.|O
DDI-DrugBank.d340.s29|0-16|Antimycobacterial|O
DDI-DrugBank.d340.s29|18-23|Agents|O
DDI-DrugBank.d340.s30|0-8|Rifabutin|O
DDI-DrugBank.d340.s30|11-26|Coadministration|O
DDI-DrugBank.d340.s30|31-39|rifabutin|O
DDI-DrugBank.d340.s30|45-52|VIRACEPT|O
DDI-DrugBank.d340.s30|54-61|resulted|O
DDI-DrugBank.d340.s30|68-69|32|O
DDI-DrugBank.d340.s30|70-70|%|O
DDI-DrugBank.d340.s30|72-79|decrease|O
DDI-DrugBank.d340.s30|84-93|nelfinavir|O
DDI-DrugBank.d340.s30|95-100|plasma|O
DDI-DrugBank.d340.s30|102-104|AUC|O
DDI-DrugBank.d340.s30|112-114|207|O
DDI-DrugBank.d340.s30|70-70|%|O
DDI-DrugBank.d340.s30|117-124|increase|O
DDI-DrugBank.d340.s30|31-39|rifabutin|O
DDI-DrugBank.d340.s30|95-100|plasma|O
DDI-DrugBank.d340.s30|146-148|A.C|O
DDI-DrugBank.d340.s30|147-147|.|O
DDI-DrugBank.d340.s31|0-1|It|O
DDI-DrugBank.d340.s31|6-16|recommended|O
DDI-DrugBank.d340.s31|27-30|dose|O
DDI-DrugBank.d340.s31|35-43|rifabutin|O
DDI-DrugBank.d340.s31|48-54|reduced|O
DDI-DrugBank.d340.s31|59-66|one-half|O
DDI-DrugBank.d340.s31|72-76|usual|O
DDI-DrugBank.d340.s31|27-30|dose|O
DDI-DrugBank.d340.s31|88-99|administered|O
DDI-DrugBank.d340.s31|106-113|VIRACEPT|O
DDI-DrugBank.d340.s31|114-114|.|O
DDI-DrugBank.d340.s32|0-7|Rifampin|O
DDI-DrugBank.d340.s32|10-25|Coadministration|O
DDI-DrugBank.d340.s32|30-37|rifampin|O
DDI-DrugBank.d340.s32|43-50|VIRACEPT|O
DDI-DrugBank.d340.s32|52-59|resulted|O
DDI-DrugBank.d340.s32|67-68|82|O
DDI-DrugBank.d340.s32|69-69|%|O
DDI-DrugBank.d340.s32|71-78|decrease|O
DDI-DrugBank.d340.s32|83-92|nelfinavir|O
DDI-DrugBank.d340.s32|94-99|plasma|O
DDI-DrugBank.d340.s32|101-103|A.C|O
DDI-DrugBank.d340.s32|102-102|.|O
DDI-DrugBank.d340.s33|0-7|VIRACEPT|O
DDI-DrugBank.d340.s33|13-20|rifampin|O
DDI-DrugBank.d340.s33|36-49|coadministered|O
DDI-DrugBank.d340.s33|50-50|.|O
DDI-DrugBank.d340.s34|0-3|Oral|O
DDI-DrugBank.d340.s34|5-18|Contraceptives|O
DDI-DrugBank.d340.s35|0-6|Ethinyl|O
DDI-DrugBank.d340.s35|8-16|Estradiol|O
DDI-DrugBank.d340.s35|22-34|Norethindrone|O
DDI-DrugBank.d340.s35|37-52|Coadministration|O
DDI-DrugBank.d340.s35|57-64|VIRACEPT|O
DDI-DrugBank.d340.s35|71-78|OVCON-35|O
DDI-DrugBank.d340.s35|80-87|resulted|O
DDI-DrugBank.d340.s35|94-95|47|O
DDI-DrugBank.d340.s35|96-96|%|O
DDI-DrugBank.d340.s35|98-105|decrease|O
DDI-DrugBank.d340.s35|110-116|ethinyl|O
DDI-DrugBank.d340.s35|118-126|estradiol|O
DDI-DrugBank.d340.s35|135-136|18|O
DDI-DrugBank.d340.s35|96-96|%|O
DDI-DrugBank.d340.s35|98-105|decrease|O
DDI-DrugBank.d340.s35|151-163|norethindrone|O
DDI-DrugBank.d340.s35|165-170|plasma|O
DDI-DrugBank.d340.s35|172-185|concentrations|O
DDI-DrugBank.d340.s35|186-186|.|O
DDI-DrugBank.d340.s36|0-8|Alternate|O
DDI-DrugBank.d340.s36|13-22|additional|O
DDI-DrugBank.d340.s36|24-36|contraceptive|O
DDI-DrugBank.d340.s36|38-45|measures|O
DDI-DrugBank.d340.s36|57-60|used|O
DDI-DrugBank.d340.s36|69-75|therapy|O
DDI-DrugBank.d340.s36|82-89|VIRACEPT|O
DDI-MedLine.d143.s0|0-0|[|O
DDI-MedLine.d143.s0|1-11|Interaction|O
DDI-MedLine.d143.s0|21-31|clopidogrel|O
DDI-MedLine.d143.s0|37-42|proton|O
DDI-MedLine.d143.s0|44-47|pump|O
DDI-MedLine.d143.s0|49-58|inhibitors|O
DDI-MedLine.d143.s0|59-59|]|O
DDI-MedLine.d143.s0|60-60|.|O
DDI-MedLine.d143.s1|0-2|The|O
DDI-MedLine.d143.s1|4-7|drug|O
DDI-MedLine.d143.s1|9-19|interaction|O
DDI-MedLine.d143.s1|29-34|proton|O
DDI-MedLine.d143.s1|36-39|pump|O
DDI-MedLine.d143.s1|41-50|inhibitors|O
DDI-MedLine.d143.s1|56-66|clopidogrel|O
DDI-MedLine.d143.s1|81-87|subject|O
DDI-MedLine.d143.s1|92-95|much|O
DDI-MedLine.d143.s1|97-101|study|O
DDI-MedLine.d143.s1|106-111|recent|O
DDI-MedLine.d143.s1|113-117|years|O
DDI-MedLine.d143.s1|118-118|.|O
DDI-MedLine.d143.s2|0-12|Contradictory|O
DDI-MedLine.d143.s2|14-20|results|O
DDI-MedLine.d143.s2|22-30|regarding|O
DDI-MedLine.d143.s2|36-41|effect|O
DDI-MedLine.d143.s2|46-51|proton|O
DDI-MedLine.d143.s2|53-56|pump|O
DDI-MedLine.d143.s2|58-67|inhibitors|O
DDI-MedLine.d143.s2|72-79|platelet|O
DDI-MedLine.d143.s2|81-90|reactivity|O
DDI-MedLine.d143.s2|99-106|clinical|O
DDI-MedLine.d143.s2|108-114|outcome|O
DDI-MedLine.d143.s2|119-137|clopidogrel-treated|O
DDI-MedLine.d143.s2|139-146|patients|O
DDI-MedLine.d143.s2|158-165|reported|O
DDI-MedLine.d143.s2|170-179|literature|O
DDI-MedLine.d143.s2|180-180|.|O
DDI-MedLine.d143.s3|0-10|Concomitant|O
DDI-MedLine.d143.s3|12-14|use|O
DDI-MedLine.d143.s3|19-28|omeprazole|O
DDI-MedLine.d143.s3|34-44|clopidogrel|O
DDI-MedLine.d143.s3|50-54|found|O
DDI-MedLine.d143.s3|59-66|decrease|O
DDI-MedLine.d143.s3|72-79|exposure|O
DDI-MedLine.d143.s3|82-84|AUC|O
DDI-MedLine.d143.s3|34-44|clopidogrel|O
DDI-MedLine.d143.s3|101-102|'s|O
DDI-MedLine.d143.s3|104-109|active|O
DDI-MedLine.d143.s3|111-120|metabolite|O
DDI-MedLine.d143.s3|125-126|50|O
DDI-MedLine.d143.s3|127-127|%|O
DDI-MedLine.d143.s3|136-142|sharply|O
DDI-MedLine.d143.s3|144-151|increase|O
DDI-MedLine.d143.s3|153-160|platelet|O
DDI-MedLine.d143.s3|162-171|reactivity|O
DDI-MedLine.d143.s3|179-184|result|O
DDI-MedLine.d143.s3|189-198|inhibition|O
DDI-MedLine.d143.s3|19-28|omeprazole|O
DDI-MedLine.d143.s3|217-223|CYP2C19|O
DDI-MedLine.d143.s3|228-237|cytochrome|O
DDI-MedLine.d143.s3|239-242|P450|O
DDI-MedLine.d143.s3|217-219|CYP|O
DDI-MedLine.d143.s3|250-255|enzyme|O
DDI-MedLine.d143.s3|256-256|.|O
DDI-MedLine.d143.s4|0-11|Pantoprazole|O
DDI-MedLine.d143.s4|19-22|much|O
DDI-MedLine.d143.s4|24-29|weaker|O
DDI-MedLine.d143.s4|31-36|effect|O
DDI-MedLine.d143.s4|41-51|clopidogrel|O
DDI-MedLine.d143.s4|52-53|'s|O
DDI-MedLine.d143.s4|55-70|pharmacokinetics|O
DDI-MedLine.d143.s4|79-86|platelet|O
DDI-MedLine.d143.s4|88-97|reactivity|O
DDI-MedLine.d143.s4|106-116|concomitant|O
DDI-MedLine.d143.s4|118-120|use|O
DDI-MedLine.d143.s4|121-121|.|O
DDI-MedLine.d143.s5|0-2|The|O
DDI-MedLine.d143.s5|4-12|influence|O
DDI-MedLine.d143.s5|27-32|proton|O
DDI-MedLine.d143.s5|34-37|pump|O
DDI-MedLine.d143.s5|39-48|inhibitors|O
DDI-MedLine.d143.s5|55-58|used|O
DDI-MedLine.d143.s5|60-73|simultaneously|O
DDI-MedLine.d143.s5|80-90|clopidogrel|O
DDI-MedLine.d143.s5|100-102|yet|O
DDI-MedLine.d143.s5|109-120|investigated|O
DDI-MedLine.d143.s5|125-134|adequately|O
DDI-MedLine.d143.s5|136-145|randomized|O
DDI-MedLine.d143.s5|147-153|studies|O
DDI-MedLine.d143.s5|154-154|.|O
DDI-MedLine.d143.s6|0-9|Regulatory|O
DDI-MedLine.d143.s6|11-18|agencies|O
DDI-MedLine.d143.s6|20-24|state|O
DDI-MedLine.d143.s6|35-45|combination|O
DDI-MedLine.d143.s6|50-60|clopidogrel|O
DDI-MedLine.d143.s6|70-76|CYP2C19|O
DDI-MedLine.d143.s6|78-87|inhibitors|O
DDI-MedLine.d143.s6|89-98|omeprazole|O
DDI-MedLine.d143.s6|104-115|esomeprazole|O
DDI-MedLine.d143.s6|127-133|avoided|O
DDI-MedLine.d143.s6|134-134|.|O
DDI-MedLine.d143.s7|0-1|To|O
DDI-MedLine.d143.s7|3-6|date|O
DDI-MedLine.d143.s7|21-30|conclusive|O
DDI-MedLine.d143.s7|32-39|evidence|O
DDI-MedLine.d143.s7|46-64|clinically-relevant|O
DDI-MedLine.d143.s7|66-76|interaction|O
DDI-MedLine.d143.s7|97-102|proton|O
DDI-MedLine.d143.s7|104-107|pump|O
DDI-MedLine.d143.s7|109-118|inhibitors|O
DDI-MedLine.d143.s7|124-134|clopidogrel|O
DDI-MedLine.d143.s7|135-135|.|O
DDI-DrugBank.d51.s0|0-7|ATROVENT|O
DDI-DrugBank.d51.s0|9-18|Inhalation|O
DDI-DrugBank.d51.s0|20-26|Aerosol|O
DDI-DrugBank.d51.s0|37-40|used|O
DDI-DrugBank.d51.s0|42-54|concomitantly|O
DDI-DrugBank.d51.s0|67-71|drugs|O
DDI-DrugBank.d51.s0|74-82|including|O
DDI-DrugBank.d51.s0|84-98|sympathomimetic|O
DDI-DrugBank.d51.s0|100-114|bronchodilators|O
DDI-DrugBank.d51.s0|117-131|methylxanthines|O
DDI-DrugBank.d51.s0|138-145|steroids|O
DDI-DrugBank.d51.s0|148-155|commonly|O
DDI-DrugBank.d51.s0|37-40|used|O
DDI-DrugBank.d51.s0|169-177|treatment|O
DDI-DrugBank.d51.s0|182-188|chronic|O
DDI-DrugBank.d51.s0|190-200|obstructive|O
DDI-DrugBank.d51.s0|202-210|pulmonary|O
DDI-DrugBank.d51.s0|212-218|disease|O
DDI-DrugBank.d51.s0|219-219|.|O
DDI-DrugBank.d51.s1|0-3|With|O
DDI-DrugBank.d51.s1|9-17|exception|O
DDI-DrugBank.d51.s1|22-30|albuterol|O
DDI-DrugBank.d51.s1|46-51|formal|O
DDI-DrugBank.d51.s1|53-59|studies|O
DDI-DrugBank.d51.s1|61-65|fully|O
DDI-DrugBank.d51.s1|67-76|evaluating|O
DDI-DrugBank.d51.s1|82-92|interaction|O
DDI-DrugBank.d51.s1|94-100|effects|O
DDI-DrugBank.d51.s1|105-112|ATROVENT|O
DDI-DrugBank.d51.s1|114-123|Inhalation|O
DDI-DrugBank.d51.s1|125-131|Aerosol|O
DDI-DrugBank.d51.s1|143-147|drugs|O
DDI-DrugBank.d51.s1|154-160|respect|O
DDI-DrugBank.d51.s1|165-177|effectiveness|O
DDI-DrugBank.d51.s1|178-178|.|O
DDI-DrugBank.d51.s2|0-14|Anticholinergic|O
DDI-DrugBank.d51.s2|16-21|agents|O
DDI-DrugBank.d51.s2|24-31|Although|O
DDI-DrugBank.d51.s2|33-43|ipratropium|O
DDI-DrugBank.d51.s2|45-51|bromide|O
DDI-DrugBank.d51.s2|56-64|minimally|O
DDI-DrugBank.d51.s2|66-73|absorbed|O
DDI-DrugBank.d51.s2|84-91|systemic|O
DDI-DrugBank.d51.s2|93-103|circulation|O
DDI-DrugBank.d51.s2|120-128|potential|O
DDI-DrugBank.d51.s2|137-144|additive|O
DDI-DrugBank.d51.s2|146-156|interaction|O
DDI-DrugBank.d51.s2|163-175|concomitantly|O
DDI-DrugBank.d51.s2|177-180|used|O
DDI-DrugBank.d51.s2|182-196|anticholinergic|O
DDI-DrugBank.d51.s2|198-208|medications|O
DDI-DrugBank.d51.s2|209-209|.|O
DDI-DrugBank.d51.s3|0-6|Caution|O
DDI-DrugBank.d51.s3|11-19|therefore|O
DDI-DrugBank.d51.s3|21-27|advised|O
DDI-DrugBank.d51.s3|36-51|coadministration|O
DDI-DrugBank.d51.s3|56-63|ATROVENT|O
DDI-DrugBank.d51.s3|65-74|Inhalation|O
DDI-DrugBank.d51.s3|76-82|Aerosol|O
DDI-DrugBank.d51.s3|95-120|anticholinergic-containing|O
DDI-DrugBank.d51.s3|122-126|drugs|O
DDI-DrugBank.d51.s3|127-127|.|O
DDI-DrugBank.d406.s0|0-2|May|O
DDI-DrugBank.d406.s0|4-11|interact|O
DDI-DrugBank.d406.s0|18-28|cefamandole|O
DDI-DrugBank.d406.s0|30-36|naftate|O
DDI-DrugBank.d406.s0|39-49|cephalothin|O
DDI-DrugBank.d406.s0|51-56|sodium|O
DDI-DrugBank.d406.s0|59-67|magnesium|O
DDI-DrugBank.d406.s0|69-75|sulfate|O
DDI-DrugBank.d406.s0|78-89|prednisolone|O
DDI-DrugBank.d406.s0|51-56|sodium|O
DDI-DrugBank.d406.s0|98-106|succinate|O
DDI-DrugBank.d406.s0|113-128|prochlorperazine|O
DDI-DrugBank.d406.s0|130-138|edisylate|O
DDI-DrugBank.d406.s0|139-139|.|O
DDI-DrugBank.d728.s0|0-1|No|O
DDI-DrugBank.d728.s0|3-10|specific|O
DDI-DrugBank.d728.s0|12-21|cytochrome|O
DDI-DrugBank.d728.s0|23-32|P450-based|O
DDI-DrugBank.d728.s0|34-37|drug|O
DDI-DrugBank.d728.s0|39-49|interaction|O
DDI-DrugBank.d728.s0|51-57|studies|O
DDI-DrugBank.d728.s0|69-77|conducted|O
DDI-DrugBank.d728.s0|78-78|.|O
DDI-DrugBank.d728.s1|0-1|No|O
DDI-DrugBank.d728.s1|3-17|pharmacokinetic|O
DDI-DrugBank.d728.s1|19-29|interaction|O
DDI-DrugBank.d728.s1|39-40|85|O
DDI-DrugBank.d728.s1|42-46|mg/m2|O
DDI-DrugBank.d728.s1|48-55|ELOXATIN|O
DDI-DrugBank.d728.s1|61-70|infusional|O
DDI-DrugBank.d728.s1|72-75|5-FU|O
DDI-DrugBank.d728.s1|86-93|observed|O
DDI-DrugBank.d728.s1|98-105|patients|O
DDI-DrugBank.d728.s1|107-113|treated|O
DDI-DrugBank.d728.s1|115-119|every|O
DDI-DrugBank.d728.s1|46-46|2|O
DDI-DrugBank.d728.s1|123-127|weeks|O
DDI-DrugBank.d728.s1|128-128|.|O
DDI-DrugBank.d728.s2|0-8|Increases|O
DDI-DrugBank.d728.s2|13-16|5-FU|O
DDI-DrugBank.d728.s2|18-23|plasma|O
DDI-DrugBank.d728.s2|25-38|concentrations|O
DDI-DrugBank.d728.s2|43-55|approximately|O
DDI-DrugBank.d728.s2|57-58|20|O
DDI-DrugBank.d728.s2|59-59|%|O
DDI-DrugBank.d728.s2|71-78|observed|O
DDI-DrugBank.d728.s2|85-89|doses|O
DDI-DrugBank.d728.s2|94-96|130|O
DDI-DrugBank.d728.s2|98-102|mg/m2|O
DDI-DrugBank.d728.s2|104-111|ELOXATIN|O
DDI-DrugBank.d728.s2|113-117|dosed|O
DDI-DrugBank.d728.s2|119-123|every|O
DDI-DrugBank.d728.s2|95-95|3|O
DDI-DrugBank.d728.s2|127-131|weeks|O
DDI-DrugBank.d728.s2|132-132|.|O
DDI-DrugBank.d728.s3|0-4|Since|O
DDI-DrugBank.d728.s3|6-13|platinum|O
DDI-DrugBank.d728.s3|15-24|containing|O
DDI-DrugBank.d728.s3|26-32|species|O
DDI-DrugBank.d728.s3|38-47|eliminated|O
DDI-DrugBank.d728.s3|49-57|primarily|O
DDI-DrugBank.d728.s3|71-76|kidney|O
DDI-DrugBank.d728.s3|79-87|clearance|O
DDI-DrugBank.d728.s3|98-105|products|O
DDI-DrugBank.d728.s3|107-109|may|O
DDI-DrugBank.d728.s3|114-122|decreased|O
DDI-DrugBank.d728.s3|127-142|coadministration|O
DDI-DrugBank.d728.s3|147-157|potentially|O
DDI-DrugBank.d728.s3|159-169|nephrotoxic|O
DDI-DrugBank.d728.s3|171-179|compounds|O
DDI-DrugBank.d728.s4|0-7|although|O
DDI-DrugBank.d728.s4|28-39|specifically|O
DDI-DrugBank.d728.s4|41-47|studied|O
DDI-DrugBank.d728.s4|48-48|.|O
DDI-DrugBank.d16.s0|0-10|Prospective|O
DDI-DrugBank.d16.s0|12-18|studies|O
DDI-DrugBank.d16.s0|27-35|potential|O
DDI-DrugBank.d16.s0|41-51|hydroxyurea|O
DDI-DrugBank.d16.s0|56-63|interact|O
DDI-DrugBank.d16.s0|76-80|drugs|O
DDI-DrugBank.d16.s0|96-104|performed|O
DDI-DrugBank.d16.s0|105-105|.|O
DDI-DrugBank.d16.s1|0-9|Concurrent|O
DDI-DrugBank.d16.s1|11-13|use|O
DDI-DrugBank.d16.s1|18-28|hydroxyurea|O
DDI-DrugBank.d16.s1|40-55|myelosuppressive|O
DDI-DrugBank.d16.s1|57-62|agents|O
DDI-DrugBank.d16.s1|67-75|radiation|O
DDI-DrugBank.d16.s1|77-83|therapy|O
DDI-DrugBank.d16.s1|85-87|may|O
DDI-DrugBank.d16.s1|89-96|increase|O
DDI-DrugBank.d16.s1|102-111|likelihood|O
DDI-DrugBank.d16.s1|116-119|bone|O
DDI-DrugBank.d16.s1|121-126|marrow|O
DDI-DrugBank.d16.s1|128-137|depression|O
DDI-DrugBank.d16.s1|148-154|adverse|O
DDI-DrugBank.d16.s1|156-161|events|O
DDI-DrugBank.d16.s1|162-162|.|O
DDI-DrugBank.d16.s2|0-4|Since|O
DDI-DrugBank.d16.s2|6-16|hydroxyurea|O
DDI-DrugBank.d16.s2|18-20|may|O
DDI-DrugBank.d16.s2|22-26|raise|O
DDI-DrugBank.d16.s2|32-36|serum|O
DDI-DrugBank.d16.s2|38-41|uric|O
DDI-DrugBank.d16.s2|43-46|acid|O
DDI-DrugBank.d16.s2|48-52|level|O
DDI-DrugBank.d16.s2|55-60|dosage|O
DDI-DrugBank.d16.s2|62-71|adjustment|O
DDI-DrugBank.d16.s2|76-85|uricosuric|O
DDI-DrugBank.d16.s2|87-96|medication|O
DDI-DrugBank.d16.s2|18-20|may|O
DDI-DrugBank.d16.s2|105-113|necessary|O
DDI-DrugBank.d16.s3|0-0|.|O
DDI-DrugBank.d743.s0|0-11|Ketoconazole|O
DDI-DrugBank.d743.s0|14-24|Spontaneous|O
DDI-DrugBank.d743.s0|26-32|adverse|O
DDI-DrugBank.d743.s0|34-41|reaction|O
DDI-DrugBank.d743.s0|43-49|reports|O
DDI-DrugBank.d743.s0|54-61|patients|O
DDI-DrugBank.d743.s0|63-68|taking|O
DDI-DrugBank.d743.s0|70-80|concomitant|O
DDI-DrugBank.d743.s0|82-93|ketoconazole|O
DDI-DrugBank.d743.s0|100-110|recommended|O
DDI-DrugBank.d743.s0|112-116|doses|O
DDI-DrugBank.d743.s0|121-131|terfenadine|O
DDI-DrugBank.d743.s0|133-143|demonstrate|O
DDI-DrugBank.d743.s0|145-146|QT|O
DDI-DrugBank.d743.s0|148-155|interval|O
DDI-DrugBank.d743.s0|157-168|prolongation|O
DDI-DrugBank.d743.s0|174-177|rare|O
DDI-DrugBank.d743.s0|179-185|serious|O
DDI-DrugBank.d743.s0|187-193|cardiac|O
DDI-DrugBank.d743.s0|195-200|events|O
DDI-DrugBank.d743.s0|203-205|e.g|O
DDI-DrugBank.d743.s0|204-204|.|O
DDI-DrugBank.d743.s1|0-4|death|O
DDI-DrugBank.d743.s1|7-13|cardiac|O
DDI-DrugBank.d743.s1|15-20|arrest|O
DDI-DrugBank.d743.s1|27-37|ventricular|O
DDI-DrugBank.d743.s1|39-48|arrhythmia|O
DDI-DrugBank.d743.s1|50-58|including|O
DDI-DrugBank.d743.s1|60-67|torsades|O
DDI-DrugBank.d743.s1|0-1|de|O
DDI-DrugBank.d743.s1|72-78|pointes|O
DDI-DrugBank.d743.s1|79-79|.|O
DDI-DrugBank.d743.s2|0-14|Pharmacokinetic|O
DDI-DrugBank.d743.s2|16-19|data|O
DDI-DrugBank.d743.s2|21-28|indicate|O
DDI-DrugBank.d743.s2|35-46|ketoconazole|O
DDI-DrugBank.d743.s2|48-55|markedly|O
DDI-DrugBank.d743.s2|57-64|inhibits|O
DDI-DrugBank.d743.s2|70-79|metabolism|O
DDI-DrugBank.d743.s2|84-94|terfenadine|O
DDI-DrugBank.d743.s2|97-105|resulting|O
DDI-DrugBank.d743.s2|110-117|elevated|O
DDI-DrugBank.d743.s2|119-124|plasma|O
DDI-DrugBank.d743.s2|84-94|terfenadine|O
DDI-DrugBank.d743.s2|138-143|levels|O
DDI-DrugBank.d743.s2|144-144|.|O
DDI-DrugBank.d743.s3|0-7|Presence|O
DDI-DrugBank.d743.s3|12-20|unchanged|O
DDI-DrugBank.d743.s3|22-32|terfenadine|O
DDI-DrugBank.d743.s3|37-46|associated|O
DDI-DrugBank.d743.s3|53-65|statistically|O
DDI-DrugBank.d743.s3|67-77|significant|O
DDI-DrugBank.d743.s3|79-90|prolongation|O
DDI-DrugBank.d743.s3|99-100|QT|O
DDI-DrugBank.d743.s3|106-108|QTc|O
DDI-DrugBank.d743.s3|110-118|intervals|O
DDI-DrugBank.d743.s3|119-119|.|O
DDI-DrugBank.d743.s4|0-10|Concomitant|O
DDI-DrugBank.d743.s4|12-25|administration|O
DDI-DrugBank.d743.s4|30-41|ketoconazole|O
DDI-DrugBank.d743.s4|47-57|terfenadine|O
DDI-DrugBank.d743.s4|62-76|contraindicated|O
DDI-DrugBank.d743.s4|77-77|.|O
DDI-DrugBank.d743.s5|0-11|Itraconazole|O
DDI-DrugBank.d743.s5|14-21|Torsades|O
DDI-DrugBank.d743.s5|19-20|de|O
DDI-DrugBank.d743.s5|26-32|pointes|O
DDI-DrugBank.d743.s5|38-45|elevated|O
DDI-DrugBank.d743.s5|47-52|parent|O
DDI-DrugBank.d743.s5|54-64|terfenadine|O
DDI-DrugBank.d743.s5|66-71|levels|O
DDI-DrugBank.d743.s5|83-90|reported|O
DDI-DrugBank.d743.s5|99-109|concomitant|O
DDI-DrugBank.d743.s5|111-113|use|O
DDI-DrugBank.d743.s5|54-64|terfenadine|O
DDI-DrugBank.d743.s5|134-145|itraconazole|O
DDI-DrugBank.d743.s5|150-157|clinical|O
DDI-DrugBank.d743.s5|159-164|trials|O
DDI-DrugBank.d743.s5|134-145|itraconazole|O
DDI-DrugBank.d743.s5|191-197|foreign|O
DDI-DrugBank.d743.s5|199-212|post-marketing|O
DDI-DrugBank.d743.s5|214-220|sources|O
DDI-DrugBank.d743.s6|0-2|One|O
DDI-DrugBank.d743.s6|4-8|death|O
DDI-DrugBank.d743.s6|14-17|also|O
DDI-DrugBank.d743.s6|24-31|reported|O
DDI-DrugBank.d743.s6|38-44|foreign|O
DDI-DrugBank.d743.s6|46-50|post-|O
DDI-DrugBank.d743.s6|52-60|marketing|O
DDI-DrugBank.d743.s6|62-68|sources|O
DDI-DrugBank.d743.s6|69-69|.|O
DDI-DrugBank.d743.s7|0-10|Concomitant|O
DDI-DrugBank.d743.s7|12-25|administration|O
DDI-DrugBank.d743.s7|30-41|itraconazole|O
DDI-DrugBank.d743.s7|47-57|terfenadine|O
DDI-DrugBank.d743.s7|62-76|contraindicated|O
DDI-DrugBank.d743.s7|77-77|.|O
DDI-DrugBank.d743.s8|0-2|Due|O
DDI-DrugBank.d743.s8|11-18|chemical|O
DDI-DrugBank.d743.s8|20-29|similarity|O
DDI-DrugBank.d743.s8|40-49|azole-type|O
DDI-DrugBank.d743.s8|51-60|antifungal|O
DDI-DrugBank.d743.s8|62-67|agents|O
DDI-DrugBank.d743.s8|70-78|including|O
DDI-DrugBank.d743.s8|80-90|fluconazole|O
DDI-DrugBank.d743.s8|93-105|metronidazole|O
DDI-DrugBank.d743.s8|112-121|miconazole|O
DDI-DrugBank.d743.s8|127-138|ketoconazole|O
DDI-DrugBank.d743.s8|145-156|itraconazole|O
DDI-DrugBank.d743.s8|159-169|concomitant|O
DDI-DrugBank.d743.s8|171-173|use|O
DDI-DrugBank.d743.s8|184-191|products|O
DDI-DrugBank.d743.s8|198-208|terfenadine|O
DDI-DrugBank.d743.s8|217-227|recommended|O
DDI-DrugBank.d743.s8|229-235|pending|O
DDI-DrugBank.d743.s8|237-240|full|O
DDI-DrugBank.d743.s8|242-252|examination|O
DDI-DrugBank.d743.s8|257-265|potential|O
DDI-DrugBank.d743.s8|267-278|interactions|O
DDI-DrugBank.d743.s8|279-279|.|O
DDI-DrugBank.d743.s9|0-9|Macrolides|O
DDI-DrugBank.d743.s9|12-19|Clinical|O
DDI-DrugBank.d743.s9|21-24|drug|O
DDI-DrugBank.d743.s9|26-36|interaction|O
DDI-DrugBank.d743.s9|38-44|studies|O
DDI-DrugBank.d743.s9|46-53|indicate|O
DDI-DrugBank.d743.s9|60-71|erythromycin|O
DDI-DrugBank.d743.s9|77-90|clarithromycin|O
DDI-DrugBank.d743.s9|96-100|exert|O
DDI-DrugBank.d743.s9|105-110|effect|O
DDI-DrugBank.d743.s9|115-125|terfenadine|O
DDI-DrugBank.d743.s9|127-136|metabolism|O
DDI-DrugBank.d743.s9|143-151|mechanism|O
DDI-DrugBank.d743.s9|159-161|may|O
DDI-DrugBank.d743.s9|166-172|similar|O
DDI-DrugBank.d743.s9|185-196|ketoconazole|O
DDI-DrugBank.d743.s9|208-213|lesser|O
DDI-DrugBank.d743.s9|215-220|extent|O
DDI-DrugBank.d743.s9|221-221|.|O
DDI-DrugBank.d743.s10|0-7|Although|O
DDI-DrugBank.d743.s10|9-20|erythromycin|O
DDI-DrugBank.d743.s10|22-31|measurably|O
DDI-DrugBank.d743.s10|33-41|decreases|O
DDI-DrugBank.d743.s10|47-55|clearance|O
DDI-DrugBank.d743.s10|64-74|terfenadine|O
DDI-DrugBank.d743.s10|76-79|acid|O
DDI-DrugBank.d743.s10|81-90|metabolite|O
DDI-DrugBank.d743.s10|97-105|influence|O
DDI-DrugBank.d743.s10|64-74|terfenadine|O
DDI-DrugBank.d743.s10|122-127|plasma|O
DDI-DrugBank.d743.s10|129-134|levels|O
DDI-DrugBank.d743.s10|139-143|still|O
DDI-DrugBank.d743.s10|151-163|investigation|O
DDI-DrugBank.d743.s10|164-164|.|O
DDI-DrugBank.d743.s11|0-0|A|O
DDI-DrugBank.d743.s11|6-16|spontaneous|O
DDI-DrugBank.d743.s11|18-25|accounts|O
DDI-DrugBank.d743.s11|30-31|QT|O
DDI-DrugBank.d743.s11|33-40|interval|O
DDI-DrugBank.d743.s11|42-53|prolongation|O
DDI-DrugBank.d743.s11|60-70|ventricular|O
DDI-DrugBank.d743.s11|72-81|arrhythmia|O
DDI-DrugBank.d743.s11|83-91|including|O
DDI-DrugBank.d743.s11|93-100|torsades|O
DDI-DrugBank.d743.s11|98-99|de|O
DDI-DrugBank.d743.s11|105-111|pointes|O
DDI-DrugBank.d743.s11|124-131|reported|O
DDI-DrugBank.d743.s11|136-143|patients|O
DDI-DrugBank.d743.s11|145-153|receiving|O
DDI-DrugBank.d743.s11|155-166|erythromycin|O
DDI-DrugBank.d743.s11|171-184|troleandomycin|O
DDI-DrugBank.d743.s11|185-185|.|O
DDI-DrugBank.d743.s12|0-10|Concomitant|O
DDI-DrugBank.d743.s12|12-25|administration|O
DDI-DrugBank.d743.s12|30-40|terfenadine|O
DDI-DrugBank.d743.s12|47-60|clarithromycin|O
DDI-DrugBank.d743.s12|63-74|erythromycin|O
DDI-DrugBank.d743.s12|80-93|troleandomycin|O
DDI-DrugBank.d743.s12|98-112|contraindicated|O
DDI-DrugBank.d743.s12|115-121|Pending|O
DDI-DrugBank.d743.s12|123-126|full|O
DDI-DrugBank.d743.s12|128-143|characterization|O
DDI-DrugBank.d743.s12|148-156|potential|O
DDI-DrugBank.d743.s12|158-169|interactions|O
DDI-DrugBank.d743.s12|172-182|concomitant|O
DDI-DrugBank.d743.s12|12-25|administration|O
DDI-DrugBank.d743.s12|30-40|terfenadine|O
DDI-DrugBank.d743.s12|225-233|macrolide|O
DDI-DrugBank.d743.s12|235-245|antibiotics|O
DDI-DrugBank.d743.s12|248-256|including|O
DDI-DrugBank.d743.s12|258-269|azithromycin|O
DDI-DrugBank.d743.s12|279-289|recommended|O
DDI-DrugBank.d743.s12|290-290|.|O
DDI-DrugBank.d743.s13|0-6|Studies|O
DDI-DrugBank.d743.s13|11-18|evaluate|O
DDI-DrugBank.d743.s13|20-28|potential|O
DDI-DrugBank.d743.s13|30-41|interactions|O
DDI-DrugBank.d743.s13|46-56|terfenadine|O
DDI-DrugBank.d743.s13|63-74|azithromycin|O
DDI-DrugBank.d743.s13|83-90|progress|O
DDI-DrugBank.d743.s13|91-91|.|O
DDI-MedLine.d103.s0|0-8|Magnesium|O
DDI-MedLine.d103.s0|14-25|therapeutics|O
DDI-MedLine.d103.s0|26-26|.|O
DDI-MedLine.d103.s1|0-2|Two|O
DDI-MedLine.d103.s1|4-12|different|O
DDI-MedLine.d103.s1|14-18|types|O
DDI-MedLine.d103.s1|23-29|therapy|O
DDI-MedLine.d103.s1|36-44|magnesium|O
DDI-MedLine.d103.s1|50-53|used|O
DDI-MedLine.d103.s1|56-68|physiological|O
DDI-MedLine.d103.s1|70-73|oral|O
DDI-MedLine.d103.s1|36-44|magnesium|O
DDI-MedLine.d103.s1|85-99|supplementation|O
DDI-MedLine.d103.s1|110-116|totally|O
DDI-MedLine.d103.s1|118-123|atoxic|O
DDI-MedLine.d103.s1|125-129|since|O
DDI-MedLine.d103.s1|134-142|palliates|O
DDI-MedLine.d103.s1|36-44|magnesium|O
DDI-MedLine.d103.s1|154-165|deficiencies|O
DDI-MedLine.d103.s1|170-175|simply|O
DDI-MedLine.d103.s1|177-187|normalizing|O
DDI-MedLine.d103.s1|36-44|magnesium|O
DDI-MedLine.d103.s1|203-208|intake|O
DDI-MedLine.d103.s1|214-228|pharmacological|O
DDI-MedLine.d103.s1|36-44|magnesium|O
DDI-MedLine.d103.s1|23-29|therapy|O
DDI-MedLine.d103.s1|254-256|may|O
DDI-MedLine.d103.s1|258-263|induce|O
DDI-MedLine.d103.s1|265-272|toxicity|O
DDI-MedLine.d103.s1|125-129|since|O
DDI-MedLine.d103.s1|283-289|creates|O
DDI-MedLine.d103.s1|291-300|iatrogenic|O
DDI-MedLine.d103.s1|36-44|magnesium|O
DDI-MedLine.d103.s1|312-319|overload|O
DDI-MedLine.d103.s1|320-320|.|O
DDI-MedLine.d103.s2|0-6|Primary|O
DDI-MedLine.d103.s2|12-20|secondary|O
DDI-MedLine.d103.s2|22-30|magnesium|O
DDI-MedLine.d103.s2|32-43|deficiencies|O
DDI-MedLine.d103.s2|45-54|constitute|O
DDI-MedLine.d103.s2|60-63|sole|O
DDI-MedLine.d103.s2|65-74|indication|O
DDI-MedLine.d103.s2|79-91|physiological|O
DDI-MedLine.d103.s2|93-96|oral|O
DDI-MedLine.d103.s2|22-30|magnesium|O
DDI-MedLine.d103.s2|108-114|therapy|O
DDI-MedLine.d103.s2|115-115|.|O
DDI-MedLine.d103.s3|0-1|It|O
DDI-MedLine.d103.s3|6-14|therefore|O
DDI-MedLine.d103.s3|16-24|necessary|O
DDI-MedLine.d103.s3|32-35|well|O
DDI-MedLine.d103.s3|37-46|acquainted|O
DDI-MedLine.d103.s3|57-64|clinical|O
DDI-MedLine.d103.s3|70-81|paraclinical|O
DDI-MedLine.d103.s3|83-89|pattern|O
DDI-MedLine.d103.s3|94-102|magnesium|O
DDI-MedLine.d103.s3|104-110|deficit|O
DDI-MedLine.d103.s3|119-130|discriminate|O
DDI-MedLine.d103.s3|94-102|magnesium|O
DDI-MedLine.d103.s3|150-159|deficiency|O
DDI-MedLine.d103.s3|161-163|due|O
DDI-MedLine.d103.s3|171-182|insufficient|O
DDI-MedLine.d103.s3|94-102|magnesium|O
DDI-MedLine.d103.s3|194-199|intake|O
DDI-MedLine.d103.s3|212-219|requires|O
DDI-MedLine.d103.s3|221-224|oral|O
DDI-MedLine.d103.s3|226-238|physiological|O
DDI-MedLine.d103.s3|240-254|supplementation|O
DDI-MedLine.d103.s3|94-102|magnesium|O
DDI-MedLine.d103.s3|270-278|depletion|O
DDI-MedLine.d103.s3|280-286|related|O
DDI-MedLine.d103.s3|293-305|dysregulation|O
DDI-MedLine.d103.s3|314-320|control|O
DDI-MedLine.d103.s3|322-331|mechanisms|O
DDI-MedLine.d103.s3|94-102|magnesium|O
DDI-MedLine.d103.s3|346-351|status|O
DDI-MedLine.d103.s3|212-219|requires|O
DDI-MedLine.d103.s3|376-379|less|O
DDI-MedLine.d103.s3|381-388|specific|O
DDI-MedLine.d103.s3|296-305|regulation|O
DDI-MedLine.d103.s3|408-413|causal|O
DDI-MedLine.d103.s3|293-305|dysregulation|O
DDI-MedLine.d103.s3|428-428|.|O
DDI-MedLine.d103.s4|0-12|Physiological|O
DDI-MedLine.d103.s4|14-17|oral|O
DDI-MedLine.d103.s4|19-27|magnesium|O
DDI-MedLine.d103.s4|29-32|load|O
DDI-MedLine.d103.s4|34-44|constitutes|O
DDI-MedLine.d103.s4|50-53|best|O
DDI-MedLine.d103.s4|55-58|tool|O
DDI-MedLine.d103.s4|64-72|diagnosis|O
DDI-MedLine.d103.s4|19-27|magnesium|O
DDI-MedLine.d103.s4|87-96|deficiency|O
DDI-MedLine.d103.s4|106-110|first|O
DDI-MedLine.d103.s4|112-115|step|O
DDI-MedLine.d103.s4|124-132|treatment|O
DDI-MedLine.d103.s4|133-133|.|O
DDI-MedLine.d103.s5|0-12|Physiological|O
DDI-MedLine.d103.s5|14-17|oral|O
DDI-MedLine.d103.s5|19-27|magnesium|O
DDI-MedLine.d103.s5|29-43|supplementation|O
DDI-MedLine.d103.s5|46-46|5|O
DDI-MedLine.d103.s5|48-56|mg/kg/day|O
DDI-MedLine.d103.s5|62-65|easy|O
DDI-MedLine.d103.s5|78-84|carried|O
DDI-MedLine.d103.s5|97-100|diet|O
DDI-MedLine.d103.s5|19-27|magnesium|O
DDI-MedLine.d103.s5|120-124|salts|O
DDI-MedLine.d103.s5|132-142|practically|O
DDI-MedLine.d103.s5|149-151|one|O
DDI-MedLine.d103.s5|153-169|contra-indication|O
DDI-MedLine.d103.s5|172-176|overt|O
DDI-MedLine.d103.s5|178-182|renal|O
DDI-MedLine.d103.s5|184-190|failure|O
DDI-MedLine.d103.s5|191-191|.|O
DDI-MedLine.d103.s6|0-7|Specific|O
DDI-MedLine.d103.s6|13-21|aspecific|O
DDI-MedLine.d103.s6|23-32|treatments|O
DDI-MedLine.d103.s6|37-45|magnesium|O
DDI-MedLine.d103.s6|47-55|depletion|O
DDI-MedLine.d103.s6|61-66|tricky|O
DDI-MedLine.d103.s6|68-72|using|O
DDI-MedLine.d103.s6|78-84|example|O
DDI-MedLine.d103.s6|37-45|magnesium|O
DDI-MedLine.d103.s6|96-102|sparing|O
DDI-MedLine.d103.s6|104-112|diuretics|O
DDI-MedLine.d103.s6|115-129|pharmacological|O
DDI-MedLine.d103.s6|131-135|doses|O
DDI-MedLine.d103.s6|140-146|vitamin|O
DDI-MedLine.d103.s6|148-149|B6|O
DDI-MedLine.d103.s6|152-164|physiological|O
DDI-MedLine.d103.s6|131-135|doses|O
DDI-MedLine.d103.s6|140-146|vitamin|O
DDI-MedLine.d103.s6|183-183|D|O
DDI-MedLine.d103.s6|192-199|selenium|O
DDI-MedLine.d103.s6|200-200|.|O
DDI-MedLine.d103.s7|0-1|In|O
DDI-MedLine.d103.s7|3-7|order|O
DDI-MedLine.d103.s7|12-14|use|O
DDI-MedLine.d103.s7|20-34|pharmacological|O
DDI-MedLine.d103.s7|36-45|properties|O
DDI-MedLine.d103.s7|50-56|induced|O
DDI-MedLine.d103.s7|58-68|therapeutic|O
DDI-MedLine.d103.s7|70-85|hypermagnesaemia|O
DDI-MedLine.d103.s7|88-91|high|O
DDI-MedLine.d103.s7|93-96|oral|O
DDI-MedLine.d103.s7|98-102|doses|O
DDI-MedLine.d103.s7|107-115|magnesium|O
DDI-MedLine.d103.s7|118-118|>|O
DDI-MedLine.d103.s7|120-121|10|O
DDI-MedLine.d103.s7|123-131|mg/kg/day|O
DDI-MedLine.d103.s7|138-146|advisable|O
DDI-MedLine.d103.s7|152-158|chronic|O
DDI-MedLine.d103.s7|160-170|indications|O
DDI-MedLine.d103.s7|180-189|parenteral|O
DDI-MedLine.d103.s7|191-195|route|O
DDI-MedLine.d103.s7|200-207|suitable|O
DDI-MedLine.d103.s7|213-217|acute|O
DDI-MedLine.d103.s7|160-170|indications|O
DDI-MedLine.d103.s7|230-230|.|O
DDI-MedLine.d103.s8|0-4|There|O
DDI-MedLine.d103.s8|10-10|3|O
DDI-MedLine.d103.s8|12-16|types|O
DDI-MedLine.d103.s8|21-31|indications|O
DDI-MedLine.d103.s8|34-41|specific|O
DDI-MedLine.d103.s8|52-60|treatment|O
DDI-MedLine.d103.s8|70-74|forms|O
DDI-MedLine.d103.s8|79-87|magnesium|O
DDI-MedLine.d103.s8|89-95|deficit|O
DDI-MedLine.d103.s8|97-99|i.e|O
DDI-MedLine.d103.s8|98-98|.|O
DDI-MedLine.d103.s8|102-106|acute|O
DDI-MedLine.d103.s8|177-181|mixed|O
DDI-MedLine.d103.s8|182-183|--|O
DDI-MedLine.d103.s8|110-124|pharmacological|O
DDI-MedLine.d103.s8|204-218|aetiopathogenic|O
DDI-MedLine.d103.s8|182-183|--|O
DDI-MedLine.d103.s8|226-232|example|O
DDI-MedLine.d103.s8|234-246|complications|O
DDI-MedLine.d103.s8|251-257|chronic|O
DDI-MedLine.d103.s8|259-268|alcoholism|O
DDI-MedLine.d103.s8|98-98|.|O
DDI-MedLine.d103.s9|0-4|Today|O
DDI-MedLine.d103.s9|6-20|pharmacological|O
DDI-MedLine.d103.s9|22-30|magnesium|O
DDI-MedLine.d103.s9|32-38|therapy|O
DDI-MedLine.d103.s9|40-45|mainly|O
DDI-MedLine.d103.s9|47-54|concerns|O
DDI-MedLine.d103.s9|60-70|obstetrical|O
DDI-MedLine.d103.s9|73-85|cardiological|O
DDI-MedLine.d103.s9|91-108|anaesthesiological|O
DDI-MedLine.d103.s9|110-115|fields|O
DDI-MedLine.d103.s10|0-2|The|O
DDI-MedLine.d103.s10|4-7|main|O
DDI-MedLine.d103.s10|9-19|indications|O
DDI-MedLine.d103.s10|25-33|eclampsia|O
DDI-MedLine.d103.s10|41-52|dysrhythmias|O
DDI-MedLine.d103.s10|55-62|torsades|O
DDI-MedLine.d103.s10|60-61|de|O
DDI-MedLine.d103.s10|67-72|pointe|O
DDI-MedLine.d103.s10|74-85|particularly|O
DDI-MedLine.d103.s10|92-101|myocardial|O
DDI-MedLine.d103.s10|103-112|ischaemias|O
DDI-MedLine.d103.s10|113-113|.|O
DDI-MedLine.d103.s11|0-2|But|O
DDI-MedLine.d103.s11|14-22|difficult|O
DDI-MedLine.d103.s11|27-33|situate|O
DDI-MedLine.d103.s11|39-43|exact|O
DDI-MedLine.d103.s11|45-49|place|O
DDI-MedLine.d103.s11|58-72|pharmacological|O
DDI-MedLine.d103.s11|74-84|indications|O
DDI-MedLine.d103.s11|89-97|magnesium|O
DDI-MedLine.d103.s11|98-98|.|O
DDI-MedLine.d103.s12|0-8|Magnesium|O
DDI-MedLine.d103.s12|10-18|infusions|O
DDI-MedLine.d103.s12|32-40|envisaged|O
DDI-MedLine.d103.s12|45-53|intensive|O
DDI-MedLine.d103.s12|55-58|care|O
DDI-MedLine.d103.s12|60-64|units|O
DDI-MedLine.d103.s12|71-77|careful|O
DDI-MedLine.d103.s12|79-88|monitoring|O
DDI-MedLine.d103.s12|93-97|pulse|O
DDI-MedLine.d103.s12|100-107|arterial|O
DDI-MedLine.d103.s12|109-116|pressure|O
DDI-MedLine.d103.s12|119-122|deep|O
DDI-MedLine.d103.s12|124-129|tendon|O
DDI-MedLine.d103.s12|131-138|reflexes|O
DDI-MedLine.d103.s12|141-146|hourly|O
DDI-MedLine.d103.s12|148-155|diuresis|O
DDI-MedLine.d103.s12|158-174|electrocardiogram|O
DDI-MedLine.d103.s12|180-190|respiratory|O
DDI-MedLine.d103.s12|192-201|recordings|O
DDI-MedLine.d103.s13|0-3|High|O
DDI-MedLine.d103.s13|5-8|oral|O
DDI-MedLine.d103.s13|10-18|magnesium|O
DDI-MedLine.d103.s13|20-24|doses|O
DDI-MedLine.d103.s13|26-32|besides|O
DDI-MedLine.d103.s13|40-47|laxative|O
DDI-MedLine.d103.s13|49-54|action|O
DDI-MedLine.d103.s13|56-58|may|O
DDI-MedLine.d103.s13|60-64|bring|O
DDI-MedLine.d103.s13|66-71|latent|O
DDI-MedLine.d103.s13|73-85|complications|O
DDI-MedLine.d103.s13|56-58|may|O
DDI-MedLine.d103.s13|97-102|reduce|O
DDI-MedLine.d103.s13|104-111|lifespan|O
DDI-MedLine.d103.s13|112-112|.|O
DDI-MedLine.d103.s14|0-4|There|O
DDI-MedLine.d103.s14|6-8|may|O
DDI-MedLine.d103.s14|10-15|remain|O
DDI-MedLine.d103.s14|22-32|indications|O
DDI-MedLine.d103.s14|41-48|laxative|O
DDI-MedLine.d103.s14|54-60|antacid|O
DDI-MedLine.d103.s14|62-71|properties|O
DDI-MedLine.d103.s14|76-78|non|O
DDI-MedLine.d103.s14|80-86|soluble|O
DDI-MedLine.d103.s14|88-96|magnesium|O
DDI-MedLine.d103.s14|99-110|particularly|O
DDI-MedLine.d103.s14|119-130|intermittent|O
DDI-MedLine.d103.s14|132-144|haemodialysis|O
DDI-MedLine.d103.s14|145-145|.|O
DDI-MedLine.d103.s15|0-5|Lastly|O
DDI-MedLine.d103.s15|7-11|local|O
DDI-MedLine.d103.s15|13-15|use|O
DDI-MedLine.d103.s15|24-36|mucocutaneous|O
DDI-MedLine.d103.s15|42-55|cytoprotective|O
DDI-MedLine.d103.s15|57-66|properties|O
DDI-MedLine.d103.s15|71-79|magnesium|O
DDI-MedLine.d103.s15|84-88|still|O
DDI-MedLine.d103.s15|90-94|valid|O
DDI-MedLine.d103.s15|100-111|cardioplegic|O
DDI-MedLine.d103.s15|113-121|solutions|O
DDI-MedLine.d103.s15|131-142|preservation|O
DDI-MedLine.d103.s15|147-157|transplants|O
DDI-MedLine.d103.s15|159-170|particularly|O
DDI-DrugBank.d143.s0|0-9|Amiodarone|O
DDI-DrugBank.d143.s0|14-24|metabolized|O
DDI-DrugBank.d143.s0|29-46|desethylamiodarone|O
DDI-DrugBank.d143.s0|55-64|cytochrome|O
DDI-DrugBank.d143.s0|66-69|P450|O
DDI-DrugBank.d143.s0|72-77|CYP450|O
DDI-DrugBank.d143.s0|80-85|enzyme|O
DDI-DrugBank.d143.s0|87-91|group|O
DDI-DrugBank.d143.s0|94-105|specifically|O
DDI-DrugBank.d143.s0|107-117|cytochromes|O
DDI-DrugBank.d143.s0|66-69|P450|O
DDI-DrugBank.d143.s0|124-126|3A4|O
DDI-DrugBank.d143.s0|129-134|CYP3A4|O
DDI-DrugBank.d143.s0|141-146|CYP2C8|O
DDI-DrugBank.d143.s0|147-147|.|O
DDI-DrugBank.d143.s1|0-2|The|O
DDI-DrugBank.d143.s1|4-9|CYP3A4|O
DDI-DrugBank.d143.s1|11-19|isoenzyme|O
DDI-DrugBank.d143.s1|24-30|present|O
DDI-DrugBank.d143.s1|44-48|liver|O
DDI-DrugBank.d143.s1|54-63|intestines|O
DDI-DrugBank.d143.s1|64-64|.|O
DDI-DrugBank.d143.s2|0-9|Amiodarone|O
DDI-DrugBank.d143.s2|14-17|also|O
DDI-DrugBank.d143.s2|19-23|known|O
DDI-DrugBank.d143.s2|34-42|inhibitor|O
DDI-DrugBank.d143.s2|47-52|CYP3A4|O
DDI-DrugBank.d143.s2|53-53|.|O
DDI-DrugBank.d143.s3|0-8|Therefore|O
DDI-DrugBank.d143.s3|11-20|amiodarone|O
DDI-DrugBank.d143.s3|30-38|potential|O
DDI-DrugBank.d143.s3|44-55|interactions|O
DDI-DrugBank.d143.s3|62-66|drugs|O
DDI-DrugBank.d143.s3|71-80|substances|O
DDI-DrugBank.d143.s3|87-89|may|O
DDI-DrugBank.d143.s3|94-103|substrates|O
DDI-DrugBank.d143.s3|106-115|inhibitors|O
DDI-DrugBank.d143.s3|120-127|inducers|O
DDI-DrugBank.d143.s3|132-137|CYP3A4|O
DDI-DrugBank.d143.s3|138-138|.|O
DDI-DrugBank.d143.s4|0-4|While|O
DDI-DrugBank.d143.s4|13-19|limited|O
DDI-DrugBank.d143.s4|21-26|number|O
DDI-DrugBank.d143.s4|34-37|vivo|O
DDI-DrugBank.d143.s4|39-47|drug-drug|O
DDI-DrugBank.d143.s4|49-60|interactions|O
DDI-DrugBank.d143.s4|67-76|amiodarone|O
DDI-DrugBank.d143.s4|88-95|reported|O
DDI-DrugBank.d143.s4|98-104|chiefly|O
DDI-DrugBank.d143.s4|115-118|oral|O
DDI-DrugBank.d143.s4|120-130|formulation|O
DDI-DrugBank.d143.s4|137-145|potential|O
DDI-DrugBank.d143.s4|49-60|interactions|O
DDI-DrugBank.d143.s4|180-190|anticipated|O
DDI-DrugBank.d143.s4|191-191|.|O
DDI-DrugBank.d143.s5|0-3|This|O
DDI-DrugBank.d143.s5|8-17|especially|O
DDI-DrugBank.d143.s5|19-27|important|O
DDI-DrugBank.d143.s5|33-37|drugs|O
DDI-DrugBank.d143.s5|39-48|associated|O
DDI-DrugBank.d143.s5|55-61|serious|O
DDI-DrugBank.d143.s5|63-70|toxicity|O
DDI-DrugBank.d143.s5|87-101|antiarrhythmics|O
DDI-DrugBank.d143.s5|102-102|.|O
DDI-DrugBank.d143.s6|0-1|If|O
DDI-DrugBank.d143.s6|8-12|drugs|O
DDI-DrugBank.d143.s6|18-23|needed|O
DDI-DrugBank.d143.s6|32-35|dose|O
DDI-DrugBank.d143.s6|47-56|reassessed|O
DDI-DrugBank.d143.s6|69-79|appropriate|O
DDI-DrugBank.d143.s6|82-87|plasma|O
DDI-DrugBank.d143.s6|89-101|concentration|O
DDI-DrugBank.d143.s6|103-110|measured|O
DDI-DrugBank.d143.s6|111-111|.|O
DDI-DrugBank.d143.s7|0-1|In|O
DDI-DrugBank.d143.s7|3-6|view|O
DDI-DrugBank.d143.s7|15-18|long|O
DDI-DrugBank.d143.s7|24-31|variable|O
DDI-DrugBank.d143.s7|33-41|half-life|O
DDI-DrugBank.d143.s7|46-55|amiodarone|O
DDI-DrugBank.d143.s7|58-66|potential|O
DDI-DrugBank.d143.s7|72-75|drug|O
DDI-DrugBank.d143.s7|77-88|interactions|O
DDI-DrugBank.d143.s7|90-95|exists|O
DDI-DrugBank.d143.s7|111-121|concomitant|O
DDI-DrugBank.d143.s7|123-132|medication|O
DDI-DrugBank.d143.s7|138-141|also|O
DDI-DrugBank.d143.s7|148-152|drugs|O
DDI-DrugBank.d143.s7|154-165|administered|O
DDI-DrugBank.d143.s7|173-187|discontinuation|O
DDI-DrugBank.d143.s7|46-55|amiodarone|O
DDI-DrugBank.d143.s7|202-202|.|O
DDI-DrugBank.d143.s8|0-4|Since|O
DDI-DrugBank.d143.s8|6-15|amiodarone|O
DDI-DrugBank.d143.s8|22-30|substrate|O
DDI-DrugBank.d143.s8|36-41|CYP3A4|O
DDI-DrugBank.d143.s8|47-52|CYP2C8|O
DDI-DrugBank.d143.s8|55-70|drugs/substances|O
DDI-DrugBank.d143.s8|77-83|inhibit|O
DDI-DrugBank.d143.s8|91-100|isoenzymes|O
DDI-DrugBank.d143.s8|102-104|may|O
DDI-DrugBank.d143.s8|106-113|decrease|O
DDI-DrugBank.d143.s8|119-128|metabolism|O
DDI-DrugBank.d143.s8|134-141|increase|O
DDI-DrugBank.d143.s8|143-147|serum|O
DDI-DrugBank.d143.s8|149-161|concentration|O
DDI-DrugBank.d143.s8|6-15|amiodarone|O
DDI-DrugBank.d143.s8|176-176|.|O
DDI-DrugBank.d143.s9|0-7|Reported|O
DDI-DrugBank.d143.s9|9-16|examples|O
DDI-DrugBank.d143.s9|18-24|include|O
DDI-DrugBank.d143.s9|30-38|following|O
DDI-DrugBank.d143.s9|41-48|Protease|O
DDI-DrugBank.d143.s9|50-59|Inhibitors|O
DDI-DrugBank.d143.s9|41-48|Protease|O
DDI-DrugBank.d143.s9|71-80|inhibitors|O
DDI-DrugBank.d143.s9|86-90|known|O
DDI-DrugBank.d143.s9|71-77|inhibit|O
DDI-DrugBank.d143.s9|103-108|CYP3A4|O
DDI-DrugBank.d143.s9|113-119|varying|O
DDI-DrugBank.d143.s9|121-127|degrees|O
DDI-DrugBank.d143.s9|128-128|.|O
DDI-DrugBank.d143.s10|0-0|A|O
DDI-DrugBank.d143.s10|2-5|case|O
DDI-DrugBank.d143.s10|7-12|report|O
DDI-DrugBank.d143.s10|17-19|one|O
DDI-DrugBank.d143.s10|21-27|patient|O
DDI-DrugBank.d143.s10|29-34|taking|O
DDI-DrugBank.d143.s10|36-45|amiodarone|O
DDI-DrugBank.d143.s10|47-49|200|O
DDI-DrugBank.d143.s10|51-52|mg|O
DDI-DrugBank.d143.s10|58-66|indinavir|O
DDI-DrugBank.d143.s10|68-70|800|O
DDI-DrugBank.d143.s10|51-52|mg|O
DDI-DrugBank.d143.s10|75-79|three|O
DDI-DrugBank.d143.s10|81-85|times|O
DDI-DrugBank.d143.s10|89-91|day|O
DDI-DrugBank.d143.s10|93-100|resulted|O
DDI-DrugBank.d143.s10|105-113|increases|O
DDI-DrugBank.d143.s10|36-45|amiodarone|O
DDI-DrugBank.d143.s10|129-142|concentrations|O
DDI-DrugBank.d143.s10|149-151|0.9|O
DDI-DrugBank.d143.s10|153-156|mg/L|O
DDI-DrugBank.d143.s10|161-163|1.3|O
DDI-DrugBank.d143.s10|153-156|mg/L|O
DDI-DrugBank.d143.s10|150-150|.|O
DDI-DrugBank.d143.s11|0-2|DEA|O
DDI-DrugBank.d143.s11|4-17|concentrations|O
DDI-DrugBank.d143.s11|28-35|affected|O
DDI-DrugBank.d143.s11|36-36|.|O
DDI-DrugBank.d143.s12|0-4|There|O
DDI-DrugBank.d143.s12|13-20|evidence|O
DDI-DrugBank.d143.s12|25-32|toxicity|O
DDI-DrugBank.d143.s12|33-33|.|O
DDI-DrugBank.d143.s13|0-9|Monitoring|O
DDI-DrugBank.d143.s13|15-24|amiodarone|O
DDI-DrugBank.d143.s13|26-33|toxicity|O
DDI-DrugBank.d143.s13|39-44|serial|O
DDI-DrugBank.d143.s13|46-56|measurement|O
DDI-DrugBank.d143.s13|15-24|amiodarone|O
DDI-DrugBank.d143.s13|72-76|serum|O
DDI-DrugBank.d143.s13|78-90|concentration|O
DDI-DrugBank.d143.s13|99-109|concomitant|O
DDI-DrugBank.d143.s13|111-118|protease|O
DDI-DrugBank.d143.s13|120-128|inhibitor|O
DDI-DrugBank.d143.s13|130-136|therapy|O
DDI-DrugBank.d143.s13|148-157|considered|O
DDI-DrugBank.d143.s13|158-158|.|O
DDI-DrugBank.d143.s14|0-8|Histamine|O
DDI-DrugBank.d143.s14|10-11|H2|O
DDI-DrugBank.d143.s14|13-23|antagonists|O
DDI-DrugBank.d143.s14|26-35|Cimetidine|O
DDI-DrugBank.d143.s14|37-44|inhibits|O
DDI-DrugBank.d143.s14|46-51|CYP3A4|O
DDI-DrugBank.d143.s14|61-68|increase|O
DDI-DrugBank.d143.s14|70-74|serum|O
DDI-DrugBank.d143.s14|76-85|amiodarone|O
DDI-DrugBank.d143.s14|87-92|levels|O
DDI-DrugBank.d143.s14|93-93|.|O
DDI-DrugBank.d143.s15|0-4|Other|O
DDI-DrugBank.d143.s15|6-15|substances|O
DDI-DrugBank.d143.s15|18-27|Grapefruit|O
DDI-DrugBank.d143.s15|29-33|juice|O
DDI-DrugBank.d143.s15|35-39|given|O
DDI-DrugBank.d143.s15|44-50|healthy|O
DDI-DrugBank.d143.s15|52-61|volunteers|O
DDI-DrugBank.d143.s15|63-71|increased|O
DDI-DrugBank.d143.s15|73-82|amiodarone|O
DDI-DrugBank.d143.s15|84-86|AUC|O
DDI-DrugBank.d143.s15|91-92|50|O
DDI-DrugBank.d143.s15|93-93|%|O
DDI-DrugBank.d143.s15|99-102|Cmax|O
DDI-DrugBank.d143.s15|107-108|84|O
DDI-DrugBank.d143.s15|93-93|%|O
DDI-DrugBank.d143.s15|112-120|resulting|O
DDI-DrugBank.d143.s15|63-71|increased|O
DDI-DrugBank.d143.s15|135-140|plasma|O
DDI-DrugBank.d143.s15|142-147|levels|O
DDI-DrugBank.d143.s15|73-82|amiodarone|O
DDI-DrugBank.d143.s15|162-162|.|O
DDI-DrugBank.d143.s16|0-9|Grapefruit|O
DDI-DrugBank.d143.s16|11-15|juice|O
DDI-DrugBank.d143.s16|31-35|taken|O
DDI-DrugBank.d143.s16|44-52|treatment|O
DDI-DrugBank.d143.s16|59-62|oral|O
DDI-DrugBank.d143.s16|64-73|amiodarone|O
DDI-DrugBank.d143.s16|74-74|.|O
DDI-DrugBank.d143.s17|0-3|This|O
DDI-DrugBank.d143.s17|5-15|information|O
DDI-DrugBank.d143.s17|27-36|considered|O
DDI-DrugBank.d143.s17|43-50|changing|O
DDI-DrugBank.d143.s17|57-67|intravenous|O
DDI-DrugBank.d143.s17|69-78|amiodarone|O
DDI-DrugBank.d143.s17|83-86|oral|O
DDI-DrugBank.d143.s17|69-78|amiodarone|O
DDI-DrugBank.d143.s17|99-99|.|O
DDI-DrugBank.d143.s18|0-9|Amiodarone|O
DDI-DrugBank.d143.s18|11-13|may|O
DDI-DrugBank.d143.s18|15-22|suppress|O
DDI-DrugBank.d143.s18|24-30|certain|O
DDI-DrugBank.d143.s18|32-37|CYP450|O
DDI-DrugBank.d143.s18|39-45|enzymes|O
DDI-DrugBank.d143.s18|48-56|including|O
DDI-DrugBank.d143.s18|58-63|CYP1A2|O
DDI-DrugBank.d143.s18|66-71|CYP2C9|O
DDI-DrugBank.d143.s18|74-79|CYP2D6|O
DDI-DrugBank.d143.s18|86-91|CYP3A4|O
DDI-DrugBank.d143.s18|92-92|.|O
DDI-DrugBank.d143.s19|0-3|This|O
DDI-DrugBank.d143.s19|5-14|inhibition|O
DDI-DrugBank.d143.s19|20-25|result|O
DDI-DrugBank.d143.s19|30-41|unexpectedly|O
DDI-DrugBank.d143.s19|43-46|high|O
DDI-DrugBank.d143.s19|48-53|plasma|O
DDI-DrugBank.d143.s19|55-60|levels|O
DDI-DrugBank.d143.s19|71-75|drugs|O
DDI-DrugBank.d143.s19|87-97|metabolized|O
DDI-DrugBank.d143.s19|108-113|CYP450|O
DDI-DrugBank.d143.s19|115-121|enzymes|O
DDI-DrugBank.d143.s19|122-122|.|O
DDI-DrugBank.d143.s20|0-7|Reported|O
DDI-DrugBank.d143.s20|9-16|examples|O
DDI-DrugBank.d143.s20|26-36|interaction|O
DDI-DrugBank.d143.s20|38-44|include|O
DDI-DrugBank.d143.s20|50-58|following|O
DDI-DrugBank.d143.s20|61-78|Immunosuppressives|O
DDI-DrugBank.d143.s20|81-92|Cyclosporine|O
DDI-DrugBank.d143.s20|95-100|CYP3A4|O
DDI-DrugBank.d143.s20|102-110|substrate|O
DDI-DrugBank.d143.s20|113-124|administered|O
DDI-DrugBank.d143.s20|129-139|combination|O
DDI-DrugBank.d143.s20|146-149|oral|O
DDI-DrugBank.d143.s20|151-160|amiodarone|O
DDI-DrugBank.d143.s20|171-178|reported|O
DDI-DrugBank.d143.s20|183-189|produce|O
DDI-DrugBank.d143.s20|191-202|persistently|O
DDI-DrugBank.d143.s20|204-211|elevated|O
DDI-DrugBank.d143.s20|213-218|plasma|O
DDI-DrugBank.d143.s20|220-233|concentrations|O
DDI-DrugBank.d143.s20|238-249|cyclosporine|O
DDI-DrugBank.d143.s20|251-259|resulting|O
DDI-DrugBank.d143.s20|204-211|elevated|O
DDI-DrugBank.d143.s20|273-282|creatinine|O
DDI-DrugBank.d143.s20|285-291|despite|O
DDI-DrugBank.d143.s20|293-301|reduction|O
DDI-DrugBank.d143.s20|306-309|dose|O
DDI-DrugBank.d143.s20|238-249|cyclosporine|O
DDI-DrugBank.d143.s20|326-326|.|O
DDI-DrugBank.d143.s21|0-6|HMG-CoA|O
DDI-DrugBank.d143.s21|8-16|Reductase|O
DDI-DrugBank.d143.s21|18-27|Inhibitors|O
DDI-DrugBank.d143.s21|30-40|Simvastatin|O
DDI-DrugBank.d143.s21|43-48|CYP3A4|O
DDI-DrugBank.d143.s21|50-58|substrate|O
DDI-DrugBank.d143.s21|64-74|combination|O
DDI-DrugBank.d143.s21|81-90|amiodarone|O
DDI-DrugBank.d143.s21|101-110|associated|O
DDI-DrugBank.d143.s21|117-123|reports|O
DDI-DrugBank.d143.s21|128-150|myopathy/rhabdomyolysis|O
DDI-DrugBank.d143.s21|151-151|.|O
DDI-DrugBank.d143.s22|0-14|Cardiovasculars|O
DDI-DrugBank.d143.s22|17-23|Cardiac|O
DDI-DrugBank.d143.s22|25-34|glycosides|O
DDI-DrugBank.d143.s22|37-38|In|O
DDI-DrugBank.d143.s22|40-47|patients|O
DDI-DrugBank.d143.s22|49-57|receiving|O
DDI-DrugBank.d143.s22|59-65|digoxin|O
DDI-DrugBank.d143.s22|67-73|therapy|O
DDI-DrugBank.d143.s22|76-89|administration|O
DDI-DrugBank.d143.s22|94-97|oral|O
DDI-DrugBank.d143.s22|99-108|amiodarone|O
DDI-DrugBank.d143.s22|110-118|regularly|O
DDI-DrugBank.d143.s22|120-126|results|O
DDI-DrugBank.d143.s22|134-141|increase|O
DDI-DrugBank.d143.s22|146-150|serum|O
DDI-DrugBank.d143.s22|59-65|digoxin|O
DDI-DrugBank.d143.s22|160-172|concentration|O
DDI-DrugBank.d143.s22|179-181|may|O
DDI-DrugBank.d143.s22|183-187|reach|O
DDI-DrugBank.d143.s22|189-193|toxic|O
DDI-DrugBank.d143.s22|195-200|levels|O
DDI-DrugBank.d143.s22|207-215|resultant|O
DDI-DrugBank.d143.s22|217-224|clinical|O
DDI-DrugBank.d143.s22|226-233|toxicity|O
DDI-DrugBank.d143.s22|234-234|.|O
DDI-DrugBank.d143.s23|0-9|Amiodarone|O
DDI-DrugBank.d143.s23|11-15|taken|O
DDI-DrugBank.d143.s23|17-29|concomitantly|O
DDI-DrugBank.d143.s23|36-42|digoxin|O
DDI-DrugBank.d143.s23|44-52|increases|O
DDI-DrugBank.d143.s23|58-62|serum|O
DDI-DrugBank.d143.s23|36-42|digoxin|O
DDI-DrugBank.d143.s23|72-84|concentration|O
DDI-DrugBank.d143.s23|89-90|70|O
DDI-DrugBank.d143.s23|91-91|%|O
DDI-DrugBank.d143.s23|7-9|one|O
DDI-DrugBank.d143.s23|103-105|day|O
DDI-DrugBank.d143.s23|106-106|.|O
DDI-DrugBank.d143.s24|0-1|On|O
DDI-DrugBank.d143.s24|3-16|administration|O
DDI-DrugBank.d143.s24|21-24|oral|O
DDI-DrugBank.d143.s24|26-35|amiodarone|O
DDI-DrugBank.d143.s24|42-45|need|O
DDI-DrugBank.d143.s24|51-59|digitalis|O
DDI-DrugBank.d143.s24|61-67|therapy|O
DDI-DrugBank.d143.s24|79-86|reviewed|O
DDI-DrugBank.d143.s24|96-99|dose|O
DDI-DrugBank.d143.s24|101-107|reduced|O
DDI-DrugBank.d143.s24|112-124|approximately|O
DDI-DrugBank.d143.s24|126-127|50|O
DDI-DrugBank.d143.s24|128-128|%|O
DDI-DrugBank.d143.s24|133-144|discontinued|O
DDI-DrugBank.d143.s24|145-145|.|O
DDI-DrugBank.d143.s25|0-1|If|O
DDI-DrugBank.d143.s25|3-11|digitalis|O
DDI-DrugBank.d143.s25|13-21|treatment|O
DDI-DrugBank.d143.s25|26-34|continued|O
DDI-DrugBank.d143.s25|37-41|serum|O
DDI-DrugBank.d143.s25|43-48|levels|O
DDI-DrugBank.d143.s25|60-66|closely|O
DDI-DrugBank.d143.s25|68-76|monitored|O
DDI-DrugBank.d143.s25|82-89|patients|O
DDI-DrugBank.d143.s25|91-98|observed|O
DDI-DrugBank.d143.s25|104-111|clinical|O
DDI-DrugBank.d143.s25|113-120|evidence|O
DDI-DrugBank.d143.s25|125-132|toxicity|O
DDI-DrugBank.d143.s25|133-133|.|O
DDI-DrugBank.d143.s26|0-4|These|O
DDI-DrugBank.d143.s26|6-16|precautions|O
DDI-DrugBank.d143.s26|18-25|probably|O
DDI-DrugBank.d143.s26|34-38|apply|O
DDI-DrugBank.d143.s26|43-51|digitoxin|O
DDI-DrugBank.d143.s26|53-66|administration|O
DDI-DrugBank.d143.s26|71-74|well|O
DDI-DrugBank.d143.s26|75-75|.|O
DDI-DrugBank.d143.s27|0-14|Antiarrhythmics|O
DDI-DrugBank.d143.s27|17-21|Other|O
DDI-DrugBank.d143.s27|23-36|antiarrhythmic|O
DDI-DrugBank.d143.s27|38-42|drugs|O
DDI-DrugBank.d143.s27|53-61|quinidine|O
DDI-DrugBank.d143.s27|64-75|procainamide|O
DDI-DrugBank.d143.s27|78-89|disopyramide|O
DDI-DrugBank.d143.s27|96-104|phenytoin|O
DDI-DrugBank.d143.s27|117-120|used|O
DDI-DrugBank.d143.s27|122-133|concurrently|O
DDI-DrugBank.d143.s27|140-149|amiodarone|O
DDI-DrugBank.d143.s27|150-150|.|O
DDI-DrugBank.d143.s28|0-4|There|O
DDI-DrugBank.d143.s28|16-19|case|O
DDI-DrugBank.d143.s28|21-27|reports|O
DDI-DrugBank.d143.s28|32-40|increased|O
DDI-DrugBank.d143.s28|42-53|steady-state|O
DDI-DrugBank.d143.s28|55-60|levels|O
DDI-DrugBank.d143.s28|65-73|quinidine|O
DDI-DrugBank.d143.s28|76-87|procainamide|O
DDI-DrugBank.d143.s28|94-102|phenytoin|O
DDI-DrugBank.d143.s28|111-121|concomitant|O
DDI-DrugBank.d143.s28|123-129|therapy|O
DDI-DrugBank.d143.s28|136-145|amiodarone|O
DDI-DrugBank.d143.s28|146-146|.|O
DDI-DrugBank.d143.s29|0-8|Phenytoin|O
DDI-DrugBank.d143.s29|10-18|decreases|O
DDI-DrugBank.d143.s29|20-24|serum|O
DDI-DrugBank.d143.s29|26-35|amiodarone|O
DDI-DrugBank.d143.s29|37-42|levels|O
DDI-DrugBank.d143.s29|43-43|.|O
DDI-DrugBank.d143.s30|0-9|Amiodarone|O
DDI-DrugBank.d143.s30|11-15|taken|O
DDI-DrugBank.d143.s30|17-29|concomitantly|O
DDI-DrugBank.d143.s30|36-44|quinidine|O
DDI-DrugBank.d143.s30|46-54|increases|O
DDI-DrugBank.d143.s30|36-44|quinidine|O
DDI-DrugBank.d143.s30|66-70|serum|O
DDI-DrugBank.d143.s30|72-84|concentration|O
DDI-DrugBank.d143.s30|89-90|33|O
DDI-DrugBank.d143.s30|91-91|%|O
DDI-DrugBank.d143.s30|99-101|two|O
DDI-DrugBank.d143.s30|103-106|days|O
DDI-DrugBank.d143.s30|107-107|.|O
DDI-DrugBank.d143.s31|0-9|Amiodarone|O
DDI-DrugBank.d143.s31|11-15|taken|O
DDI-DrugBank.d143.s31|17-29|concomitantly|O
DDI-DrugBank.d143.s31|36-47|procainamide|O
DDI-DrugBank.d143.s31|53-56|less|O
DDI-DrugBank.d143.s31|63-67|seven|O
DDI-DrugBank.d143.s31|69-72|days|O
DDI-DrugBank.d143.s31|74-82|increases|O
DDI-DrugBank.d143.s31|84-89|plasma|O
DDI-DrugBank.d143.s31|91-104|concentrations|O
DDI-DrugBank.d143.s31|36-47|procainamide|O
DDI-DrugBank.d143.s31|126-133|n-acetyl|O
DDI-DrugBank.d143.s31|36-47|procainamide|O
DDI-DrugBank.d143.s31|151-152|55|O
DDI-DrugBank.d143.s31|153-153|%|O
DDI-DrugBank.d143.s31|159-160|33|O
DDI-DrugBank.d143.s31|153-153|%|O
DDI-DrugBank.d143.s31|164-175|respectively|O
DDI-DrugBank.d143.s31|176-176|.|O
DDI-DrugBank.d143.s32|0-8|Quinidine|O
DDI-DrugBank.d143.s32|14-25|procainamide|O
DDI-DrugBank.d143.s32|27-31|doses|O
DDI-DrugBank.d143.s32|43-49|reduced|O
DDI-DrugBank.d143.s32|54-62|one-third|O
DDI-DrugBank.d143.s32|69-74|either|O
DDI-DrugBank.d143.s32|79-90|administered|O
DDI-DrugBank.d143.s32|97-106|amiodarone|O
DDI-DrugBank.d143.s32|107-107|.|O
DDI-DrugBank.d143.s33|0-5|Plasma|O
DDI-DrugBank.d143.s33|7-12|levels|O
DDI-DrugBank.d143.s33|17-26|flecainide|O
DDI-DrugBank.d143.s33|38-45|reported|O
DDI-DrugBank.d143.s33|50-57|increase|O
DDI-DrugBank.d143.s33|66-73|presence|O
DDI-DrugBank.d143.s33|78-81|oral|O
DDI-DrugBank.d143.s33|83-92|amiodarone|O
DDI-DrugBank.d143.s34|21-26|dosage|O
DDI-DrugBank.d143.s34|31-40|flecainide|O
DDI-DrugBank.d143.s34|52-59|adjusted|O
DDI-DrugBank.d143.s34|72-76|drugs|O
DDI-DrugBank.d143.s34|82-93|administered|O
DDI-DrugBank.d143.s34|95-107|concomitantly|O
DDI-DrugBank.d143.s34|108-108|.|O
DDI-DrugBank.d143.s35|0-1|In|O
DDI-DrugBank.d143.s35|3-9|general|O
DDI-DrugBank.d143.s35|16-20|added|O
DDI-DrugBank.d143.s35|22-35|antiarrhythmic|O
DDI-DrugBank.d143.s35|37-40|drug|O
DDI-DrugBank.d143.s35|52-60|initiated|O
DDI-DrugBank.d143.s35|67-71|lower|O
DDI-DrugBank.d143.s35|78-82|usual|O
DDI-DrugBank.d143.s35|84-87|dose|O
DDI-DrugBank.d143.s35|94-100|careful|O
DDI-DrugBank.d143.s35|102-111|monitoring|O
DDI-DrugBank.d143.s35|112-112|.|O
DDI-DrugBank.d143.s36|0-10|Combination|O
DDI-DrugBank.d143.s36|15-24|amiodarone|O
DDI-DrugBank.d143.s36|37-50|antiarrhythmic|O
DDI-DrugBank.d143.s36|52-58|therapy|O
DDI-DrugBank.d143.s36|70-77|reserved|O
DDI-DrugBank.d143.s36|83-90|patients|O
DDI-DrugBank.d143.s36|97-112|life-threatening|O
DDI-DrugBank.d143.s36|114-124|ventricular|O
DDI-DrugBank.d143.s36|126-136|arrhythmias|O
DDI-DrugBank.d143.s36|146-157|incompletely|O
DDI-DrugBank.d143.s36|159-168|responsive|O
DDI-DrugBank.d143.s36|175-180|single|O
DDI-DrugBank.d143.s36|182-186|agent|O
DDI-DrugBank.d143.s36|146-157|incompletely|O
DDI-DrugBank.d143.s36|159-168|responsive|O
DDI-DrugBank.d143.s36|15-24|amiodarone|O
DDI-DrugBank.d143.s36|228-228|.|O
DDI-DrugBank.d143.s37|0-5|During|O
DDI-DrugBank.d143.s37|7-14|transfer|O
DDI-DrugBank.d143.s37|19-22|oral|O
DDI-DrugBank.d143.s37|24-33|amiodarone|O
DDI-DrugBank.d143.s37|40-43|dose|O
DDI-DrugBank.d143.s37|45-50|levels|O
DDI-DrugBank.d143.s37|55-64|previously|O
DDI-DrugBank.d143.s37|66-77|administered|O
DDI-DrugBank.d143.s37|79-84|agents|O
DDI-DrugBank.d143.s37|96-102|reduced|O
DDI-DrugBank.d143.s37|107-108|30|O
DDI-DrugBank.d143.s37|113-114|50|O
DDI-DrugBank.d143.s37|115-115|%|O
DDI-DrugBank.d143.s37|117-123|several|O
DDI-DrugBank.d143.s37|125-128|days|O
DDI-DrugBank.d143.s37|140-147|addition|O
DDI-DrugBank.d143.s37|19-22|oral|O
DDI-DrugBank.d143.s37|24-33|amiodarone|O
DDI-DrugBank.d143.s37|167-167|.|O
DDI-DrugBank.d143.s38|0-2|The|O
DDI-DrugBank.d143.s38|4-12|continued|O
DDI-DrugBank.d143.s38|14-17|need|O
DDI-DrugBank.d143.s38|33-46|antiarrhythmic|O
DDI-DrugBank.d143.s38|48-52|agent|O
DDI-DrugBank.d143.s38|64-71|reviewed|O
DDI-DrugBank.d143.s38|83-89|effects|O
DDI-DrugBank.d143.s38|94-103|amiodarone|O
DDI-DrugBank.d143.s38|115-125|established|O
DDI-DrugBank.d143.s38|132-146|discontinuation|O
DDI-DrugBank.d143.s38|148-157|ordinarily|O
DDI-DrugBank.d143.s38|169-177|attempted|O
DDI-DrugBank.d143.s39|0-1|If|O
DDI-DrugBank.d143.s39|7-15|treatment|O
DDI-DrugBank.d143.s39|20-28|continued|O
DDI-DrugBank.d143.s39|37-44|patients|O
DDI-DrugBank.d143.s39|56-67|particularly|O
DDI-DrugBank.d143.s39|69-77|carefully|O
DDI-DrugBank.d143.s39|79-87|monitored|O
DDI-DrugBank.d143.s39|93-99|adverse|O
DDI-DrugBank.d143.s39|101-107|effects|O
DDI-DrugBank.d143.s39|110-119|especially|O
DDI-DrugBank.d143.s39|121-130|conduction|O
DDI-DrugBank.d143.s39|132-143|disturbances|O
DDI-DrugBank.d143.s39|149-160|exacerbation|O
DDI-DrugBank.d143.s39|165-180|tachyarrhythmias|O
DDI-DrugBank.d143.s39|186-195|amiodarone|O
DDI-DrugBank.d143.s39|20-28|continued|O
DDI-DrugBank.d143.s39|209-209|.|O
DDI-DrugBank.d143.s40|0-1|In|O
DDI-DrugBank.d143.s40|3-20|amiodarone-treated|O
DDI-DrugBank.d143.s40|22-29|patients|O
DDI-DrugBank.d143.s40|35-41|require|O
DDI-DrugBank.d143.s40|43-52|additional|O
DDI-DrugBank.d143.s40|54-67|antiarrhythmic|O
DDI-DrugBank.d143.s40|69-75|therapy|O
DDI-DrugBank.d143.s40|82-88|initial|O
DDI-DrugBank.d143.s40|90-93|dose|O
DDI-DrugBank.d143.s40|103-108|agents|O
DDI-DrugBank.d143.s40|120-132|approximately|O
DDI-DrugBank.d143.s40|134-137|half|O
DDI-DrugBank.d143.s40|146-150|usual|O
DDI-DrugBank.d143.s40|152-162|recommended|O
DDI-DrugBank.d143.s40|90-93|dose|O
DDI-DrugBank.d143.s40|168-168|.|O
DDI-DrugBank.d143.s41|0-16|Antihypertensives|O
DDI-DrugBank.d143.s41|19-28|Amiodarone|O
DDI-DrugBank.d143.s41|40-43|used|O
DDI-DrugBank.d143.s41|50-56|caution|O
DDI-DrugBank.d143.s41|61-68|patients|O
DDI-DrugBank.d143.s41|70-78|receiving|O
DDI-DrugBank.d143.s41|81-89|-receptor|O
DDI-DrugBank.d143.s41|91-98|blocking|O
DDI-DrugBank.d143.s41|100-105|agents|O
DDI-DrugBank.d143.s41|108-111|e.g.|O
DDI-DrugBank.d143.s41|114-124|propranolol|O
DDI-DrugBank.d143.s41|129-134|CYP3A4|O
DDI-DrugBank.d143.s41|136-144|inhibitor|O
DDI-DrugBank.d143.s41|150-156|calcium|O
DDI-DrugBank.d143.s41|158-164|channel|O
DDI-DrugBank.d143.s41|166-176|antagonists|O
DDI-DrugBank.d143.s41|108-111|e.g.|O
DDI-DrugBank.d143.s41|185-193|verapamil|O
DDI-DrugBank.d143.s41|129-134|CYP3A4|O
DDI-DrugBank.d143.s41|205-213|substrate|O
DDI-DrugBank.d143.s41|220-228|diltiazem|O
DDI-DrugBank.d143.s41|129-134|CYP3A4|O
DDI-DrugBank.d143.s41|136-144|inhibitor|O
DDI-DrugBank.d143.s41|266-273|possible|O
DDI-DrugBank.d143.s41|275-286|potentiation|O
DDI-DrugBank.d143.s41|291-301|bradycardia|O
DDI-DrugBank.d143.s41|304-308|sinus|O
DDI-DrugBank.d143.s41|310-315|arrest|O
DDI-DrugBank.d143.s41|322-323|AV|O
DDI-DrugBank.d143.s41|91-95|block|O
DDI-DrugBank.d143.s42|3-11|necessary|O
DDI-DrugBank.d143.s42|14-23|amiodarone|O
DDI-DrugBank.d143.s42|29-36|continue|O
DDI-DrugBank.d143.s42|44-47|used|O
DDI-DrugBank.d143.s42|55-63|insertion|O
DDI-DrugBank.d143.s42|70-78|pacemaker|O
DDI-DrugBank.d143.s42|83-90|patients|O
DDI-DrugBank.d143.s42|97-102|severe|O
DDI-DrugBank.d143.s42|104-114|bradycardia|O
DDI-DrugBank.d143.s42|119-123|sinus|O
DDI-DrugBank.d143.s42|125-130|arrest|O
DDI-DrugBank.d143.s42|131-131|.|O
DDI-DrugBank.d143.s43|0-13|Anticoagulants|O
DDI-DrugBank.d143.s43|16-27|Potentiation|O
DDI-DrugBank.d143.s43|32-44|warfarin-type|O
DDI-DrugBank.d143.s43|47-52|CYP2C9|O
DDI-DrugBank.d143.s43|58-63|CYP3A4|O
DDI-DrugBank.d143.s43|65-73|substrate|O
DDI-DrugBank.d143.s43|76-88|anticoagulant|O
DDI-DrugBank.d143.s43|90-97|response|O
DDI-DrugBank.d143.s43|102-107|almost|O
DDI-DrugBank.d143.s43|109-114|always|O
DDI-DrugBank.d143.s43|116-119|seen|O
DDI-DrugBank.d143.s43|124-131|patients|O
DDI-DrugBank.d143.s43|133-141|receiving|O
DDI-DrugBank.d143.s43|143-152|amiodarone|O
DDI-DrugBank.d143.s43|162-167|result|O
DDI-DrugBank.d143.s43|172-178|serious|O
DDI-DrugBank.d143.s43|183-187|fatal|O
DDI-DrugBank.d143.s43|189-196|bleeding|O
DDI-DrugBank.d143.s43|197-197|.|O
DDI-DrugBank.d143.s44|0-4|Since|O
DDI-DrugBank.d143.s44|10-20|concomitant|O
DDI-DrugBank.d143.s44|22-35|administration|O
DDI-DrugBank.d143.s44|40-47|warfarin|O
DDI-DrugBank.d143.s44|54-63|amiodarone|O
DDI-DrugBank.d143.s44|65-73|increases|O
DDI-DrugBank.d143.s44|79-89|prothrombin|O
DDI-DrugBank.d143.s44|91-94|time|O
DDI-DrugBank.d143.s44|99-101|100|O
DDI-DrugBank.d143.s44|102-102|%|O
DDI-DrugBank.d143.s44|110-110|3|O
DDI-DrugBank.d143.s44|115-115|4|O
DDI-DrugBank.d143.s44|117-120|days|O
DDI-DrugBank.d143.s44|127-130|dose|O
DDI-DrugBank.d143.s44|139-151|anticoagulant|O
DDI-DrugBank.d143.s44|163-169|reduced|O
DDI-DrugBank.d143.s44|174-182|one-third|O
DDI-DrugBank.d143.s44|187-194|one-half|O
DDI-DrugBank.d143.s44|79-89|prothrombin|O
DDI-DrugBank.d143.s44|213-217|times|O
DDI-DrugBank.d143.s44|229-237|monitored|O
DDI-DrugBank.d143.s44|239-245|closely|O
DDI-DrugBank.d143.s44|246-246|.|O
DDI-DrugBank.d143.s45|0-3|Some|O
DDI-DrugBank.d143.s45|5-20|drugs/substances|O
DDI-DrugBank.d143.s45|26-30|known|O
DDI-DrugBank.d143.s45|35-44|accelerate|O
DDI-DrugBank.d143.s45|50-59|metabolism|O
DDI-DrugBank.d143.s45|64-73|amiodarone|O
DDI-DrugBank.d143.s45|78-88|stimulating|O
DDI-DrugBank.d143.s45|94-102|synthesis|O
DDI-DrugBank.d143.s45|107-112|CYP3A4|O
DDI-DrugBank.d143.s45|115-120|enzyme|O
DDI-DrugBank.d143.s45|122-130|induction|O
DDI-DrugBank.d143.s45|132-132|.|O
DDI-DrugBank.d143.s46|0-3|This|O
DDI-DrugBank.d143.s46|5-7|may|O
DDI-DrugBank.d143.s46|9-12|lead|O
DDI-DrugBank.d143.s46|17-19|low|O
DDI-DrugBank.d143.s46|21-30|amiodarone|O
DDI-DrugBank.d143.s46|32-36|serum|O
DDI-DrugBank.d143.s46|38-43|levels|O
DDI-DrugBank.d143.s46|49-57|potential|O
DDI-DrugBank.d143.s46|59-66|decrease|O
DDI-DrugBank.d143.s46|71-78|efficacy|O
DDI-DrugBank.d143.s46|79-79|.|O
DDI-DrugBank.d143.s47|0-7|Reported|O
DDI-DrugBank.d143.s47|9-16|examples|O
DDI-DrugBank.d143.s47|26-36|interaction|O
DDI-DrugBank.d143.s47|38-44|include|O
DDI-DrugBank.d143.s47|50-58|following|O
DDI-DrugBank.d143.s47|61-71|Antibiotics|O
DDI-DrugBank.d143.s47|74-81|Rifampin|O
DDI-DrugBank.d143.s47|88-93|potent|O
DDI-DrugBank.d143.s47|95-101|inducer|O
DDI-DrugBank.d143.s47|106-111|CYP3A4|O
DDI-DrugBank.d143.s47|112-112|.|O
DDI-DrugBank.d143.s48|0-13|Administration|O
DDI-DrugBank.d143.s48|18-25|rifampin|O
DDI-DrugBank.d143.s48|27-39|concomitantly|O
DDI-DrugBank.d143.s48|46-49|oral|O
DDI-DrugBank.d143.s48|51-60|amiodarone|O
DDI-DrugBank.d143.s48|71-75|shown|O
DDI-DrugBank.d143.s48|80-85|result|O
DDI-DrugBank.d143.s48|90-98|decreases|O
DDI-DrugBank.d143.s48|103-107|serum|O
DDI-DrugBank.d143.s48|109-122|concentrations|O
DDI-DrugBank.d143.s48|51-60|amiodarone|O
DDI-DrugBank.d143.s48|142-159|desethylamiodarone|O
DDI-DrugBank.d143.s48|160-160|.|O
DDI-DrugBank.d143.s49|0-4|Other|O
DDI-DrugBank.d143.s49|6-15|substances|O
DDI-DrugBank.d143.s49|18-26|including|O
DDI-DrugBank.d143.s49|28-33|herbal|O
DDI-DrugBank.d143.s49|35-46|preparations|O
DDI-DrugBank.d143.s49|49-51|St.|O
DDI-DrugBank.d143.s49|53-56|John|O
DDI-DrugBank.d143.s49|60-63|Wort|O
DDI-DrugBank.d143.s49|66-74|Hypericum|O
DDI-DrugBank.d143.s49|76-85|perforatum|O
DDI-DrugBank.d143.s49|88-94|induces|O
DDI-DrugBank.d143.s49|96-101|CYP3A4|O
DDI-DrugBank.d143.s49|51-51|.|O
DDI-DrugBank.d143.s50|0-4|Since|O
DDI-DrugBank.d143.s50|6-15|amiodarone|O
DDI-DrugBank.d143.s50|22-30|substrate|O
DDI-DrugBank.d143.s50|36-41|CYP3A4|O
DDI-DrugBank.d143.s50|57-65|potential|O
DDI-DrugBank.d143.s50|76-78|use|O
DDI-DrugBank.d143.s50|83-85|St.|O
DDI-DrugBank.d143.s50|87-90|John|O
DDI-DrugBank.d143.s50|94-97|Wort|O
DDI-DrugBank.d143.s50|102-109|patients|O
DDI-DrugBank.d143.s50|111-119|receiving|O
DDI-DrugBank.d143.s50|6-15|amiodarone|O
DDI-DrugBank.d143.s50|132-136|could|O
DDI-DrugBank.d143.s50|138-143|result|O
DDI-DrugBank.d143.s50|148-154|reduced|O
DDI-DrugBank.d143.s50|6-15|amiodarone|O
DDI-DrugBank.d143.s50|167-172|levels|O
DDI-DrugBank.d143.s50|85-85|.|O
DDI-DrugBank.d143.s51|0-4|Other|O
DDI-DrugBank.d143.s51|6-13|reported|O
DDI-DrugBank.d143.s51|15-26|interactions|O
DDI-DrugBank.d143.s51|33-42|amiodarone|O
DDI-DrugBank.d143.s51|45-52|Fentanyl|O
DDI-DrugBank.d143.s51|55-60|CYP3A4|O
DDI-DrugBank.d143.s51|62-70|substrate|O
DDI-DrugBank.d143.s51|76-86|combination|O
DDI-DrugBank.d143.s51|33-42|amiodarone|O
DDI-DrugBank.d143.s51|104-106|may|O
DDI-DrugBank.d143.s51|108-112|cause|O
DDI-DrugBank.d143.s51|114-124|hypotension|O
DDI-DrugBank.d143.s51|127-137|bradycardia|O
DDI-DrugBank.d143.s51|144-152|decreased|O
DDI-DrugBank.d143.s51|154-160|cardiac|O
DDI-DrugBank.d143.s51|162-167|output|O
DDI-DrugBank.d143.s51|168-168|.|O
DDI-DrugBank.d143.s52|0-4|Sinus|O
DDI-DrugBank.d143.s52|6-16|bradycardia|O
DDI-DrugBank.d143.s52|27-34|reported|O
DDI-DrugBank.d143.s52|41-44|oral|O
DDI-DrugBank.d143.s52|46-55|amiodarone|O
DDI-DrugBank.d143.s52|60-70|combination|O
DDI-DrugBank.d143.s52|77-85|lidocaine|O
DDI-DrugBank.d143.s52|88-93|CYP3A4|O
DDI-DrugBank.d143.s52|95-103|substrate|O
DDI-DrugBank.d143.s52|106-110|given|O
DDI-DrugBank.d143.s52|116-120|local|O
DDI-DrugBank.d143.s52|122-131|anesthesia|O
DDI-DrugBank.d143.s52|132-132|.|O
DDI-DrugBank.d143.s53|0-6|Seizure|O
DDI-DrugBank.d143.s53|9-18|associated|O
DDI-DrugBank.d143.s53|25-33|increased|O
DDI-DrugBank.d143.s53|35-43|lidocaine|O
DDI-DrugBank.d143.s53|45-58|concentrations|O
DDI-DrugBank.d143.s53|70-77|reported|O
DDI-DrugBank.d143.s53|84-94|concomitant|O
DDI-DrugBank.d143.s53|96-109|administration|O
DDI-DrugBank.d143.s53|114-124|intravenous|O
DDI-DrugBank.d143.s53|126-135|amiodarone|O
DDI-DrugBank.d143.s53|136-136|.|O
DDI-DrugBank.d143.s54|0-15|Dextromethorphan|O
DDI-DrugBank.d143.s54|22-30|substrate|O
DDI-DrugBank.d143.s54|41-46|CYP2D6|O
DDI-DrugBank.d143.s54|52-57|CYP3A4|O
DDI-DrugBank.d143.s54|58-58|.|O
DDI-DrugBank.d143.s55|0-9|Amiodarone|O
DDI-DrugBank.d143.s55|11-18|inhibits|O
DDI-DrugBank.d143.s55|20-25|CYP2D6|O
DDI-DrugBank.d143.s55|26-26|.|O
DDI-DrugBank.d143.s56|0-13|Cholestyramine|O
DDI-DrugBank.d143.s56|15-23|increases|O
DDI-DrugBank.d143.s56|25-37|enterohepatic|O
DDI-DrugBank.d143.s56|39-49|elimination|O
DDI-DrugBank.d143.s56|54-63|amiodarone|O
DDI-DrugBank.d143.s56|69-71|may|O
DDI-DrugBank.d143.s56|73-78|reduce|O
DDI-DrugBank.d143.s56|84-88|serum|O
DDI-DrugBank.d143.s56|90-95|levels|O
DDI-DrugBank.d143.s56|101-104|t1/2|O
DDI-DrugBank.d143.s56|105-105|.|O
DDI-DrugBank.d143.s57|0-11|Disopyramide|O
DDI-DrugBank.d143.s57|13-21|increases|O
DDI-DrugBank.d143.s57|23-24|QT|O
DDI-DrugBank.d143.s57|26-37|prolongation|O
DDI-DrugBank.d143.s57|45-49|could|O
DDI-DrugBank.d143.s57|51-55|cause|O
DDI-DrugBank.d143.s57|57-66|arrhythmia|O
DDI-DrugBank.d143.s57|67-67|.|O
DDI-DrugBank.d143.s58|0-15|Fluoroquinolones|O
DDI-DrugBank.d143.s58|18-26|macrolide|O
DDI-DrugBank.d143.s58|28-38|antibiotics|O
DDI-DrugBank.d143.s58|45-50|azoles|O
DDI-DrugBank.d143.s58|56-60|known|O
DDI-DrugBank.d143.s58|65-69|cause|O
DDI-DrugBank.d143.s58|71-73|QTc|O
DDI-DrugBank.d143.s58|75-86|prolongation|O
DDI-DrugBank.d143.s58|87-87|.|O
DDI-DrugBank.d143.s59|0-4|There|O
DDI-DrugBank.d143.s59|16-22|reports|O
DDI-DrugBank.d143.s59|27-29|QTc|O
DDI-DrugBank.d143.s59|31-42|prolongation|O
DDI-DrugBank.d143.s59|53-59|without|O
DDI-DrugBank.d143.s59|61-63|TdP|O
DDI-DrugBank.d143.s59|69-76|patients|O
DDI-DrugBank.d143.s59|78-83|taking|O
DDI-DrugBank.d143.s59|85-94|amiodarone|O
DDI-DrugBank.d143.s59|101-116|fluoroquinolones|O
DDI-DrugBank.d143.s59|119-127|macrolide|O
DDI-DrugBank.d143.s59|129-139|antibiotics|O
DDI-DrugBank.d143.s59|145-150|azoles|O
DDI-DrugBank.d143.s59|157-168|administered|O
DDI-DrugBank.d143.s59|170-182|concomitantly|O
DDI-DrugBank.d143.s59|183-183|.|O
DDI-DrugBank.d143.s60|0-10|Hemodynamic|O
DDI-DrugBank.d143.s60|16-33|electrophysiologic|O
DDI-DrugBank.d143.s60|35-46|interactions|O
DDI-DrugBank.d143.s60|53-56|also|O
DDI-DrugBank.d143.s60|63-70|observed|O
DDI-DrugBank.d143.s60|78-88|concomitant|O
DDI-DrugBank.d143.s60|90-103|administration|O
DDI-DrugBank.d143.s60|110-120|propranolol|O
DDI-DrugBank.d143.s60|123-131|diltiazem|O
DDI-DrugBank.d143.s60|138-146|verapamil|O
DDI-DrugBank.d143.s60|147-147|.|O
DDI-DrugBank.d143.s61|0-7|Volatile|O
DDI-DrugBank.d143.s61|9-18|Anesthetic|O
DDI-DrugBank.d143.s61|20-25|Agents|O
DDI-DrugBank.d143.s61|27-27|.|O
DDI-DrugBank.d143.s62|0-1|In|O
DDI-DrugBank.d143.s62|3-10|addition|O
DDI-DrugBank.d143.s62|19-30|interactions|O
DDI-DrugBank.d143.s62|32-36|noted|O
DDI-DrugBank.d143.s62|45-51|chronic|O
DDI-DrugBank.d143.s62|56-56|2|O
DDI-DrugBank.d143.s62|58-62|weeks|O
DDI-DrugBank.d143.s62|65-68|oral|O
DDI-DrugBank.d143.s62|70-78|Cordarone|O
DDI-DrugBank.d143.s62|80-93|administration|O
DDI-DrugBank.d143.s62|95-101|impairs|O
DDI-DrugBank.d143.s62|103-112|metabolism|O
DDI-DrugBank.d143.s62|117-125|phenytoin|O
DDI-DrugBank.d143.s62|128-143|dextromethorphan|O
DDI-DrugBank.d143.s62|150-161|methotrexate|O
DDI-DrugBank.d143.s62|162-162|.|O
DDI-DrugBank.d143.s63|0-10|Electrolyte|O
DDI-DrugBank.d143.s63|12-23|Disturbances|O
DDI-DrugBank.d143.s63|25-32|Patients|O
DDI-DrugBank.d143.s63|39-49|hypokalemia|O
DDI-DrugBank.d143.s63|54-67|hypomagnesemia|O
DDI-DrugBank.d143.s63|85-93|condition|O
DDI-DrugBank.d143.s63|95-103|corrected|O
DDI-DrugBank.d143.s63|105-112|whenever|O
DDI-DrugBank.d143.s63|114-121|possible|O
DDI-DrugBank.d143.s63|136-142|treated|O
DDI-DrugBank.d143.s63|149-157|Cordarone|O
DDI-DrugBank.d143.s63|159-162|I.V.|O
DDI-DrugBank.d143.s63|174-182|disorders|O
DDI-DrugBank.d143.s63|188-197|exaggerate|O
DDI-DrugBank.d143.s63|203-208|degree|O
DDI-DrugBank.d143.s63|213-215|QTc|O
DDI-DrugBank.d143.s63|217-228|prolongation|O
DDI-DrugBank.d143.s63|234-241|increase|O
DDI-DrugBank.d143.s63|247-255|potential|O
DDI-DrugBank.d143.s63|261-263|TdP|O
DDI-DrugBank.d143.s63|160-160|.|O
DDI-DrugBank.d143.s64|0-6|Special|O
DDI-DrugBank.d143.s64|8-16|attention|O
DDI-DrugBank.d143.s64|28-32|given|O
DDI-DrugBank.d143.s64|37-47|electrolyte|O
DDI-DrugBank.d143.s64|53-61|acid-base|O
DDI-DrugBank.d143.s64|63-69|balance|O
DDI-DrugBank.d143.s64|74-81|patients|O
DDI-DrugBank.d143.s64|83-94|experiencing|O
DDI-DrugBank.d143.s64|96-101|severe|O
DDI-DrugBank.d143.s64|106-114|prolonged|O
DDI-DrugBank.d143.s64|116-123|diarrhea|O
DDI-DrugBank.d143.s64|74-81|patients|O
DDI-DrugBank.d143.s64|140-148|receiving|O
DDI-DrugBank.d143.s64|150-160|concomitant|O
DDI-DrugBank.d143.s64|162-170|diuretics|O
DDI-DrugBank.d143.s64|171-171|.|O
DDI-DrugBank.d665.s0|0-9|Concurrent|O
DDI-DrugBank.d665.s0|11-24|administration|O
DDI-DrugBank.d665.s0|29-42|bacteriostatic|O
DDI-DrugBank.d665.s0|44-54|antibiotics|O
DDI-DrugBank.d665.s0|57-60|e.g.|O
DDI-DrugBank.d665.s0|63-74|erythromycin|O
DDI-DrugBank.d665.s0|77-88|tetracycline|O
DDI-DrugBank.d665.s0|91-93|may|O
DDI-DrugBank.d665.s0|95-102|diminish|O
DDI-DrugBank.d665.s0|108-119|bactericidal|O
DDI-DrugBank.d665.s0|121-127|effects|O
DDI-DrugBank.d665.s0|132-142|penicillins|O
DDI-DrugBank.d665.s0|147-153|slowing|O
DDI-DrugBank.d665.s0|159-162|rate|O
DDI-DrugBank.d665.s0|167-175|bacterial|O
DDI-DrugBank.d665.s0|177-182|growth|O
DDI-DrugBank.d665.s0|58-58|.|O
DDI-DrugBank.d665.s1|0-11|Bactericidal|O
DDI-DrugBank.d665.s1|13-18|agents|O
DDI-DrugBank.d665.s1|20-23|work|O
DDI-DrugBank.d665.s1|30-40|effectively|O
DDI-DrugBank.d665.s1|54-61|immature|O
DDI-DrugBank.d665.s1|63-66|cell|O
DDI-DrugBank.d665.s1|68-71|wall|O
DDI-DrugBank.d665.s1|76-82|rapidly|O
DDI-DrugBank.d665.s1|84-96|proliferating|O
DDI-DrugBank.d665.s1|98-111|microorganisms|O
DDI-DrugBank.d665.s1|112-112|.|O
DDI-DrugBank.d665.s2|0-3|This|O
DDI-DrugBank.d665.s2|14-25|demonstrated|O
DDI-DrugBank.d665.s2|30-34|vitro|O
DDI-DrugBank.d665.s3|0-6|however|O
DDI-DrugBank.d665.s3|13-20|clinical|O
DDI-DrugBank.d665.s3|22-33|significance|O
DDI-DrugBank.d665.s3|43-53|interaction|O
DDI-DrugBank.d665.s3|62-65|well|O
DDI-DrugBank.d665.s3|67-76|documented|O
DDI-DrugBank.d665.s3|77-77|.|O
DDI-DrugBank.d665.s4|0-4|There|O
DDI-DrugBank.d665.s4|14-21|clinical|O
DDI-DrugBank.d665.s4|23-32|situations|O
DDI-DrugBank.d665.s4|47-56|concurrent|O
DDI-DrugBank.d665.s4|58-60|use|O
DDI-DrugBank.d665.s4|-1-0|``|O
DDI-DrugBank.d665.s4|67-72|static|O
DDI-DrugBank.d665.s4|65-66|''|O
DDI-DrugBank.d665.s4|-1-0|``|O
DDI-DrugBank.d665.s4|82-86|cidal|O
DDI-DrugBank.d665.s4|-1-0|``|O
DDI-DrugBank.d665.s4|91-101|antibiotics|O
DDI-DrugBank.d665.s4|107-115|indicated|O
DDI-DrugBank.d665.s5|0-6|However|O
DDI-DrugBank.d665.s5|12-19|selected|O
DDI-DrugBank.d665.s5|21-33|circumstances|O
DDI-DrugBank.d665.s5|49-55|therapy|O
DDI-DrugBank.d665.s5|60-70|appropriate|O
DDI-DrugBank.d665.s5|73-77|using|O
DDI-DrugBank.d665.s5|79-86|adequate|O
DDI-DrugBank.d665.s5|88-92|doses|O
DDI-DrugBank.d665.s5|97-109|antibacterial|O
DDI-DrugBank.d665.s5|111-116|agents|O
DDI-DrugBank.d665.s5|122-130|beginning|O
DDI-DrugBank.d665.s5|132-141|penicillin|O
DDI-DrugBank.d665.s5|49-55|therapy|O
DDI-DrugBank.d665.s5|151-155|first|O
DDI-DrugBank.d665.s5|165-172|minimize|O
DDI-DrugBank.d665.s5|178-186|potential|O
DDI-DrugBank.d665.s5|192-202|interaction|O
DDI-DrugBank.d665.s5|203-203|.|O
DDI-DrugBank.d665.s6|0-9|Penicillin|O
DDI-DrugBank.d665.s6|11-15|blood|O
DDI-DrugBank.d665.s6|17-22|levels|O
DDI-DrugBank.d665.s6|24-26|may|O
DDI-DrugBank.d665.s6|31-39|prolonged|O
DDI-DrugBank.d665.s6|44-53|concurrent|O
DDI-DrugBank.d665.s6|55-68|administration|O
DDI-DrugBank.d665.s6|73-82|probenecid|O
DDI-DrugBank.d665.s6|90-95|blocks|O
DDI-DrugBank.d665.s6|101-105|renal|O
DDI-DrugBank.d665.s6|107-113|tubular|O
DDI-DrugBank.d665.s6|115-123|secretion|O
DDI-DrugBank.d665.s6|128-138|penicillins|O
DDI-DrugBank.d665.s6|139-139|.|O
DDI-DrugBank.d665.s7|0-11|Displacement|O
DDI-DrugBank.d665.s7|16-25|penicillin|O
DDI-DrugBank.d665.s7|32-37|plasma|O
DDI-DrugBank.d665.s7|39-45|protein|O
DDI-DrugBank.d665.s7|47-53|binding|O
DDI-DrugBank.d665.s7|55-59|sites|O
DDI-DrugBank.d665.s7|66-72|elevate|O
DDI-DrugBank.d665.s7|78-82|level|O
DDI-DrugBank.d665.s7|87-90|free|O
DDI-DrugBank.d665.s7|16-25|penicillin|O
DDI-DrugBank.d665.s7|110-114|serum|O
DDI-DrugBank.d665.s7|115-115|.|O
DDI-DrugBank.d585.s0|0-2|The|O
DDI-DrugBank.d585.s0|4-12|following|O
DDI-DrugBank.d585.s0|14-19|agents|O
DDI-DrugBank.d585.s0|21-23|may|O
DDI-DrugBank.d585.s0|25-32|increase|O
DDI-DrugBank.d585.s0|34-40|certain|O
DDI-DrugBank.d585.s0|42-48|actions|O
DDI-DrugBank.d585.s0|53-56|side|O
DDI-DrugBank.d585.s0|58-64|effects|O
DDI-DrugBank.d585.s0|69-83|anticholinergic|O
DDI-DrugBank.d585.s0|85-89|drugs|O
DDI-DrugBank.d585.s0|92-101|amantadine|O
DDI-DrugBank.d585.s0|104-117|antiarrhythmic|O
DDI-DrugBank.d585.s0|14-19|agents|O
DDI-DrugBank.d585.s0|129-133|class|O
DDI-DrugBank.d585.s0|135-135|I|O
DDI-DrugBank.d585.s0|138-141|e.g.|O
DDI-DrugBank.d585.s0|144-152|quinidine|O
DDI-DrugBank.d585.s0|156-169|antihistamines|O
DDI-DrugBank.d585.s0|172-184|antipsychotic|O
DDI-DrugBank.d585.s0|14-19|agents|O
DDI-DrugBank.d585.s0|138-141|e.g.|O
DDI-DrugBank.d585.s0|200-213|phenothiazines|O
DDI-DrugBank.d585.s0|217-231|benzodiazepines|O
DDI-DrugBank.d585.s0|234-236|MAO|O
DDI-DrugBank.d585.s0|238-247|inhibitors|O
DDI-DrugBank.d585.s0|250-257|narcotic|O
DDI-DrugBank.d585.s0|259-268|analgesics|O
DDI-DrugBank.d585.s0|138-141|e.g.|O
DDI-DrugBank.d585.s0|277-286|meperidine|O
DDI-DrugBank.d585.s0|290-297|nitrates|O
DDI-DrugBank.d585.s0|303-310|nitrites|O
DDI-DrugBank.d585.s0|313-327|sympathomimetic|O
DDI-DrugBank.d585.s0|14-19|agents|O
DDI-DrugBank.d585.s0|337-345|tricyclic|O
DDI-DrugBank.d585.s0|347-361|antidepressants|O
DDI-DrugBank.d585.s0|85-89|drugs|O
DDI-DrugBank.d585.s0|69-83|anticholinergic|O
DDI-DrugBank.d585.s0|403-410|activity|O
DDI-DrugBank.d585.s0|139-139|.|O
DDI-DrugBank.d585.s1|0-15|Anticholinergics|O
DDI-DrugBank.d585.s1|17-26|antagonize|O
DDI-DrugBank.d585.s1|32-38|effects|O
DDI-DrugBank.d585.s1|43-54|antiglaucoma|O
DDI-DrugBank.d585.s1|56-61|agents|O
DDI-DrugBank.d585.s1|62-62|.|O
DDI-DrugBank.d585.s2|0-14|Anticholinergic|O
DDI-DrugBank.d585.s2|16-20|drugs|O
DDI-DrugBank.d585.s2|29-36|presence|O
DDI-DrugBank.d585.s2|41-49|increased|O
DDI-DrugBank.d585.s2|51-61|intraocular|O
DDI-DrugBank.d585.s2|63-70|pressure|O
DDI-DrugBank.d585.s2|72-74|may|O
DDI-DrugBank.d585.s2|79-87|hazardous|O
DDI-DrugBank.d585.s2|94-98|taken|O
DDI-DrugBank.d585.s2|100-111|concurrently|O
DDI-DrugBank.d585.s2|118-123|agents|O
DDI-DrugBank.d585.s2|133-147|corticosteroids|O
DDI-DrugBank.d585.s2|148-148|.|O
DDI-DrugBank.d585.s3|0-14|Anticholinergic|O
DDI-DrugBank.d585.s3|16-21|agents|O
DDI-DrugBank.d585.s3|23-25|may|O
DDI-DrugBank.d585.s3|27-32|affect|O
DDI-DrugBank.d585.s3|34-49|gastrointestinal|O
DDI-DrugBank.d585.s3|51-60|absorption|O
DDI-DrugBank.d585.s3|65-71|various|O
DDI-DrugBank.d585.s3|73-77|drugs|O
DDI-DrugBank.d585.s3|88-93|slowly|O
DDI-DrugBank.d585.s3|95-104|dissolving|O
DDI-DrugBank.d585.s3|106-111|dosage|O
DDI-DrugBank.d585.s3|113-117|forms|O
DDI-DrugBank.d585.s3|122-128|digoxin|O
DDI-DrugBank.d585.s4|0-8|increased|O
DDI-DrugBank.d585.s4|10-14|serum|O
DDI-DrugBank.d585.s4|16-22|digoxin|O
DDI-DrugBank.d585.s4|24-37|concentrations|O
DDI-DrugBank.d585.s4|39-41|may|O
DDI-DrugBank.d585.s4|43-48|result|O
DDI-DrugBank.d585.s4|49-49|.|O
DDI-DrugBank.d585.s5|0-14|Anticholinergic|O
DDI-DrugBank.d585.s5|16-20|drugs|O
DDI-DrugBank.d585.s5|22-24|may|O
DDI-DrugBank.d585.s5|26-35|antagonize|O
DDI-DrugBank.d585.s5|41-47|effects|O
DDI-DrugBank.d585.s5|16-20|drugs|O
DDI-DrugBank.d585.s5|63-67|alter|O
DDI-DrugBank.d585.s5|69-84|gastrointestinal|O
DDI-DrugBank.d585.s5|86-93|motility|O
DDI-DrugBank.d585.s5|104-117|metoclopramide|O
DDI-DrugBank.d585.s5|118-118|.|O
DDI-DrugBank.d585.s6|0-6|Because|O
DDI-DrugBank.d585.s6|8-15|antacids|O
DDI-DrugBank.d585.s6|17-19|may|O
DDI-DrugBank.d585.s6|21-29|interfere|O
DDI-DrugBank.d585.s6|40-49|absorption|O
DDI-DrugBank.d585.s6|54-68|anticholinergic|O
DDI-DrugBank.d585.s6|70-75|agents|O
DDI-DrugBank.d585.s6|78-89|simultaneous|O
DDI-DrugBank.d585.s6|4-6|use|O
DDI-DrugBank.d585.s6|104-108|drugs|O
DDI-DrugBank.d585.s6|120-126|avoided|O
DDI-DrugBank.d585.s6|127-127|.|O
DDI-DrugBank.d585.s7|0-2|The|O
DDI-DrugBank.d585.s7|4-13|inhibiting|O
DDI-DrugBank.d585.s7|15-21|effects|O
DDI-DrugBank.d585.s7|26-40|anticholinergic|O
DDI-DrugBank.d585.s7|42-46|drugs|O
DDI-DrugBank.d585.s7|51-57|gastric|O
DDI-DrugBank.d585.s7|59-70|hydrochloric|O
DDI-DrugBank.d585.s7|72-75|acid|O
DDI-DrugBank.d585.s7|77-85|secretion|O
DDI-DrugBank.d585.s7|91-101|antagonized|O
DDI-DrugBank.d585.s7|106-111|agents|O
DDI-DrugBank.d585.s7|113-116|used|O
DDI-DrugBank.d585.s7|121-125|treat|O
DDI-DrugBank.d585.s7|127-138|achlorhydria|O
DDI-DrugBank.d585.s7|113-116|used|O
DDI-DrugBank.d585.s7|158-161|test|O
DDI-DrugBank.d585.s7|51-57|gastric|O
DDI-DrugBank.d585.s7|77-85|secretion|O
DDI-DrugBank.d585.s7|180-180|.|O
DDI-DrugBank.d634.s0|0-13|Anticoagulants|O
DDI-DrugBank.d634.s0|16-19|oral|O
DDI-DrugBank.d634.s0|23-25|The|O
DDI-DrugBank.d634.s0|27-34|activity|O
DDI-DrugBank.d634.s0|16-19|oral|O
DDI-DrugBank.d634.s0|44-57|anticoagulants|O
DDI-DrugBank.d634.s0|59-61|may|O
DDI-DrugBank.d634.s0|66-76|potentiated|O
DDI-DrugBank.d634.s0|81-94|anti-vitamin-K|O
DDI-DrugBank.d634.s0|27-34|activity|O
DDI-DrugBank.d634.s0|105-114|attributed|O
DDI-DrugBank.d634.s0|119-129|methimazole|O
DDI-DrugBank.d634.s0|130-130|.|O
DDI-DrugBank.d634.s1|0-10|-adrenergic|O
DDI-DrugBank.d634.s1|12-19|blocking|O
DDI-DrugBank.d634.s1|21-26|agents|O
DDI-DrugBank.d634.s1|29-43|Hyperthyroidism|O
DDI-DrugBank.d634.s1|45-47|may|O
DDI-DrugBank.d634.s1|49-53|cause|O
DDI-DrugBank.d634.s1|58-66|increased|O
DDI-DrugBank.d634.s1|68-76|clearance|O
DDI-DrugBank.d634.s1|81-84|beta|O
DDI-DrugBank.d634.s1|86-90|ratio|O
DDI-DrugBank.d634.s1|91-91|.|O
DDI-DrugBank.d634.s2|0-0|A|O
DDI-DrugBank.d634.s2|2-5|dose|O
DDI-DrugBank.d634.s2|7-15|reduction|O
DDI-DrugBank.d634.s2|20-34|beta-adrenergic|O
DDI-DrugBank.d634.s2|36-43|blockers|O
DDI-DrugBank.d634.s2|45-47|may|O
DDI-DrugBank.d634.s2|52-57|needed|O
DDI-DrugBank.d634.s2|66-77|hyperthyroid|O
DDI-DrugBank.d634.s2|79-85|patient|O
DDI-DrugBank.d634.s2|87-93|becomes|O
DDI-DrugBank.d634.s2|95-103|euthyroid|O
DDI-DrugBank.d634.s2|104-104|.|O
DDI-DrugBank.d634.s3|0-8|Digitalis|O
DDI-DrugBank.d634.s3|10-19|glycosides|O
DDI-DrugBank.d634.s3|22-26|Serum|O
DDI-DrugBank.d634.s3|28-36|digitalis|O
DDI-DrugBank.d634.s3|38-43|levels|O
DDI-DrugBank.d634.s3|45-47|may|O
DDI-DrugBank.d634.s3|52-60|increased|O
DDI-DrugBank.d634.s3|67-78|hyperthyroid|O
DDI-DrugBank.d634.s3|80-87|patients|O
DDI-DrugBank.d634.s3|94-99|stable|O
DDI-DrugBank.d634.s3|28-36|digitalis|O
DDI-DrugBank.d634.s3|10-18|glycoside|O
DDI-DrugBank.d634.s3|121-127|regimen|O
DDI-DrugBank.d634.s3|129-134|become|O
DDI-DrugBank.d634.s3|136-144|euthyroid|O
DDI-DrugBank.d634.s4|0-6|reduced|O
DDI-DrugBank.d634.s4|8-13|dosage|O
DDI-DrugBank.d634.s4|18-26|digitalis|O
DDI-DrugBank.d634.s4|28-37|glycosides|O
DDI-DrugBank.d634.s4|39-41|may|O
DDI-DrugBank.d634.s4|46-53|required|O
DDI-DrugBank.d634.s4|54-54|.|O
DDI-DrugBank.d634.s5|0-11|Theophylline|O
DDI-DrugBank.d634.s5|0-11|Theophylline|O
DDI-DrugBank.d634.s5|27-35|clearance|O
DDI-DrugBank.d634.s5|37-39|may|O
DDI-DrugBank.d634.s5|41-48|decrease|O
DDI-DrugBank.d634.s5|55-66|hyperthyroid|O
DDI-DrugBank.d634.s5|68-75|patients|O
DDI-DrugBank.d634.s5|82-87|stable|O
DDI-DrugBank.d634.s5|89-100|theophylline|O
DDI-DrugBank.d634.s5|102-108|regimen|O
DDI-DrugBank.d634.s5|110-115|become|O
DDI-DrugBank.d634.s5|117-125|euthyroid|O
DDI-DrugBank.d634.s6|2-8|reduced|O
DDI-DrugBank.d634.s6|10-13|dose|O
DDI-DrugBank.d634.s6|18-29|theophylline|O
DDI-DrugBank.d634.s6|31-33|may|O
DDI-DrugBank.d634.s6|38-43|needed|O
DDI-DrugBank.d634.s6|44-44|.|O
DDI-DrugBank.d404.s0|0-11|Interactions|O
DDI-DrugBank.d404.s0|17-23|vitamin|O
DDI-DrugBank.d404.s0|25-25|D|O
DDI-DrugBank.d404.s0|27-35|analogues|O
DDI-DrugBank.d404.s0|38-44|Vitamin|O
DDI-DrugBank.d404.s0|46-47|D2|O
DDI-DrugBank.d404.s0|38-44|Vitamin|O
DDI-DrugBank.d404.s0|58-59|D3|O
DDI-DrugBank.d404.s0|62-71|Calcitriol|O
DDI-DrugBank.d404.s0|78-86|Calcidiol|O
DDI-DrugBank.d404.s0|90-103|Cholestyramine|O
DDI-DrugBank.d404.s0|90-103|Cholestyramine|O
DDI-DrugBank.d404.s0|130-137|reported|O
DDI-DrugBank.d404.s0|142-147|reduce|O
DDI-DrugBank.d404.s0|149-158|intestinal|O
DDI-DrugBank.d404.s0|160-169|absorption|O
DDI-DrugBank.d404.s0|174-176|fat|O
DDI-DrugBank.d404.s0|178-184|soluble|O
DDI-DrugBank.d404.s0|186-193|vitamins|O
DDI-DrugBank.d404.s1|11-13|may|O
DDI-DrugBank.d404.s1|15-20|impair|O
DDI-DrugBank.d404.s1|22-31|intestinal|O
DDI-DrugBank.d404.s1|33-42|absorption|O
DDI-DrugBank.d404.s1|54-60|vitamin|O
DDI-DrugBank.d404.s1|62-62|D|O
DDI-DrugBank.d404.s1|63-63|.|O
DDI-DrugBank.d404.s2|0-22|Phenytoin/Phenobarbital|O
DDI-DrugBank.d404.s2|25-27|The|O
DDI-DrugBank.d404.s2|29-44|coadministration|O
DDI-DrugBank.d404.s2|49-57|phenytoin|O
DDI-DrugBank.d404.s2|62-74|phenobarbital|O
DDI-DrugBank.d404.s2|85-90|affect|O
DDI-DrugBank.d404.s2|92-97|plasma|O
DDI-DrugBank.d404.s2|99-112|concentrations|O
DDI-DrugBank.d404.s2|117-123|vitamin|O
DDI-DrugBank.d404.s2|125-125|D|O
DDI-DrugBank.d404.s2|132-134|may|O
DDI-DrugBank.d404.s2|136-141|reduce|O
DDI-DrugBank.d404.s2|143-152|endogenous|O
DDI-DrugBank.d404.s2|92-97|plasma|O
DDI-DrugBank.d404.s2|161-166|levels|O
DDI-DrugBank.d404.s2|171-195|calcitriol/ergocalcitriol|O
DDI-DrugBank.d404.s2|200-211|accelerating|O
DDI-DrugBank.d404.s2|213-222|metabolism|O
DDI-DrugBank.d404.s2|223-223|.|O
DDI-DrugBank.d404.s3|0-4|Since|O
DDI-DrugBank.d404.s3|6-10|blood|O
DDI-DrugBank.d404.s3|12-16|level|O
DDI-DrugBank.d404.s3|21-45|calcitriol/ergocalcitriol|O
DDI-DrugBank.d404.s3|55-61|reduced|O
DDI-DrugBank.d404.s3|64-69|higher|O
DDI-DrugBank.d404.s3|71-75|doses|O
DDI-DrugBank.d404.s3|80-88|Rocaltrol|O
DDI-DrugBank.d404.s3|90-92|may|O
DDI-DrugBank.d404.s3|97-105|necessary|O
DDI-DrugBank.d404.s3|116-120|drugs|O
DDI-DrugBank.d404.s3|126-137|administered|O
DDI-DrugBank.d404.s3|139-152|simultaneously|O
DDI-DrugBank.d404.s3|153-153|.|O
DDI-DrugBank.d404.s4|0-8|Thiazides|O
DDI-DrugBank.d404.s4|0-8|Thiazides|O
DDI-DrugBank.d404.s4|25-29|known|O
DDI-DrugBank.d404.s4|34-39|induce|O
DDI-DrugBank.d404.s4|41-53|hypercalcemia|O
DDI-DrugBank.d404.s4|62-70|reduction|O
DDI-DrugBank.d404.s4|75-81|calcium|O
DDI-DrugBank.d404.s4|83-91|excretion|O
DDI-DrugBank.d404.s4|96-100|urine|O
DDI-DrugBank.d404.s4|101-101|.|O
DDI-DrugBank.d404.s5|0-3|Some|O
DDI-DrugBank.d404.s5|5-11|reports|O
DDI-DrugBank.d404.s5|18-22|shown|O
DDI-DrugBank.d404.s5|33-43|concomitant|O
DDI-DrugBank.d404.s5|45-58|administration|O
DDI-DrugBank.d404.s5|63-71|thiazides|O
DDI-DrugBank.d404.s5|78-84|vitamin|O
DDI-DrugBank.d404.s5|86-86|D|O
DDI-DrugBank.d404.s5|88-93|causes|O
DDI-DrugBank.d404.s5|95-107|hypercalcemia|O
DDI-DrugBank.d404.s5|108-108|.|O
DDI-DrugBank.d404.s6|0-8|Therefore|O
DDI-DrugBank.d404.s6|11-20|precaution|O
DDI-DrugBank.d404.s6|32-36|taken|O
DDI-DrugBank.d404.s6|43-58|coadministration|O
DDI-DrugBank.d404.s6|63-71|necessary|O
DDI-DrugBank.d404.s6|72-72|.|O
DDI-DrugBank.d404.s7|0-8|Digitalis|O
DDI-DrugBank.d404.s7|11-17|Vitamin|O
DDI-DrugBank.d404.s7|0-0|D|O
DDI-DrugBank.d404.s7|21-26|dosage|O
DDI-DrugBank.d404.s7|28-31|must|O
DDI-DrugBank.d404.s7|36-45|determined|O
DDI-DrugBank.d404.s7|52-55|care|O
DDI-DrugBank.d404.s7|60-67|patients|O
DDI-DrugBank.d404.s7|69-78|undergoing|O
DDI-DrugBank.d404.s7|80-88|treatment|O
DDI-DrugBank.d404.s7|95-103|digitalis|O
DDI-DrugBank.d404.s7|109-121|hypercalcemia|O
DDI-DrugBank.d404.s7|60-67|patients|O
DDI-DrugBank.d404.s7|140-142|may|O
DDI-DrugBank.d404.s7|144-154|precipitate|O
DDI-DrugBank.d404.s7|156-162|cardiac|O
DDI-DrugBank.d404.s7|164-174|arrhythmias|O
DDI-DrugBank.d404.s7|175-175|.|O
DDI-DrugBank.d404.s8|0-11|Ketoconazole|O
DDI-DrugBank.d404.s8|0-11|Ketoconazole|O
DDI-DrugBank.d404.s8|27-29|may|O
DDI-DrugBank.d404.s8|31-37|inhibit|O
DDI-DrugBank.d404.s8|44-52|synthetic|O
DDI-DrugBank.d404.s8|58-66|catabolic|O
DDI-DrugBank.d404.s8|68-74|enzymes|O
DDI-DrugBank.d404.s8|79-85|vitamin|O
DDI-DrugBank.d404.s8|87-87|D|O
DDI-DrugBank.d404.s8|88-88|.|O
DDI-DrugBank.d404.s9|0-9|Reductions|O
DDI-DrugBank.d404.s9|14-18|serum|O
DDI-DrugBank.d404.s9|20-29|endogenous|O
DDI-DrugBank.d404.s9|31-37|vitamin|O
DDI-DrugBank.d404.s9|39-39|D|O
DDI-DrugBank.d404.s9|41-54|concentrations|O
DDI-DrugBank.d404.s9|66-73|observed|O
DDI-DrugBank.d404.s9|75-83|following|O
DDI-DrugBank.d404.s9|89-102|administration|O
DDI-DrugBank.d404.s9|107-109|300|O
DDI-DrugBank.d404.s9|111-116|mg/day|O
DDI-DrugBank.d404.s9|121-124|1200|O
DDI-DrugBank.d404.s9|111-116|mg/day|O
DDI-DrugBank.d404.s9|133-144|ketoconazole|O
DDI-DrugBank.d404.s9|152-155|week|O
DDI-DrugBank.d404.s9|160-166|healthy|O
DDI-DrugBank.d404.s9|168-170|men|O
DDI-DrugBank.d404.s9|171-171|.|O
DDI-DrugBank.d404.s10|0-6|However|O
DDI-DrugBank.d404.s10|12-15|vivo|O
DDI-DrugBank.d404.s10|17-20|drug|O
DDI-DrugBank.d404.s10|22-32|interaction|O
DDI-DrugBank.d404.s10|34-40|studies|O
DDI-DrugBank.d404.s10|45-56|ketoconazole|O
DDI-DrugBank.d404.s10|63-69|vitamin|O
DDI-DrugBank.d404.s10|71-71|D|O
DDI-DrugBank.d404.s10|87-98|investigated|O
DDI-DrugBank.d404.s10|99-99|.|O
DDI-DrugBank.d404.s11|0-14|Corticosteroids|O
DDI-DrugBank.d404.s11|17-17|A|O
DDI-DrugBank.d404.s11|19-30|relationship|O
DDI-DrugBank.d404.s11|35-44|functional|O
DDI-DrugBank.d404.s11|46-55|antagonism|O
DDI-DrugBank.d404.s11|57-62|exists|O
DDI-DrugBank.d404.s11|72-78|vitamin|O
DDI-DrugBank.d404.s11|80-80|D|O
DDI-DrugBank.d404.s11|82-90|analogues|O
DDI-DrugBank.d404.s11|99-105|promote|O
DDI-DrugBank.d404.s11|107-113|calcium|O
DDI-DrugBank.d404.s11|115-124|absorption|O
DDI-DrugBank.d404.s11|131-145|corticosteroids|O
DDI-DrugBank.d404.s11|154-160|inhibit|O
DDI-DrugBank.d404.s11|107-113|calcium|O
DDI-DrugBank.d404.s11|115-124|absorption|O
DDI-DrugBank.d404.s11|180-180|.|O
DDI-DrugBank.d404.s12|0-16|Phosphate-Binding|O
DDI-DrugBank.d404.s12|18-23|Agents|O
DDI-DrugBank.d404.s12|26-30|Since|O
DDI-DrugBank.d404.s12|32-38|vitamin|O
DDI-DrugBank.d404.s12|40-40|D|O
DDI-DrugBank.d404.s12|42-45|also|O
DDI-DrugBank.d404.s12|54-59|effect|O
DDI-DrugBank.d404.s12|64-72|phosphate|O
DDI-DrugBank.d404.s12|74-82|transport|O
DDI-DrugBank.d404.s12|91-99|intestine|O
DDI-DrugBank.d404.s12|102-108|kidneys|O
DDI-DrugBank.d404.s12|114-118|bones|O
DDI-DrugBank.d404.s12|125-130|dosage|O
DDI-DrugBank.d404.s12|135-151|phosphate-binding|O
DDI-DrugBank.d404.s12|153-158|agents|O
DDI-DrugBank.d404.s12|160-163|must|O
DDI-DrugBank.d404.s12|168-175|adjusted|O
DDI-DrugBank.d404.s12|180-189|accordance|O
DDI-DrugBank.d404.s12|200-204|serum|O
DDI-DrugBank.d404.s12|64-72|phosphate|O
DDI-DrugBank.d404.s12|216-228|concentration|O
DDI-DrugBank.d404.s12|229-229|.|O
DDI-DrugBank.d404.s13|0-6|Vitamin|O
DDI-DrugBank.d404.s13|8-8|D|O
DDI-DrugBank.d404.s13|11-13|The|O
DDI-DrugBank.d404.s13|15-30|coadministration|O
DDI-DrugBank.d404.s13|46-52|vitamin|O
DDI-DrugBank.d404.s13|8-8|D|O
DDI-DrugBank.d404.s13|56-64|analogues|O
DDI-DrugBank.d404.s13|76-82|avoided|O
DDI-DrugBank.d404.s13|92-96|could|O
DDI-DrugBank.d404.s13|98-103|create|O
DDI-DrugBank.d404.s13|105-112|possible|O
DDI-DrugBank.d404.s13|114-121|additive|O
DDI-DrugBank.d404.s13|123-129|effects|O
DDI-DrugBank.d404.s13|135-147|hypercalcemia|O
DDI-DrugBank.d404.s13|148-148|.|O
DDI-DrugBank.d404.s14|0-6|Calcium|O
DDI-DrugBank.d404.s14|8-18|Supplements|O
DDI-DrugBank.d404.s14|21-32|Uncontrolled|O
DDI-DrugBank.d404.s14|34-39|intake|O
DDI-DrugBank.d404.s14|44-53|additional|O
DDI-DrugBank.d404.s14|55-72|calcium-containing|O
DDI-DrugBank.d404.s14|74-85|preparations|O
DDI-DrugBank.d404.s14|97-103|avoided|O
DDI-DrugBank.d404.s14|104-104|.|O
DDI-DrugBank.d404.s15|0-8|Magnesium|O
DDI-DrugBank.d404.s15|11-30|Magnesium-containing|O
DDI-DrugBank.d404.s15|32-43|preparations|O
DDI-DrugBank.d404.s15|46-47|eg|O
DDI-DrugBank.d404.s15|50-57|antacids|O
DDI-DrugBank.d404.s15|60-62|may|O
DDI-DrugBank.d404.s15|64-68|cause|O
DDI-DrugBank.d404.s15|70-84|hypermagnesemia|O
DDI-DrugBank.d404.s15|97-105|therefore|O
DDI-DrugBank.d404.s15|114-118|taken|O
DDI-DrugBank.d404.s15|127-133|therapy|O
DDI-DrugBank.d404.s15|140-146|vitamin|O
DDI-DrugBank.d404.s15|148-148|D|O
DDI-DrugBank.d404.s15|153-160|patients|O
DDI-DrugBank.d404.s15|165-171|chronic|O
DDI-DrugBank.d404.s15|173-177|renal|O
DDI-DrugBank.d404.s15|179-186|dialysis|O
DDI-DrugBank.d404.s15|187-187|.|O
DDI-MedLine.d113.s0|0-13|Acid-catalyzed|O
DDI-MedLine.d113.s0|15-25|ethanolysis|O
DDI-MedLine.d113.s0|30-38|temazepam|O
DDI-MedLine.d113.s0|43-51|anhydrous|O
DDI-MedLine.d113.s0|57-63|aqueous|O
DDI-MedLine.d113.s0|15-21|ethanol|O
DDI-MedLine.d113.s0|73-81|solutions|O
DDI-MedLine.d113.s1|0-2|The|O
DDI-MedLine.d113.s1|4-18|benzodiazepines|O
DDI-MedLine.d113.s1|26-31|family|O
DDI-MedLine.d113.s1|36-45|anxiolytic|O
DDI-MedLine.d113.s1|51-58|hypnotic|O
DDI-MedLine.d113.s1|60-64|drugs|O
DDI-MedLine.d113.s1|65-65|.|O
DDI-MedLine.d113.s2|0-3|When|O
DDI-MedLine.d113.s2|5-9|taken|O
DDI-MedLine.d113.s2|11-22|concurrently|O
DDI-MedLine.d113.s2|29-35|ethanol|O
DDI-MedLine.d113.s2|40-54|pharmacological|O
DDI-MedLine.d113.s2|56-66|interaction|O
DDI-MedLine.d113.s2|68-70|may|O
DDI-MedLine.d113.s2|72-76|occur|O
DDI-MedLine.d113.s2|79-90|potentiating|O
DDI-MedLine.d113.s2|96-102|central|O
DDI-MedLine.d113.s2|104-110|nervous|O
DDI-MedLine.d113.s2|112-117|system|O
DDI-MedLine.d113.s2|119-128|depression|O
DDI-MedLine.d113.s2|130-137|produced|O
DDI-MedLine.d113.s2|142-147|either|O
DDI-MedLine.d113.s2|149-152|drug|O
DDI-MedLine.d113.s2|153-153|.|O
DDI-MedLine.d113.s3|0-1|In|O
DDI-MedLine.d113.s3|3-10|addition|O
DDI-MedLine.d113.s3|20-34|pharmacological|O
DDI-MedLine.d113.s3|36-46|interaction|O
DDI-MedLine.d113.s3|54-59|report|O
DDI-MedLine.d113.s3|61-69|describes|O
DDI-MedLine.d113.s3|73-77|novel|O
DDI-MedLine.d113.s3|79-86|chemical|O
DDI-MedLine.d113.s3|88-95|reaction|O
DDI-MedLine.d113.s3|105-113|temazepam|O
DDI-MedLine.d113.s3|118-131|benzodiazepine|O
DDI-MedLine.d113.s3|138-144|ethanol|O
DDI-MedLine.d113.s3|152-157|acidic|O
DDI-MedLine.d113.s3|159-168|conditions|O
DDI-MedLine.d113.s3|170-176|similar|O
DDI-MedLine.d113.s3|187-191|found|O
DDI-MedLine.d113.s3|196-199|vivo|O
DDI-MedLine.d113.s3|202-210|resulting|O
DDI-MedLine.d113.s3|217-229|3-ethoxylated|O
DDI-MedLine.d113.s3|231-237|product|O
DDI-MedLine.d113.s3|238-238|.|O
DDI-MedLine.d113.s4|0-6|Optimal|O
DDI-MedLine.d113.s4|8-17|conditions|O
DDI-MedLine.d113.s4|20-27|kinetics|O
DDI-MedLine.d113.s4|30-40|equilibrium|O
DDI-MedLine.d113.s4|51-59|mechanism|O
DDI-MedLine.d113.s4|69-82|acid-catalyzed|O
DDI-MedLine.d113.s4|84-94|ethanolysis|O
DDI-MedLine.d113.s4|100-107|reported|O
DDI-MedLine.d113.s4|108-108|.|O
DDI-MedLine.d113.s5|0-2|The|O
DDI-MedLine.d113.s5|4-10|results|O
DDI-MedLine.d113.s5|12-16|raise|O
DDI-MedLine.d113.s5|22-32|possibility|O
DDI-MedLine.d113.s5|43-53|ethanolysis|O
DDI-MedLine.d113.s5|55-62|reaction|O
DDI-MedLine.d113.s5|64-66|may|O
DDI-MedLine.d113.s5|68-72|occur|O
DDI-MedLine.d113.s5|81-87|stomach|O
DDI-MedLine.d113.s5|92-97|people|O
DDI-MedLine.d113.s5|103-109|consume|O
DDI-MedLine.d113.s5|111-117|alcohol|O
DDI-MedLine.d113.s5|123-150|3-hydroxy-1,4-benzodiazepine|O
DDI-MedLine.d113.s5|157-163|regular|O
DDI-MedLine.d113.s5|165-169|basis|O
DDI-MedLine.d113.s5|170-170|.|O
DDI-MedLine.d113.s6|0-2|The|O
DDI-MedLine.d113.s6|4-17|acid-catalyzed|O
DDI-MedLine.d113.s6|19-30|ethanol-drug|O
DDI-MedLine.d113.s6|32-39|reaction|O
DDI-MedLine.d113.s6|46-55|relatively|O
DDI-MedLine.d113.s6|57-66|unexplored|O
DDI-MedLine.d113.s6|68-71|area|O
DDI-MedLine.d113.s6|77-79|may|O
DDI-MedLine.d113.s6|81-85|alter|O
DDI-MedLine.d113.s6|91-105|pharmacological|O
DDI-MedLine.d113.s6|34-39|action|O
DDI-MedLine.d113.s6|122-126|drugs|O
DDI-MedLine.d113.s6|127-127|.|O
DDI-DrugBank.d716.s0|0-2|You|O
DDI-DrugBank.d716.s0|11-14|take|O
DDI-DrugBank.d716.s0|16-23|mazindol|O
DDI-DrugBank.d716.s0|37-41|taken|O
DDI-DrugBank.d716.s0|45-53|monoamine|O
DDI-DrugBank.d716.s0|55-61|oxidase|O
DDI-DrugBank.d716.s0|63-71|inhibitor|O
DDI-DrugBank.d716.s0|74-77|MAOI|O
DDI-DrugBank.d716.s0|88-100|isocarboxazid|O
DDI-DrugBank.d716.s0|103-109|Marplan|O
DDI-DrugBank.d716.s0|113-127|tranylcypromine|O
DDI-DrugBank.d716.s0|130-136|Parnate|O
DDI-DrugBank.d716.s0|143-152|phenelzine|O
DDI-DrugBank.d716.s0|155-160|Nardil|O
DDI-DrugBank.d716.s0|170-173|last|O
DDI-DrugBank.d716.s0|175-176|14|O
DDI-DrugBank.d716.s0|178-181|days|O
DDI-DrugBank.d716.s0|182-182|.|O
DDI-DrugBank.d716.s1|0-6|Changes|O
DDI-DrugBank.d716.s1|11-17|insulin|O
DDI-DrugBank.d716.s1|29-36|diabetes|O
DDI-DrugBank.d716.s1|38-41|drug|O
DDI-DrugBank.d716.s1|43-51|therapies|O
DDI-DrugBank.d716.s1|53-55|may|O
DDI-DrugBank.d716.s1|60-68|necessary|O
DDI-DrugBank.d716.s1|77-85|treatment|O
DDI-DrugBank.d716.s1|92-99|mazindol|O
DDI-DrugBank.d716.s1|100-100|.|O
DDI-DrugBank.d716.s2|0-7|Mazindol|O
DDI-DrugBank.d716.s2|9-11|may|O
DDI-DrugBank.d716.s2|13-18|reduce|O
DDI-DrugBank.d716.s2|24-30|effects|O
DDI-DrugBank.d716.s2|35-46|guanethidine|O
DDI-DrugBank.d716.s2|49-55|Ismelin|O
DDI-DrugBank.d716.s2|57-57|.|O
DDI-DrugBank.d716.s3|0-3|This|O
DDI-DrugBank.d716.s3|5-9|could|O
DDI-DrugBank.d716.s3|11-14|lead|O
DDI-DrugBank.d716.s3|22-29|increase|O
DDI-DrugBank.d716.s3|34-38|blood|O
DDI-DrugBank.d716.s3|40-47|pressure|O
DDI-DrugBank.d716.s3|48-48|.|O
DDI-DrugBank.d716.s4|0-3|Tell|O
DDI-DrugBank.d716.s4|10-15|doctor|O
DDI-DrugBank.d716.s4|28-33|taking|O
DDI-DrugBank.d716.s4|35-46|guanethidine|O
DDI-DrugBank.d716.s4|47-47|.|O
DDI-DrugBank.d716.s5|0-5|Before|O
DDI-DrugBank.d716.s5|7-12|taking|O
DDI-DrugBank.d716.s5|19-28|medication|O
DDI-DrugBank.d716.s5|31-34|tell|O
DDI-DrugBank.d716.s5|41-46|doctor|O
DDI-DrugBank.d716.s5|7-12|taking|O
DDI-DrugBank.d716.s5|68-76|tricyclic|O
DDI-DrugBank.d716.s5|78-91|antidepressant|O
DDI-DrugBank.d716.s5|101-113|amitriptyline|O
DDI-DrugBank.d716.s5|116-121|Elavil|O
DDI-DrugBank.d716.s5|125-133|amoxapine|O
DDI-DrugBank.d716.s5|136-142|Asendin|O
DDI-DrugBank.d716.s5|146-152|doxepin|O
DDI-DrugBank.d716.s5|155-162|Sinequan|O
DDI-DrugBank.d716.s5|166-178|nortriptyline|O
DDI-DrugBank.d716.s5|181-187|Pamelor|O
DDI-DrugBank.d716.s5|191-200|imipramine|O
DDI-DrugBank.d716.s5|203-210|Tofranil|O
DDI-DrugBank.d716.s5|214-225|clomipramine|O
DDI-DrugBank.d716.s5|228-236|Anafranil|O
DDI-DrugBank.d716.s5|240-252|protriptyline|O
DDI-DrugBank.d716.s5|255-262|Vivactil|O
DDI-DrugBank.d716.s5|269-279|desipramine|O
DDI-DrugBank.d716.s5|282-290|Norpramin|O
DDI-DrugBank.d716.s5|292-292|.|O
DDI-DrugBank.d716.s6|0-4|These|O
DDI-DrugBank.d716.s6|6-10|drugs|O
DDI-DrugBank.d716.s6|12-14|may|O
DDI-DrugBank.d716.s6|16-23|decrease|O
DDI-DrugBank.d716.s6|29-35|effects|O
DDI-DrugBank.d716.s6|40-47|mazindol|O
DDI-DrugBank.d716.s6|48-48|.|O
DDI-DrugBank.d412.s0|0-1|In|O
DDI-DrugBank.d412.s0|3-5|one|O
DDI-DrugBank.d412.s0|7-12|survey|O
DDI-DrugBank.d412.s0|15-17|2.3|O
DDI-DrugBank.d412.s0|18-18|%|O
DDI-DrugBank.d412.s0|23-30|patients|O
DDI-DrugBank.d412.s0|32-37|taking|O
DDI-DrugBank.d412.s0|39-47|labetalol|O
DDI-DrugBank.d412.s0|49-51|HCl|O
DDI-DrugBank.d412.s0|56-66|combination|O
DDI-DrugBank.d412.s0|73-81|tricyclic|O
DDI-DrugBank.d412.s0|83-97|antidepressants|O
DDI-DrugBank.d412.s0|99-109|experienced|O
DDI-DrugBank.d412.s0|111-116|tremor|O
DDI-DrugBank.d412.s0|122-129|compared|O
DDI-DrugBank.d412.s0|134-136|0.7|O
DDI-DrugBank.d412.s0|18-18|%|O
DDI-DrugBank.d412.s0|139-146|reported|O
DDI-DrugBank.d412.s0|151-155|occur|O
DDI-DrugBank.d412.s0|39-47|labetalol|O
DDI-DrugBank.d412.s0|49-51|HCl|O
DDI-DrugBank.d412.s0|176-180|alone|O
DDI-DrugBank.d412.s0|16-16|.|O
DDI-DrugBank.d412.s1|0-2|The|O
DDI-DrugBank.d412.s1|4-15|contribution|O
DDI-DrugBank.d412.s1|32-41|treatments|O
DDI-DrugBank.d412.s1|51-57|adverse|O
DDI-DrugBank.d412.s1|59-66|reaction|O
DDI-DrugBank.d412.s1|71-77|unknown|O
DDI-DrugBank.d412.s1|87-97|possibility|O
DDI-DrugBank.d412.s1|104-107|drug|O
DDI-DrugBank.d412.s1|109-119|interaction|O
DDI-DrugBank.d412.s1|131-138|excluded|O
DDI-DrugBank.d412.s1|139-139|.|O
DDI-DrugBank.d412.s2|0-4|Drugs|O
DDI-DrugBank.d412.s2|6-15|possessing|O
DDI-DrugBank.d412.s2|17-29|beta-blocking|O
DDI-DrugBank.d412.s2|31-40|properties|O
DDI-DrugBank.d412.s2|46-50|blunt|O
DDI-DrugBank.d412.s2|56-69|bronchodilator|O
DDI-DrugBank.d412.s2|71-76|effect|O
DDI-DrugBank.d412.s2|81-93|beta-receptor|O
DDI-DrugBank.d412.s2|95-101|agonist|O
DDI-DrugBank.d412.s2|103-107|drugs|O
DDI-DrugBank.d412.s2|112-119|patients|O
DDI-DrugBank.d412.s2|126-137|bronchospasm|O
DDI-DrugBank.d412.s3|0-8|therefore|O
DDI-DrugBank.d412.s3|11-15|doses|O
DDI-DrugBank.d412.s3|17-23|greater|O
DDI-DrugBank.d412.s3|34-39|normal|O
DDI-DrugBank.d412.s3|41-53|antiasthmatic|O
DDI-DrugBank.d412.s3|11-14|dose|O
DDI-DrugBank.d412.s3|63-74|beta-agonist|O
DDI-DrugBank.d412.s3|76-89|bronchodilator|O
DDI-DrugBank.d412.s3|91-95|drugs|O
DDI-DrugBank.d412.s3|97-99|may|O
DDI-DrugBank.d412.s3|104-111|required|O
DDI-DrugBank.d412.s3|112-112|.|O
DDI-DrugBank.d412.s4|0-9|Cimetidine|O
DDI-DrugBank.d412.s4|20-24|shown|O
DDI-DrugBank.d412.s4|29-36|increase|O
DDI-DrugBank.d412.s4|42-56|bioavailability|O
DDI-DrugBank.d412.s4|61-69|labetalol|O
DDI-DrugBank.d412.s4|71-73|HCl|O
DDI-DrugBank.d412.s4|74-74|.|O
DDI-DrugBank.d412.s5|0-4|Since|O
DDI-DrugBank.d412.s5|11-15|could|O
DDI-DrugBank.d412.s5|20-28|explained|O
DDI-DrugBank.d412.s5|30-35|either|O
DDI-DrugBank.d412.s5|40-47|enhanced|O
DDI-DrugBank.d412.s5|49-58|absorption|O
DDI-DrugBank.d412.s5|69-78|alteration|O
DDI-DrugBank.d412.s5|83-89|hepatic|O
DDI-DrugBank.d412.s5|91-100|metabolism|O
DDI-DrugBank.d412.s5|105-113|labetalol|O
DDI-DrugBank.d412.s5|115-117|HCl|O
DDI-DrugBank.d412.s5|120-126|special|O
DDI-DrugBank.d412.s5|128-131|care|O
DDI-DrugBank.d412.s5|143-146|used|O
DDI-DrugBank.d412.s5|151-162|establishing|O
DDI-DrugBank.d412.s5|168-171|dose|O
DDI-DrugBank.d412.s5|173-180|required|O
DDI-DrugBank.d412.s5|186-190|blood|O
DDI-DrugBank.d412.s5|192-199|pressure|O
DDI-DrugBank.d412.s5|201-207|control|O
DDI-DrugBank.d412.s5|217-224|patients|O
DDI-DrugBank.d412.s5|225-225|.|O
DDI-DrugBank.d412.s6|0-8|Synergism|O
DDI-DrugBank.d412.s6|19-23|shown|O
DDI-DrugBank.d412.s6|33-41|halothane|O
DDI-DrugBank.d412.s6|43-52|anesthesia|O
DDI-DrugBank.d412.s6|58-70|intravenously|O
DDI-DrugBank.d412.s6|72-83|administered|O
DDI-DrugBank.d412.s6|85-93|labetalol|O
DDI-DrugBank.d412.s6|95-97|HCl|O
DDI-DrugBank.d412.s6|98-98|.|O
DDI-DrugBank.d412.s7|0-5|During|O
DDI-DrugBank.d412.s7|7-16|controlled|O
DDI-DrugBank.d412.s7|18-28|hypotensive|O
DDI-DrugBank.d412.s7|30-39|anesthesia|O
DDI-DrugBank.d412.s7|41-45|using|O
DDI-DrugBank.d412.s7|47-55|labetalol|O
DDI-DrugBank.d412.s7|57-59|HCl|O
DDI-DrugBank.d412.s7|64-74|association|O
DDI-DrugBank.d412.s7|81-89|halothane|O
DDI-DrugBank.d412.s7|92-95|high|O
DDI-DrugBank.d412.s7|97-110|concentrations|O
DDI-DrugBank.d412.s7|113-113|3|O
DDI-DrugBank.d412.s7|114-114|%|O
DDI-DrugBank.d412.s7|81-89|halothane|O
DDI-DrugBank.d412.s7|153-156|used|O
DDI-DrugBank.d412.s7|170-175|degree|O
DDI-DrugBank.d412.s7|180-190|hypotension|O
DDI-DrugBank.d412.s7|200-208|increased|O
DDI-DrugBank.d412.s7|229-239|possibility|O
DDI-DrugBank.d412.s7|246-250|large|O
DDI-DrugBank.d412.s7|252-260|reduction|O
DDI-DrugBank.d412.s7|265-271|cardiac|O
DDI-DrugBank.d412.s7|273-278|output|O
DDI-DrugBank.d412.s7|200-207|increase|O
DDI-DrugBank.d412.s7|299-305|central|O
DDI-DrugBank.d412.s7|307-312|venous|O
DDI-DrugBank.d412.s7|314-321|pressure|O
DDI-DrugBank.d412.s7|322-322|.|O
DDI-DrugBank.d412.s8|0-2|The|O
DDI-DrugBank.d412.s8|4-19|anesthesiologist|O
DDI-DrugBank.d412.s8|31-38|informed|O
DDI-DrugBank.d412.s8|47-53|patient|O
DDI-DrugBank.d412.s8|58-66|receiving|O
DDI-DrugBank.d412.s8|68-76|labetalol|O
DDI-DrugBank.d412.s8|78-80|HCl|O
DDI-DrugBank.d412.s8|81-81|.|O
DDI-DrugBank.d412.s9|0-8|Labetalol|O
DDI-DrugBank.d412.s9|10-12|HCl|O
DDI-DrugBank.d412.s9|14-19|blunts|O
DDI-DrugBank.d412.s9|25-30|reflex|O
DDI-DrugBank.d412.s9|32-42|tachycardia|O
DDI-DrugBank.d412.s9|44-51|produced|O
DDI-DrugBank.d412.s9|56-68|nitroglycerin|O
DDI-DrugBank.d412.s9|70-76|without|O
DDI-DrugBank.d412.s9|78-87|preventing|O
DDI-DrugBank.d412.s9|93-103|hypotensive|O
DDI-DrugBank.d412.s9|105-110|effect|O
DDI-DrugBank.d412.s9|111-111|.|O
DDI-DrugBank.d412.s10|0-1|If|O
DDI-DrugBank.d412.s10|3-11|labetalol|O
DDI-DrugBank.d412.s10|13-15|HCl|O
DDI-DrugBank.d412.s10|20-23|used|O
DDI-DrugBank.d412.s10|30-42|nitroglycerin|O
DDI-DrugBank.d412.s10|47-54|patients|O
DDI-DrugBank.d412.s10|61-66|angina|O
DDI-DrugBank.d412.s10|68-75|pectoris|O
DDI-DrugBank.d412.s10|78-87|additional|O
DDI-DrugBank.d412.s10|89-104|antihypertensive|O
DDI-DrugBank.d412.s10|106-112|effects|O
DDI-DrugBank.d412.s10|114-116|may|O
DDI-DrugBank.d412.s10|118-122|occur|O
DDI-DrugBank.d412.s10|123-123|.|O
DDI-DrugBank.d412.s11|0-3|Care|O
DDI-DrugBank.d412.s11|15-19|taken|O
DDI-DrugBank.d412.s11|24-32|labetalol|O
DDI-DrugBank.d412.s11|37-40|used|O
DDI-DrugBank.d412.s11|42-54|concomitantly|O
DDI-DrugBank.d412.s11|61-67|calcium|O
DDI-DrugBank.d412.s11|69-79|antagonists|O
DDI-DrugBank.d412.s11|88-96|verapamil|O
DDI-DrugBank.d412.s11|98-101|type|O
DDI-DrugBank.d412.s11|102-102|.|O
DDI-DrugBank.d412.s12|0-3|Risk|O
DDI-DrugBank.d412.s12|8-19|Anaphylactic|O
DDI-DrugBank.d412.s12|21-28|Reaction|O
DDI-DrugBank.d412.s12|30-34|While|O
DDI-DrugBank.d412.s12|36-41|taking|O
DDI-DrugBank.d412.s12|43-55|beta-blockers|O
DDI-DrugBank.d412.s12|58-65|patients|O
DDI-DrugBank.d412.s12|74-80|history|O
DDI-DrugBank.d412.s12|85-90|severe|O
DDI-DrugBank.d412.s12|92-103|anaphylactic|O
DDI-DrugBank.d412.s12|105-112|reaction|O
DDI-DrugBank.d412.s12|119-125|variety|O
DDI-DrugBank.d412.s12|130-138|allergens|O
DDI-DrugBank.d412.s12|140-142|may|O
DDI-DrugBank.d412.s12|152-159|reactive|O
DDI-DrugBank.d412.s12|164-171|repeated|O
DDI-DrugBank.d412.s12|173-181|challenge|O
DDI-DrugBank.d412.s12|184-189|either|O
DDI-DrugBank.d412.s12|191-200|accidental|O
DDI-DrugBank.d412.s12|203-212|diagnostic|O
DDI-DrugBank.d412.s12|218-228|therapeutic|O
DDI-DrugBank.d412.s12|229-229|.|O
DDI-DrugBank.d412.s13|0-3|Such|O
DDI-DrugBank.d412.s13|5-12|patients|O
DDI-DrugBank.d412.s13|14-16|may|O
DDI-DrugBank.d412.s13|21-32|unresponsive|O
DDI-DrugBank.d412.s13|41-45|usual|O
DDI-DrugBank.d412.s13|47-51|doses|O
DDI-DrugBank.d412.s13|56-66|epinephrine|O
DDI-DrugBank.d412.s13|68-71|used|O
DDI-DrugBank.d412.s13|76-80|treat|O
DDI-DrugBank.d412.s13|82-89|allergic|O
DDI-DrugBank.d412.s13|91-98|reaction|O
DDI-DrugBank.d412.s13|99-99|.|O
DDI-DrugBank.d412.s14|0-14|Drug/Laboratory|O
DDI-DrugBank.d412.s14|16-19|Test|O
DDI-DrugBank.d412.s14|21-32|Interactions|O
DDI-DrugBank.d412.s14|34-36|The|O
DDI-DrugBank.d412.s14|38-45|presence|O
DDI-DrugBank.d412.s14|50-58|labetalol|O
DDI-DrugBank.d412.s14|60-70|metabolites|O
DDI-DrugBank.d412.s14|79-83|urine|O
DDI-DrugBank.d412.s14|85-87|may|O
DDI-DrugBank.d412.s14|89-94|result|O
DDI-DrugBank.d412.s14|99-105|falsely|O
DDI-DrugBank.d412.s14|107-114|elevated|O
DDI-DrugBank.d412.s14|116-121|levels|O
DDI-DrugBank.d412.s14|126-132|urinary|O
DDI-DrugBank.d412.s14|134-147|catecholamines|O
DDI-DrugBank.d412.s14|150-161|metanephrine|O
DDI-DrugBank.d412.s14|164-178|normetanephrine|O
DDI-DrugBank.d412.s14|184-199|vanillylmandelic|O
DDI-DrugBank.d412.s14|201-204|acid|O
DDI-DrugBank.d412.s14|211-218|measured|O
DDI-DrugBank.d412.s14|223-234|fluorimetric|O
DDI-DrugBank.d412.s14|239-249|photometric|O
DDI-DrugBank.d412.s14|251-257|methods|O
DDI-DrugBank.d412.s14|258-258|.|O
DDI-DrugBank.d412.s15|0-1|In|O
DDI-DrugBank.d412.s15|3-11|screening|O
DDI-DrugBank.d412.s15|13-20|patients|O
DDI-DrugBank.d412.s15|22-30|suspected|O
DDI-DrugBank.d412.s15|44-59|pheochromocytoma|O
DDI-DrugBank.d412.s15|71-77|treated|O
DDI-DrugBank.d412.s15|84-92|labetalol|O
DDI-DrugBank.d412.s15|94-96|HCl|O
DDI-DrugBank.d412.s15|101-108|specific|O
DDI-DrugBank.d412.s15|110-115|method|O
DDI-DrugBank.d412.s15|128-131|high|O
DDI-DrugBank.d412.s15|133-143|performance|O
DDI-DrugBank.d412.s15|145-150|liquid|O
DDI-DrugBank.d412.s15|152-166|chromatographic|O
DDI-DrugBank.d412.s15|168-172|assay|O
DDI-DrugBank.d412.s15|179-183|solid|O
DDI-DrugBank.d412.s15|185-189|phase|O
DDI-DrugBank.d412.s15|191-200|extraction|O
DDI-DrugBank.d412.s15|203-206|e.g.|O
DDI-DrugBank.d412.s15|209-209|J|O
DDI-DrugBank.d412.s15|211-220|Chromatogr|O
DDI-DrugBank.d412.s15|222-233|385:241,1987|O
DDI-DrugBank.d412.s15|246-253|employed|O
DDI-DrugBank.d412.s15|258-268|determining|O
DDI-DrugBank.d412.s15|270-275|levels|O
DDI-DrugBank.d412.s15|280-293|catecholamines|O
DDI-DrugBank.d412.s15|204-204|.|O
DDI-DrugBank.d412.s16|0-8|Labetalol|O
DDI-DrugBank.d412.s16|10-12|HCl|O
DDI-DrugBank.d412.s16|18-21|also|O
DDI-DrugBank.d412.s16|28-35|reported|O
DDI-DrugBank.d412.s16|40-46|produce|O
DDI-DrugBank.d412.s16|50-54|false|O
DDI-DrugBank.d412.s16|56-63|positive|O
DDI-DrugBank.d412.s16|65-68|test|O
DDI-DrugBank.d412.s16|74-84|amphetamine|O
DDI-DrugBank.d412.s16|91-99|screening|O
DDI-DrugBank.d412.s16|101-105|urine|O
DDI-DrugBank.d412.s16|115-122|presence|O
DDI-DrugBank.d412.s16|127-131|drugs|O
DDI-DrugBank.d412.s16|133-137|using|O
DDI-DrugBank.d412.s16|143-154|commercially|O
DDI-DrugBank.d412.s16|156-164|available|O
DDI-DrugBank.d412.s16|166-170|assay|O
DDI-DrugBank.d412.s16|172-178|methods|O
DDI-DrugBank.d412.s16|180-187|Toxi-Lab|O
DDI-DrugBank.d412.s16|189-189|A|O
DDI-DrugBank.d412.s16|193-202|thin-layer|O
DDI-DrugBank.d412.s16|204-218|chromatographic|O
DDI-DrugBank.d412.s16|166-170|assay|O
DDI-DrugBank.d412.s16|231-240|Emit-d.a.u|O
DDI-DrugBank.d412.s16|237-237|.|O
DDI-DrugBank.d412.s17|0-3|When|O
DDI-DrugBank.d412.s17|5-12|patients|O
DDI-DrugBank.d412.s17|20-26|treated|O
DDI-DrugBank.d412.s17|33-41|labetalol|O
DDI-DrugBank.d412.s17|50-57|positive|O
DDI-DrugBank.d412.s17|59-63|urine|O
DDI-DrugBank.d412.s17|65-68|test|O
DDI-DrugBank.d412.s17|74-84|amphetamine|O
DDI-DrugBank.d412.s17|86-90|using|O
DDI-DrugBank.d412.s17|98-107|techniques|O
DDI-DrugBank.d412.s17|109-120|confirmation|O
DDI-DrugBank.d412.s17|132-135|made|O
DDI-DrugBank.d412.s17|86-90|using|O
DDI-DrugBank.d412.s17|151-158|specific|O
DDI-DrugBank.d412.s17|160-166|methods|O
DDI-DrugBank.d412.s17|178-180|gas|O
DDI-DrugBank.d412.s17|182-201|chromatographic-mass|O
DDI-DrugBank.d412.s17|203-214|spectrometer|O
DDI-DrugBank.d412.s17|98-106|technique|O
DDI-DrugBank.d412.s17|225-225|.|O
DDI-DrugBank.d34.s0|0-7|Although|O
DDI-DrugBank.d34.s0|9-17|acid-base|O
DDI-DrugBank.d34.s0|23-33|electrolyte|O
DDI-DrugBank.d34.s0|35-46|disturbances|O
DDI-DrugBank.d34.s0|57-64|reported|O
DDI-DrugBank.d34.s0|73-80|clinical|O
DDI-DrugBank.d34.s0|82-87|trials|O
DDI-DrugBank.d34.s0|94-104|dorzolamide|O
DDI-DrugBank.d34.s0|35-46|disturbances|O
DDI-DrugBank.d34.s0|57-64|reported|O
DDI-DrugBank.d34.s0|150-153|oral|O
DDI-DrugBank.d34.s0|155-162|carbonic|O
DDI-DrugBank.d34.s0|164-172|anhydrase|O
DDI-DrugBank.d34.s0|174-183|inhibitors|O
DDI-DrugBank.d34.s0|203-211|instances|O
DDI-DrugBank.d34.s0|214-221|resulted|O
DDI-DrugBank.d34.s0|226-229|drug|O
DDI-DrugBank.d34.s0|231-242|interactions|O
DDI-DrugBank.d34.s0|245-248|e.g.|O
DDI-DrugBank.d34.s0|251-258|toxicity|O
DDI-DrugBank.d34.s0|260-269|associated|O
DDI-DrugBank.d34.s0|276-284|high-dose|O
DDI-DrugBank.d34.s0|286-295|salicylate|O
DDI-DrugBank.d34.s0|297-303|therapy|O
DDI-DrugBank.d34.s0|246-246|.|O
DDI-DrugBank.d34.s1|0-8|Therefore|O
DDI-DrugBank.d34.s1|15-23|potential|O
DDI-DrugBank.d34.s1|34-37|drug|O
DDI-DrugBank.d34.s1|39-50|interactions|O
DDI-DrugBank.d34.s1|62-71|considered|O
DDI-DrugBank.d34.s1|76-83|patients|O
DDI-DrugBank.d34.s1|85-93|receiving|O
DDI-DrugBank.d34.s1|95-105|dorzolamide|O
DDI-DrugBank.d34.s1|106-106|.|O
DDI-DrugBank.d453.s0|0-7|Cytosine|O
DDI-DrugBank.d453.s0|9-19|arabinoside|O
DDI-DrugBank.d453.s0|24-33|cytostatic|O
DDI-DrugBank.d453.s0|35-39|agent|O
DDI-DrugBank.d453.s0|51-58|reported|O
DDI-DrugBank.d453.s0|63-72|inactivate|O
DDI-DrugBank.d453.s0|78-87|antifungal|O
DDI-DrugBank.d453.s0|89-96|activity|O
DDI-DrugBank.d453.s0|101-111|flucytosine|O
DDI-DrugBank.d453.s0|116-126|competitive|O
DDI-DrugBank.d453.s0|128-137|inhibition|O
DDI-DrugBank.d453.s0|138-138|.|O
DDI-DrugBank.d453.s1|0-4|Drugs|O
DDI-DrugBank.d453.s1|12-17|impair|O
DDI-DrugBank.d453.s1|19-28|glomerular|O
DDI-DrugBank.d453.s1|30-39|filtration|O
DDI-DrugBank.d453.s1|41-43|may|O
DDI-DrugBank.d453.s1|45-51|prolong|O
DDI-DrugBank.d453.s1|57-66|biological|O
DDI-DrugBank.d453.s1|68-76|half-life|O
DDI-DrugBank.d453.s1|81-91|flucytosine|O
DDI-DrugBank.d453.s1|92-92|.|O
DDI-DrugBank.d453.s2|0-14|Drug/Laboratory|O
DDI-DrugBank.d453.s2|16-19|Test|O
DDI-DrugBank.d453.s2|21-32|Interactions|O
DDI-DrugBank.d453.s2|35-45|Measurement|O
DDI-DrugBank.d453.s2|50-54|serum|O
DDI-DrugBank.d453.s2|56-65|creatinine|O
DDI-DrugBank.d453.s2|67-72|levels|O
DDI-DrugBank.d453.s2|84-93|determined|O
DDI-DrugBank.d453.s2|102-106|Jaffe|O
DDI-DrugBank.d453.s2|108-115|reaction|O
DDI-DrugBank.d453.s2|118-122|since|O
DDI-DrugBank.d453.s2|124-130|Ancobon|O
DDI-DrugBank.d453.s2|141-149|interfere|O
DDI-DrugBank.d453.s2|160-172|determination|O
DDI-DrugBank.d453.s2|56-65|creatinine|O
DDI-DrugBank.d453.s2|188-193|values|O
DDI-DrugBank.d453.s2|203-208|method|O
DDI-DrugBank.d453.s2|209-209|.|O
DDI-DrugBank.d453.s3|0-3|Most|O
DDI-DrugBank.d453.s3|5-13|automated|O
DDI-DrugBank.d453.s3|15-23|equipment|O
DDI-DrugBank.d453.s3|29-39|measurement|O
DDI-DrugBank.d453.s3|44-53|creatinine|O
DDI-DrugBank.d453.s3|55-59|makes|O
DDI-DrugBank.d453.s3|61-63|use|O
DDI-DrugBank.d453.s3|72-76|Jaffe|O
DDI-DrugBank.d453.s3|78-85|reaction|O
DDI-DrugBank.d453.s3|86-86|.|O
DDI-DrugBank.d603.s0|0-3|When|O
DDI-DrugBank.d603.s0|5-16|administered|O
DDI-DrugBank.d603.s0|18-30|concomitantly|O
DDI-DrugBank.d603.s0|37-46|ProAmatine|O
DDI-DrugBank.d603.s0|52-58|cardiac|O
DDI-DrugBank.d603.s0|60-69|glycosides|O
DDI-DrugBank.d603.s0|71-73|may|O
DDI-DrugBank.d603.s0|75-81|enhance|O
DDI-DrugBank.d603.s0|86-96|precipitate|O
DDI-DrugBank.d603.s0|98-108|bradycardia|O
DDI-DrugBank.d603.s0|111-113|A.V|O
DDI-DrugBank.d603.s0|112-112|.|O
DDI-DrugBank.d603.s1|0-4|block|O
DDI-DrugBank.d603.s1|9-18|arrhythmia|O
DDI-DrugBank.d603.s1|19-19|.|O
DDI-DrugBank.d603.s2|0-2|The|O
DDI-DrugBank.d603.s2|4-6|use|O
DDI-DrugBank.d603.s2|11-15|drugs|O
DDI-DrugBank.d603.s2|22-30|stimulate|O
DDI-DrugBank.d603.s2|32-47|alpha-adrenergic|O
DDI-DrugBank.d603.s2|49-57|receptors|O
DDI-DrugBank.d603.s2|60-63|e.g.|O
DDI-DrugBank.d603.s2|66-78|phenylephrine|O
DDI-DrugBank.d603.s2|81-95|pseudoephedrine|O
DDI-DrugBank.d603.s2|87-95|ephedrine|O
DDI-DrugBank.d603.s2|109-127|phenylpropanolamine|O
DDI-DrugBank.d603.s2|132-148|dihydroergotamine|O
DDI-DrugBank.d603.s2|151-153|may|O
DDI-DrugBank.d603.s2|155-161|enhance|O
DDI-DrugBank.d603.s2|166-175|potentiate|O
DDI-DrugBank.d603.s2|181-187|pressor|O
DDI-DrugBank.d603.s2|189-195|effects|O
DDI-DrugBank.d603.s2|200-209|ProAmatine|O
DDI-DrugBank.d603.s2|61-61|.|O
DDI-DrugBank.d603.s2|215-223|Therefore|O
DDI-DrugBank.d603.s2|284-296|concomitantly|O
DDI-DrugBank.d603.s2|303-308|agents|O
DDI-DrugBank.d603.s2|315-319|cause|O
DDI-DrugBank.d603.s2|321-336|vasoconstriction|O
DDI-DrugBank.d603.s2|61-61|.|O
DDI-DrugBank.d603.s3|0-9|ProAmatine|O
DDI-DrugBank.d603.s3|23-26|used|O
DDI-DrugBank.d603.s3|31-38|patients|O
DDI-DrugBank.d603.s3|40-52|concomitantly|O
DDI-DrugBank.d603.s3|54-60|treated|O
DDI-DrugBank.d603.s3|67-80|salt-retaining|O
DDI-DrugBank.d603.s3|82-88|steroid|O
DDI-DrugBank.d603.s3|90-96|therapy|O
DDI-DrugBank.d603.s3|99-102|i.e.|O
DDI-DrugBank.d603.s3|105-119|fludrocortisone|O
DDI-DrugBank.d603.s3|121-127|acetate|O
DDI-DrugBank.d603.s3|139-145|without|O
DDI-DrugBank.d603.s3|67-70|salt|O
DDI-DrugBank.d603.s3|152-166|supplementation|O
DDI-DrugBank.d603.s3|100-100|.|O
DDI-DrugBank.d603.s4|0-2|The|O
DDI-DrugBank.d603.s4|4-12|potential|O
DDI-DrugBank.d603.s4|18-23|supine|O
DDI-DrugBank.d603.s4|25-36|hypertension|O
DDI-DrugBank.d603.s4|48-56|carefully|O
DDI-DrugBank.d603.s4|58-66|monitored|O
DDI-DrugBank.d603.s4|77-84|patients|O
DDI-DrugBank.d603.s4|90-92|may|O
DDI-DrugBank.d603.s4|97-105|minimized|O
DDI-DrugBank.d603.s4|110-115|either|O
DDI-DrugBank.d603.s4|117-124|reducing|O
DDI-DrugBank.d603.s4|130-133|dose|O
DDI-DrugBank.d603.s4|138-152|fludrocortisone|O
DDI-DrugBank.d603.s4|154-160|acetate|O
DDI-DrugBank.d603.s4|165-174|decreasing|O
DDI-DrugBank.d603.s4|180-183|salt|O
DDI-DrugBank.d603.s4|185-190|intake|O
DDI-DrugBank.d603.s4|192-196|prior|O
DDI-DrugBank.d603.s4|201-210|initiation|O
DDI-DrugBank.d603.s4|215-223|treatment|O
DDI-DrugBank.d603.s4|229-229|.|O
DDI-DrugBank.d603.s5|0-9|ProAmatine|O
DDI-DrugBank.d603.s5|10-10|.|O
DDI-DrugBank.d603.s5|12-27|Alpha-adrenergic|O
DDI-DrugBank.d603.s5|29-36|blocking|O
DDI-DrugBank.d603.s5|38-43|agents|O
DDI-DrugBank.d603.s5|54-61|prazosin|O
DDI-DrugBank.d603.s5|64-72|terazosin|O
DDI-DrugBank.d603.s5|79-87|doxazosin|O
DDI-DrugBank.d603.s5|94-103|antagonize|O
DDI-DrugBank.d603.s5|109-115|effects|O
DDI-DrugBank.d603.s5|0-9|ProAmatine|O
DDI-DrugBank.d603.s5|10-10|.|O
DDI-DrugBank.d603.s5|132-140|Potential|O
DDI-DrugBank.d603.s5|146-149|Drug|O
DDI-DrugBank.d603.s5|151-162|Interactions|O
DDI-DrugBank.d603.s5|165-166|It|O
DDI-DrugBank.d603.s5|168-174|appears|O
DDI-DrugBank.d603.s5|176-183|possible|O
DDI-DrugBank.d603.s5|186-193|although|O
DDI-DrugBank.d603.s5|207-216|supporting|O
DDI-DrugBank.d603.s5|218-229|experimental|O
DDI-DrugBank.d603.s5|231-238|evidence|O
DDI-DrugBank.d603.s5|250-253|high|O
DDI-DrugBank.d603.s5|255-259|renal|O
DDI-DrugBank.d603.s5|261-269|clearance|O
DDI-DrugBank.d603.s5|274-288|desglymidodrine|O
DDI-DrugBank.d603.s5|293-296|base|O
DDI-DrugBank.d603.s5|302-304|due|O
DDI-DrugBank.d603.s5|309-314|active|O
DDI-DrugBank.d603.s5|316-322|tubular|O
DDI-DrugBank.d603.s5|324-332|secretion|O
DDI-DrugBank.d603.s5|341-354|base-secreting|O
DDI-DrugBank.d603.s5|356-361|system|O
DDI-DrugBank.d603.s5|363-366|also|O
DDI-DrugBank.d603.s5|368-378|responsible|O
DDI-DrugBank.d603.s5|324-332|secretion|O
DDI-DrugBank.d603.s5|406-410|drugs|O
DDI-DrugBank.d603.s5|415-423|metformin|O
DDI-DrugBank.d603.s5|426-435|cimetidine|O
DDI-DrugBank.d603.s5|438-447|ranitidine|O
DDI-DrugBank.d603.s5|450-461|procainamide|O
DDI-DrugBank.d603.s5|464-474|triamterene|O
DDI-DrugBank.d603.s5|477-486|flecainide|O
DDI-DrugBank.d603.s5|493-501|quinidine|O
DDI-DrugBank.d603.s6|0-3|Thus|O
DDI-DrugBank.d603.s6|11-13|may|O
DDI-DrugBank.d603.s6|20-28|potential|O
DDI-DrugBank.d603.s6|34-42|drug-drug|O
DDI-DrugBank.d603.s6|44-55|interactions|O
DDI-DrugBank.d603.s6|68-72|drugs|O
DDI-DrugBank.d603.s6|73-73|.|O
DDI-DrugBank.d158.s0|0-6|Urinary|O
DDI-DrugBank.d158.s0|8-17|acidifying|O
DDI-DrugBank.d158.s0|19-24|agents|O
DDI-DrugBank.d158.s0|26-30|These|O
DDI-DrugBank.d158.s0|19-24|agents|O
DDI-DrugBank.d158.s0|40-47|ammonium|O
DDI-DrugBank.d158.s0|49-56|chloride|O
DDI-DrugBank.d158.s0|59-64|sodium|O
DDI-DrugBank.d158.s0|8-11|acid|O
DDI-DrugBank.d158.s0|71-79|phosphate|O
DDI-DrugBank.d158.s0|82-84|etc|O
DDI-DrugBank.d158.s0|85-85|.|O
DDI-DrugBank.d158.s0|88-95|increase|O
DDI-DrugBank.d158.s0|101-113|concentration|O
DDI-DrugBank.d158.s0|122-128|ionized|O
DDI-DrugBank.d158.s0|130-136|species|O
DDI-DrugBank.d158.s0|145-155|amphetamine|O
DDI-DrugBank.d158.s0|157-164|molecule|O
DDI-DrugBank.d158.s0|167-173|thereby|O
DDI-DrugBank.d158.s0|175-184|increasing|O
DDI-DrugBank.d158.s0|186-192|urinary|O
DDI-DrugBank.d158.s0|194-202|excretion|O
DDI-DrugBank.d158.s0|85-85|.|O
DDI-DrugBank.d158.s1|0-3|Both|O
DDI-DrugBank.d158.s1|5-10|groups|O
DDI-DrugBank.d158.s1|15-20|agents|O
DDI-DrugBank.d158.s1|22-26|lower|O
DDI-DrugBank.d158.s1|28-32|blood|O
DDI-DrugBank.d158.s1|34-39|levels|O
DDI-DrugBank.d158.s1|45-52|efficacy|O
DDI-DrugBank.d158.s1|57-68|amphetamines|O
DDI-DrugBank.d158.s1|69-69|.|O
DDI-DrugBank.d158.s2|0-9|Adrenergic|O
DDI-DrugBank.d158.s2|11-18|blockers|O
DDI-DrugBank.d158.s2|0-9|Adrenergic|O
DDI-DrugBank.d158.s2|11-18|blockers|O
DDI-DrugBank.d158.s2|44-52|inhibited|O
DDI-DrugBank.d158.s2|57-68|amphetamines|O
DDI-DrugBank.d158.s3|0-14|Antidepressants|O
DDI-DrugBank.d158.s3|17-25|tricyclic|O
DDI-DrugBank.d158.s3|27-38|Amphetamines|O
DDI-DrugBank.d158.s3|40-42|may|O
DDI-DrugBank.d158.s3|44-50|enhance|O
DDI-DrugBank.d158.s3|56-63|activity|O
DDI-DrugBank.d158.s3|17-25|tricyclic|O
DDI-DrugBank.d158.s3|78-92|antidepressants|O
DDI-DrugBank.d158.s3|97-111|sympathomimetic|O
DDI-DrugBank.d158.s3|113-118|agents|O
DDI-DrugBank.d158.s4|0-12|d-amphetamine|O
DDI-DrugBank.d158.s4|19-29|desipramine|O
DDI-DrugBank.d158.s4|34-46|protriptyline|O
DDI-DrugBank.d158.s4|52-59|possibly|O
DDI-DrugBank.d158.s4|67-76|tricyclics|O
DDI-DrugBank.d158.s4|78-82|cause|O
DDI-DrugBank.d158.s4|84-91|striking|O
DDI-DrugBank.d158.s4|97-105|sustained|O
DDI-DrugBank.d158.s4|107-115|increases|O
DDI-DrugBank.d158.s4|124-136|concentration|O
DDI-DrugBank.d158.s4|0-12|d-amphetamine|O
DDI-DrugBank.d158.s4|162-166|brain|O
DDI-DrugBank.d158.s5|0-13|cardiovascular|O
DDI-DrugBank.d158.s5|15-21|effects|O
DDI-DrugBank.d158.s5|30-40|potentiated|O
DDI-DrugBank.d158.s5|41-41|.|O
DDI-DrugBank.d158.s6|0-2|MAO|O
DDI-DrugBank.d158.s6|4-13|inhibitors|O
DDI-DrugBank.d158.s6|15-18|MAOI|O
DDI-DrugBank.d158.s6|20-34|antidepressants|O
DDI-DrugBank.d158.s6|40-43|well|O
DDI-DrugBank.d158.s6|50-59|metabolite|O
DDI-DrugBank.d158.s6|64-75|furazolidone|O
DDI-DrugBank.d158.s6|78-81|slow|O
DDI-DrugBank.d158.s6|83-93|amphetamine|O
DDI-DrugBank.d158.s6|95-104|metabolism|O
DDI-DrugBank.d158.s6|105-105|.|O
DDI-DrugBank.d158.s7|0-3|This|O
DDI-DrugBank.d158.s7|5-11|slowing|O
DDI-DrugBank.d158.s7|13-23|potentiates|O
DDI-DrugBank.d158.s7|25-36|amphetamines|O
DDI-DrugBank.d158.s7|39-48|increasing|O
DDI-DrugBank.d158.s7|56-61|effect|O
DDI-DrugBank.d158.s7|70-76|release|O
DDI-DrugBank.d158.s7|81-94|norepinephrine|O
DDI-DrugBank.d158.s7|106-115|monoamines|O
DDI-DrugBank.d158.s7|122-131|adrenergic|O
DDI-DrugBank.d158.s7|133-137|nerve|O
DDI-DrugBank.d158.s7|139-145|endings|O
DDI-DrugBank.d158.s8|9-13|cause|O
DDI-DrugBank.d158.s8|15-23|headaches|O
DDI-DrugBank.d158.s8|35-39|signs|O
DDI-DrugBank.d158.s8|44-55|hypertensive|O
DDI-DrugBank.d158.s8|57-62|crisis|O
DDI-DrugBank.d158.s8|63-63|.|O
DDI-DrugBank.d158.s9|0-0|A|O
DDI-DrugBank.d158.s9|2-8|variety|O
DDI-DrugBank.d158.s9|13-17|toxic|O
DDI-DrugBank.d158.s9|19-30|neurological|O
DDI-DrugBank.d158.s9|32-38|effects|O
DDI-DrugBank.d158.s9|44-52|malignant|O
DDI-DrugBank.d158.s9|54-65|hyperpyrexia|O
DDI-DrugBank.d158.s9|71-75|occur|O
DDI-DrugBank.d158.s9|78-86|sometimes|O
DDI-DrugBank.d158.s9|93-97|fatal|O
DDI-DrugBank.d158.s9|99-105|results|O
DDI-DrugBank.d158.s9|106-106|.|O
DDI-DrugBank.d158.s10|0-13|Antihistamines|O
DDI-DrugBank.d158.s10|16-27|Amphetamines|O
DDI-DrugBank.d158.s10|29-31|may|O
DDI-DrugBank.d158.s10|33-42|counteract|O
DDI-DrugBank.d158.s10|48-55|sedative|O
DDI-DrugBank.d158.s10|57-62|effect|O
DDI-DrugBank.d158.s10|67-80|antihistamines|O
DDI-DrugBank.d158.s10|81-81|.|O
DDI-DrugBank.d158.s11|0-16|Antihypertensives|O
DDI-DrugBank.d158.s11|19-30|Amphetamines|O
DDI-DrugBank.d158.s11|32-34|may|O
DDI-DrugBank.d158.s11|36-45|antagonize|O
DDI-DrugBank.d158.s11|51-61|hypotensive|O
DDI-DrugBank.d158.s11|63-69|effects|O
DDI-DrugBank.d158.s11|74-90|antihypertensives|O
DDI-DrugBank.d158.s11|91-91|.|O
DDI-DrugBank.d158.s12|0-13|Chlorpromazine|O
DDI-DrugBank.d158.s12|0-13|Chlorpromazine|O
DDI-DrugBank.d158.s12|31-36|blocks|O
DDI-DrugBank.d158.s12|38-45|dopamine|O
DDI-DrugBank.d158.s12|51-64|norepinephrine|O
DDI-DrugBank.d158.s12|66-74|receptors|O
DDI-DrugBank.d158.s12|77-80|thus|O
DDI-DrugBank.d158.s12|82-91|inhibiting|O
DDI-DrugBank.d158.s12|97-103|central|O
DDI-DrugBank.d158.s12|105-113|stimulant|O
DDI-DrugBank.d158.s12|115-121|effects|O
DDI-DrugBank.d158.s12|126-137|amphetamines|O
DDI-DrugBank.d158.s12|150-153|used|O
DDI-DrugBank.d158.s12|158-162|treat|O
DDI-DrugBank.d158.s12|126-136|amphetamine|O
DDI-DrugBank.d158.s12|176-184|poisoning|O
DDI-DrugBank.d158.s12|185-185|.|O
DDI-DrugBank.d158.s13|0-11|Ethosuximide|O
DDI-DrugBank.d158.s13|14-25|Amphetamines|O
DDI-DrugBank.d158.s13|27-29|may|O
DDI-DrugBank.d158.s13|31-35|delay|O
DDI-DrugBank.d158.s13|37-46|intestinal|O
DDI-DrugBank.d158.s13|48-57|absorption|O
DDI-DrugBank.d158.s13|62-73|ethosuximide|O
DDI-DrugBank.d158.s13|74-74|.|O
DDI-DrugBank.d158.s14|0-10|Haloperidol|O
DDI-DrugBank.d158.s14|0-10|Haloperidol|O
DDI-DrugBank.d158.s14|25-30|blocks|O
DDI-DrugBank.d158.s14|32-39|dopamine|O
DDI-DrugBank.d158.s14|41-49|receptors|O
DDI-DrugBank.d158.s14|52-55|thus|O
DDI-DrugBank.d158.s14|57-66|inhibiting|O
DDI-DrugBank.d158.s14|72-78|central|O
DDI-DrugBank.d158.s14|80-88|stimulant|O
DDI-DrugBank.d158.s14|90-96|effects|O
DDI-DrugBank.d158.s14|101-112|amphetamines|O
DDI-DrugBank.d158.s14|113-113|.|O
DDI-DrugBank.d158.s15|0-6|Lithium|O
DDI-DrugBank.d158.s15|8-16|carbonate|O
DDI-DrugBank.d158.s15|19-21|The|O
DDI-DrugBank.d158.s15|23-31|anorectic|O
DDI-DrugBank.d158.s15|37-47|stimulatory|O
DDI-DrugBank.d158.s15|49-55|effects|O
DDI-DrugBank.d158.s15|60-71|amphetamines|O
DDI-DrugBank.d158.s15|73-75|may|O
DDI-DrugBank.d158.s15|80-88|inhibited|O
DDI-DrugBank.d158.s15|93-99|lithium|O
DDI-DrugBank.d158.s15|8-16|carbonate|O
DDI-DrugBank.d158.s15|110-110|.|O
DDI-DrugBank.d158.s16|0-9|Meperidine|O
DDI-DrugBank.d158.s16|12-23|Amphetamines|O
DDI-DrugBank.d158.s16|25-34|potentiate|O
DDI-DrugBank.d158.s16|40-48|analgesic|O
DDI-DrugBank.d158.s16|50-55|effect|O
DDI-DrugBank.d158.s16|60-69|meperidine|O
DDI-DrugBank.d158.s17|0-10|Methenamine|O
DDI-DrugBank.d158.s17|12-18|therapy|O
DDI-DrugBank.d158.s17|20-26|Urinary|O
DDI-DrugBank.d158.s17|28-36|excretion|O
DDI-DrugBank.d158.s17|41-52|amphetamines|O
DDI-DrugBank.d158.s17|57-65|increased|O
DDI-DrugBank.d158.s17|72-79|efficacy|O
DDI-DrugBank.d158.s17|84-90|reduced|O
DDI-DrugBank.d158.s17|95-104|acidifying|O
DDI-DrugBank.d158.s17|106-111|agents|O
DDI-DrugBank.d158.s17|113-116|used|O
DDI-DrugBank.d158.s17|121-131|methenamine|O
DDI-DrugBank.d158.s17|12-18|therapy|O
DDI-DrugBank.d158.s17|140-140|.|O
DDI-DrugBank.d158.s18|0-13|Norepinephrine|O
DDI-DrugBank.d158.s18|16-27|Amphetamines|O
DDI-DrugBank.d158.s18|29-35|enhance|O
DDI-DrugBank.d158.s18|41-50|adrenergic|O
DDI-DrugBank.d158.s18|52-57|effect|O
DDI-DrugBank.d158.s18|62-75|norepinephrine|O
DDI-DrugBank.d158.s18|76-76|.|O
DDI-DrugBank.d158.s19|0-12|Phenobarbital|O
DDI-DrugBank.d158.s19|15-26|Amphetamines|O
DDI-DrugBank.d158.s19|28-30|may|O
DDI-DrugBank.d158.s19|32-36|delay|O
DDI-DrugBank.d158.s19|38-47|intestinal|O
DDI-DrugBank.d158.s19|49-58|absorption|O
DDI-DrugBank.d158.s19|63-75|phenobarbital|O
DDI-DrugBank.d158.s20|0-16|co-administration|O
DDI-DrugBank.d158.s20|21-33|phenobarbital|O
DDI-DrugBank.d158.s20|35-37|may|O
DDI-DrugBank.d158.s20|39-45|produce|O
DDI-DrugBank.d158.s20|49-59|synergistic|O
DDI-DrugBank.d158.s20|61-74|anticonvulsant|O
DDI-DrugBank.d158.s20|76-81|action|O
DDI-DrugBank.d158.s20|82-82|.|O
DDI-DrugBank.d158.s21|0-8|Phenytoin|O
DDI-DrugBank.d158.s21|11-22|Amphetamines|O
DDI-DrugBank.d158.s21|24-26|may|O
DDI-DrugBank.d158.s21|28-32|delay|O
DDI-DrugBank.d158.s21|34-43|intestinal|O
DDI-DrugBank.d158.s21|45-54|absorption|O
DDI-DrugBank.d158.s21|59-67|phenytoin|O
DDI-DrugBank.d158.s22|0-16|co-administration|O
DDI-DrugBank.d158.s22|21-29|phenytoin|O
DDI-DrugBank.d158.s22|31-33|may|O
DDI-DrugBank.d158.s22|35-41|produce|O
DDI-DrugBank.d158.s22|45-55|synergistic|O
DDI-DrugBank.d158.s22|57-70|anticonvulsant|O
DDI-DrugBank.d158.s22|72-77|action|O
DDI-DrugBank.d158.s22|78-78|.|O
DDI-DrugBank.d158.s23|0-11|Propoxyphene|O
DDI-DrugBank.d158.s23|14-15|In|O
DDI-DrugBank.d158.s23|17-21|cases|O
DDI-DrugBank.d158.s23|26-37|propoxyphene|O
DDI-DrugBank.d158.s23|39-48|overdosage|O
DDI-DrugBank.d158.s23|51-61|amphetamine|O
DDI-DrugBank.d158.s23|63-65|CNS|O
DDI-DrugBank.d158.s23|67-77|stimulation|O
DDI-DrugBank.d158.s23|82-92|potentiated|O
DDI-DrugBank.d158.s23|98-102|fatal|O
DDI-DrugBank.d158.s23|104-114|convulsions|O
DDI-DrugBank.d158.s23|120-124|occur|O
DDI-DrugBank.d158.s23|125-125|.|O
DDI-DrugBank.d158.s24|0-7|Veratrum|O
DDI-DrugBank.d158.s24|9-17|alkaloids|O
DDI-DrugBank.d158.s24|20-31|Amphetamines|O
DDI-DrugBank.d158.s24|33-39|inhibit|O
DDI-DrugBank.d158.s24|45-55|hypotensive|O
DDI-DrugBank.d158.s24|57-62|effect|O
DDI-DrugBank.d158.s24|67-74|veratrum|O
DDI-DrugBank.d158.s24|9-17|alkaloids|O
DDI-DrugBank.d158.s25|0-14|Drug/Laboratory|O
DDI-DrugBank.d158.s25|16-19|Test|O
DDI-DrugBank.d158.s25|21-32|Interactions|O
DDI-DrugBank.d158.s25|35-46|Amphetamines|O
DDI-DrugBank.d158.s25|52-56|cause|O
DDI-DrugBank.d158.s25|60-70|significant|O
DDI-DrugBank.d158.s25|72-80|elevation|O
DDI-DrugBank.d158.s25|85-90|plasma|O
DDI-DrugBank.d158.s25|92-105|corticosteroid|O
DDI-DrugBank.d158.s25|107-112|levels|O
DDI-DrugBank.d158.s25|113-113|.|O
DDI-DrugBank.d158.s26|0-3|This|O
DDI-DrugBank.d158.s26|5-12|increase|O
DDI-DrugBank.d158.s26|17-24|greatest|O
DDI-DrugBank.d158.s26|33-39|evening|O
DDI-DrugBank.d158.s26|40-40|.|O
DDI-DrugBank.d158.s27|0-11|Amphetamines|O
DDI-DrugBank.d158.s27|13-15|may|O
DDI-DrugBank.d158.s27|17-25|interfere|O
DDI-DrugBank.d158.s27|32-38|urinary|O
DDI-DrugBank.d158.s27|40-46|steroid|O
DDI-DrugBank.d158.s27|48-61|determinations|O
DDI-DrugBank.d158.s27|62-62|.|O
DDI-DrugBank.d544.s0|0-1|No|O
DDI-DrugBank.d544.s0|3-6|dose|O
DDI-DrugBank.d544.s0|8-17|adjustment|O
DDI-DrugBank.d544.s0|22-30|necessary|O
DDI-DrugBank.d544.s0|37-44|Simulect|O
DDI-DrugBank.d544.s0|49-53|added|O
DDI-DrugBank.d544.s0|58-81|triple-immunosuppression|O
DDI-DrugBank.d544.s0|83-90|regimens|O
DDI-DrugBank.d544.s0|92-100|including|O
DDI-DrugBank.d544.s0|102-113|cyclosporine|O
DDI-DrugBank.d544.s0|116-130|corticosteroids|O
DDI-DrugBank.d544.s0|137-142|either|O
DDI-DrugBank.d544.s0|144-155|azathioprine|O
DDI-DrugBank.d544.s0|160-172|mycophenolate|O
DDI-DrugBank.d544.s0|174-180|mofetil|O
DDI-DrugBank.d544.s0|181-181|.|O
DDI-DrugBank.d544.s1|0-4|Three|O
DDI-DrugBank.d544.s1|6-13|clinical|O
DDI-DrugBank.d544.s1|15-20|trials|O
DDI-DrugBank.d544.s1|27-38|investigated|O
DDI-DrugBank.d544.s1|40-47|Simulect|O
DDI-DrugBank.d544.s1|49-51|use|O
DDI-DrugBank.d544.s1|56-66|combination|O
DDI-DrugBank.d544.s1|73-86|triple-therapy|O
DDI-DrugBank.d544.s1|88-95|regimens|O
DDI-DrugBank.d544.s1|96-96|.|O
DDI-DrugBank.d544.s2|0-15|Pharmacokinetics|O
DDI-DrugBank.d544.s2|22-29|assessed|O
DDI-DrugBank.d544.s2|34-36|two|O
DDI-DrugBank.d544.s2|47-52|trials|O
DDI-DrugBank.d544.s2|53-53|.|O
DDI-DrugBank.d544.s3|0-4|Total|O
DDI-DrugBank.d544.s3|6-9|body|O
DDI-DrugBank.d544.s3|11-19|clearance|O
DDI-DrugBank.d544.s3|24-31|Simulect|O
DDI-DrugBank.d544.s3|37-43|reduced|O
DDI-DrugBank.d544.s3|51-57|average|O
DDI-DrugBank.d544.s3|59-60|22|O
DDI-DrugBank.d544.s3|61-61|%|O
DDI-DrugBank.d544.s3|67-68|51|O
DDI-DrugBank.d544.s3|61-61|%|O
DDI-DrugBank.d544.s3|76-87|azathioprine|O
DDI-DrugBank.d544.s3|93-105|mycophenolate|O
DDI-DrugBank.d544.s3|107-113|mofetil|O
DDI-DrugBank.d544.s3|116-127|respectively|O
DDI-DrugBank.d544.s3|135-139|added|O
DDI-DrugBank.d544.s3|146-152|regimen|O
DDI-DrugBank.d544.s3|154-163|consisting|O
DDI-DrugBank.d544.s3|168-179|cyclosporine|O
DDI-DrugBank.d544.s3|182-184|USP|O
DDI-DrugBank.d544.s3|187-194|MODIFIED|O
DDI-DrugBank.d544.s3|201-215|corticosteroids|O
DDI-DrugBank.d544.s3|216-216|.|O
DDI-DrugBank.d544.s4|0-10|Nonetheless|O
DDI-DrugBank.d544.s4|17-21|range|O
DDI-DrugBank.d544.s4|26-35|individual|O
DDI-DrugBank.d544.s4|37-44|Simulect|O
DDI-DrugBank.d544.s4|46-54|clearance|O
DDI-DrugBank.d544.s4|56-61|values|O
DDI-DrugBank.d544.s4|70-77|presence|O
DDI-DrugBank.d544.s4|82-93|azathioprine|O
DDI-DrugBank.d544.s4|96-100|12-57|O
DDI-DrugBank.d544.s4|102-105|mL/h|O
DDI-DrugBank.d544.s4|111-123|mycophenolate|O
DDI-DrugBank.d544.s4|125-131|mofetil|O
DDI-DrugBank.d544.s4|134-137|7-54|O
DDI-DrugBank.d544.s4|102-105|mL/h|O
DDI-DrugBank.d544.s4|153-158|extend|O
DDI-DrugBank.d544.s4|160-166|outside|O
DDI-DrugBank.d544.s4|17-21|range|O
DDI-DrugBank.d544.s4|178-185|observed|O
DDI-DrugBank.d544.s4|32-35|dual|O
DDI-DrugBank.d544.s4|197-203|therapy|O
DDI-DrugBank.d544.s4|206-210|10-78|O
DDI-DrugBank.d544.s4|102-105|mL/h|O
DDI-DrugBank.d544.s4|217-217|.|O
DDI-DrugBank.d544.s5|0-2|The|O
DDI-DrugBank.d544.s5|4-12|following|O
DDI-DrugBank.d544.s5|14-24|medications|O
DDI-DrugBank.d544.s5|36-47|administered|O
DDI-DrugBank.d544.s5|52-59|clinical|O
DDI-DrugBank.d544.s5|61-66|trials|O
DDI-DrugBank.d544.s5|73-80|Simulect|O
DDI-DrugBank.d544.s5|90-97|increase|O
DDI-DrugBank.d544.s5|102-108|adverse|O
DDI-DrugBank.d544.s5|110-118|reactions|O
DDI-DrugBank.d544.s5|121-127|ATG/ALG|O
DDI-DrugBank.d544.s5|130-141|azathioprine|O
DDI-DrugBank.d544.s5|144-158|corticosteroids|O
DDI-DrugBank.d544.s5|161-172|cyclosporine|O
DDI-DrugBank.d544.s5|175-187|mycophenolate|O
DDI-DrugBank.d544.s5|189-195|mofetil|O
DDI-DrugBank.d544.s5|202-214|muromonab-CD3|O
DDI-DrugBank.d544.s5|215-215|.|O
DDI-DrugBank.d229.s0|0-3|Drug|O
DDI-DrugBank.d229.s0|5-15|Interaction|O
DDI-DrugBank.d229.s0|17-22|During|O
DDI-DrugBank.d229.s0|24-32|Pregnancy|O
DDI-DrugBank.d229.s0|35-42|Cromolyn|O
DDI-DrugBank.d229.s0|44-49|sodium|O
DDI-DrugBank.d229.s0|55-67|isoproterenol|O
DDI-DrugBank.d229.s0|74-80|studied|O
DDI-DrugBank.d229.s0|82-90|following|O
DDI-DrugBank.d229.s0|92-103|subcutaneous|O
DDI-DrugBank.d229.s0|105-114|injections|O
DDI-DrugBank.d229.s0|119-126|pregnant|O
DDI-DrugBank.d229.s0|128-131|mice|O
DDI-DrugBank.d229.s0|132-132|.|O
DDI-DrugBank.d229.s1|0-7|Cromolyn|O
DDI-DrugBank.d229.s1|9-14|sodium|O
DDI-DrugBank.d229.s1|16-20|alone|O
DDI-DrugBank.d229.s1|25-29|doses|O
DDI-DrugBank.d229.s1|37-39|540|O
DDI-DrugBank.d229.s1|41-49|mg/kg/day|O
DDI-DrugBank.d229.s1|52-64|approximately|O
DDI-DrugBank.d229.s1|66-68|340|O
DDI-DrugBank.d229.s1|70-74|times|O
DDI-DrugBank.d229.s1|80-86|maximum|O
DDI-DrugBank.d229.s1|88-98|recommended|O
DDI-DrugBank.d229.s1|100-104|daily|O
DDI-DrugBank.d229.s1|106-115|inhalation|O
DDI-DrugBank.d229.s1|25-28|dose|O
DDI-DrugBank.d229.s1|125-130|adults|O
DDI-DrugBank.d229.s1|137-141|mg/m2|O
DDI-DrugBank.d229.s1|143-147|basis|O
DDI-DrugBank.d229.s1|158-162|cause|O
DDI-DrugBank.d229.s1|164-174|significant|O
DDI-DrugBank.d229.s1|176-184|increases|O
DDI-DrugBank.d229.s1|189-199|resorptions|O
DDI-DrugBank.d229.s1|204-208|major|O
DDI-DrugBank.d229.s1|210-222|malformations|O
DDI-DrugBank.d229.s1|223-223|.|O
DDI-DrugBank.d229.s2|0-12|Isoproterenol|O
DDI-DrugBank.d229.s2|14-18|alone|O
DDI-DrugBank.d229.s2|25-28|dose|O
DDI-DrugBank.d229.s2|33-35|2.7|O
DDI-DrugBank.d229.s2|37-45|mg/kg/day|O
DDI-DrugBank.d229.s2|48-60|approximately|O
DDI-DrugBank.d229.s2|35-35|7|O
DDI-DrugBank.d229.s2|64-68|times|O
DDI-DrugBank.d229.s2|74-80|maximum|O
DDI-DrugBank.d229.s2|82-92|recommended|O
DDI-DrugBank.d229.s2|94-98|daily|O
DDI-DrugBank.d229.s2|100-109|inhalation|O
DDI-DrugBank.d229.s2|25-28|dose|O
DDI-DrugBank.d229.s2|119-124|adults|O
DDI-DrugBank.d229.s2|131-135|mg/m2|O
DDI-DrugBank.d229.s2|137-141|basis|O
DDI-DrugBank.d229.s2|144-152|increased|O
DDI-DrugBank.d229.s2|159-169|resorptions|O
DDI-DrugBank.d229.s2|175-187|malformations|O
DDI-DrugBank.d229.s2|34-34|.|O
DDI-DrugBank.d229.s3|0-2|The|O
DDI-DrugBank.d229.s3|4-11|addition|O
DDI-DrugBank.d229.s3|16-18|540|O
DDI-DrugBank.d229.s3|20-28|mg/kg/day|O
DDI-DrugBank.d229.s3|33-40|cromolyn|O
DDI-DrugBank.d229.s3|42-47|sodium|O
DDI-DrugBank.d229.s3|50-62|approximately|O
DDI-DrugBank.d229.s3|64-66|340|O
DDI-DrugBank.d229.s3|68-72|times|O
DDI-DrugBank.d229.s3|78-84|maximum|O
DDI-DrugBank.d229.s3|86-96|recommended|O
DDI-DrugBank.d229.s3|98-102|daily|O
DDI-DrugBank.d229.s3|104-113|inhalation|O
DDI-DrugBank.d229.s3|115-118|dose|O
DDI-DrugBank.d229.s3|123-128|adults|O
DDI-DrugBank.d229.s3|135-139|mg/m2|O
DDI-DrugBank.d229.s3|141-145|basis|O
DDI-DrugBank.d229.s3|151-153|2.7|O
DDI-DrugBank.d229.s3|20-28|mg/kg/day|O
DDI-DrugBank.d229.s3|168-180|isoproterenol|O
DDI-DrugBank.d229.s3|50-62|approximately|O
DDI-DrugBank.d229.s3|153-153|7|O
DDI-DrugBank.d229.s3|68-72|times|O
DDI-DrugBank.d229.s3|78-84|maximum|O
DDI-DrugBank.d229.s3|86-96|recommended|O
DDI-DrugBank.d229.s3|98-102|daily|O
DDI-DrugBank.d229.s3|104-113|inhalation|O
DDI-DrugBank.d229.s3|115-118|dose|O
DDI-DrugBank.d229.s3|123-128|adults|O
DDI-DrugBank.d229.s3|135-139|mg/m2|O
DDI-DrugBank.d229.s3|141-145|basis|O
DDI-DrugBank.d229.s3|279-285|appears|O
DDI-DrugBank.d229.s3|295-303|increased|O
DDI-DrugBank.d229.s3|309-317|incidence|O
DDI-DrugBank.d229.s3|327-337|resorptions|O
DDI-DrugBank.d229.s3|343-355|malformations|O
DDI-DrugBank.d229.s3|152-152|.|O
